#version: 0.2
i n
t i
r e
t h
a n
e n
e r
e d</w>
o n
o f</w>
a t
r o
i n</w>
th e</w>
an d</w>
i t
o n</w>
a ti
s i
a s
a r
a l
s t
o r
e l
i c
a l</w>
a c
e c
d i
o l
o r</w>
re s
in g</w>
u l
e s
a s</w>
t o</w>
e r</w>
e s</w>
u c
en t
o m
p ro
u r
it h</w>
w ith</w>
p h
a m
d e
ati on</w>
o s
o c
at ed</w>
d uc
en t</w>
i d
l e
ti v
e x
a t</w>
h i
t r
o u
a n</w>
l y</w>
f f
s .</w>
c on
m e
i s
w as</w>
i c</w>
a p
o t
er e</w>
o p
in e</w>
T h
b y</w>
p res
o x
ti on</w>
i s</w>
h e
c el
a d
s u
i m
a g
w ere</w>
g en
a b
in duc
l o
th at</w>
t er
u s
u n
i l
f or</w>
p ati
u m
p er
t s</w>
ff ec
c om
t e
c h
ati on
as e</w>
i f
e t
t re
Th e</w>
v e</w>
e n</w>
in c
e p
it y</w>
at e</w>
p l
ac tiv
v er
h y
ent s</w>
e ffec
s e
si on</w>
induc ed</w>
s ,</w>
an c
a r</w>
re c
l e</w>
u t
g n
re n
r i
m ent</w>
p a
cel l
n e
ti on
n o
re as
m o
re d</w>
ti c</w>
in e
u d
l i
en c
si gn
y l
si s</w>
hi b
w e
v el
st r
an t</w>
m a
c l
ex pres
v i
tre at
pati ents</w>
0 .
t er</w>
s y
h a
in hib
y .</w>
m ic
as s
c ar
q u
an t
) ,</w>
a f
h o
on e</w>
- induced</w>
) .</w>
o g
v e
m in
th er
tr an
if ic
ro u
p re
p or
y ,</w>
ul ar</w>
t ed</w>
res p
en d
m on
tiv e</w>
an ti
t ro
e m
tran s
g h
i r
pro te
or m
in d
c y
t o
sign ific
e .</w>
b e
reas ed</w>
d os
no t</w>
I n</w>
e v
w h
treat ment</w>
b e</w>
expres sion</w>
c o
p o
d r
es e</w>
ur e</w>
f l
th er</w>
cel l</w>
af ter</w>
e ,</w>
p os
u m</w>
ic al</w>
re g
s er
e st
in g
v ed</w>
p ar
ro m</w>
th e
i z
o b
d .</w>
cell s</w>
an g
i d</w>
ou s</w>
f rom</w>
inhib it
b et
s p
s e</w>
r at
st ud
r a
g /
ther ap
m or
b u
d ro
e -
s ho
ar e</w>
oc i
ou n
- 1
effec ts</w>
h um
id e</w>
ep t
g rou
th is</w>
ar y</w>
ti c
ent r
es .</w>
re l
al ly</w>
d a
si on
enc e</w>
ass oci
resp on
en ti
in v
ation s</w>
res ul
g l
d er
re duc
S :</w>
lo w
le vel
ac t
a in
rec ept
hum an</w>
o l</w>
y p
dr u
su b
ati ve</w>
f i
ti m
m i
d ec
b l
c a
O N
N A</w>
g h</w>
t en
or y</w>
de p
0. 0
c anc
inc reased</w>
di s
tr i
effec t</w>
bu t</w>
a z
p ot
com p
tre ated</w>
hy per
ol og
c or
u re
un c
ff e
W e</w>
ox ic
m ent
me th
u s</w>
m g/
ic h</w>
g g
in ter
ant ly</w>
i th
con tro
associ ated</w>
wh ich</w>
ma y</w>
activ ity</w>
stud y</w>
me t
pa th
prote in</w>
s en
y m
us ed</w>
o d
st e
f ol
me di
op to
dep end
sho w
or s</w>
ot h</w>
ec h
f orm
al s
e i
reg ul
signific antly</w>
th an</w>
u ro
ffe ren
car di
ap opto
min i
su gg
o d</w>
mic ro
level s</w>
al y
an d
ha ve</w>
( 2
ation .</w>
e ar
als o</w>
re ase</w>
am in
w e</w>
sp ec
es ,</w>
b r
ad mini
di fferen
m at
1 0
w he
i al</w>
al l
j ec
c entr
f unc
es t</w>
anc e</w>
i ti
ex pos
sy n
de vel
d ur
al ph
be en</w>
v er</w>
ag e</w>
us e</w>
ar i
re por
+ /
f act
th ese</w>
el y</w>
e d
oc y
en z
c ri
t um
a th
k in
o gen
devel op
it s</w>
canc er</w>
c he
gen e</w>
pro duc
m y
ox id
b oth</w>
in f
i a</w>
al u
t ec
hy dro
pres s
ha d</w>
u di
a -
resul ts</w>
h as</w>
ech an
recept or</w>
u b
si st
es s</w>
dos e</w>
c ur
ut e</w>
os ph
si ve</w>
a v
hi gh
as t
m echan
es s
depend ent</w>
ph en
C Y
st udi
u p
ab ol
ne uro
al l</w>
ph osph
ch ang
in fl
i t</w>
di se
in tr
con centr
p ol
t w
grou p
b in
p r
( 1
ver ,</w>
ob ser
dur ing</w>
an aly
A T
mo d
am ine</w>
y s</w>
5 -
mg/ k
c in
w a
c as
S I
mechan is
w ith
at ing</w>
CY P
t oxic
g r
ab le</w>
ti g
oun d</w>
t h</w>
cell s.</w>
s t</w>
b lo
n orm
pro l
con t
s c
we en</w>
su p
signific ant</w>
T hi
pa red</w>
R NA</w>
e th
C L
- 1</w>
bet ween</w>
Th ese</w>
ag on
therap y</w>
b i
d e</w>
v ari
a .</w>
we e
gh t</w>
r on
cy t
r is
rat s</w>
ro m
P A
rel ated</w>
ation ,</w>
t a
es tig
at es</w>
R E
cl in
met abol
el ec
y s
show ed</w>
inv estig
+/ -</w>
ou t</w>
M E
m ut
ar g
admini str
dru g
per i
com pared</w>
m a</w>
Thi s</w>
F -
activ ation</w>
n o</w>
fol low
com bin
grou p</w>
inc rease</w>
A C
ou r</w>
re e</w>
I n
pati ent
ul d</w>
er s</w>
il ity</w>
ren al</w>
( P
ocy t
tion s</w>
respon se</w>
l in
n on
prote in
1 .
- 2
i v
blo od</w>
m un
m ol
ox y
ind ic
el l
d o
on g
f or
b le</w>
pot enti
E R
si s.</w>
tion .</w>
m al
m an
us ing</w>
tw o</w>
L T
a ,</w>
v as
f ir
dru g</w>
oc ar
e d.</w>
m ar
it y.</w>
t yp
s ec
o ther</w>
os e</w>
i tion</w>
te st
uc le
oc k
ro le</w>
al s</w>
mor ph
p t
s ur
reduc ed</w>
ac tion</w>
iz ed</w>
de ter
tion al</w>
T H
S U
vi v
rec ei
ve l</w>
i r</w>
v it
ul ation</w>
O D
re qu
d er</w>
infl am
dec reased</w>
we ver,</w>
path wa
st er
f ound</w>
g ro
li ver</w>
tion ,</w>
inc l
oc h
m it
mon str
de monstr
er g
a il
re at
m RNA</w>
n it
p at
inv ol
id ence</w>
de f
i st
om a</w>
obser ved</w>
L -
ev alu
ti s
c ol
contro l
apopto sis</w>
A l
im mun
0 0
pl ic
mor e</w>
olog ical</w>
N A
ac ute</w>
meth yl
if er
SI ON
ac id</w>
o ph
ine ,</w>
3 -
m s</w>
incl ud
5 0</w>
wee k
C ON
k e</w>
( A
resp ec
ch ol
contro l</w>
sugg est</w>
m il
CL U
t ing</w>
oc a
CON CLU
CONCLU SION
administr ation</w>
ff ic
b as
lo w</w>
di d</w>
gro w
( C
medi ated</w>
o di
treat ment
re sist
d ic
s tim
2 -
SU LT
clin ical</w>
sen si
p e
pati ent</w>
re ,</w>
el l</w>
c ul
s uc
pres ent</w>
g en</w>
pre v
y c
on d
s ul
inhib ition</w>
pol y
pro tec
enz ym
expos ure</w>
ati c</w>
mic e</w>
c an</w>
d at
RE SULT
me as
he ar
y ear
gen er
comp le
4 -
ac et
hyper ten
1 ,</w>
ad di
s ti
c ular</w>
RESULT S:</w>
m ot
C D
hi st
u e</w>
D NA</w>
sugg est
func tion</w>
pl as
i de
ris k</w>
tum or</w>
m ac
R O
in ,</w>
e t</w>
trans cri
) -
a c</w>
ine .</w>
prol ifer
th rou
pl a
respec tiv
ou s
car cin
it e</w>
ot yp
os t</w>
norm al</w>
5 0
mar k
ME TH
wh o</w>
in jec
in -
H o
un der
m g</w>
chang es</w>
l as
he pati
en h
w ell</w>
sion .</w>
the ir</w>
2 .
ma in
ant agon
E C
tr ac
b ind
y l</w>
METH OD
1 0</w>
studi es</w>
f ail
on ly</w>
por t
id enti
a x
e tic</w>
pl ac
c e
f er
i es</w>
th i
sy m
P -
om e</w>
n ucle
st res
bl ock
grow th</w>
c al
ab ility</w>
respectiv el
b ro
fl u
Ho wever,</w>
c at
alph a</w>
ch ron
est er
i p
e u
c e</w>
transcri p
re t
no w
fact or</w>
si ble</w>
l oc
v id
activ e</w>
dat a</w>
hi gh</w>
inc reas
in al</w>
k now
el ial</w>
u red</w>
toxic ity</w>
f e
a ffec
( M
c hi
ure s</w>
s )</w>
se qu
throu gh</w>
inhibit ed</w>
potenti al</w>
P C
le u
oc cur
m ul
T o</w>
is m</w>
( 3
dise as
I I
o -
y -
an im
C A
ser um</w>
sy st
ver se</w>
se v
sion ,</w>
il l
ass a
inflam mat
pt om
high er</w>
cy c
ox ic</w>
S T
V E
r ate</w>
enh anc
anti -
typ e</w>
entr ic
f ind
ent ly</w>
tis su
ocar di
o ver
1 -
o th
vas cular</w>
inflammat ory</w>
an e
o id</w>
ca used</w>
he pat
stim ul
m ost</w>
bind ing</w>
5 %</w>
u r</w>
re le
tim e</w>
im pro
hear t</w>
c oca
whe n</w>
press ure</w>
METHOD S:</w>
dise ase</w>
po si
s ed</w>
gen es</w>
v ing</w>
suc h</w>
pres sion</w>
sign al
ur on
d ys
y r
a di
A P
at ory</w>
on g</w>
syn dro
do w
ain ed</w>
mon th
chron ic</w>
% )</w>
ar ac
ous ly</w>
pro g
l un
' s</w>
co uld</w>
d am
regul ation</w>
c um
plas ma</w>
if ic</w>
it y,</w>
er .</w>
ex amin
follow ing</w>
as e-
enc y</w>
s h
analy sis</w>
hydro x
N -
ing s</w>
che mo
v entric
1 )</w>
T I
cardi ac</w>
l ess</w>
th ou
o re
induc tion</w>
ox ide</w>
or al</w>
dos es</w>
d el
2 ,</w>
car b
v en
d es
at ro
an e</w>
im port
da y</w>
s elec
th ree</w>
op ath
ar ter
mg/k g
e ffic
b ut
N F-
spec ific</w>
z ed</w>
ti n</w>
pro mot
inhibit or</w>
0 0</w>
rat s.</w>
y n
in to</w>
op er
( H
f r
concentr ations</w>
si s,</w>
ed ,</w>
le vel</w>
ine -induced</w>
b ra
ag ain
si mil
se iz
ati n</w>
c ase</w>
develop ed</w>
c i
again st</w>
d ue</w>
si de</w>
d ,</w>
effec t
( T
includ ing</w>
x im
gl uc
da ys</w>
ti s</w>
n ec
with out</w>
f u
er al</w>
ot oxic
fi ed</w>
sym ptom
in .</w>
( S
th ose</w>
pro st
c ap
sub jec
o id
s es</w>
combin ation</w>
ell ular</w>
an ts</w>
hi le</w>
d s</w>
mo de
mechanis m</w>
ei ther</w>
ro s
ogen e
re as</w>
p er</w>
therap eu
in j
as t</w>
re ve
de tec
( P</w>
fir st</w>
t arg
kin ase</w>
pr im
per im
mol ec
ri al</w>
for e</w>
repor ted</w>
ne ph
dec rease</w>
pre vi
G F
R P
ventric ular</w>
gl ut
po st
l at
plac e
R A
mod el
em ia</w>
phosph or
develop ment</w>
3 .
m us
i on
non -
i .
differen t</w>
om e
mode l</w>
mg/k g</w>
l or
arac ter
iti es</w>
thou gh</w>
leu k
s am
b reas
erg ic</w>
si a</w>
li p
cont in
inj ur
al ed</w>
i l</w>
CYP 2
U N
ine -
bet a-
l im
a in</w>
m is
lun g</w>
demonstr ated</w>
ang i
investig ated</w>
therapeu tic</w>
oxid ative</w>
1 2
recei ved</w>
breas t</w>
f ur
b enz
invol ved</w>
och ond
ch aracter
ot al</w>
f requ
ep ti
differen ti
r at</w>
um b
syst em
l y,</w>
deter min
le p
u al</w>
i ly</w>
com par
est ro
find ings</w>
l it
en s
ra ph
is h
treatment .</w>
r o</w>
ing .</w>
ol d</w>
k ing</w>
se ver
0.0 0
ex perim
low er</w>
phosphor yl
contin u
sev ere</w>
f o
- 2</w>
g e
O ur</w>
simil ar</w>
1 9
sion s</w>
stud y,</w>
me m
az ol
ac h</w>
place b
CONCLUSION S:</w>
l ine</w>
activ ated</w>
drug s</w>
know n</w>
M P
b le
mit ochond
ass ess
di vid
effec tive</w>
import ant</w>
reduc tion</w>
ent ed</w>
v alu
w hile</w>
dow n
my ocardi
ic in</w>
( I
cell s,</w>
in iti
( N
me an</w>
ar mac
form ation</w>
ap pro
hy po
admini ste
d om
repor t</w>
m e</w>
di st
c is
poly morph
l os
ep i
at ten
1 A
patient s.</w>
con tr
t ac
ol ic</w>
is t</w>
whe ther</w>
( D
expos ed</w>
sur viv
therap y.</w>
ver atro
fi bro
al ter
mechanis ms</w>
d op
vit ro</w>
reve aled</w>
com m
mul ti
F ur
h al
el ev
ur al</w>
ne uron
v al
l ed</w>
signal ing</w>
effic ac
g iv
c le
t ol
stres s</w>
4 .
A n
def ic
cul t
ain ing</w>
per form
3 ,</w>
con cl
whe reas</w>
dis or
y ing</w>
hepati c</w>
f am
t otal</w>
1 2</w>
or -
l ong
M C
group s</w>
end oth
administe red</w>
ou t
str uc
vi a</w>
ar r
ex c
on e
pro c
ren t</w>
ap pa
o sis</w>
is o
regul ated</w>
K G
show n</w>
ac id
inf u
it ed</w>
0.0 5
cas p
T -
we i
neph ro
l d
a w
dos e-
O X
week s</w>
6 -
meas ured</w>
D :</w>
examin ed</w>
cas es</w>
ad e</w>
and om
re x
prog res
ar sen
a m</w>
enzym e</w>
st at
bra in</w>
re ver
n umb
p 5
ma j
B AC
1 7
n er
pa in</w>
m ic</w>
d ing</w>
con tri
i red</w>
ter m</w>
trans por
C a
coca ine</w>
giv en</w>
( G
b od
t ly</w>
- dependent</w>
RO UN
KG ROUN
BAC KGROUN
ste m</w>
ad en
I t</w>
p sy
en e
k ine
f t</w>
C h
M D
b ec
fur ther</w>
i g
ph armac
w om
w or
be fore</w>
p ine</w>
lo ro
S )</w>
resist ance</w>
d -
tic al</w>
ure .</w>
ad verse</w>
2 4</w>
r andom
s ing
cy cl
di rec
ha vi
di ab
da y
I I</w>
deter m
produc tion</w>
g reat
ent al</w>
induc e</w>
concentr ation</w>
intr av
( -
con di
mic e.</w>
og raph
myocardi al</w>
g am
cell ular</w>
th rom
sup press
es the
atten u
2 0</w>
ad ren
id ine</w>
b il
en e</w>
I L
acet yl
2 0
elec tro
sho w</w>
am ide</w>
ro ph
f ic
th ere</w>
tiv ity</w>
ic ally</w>
ph y
ep ith
5 .
re st
p ul
a d</w>
syn the
pl at
pl e</w>
prim ary</w>
li ke</w>
] .</w>
evalu ated</w>
% ,</w>
hy th
enhanc ed</w>
ch lor
R )</w>
ev idence</w>
o ver</w>
comp oun
s al
vi r
gl yc
be havi
A N
O B
indic ate</w>
3 0</w>
d ox
t ub
m ents</w>
us ,</w>
el i
an al
at h</w>
ing ,</w>
iz ation</w>
a ut
M A
c r
produc ed</w>
ap p
fail ure</w>
ca use</w>
8 -
r ic</w>
ve ment</w>
B P
l ym
pres ence</w>
pathwa y</w>
inc idence</w>
gen otyp
with in</w>
ac tions</w>
identi fied</w>
i ed</w>
efficac y</w>
otoxic ity</w>
al e</w>
prolifer ation</w>
im pa
J EC
or g
intr ac
ish ed</w>
( 4
id ne
C C
ocyt es</w>
oc he
mic al</w>
Fur ther
throm b
a use</w>
determin ed</w>
az ep
f ac
de ath</w>
2 )</w>
protec tive</w>
chi ld
10 0</w>
1 ).</w>
bod y</w>
respectivel y.</w>
apopto tic</w>
posi tive</w>
ec ted</w>
n ic
syndro me</w>
di ag
cy to
at al</w>
s m
li g
w ar
maj or</w>
D E
ath i
BACKGROUN D:</w>
or ub
nec ro
mem br
intrav en
hy p
OB JEC
I L-
A D
a k
associ ation</w>
in divid
A c
TI VE
par tic
ne w</w>
trans fer
M T
my el
nucle ar</w>
r ang
k idne
des cri
pro f
CONCLUSION :</w>
si de
OBJEC TIVE
k e
1 4
r ati
at ely</w>
A B
A d
no vel</w>
norm al
v ul
mitochond rial</w>
v ol
m ou
epi lep
dam age</w>
f em
flu o
am p
veratro l</w>
tol er
inhibit or
c op
symptom s</w>
numb er</w>
s ing</w>
N T
ver y</w>
bet a</w>
R -
om er
a u
Th ere</w>
j u
A L
s ol
resul ted</w>
c er
gen ic</w>
infl u
1 /
6 .
ab l
comple t
injec tion</w>
tic s</w>
increas es</w>
( E
studi ed</w>
hy pot
l u
- term</w>
bas ed</w>
t u
lym ph
k ed</w>
an y</w>
inhibit ors</w>
on ic</w>
5 ,</w>
u p</w>
et y</w>
H e
i a.</w>
alph a-
s hi
ac h
recei ving</w>
f our</w>
alph a
ear ly</w>
determ ine</w>
month s</w>
previ ously</w>
E x
con fir
P ro
b ility</w>
gen etic</w>
S -
he al
mon ary</w>
activ ity.</w>
induc es</w>
protein s</w>
olog y</w>
perform ed</w>
in ary</w>
mo re,</w>
endoth elial</w>
p ac
hypot en
ogene sis</w>
al ,</w>
tissu e</w>
on ary</w>
k appa
great er</w>
mal e</w>
is ol
pos sible</w>
addi tion,</w>
recept ors</w>
sever al</w>
s k
o tic</w>
( p</w>
mo di
9 5%</w>
re main
a sis</w>
s on
A f
an n
M )</w>
A -
c es</w>
molec ular</w>
mi a</w>
n i
i gn
p le
t oxic</w>
ane ous</w>
at or</w>
ra di
Af ter</w>
t ained</w>
all el
g as
in -induced</w>
s ome</w>
m .</w>
transcrip tion</w>
Further more,</w>
w il
sho uld</w>
S C
defic i
assess ed</w>
f ul
I F
A )</w>
rele ase</w>
r ine</w>
hydrox y
anim als</w>
psy ch
eth yl
l ab
com plic
ac cum
selec tive</w>
N O
(2 )</w>
1 5</w>
ar c
ce re
at ed.</w>
e ment</w>
6 0</w>
ret in
fact ors</w>
ec t
l arg
p p
phosphoryl ation</w>
mut ations</w>
r ap
ho ur
pro v
po in
e ach</w>
( B
in sul
p ir
da ily</w>
antagon ist
nit ro
comm on</w>
ti al</w>
investig ate</w>
o ve
arr hyth
ment al</w>
se t</w>
sing le</w>
cyc lo
p ri
- old</w>
sy stem</w>
mod ul
c oun
7 .
1 8
d ed</w>
suggest ing</w>
s odi
om y
anti oxid
high -
sensi tivity</w>
injur y</w>
ar ly</w>
t ,</w>
hyperten sive</w>
m in</w>
respon ses</w>
C om
subjec ts</w>
s -
surviv al</w>
p op
olog ic</w>
an s</w>
C on
ph eral</w>
fu l</w>
cor onary</w>
resist ant</w>
occur red</w>
ar b
ogen ic</w>
re tion</w>
ocyt e</w>
dox orub
T w
bet a
ne g
s it
ex trac
mou se</w>
epith elial</w>
( 0.
Al though</w>
metabol ism</w>
viv o</w>
k g
R NA
phy si
p yr
re vi
recept or
targ et</w>
( L
am in</w>
A s
S H
mi ght</w>
cal ci
on e,</w>
expres sed</w>
och rom
pot ent</w>
A I
ation s.</w>
follow ed</w>
tiv ely</w>
op las
dr aw
c le</w>
h or
v es</w>
0 %</w>
er ,</w>
ol ,</w>
ex hib
th al
am ph
am ong</w>
( O
tr ic</w>
as e,</w>
s el
prost ate</w>
ta ke</w>
los s</w>
con vul
i on</w>
4 ,</w>
d ou
c -
C I
us e
me dic
S E
bas el
6 ,</w>
s :</w>
intraven ous</w>
e g
expres sion.</w>
combin ed</w>
ab s
PA R
- treated</w>
al .</w>
le ft</w>
disor der
pul monary</w>
ren ce</w>
1 ,
cardi o
inflam m
yc in</w>
le ad
chang e</w>
con sist
1 3
r h
phen yl
casp ase-
m ed</w>
diseas e.</w>
( n</w>
' -
ag ents</w>
0 ,</w>
peri pheral</w>
e re
y ed</w>
t est</w>
ca us
ol e</w>
differen ces</w>
chol ester
an esthe
detec ted</w>
s y</w>
qu in
ag ent</w>
un der</w>
pre dic
de x
a i
mol /
H C
mus cle</w>
fol d</w>
dec reas
struc t
athi one</w>
sup por
ph ase</w>
s af
sensi tive</w>
patient s,</w>
on e.</w>
A M
as es</w>
ab il
gr am
p it
S t
al -
sc op
wee k</w>
R es
sodi um</w>
ox if
infu sion</w>
elev ated</w>
(2 )
tri al</w>
lo b
hyperten sion</w>
cyc le</w>
placeb o</w>
h om
vari ous</w>
canc er.</w>
col l
p5 3</w>
su per
1 .</w>
year -old</w>
demonstr ate</w>
all y,</w>
as s</w>
vel y</w>
with draw
pl ant
lin es</w>
pe a
ochrom e</w>
OBJECTIVE :</w>
( +
sm all</w>
t y</w>
oxy gen</w>
m es
i a,</w>
ab ly</w>
lip id</w>
pro per
sul f
1 5
ud e</w>
t al</w>
ex er
I C
P 4
tic ally</w>
ad ul
is che
in dependent</w>
ac in</w>
hypo the
estro gen</w>
g o
ur ine</w>
m el
r an
org an
glut athione</w>
cor rel
o st
pro p
compoun ds</w>
al one</w>
1 6
p ec
fi br
prol ong
t op
H T
g er
activ ities</w>
ag ent
P )</w>
man n
re n</w>
f ree</w>
inhibit ory</w>
( -1
wei ght</w>
m en
f low</w>
en g
res veratrol</w>
func tional</w>
o z
e ter
sh or
stimul ated</w>
year s</w>
inhib it</w>
c ir
membr ane</w>
ur inary</w>
ro l
bec ause</w>
o ti
E ffec
su s</w>
G F-
carcin oma</w>
yn am
seiz ures</w>
si c</w>
pla y</w>
ph al
s mo
8 .
Al l</w>
u res
ot oxic</w>
re active</w>
2 5</w>
O n
st and
sam e</w>
oxy gen
in test
multi ple</w>
inf arc
ti me
lo g
cyt ochrome</w>
o ver,</w>
neuro path
agon ist
s om
experim ental</w>
tum ors</w>
vit amin</w>
br al</w>
ox i
su sc
polymorph is
e qu
im plic
susc epti
t s.</w>
m er
P G
tran si
f en
b ed</w>
promot er</w>
arter ial</w>
rec ur
cont aining</w>
te m
ho wever,</w>
b ac
ster oid
4 0</w>
ogen ous</w>
antagon ist</w>
necro sis</w>
ast ,</w>
CYP 1A
3 A
tro ph
per c
2 9
g/ m
der i
tum or
ag es</w>
M ore
r up
p .
dop amine</w>
og e
amph et
N o</w>
gr ad
con duc
reat ment</w>
n at
c it
ri l</w>
child ren</w>
arsen ic</w>
long -term</w>
( R
inhibit s</w>
ti co
1 ),</w>
an dro
prof il
fact or
calci um</w>
b ene
the re
nic ot
2 ,
affec ted</w>
i um</w>
N F
More over,</w>
P T
y ro
mal ign
gener ation</w>
o .</w>
er at
for m</w>
stud y.</w>
D -
pl us</w>
intrac ellular</w>
1 6</w>
transfer ase</w>
enc ed</w>
test ed</w>
ox in</w>
N e
C B
o f
up -
qu anti
7 -
1 4</w>
proper ti
t al
IL -1
trans f
ar t
metabol it
g li
rati o</w>
ol y
A t</w>
P ati
prov ide</w>
ot ens
deri ved</w>
kidne y</w>
cat al
indic ated</w>
chemo therapy</w>
cardio vascular</w>
C -
centr al</w>
g u
ver sus</w>
opath y</w>
bl ad
suggest ed</w>
ar d</w>
te red</w>
pre g
evalu ate</w>
al lo
m uc
y g
mg/kg )</w>
D )</w>
oc c
pro b
e str
ad v
P h
ove rex
or ph
activ ity,</w>
K -
app ear
t -
apopto sis.</w>
2 .</w>
sec ond
antioxid ant</w>
contr ast,</w>
ation shi
assa y</w>
sti tu
v ast
basel ine</w>
immun o
gl omer
t .</w>
ol ol</w>
met ast
tr a
e l</w>
individ u
G S
ro p
gen e
inf ec
f y</w>
neg ative</w>
sub st
8 ,</w>
is tic</w>
N P
prev ented</w>
enzym es</w>
stat us</w>
dis continu
oc k</w>
B cl
res t</w>
mon it
est abl
ati s
as si
enti al</w>
i ous</w>
on set</w>
H ep
ation al</w>
concl u
fem ale</w>
0 -
ic e</w>
T reatment</w>
tac hy
affec t</w>
D i
and /
ob tained</w>
heal th
ble -
suggest s</w>
C l
tion s.</w>
P ar
re s</w>
kin son
valu es</w>
and/ or</w>
inter action</w>
s o
attenu ated</w>
rel ationshi
m al</w>
y st
differen ce</w>
par am
treatment ,</w>
ol .</w>
ma xim
m g
dose- dependent</w>
o d.</w>
ra z
effect s.</w>
de ath
mut ation</w>
peri od</w>
confir med</w>
et al</w>
z e</w>
ti l
le ast</w>
system ic</w>
AN D</w>
low -
addi tion</w>
suppress ed</w>
oper id
group .</w>
oche mical</w>
as pir
toxic ity.</w>
li k
on t
co ur
vi ron
di pine</w>
li thi
te d.</w>
o ste
hepati tis</w>
cl on
B oth</w>
er s.</w>
u preg
fi ve</w>
sk in</w>
f ar
y th
1 1</w>
cardi a</w>
down -
pathwa ys</w>
on in</w>
+/ -
re action</w>
3 )</w>
Th us,</w>
L P
( V
dou ble-
cor related</w>
e )</w>
ex peri
Pati ents</w>
angi otens
2 5
the y</w>
p -
out com
C OX
e ti
al s.</w>
molec ul
impa ir
p 3
se en</w>
impro ved</w>
metabol ic</w>
A ,</w>
c an
ab out</w>
ev ents</w>
D H
A R
me n</w>
oph ag
( F
sub sequ
P I
pat ter
resul t</w>
control led</w>
dam ag
character ized</w>
z ap
inter v
p ur
l y
kappa B</w>
P D
s ;</w>
A S
G T
includ ed</w>
ag g
res c
direc t</w>
stim ulation</w>
group s.</w>
sam pl
influ ence</w>
am eth
si d
en d</w>
cl er
blad der</w>
cur rent</w>
glyc er
gluc ose</w>
n os
level s.</w>
on d</w>
revi e
ter min
si x</w>
w at
hal operid
xim ately</w>
ro n</w>
accum ulation</w>
ta k
ide ,</w>
en viron
amin o
n ot
mg/ m
pl atin</w>
t oge
ex p
is on</w>
9 .
st ri
ch loro
bi o
requ ired</w>
phen otyp
M M
polymorphis ms</w>
op i
mo der
o ic</w>
f oc
N S
sti l
frequ ency</w>
A s</w>
hour s</w>
at e,</w>
pro vid
op en
caus es</w>
immun e</w>
diab etic</w>
y e
k et
inc e</w>
ai m</w>
st ro
sub str
syndro me
in s</w>
G F</w>
wom en</w>
S O
A r
er yth
dys function</w>
v is
fo re,</w>
u s.</w>
I m
pres su
b one</w>
C O
hi pp
ac t</w>
st re
pol ym
ure ,</w>
spec ies</w>
per oxid
micro gram
ch ain</w>
mg/kg ,</w>
intest inal</w>
T NF-
cl u
P A</w>
H B
transcrip tional</w>
oc amp
pos si
and ,</w>
l ac
s a
v s.</w>
s ).</w>
param eter
T CD
isol ated</w>
gam ma</w>
th en</w>
reg ion
b ute</w>
ed ly</w>
cardi omy
func tion.</w>
syn th
ent .</w>
p epti
l if
health y</w>
o s</w>
H -
os pit
p i
3 ,
comple x</w>
0.05 ).</w>
appro ximately</w>
t am
high ly</w>
pre treatment</w>
ex pl
diab et
2 1</w>
G ST
mac roph
s /
k n
A k
d og
v ant</w>
L )</w>
W he
( 5
hipp ocamp
he ter
l ying</w>
in ine</w>
con side
dur ation</w>
contri bute</w>
increas ing</w>
al tered</w>
cere bral</w>
n a
CYP2 C
oz yg
CYP 3A
pos e</w>
nit ric</w>
morph ine</w>
ab normal
per id
em ic</w>
analy zed</w>
mor tal
an th
up take</w>
cholester ol</w>
H g
gam ma
P4 50</w>
1 3</w>
R e
C )</w>
R ec
c reat
su m
control s</w>
double- bl
cult ured</w>
con ver
ev en</w>
methyl ation</w>
ad ju
under lying</w>
h er
str ic
a re
M e
C R
pre gn
re pe
fluo ro
ar di
conclu sion,</w>
pri or</w>
si l
neuron al</w>
p rec
qu er
. ,</w>
- related</w>
iti s</w>
con f
n ing</w>
ation s,</w>
arter y</w>
in ten
al though</w>
T R
8 0</w>
um .</w>
os om
synthe sis</w>
ac hi
7 ,</w>
1 8</w>
r u
ti z
sp ont
3 4
os ine</w>
ent ,</w>
de g
previ ous</w>
car ri
polym er
W ester
om eth
( 6
de hy
P PAR
p anc
ati vely</w>
complet e</w>
2 /
obser v
lik ely</w>
e de
c ess
medi an</w>
insul in</w>
st ar
H S
ve d.</w>
as th
alter ations</w>
H O
mark edly</w>
c ut
in d</w>
AT P
ex t
A n</w>
hypoten sion</w>
resul ting</w>
b a
m am
m ,</w>
rang e</w>
estr adi
dom in
- mediated</w>
block ed</w>
as e.</w>
diag nos
c ros
Wester n</w>
pop ul
vit ro
p u
do es</w>
ine ph
al ized</w>
a ff
wil d-
diag no
) )</w>
sec retion</w>
2 4
fic ation</w>
i f</w>
leuk emia</w>
c h</w>
man y</w>
di et
differenti ation</w>
be ing</w>
H D
) ;</w>
exhib ited</w>
mark ed</w>
tim es</w>
3 .</w>
w id
rel ative</w>
P re
mon o
enc e
R ,</w>
D O
S er
rec or
indic ating</w>
i od
ur ing</w>
fl av
oper ative</w>
le sions</w>
ur ia</w>
a si
I N
progres sion</w>
L D
random ized</w>
polymorph ism</w>
le v
doxorub icin</w>
reduc e</w>
G 2</w>
% ),</w>
relationshi p</w>
ynam ic</w>
5- F
inc ub
A h
i an</w>
O n</w>
withdraw al</w>
group ,</w>
gas tric</w>
R A</w>
trans plant
anc ed</w>
D P
z in
anal ge
G N
( p
respectivel y
p tion</w>
wei gh
ma in</w>
k al
it az
l and
d oc
conside red</w>
ster one</w>
G rou
gl itaz
H I
v s</w>
st atis
pres ented</w>
wild- type</w>
expres sion,</w>
y s.</w>
t s,</w>
2 00
M AP
sequ enc
Tw o</w>
9 ,</w>
lit ax
de oxy
al dehy
sec ond</w>
ad y
str ong
second ary</w>
in te
-1 ,</w>
i ble</w>
) -induced</w>
fibro bl
fact or-
8 0
si m
h ospit
h ex
model s</w>
d ul
vast atin</w>
fl ur
ke y</w>
comp on
neuron s</w>
resp ir
plat el
at ors</w>
ameth as
ocar cin
ce tin</w>
agon ist</w>
k ine</w>
dis rup
av ail
respon se
rat es</w>
super oxide</w>
is on
I )</w>
prolong ed</w>
comp an
cis platin</w>
C P
E n
r ing</w>
g lob
fam ily</w>
estro gen
anim al</w>
(2 +
om as</w>
th yro
respon sible</w>
ide .</w>
ograph y</w>
l ast
ch rom
anti- inflammatory</w>
m m</w>
abs ence</w>
pla ys</w>
O R
glut am
fu sion</w>
ass ess</w>
sp inal</w>
c lo
cat aly
PC R</w>
targ et
at or
1 B
te n</w>
on ucle
n al</w>
control s.</w>
al co
tam oxif
4 8</w>
p ite</w>
% ).</w>
o ur
malign ant</w>
rat s,</w>
ment .</w>
inflamm ation</w>
A K
oc or
it al</w>
Th ere
sign ed</w>
meas ure
he mat
5 )</w>
um ,</w>
hi z
ence phal
ac compan
ER K
2 7
lead ing</w>
c ad
ther ,</w>
ess ential</w>
der iv
del a
reduc t
. 0
week s.</w>
gl y
ye ar</w>
1 %</w>
identi fy</w>
adul t</w>
de press
protec tion</w>
gr an
im en
suscepti bility</w>
oca ine</w>
r ac
anc e.</w>
par ti
is h</w>
addi tional</w>
sur ger
1 7</w>
suppor t</w>
i es.</w>
h loro
fe at
B -
use ful</w>
P K
at ric</w>
an a
respectivel y,</w>
f at
3 0
le ad</w>
ine d.</w>
em br
contri but
prev en
de grad
initi al</w>
br ady
ap pea
therap y,</w>
ar th
(1 )</w>
x en
p il
pr an
properti es</w>
genotyp e</w>
azol e</w>
pathwa y.</w>
hyper troph
eth an
proc ess
prev ent</w>
t oc
pres ent
polymer ase</w>
o ,</w>
-2 -
impro vement</w>
war far
ne l</w>
ent an
enc od
complet ely</w>
ti s.</w>
en ing</w>
al ge
t ur
s ite</w>
a ver
E R</w>
N a
bu tion</w>
inhibitor ,</w>
mat ri
ta in</w>
w ell
C o
ag e,</w>
partic ul
fam il
T )</w>
On e</w>
le ar
compar ison</w>
1 9</w>
i ally</w>
sup ple
spec ific
o vari
o red</w>
ex tr
ures .</w>
eryth ro
inter fer
reg ion</w>
ol -induced</w>
end ogenous</w>
mot or</w>
it one
comp ound</w>
mis sion</w>
hum an
J N
individu als</w>
extrac ellular</w>
dep le
i. v
m ag
SI GN
ap plic
ment ation</w>
angiotens in</w>
u tion</w>
pac litax
ind ometh
ag land
an nel</w>
un d
ul ated</w>
cop per</w>
inv a
lin ked</w>
larg e</w>
interv al</w>
L C
saf ety</w>
or ing</w>
embr y
d ens
consist ent</w>
n .</w>
sc hiz
m m
rec over
ch annel</w>
cy ste
10 (-
s co
mil d</w>
ner v
cap sa
bi op
b o
sampl es</w>
kn ock
injec ted</w>
R .</w>
sup pression</w>
disor der</w>
Whe n</w>
at e.</w>
arrhyth mi
cyclo phosph
seiz ure</w>
phosph ate</w>
moder ate</w>
dys kine
orm one</w>
ne ut
in i
6 )</w>
diagno sis</w>
b -
art an</w>
r s
or der</w>
wat er</w>
di ff
( 7
am ycin</w>
m RNA
lig and
( i
s ),</w>
az ine</w>
col on</w>
quanti t
le ,</w>
re d.</w>
me mor
cle ar
phen y
i di
3 %</w>
er ing</w>
respir atory</w>
sc re
invol vement</w>
ffic i
4 )</w>
per sist
om a.</w>
parameter s</w>
duc tion</w>
B P</w>
spec tive</w>
post -
metabolit es</w>
le .</w>
it ing</w>
H g</w>
N O</w>
t y
accompan ied</w>
og en</w>
mel an
anal og
pil ocar
. )</w>
cour se</w>
o p</w>
lo l</w>
in de
cyt otoxicity</w>
o sis.</w>
h ormone</w>
ful ly</w>
2 %</w>
oti de</w>
amphet amine</w>
op o
There fore,</w>
oph ren
if e
l id
remain ed</w>
induc ing</w>
appear s</w>
A .</w>
hyper alge
correl ation</w>
transpor t</w>
rever sed</w>
hist ory</w>
am id
co -
ev ed</w>
st age</w>
O -
s or
m id
micro M</w>
hydrox yl
zin c</w>
th us</w>
p y
om ic</w>
he mor
COX -2</w>
E T
In c
mi x
de hydro
S .</w>
5- HT
syst olic</w>
( 50
synth ase</w>
ocyt es.</w>
mann er.</w>
f -
end ed</w>
li po
ser ot
che mical</w>
day s.</w>
l y.</w>
expres sing</w>
hemor rh
G -
syn erg
ar rest</w>
co gn
aly sis</w>
tub ul
over all</w>
administr ation.</w>
y cl
schiz ophren
ph yl
k g</w>
follow -
appea red</w>
re pa
aspir in</w>
mut ant</w>
dis c
C T
aff in
r f
adv anced</w>
si a.</w>
neuro log
su ffici
es tim
e -induced</w>
dex amethas
P R
(1 0</w>
cyto kin
bas al</w>
U sing</w>
ster oid</w>
iz e</w>
ri tis</w>
a ro
subsequ ent</w>
lithi um</w>
conduc ted</w>
h ic
p ent
fic ial</w>
cri tical</w>
RO S</w>
allel e</w>
ex ten
H y
ar ra
level s,</w>
mic e,</w>
di l
S im
E )</w>
behavi oral</w>
b er</w>
NF- kappaB</w>
s ep
defici ency</w>
prost agland
ner ve</w>
decreas es</w>
C S
ap er
man ag
fibr ill
b is
hor mon
com mon
str at
st ained</w>
com it
cor e</w>
G AB
i qu
dist ri
activ ation.</w>
a or
P U
catal ep
C N
E 2</w>
9 0</w>
b or
st ate</w>
Effec ts</w>
es pec
concl ude</w>
par tial</w>
b ol
t y-
medi ate</w>
ev ent
es tic
g ra
cont ent</w>
M ,</w>
% .</w>
zap ine</w>
w o
il tr
chlor ide</w>
re ac
li ght</w>
iz ing</w>
at eral</w>
del i
carb on</w>
C H
espec ially</w>
dow n</w>
che mic
b al
min ut
lit erat
am y
mark ers</w>
ep id
re tro
MC F-
- like</w>
peri od
or e</w>
n ess</w>
bil e</w>
a ther
3 5
fail ure.</w>
os cler
k s</w>
trans loc
I P
tub ular</w>
o gn
vol um
s in
effect .</w>
descri bed</w>
panc re
fluo resc
sever ity</w>
i. p.
mg/k g/
cut aneous</w>
(3 )</w>
pharmac o
di et</w>
B a
ty ros
prog ester
ot rex
individ ual</w>
hypothe sis</w>
ep is
pyr id
p3 8</w>
lin ical</w>
bl ock</w>
8 %</w>
def ec
R T-
x i
contr ast</w>
D NA
-1 )</w>
leu kin
remain s</w>
i ron</w>
partic ip
k ers</w>
ta king</w>
-1 -
re actions</w>
gr ade</w>
drug s.</w>
pro -
p en
ane ously</w>
transpor ter</w>
res h
hy dr
he ad
S M
He re,</w>
pro po
wid ely</w>
5 4
inhibit ing</w>
b ly</w>
i tive</w>
ex amine</w>
ot rop
coll ag
ob arb
phosph at
on e-
rap id</w>
wa y</w>
clin ically</w>
methyl -
b odi
de pres
G l
ocy tic</w>
adren ergic</w>
reduc es</w>
establ ished</w>
F or</w>
strat eg
end ome
rec ently</w>
quer cetin</w>
fr ag
effic i
er s,</w>
antagonist s</w>
Par kinson
li ver
2 O
min im
AC h
wo uld</w>
recept or-
infarc tion</w>
impa ired</w>
ad he
In hib
micro scop
a )</w>
repor ts</w>
ovari an</w>
ve hic
at rial</w>
tion s,</w>
path ogenesis</w>
metabol is
glomer ular</w>
cyt otoxic</w>
0.05 )</w>
R S
mi gr
oc l
li gh
re verse</w>
fibro sis</w>
stil l</w>
rec ogn
ann el
F )</w>
2 6
res ol
gran ul
t le</w>
al ine</w>
environ mental</w>
defici ent</w>
fr act
M T</w>
Grou p</w>
sub un
S e
transi ent</w>
pro pran
or s
vari ants</w>
epis od
am oun
micro som
estradi ol</w>
par t</w>
direc tly</w>
overex pression</w>
par t
reduc ing</w>
al b
stre am</w>
el ic
prote ren
pro mis
doxorub ic
strong ly</w>
fat ty</w>
dehydro gen
Hep G2</w>
ch annel
G en
ti zed</w>
glitaz one</w>
9 -
implic ated</w>
se d.</w>
inde x</w>
o v
n ife
tachy cardia</w>
in ic</w>
D C
B ec
reg i
chol est
warfar in</w>
b ri
5 7
um -
em ia.</w>
Ac ute</w>
cur ren
l am
o si
E -
n or
induc ible</w>
retin oic</w>
ozyg ous</w>
injur y.</w>
valu e</w>
respon sive</w>
depend ently</w>
nicot ine</w>
NO S</w>
ain s</w>
( 1</w>
poin t</w>
convul s
2 ).</w>
con trac
di ast
C I</w>
up on</w>
neuropath y</w>
all eng
NF- k
reduct ase</w>
produc e</w>
s oci
statis tically</w>
ing ly,</w>
diabet es</w>
t ech
amin ergic</w>
u su
tri gg
f le
e ts</w>
A R</w>
r ad
pre -
p iv
on -
oc ellular</w>
s et
high- dose</w>
0.0 00
under st
osom al</w>
sal ine</w>
tissu es</w>
nerv ous</w>
N rf
2 00</w>
(P <
mitochond ri
T ran
( n
oc ic
hyperten sion.</w>
ei ght</w>
4 0
mortal ity</w>
disc us
comple x
cis plat
sequ ence</w>
ob jec
typ es</w>
dos age</w>
obser ved.</w>
at ed,</w>
con comit
A H
II I</w>
pharmac ological</w>
m l
S R
posi tion</w>
cyt os
( 10
br on
U GT
termin al</w>
a ir
y oun
impair ment</w>
f entan
d ine</w>
tr ic
frequ ently</w>
alter n
2 ),</w>
t e</w>
st able</w>
experi enced</w>
8 )</w>
r it
evalu ation</w>
ob las
model .</w>
mi um</w>
e very</w>
character is
2 3
benz o
O f</w>
preven tion</w>
form s</w>
expos ure.</w>
c al</w>
Ak t</w>
S ,</w>
syndrome .</w>
per ox
ot or</w>
o ff
tak en</w>
man if
n al
im in
ch alleng
ris perid
ocor tico
inter leukin
def in
reg res
physi ological</w>
am iod
amiod ar
w ide</w>
sign al</w>
le -
bi ological</w>
L ,</w>
re sid
oid s</w>
h e</w>
f ed</w>
bi om
2 8</w>
meth otrex
AT I
t om
ineph rine</w>
co ag
E P
ur ac
quantit ative</w>
m ass</w>
7 0</w>
si zed</w>
(1 .
sensi tiz
au th
con stitu
SE :</w>
to war
sur fac
di d
agonist s</w>
sev en</w>
recover y</w>
bi ochemical</w>
as .</w>
E 1</w>
of ten</w>
oc ept
creat inine</w>
ch ro
stand ard</w>
if ied</w>
exc retion</w>
ho l</w>
death .</w>
nec ess
transf ected</w>
a qu
ar com
lab or
E GF
subst anti
rever sible</w>
e p</w>
e ff
mi str
B ,</w>
rec tal</w>
nephro path
tamoxif en</w>
caspase- 3</w>
b en
oph yl
o ked</w>
cogn itive</w>
TCD D</w>
viv o.</w>
aut o
platel et</w>
lin es.</w>
diast olic</w>
dis mut
concentr ation
ch ed</w>
blo t</w>
I S
D e
main ly</w>
n or</w>
regul atory</w>
p ren
m an</w>
prolifer ative</w>
regul ates</w>
dens ity</w>
cyto kine</w>
sign s</w>
l a
en .</w>
2 3</w>
memor y</w>
d n
vitro .</w>
ac a
volum e</w>
ro lim
re .</w>
ev id
loc al</w>
pop ulation</w>
M B
pharmaco kine
mechanis m
haloperid ol</w>
ud ed</w>
nit ros
bet ter</w>
am pl
(2) O
ome tr
wom an</w>
repor ter</w>
inter sti
P er
MCF- 7</w>
D R
adren ocept
abnormal ities</w>
th resh
c ou
yl -
val pro
al s,</w>
Q u
si der
og r
inter actions</w>
act ing</w>
adi p
es c
Bcl -2</w>
6 %</w>
ent ly,</w>
apopto sis,</w>
anc es</w>
RP O
PU RPO
profil e</w>
S i
R T
D D
ne w
s ex
azep ine</w>
C ,</w>
mark er</w>
r are</w>
descri be</w>
iso proteren
ap am
pot assi
oc on
r he
casp ase</w>
Ad di
vi r</w>
prostagland in</w>
l -
affin ity</w>
4 ,
cycl in</w>
Bec ause</w>
uc id
es s,</w>
am ine-induced</w>
te tr
im pac
block ade</w>
G )</w>
di g
ag e.</w>
toge ther,</w>
st abil
p ap
ac c
y me
pos ed</w>
PURPO SE:</w>
bl ast
rele vant</w>
h .</w>
ol ar</w>
deg ree</w>
trans form
assa ys</w>
sup pres
A T</w>
L i
prob ably</w>
h ap
B )</w>
met allo
cap ac
bl ot
metast atic</w>
r il
19 9
ul f
t ox
experim ents</w>
alb um
3 9
pl ant</w>
id es</w>
ex ist
cur cum
2 7</w>
on al</w>
de pression</w>
parti ally</w>
occ ur</w>
analy ses</w>
aldehy de</w>
M S
potenti ally</w>
epilep tic</w>
MM P-
complic ations</w>
ab normal</w>
month s.</w>
C d
ra m</w>
wor k</w>
U n
mar ro
hepat ocellular</w>
ri st
requ i
gas tro
metabol ite</w>
th ir
mod ynamic</w>
assa y.</w>
aper itone
phen ol</w>
en ,</w>
rec ip
cl ass</w>
CYP1A 1</w>
Ah R</w>
3 1</w>
maxim um</w>
know n.</w>
tyros ine</w>
progester one</w>
effec tiv
carb am
ograph ic</w>
fem al
cor tico
R 1</w>
00 0</w>
p ut
j unc
are a</w>
( 9
ep t</w>
D N
( K
spont aneous</w>
ati c
ag ed</w>
tri als</w>
pepti de</w>
intersti tial</w>
b asis</w>
vari ant</w>
manif est
condi tions</w>
al ap
pancre atic</w>
reg imen
h ,</w>
deriv ati
aut ophag
an emia</w>
anti psych
Parkinson 's</w>
aden ocarcin
V -
D uring</w>
bene ficial</w>
re li
ed ed</w>
7 %</w>
dop aminergic</w>
M .</w>
u ter
me tr
ni qu
di hydro
ocic ep
ische mic</w>
immuno hist
eli or
common ly</w>
protein ,</w>
pro gn
oxygen ase-
el ucid
biom ar
patter n</w>
otoxic ity.</w>
conf idence</w>
analy sis.</w>
revie w</w>
V )</w>
particul arly</w>
disorder s</w>
su stained</w>
al ter</w>
aden osine</w>
ad duc
S ub
gluc uron
ed ing</w>
it er
effect s,</w>
activ ator</w>
reg ar
ol -
an ,</w>
feat ures</w>
( 95%</w>
50 %</w>
se em
ic s</w>
regul ate</w>
L e
test o
an xi
diagnos ed</w>
grow th
d )</w>
con sum
vas cul
occur rence</w>
T ak
4 %</w>
-1 .
s ity</w>
p to
f ol</w>
I V</w>
lit tle</w>
cyste ine</w>
er b
co hor
O )</w>
outcom e</w>
dist inc
anc e,</w>
P L
0. 5</w>
o w
fail ed</w>
f etal</w>
as ed</w>
sit es</w>
mod ulation</w>
1 1
y )</w>
fi b
An ti
rap id
main ten
2 2</w>
treat ments</w>
continu ous</w>
A p
develop ing</w>
av age</w>
-2 ,</w>
vi ability</w>
suc cess
t ure</w>
re fract
ogene sis.</w>
anim als.</w>
as tro
al ization</w>
Effec t</w>
T GF-
0. 9
. 00
t el
ca ffe
) /
perc ent
at e-
s le
om otor</w>
degrad ation</w>
test s</w>
chol in
3 7</w>
an ese</w>
5 6
transpor ter
membr an
e red</w>
d on
rel ap
oche mistr
matri x</w>
drug .</w>
repa ir</w>
block ing</w>
1/ 2</w>
dist ur
al- time</w>
cult ure</w>
pea k</w>
exer cis
7 5</w>
iz ed,</w>
fe rence</w>
tw ice</w>
ser ious</w>
W ist
7 )</w>
te trac
s core</w>
tri but
func tion,</w>
H E
ol ig
dog s</w>
ap pe
am elior
H um
func tions</w>
= 0.0
up- regulation</w>
under go
convuls ant</w>
andro gen</w>
Th ree</w>
elev ation</w>
ec tion</w>
cor ding</w>
Tak en</w>
L /
re combin
there fore</w>
repe ated</w>
lim ited</w>
intr aperitone
impac t</w>
D 1</w>
4 .</w>
di min
P B
0.00 1).</w>
pregn anc
al le
acetyl chol
T C
sec re
opi oid</w>
diseas e,</w>
str ong</w>
regul ating</w>
ri pt
ri ght</w>
M y
neut roph
cor respon
ag ing</w>
activ ate</w>
ag e-
M RP
AI D
vis ual</w>
oxid ase</w>
ju g
impro ve</w>
lead s</w>
H IF
Ca (2+
si ze</w>
my c
high est</w>
achi eved</w>
S ince</w>
ud ine</w>
ob ut
progres sive</w>
che m
adju st
pro xim
o rectal</w>
microgram s/
i or</w>
al ity</w>
( 8
prev al
n s</w>
2. 5</w>
O R</w>
rel atively</w>
re comm
i o
mat er
amin o</w>
es s.</w>
3 2</w>
del e
ab dom
gly co
cytokin es</w>
trans l
abol ished</w>
K )</w>
hyp ox
gluc os
selec ted</w>
l ong</w>
initi ation</w>
lid ocaine</w>
l ,</w>
toler ance</w>
the tic</w>
devel op</w>
activ ating</w>
a im
2 8
(+ )</w>
es tive</w>
7 2</w>
l act
is ed</w>
anti bodi
wh ere</w>
fluoro urac
au tis
Inhib ition</w>
w ent</w>
carcin ogen
follow- up</w>
U T
M n
A MP
ede ma</w>
b rom
he par
gener al</w>
H L
system .</w>
frequ ent</w>
in si
sen s
ext ent</w>
C .</w>
fe w</w>
vir us</w>
A mon
p estic
lig and</w>
MAP K</w>
se d
paclitax el</w>
injec tions</w>
concomit ant</w>
7 ,
st aining</w>
fl ox
ari ly</w>
6 0
monit oring</w>
surfac e</w>
possi bly</w>
mon th</w>
is e</w>
2 6</w>
te en</w>
lab el
N- acetyl
BP A</w>
col orectal</w>
diet ary</w>
de ,</w>
M G
s .
random ly</w>
au g
refract ory</w>
pre dn
oxid ation</w>
azep am</w>
de gener
ather oscler
os in</w>
mainten ance</w>
6 5</w>
l ys
g a
e m</w>
doc um
mat ure</w>
enc ing</w>
se g
response .</w>
muc os
indometh acin</w>
ic ill
glomer ul
meth od</w>
tech niqu
end oc
SO D</w>
Amon g</w>
0.0 1).</w>
regi men</w>
proc ess</w>
Res veratrol</w>
50 0</w>
collag en</w>
at tribut
S P
or b
oph il
inte gr
avail able</w>
potassi um</w>
drug -
down- regulation</w>
d o</w>
d in
compar able</w>
D I
dexamethas one</w>
immun os
iti es.</w>
invol ving</w>
divid ed</w>
X R</w>
f as
double-bl ind</w>
cl es</w>
Tw ent
si mul
S N
s ince</w>
le sion
gluc ocortico
upreg ulation</w>
marro w</w>
un treated</w>
recei ve</w>
oplas tic</w>
o side</w>
manag ement</w>
aor tic</w>
enz yme
anti cancer</w>
applic ation</w>
S OD
c ed</w>
ana esthe
recombin ant</w>
r ic
g al
discontinu ation</w>
cl os
ment ed</w>
l eng
it ation</w>
carb on
am ine,</w>
Hum an</w>
g er</w>
thyro id</w>
pres cri
ethan ol</w>
damag e.</w>
organ ic</w>
ST AT
9 )</w>
7 0
me d
cell -
de signed</w>
ap pl
C linical</w>
os in
undergo ing</w>
under went</w>
objec tive</w>
en si
4 5</w>
nife dipine</w>
medic ation</w>
perox is
per fusion</w>
n g/m
l ic
F in
differenti al</w>
dela yed</w>
M -
H ere</w>
(-1 )</w>
tem por
on ce</w>
ver apam
en alap
II I
(2 .
gen e.</w>
all -
ri b
pro phyl
as ,</w>
h ome
In ter
propo fol</w>
h our</w>
wil l</w>
/ -
ul ative</w>
serot onin</w>
mam mal
f av
cir cul
b re
en al</w>
meth yl</w>
meth od
foc al</w>
3 5</w>
ex am
day )</w>
well -
vas odi
ific ation</w>
distri bution</w>
arra y</w>
tre at</w>
provid es</w>
ne on
ti l</w>
rhe um
3 6</w>
can did
at s</w>
( m
ox et
op r
neuro toxicity</w>
dehydrogen ase</w>
gen es,</w>
- activated</w>
regres sion</w>
n ine</w>
P E
I g
v inc
id om
des pite</w>
expres sions</w>
ren e</w>
proxim al</w>
ind ,</w>
ic ,</w>
er mal</w>
am e</w>
Sim il
mann er</w>
clear ance</w>
rec ent</w>
minut es</w>
ax is</w>
activ ation,</w>
throu gh
micro mol/
con jug
chang ed</w>
syn ap
ol amine</w>
Q T</w>
occur ring</w>
not ed</w>
da il
pre domin
micro g/
re fle
oplas mic</w>
flav on
spec tr
pro por
occur s</w>
enc es</w>
sti t
propran olol</w>
cyclophosph amide</w>
H i
sep ar
i a
anti hypertensive</w>
es sive</w>
VE GF</w>
L .</w>
re al-time</w>
pro ble
vari ety</w>
u tive</w>
lun g
con sider
to -
GS H</w>
chi atric</w>
aver age</w>
IL- 6</w>
placeb o-
enhanc es</w>
sen se</w>
dismut ase</w>
P M
l ec
ine ster
cl assi
pla yed</w>
gamma -
par kinson
otrop ic</w>
an ine</w>
opath y.</w>
post operative</w>
pa ren
fac il
N B
substr ate</w>
stand ing</w>
l uc
acid ,</w>
( ER
res veratro
appro ach</w>
nucle otide</w>
4 8
P revi
b ound</w>
ab in
U C
rat e,</w>
de .</w>
o in
cal c
us e.</w>
recur rent</w>
rapid ly</w>
Wist ar</w>
D .</w>
B y</w>
sel en
or ally</w>
defin ed</w>
cros s-
c ent
ant ,</w>
alph a,</w>
ac tin</w>
M I
anti depress
al one.</w>
es ophag
micro M)</w>
human s.</w>
ent am
% ;</w>
os por
es )</w>
e :</w>
TNF- alpha</w>
OBJECTIVE S:</w>
r in</w>
lam iv
inf iltr
drug -induced</w>
( mean</w>
ac r
HO -1</w>
u es</w>
adhe sion</w>
examin ation</w>
di ure
compoun d
pheny to
ol s</w>
labor atory</w>
inter ac
ob last
hippocamp al</w>
Z n
nat ural</w>
antagonist ,</w>
P P
rol es</w>
MD A</w>
s che
da ys
AI M
encod ing</w>
cholin ergic</w>
requ ir
re p
mag ne
k erat
sco res</w>
p .</w>
intr a
ab o
Ne uro
( 5</w>
peri od.</w>
i.v .</w>
vol un
main tained</w>
al k
ac coun
CYP2 A
-1 0
pur pose</w>
h el
Ex pression</w>
muc h</w>
maxim al</w>
lat er</w>
1 2-
inhib i
ch o
D 2</w>
vir al</w>
mer cur
distur b
dr in
C y
t able</w>
ER K</w>
proc ed
G 1</w>
mit ted</w>
con sec
CYP3A 4</w>
auth ors</w>
ar yl</w>
transloc ation</w>
di z
s w
diseas es</w>
re stric
med ical</w>
youn g</w>
migr ation</w>
complic ation</w>
T RA
em ia,</w>
a ph
toler ated</w>
las t</w>
func tion
s in</w>
olog ically</w>
distinc t</w>
B e
m ary</w>
appe ar</w>
ve di
5- fluorourac
tri glycer
toge ther</w>
dom ain</w>
con ven
chemo therapeutic</w>
enh ance</w>
er gen
Fin ally,</w>
pot ency</w>
prev ent
gen es.</w>
ec al</w>
capac ity</w>
assess ment</w>
lif e</w>
home ost
fr action</w>
carri ed</w>
am ine.</w>
perform ance</w>
at tac
A ),</w>
z ol
sel f-
p s</w>
neuro lep
in a</w>
r ho
phenotyp e</w>
epilep tic
smo oth</w>
agent s.</w>
acid s</w>
ab ine</w>
3 3
i es,</w>
as ts</w>
4 7
(n =
na use
m as
hepat ocytes</w>
el etal</w>
NP s</w>
yl )
ic ro
C X
effec tively</w>
od op
i ve</w>
hydro carbon</w>
le y</w>
infec tion</w>
hyperalge sia</w>
M et
po or</w>
cum ulative</w>
pro toc
m urine</w>
ac cording</w>
IL- 8</w>
9 %</w>
show s</w>
low ing</w>
d es</w>
cer tain</w>
glutam ate</w>
Im mun
( RO
vedi lol</w>
oxygen ase</w>
nucle us</w>
cor tical</w>
(2 -
side -
concl uded</w>
struct ural</w>
risperid one</w>
per me
ide -induced</w>
ev oked</w>
PI 3
5-F U</w>
ment ,</w>
k .</w>
ant .</w>
C ardi
l ine
( PA
g est
0. 6
C G
0. 8
stro ke</w>
rolim us</w>
ophyl line</w>
Tran s
identi fi
te x</w>
D ,</w>
C F
0. 5
dos e.</w>
cat ech
w ho
pressu re,</w>
lac k</w>
an other</w>
y :</w>
receptor s.</w>
c ann
10 -
( W
pre treated</w>
ent s.</w>
th ym
one -induced</w>
he mo
T P
si g
os ome</w>
cr iter
conver ting</w>
9 0
pathwa ys.</w>
P F
D es
inter val
protein .</w>
cor tis
tre m
ser ies</w>
piv aca
mol y
methotrex ate</w>
anesthe sia</w>
C u
C r
un known.</w>
capsa icin</w>
b ul
DE SIGN
ven ous</w>
ro d
behavi or</w>
In te
hist one</w>
10 0
mat ched</w>
p 2
fi el
p an
inter ven
abo ve</w>
Fur ther</w>
id s</w>
hypertroph y</w>
2 4-
produc ts</w>
arrhyth mic</w>
Res ul
- specific</w>
t a</w>
modi fied</w>
head ach
tumor s.</w>
stres s.</w>
affec ting</w>
M ),</w>
no rep
b ic
anti body</w>
e /
testo sterone</w>
inc id
alco hol</w>
alco h
3 00</w>
y s,</w>
ures ,</w>
persist ent</w>
neurolog ical</w>
hum ans</w>
gene sis</w>
X R
consec utive</w>
compar e</w>
comp eti
3 /
protein uria</w>
prev ents</w>
double-bl ind,</w>
deple tion</w>
b ,</w>
3 8
percent age</w>
down stream</w>
A 1</w>
in suffici
2 5-
n ul
altern ative</w>
ER I
ra ther</w>
jec tion</w>
el der
or ig
volun te
od ds</w>
ffe red</w>
rheum at
characteris tics</w>
m u
cult ures</w>
cor tex</w>
sur g
random ized,</w>
pa thetic</w>
p al
epith eli
7 7
contribut es</w>
ant s.</w>
T r
] ,</w>
seiz ures.</w>
re ly</w>
l otyp
enc e,</w>
b ar
amiodar one</w>
up- regulated</w>
In tr
flur ane</w>
ech ocardi
biop sy</w>
air way</w>
0.00 1)</w>
group s,</w>
CA M
( 100</w>
uc t
oly tic</w>
observ ations</w>
low- dose</w>
e al</w>
O r
lo ad
compon ent</w>
tum our</w>
ret ur
M R
diseas es.</w>
Th e
2 50</w>
un til</w>
psy chiatric</w>
melan oma</w>
ac erb
ect om
g entam
trans plant</w>
sim vastatin</w>
op re
DESIGN :</w>
unc lear
ti le</w>
lev odop
includ e</w>
S pr
om i
im id
catalep sy</w>
U D
A A</w>
v an
ut ed</w>
meth oxy
underst o
treat ing</w>
rec ru
Ch in
til ity</w>
seem s</w>
heal th</w>
al kal
ac qu
re fl
ne ed</w>
in tro
y si
surger y</w>
pre par
mammal ian</w>
cor rec
tri oxide</w>
s es.</w>
perc ent</w>
ha ving</w>
v om
incub ation</w>
be g
Thi r
tumor i
om ycin</w>
A m
studi ed.</w>
ische mia</w>
en sive</w>
da y,</w>
curcum in</w>
overex press
mam mary</w>
de n</w>
Ser um</w>
vinc rist
pilocar p
who m</w>
gr af
U V
Resul ts</w>
L N
rel ation</w>
om orph
prolifer ation,</w>
enc ies</w>
d ri
l ing</w>
appl ied</w>
promis ing</w>
hist opath
the m</w>
s qu
region s</w>
pen icill
o w</w>
em p
el imin
at ri
an o
ac ch
os yn
agg reg
s ligh
on ,</w>
ur ic</w>
pu t</w>
in take</w>
con cer
chemo therapy.</w>
2 9</w>
flu id</w>
H ER
C ol
C E
p ig
ma .</w>
Hy per
sche dul
investig ated.</w>
mit ogen
mi a.</w>
Nrf 2</w>
ocyt open
long er</w>
facil it
RT- PCR</w>
(- /-
ro x
import ance</w>
3 7
rest ingly,</w>
repor ted.</w>
ini b</w>
D aw
6 .</w>
subun it</w>
peroxis ome</w>
Ca 2
peroxid ation</w>
il e</w>
al ong</w>
T NF
R F
P las
4 5
rheumat oid</w>
id ity</w>
i.p. )</w>
myc in</w>
l ate</w>
H ]
toxic ity,</w>
literat ure</w>
ir ub
gen e,</w>
A F
steroid al</w>
fibrill ation</w>
endome trial</w>
tic ul
he moly
child ren
at ,</w>
A G
upreg ulated</w>
bu pivaca
anti tumor</w>
abs or
sing le-
it ary</w>
Spr ag
vehic le</w>
le th
P D</w>
- associated</w>
u e-
m T
S E</w>
acet ate</w>
investig ation</w>
genotyp es</w>
a -induced</w>
F ol
stri atal</w>
molecul es</w>
go od</w>
st -
si vely</w>
ear ch</w>
P ,</w>
thresh old</w>
targ ets</w>
condi tion
d en
U /
H T</w>
sh ock</w>
s ca
brady cardia</w>
2, 3,
recor ded</w>
JN K</w>
simul t
respectively ).</w>
benz ene</w>
Daw ley</w>
A b
0.0 1)</w>
develop mental</w>
curren tly</w>
typ ical</w>
ex acerb
d g
sin us</w>
ul tr
si a,</w>
on co
in toxic
cyt ometr
SI RT
enc e.</w>
el em
T ,</w>
ol ip
fol ate</w>
di p
al g
A /
pro spective</w>
conven tional</w>
aim ed</w>
prim arily</w>
in es</w>
antibodi es</w>
D A</w>
oph ysi
op tim
fluoresc ence</w>
c .
adju vant</w>
D is
( 4-
p as
cap top
ad ri
hospit al</w>
en rol
down regulation</w>
dis played</w>
pu bl
protec ts</w>
necess ary</w>
3 ).</w>
i ary</w>
estim ated</w>
correspon ding</w>
amoun t</w>
Ex pos
AM P</w>
b el
IF N-
prevent ing</w>
clo zapine</w>
thir d</w>
te d,</w>
indic ates</w>
com pl
M ).</w>
1 A</w>
struct ure</w>
spec tro
s '</w>
pa in.</w>
in a
h ere</w>
g em
continu ed</w>
clon idine</w>
ath ecal</w>
as al</w>
W hile</w>
N K
inf ected</w>
hypothe sized</w>
Inte restingly,</w>
re main</w>
all ,</w>
year s.</w>
preval ence</w>
inester ase</w>
candid ate</w>
block er</w>
- binding</w>
om en
loc omotor</w>
coll ected</w>
appro pri
pr on
amy cin
sy .</w>
protec t</w>
m ade</w>
inten sity</w>
( AT
u ally</w>
m ang
er ous</w>
di methyl
car r
adrenocept or</w>
W ith</w>
ro g
re present</w>
l ine,</w>
de generation</w>
andro gen
agg res
subjec ts.</w>
st er</w>
es tion</w>
o sis,</w>
CI ,</w>
stri at
modul ate</w>
h er</w>
level .</w>
tic s.</w>
possi bility</w>
ne i
ine- treated</w>
fi t</w>
cohor t</w>
7, 8-
episod es</w>
e osin
bron chi
test ing</w>
macroph ages</w>
hap lotyp
drin king</w>
ch arg
Com par
mg/ d
endoc rine</w>
A Z
analge sic</w>
[ a
ti s,</w>
nal ox
d yst
-1 .</w>
pres ents</w>
po ison
amid al</w>
y et</w>
synthe tic</w>
studi es.</w>
s o</w>
ro si
ic ity</w>
drug s,</w>
cat en
B R
1. 0
si ven
nul l</w>
n ed</w>
canc er,</w>
X -
ti li
gener ated</w>
b ur
ocyt es,</w>
gastro intestinal</w>
K /
re mo
mi gra
r hyth
os fam
fibrobl asts</w>
synerg istic</w>
rat .</w>
hypoten sive</w>
ac u
1. 5</w>
ca using</w>
all ergic</w>
4 3</w>
on es</w>
hepat otoxicity</w>
day s,</w>
ar rest
H )</w>
5 ).</w>
sh e</w>
ha em
time -dependent</w>
produc t</w>
el y,</w>
HB V</w>
E NT
tw o-
re plic
cycl ic</w>
cy sti
P PA
E E
0. 7
transplant ation</w>
st op
exercis e</w>
C A</w>
ne ural</w>
medi ates</w>
AT P</w>
Twent y-
pos s
medi um</w>
arrhythmi as</w>
opre ven
tion ally,</w>
through out</w>
find ing</w>
con sc
S ign
ve ,</w>
in formation</w>
sens ory</w>
in os
hyper pla
bac ter
O ver
sol ub
L R
kerat in
appa rent</w>
vi e
nephro toxicity</w>
0. 1</w>
we ak
Expos ure</w>
Des pite</w>
unclear .</w>
elic ited</w>
cal cul
1B 1</w>
con g
trans -
radi o
oc clu
he modynamic</w>
gener ally</w>
H ist
o ther
Se ver
D 3</w>
op ic</w>
epid ermal</w>
exc ept</w>
NF-k B</w>
F our</w>
5 .</w>
flu oxet
studi es,</w>
B .</w>
sligh tly</w>
poin t
patient 's</w>
ox yl
es :</w>
effectiv en
J ap
- 3</w>
towar d</w>
eff lu
caffe ine</w>
ar d
St ud
phosph ati
inf ants</w>
Ch ron
Q T
usu ally</w>
detec tion</w>
convul sions</w>
cl ar
ris e</w>
on ate</w>
ifer ase</w>
MT X</w>
I ,</w>
trans genic</w>
cardiomy opathy</w>
Sprag ue-
5 ,
ogr af
n an
chro mat
ch est</w>
anti gen</w>
Ad mini
us ers</w>
specific ally</w>
pla in</w>
if amp
cas es.</w>
ap yr
3 8</w>
3 6
( e
tr yp
r ab
B 1</w>
wh ose</w>
quin one</w>
iv al
S ),</w>
sle ep</w>
ill ary</w>
lo fen
car e</w>
l )</w>
arth ritis</w>
week s,</w>
re ticul
l ine.</w>
dr am
cel er
cad mium</w>
A C</w>
monit ored</w>
hist ological</w>
P -1</w>
- based</w>
phen omen
on .</w>
leng th</w>
k ,</w>
al do
Inc reased</w>
(I L
stres s,</w>
de d.</w>
P r
wh ite</w>
metallo protein
clin ic
analy sis,</w>
profil es</w>
or th
e f</w>
di ed</w>
consum ption</w>
blast oma</w>
arcom a</w>
Pre treatment</w>
sym pathetic</w>
sub stitu
mitogen -activated</w>
idom ide</w>
Plas ma</w>
tiv e,</w>
revie w
nei ther</w>
incub ated</w>
ent s,</w>
dimin ished</w>
et er</w>
deg re
at or-
a k</w>
Sprague- Dawley</w>
te tra
shor t</w>
k er</w>
cycl ospor
surg ical</w>
provid ed</w>
channel s</w>
I NT
spont aneously</w>
The y</w>
D ru
( II
spectr um</w>
malign anc
gu an
phosphat ase</w>
or ity</w>
cyt es</w>
P <
nephro tic</w>
asth ma</w>
phen obarb
I T
A P</w>
5-F U
mechan ical</w>
target ing</w>
ol an
mater nal</w>
ligand s</w>
g re
fe ren
carcin ogenesis</w>
M A</w>
I -
strateg y</w>
im aging</w>
erg y</w>
G C
(4 )</w>
z ot
immunos up
at onin</w>
amin oph
T RP
al most</w>
or ation</w>
is ,</w>
chem opreven
accum ul
hyper activity</w>
e y
duc ed</w>
ath ion
aminoph en</w>
M MP
molecul e</w>
Chron ic</w>
vari ation</w>
f atal</w>
3 ),</w>
path ophysi
knock down</w>
h and,</w>
ba vir
R ats</w>
un g
show ing</w>
path ological</w>
mg/m 2</w>
control .</w>
T B
electro cardi
c y</w>
rel ax
coun ter
cir rho
VE GF
E D
Admini str
b ic</w>
AC E</w>
(+ )-
( i.
pron oun
ph ot
m mol/
E i
Addi tionally,</w>
4 6
em ergen
affec ts</w>
UGT 1A
- -
al ve
th re
sca ven
er r
dys function.</w>
ac celer
M AT
sequenc es</w>
pilocar pine</w>
HIF -1
synap tic</w>
op l
thromb ocytopen
as signed</w>
O x
hom ozygous</w>
cataly tic</w>
car vedilol</w>
R enal</w>
fr ac
coca ine-
esophag eal</w>
coag ul
capsa ic
SH -
(A B
thal am
ob es
l ation</w>
diff er</w>
D el
5 %)</w>
scre ening</w>
ent er
ad ded</w>
EGF R</w>
produc tion.</w>
ocicep tive</w>
met al</w>
os yl
nephropath y</w>
l .</w>
inva sive</w>
g all
depend ence</w>
E D</w>
Ac tiv
activ ates</w>
A 54
ub iqu
(50 )</w>
prote as
chrom osome</w>
symptom s.</w>
n am
elder ly</w>
con st
appear ance</w>
saf e</w>
g raph
10 ,</w>
electro ph
A g
im medi
ev ent</w>
chemic als</w>
bene fit</w>
ant s,</w>
Rec ent</w>
tion -
process es</w>
hist amine</w>
enalap ril</w>
derivati ves</w>
carcin ogenic</w>
docum ented</w>
b ell
3 3</w>
0. 4
supple mentation</w>
minim al</w>
ine )</w>
cor d</w>
concentration -dependent</w>
sulf ate</w>
sk eletal</w>
f at</w>
con gen
c- J
(-/- )</w>
year s,</w>
ve si
electro n</w>
decreas ing</w>
[a ]
xen ograf
phosphoryl ated</w>
o tri
mi R
ul in</w>
P S
Com pared</w>
steroid s</w>
rest ored</w>
in activation</w>
hal oth
detec table</w>
CYP2 D
cardi otoxicity</w>
recip i
extrac t</w>
Previ ous</w>
G lu
mut ag
( 2</w>
s cler
prolifer ation.</w>
ma z
m im
exp lo
cle arly</w>
G L
radi ation</w>
patter ns</w>
low ering</w>
c et
G E
org an</w>
luc iferase</w>
enhanc ement</w>
adenocarcin oma</w>
C /
1 5-
stop p
di oxin</w>
E v
om e-
2 A</w>
- regulated</w>
(A D
d yl
confir m</w>
anth rac
ag ic</w>
C ell</w>
B i
A L</w>
under standing</w>
arsen ic
appropri ate</w>
subsequ ently</w>
P .</w>
M P</w>
symptom atic</w>
rab b
promot e</w>
per for
lipo protein</w>
in -1</w>
assa y,</w>
he me</w>
arth ri
headach e</w>
Ba x</w>
us t</w>
si RNA</w>
promot es</w>
expl ore</w>
exc it
effectiven ess</w>
dele tion</w>
condi tion</w>
am ,</w>
ri g
f ron
arrhyth mia</w>
f ore
cou pl
a sis.</w>
ON :</w>
N )</w>
thromb osis</w>
resist ance.</w>
anesthe tized</w>
ac ts</w>
star ting</w>
pronoun ced</w>
shor t
prol act
intr athecal</w>
down- regulated</w>
ant ly,</w>
ure a</w>
prolifer ator-
enc y.</w>
canc ers</w>
Di fferen
' ,
ne eded</w>
il lin
el ement</w>
di atric</w>
9 9
immun ore
fac ial</w>
suscepti ble</w>
metabolis m.</w>
cas es,</w>
( h
protein s.</w>
prof en</w>
cong estive</w>
A PA
there by</w>
benz odi
anti convulsant</w>
S p
NA S
NA DP
Chin ese</w>
expos ure,</w>
defec ts</w>
M ut
xen ob
v in
suppres s</w>
o ro
er -
demonstr ates</w>
attribut ed</w>
R eg
An g
Administr ation</w>
verapam il</w>
n ar
le dg
am ine-
un iqu
ochemistr y</w>
compon ents</w>
catal ase</w>
sub cutaneous</w>
sp as
protein s,</w>
lin es,</w>
iti es,</w>
hypox ia</w>
f il
concentr ations.</w>
w er</w>
ve ments</w>
u n</w>
ti az
ta il
end -
c DNA</w>
at ur
s al</w>
proliferator- activated</w>
con struc
understo od.</w>
th at,</w>
signific ance</w>
po or
fo od</w>
de qu
at es.</w>
MA P</w>
ad ol
N MDA</w>
ti dine</w>
pro posed</w>
develop ment.</w>
appro ach
E L
B lo
attenu ates</w>
inva sion</w>
y ;</w>
thi az
suppress or</w>
regul ator</w>
poin ts</w>
meas ures</w>
. g
phenyto in</w>
pathwa y,</w>
mechanis m.</w>
form ed</w>
der s</w>
cop per
sensi tiv
estro genic</w>
antipsych otic</w>
NF- kappa
4 2</w>
me to
equ al</w>
dos ing</w>
(2 0</w>
ys acch
produc es</w>
kin ases</w>
hi s</w>
Sever al</w>
5-fluorourac il</w>
the ophylline</w>
target ed</w>
er 's</w>
am ne
G P
Ar sen
4 00</w>
ve .</w>
myel oma</w>
month s,</w>
ex plain</w>
condi tions.</w>
hear ing</w>
all y.</w>
tre n
res er
rat e.</w>
long -
bec ame</w>
phosph olip
nitro glycer
meas ure</w>
fiel d</w>
T H</w>
ym ptom
pr ac
mg/ day</w>
meth amphetamine</w>
drug ,</w>
H .</w>
thou ght</w>
rad ical</w>
ph thal
embry onic</w>
arac h
S -induced</w>
refle x</w>
popul ation.</w>
isoproteren ol</w>
hloro di
re ach
r in
epilep sy</w>
ear li
Q O
mitochondri a</w>
an .</w>
ab und
P4 50
K ,</w>
i )</w>
autophag y</w>
Com bin
tachy cardi
present ing</w>
model s.</w>
d y
d obut
(p <
re mission</w>
r ifamp
n ex
flox acin</w>
encephal opathy</w>
col on
associ ations</w>
P ATI
-1 0</w>
z e
trans formation</w>
sp ir
iti s.</w>
en ic</w>
disorder s.</w>
4 /
as part
P ON
4 ).</w>
week ly</w>
receptor .</w>
k ill
re -
mechanism s.</w>
di ethyl
he at</w>
fo ur
CY P</w>
oc ular</w>
gen omic</w>
at a</w>
( 50</w>
lymph oma</w>
M E</w>
M 1</w>
su spec
potenti ated</w>
ed -
ang li
M ul
C or
neutroph il
know ledg
exhib it</w>
dos e,</w>
4 4</w>
im plant
en ia</w>
av oid
t oxin</w>
ma ,</w>
emp lo
ob struc
norep inephrine</w>
los artan</w>
id ation</w>
hy bri
adren aline</w>
[ 3
S cal
H L-
F GF
tempor al</w>
initi ated</w>
exp ected</w>
S Y
1 50</w>
ri bavir
respon siven
ic an</w>
neon atal</w>
tri al.</w>
sc ale</w>
h r</w>
atic ally</w>
PATI ENT
E ,</w>
yl ate</w>
si s-
op ol
expres s</w>
G ,</w>
protec ted</w>
v es
pr us
cle avage</w>
ar ,</w>
ac ro
( a</w>
v ag
shi ft</w>
olog y.</w>
mus cular</w>
inos it
discus sed.</w>
C ur
liver .</w>
exer t</w>
defic its</w>
ur ally</w>
raz ole</w>
observ ation</w>
circul ating</w>
b ir
at yp
E p
reduc tions</w>
onucle ar</w>
model ,</w>
f ying</w>
I P</w>
H P
lo we
insul in-
(M AP
rec ove
mem b
d yn
pol ar</w>
ve in</w>
implic ations</w>
exten sive</w>
ad mitted</w>
ultr as
trigg ered</w>
carcin omas</w>
a reas</w>
- derived</w>
t in
if osfam
form ation.</w>
apyr amidal</w>
I GF
Ca(2+ )</w>
un d</w>
ste re
pit u
o g</w>
am ide,</w>
receptor s,</w>
i az
ho w</w>
hippocamp us</w>
b )</w>
2 2
transcri pt
he im
ex clu
e ;</w>
competi tive</w>
ac tic</w>
AT RA</w>
stimul ating</w>
regar ding</w>
qu ine</w>
m M</w>
PPAR gamma</w>
N or
F 1</w>
Blo od</w>
predn isol
or i
differenti ated</w>
abil ity,</w>
S NPs</w>
degre es</w>
F L
3 4</w>
ro ten
exam ined.</w>
cl op
O H-
As 2O
tic s,</w>
respec t</w>
pro inflammatory</w>
lim iting</w>
in sic</w>
solub le</w>
res earch</w>
opol ysacch
M S</w>
( RA
trans mission</w>
placeb o.</w>
ocy to
no w</w>
suppress es</w>
p5 3-
differenti ally</w>
acet aminophen</w>
Al z
biomar kers</w>
bi osyn
C 1</w>
invol ves</w>
squ am
efflu x</w>
ser ved</w>
meth ad
injec tion.</w>
ch ym
bar ri
alter ation</w>
A54 9</w>
4 9
recogn ized</w>
opo i
o t</w>
lear ning</w>
ap omorph
S he</w>
phosphati dyl
factor s.</w>
coca ine-induced</w>
Sign ific
1. 0</w>
ret inal</w>
resol ved</w>
ne um
ex ogenous</w>
A A
u tili
per oxide</w>
on s</w>
mal es</w>
lat eral</w>
cr uc
behavi or
LP S</w>
Alz heim
z af
macroph age</w>
es ;</w>
c u
pp m</w>
M L
H )
CYP2C 9</w>
put ative</w>
endoth el
e -</w>
amin es</w>
MMP- 9</w>
( AC
re press
patient .</w>
interleukin -
detec t</w>
lamiv udine</w>
glob al</w>
dis co
administr ation,</w>
ab use</w>
R ),</w>
Ph armac
(RO S)</w>
top ical</w>
opath ic</w>
gener alized</w>
gem cit
block ers</w>
pressu re.</w>
me dul
immedi ately</w>
ide mi
dis charg
bil ateral</w>
ren in</w>
min ,</w>
ch el
I V
ros s</w>
ome tric</w>
h am
al anine</w>
ag es.</w>
ad ine</w>
On ly</w>
time ,</w>
t or</w>
hemorrh age</w>
enzym atic</w>
uniqu e</w>
su peri
prolong ation</w>
lo id</w>
hyperten sion,</w>
e tin</w>
ar ti
ab rog
ket amine</w>
da y.</w>
cere bell
adjust ed</w>
U NAS
UNAS SIGN
M eth
arter i
UNASSIGN E
UNASSIGNE D:</w>
ox im
myel oid</w>
model ing</w>
mm Hg
ant in
an ter
album in</w>
si c
mon ke
hydrox y-
fentan yl</w>
poor ly</w>
ocy cl
min or</w>
elucid ate</w>
alve olar</w>
recomm ended</w>
neuro blastoma</w>
m l</w>
glob in</w>
N R
le ph
cann abin
at en
Fol lowing</w>
5 3</w>
pre dis
MD A-
nitro prus
g angli
et ax
c re
op en</w>
me tic</w>
level ,</w>
alpha )</w>
prop yl
n -
n ,</w>
abil ity.</w>
A mer
A D</w>
respectiv ely</w>
p recur
op a
gli al</w>
c AMP</w>
ATP ase</w>
(2 )-
e ve</w>
control s,</w>
a emia</w>
M ost</w>
pro lol</w>
i bu
e .,</w>
app a</w>
PG E
se m
maj ority</w>
di azepam</w>
ad ap
R B
soci ation</w>
multi drug</w>
mix ed</w>
is ch
domin ant</w>
blo od
be st
-1 ,
per son
ol ine</w>
find ing
f oun
acid .</w>
( 0.0
ineph r
degener ative</w>
caten in</w>
myel ocytic</w>
u str
st a
squam ous</w>
bil iary</w>
L- DO
pro gram
in ated</w>
dil tiaz
acet am
retur ned</w>
prescri bed</w>
mm Hg</w>
ffic ul
benz o-
HC C</w>
C 57
i ste
i el
v enti
us al</w>
p um
micro array</w>
mg/kg ),</w>
dose- dependently</w>
disrup tion</w>
aspart ate</w>
alk yl
sign all
re ad
lymph ocytes</w>
it .</w>
in um</w>
di pyrid
cle ar</w>
cas e-
atyp ical</w>
agent ,</w>
abdom inal</w>
(O H)
i NOS</w>
gli oma</w>
estrogen s</w>
V PA</w>
Me an</w>
3 %)</w>
tac t</w>
smo king</w>
recur rence</w>
predic ted</w>
mel atonin</w>
determ ined.</w>
ch ic
wh ole</w>
on ia</w>
oly sis</w>
il ,</w>
s es
rati os</w>
PC B
PA )</w>
oblas tic</w>
E r
response ,</w>
oxi b</w>
ot er
f en</w>
e jection</w>
MAT ERI
ERK 1/2</w>
elec tr
B ased</w>
( 3</w>
signal ing.</w>
loc ated</w>
dipyrid am
tetra hydro
s. c
requi re
loc alization</w>
lip opolysacch
if y</w>
ex on</w>
eosin ophil
ab err
(I C
system s</w>
microsom es</w>
experi ence</w>
equ ival
at ure</w>
arsen ite</w>
ad dic
AL S</w>
rosi glitazone</w>
h aled</w>
epileptic us</w>
placebo- controlled</w>
hepat oma</w>
bol us</w>
antagon ized</w>
an -
promot ed</w>
intraven ously</w>
cr an
t ing.</w>
r as
p raz
me ans</w>
interfer on</w>
di fficul
-2 .
protein -
pro spec
micro g</w>
Pro te
P oly
us es</w>
ubiqu it
trac t</w>
sum mar
ha e
h ar
F .</w>
D a
challeng e</w>
tissu es.</w>
th reat
carbam azepine</w>
3 9</w>
um -induced</w>
ou ab
N G
transporter s</w>
intraperitone al</w>
ine /
impro ves</w>
damag e,</w>
ocon stric
leuk in</w>
larg ely</w>
dyskine sia</w>
auto immune</w>
( U
( CYP
ocy ste
li ver,</w>
carcin om
benzo- p-
ang ina</w>
12 0</w>
0.05 ),</w>
f et
allel es</w>
F ive</w>
C AT
t an
identi fication</w>
hydro gen</w>
he ad</w>
glucocortico id</w>
canc ers.</w>
atro ph
) :</w>
success fully</w>
indometh ac
selec tively</w>
man ner
bre ak
S ev
I N</w>
1 2.
- resistant</w>
recove red</w>
re ten
promot ing</w>
inc or
hyper sensitivity</w>
1 ;</w>
re presents</w>
interfer ing</w>
descri be
R ep
yc lo
sw it
mono therapy</w>
lo t</w>
glut athion
H e</w>
vitro ,</w>
vari ability</w>
phen yl</w>
new ly</w>
-2 )</w>
(3 )
propor tion</w>
oxi di
omer ase</w>
exer ts</w>
di am
cros s
S ur
N AT
t ab
ran ial</w>
bronchi al</w>
pro myelocytic</w>
period ,</w>
bupivaca ine</w>
out put</w>
l d</w>
di an</w>
[3 H]
E .</w>
ve d,</w>
refl ec
olog y,</w>
mid azol
interv als</w>
ine mia</w>
contri bution</w>
LN Ca
C M
schizophren ia</w>
ro ut
neuro protective</w>
ec tin</w>
character istic</w>
y iel
produc ing</w>
cyclo oxygenase-
ac ross</w>
B /
v ect
surger y.</w>
superi or</w>
pregnanc y</w>
mo l</w>
leth al</w>
h all
fail ure,</w>
endoth eli
anti arrhythmic</w>
M ale</w>
D F
de acetyl
at tem
endome tri
se .</w>
id ate</w>
arg inine</w>
a rom
T S
E X
ACh E</w>
2,3, 7,8-
1 1.
t /
ge l</w>
dyskine si
ER alpha</w>
A 2</w>
5 '-
vast at
t )</w>
st ain
s ph
paclitax el
oxid ant</w>
mul tic
min .</w>
l ut
end ing</w>
bene f
H ,</w>
st ability</w>
men ing
t ors
sion al</w>
se ud
oblast oma</w>
incor por
in hal
i b
am lo
ad renal</w>
T N
( group</w>
smo k
measure ments</w>
hyp oxi
criter ia</w>
C57 B
An alysis</w>
vari abl
receptor ,</w>
in tact</w>
discontinu ed</w>
al azine</w>
NS AID
Bcl -
tum our
ma x
enrol led</w>
cess ation</w>
H R
ox al
co d
c-J un</w>
se ve
pres sive</w>
ome- wide</w>
fir st-
a /
I .</w>
4 1</w>
v ation</w>
pre mature</w>
neurolog ic</w>
mg )</w>
le sion</w>
ep inephrine</w>
der mal</w>
cruc ial</w>
4 ),</w>
short -term</w>
s or</w>
hepat ocyte</w>
epi genetic</w>
deter i
depres sive</w>
t ex
rest ing</w>
pharmacokine tic</w>
norm ot
inflamm ation.</w>
e dr
do x</w>
analge sia</w>
5 9
ve red</w>
transf ection</w>
t as
rad ic
h )</w>
C ac
place ment</w>
iz ation.</w>
P O
A S</w>
spec imen
coupl ed</w>
acetylchol ine</w>
L O
D S)</w>
0. 2</w>
ti es</w>
og ram</w>
heter ozygous</w>
f uro
sensitiz ation</w>
las tic</w>
inhibitor s,</w>
fer red</w>
quer cet
qu es
o in</w>
larg er</w>
ad d
GAB A
tem per
partic ular</w>
me d.</w>
ul t
ste at
predomin antly</w>
evalu ated.</w>
wor sen
kin as
h und
extr apyramidal</w>
Arsen ic</w>
sal t</w>
regimen s</w>
pheny leph
pa rox
en ergy</w>
carri ers</w>
bin d</w>
D ec
5 5</w>
yl chol
st ages</w>
sc al
responsiven ess</w>
conduc tion</w>
biosyn the
SN P</w>
0. 3</w>
star ted</w>
off sp
mg ,</w>
inhibitor s.</w>
d u
bra in.</w>
8 .</w>
(3 .
p neum
glyco protein</w>
(i )</w>
ynam ics</w>
sion s.</w>
pres er
it ro
Jap anese</w>
F e
neuron s.</w>
mus car
cere bro
LD L</w>
F or
As (2)O
n M</w>
morph ological</w>
m atic</w>
knock out</w>
in n
stimul ate</w>
so ur
pa in,</w>
mus t</w>
control ,</w>
agonist ,</w>
men opa
stre pto
kine tic</w>
fron tal</w>
am mon
al one,</w>
F ,</w>
micro g/m
d ors
tub er
se x</w>
s low</w>
re produc
li qu
Rec ently,</w>
B M
usu al</w>
thal idomide</w>
re dox</w>
hlorodi benzo-p-
I GF-
CS F</w>
dic lofen
ca th
4 '-
pr amine</w>
ar ly,</w>
L ong
system ,</w>
substr ates</w>
pro m
modul ates</w>
inter leukin</w>
Ch ang
tissu e.</w>
test .</w>
si z
ho od</w>
cytos olic</w>
cyt e</w>
analy z
al low
agent .</w>
ac tion.</w>
1 3.
viv o,</w>
predic t</w>
mercur y</w>
magne si
last ing</w>
hydro ly
doc etax
GAB A</w>
repor t.</w>
outcom es</w>
modi fication</w>
af ter
SY 5
up per</w>
ul cer
s per
rou s</w>
hemoly tic</w>
effect ,</w>
ble eding</w>
4 7</w>
pilocarp ine-induced</w>
m s.</w>
infu sion.</w>
hepar in</w>
am .</w>
absor ption</w>
w arr
ste ad
RT- PC
HL- 60</w>
H yp
F K
2 %)</w>
um erous</w>
reve al</w>
pe diatric</w>
in ning</w>
character ize</w>
ar m</w>
T 1</w>
HC T
zot oc
w all</w>
NA D
vas oconstric
u tri
thi azol
s atur
lat ter</w>
l ess
il i
congen ital</w>
V D
1 %)</w>
remain ing</w>
physi cal</w>
lowe red</w>
diagnos tic</w>
6 6
subjec ted</w>
mag nit
injur y,</w>
dos es.</w>
chemopreven tive</w>
perme ability</w>
parkinson ian</w>
oc ript
activ ities.</w>
(M T
( 3-
ter ms</w>
sam ple</w>
inhibi tion.</w>
f low
exist ing</w>
TRP V
CD K
dou ble</w>
SIRT 1</w>
In duction</w>
suffici ent</w>
rang e,</w>
mor b
modul ating</w>
hydroxyl ase</w>
dic hloro
clos ely</w>
migra ine</w>
inosit ol</w>
ul monary</w>
trans duction</w>
mucos al</w>
mem ber</w>
captop ril</w>
bal ance</w>
adduc ts</w>
K 56
0.0 5</w>
us ed.</w>
disorder .</w>
angiotens in-
Stud y</w>
= 0.00
rever sal</w>
op res
o- 2</w>
iz es</w>
th ic
sul ph
sil encing</w>
serot on
loc alized</w>
arom atic</w>
suspec ted</w>
sex ual</w>
l ot
in )</w>
g ain</w>
(C OX
signal -regulated</w>
re mark
peroxid ase</w>
fluoxet ine</w>
evid ent</w>
coag ulation</w>
B r
B D
A ).</w>
op yr
my ocl
down regulated</w>
C ar
retro spective</w>
ml /
ha z
expl ained</w>
de m
ST R
O ther</w>
HS P
te ste
pharmacokine tics</w>
ic -
homeost asis</w>
fibrobl ast
em bol
complex es</w>
L V</w>
20 %</w>
( c
su d
open -
medic ations</w>
medi ating</w>
lact ate</w>
suc cin
stro k
o m</w>
attem p
alle l</w>
agent s,</w>
AK R
sol ution</w>
s on</w>
mut ated</w>
kg )</w>
k g/
f ung
deriv ative</w>
alle vi
W T</w>
signall ing</w>
predic tive</w>
muscar inic</w>
b eli
amino transferase</w>
2 B
0 /
towar ds</w>
su ff
ME NT
C s
hund red</w>
h r
chang es.</w>
CYP2 E1</w>
os tic</w>
lat ency</w>
dist al</w>
S- transferase</w>
mi a,</w>
lip id
electroph ore
bi polar</w>
attenu ate</w>
anxi ety</w>
F rom</w>
5 2</w>
threat ening</w>
therap ies</w>
subst ance</w>
pul se</w>
le uc
effici ent</w>
constitu tive</w>
anter ior</w>
accoun t</w>
a ud
C C</w>
AP -1</w>
7 %)</w>
-2 ,
ol e-
n one</w>
n asal</w>
mon onuclear</w>
ison iaz
earli er</w>
children .</w>
ar ing</w>
acqu ired</w>
F A</w>
Activ ation</w>
weigh t,</w>
syndrome ,</w>
r as</w>
properti es.</w>
normal ized</w>
menopa usal</w>
mT OR</w>
kg (-1)</w>
D ata</w>
19 8
s ha
recru it
pregn ant</w>
par t,</w>
inf used</w>
elec tive</w>
bet a,</w>
al oxif
S uc
vasodi lat
sig n</w>
produc tion,</w>
i le
hyperpla sia</w>
der m
cor d
cont amin
aggres sive</w>
V K
MC F
Alzheim er's</w>
par aqu
en ed</w>
dobut amine</w>
al ol</w>
S S
deoxy chol
St udi
Sev ere</w>
P 1</w>
(O R</w>
respec tive</w>
dequ ate</w>
an ol</w>
sit u</w>
prol actin</w>
i dis
T .</w>
C d</w>
cholest atic</w>
(3 0</w>
olog ous</w>
nalox one</w>
metast asis</w>
e ),</w>
adol esc
a e</w>
] -
TI ON:</w>
S yn
PG E2</w>
Ar g
prop ion
et opo
co bal
L- NA
on dro
hal f-
arc h</w>
P 2
Over all,</w>
Cac o-2</w>
Ca2 +</w>
ul c
s ].</w>
hal f</w>
ati tis</w>
H ear
D ox
pre feren
one ph
om al</w>
gentam icin</w>
del ta</w>
cor tex
M K
50 ,</w>
enhanc ing</w>
carcin oma.</w>
antipsych o
U S
Simil ar</w>
F as
gen iste
factor s,</w>
comple ted</w>
9 5</w>
3 '-
transplant ation.</w>
respon ses.</w>
R el
Immun o
EC G</w>
valpro ate</w>
opl atin</w>
carcin ogenesis.</w>
anti gen
AC T</w>
v al</w>
sec ret
fi x
dors al</w>
cyt oplasmic</w>
U -
N ot
s plic
pol ar
po d
k ind
it ory</w>
femal es</w>
depress ed</w>
am ide.</w>
CA 1</w>
20 -
yl ated</w>
p ic
ocardi al</w>
g p</w>
chym al</w>
ce f
F if
17 beta-
(N S
sm all
s ou
memb ers</w>
lif e-
est er</w>
em erg
stimul ates</w>
organ o
n mol/
kine tics</w>
infiltr ation</w>
il .</w>
beta 1</w>
j a
incl u
id en
dog s.</w>
R et
in haled</w>
conver sion</w>
consist ed</w>
cap able</w>
canc er
ab le.</w>
X )</w>
tic ,</w>
intr insic</w>
hypo kal
D op
5- az
3 A</w>
10 %</w>
t or
penicill amine</w>
ocy te
ocl opr
numb ers</w>
l yc
fibrobl ast</w>
dec line</w>
cr yst
ch ing</w>
H F
Cy t
CD 4
4 %)</w>
(1 -
se mi
microscop y</w>
influ enced</w>
clop id
Qu er
Ph en
N P</w>
5 ),</w>
toler ability</w>
tac rolimus</w>
requir ing</w>
rap amycin</w>
publ ished</w>
pro- inflammatory</w>
nause a</w>
death ,</w>
case- control</w>
C T</w>
re d,</w>
p 21</w>
neut rop
l up
iso forms</w>
aug mented</w>
Ap opto
5 1</w>
( r</w>
ver s
p sor
iz ation,</w>
it s.</w>
is su
control le
b cl
S L
ti d</w>
ni acin</w>
is m.</w>
hour s.</w>
SY5 Y</w>
1A 1</w>
t on
spectro metr
otoxic ity,</w>
is he
ce phal
M it
metabol izing</w>
convul sive</w>
compound s.</w>
adi pose</w>
O P
N I
vincrist ine</w>
par allel</w>
exc ess</w>
a ir</w>
P XR</w>
vie w</w>
op tic</w>
mo tion</w>
metabolis m,</w>
liqu id</w>
invol ve</w>
hom ocyste
f all</w>
) ).</w>
str ain
ret ard
region al</w>
pitu itary</w>
exc re
e ).</w>
anti bio
DNA -
tiv ari
st en
loc us</w>
N QO
II ,</w>
B ax
transform ing</w>
thromb o
ograph y.</w>
initi ally</w>
apopto sis-
amoun ts</w>
aldo sterone</w>
E uro
BP )</w>
9 8
) ),</w>
( EC
trem or</w>
ogene sis,</w>
neurolep tic</w>
hemorrh agic</w>
doxorubic in-induced</w>
CAM -1</w>
volunte ers</w>
prophyl axis</w>
prac tic
intrac ere
fav or
ev er</w>
entr al</w>
cy st
Studi es</w>
Signific ant</w>
2 ;</w>
-1 ),</w>
( s)</w>
v ar
th o
specific ity</w>
mes sen
consc ious</w>
Chang es</w>
( r
us e,</w>
str ains</w>
progn ostic</w>
intrac ranial</w>
growth .</w>
establ ish</w>
W il
UV EC
N- terminal</w>
AT O</w>
surviv al.</w>
substanti al</w>
requi res</w>
pur ified</w>
bil irub
Si x</w>
EL IS
A Q
(e .g
(M D
s es,</w>
k el
in dependently</w>
cal cit
bor n</w>
angi ogenesis</w>
CI :</w>
pto m</w>
ol der</w>
occ u
mod e</w>
describe d.</w>
anim als,</w>
ut ure</w>
respon ded</w>
res on
magnit ude</w>
epid ural</w>
bacter ial</w>
P- rib
O P</w>
N either</w>
G ene</w>
1 0.
(- )-
increas ed.</w>
days )</w>
G R
CYP1A 2</w>
ribavir in</w>
pro min
op ril</w>
di ox
alph a.</w>
add res
ATP 7
un known</w>
un changed</w>
symptom s,</w>
prednisol one</w>
mix ture</w>
ful l</w>
enc y,</w>
em at
di hydroxy
+ )</w>
strepto zotoc
prec ip
ne oplastic</w>
microsom al</w>
kin in</w>
ent er</w>
con nec
calcul ated</w>
par tly</w>
p on
i .</w>
he av
at e-induced</w>
as best
7 .</w>
sul ind
success ful</w>
beg inning</w>
atten tion</w>
H (2)O
ur g
t ent</w>
medi a</w>
loc i</w>
infarc tion.</w>
cycl es</w>
amino phen
Hi gh</w>
6 %)</w>
tuber cul
thromb in</w>
sequenc ing</w>
par allel
olan zapine</w>
meth ion
meas uring</w>
i asis</w>
hlorodibenzo-p- dioxin</w>
g ab
biop si
bel ow</w>
barri er</w>
S B
RNA s</w>
PT E
E lec
Cardi ac</w>
C57B L/
1 2,</w>
we ak</w>
sol id</w>
qu ality</w>
6 7</w>
(G SH
s ar
occu pati
normot ensive</w>
neph ritis</w>
manner ,</w>
l an
k age</w>
deli very</w>
M icro
K 1</w>
Con tro
t ended</w>
hybri diz
cross over</w>
ch ondro
autis m</w>
adul ts</w>
st rom
brom ocript
6 00</w>
3 0%</w>
underst and</w>
po i
optim al</w>
ol ec
ol ar
n et
ide -
hel p</w>
g )</w>
f iltr
ess el
Scal e</w>
scop ol
reach ed</w>
cysti tis</w>
co ding</w>
assa ys.</w>
W ith
METHOD S</w>
transform ed</w>
resol ution</w>
resid ues</w>
rele v
pestic ides</w>
on ectin</w>
min )</w>
ing estion</w>
amin o-
N i
LNCa P</w>
) ]</w>
year s)</w>
statis tical</w>
st om
plac ental</w>
p H</w>
inf er
as cor
v essel
exc essive</w>
ci pro
brady cardi
bac k
ation -
transi tion</w>
tr act
op recip
inflamm ation,</w>
fas hi
adv ant
5 4</w>
pren atal</w>
method s</w>
cy s
T A
ter at
t end
requir e</w>
pro ved</w>
enzym es,</w>
em ph
carb oplatin</w>
STR ACT</w>
particip ants</w>
os ensi
o il</w>
m ine</w>
immun ob
en s</w>
di arr
carr ying</w>
block s</w>
bec ome</w>
addi tive</w>
2 A
so ,</w>
ar tic
Ex perim
reticul um</w>
literat ure.</w>
adri amycin</w>
UN CAT
TR UNCAT
Compar ison</w>
2,3,7,8- tetrac
1 4.
(AB STRACT</w>
gen otoxic</w>
concentr ations,</w>
W OR
Si x
O S</w>
ther n</w>
reson ance</w>
rang ing</w>
manifest ations</w>
lat er,</w>
7 8
scop olamine</w>
opoi etic</w>
om al
no v
compar ing</w>
A fr
z ym
ur ia,</w>
toxic ities</w>
se em</w>
s acr
neuro degenerative</w>
medul l
i. p.</w>
S K
9 .</w>
re l</w>
modul ated</w>
ic ardi
am ate</w>
H D</w>
GS T</w>
5 8
st ly</w>
reac tion.</w>
mo graph
h lor
condi tions,</w>
af en
WOR DS)</w>
TRUNCAT ED</w>
A z
tra um
thrombocytopen ia</w>
summar y,</w>
scaven g
respectively )</w>
py rene</w>
poly phen
neuropath y.</w>
methyl transferase</w>
cortis ol</w>
b us
C 3
vari able</w>
tr uct
sed ation</w>
par acetam
n atal</w>
complic ated</w>
anti- apoptotic</w>
H 2O
se ,</w>
microgram s</w>
ing ly</w>
at er
(- )</w>
ne oplas
ig n</w>
i br
follow- up
de tox
at es,</w>
HI V</w>
CYP 1B1</w>
2 '-
v ical</w>
p2 1
neutroph il</w>
kidne ys</w>
de sign
ac y</w>
M MA
( 5-
omy cin
mang anese</w>
anti epileptic</w>
angi ogenic</w>
SE T
PK C</w>
lu te
ar -
Mn SOD</w>
Hi gh
E 2
6 ).</w>
proc ess.</w>
plac ed</w>
methad one</w>
measure ment</w>
measure d.</w>
fibro sis.</w>
chrom atin</w>
bind s</w>
valpro ic</w>
thromb otic</w>
meto prolol</w>
magnesi um</w>
frag mentation</w>
dram atically</w>
correl ate</w>
antidepress ant</w>
anti proliferative</w>
Li ver</w>
4 00
str ain</w>
quin ol
os arcoma</w>
haloperid ol-induced</w>
T ri
Simil arly,</w>
SH- SY5Y</w>
AIM S:</w>
uc in
respon d</w>
in- treated</w>
ar ide</w>
ap lastic</w>
C ell
- negative</w>
hepat ocarcin
con sequences</w>
S ome</w>
S D
P ost
M C</w>
LP S-induced</w>
upreg ul
ste p</w>
protoc ol</w>
cyclooxygenase- 2</w>
N- methyl-
L 1</w>
C P</w>
1 3-
(A L
under g
ris ks</w>
relap se</w>
inter mediate</w>
insuffici ency</w>
deli ri
condition ed</w>
bis phenol</w>
anesthe tic</w>
S ).</w>
F lu
- independent</w>
we ster
stit uted</w>
seg ment</w>
orub icin</w>
ocy an
mg/kg/ day</w>
e f
ac etic</w>
D ex
4 50</w>
tumor s,</w>
pro t
gen e-
S m
vom iting</w>
separ ate</w>
inter ference</w>
gu ine
cholest asis</w>
abdom y
T R</w>
5 9</w>
, 000</w>
tran s</w>
rele as
neuro toxic</w>
la y
equival ent</w>
PPA R-
mes oth
ir rit
heav y</w>
group s:</w>
4 9</w>
z inc
pol lut
p seud
ol i
non steroidal</w>
modi fy</w>
messen ger</w>
l um
amin onucle
tion ally</w>
ris k.</w>
ozyg ot
mRNA ,</w>
kin ase-
he modi
diure tic</w>
combin ations</w>
Thir ty-
MATERI ALS</w>
under taken</w>
sen esc
seiz ures,</w>
oc ca
frequ encies</w>
descri b
const ant</w>
ampl it
I d
HL A-
E C</w>
As2O 3</w>
5 /
(G ST
re si
pro maz
perfor med.</w>
hydro chloride</w>
ell it
cl ose</w>
chloro thiaz
az athi
anti coagul
a wa
PA -induced</w>
vas opres
tubul e</w>
s light</w>
overexpress ing</w>
methyl ated</w>
ing u
in dex
f el
evid enced</w>
eti ology</w>
ation )</w>
M ed
7 3</w>
0.00 1),</w>
ve -
ul fir
ne u
VK OR
T LR
N ic
yl ation</w>
side- effects</w>
ret te</w>
patient ,</w>
or din
i odi
explo red</w>
bac k</w>
W n
C l</w>
phenobarb ital</w>
period s</w>
n im
ment s.</w>
emergen cy</w>
carcin ogen</w>
b est</w>
attenu ation</w>
anal og</w>
U r
Gen etic</w>
EE G</w>
wester n</w>
nitroglycer in</w>
idi opathic</w>
famil ies</w>
0. 4</w>
0 )</w>
( a
point es</w>
p uro
n umerous</w>
medi ators</w>
ke l</w>
differenti ation.</w>
con current</w>
amin og
NS CL
Further ,</w>
ymptom atic</w>
y -induced</w>
im i
haplotyp e</w>
gen ome-wide</w>
g on
T S</w>
CN S</w>
(T CD
reten tion</w>
kg (-1
ine d,</w>
event s.</w>
amphet amine-induced</w>
H M
wa ys</w>
time -
t aining</w>
progn osis</w>
pr inc
ous ly,</w>
fol lic
catech ol
N H
psych otic</w>
mes en
mal on
gen it
defec t</w>
c ic
H a
un dic
suppress ing</w>
mRNA .</w>
end oplasmic</w>
b ine</w>
S T</w>
D B
tren d</w>
r al</w>
pres um
placeb o,</w>
lo ad</w>
le g
epitheli um</w>
cur ve</w>
clo zap
ap o
and s</w>
H N
0.0 1),</w>
uter ine</w>
trans amin
time .</w>
strateg ies</w>
ro tid</w>
pre ad</w>
ob vi
ob ese</w>
hy pe
can not</w>
a ox
Mul ti
MT T</w>
enzym es.</w>
L Y
syndro m
hepat ocytes.</w>
growth ,</w>
fe wer</w>
di aph
amlo dipine</w>
acro le
He L
C ),</w>
6 3</w>
4 6</w>
rever si
o edema</w>
immun oprecip
deoxychol ic</w>
character ization</w>
Hear t</w>
5- HT</w>
( rs
sur ve
hydroxyl ation</w>
histopath ological</w>
blot ting</w>
He pati
val ent</w>
there fore,</w>
over -
m ellit
kg -1</w>
id ov
gl and</w>
filtr ation</w>
alkal ine</w>
T- cell</w>
1 5.
te d
lid oca
ion s</w>
heter ogene
hemo globin</w>
as p
analy sed</w>
(2+ )</w>
up stream</w>
levodop a</w>
SU RE
BACKGROUN D</w>
AIM :</w>
8 %)</w>
6 9
0 %)</w>
poss ess
per itone
intr am
emplo yed</w>
avail ability</w>
NADP H</w>
METHOD :</w>
3 0-
wor kers</w>
v acu
te z
t ors</w>
sud den</w>
control ling</w>
E lev
7 8</w>
sym ptom</w>
simil ar
sid es</w>
sal ic
of -
nit r
iden tical</w>
hyper glyc
haloth ane</w>
dose- response</w>
STAT 3</w>
r aloxif
os pas
interven tion</w>
diltiaz em</w>
b .</w>
al in</w>
P N
O V
ME A
An im
ur ia.</w>
sub -
plas tic</w>
om a,</w>
m ing</w>
it sel
i.v .)</w>
hypo thalam
great ly</w>
fl uc
di men
atro pine</w>
CYP2 B
substanti ally</w>
posi tively</w>
pan ic</w>
at ax
V al
MEA SURE
A -induced</w>
ure -
tiv ely,</w>
sub set</w>
p <
graf t</w>
S pec
M N
st ep
s kin
psych osis</w>
aro mat
O H
transcrip t</w>
specimen s</w>
sacr ific
hormon al</w>
gene sis.</w>
S yst
P -induced</w>
C ap
-2 .</w>
popul ations</w>
physi ologic</w>
line ar</w>
leuk emic</w>
label ing</w>
label ed</w>
cytometr y</w>
RA R
L ),</w>
y o
ser ine</w>
res .</w>
modi fic
micro M,</w>
mRNA s</w>
junc tion</w>
ith ro
gene tically</w>
gemcit abine</w>
avoid ance</w>
MD R1</w>
M I</w>
I ts</w>
Ad verse</w>
th em
dos es,</w>
cer vical</w>
ass es
alter s</w>
acid -induced</w>
acet aminophen
C hi
C al
4 0%</w>
p. o
om ers</w>
met oclopr
mac ro
induc tion.</w>
erythro poi
com mun
ca re
ast ing</w>
C yp
34 4</w>
(P D
( range</w>
val id
re mia</w>
re activity</w>
r ag
precip it
ifosfam ide</w>
demonstr ating</w>
cardiomy opathy.</w>
SET TI
I L</w>
4, 5-
w ise</w>
thresh ol
hypoten sion.</w>
he re
ci ga
anc er</w>
O 2</w>
(2) )</w>
x anth
we l</w>
small er</w>
re placement</w>
pre lim
k D
h ed</w>
chloro quine</w>
cataly zed</w>
ath yro
antioxid ants</w>
M echan
AH R</w>
striat um</w>
shor ten
lesion s.</w>
ethyl ene</w>
epilep sy.</w>
D P</w>
wil d</w>
ser ve</w>
ques tion
phosphoryl ation.</w>
midazol am</w>
low est</w>
extrac ts</w>
exer ted</w>
as es.</w>
abrog ated</w>
ol /
o [
k es</w>
inhibitor .</w>
contribut ing</w>
col onic</w>
col itis</w>
chron ically</w>
allo dyn
Hy dro
Dru g</w>
DO X</w>
ur k
tez omi
test ,</w>
sensi tized</w>
re modeling</w>
on it
lymph ocyte</w>
gh ts</w>
e NOS</w>
de si
( +/-
tivari ate</w>
j oin
fluoresc ent</w>
contrac ep
ET -1</w>
subst ances</w>
lip ide
in /
foun d.</w>
f inal</w>
cod on</w>
biomar ker</w>
ap ine</w>
R ole</w>
10 00</w>
substitu tion</w>
sou ght</w>
ro w
normal .</w>
mat ur
factor- alpha</w>
de tail
angiotensin- converting</w>
ad es</w>
PK C
ti tr
rod ent</w>
retin oid</w>
proteas ome</w>
metabol ized</w>
inter mit
insi ght</w>
influ ences</w>
en ous</w>
con c
as cular</w>
Quer cetin</w>
G R</w>
6 1</w>
vol t
review ed</w>
ox amine</w>
os tig
n es
min ant</w>
magne tic</w>
fibr in
T um
C ocaine</w>
2 C
ti d
synthe sized</w>
star t</w>
se l</w>
o k</w>
life- threatening</w>
hall ucin
effici ency</w>
be aring</w>
T A</w>
CB 1</w>
6 ),</w>
ycl ine</w>
re ference</w>
overexpress ed</w>
lim it
k appa</w>
ja undic
di azep
S F
IC 50</w>
nan op
is ms</w>
in sec
arter ies</w>
N one</w>
DC A</w>
t ot
rex pression</w>
predn is
n ai
mo bility</w>
leuk emia.</w>
interfer on-
T oge
M R</w>
ter s</w>
su ffered</w>
st in
simil arly</w>
rele ased</w>
post natal</w>
phy to
le t</w>
aten olol</w>
R 2</w>
O ve
Col lec
s low
progres sion.</w>
per f
mid d
es /
controlle d,</w>
ca rotid</w>
CYP2D 6</w>
B B
transf er</w>
tr adi
mo ther
lin k</w>
en e,</w>
cont act</w>
compar ative</w>
T oxic
M O
He al
techniqu e</w>
sequ ently,</w>
recruit ment</w>
promin ent</w>
ne ur
famil ial</w>
coca ine.</w>
b ase</w>
CYP2A 6</w>
8 8
tro glitazone</w>
physi ci
nitroprus side</w>
clopid og
bo wel</w>
antagon ism</w>
am bul
u st
pol yp
oxygenase- 1</w>
nicot inic</w>
hydro chlorothiaz
compound s,</w>
synthe sis.</w>
suppor ted</w>
suff ering</w>
l is
favor able</w>
def en
chi ld</w>
ch ec
analog ue</w>
T E
SC s</w>
D OX
variabl es</w>
tetr azol
pestic ide</w>
ol e
occlu sion</w>
obarb it
infu sions</w>
cad mi
CC l
(T NF-
vascul itis</w>
puro mycin</w>
or rh
li st
investig ations</w>
dela y</w>
ar one</w>
ATI ON
replic ation</w>
ot ec
om at
mo vements</w>
m um
in ser
identifi ed.</w>
i otic</w>
g el
en anti
disturb ances</w>
dep ri
con sequence</w>
bir th</w>
S D</w>
opath y,</w>
oc occ
mal form
clar ify</w>
c ot
ar in</w>
amph oter
H sp
G 2/
vol u
ot ox
oph er
mus cle
inten sive</w>
acetylchol inesterase</w>
ac he
R OD
NA C</w>
M ice</w>
CYP2C 9
C K
AL DH
tiv ir
eth yl</w>
episod e</w>
ep sil
diff use</w>
d al
coun t</w>
blood -
beta- adrenergic</w>
be zaf
arsen it
amelior ated</w>
H u
2 5%</w>
prelim inary</w>
iso form</w>
intr a-
ec oxib</w>
cad her
ar y
SH R</w>
M K-
Euro pe
9 6</w>
sol u
olec ular</w>
mon ocyte</w>
mg/kg ).</w>
hist or
cyclo hex
an tr
P-rib os
Long -term</w>
B E
relev ance</w>
prote ase</w>
il ateral</w>
fibr ate</w>
as pec
al op
Intr av
un related</w>
pum p</w>
p icro
oxidi zed</w>
CA SE</w>
1 4-
( 4.
pro pose</w>
peritone al</w>
p ly</w>
mol ar</w>
ex trem
cy clin
concentr ation.</w>
IL-1 beta</w>
( from</w>
immunohist ochemical</w>
f uture</w>
de -
PATIENT S</w>
s pl
regul ation.</w>
lipopolysacch aride</w>
lep tin</w>
g ,</w>
expos ures</w>
cys tic</w>
alcoh olic</w>
T P</w>
G .</w>
1 *
sion s,</w>
my opathy</w>
lim b</w>
adren al
T /
S MC
S /
G r
vis c
phenyl )
on c
n utri
form ul
diabet es.</w>
atheroscler osis</w>
T en</w>
R is
I D
Al so,</w>
( ERK
wom en.</w>
umb il
trans membrane</w>
propran ol
on omic</w>
om as.</w>
i b</w>
e rec
a :</w>
Ove rexpression</w>
Apopto sis</w>
2. 0</w>
- free</w>
reli ef</w>
read y</w>
o ural</w>
less er</w>
elem ents</w>
dipyridam ole</w>
def ect
AK T</w>
7 6</w>
5 6</w>
0. 3
vom it
vel oc
pathophysi ology</w>
dose- related</w>
de sign</w>
T F
wor k
van com
ther mal</w>
su it
s por
pyr idine</w>
fl ut
R S</w>
M ethyl
CA R</w>
umbil ical</w>
tum or-
thi one
strom al</w>
pre pared</w>
plac e</w>
p5 3,</w>
intraperitone ally</w>
electr ical</w>
carb oxy
SETTI NG
PI3 K</w>
CX CR
us h
os cop
olog ic
n a</w>
ket ocon
intoxic ation</w>
in her
immunosup pressive</w>
di verse</w>
creat ine</w>
a emic</w>
H U
F R</w>
(2 00</w>
tu be</w>
re m
pro found</w>
infec tion.</w>
experim ent</w>
determin ation</w>
chemo kine</w>
benef its</w>
adduc t</w>
P ),</w>
AT P-
-1 00</w>
(S OD
trans mit
rou gh</w>
nucle oti
lac king</w>
head ache
cyclo oxygenase</w>
cerebell ar</w>
amphoter icin</w>
R ).</w>
E valu
Con ver
C arb
v en</w>
resul ts,</w>
rele ase.</w>
depend ent.</w>
U nit
S up
PA ,</w>
Collec tively,</w>
6 4</w>
. (ABSTRACT</w>
volu me
recipi ents</w>
re perfusion</w>
rang ed</w>
nov o</w>
nat ri
infec tions</w>
i ,</w>
am ide-induced</w>
ain .</w>
agg ra
C ys
6 00
3 T
res or
phenomen on</w>
form ation,</w>
ectom y</w>
b al</w>
assa yed</w>
arach id
activ it
X ,</w>
Mut ations</w>
HeL a</w>
DI SC
C ancer</w>
z idov
selen ium</w>
ou re
on azole</w>
on at
morb idity</w>
malon di
ill in</w>
ic illin
hemat opoietic</w>
g ir
ex cl
MDA- MB
17 -
sy ,</w>
press or</w>
ph ase.</w>
im mediate</w>
f it
cyt otoxicity.</w>
cho ice</w>
SETTING :</w>
S LC
7 5
ta il</w>
natri ure
mo bil
en ric
L ).</w>
F as</w>
ta x
precur sor</w>
p el
om ethyl
nor adrenaline</w>
detox ification</w>
consist ing</w>
ar y,</w>
T e
R s</w>
I AP
un affected</w>
pro genit
pharmac ologic</w>
neuropath ic</w>
lup us</w>
ion ic</w>
inter act</w>
he m
genotyp ed</w>
f in
exhib its</w>
am il
am ide
T O
Bcl- x
ur in
un chang
os e-
leuk otri
hear ts</w>
elimin ation</w>
docetax el</w>
dis appeared</w>
th el
struct ures</w>
s -induced</w>
p up
f ind</w>
environ ment</w>
aut osomal</w>
aromat ase</w>
9 %)</w>
min /
medi ator</w>
dri ven</w>
classi cal</w>
acetyl ation</w>
S V
K56 2</w>
HIF-1 alpha</w>
7. 5</w>
(0. 5</w>
ript yl
r ich</w>
occupati onal</w>
meth od.</w>
g p
fr uct
dep olar
d ual</w>
ci me
aggreg ation</w>
Or al</w>
5 7</w>
25 (OH)
2,3,7,8-tetrac hlorodibenzo-p-dioxin</w>
schizophren ic</w>
al ready</w>
ROD UC
P hy
INT RODUC
Elec tro
E GF</w>
(2 ),</w>
toc opher
simult aneous</w>
schizophren ia.</w>
restric ted</w>
ne ar</w>
dist ingu
correl ates</w>
Del ta
to ph
pla qu
om ep
o x</w>
mut ants</w>
ibr ate</w>
f ill
cyt oplas
an ion</w>
C lin
Ac et
5 8</w>
2 D
(AD P-ribos
x -
tak e.</w>
t ing
sulind ac</w>
subjec ts,</w>
simult aneously</w>
rh abdomy
respon ders</w>
res em
paren tal</w>
orph ine</w>
neutrophil s</w>
liver s</w>
cis -
bron ch
As sociation</w>
1 -1</w>
/ d
(i. e.,</w>
( 4</w>
to ol</w>
on ium</w>
injec tion,</w>
form in</w>
cour ses</w>
as h
arti cles</w>
app ing</w>
aberr ant</w>
Ph ase</w>
JN K
7 ).</w>
+/ -1
(C D
tre mor
transcrip ts</w>
stit ute</w>
reg ular</w>
ogen etic</w>
immunore activity</w>
hyp oxic</w>
INT ER
B H
2 5,</w>
reg ard</w>
ra rely</w>
quanti fied</w>
on id
mesen chymal</w>
m )</w>
dig oxin</w>
cannabin oid</w>
ation ;</w>
ac idi
P- glycoprotein</w>
/ -</w>
w k</w>
vers ely</w>
sist ent</w>
main tain</w>
la sia</w>
hepati tis.</w>
es ul
cirrho sis</w>
biosynthe sis</w>
am it
ain ,</w>
L eu
Immuno hist
(A h
triglycer ide</w>
sub cut
sil ic
poison ing</w>
over dose</w>
oche mic
nic kel</w>
neu tr
mo vement</w>
kin ase,</w>
gentam ic
fo s</w>
e- specific</w>
di alysis</w>
compar ison
chang es,</w>
bor tezomi
biopsi es</w>
al um
ac e
TN F</w>
APA P</w>
thi op
suppor ts</w>
st ably</w>
pharmac od
mis sense</w>
interval ,</w>
i -
e x</w>
direc ted</w>
defic it</w>
ben ign</w>
( N</w>
subjec tive</w>
sign als</w>
resid ual</w>
ful minant</w>
en -
clon id
ation :</w>
asses sed.</w>
amne sia</w>
O c
M ore</w>
ves sel</w>
spec i
recogn ition</w>
in s,</w>
di phenyl
cyclospor ine</w>
ab stin
Sub jec
Cur cum
A V
8 ),</w>
7 7</w>
6 *
(D E
un usual</w>
ot om
nat ure</w>
macroph ages.</w>
inte rest</w>
c ,</w>
anti sense</w>
anesthe sia.</w>
S r
QT c</w>
9 ).</w>
( >
wa ve</w>
repe at</w>
prophyl actic</w>
ot oxin</w>
or ,</w>
ocyto sis</w>
ir reversible</w>
foc i</w>
ex ter
d end
chlor promaz
MA IN</w>
INTRODUC TION:</w>
AS A</w>
1 5,</w>
(M MP
war d</w>
stimul i</w>
s l
po ster
cont ained</w>
child hood</w>
ar yn
I /
ER -
C R</w>
stres s-
sle ep
sel y,</w>
recor d
n ociceptive</w>
GL UT
5-az a-
(N O)</w>
restric tion</w>
neuro toxicity.</w>
ly co
iso flurane</w>
f ish</w>
depres sion.</w>
d one</w>
Unit ed</w>
U 9
U )</w>
un i
str and</w>
intermit tent</w>
ill ustr
he mod
entr y</w>
TRA IL</w>
CA )</w>
B AL
18 .
0.0 1</w>
z ing</w>
we ver</w>
uc asi
se min
port al</w>
grad ually</w>
ep idemi
com e</w>
ag e
N E
DISC US
8 ).</w>
0. 6</w>
- L-
(P PAR
withdraw al.</w>
tre x
su matri
sumatri pt
stere otyp
spec ies.</w>
signific ant
s ome
repa ir
na ph
k B</w>
hormon e-
ev ol
as ymptomatic</w>
acceler ated</w>
acc ept
a dequate</w>
S R</w>
M M</w>
Im port
IC (50)</w>
As(2)O (3)</w>
(I L-
transcrip tion-
provid ing</w>
non- small</w>
lo id
entric ular</w>
arthri tis.</w>
ab le,</w>
R a
B CN
6 6</w>
treatment s.</w>
trans activation</w>
synthe sis,</w>
sol ute</w>
secre tion.</w>
pro motion</w>
poss ess</w>
per fu
n ia</w>
mg .
increas ed,</w>
fen flur
describ es</w>
T G
8 5</w>
3- methyl
synerg is
raz ol
not .</w>
nitro gen</w>
lung s</w>
ibu profen</w>
guine a</w>
fib ers</w>
def ine</w>
cle a
ST UD
P H
F unc
vari ations</w>
t onic</w>
subjec t</w>
p 65</w>
inhal ation</w>
car nit
ac ted</w>
sem ide</w>
olig onucle
ent ate</w>
V it
(H D
se arch</w>
s atis
prov en</w>
phenyleph rine</w>
n ational</w>
myocl on
ciga rette</w>
S ec
PI3 K/
C p
B et
truct ural</w>
resist ance,</w>
nephropath y.</w>
m s,</w>
ishe d.</w>
hypoxi a-
flox ac
comp ris
ambul atory</w>
achi eve</w>
E ach</w>
(P C
trans duc
proble m</w>
post menopausal</w>
persist ed</w>
og lob
dos e-</w>
complic ations.</w>
cobal t</w>
ca the
UN E
PON 1</w>
E V
AD R</w>
12 5</w>
sp i
rhyth m</w>
lim it</w>
kg ,</w>
insi ghts</w>
hormon es</w>
activ ators</w>
Cr (V
tro p
soci al</w>
prost atic</w>
obes ity</w>
ne a</w>
morph ology</w>
coll ec
co ordin
classi fied</w>
analy ze</w>
7 4</w>
3- kinase</w>
20 ,</w>
) ].</w>
stimul ation.</w>
promot er.</w>
par athyro
mim ic
ir t
il ic</w>
hyper prolact
consist ently</w>
compar t
appa ren
S W
Pro tec
N on
Ei ght</w>
Ca ucasi
rati o,</w>
le ar</w>
l ind
inter f
interf ere</w>
factor ,</w>
appro ved</w>
S even</w>
P- gp</w>
N ,</w>
50 -
x ,</w>
r e</w>
or s.</w>
lin kage</w>
Y :</w>
H CC
Co A</w>
B I
( 5.
tr im
supple mented</w>
ra ised</w>
propo fol
po w
m os
hyper ther
ext ended</w>
ane ur
C RE
(2 5</w>
tol u
pe op
mon ocytes</w>
microscop ic</w>
mg .</w>
hypoten sion,</w>
dys function,</w>
don or</w>
da un
DISCUS SION
relax ation</w>
profil ing</w>
p g/m
n ude</w>
miR -2
glomerul oneph
echocardi ography</w>
dyskinesi as</w>
dis ulfir
behavi oural</w>
ap ical</w>
anti apoptotic</w>
ang ial</w>
aneur ys
PA N</w>
Id enti
3 ;</w>
1. 2</w>
(T NF
xenob io
sequ ential</w>
pos ite</w>
no de</w>
n g/
mat ter</w>
immunohist ochemistry</w>
hemat ologic</w>
foc used</w>
ep irub
dis play</w>
azol e,</w>
asth ma.</w>
ag ain</w>
Evalu ation</w>
(P B
pas sive</w>
oc al
intram us
ine :</w>
deacetyl ase</w>
attribut able</w>
am yg
4 4
1 1-
-1 /
xenob iotic</w>
s ot
pro- apoptotic</w>
lamiv ud
ket o
dem enti
amyg dal
Ox id
- dose</w>
x .</w>
wh at</w>
thi o
necro sis.</w>
morph ine-induced</w>
in s.</w>
form ing</w>
equ ally</w>
be at
atroph y</w>
tradi tional</w>
re th
diclofen ac</w>
death s</w>
M 2</w>
HE K
DISCUSSION :</w>
B 2</w>
A t
ren in-
par aox
ol act
hybridiz ation</w>
an e-
an e,</w>
TCD D
St at
M any</w>
Intrav enous</w>
B u
w is
to ok</w>
sm all-
shor ter</w>
phosphoryl ation,</w>
ol ide</w>
methion ine</w>
mas sive</w>
glob ulin</w>
fentan il</w>
differenti ation,</w>
diarr he
ba sic</w>
b er
Ne w</w>
MDA-MB -2
AT RA
10 )</w>
thyro idis
s pati
res ,</w>
og lyc
mic ron
m -
ex pec
estic ular</w>
an omal
P- 2</w>
FK 50
6 8</w>
y ).</w>
st atin</w>
st ,</w>
releas ing</w>
princ ip
op rine</w>
offsp ring</w>
mo od</w>
mg/kg .</w>
iti s,</w>
go al</w>
ep inephr
cisplat in-induced</w>
c all
Heal th</w>
An g</w>
A E
(ER )</w>
stat us.</w>
oblas t</w>
n =
ma ze</w>
enzyme -
Europe an</w>
E arly</w>
th or
suit able</w>
pathwa ys,</w>
o is
j ac
flu or
deteri oration</w>
creat in
constitu tively</w>
beta- catenin</w>
benzodi azepine</w>
ass es</w>
amit riptyl
aminonucle oside</w>
alter ing</w>
N-acetyl cysteine</w>
L V
Dru g
6 2</w>
10 (-1
tri pt
sup ra
si RNA
receptor- mediated</w>
rat e-
pa rent</w>
o ventricular</w>
n ess,</w>
ish man
fac t</w>
chlor am
c ent</w>
b .
S u
PPAR alpha</w>
Amer ican</w>
veloc ity</w>
var ying</w>
tivir al</w>
par as
m ast</w>
lat er.</w>
fi ber</w>
decreas ed.</w>
d entate</w>
ucle ar</w>
tric hloro
tiv es</w>
protein -1</w>
pi lot</w>
lab el</w>
determin ing</w>
attac ks</w>
aden omas</w>
T GF
P C</w>
AM P-
(P =0.0
ver sity</w>
oli po
ol in</w>
mes angial</w>
lymph oblastic</w>
hyper calc
emph asi
concentr ation,</w>
br af
Suc h</w>
Gl ut
succin ylchol
oph thal
interleukin -1
fol d,</w>
deoxy cy
ap olipo
amy loid</w>
activ ities,</w>
a fferen
Z )</w>
B l
8 7</w>
1 6.
ure th
no vi
incid ences</w>
im pl
human s,</w>
es artan</w>
coun ts</w>
c- fos</w>
Z -
W e
PTE N</w>
G2/ M</w>
B is
AC )</w>
(1 5</w>
(1 )-
ycl ic</w>
visc eral</w>
ind ina
immunob lot
es cal
comp ens
cholester ol
carbam azep
c. v
anaesthe sia</w>
Th er
P DE
N T</w>
transl ational</w>
ri tic</w>
isoproteren ol-induced</w>
el ve</w>
cholester ol,</w>
apomorph ine</w>
P B</w>
relationshi ps</w>
ha ir</w>
disorder s,</w>
diaph rag
chemo therap
ca ud
bra in,</w>
all- trans</w>
D U
C ).</w>
B CL
ulc er</w>
ril ,</w>
ous ly.</w>
mucos a</w>
b uc
NSAID s</w>
Differen tial</w>
su sp
resveratro l,</w>
od g
load ing</w>
iz ed.</w>
es ).</w>
dat a,</w>
back gro
T ol
A u
vas ospas
to bac
syn cop
rig idity</w>
reproduc tive</w>
knowledg e,</w>
ische mia.</w>
insec tic
anxi et
CR P</w>
4- hydroxy
(P K
tom ography</w>
stimul atory</w>
r am
phosph o-
nife dip
isoniaz id</w>
ey e</w>
e ph
de part
ab or
H odg
F l
- sensitive</w>
sh ock
process ing</w>
pro fi
potenti ation</w>
platel et
ot roph
fol ic</w>
c e.</w>
Conver sely,</w>
Cell s</w>
3. 5</w>
(e.g .,</w>
( max
vari ed</w>
trans port
th elial</w>
sit u
poster ior</w>
norm ally</w>
met a-
main taining</w>
ep tion</w>
en sion</w>
depend ence.</w>
cr imin
con served</w>
VKOR C1</w>
Tran si
Toge ther,</w>
AQ P
(A P
tumour s</w>
plac ent
parox et
p h</w>
os ,</w>
gu id
ex ce
encod es</w>
ant ine
analog s</w>
D M
Cs A</w>
8 0%</w>
troph ic</w>
surviv in</w>
selec tivity</w>
secre ted</w>
path ology</w>
pa w</w>
odi pine</w>
l es</w>
granul e</w>
embry os</w>
atheroscler otic</w>
adip ocytes</w>
TH P-1</w>
PA RP
M olecular</w>
Ang i
6 /
w hi
vul ner
tr am
seve rely</w>
ro se</w>
rat ing</w>
om es</w>
neg atively</w>
li pos
it ,</w>
hepat otoxicity.</w>
haz ard</w>
finding s,</w>
bro ad</w>
allel ic</w>
N K</w>
M G</w>
IL- 6,</w>
6 0%</w>
trac he
per man
mg/ day)</w>
hydro carbon
analog ues</w>
allow ed</w>
a b</w>
IL -1</w>
1 C
(GSH )</w>
(ADP-ribos e)</w>
z es</w>
stopp ed</w>
ocycl ine</w>
min ute</w>
le thal
kD a</w>
inf ant</w>
ine ur
cortico steroid</w>
ba ro
aw are</w>
arg in
Z D
MC P-1</w>
J an
F OX
CX CL
CC )</w>
0.000 1).</w>
(P I
ter but
pre- treatment</w>
nephro toxicity.</w>
immunohist ochemistr
frag ment</w>
electro ly
diseas es,</w>
all oc
a sic</w>
Gl uc
9 0%</w>
week ,</w>
valu es.</w>
rec essive</w>
ra y</w>
pi per
mo ti
m L</w>
geniste in</w>
frag ment
ad mis
R I
O A</w>
Import antly,</w>
Hg Cl
HI V
CYP2 E
sp le
pe ak
mechanis tic</w>
i ans</w>
e- associated</w>
cl onic</w>
a y
8 /
1 %,</w>
( range,</w>
venti l
vect or</w>
re pression</w>
prop ion</w>
prec linical</w>
ouab ain</w>
necro tic</w>
inf or
in stil
flavon oids</w>
ester ase</w>
defen se</w>
bromocript ine</w>
O b
wid es
underg o</w>
tr aining</w>
sour ce</w>
scre en</w>
monke ys</w>
l y-
h n
gon ad
glucuron idation</w>
dos ages</w>
cont ex
Prote in</w>
Anim als</w>
1 -1
valid ated</w>
ti car
scre ened</w>
pepti des</w>
paracetam ol</w>
pa ir
metallo thione
in otropic</w>
if or
beli eved</w>
az one</w>
Ther ap
T i
G B
(N O
transfer ases</w>
signal ing,</w>
proced ure</w>
opi oid
medi al</w>
m E
lo fen</w>
le ts</w>
keratin ocytes</w>
evalu able</w>
deple ted</w>
depend ing</w>
bl un
Hepati c</w>
A M</w>
(4 0</w>
( 5-FU
xenograf t</w>
schedul e</w>
predomin ant</w>
neg ati
duc t</w>
dis crimin
benzodi azep
anti- cancer</w>
C D</w>
8 4</w>
1. 3</w>
ze braf
ulf an</w>
tri als.</w>
thic kn
re activation</w>
modi fi
in organic</w>
estim ate</w>
epti de</w>
cyto k
ble .</w>
PAR P</w>
P a
5 %,</w>
sp ac
sensitiv ity.</w>
scler osis</w>
preven tive</w>
polymorph ic</w>
fol d
diet .</w>
d ynamic</w>
bl ind
bcl -2</w>
an il
ain ide</w>
L ith
G AD
(CYP )</w>
ter .</w>
os a</w>
nec k</w>
fix ed</w>
first- line</w>
fibroblast s.</w>
behavi ors</w>
assa ys,</w>
arrhythmi as.</w>
al low</w>
afen ib</w>
ac k</w>
My ocardial</w>
I CAM-1</w>
HI V-
H R</w>
Ev idence</w>
CYP2C9 *
CF TR</w>
9 80
29 3</w>
teste d.</w>
s he
oxal i
ox ane</w>
om er</w>
gest ational</w>
fact ory</w>
enzyme .</w>
col chic
cap illary</w>
atri oventricular</w>
T otal</w>
N- nitros
L os
In v
AP L</w>
( NA
k i
em ent.</w>
bro mo
ascor bic</w>
ane l</w>
T T</w>
Ne ph
17 .
1, 25-
un it</w>
tur no
sy novi
prob able</w>
plas min
k in</w>
k ain
f ever</w>
encod ed</w>
depend ent,</w>
benzo [a]
adi po
a er
J AK
H 1</w>
C is
Al ter
7 0%</w>
m t
id al</w>
ffic acy</w>
ax onal</w>
at ed
aro und</w>
a sis,</w>
STUD Y</w>
S G
D MA
t esticular</w>
ne arly</w>
me tric</w>
iso form
factor .</w>
cir cum
c G
V T</w>
TRPV 1</w>
RP )</w>
I R</w>
Ca2 +
C s</w>
(0. 1</w>
worsen ing</w>
suppor ting</w>
parti cles</w>
ol )</w>
facilit ate</w>
can ine</w>
aspec ts</w>
Vit amin</w>
Th us</w>
K O</w>
3 0,</w>
st atic</w>
nex t</w>
myel oper
malondi aldehyde</w>
immunoprecip itation</w>
id in</w>
furo semide</w>
em b
der ,</w>
calcit ri
arb oxyl
ag es,</w>
affec ted.</w>
PPA R</w>
P R</w>
D ep
C u</w>
50 )</w>
3 2
0 .</w>
(E GF
( median</w>
suc c
s well
opi ate</w>
micromol/ L</w>
mal e
kidne y.</w>
h O
ex tre
dop a</w>
develop ment,</w>
b yp
ar ch
adri amycin
RS V</w>
Oxid ative</w>
DN F</w>
y /
v ic
synergis tically</w>
sequ ent</w>
sen sor
phenobarb it
mut ations.</w>
l umb
id ,</w>
gli oblastoma</w>
bi otic</w>
as es,</w>
analyz ed.</w>
Hep at
(H O
phosphatidyl inositol</w>
oste osarcoma</w>
nitr ite</w>
nat urally</w>
mod est</w>
mo zol
los s.</w>
lo be</w>
cy an
con stric
basel ine,</w>
arachid onic</w>
antin ociceptive</w>
album in
ac cur
O H</w>
MG MT</w>
H C</w>
(R T-
wides pread</w>
u ary</w>
present ation</w>
pre term</w>
pot ently</w>
paraqu at</w>
mesoth eli
erythro cyte</w>
em i
chrom osomal</w>
az ol</w>
aggra v
V ari
J urk
I f</w>
3, 4-
( a)</w>
struct urally</w>
rout ine</w>
resveratro l.</w>
pro apoptotic</w>
patient s)</w>
nause a,</w>
midd le</w>
lys osomal</w>
evalu ating</w>
MMP- 2</w>
In trac
B A
AT )</w>
AMP K</w>
n e</w>
in yl</w>
imid az
hist ologic</w>
high- risk</w>
gre at</w>
fol d)</w>
ad mission</w>
U9 37</w>
Ei gh
y ),</w>
well- known</w>
thym idine</w>
t ation</w>
rele ase,</w>
pro be</w>
otec an</w>
mul tivariate</w>
fibro tic</w>
chemo therapy,</w>
c ade</w>
ab ly,</w>
Transi ent</w>
T M
H(2)O (2)</w>
H 2</w>
Combin ed</w>
7 /
7 ),</w>
y ].</w>
qu al
myocardi um</w>
kill ed</w>
in tub
in active</w>
d ap
astro cyt
Me dian</w>
)- mediated</w>
( the</w>
mozol om
kidne y,</w>
it s,</w>
et ing</w>
com promis
cl as
cas cade</w>
b p</w>
R ho
Pr im
NQO 1</w>
I kappa
B C
(I F
( in</w>
signific ant.</w>
p '-
o der
medic ation.</w>
log istic</w>
leuk ocyte</w>
indic es</w>
ex in</w>
correc ted</w>
concentration -
astro cytes</w>
Subjec ts</w>
L-NA ME</w>
IN D
G SH
E stro
8 9
u tility</w>
som atic</w>
p anel</w>
k -
Re ver
F 2</w>
0. 8</w>
my alg
hydrochlorothiaz ide</w>
contr action</w>
consc i
c d
] )</w>
Un der</w>
E fficacy</w>
surviv al,</w>
st ren
spectrometr y</w>
op ir
om od
o protective</w>
it y-
is op
consider able</w>
ac ut
MDA-MB-2 31</w>
C/ E
(II )</w>
spati al</w>
sev o
quin idine</w>
on olact
ome gal
micro arra
incorpor ation</w>
impro ving</w>
ex act</w>
curren ts</w>
M od
(RT- PC
yr in</w>
retro viral</w>
resem bl
obstruc tive</w>
miR -1
individu als.</w>
inc re
apparen tly</w>
activ ator
U DCA</w>
For ty-
C at
Ad ri
14 ,</w>
1 16</w>
th es
revie we
respectively ;</w>
nephro toxic</w>
Res pon
O- de
Nor thern</w>
MR I</w>
7 9
( 0
temper ature</w>
sub typ
sacrific ed</w>
s.c .)</w>
resc ue</w>
remo val</w>
lis in
excit atory</w>
capsaic in-induced</w>
as one</w>
acid -
T D
st y
obser ved,</w>
mum ol/
lin ed</w>
is ing</w>
exp an
difficul t</w>
d- release</w>
cisplat in,</w>
T C</w>
R /
II )</w>
C yclo
A spir
wor ld
trigg er</w>
t ing,</w>
p ect
knowledg e</w>
abol ic</w>
R ap
R P</w>
NO S)</w>
CC 1</w>
transcrip tion.</w>
prepar ations</w>
phenotyp e.</w>
neuro transmit
i s.</w>
bilirub in</w>
benz yl
TNF- a</w>
P X
H is
A mi
salic yl
s lic
re uptake</w>
pressu res</w>
pos ing</w>
on i
moder ately</w>
ge fit
aud itory</w>
T ER
PR L</w>
M T-
( VEGF
( ME
perf used</w>
ocicep tion</w>
n M)</w>
in ium</w>
etopo side</w>
elucid ated.</w>
detec ted.</w>
deliri um</w>
defec tive</w>
contro ver
cont ain</w>
c )</w>
alpha -induced</w>
abs ent</w>
T F</w>
CD 8
0. 7</w>
ut aneous</w>
phosph o
pa infu
painfu l</w>
mo stly</w>
g avage</w>
famil y,</w>
enzyme ,</w>
diam eter</w>
de ep</w>
cont ains</w>
arach no
an ch
amplit ude</w>
Identi fication</w>
C M</w>
(a )
x y
tumori genesis</w>
s ess
pos t</w>
plasmin ogen</w>
nanop articles</w>
mi R-
methyl- 4-
ische mi
in direct</w>
gest ation</w>
el y.</w>
UGT 2B
R ating</w>
PC B</w>
O D</w>
NSCL C</w>
7 9</w>
ventric le</w>
ng/m l</w>
methyl phen
ma x</w>
i si
ep oxide</w>
e ous</w>
depend s</w>
am ant
S ER
PC -3</w>
N .</w>
IL-1 0</w>
F os</w>
EX P
Cp G</w>
6 9</w>
3. 0</w>
ul ate</w>
tra ffic
sim ple</w>
shi f
respon ding</w>
reflec t</w>
por t</w>
per g
ogr am
micro M),</w>
mg/m (2)</w>
ine ;</w>
hi m
exten sively</w>
diz zin
derm atitis</w>
del t
contribut ed</w>
bezaf ibrate</w>
adip onectin</w>
S K-
Qu anti
NB 4</w>
G ),</w>
D AT
val ve</w>
transi ently</w>
sur vi
re infor
peop le</w>
osom es</w>
o yl
leukotri ene</w>
em is
ede ma,</w>
defici ency.</w>
dail y,</w>
compl i
cat eg
U ni
RA )</w>
PA I
G D
F GF-
C V
(1 ,
seroton ergic</w>
prom p
per tur
mix t
loc al
inter nal</w>
in stitu
in ase</w>
gen in</w>
cell s:</w>
c m
but yl
Q -
P ot
MAP K
M an
G A</w>
2 +</w>
10 0%</w>
, p'-
( 6.
strong er</w>
ne ver</w>
as e)</w>
apolipo protein</w>
a vir</w>
TI MP
PA .</w>
7 1</w>
(A s
rifamp icin</w>
regar d
oste o
nim esul
inter rup
half- life</w>
f re
f ell</w>
di ol</w>
analge sic
SC C</w>
Per i
AM L</w>
0. 2
ver thel
tachycardi a.</w>
stren g
seem ed</w>
raloxif ene</w>
mit otic</w>
haem orrh
h ost</w>
elev ations</w>
efficac ious</w>
di ffered</w>
cadher in</w>
angi ography</w>
an emia.</w>
aminog lyco
T a
H A
G iv
withdraw n</w>
unchang ed.</w>
ster ing</w>
modific ations</w>
ithro mycin</w>
insulin- like</w>
f ati
f ar</w>
diseas e-
al az
R- mediated</w>
P os
M on
M in
M a
M TH
D S
2- fold</w>
(2 ,
vancom ycin</w>
tion )</w>
regard less</w>
rec i
embol ism</w>
doxorubic in.</w>
clopidog rel</w>
anti biotic</w>
L-DO PA</w>
II .</w>
D L
CYP2C 19</w>
(H B
y- state</w>
ul tim
tors ade</w>
secret ory</w>
properti es,</w>
pre h
mal ari
ir e</w>
hour s,</w>
extrem ely</w>
dis sec
dail y.</w>
cisplat in.</w>
cardi otoxicity.</w>
bl ind</w>
F ox
F A
4 ;</w>
under li
tissu es,</w>
particul ar,</w>
op ulmonary</w>
odi um</w>
oc al</w>
ne ed
manifest ed</w>
lym ph</w>
fung al</w>
et ed</w>
dat ab
chro mium</w>
chem osensi
ap ril</w>
O HD
Neph ro
I CA
H UVEC
Giv en</w>
yr ic</w>
tri al,</w>
tic -
ti ally</w>
system s.</w>
sub types</w>
re al</w>
potenti als</w>
plat in
mortal ity.</w>
micro M.</w>
metoclopr amide</w>
fe eding</w>
eryth emat
electrocardi ographic</w>
dex tro
but y
azathi oprine</w>
VD R</w>
RT-PC R.</w>
H P</w>
Anti -
vacu ol
shor t-
scopol amine-induced</w>
r ul
met formin</w>
low- density</w>
le b
h arb
group )</w>
glyc ogen</w>
gly col
func tions.</w>
dys pla
cyc le.</w>
che mot
an e.</w>
Nic ot
B P-
Afr ican</w>
9 3</w>
5- fold</w>
thre e-
th ,</w>
se e
per icardi
ox antr
inhibi tion,</w>
il l</w>
high ligh
g as</w>
effici ently</w>
abund ance</w>
V er
19 ,</w>
youn ger</w>
um -dependent</w>
re ferred</w>
ou s,</w>
org ans</w>
ocl onal</w>
neuron s,</w>
lu tion</w>
induc er</w>
hydro chlor
S event
5. 0</w>
2 a</w>
1 1,</w>
( 6</w>
vie w
ver te
time -</w>
ster ol</w>
retro spec
prednis one</w>
potenti ates</w>
pap er</w>
other s</w>
model s,</w>
lu oro
conjug ated</w>
cardiomy ocytes</w>
) ]
( s
ter al</w>
subun its</w>
s op
phenotyp ic</w>
n ess.</w>
itsel f</w>
infu sion,</w>
ine -</w>
et om
del eter
carnit ine</w>
(C B
vasodi l
ur ticar
set ting</w>
selec tion</w>
prospec tive,</w>
ph or
neutrop enia</w>
in st
im idine</w>
ili bri
ic ation</w>
fo od
ent ered</w>
do g</w>
de -induced</w>
chromat ography</w>
alpha ,
Sm ad
K 2</w>
D ow
9 5
19 .
vessel s</w>
ul atory</w>
tri ax
pepti d
outcom e.</w>
impro ve
identifi es</w>
expl an
ex cell
event s,</w>
doxorubic in,</w>
dos ed</w>
disrup ting</w>
am -
aden o
Tum or</w>
L I
Inc reas
AZ T</w>
2. 0
2 7-
( odds</w>
vi sion</w>
vel op
tr unc
relap sed</w>
rec tom
pr ur
ond an
immuno deficiency</w>
fen o
detail ed</w>
canc ers,</w>
T ),</w>
H is</w>
E (2)</w>
sampl es.</w>
s ept
resi due</w>
os .</w>
lab et
l ox
in ation</w>
approach es</w>
anti bod
P =0.0
M Y
I B
Contro l</w>
8 9</w>
29 400
tel omerase</w>
sub type</w>
se d,</w>
s arcoma</w>
nephro sis</w>
na pro
fe ed
ede ma.</w>
e me
dil ated</w>
de position</w>
carb oxyl
bl ue</w>
az en
ampl ification</w>
al )</w>
abnormal ities.</w>
a ur
T UNE
5- year-old</w>
1 a
( d
super nat
so deoxycholic</w>
re mis
nucle oside</w>
n ative</w>
inher ited</w>
haem at
g yr
fer ri
cipro floxacin</w>
cerebro spinal</w>
Ur inary</w>
F AN
v als
sim vastat
proble ms</w>
placebo- controlled,</w>
ph ase,</w>
neuro muscular</w>
natriure tic</w>
log ical</w>
is ot
implant ed</w>
hypertroph ic</w>
glucuron ide</w>
glucos e-
cortico steroids</w>
arr ang
TRA IL
Com ple
00 ,</w>
- containing</w>
sub stituted</w>
ser tr
reac tions.</w>
present ed.</w>
orb ent</w>
occ up
o vascular</w>
fr actions</w>
enric hed</w>
anc y</w>
ab solute</w>
Z n</w>
W h
N ine</w>
B 6
8- year-old</w>
1 5%</w>
- >
(G rou
resveratro l
renin- angiotensin</w>
ment s,</w>
intro duction</w>
fibro sis,</w>
enti re</w>
ect opic</w>
dyst roph
dend ritic</w>
accum ben
ac arb
O ,</w>
MRP 1</w>
L ow
E SR
Bcl -2,</w>
1 :
resul ts.</w>
r un
process es.</w>
m M)</w>
ind ol
hypertroph y.</w>
hyper cholesterol
glyc ine</w>
dram atic</w>
dail y)</w>
blood- brain</w>
ana emia</w>
MRP 2</w>
ME TH</w>
L VE
I s</w>
Grou ps</w>
Func tional</w>
ER beta</w>
D- penicillamine</w>
C HO
8 6
8 2</w>
1, 3-
1 6-
thor ac
stat us,</w>
prospec tively</w>
prolifer ating</w>
ograph y,</w>
obarb ital</w>
nucle i</w>
mon oclonal</w>
heal ing</w>
f ing
erythro id</w>
emb olic</w>
em ia
deleter ious</w>
as ter
adi g
Combin ation</w>
C ase</w>
As sess
24- h</w>
17beta- estradiol</w>
(m )</w>
weigh ts</w>
vi gab
tak e,</w>
subcut aneously</w>
sub group</w>
regul ators</w>
prob ability</w>
pl er</w>
ph ag
par adig
p ure</w>
p ast</w>
metalloprotein ase-
lip ids</w>
homocyste ine</w>
factor- kappaB</w>
ectom ized</w>
d an
chlor inated</w>
acut ely</w>
S NP
EXP ERI
E S</w>
C57BL/ 6</w>
C ad
(II I)</w>
vigab at
testo ster
satur ated</w>
pent yl
occur red.</w>
n ic</w>
met als</w>
induc tion,</w>
flav one</w>
f lo
experim ents,</w>
der mat
cou mar
consider ably</w>
cardio protective</w>
P V
IN G
HD AC
H ospit
Con sistent</w>
Ba P</w>
9 9</w>
5- hydroxy
2 %,</w>
v ity</w>
v entral</w>
ure mic</w>
sulf on
sp e
ro sis</w>
piv otal</w>
ne o
finding s.</w>
c ulation</w>
c ending</w>
block a
acqu isi
U se</w>
MENT AL</w>
G /
EXPERI MENTAL</w>
Amer ic
8 7
vasopres sin</w>
te mozolom
syn ucle
sugg estive</w>
recru ited</w>
mit omycin</w>
metabolit es.</w>
in verse</w>
ham ster</w>
enti n</w>
eff or
consum p
assess ing</w>
am but
P sy
M g
I ),</w>
(P< 0.05).</w>
us ers.</w>
sym path
pi g</w>
ostig mine</w>
lim bic</w>
hyperalge sia.</w>
f if
b oth
ad junc
With in</w>
Multi ple</w>
HD L</w>
suppres sive</w>
s arcom
phospholip ase</w>
of f</w>
heter odi
Twent y</w>
Th r
Prim ary</w>
K +</w>
HIF -1</w>
B DNF</w>
8 00</w>
24- hour</w>
zebraf ish</w>
sc i
progenit or</w>
prec eded</w>
no d
n oc
lev o
immunos orbent</w>
di thi
def o
contrac tile</w>
continu ously</w>
ation -induced</w>
alop ram</w>
al ways</w>
ST -
P ath
M n</w>
IFN- gamma</w>
D A
C o-
A po
8 1</w>
1- mediated</w>
us cit
t es
scop ic</w>
ro ot</w>
random ised</w>
ph ys
perman ent</w>
parameter s.</w>
p id
oper ated</w>
om o
ocar b
micro M).</w>
metalloprotein ase</w>
membran es</w>
in effective</w>
electro encephal
di one</w>
bu propion</w>
autis tic</w>
arachno id</w>
ap r
anti inflammatory</w>
S 2</w>
D ),</w>
9 1</w>
5 5
1 6,</w>
+/ -1.
(Grou p</w>
z ation</w>
te ,</w>
neuro n</w>
mono amine</w>
m Glu
jac ent</w>
is m,</w>
intracere bral</w>
hyp onat
com pa
ca ution</w>
anti cholinergic</w>
an s.</w>
VE N
PG J
MK- 80
AT 1</w>
1. 4</w>
( X
tri meth
tors ades</w>
test s.</w>
ri tis.</w>
remark able</w>
rabb its</w>
pregnanc y.</w>
plat inum</w>
impro vements</w>
hyper methylation</w>
great est</w>
en o
efficac y.</w>
e mo
discus sed</w>
beta )</w>
bac lofen</w>
aut onomic</w>
SM -
PA H
L ow</w>
C ycl
12 6</w>
tram ad
ten sion</w>
t one</w>
reg urg
ox ide,</w>
os up
iodi de</w>
inter pre
h and
fas cic
electro physiological</w>
bo y</w>
INTER VEN
I K
us -
transl ation</w>
significant ly.</w>
lymph ocytic</w>
imi pramine</w>
follow-up .</w>
diethyl stil
del ta
coun tri
coca ine,</w>
cath ep
brom ide</w>
abund ant</w>
Se iz
I so
Clin ic
B enz
1. 1</w>
zidov udine</w>
reve als</w>
radic als</w>
phosph on
my o
multic enter</w>
mo i
l en
join t</w>
inn er</w>
g lo
four th</w>
es ),</w>
en e-
ei r</w>
distri bu
condi tion.</w>
c ro
but am
ach loro
N-methyl- D-
LP S-
H al
C ere
C -1
A F</w>
syndrom es</w>
spir onolact
refl ected</w>
out patient</w>
os mol
ish ing</w>
hydrox yl</w>
feat ure</w>
disorder ,</w>
cle av
call ed</w>
a ),</w>
X .</w>
Th eir</w>
Sec ond
S 100
Ph osph
O ATP
L A</w>
IGF- I</w>
F 344</w>
= 0.
9 ),</w>
7 6
wom en,</w>
vi ability,</w>
stain ing.</w>
on set
non- steroidal</w>
intest ine</w>
enc oun
di c</w>
cyto protective</w>
av oid</w>
an tiviral</w>
ad jacent</w>
S 1</w>
IND ING
F INDING
3- fold</w>
1, 25(OH)
(i i)</w>
tubul es</w>
stres s-induced</w>
preferen tially</w>
oxid o
id es,</w>
i. e.</w>
glucos e,</w>
fam oti
extrac ted</w>
b ]
az osin</w>
M el
CH F</w>
AC TH</w>
2 1
1. 6</w>
opath ological</w>
list at</w>
glomerul i</w>
ger an
enter ic</w>
cont ent,</w>
col d</w>
chol ine</w>
beat s/
b 1</w>
ation /
alloc ated</w>
T :</w>
Phy si
Jurk at</w>
GABA ergic</w>
Curcum in</w>
Ami od
6 ,
( ST
tic -induced</w>
respon ses,</w>
predic tors</w>
oure a</w>
on ly.</w>
minim um</w>
inter medi
hypo ther
form ulation</w>
dimen sional</w>
deoxycy tidine</w>
at e
ar yl
alpha- tocopher
alkyl ating</w>
Rep or
L E
H 3</w>
(2. 5</w>
v es.</w>
recur ren
pe g
path ologic</w>
off er</w>
las ted</w>
ir radi
day ).</w>
chol inesterase</w>
cas e,</w>
am ic</w>
U p
S AH
R h
P E</w>
DD T</w>
(S NP
volunte ers.</w>
tryp toph
tetrazol ium</w>
stead y-state</w>
stabil ization</w>
repor t,</w>
py ren
pap illary</w>
ol ateral</w>
multi -
lumb ar</w>
l amin
ir radiation</w>
influ x</w>
fl ic
exist ence</w>
c ine</w>
at om
an ser
SU MMA
PD .</w>
(P GE
wh ole-
transcription- polymerase</w>
substanti a</w>
spec ies,</w>
sequ el
phosphor us</w>
ob ic</w>
le ishman
is ation</w>
infarc t</w>
indic ative</w>
hydroly sis</w>
gen ome</w>
frac tional</w>
cir culation</w>
bet a.</w>
beg an</w>
as alazine</w>
PC R.</w>
IL- 4</w>
FINDING S:</w>
E th
E G
C CL
3 K
tr in
t ative</w>
one )</w>
mut ations,</w>
mer ic</w>
m er</w>
m L/
increas ingly</w>
glutathion e-
function ing</w>
fl ush
en larg
cyclin -dependent</w>
cont ents</w>
combin ation.</w>
challeng ed</w>
az od
MD R
D H</w>
C lo
vehic le
side ,</w>
sec tions</w>
regimen .</w>
pneum on
no dul
mening itis</w>
l ost</w>
ing -
hear t.</w>
enti ally</w>
cytometr y.</w>
antagon istic</w>
ampl ified</w>
MT )</w>
M or
De velop
C asp
( 5-HT
sumatript an</w>
st ed</w>
ser ial</w>
res ce
pyr imidine</w>
phthal ate</w>
oste opo
or .</w>
oblas ts</w>
morph ine.</w>
micro gli
k ary
infarc tion,</w>
includ es</w>
erythropoi etin</w>
caspase- 3,</w>
ble ed
adi ly</w>
addres s</w>
adap tive</w>
N S</w>
8 8</w>
2 4,</w>
1, 2-
reviewe d.</w>
region .</w>
princip al</w>
potenti ate</w>
phenotyp es</w>
patient s'</w>
p5 3
l ase</w>
it rate</w>
ic os
for ced</w>
fl un
endothel in-1</w>
cl asses</w>
cisplat in-
bu s</w>
V ,</w>
S A</w>
In de
D 1,</w>
(P T
( t
w ash
valu able</w>
use ful
u sion</w>
sit e.</w>
prepar ation</w>
pa ired</w>
ox ide.</w>
osi tis</w>
orig in</w>
op lasia</w>
lay er</w>
isop ren
hydro lase</w>
ga ve</w>
de struc
damag ed</w>
colon y</w>
az in
antagonist s,</w>
acrole in</w>
U C</w>
N ational</w>
In iti
HC V</w>
2, 4-
(A R
tion ed</w>
steat osis</w>
q /
l ad
gir l</w>
flavon oid</w>
exter nal</w>
enzyme- linked</w>
dom eth
disulfir am</w>
depres sion,</w>
Tw elve</w>
Mit ochond
H em
F ir
-2 0
second -
proc ain
particip ate</w>
modi fying</w>
metabolit es,</w>
k ast</w>
identi fying</w>
gre en</w>
consci ous
behavi our</w>
SUMMA R
P RO
L M
9 /
( III
to genic</w>
sit es.</w>
path ogenic</w>
obvi ous</w>
inter acting</w>
initi ating</w>
establ ished.</w>
el ine</w>
con si
allodyn ia</w>
adren ocor
T G</w>
2- year-old</w>
-1 2</w>
- exposed</w>
( ></w>
tubercul osis</w>
tas k</w>
sub arachnoid</w>
se -
ril .</w>
ock ing</w>
im e</w>
ep tic</w>
disco very</w>
combin ing</w>
chemic ally</w>
chec k
cel ecoxib</w>
behavior .</w>
S te
S al
- M
ven tion</w>
temper at
su med</w>
spas m</w>
rabb it</w>
quercet in,</w>
pharmacod ynamic</w>
olan zap
nicot ine-induced</w>
g ing
en oic</w>
elimin ated</w>
catech olamine</w>
carcinogen s</w>
bortezomi b</w>
antagonist s.</w>
V .</w>
Trans cri
S A
P ain</w>
N E</w>
In dometh
(TCD D)</w>
( ACh
( 7.
ur idine</w>
u z
p ine,</w>
om as,</w>
jaundic e</w>
im mortal
erythemat os
disturb ance</w>
concer ning</w>
comm er
ab use.</w>
Whe reas</w>
Ph IP</w>
GST P1</w>
BAL B/
AC E
12 )</w>
vasoconstric tion</w>
smo ke</w>
resc u
pr is
pap ill
p mol/
on ine</w>
ni gr
mechanism s,</w>
integr ity</w>
beta 2-
ardi ve</w>
ant ed</w>
EC s</w>
4. 7</w>
18 0</w>
y clin
tr if
tissu e,</w>
recor ded.</w>
psych ological</w>
ong o
mut ation.</w>
micrograms/ kg</w>
mg/kg/ day)</w>
ment ary</w>
impair ments</w>
hom ozygot
clu ster</w>
attemp t</w>
ati vel
ann ing</w>
M cl
00 -
-2 /
- 9</w>
volt age-
toler ant</w>
smo kers</w>
re gener
pentyl ene
opir id
oc t
modul ator</w>
min er
microscop y.</w>
li um</w>
know n,</w>
fil am
excell ent</w>
dec lined</w>
cult ures.</w>
b s</w>
3 %,</w>
1/ 2,</w>
0. 5%</w>
(A )</w>
x )</w>
typ ically</w>
pyr if
presum ably</w>
prec ise</w>
my asth
man nit
intramus cular</w>
id ine,</w>
fl ec
cortico steroid
cortex ,</w>
conver ted</w>
com preh
cathe ter
arrest .</w>
adi c</w>
N-acetyl -
N it
Hg ,</w>
CYP2A 6*
18 ,</w>
0.05 ,</w>
yiel ded</w>
vomit ing,</w>
tur n</w>
transamin ase</w>
repress ed</w>
reduc ed.</w>
out put
neoplas ms</w>
myeloper oxidase</w>
my osin</w>
levodop a-induced</w>
function ally</w>
eth oxy
e ar</w>
chlorpromaz ine</w>
arsenic -induced</w>
HER G</w>
9 2</w>
1. 7</w>
un ilateral</w>
sol v
praz osin</w>
os mo
op e</w>
lipide mia</w>
lesion s,</w>
iv aca
in som
impa ir</w>
i. c.v
fluo resce
exacerb ation</w>
effectiv e.</w>
dig it
determin ant</w>
an d.</w>
R R</w>
G >
Dop pler</w>
3- year-old</w>
1 60</w>
(O R
( by</w>
weak ness</w>
verthel ess,</w>
rem if
psych os
prop an
program med</w>
ph orb
m id</w>
in- mediated</w>
h ab
d ly</w>
c e,</w>
bu pren
b ial</w>
antagonist .</w>
Protec tive</w>
P Q</w>
M ic
M al
G ly
DH )</w>
(E D
utili zed</w>
tiz ation</w>
th ec
neuro trophic</w>
lind ane</w>
d ant
caspase- 8</w>
apoptosis- inducing</w>
angi oedema</w>
Quanti tative</w>
Or g
IL- 2</w>
8 6</w>
+/- 0.
vasodilat or</w>
thi our
rat ,</w>
plas tic
os arcom
net work</w>
mother s</w>
in versely</w>
ge al</w>
f asting</w>
er )</w>
decreas ed,</w>
clea ved</w>
caus ative</w>
car til
c o</w>
blot ting.</w>
anticoagul ant</w>
anti coagulation</w>
HS D
G G
) -</w>
(L P
v ular</w>
toxic ological</w>
thickn ess</w>
str adi
stom ach</w>
re dox
open- label</w>
nam ely</w>
los s,</w>
indic ator</w>
ifor m</w>
ch r
byp ass</w>
atheroscler osis.</w>
an es
acet yl</w>
TGF- beta</w>
S ing
S ide</w>
P ac
O L
Nrf 2-
MP P
CA -
1 B</w>
vi ol
tolu ene</w>
thiour ac
rest oration</w>
ra -
phorb ol</w>
omat ous</w>
lo op</w>
inten se</w>
hydrocarbon s</w>
e- 1</w>
c il
acc id
R as</w>
Pos sible</w>
F T
Ch aracter
C op
C i
Aspir in</w>
Addi tional</w>
A g</w>
24 h</w>
1. 4
stro l</w>
set ron</w>
predic tor</w>
pr one</w>
norep inephr
mutag enic</w>
metabolit e,</w>
matur ation</w>
invol ved.</w>
intro duced</w>
interleukin- 6</w>
ho wever</w>
hae modynamic</w>
end ro
e ach
bec l
b p
autis m.</w>
amelior ates</w>
affec tive</w>
T am
Peri pheral</w>
J un
GST M1</w>
G u
G lob
C TR
BCN U</w>
6- OHD
(P )
sex ,</w>
r p
qu eti
potenti al.</w>
out .</w>
mic ro</w>
ilibri um</w>
i. e.,</w>
hospit alized</w>
foc us</w>
chol ec
at rac
antibio tics</w>
ane -induced</w>
SUMMAR Y:</w>
K 3
He re
2 -</w>
( 8.
( 10(-
triglycer ides</w>
the ophyl
ser v
potenti al,</w>
popul ations.</w>
over come</w>
membran e-
lig ation</w>
inj ured</w>
hemodi alysis</w>
fe ver,</w>
dis ulf
de pos
ch aper
O UT
I MP
H ence,</w>
DNA .</w>
CYP 3A</w>
CD H</w>
5 ;</w>
14 0</w>
(3 ,
stat ins</w>
sal butam
ot s</w>
normal ization</w>
mu st
mit oxantr
id ine
glyc osyl
fentan yl
comp uted</w>
afferen t</w>
acquisi tion</w>
S 6
OUT CO
En h
Ch ol
Ak t,</w>
2 -induced</w>
1. 8</w>
terbut aline</w>
so ft</w>
si rolimus</w>
prur it
prov oked</w>
predic ting</w>
ph asic</w>
o od</w>
lim its</w>
lesion ed</w>
issu e</w>
insi pid
genotyp e.</w>
emis sion</w>
discus s</w>
cur ves</w>
correl ations</w>
conduc t
calc ineur
ben azep
b- catenin</w>
b ing</w>
aryn geal</w>
ar dipine</w>
antine oplastic</w>
advant age</w>
adjust ment</w>
X en
P I</w>
Dox orubicin</w>
Chi ld
B ra
AL K</w>
6 4
yo him
ul t</w>
tiv e.</w>
synth et
phyl ococc
pat ch
parkinson ism</w>
op posite</w>
new born</w>
metast ases</w>
experim ent
exacerb ated</w>
disco vered</w>
clon ed</w>
at opic</w>
artic le</w>
amethas one</w>
achi ev
T X
Glob al</w>
F B
CYP 4
4. 5</w>
. ),</w>
tubul o
transcript ase</w>
side -induced</w>
phen ic
overex pres
orph an</w>
n g</w>
mellit us</w>
leuk o
l or</w>
immunore active</w>
glomeruloneph ritis</w>
e- daily</w>
e metic</w>
discontinu ed.</w>
copper -
ca ve
c 2</w>
anthrac ycline</w>
K et
Ha Ca
En do
ELIS A</w>
E A</w>
C ro
A ut
(IL -1
vas o
supra ventricular</w>
res uscit
require ment</w>
remo ved</w>
post synaptic</w>
possess es</w>
pat ch</w>
oxim e</w>
malform ations</w>
las er</w>
emergen ce</w>
condition ing</w>
aly sis.</w>
Sim vastatin</w>
Ret in
Pro long
Poly morph
L ip
D BP</w>
( <
yl )-
un able</w>
turno ver</w>
ter ol</w>
surger y,</w>
stud ying</w>
se ts</w>
pati ble</w>
mg/ d</w>
inter cellular</w>
di lat
acid osis</w>
a vi
Pro g
In vol
G M-
CA T</w>
B6 C3
8 3</w>
1 8-
0.000 1)</w>
-1 5</w>
- SOD</w>
venti lation</w>
ut ing</w>
sevo flurane</w>
rin one</w>
re polar
popul ation,</w>
poly cyclic</w>
p.o .)</w>
ost atic</w>
oscler osis</w>
oph il</w>
och lor
necro sis,</w>
l ).</w>
in amide</w>
immun oglob
hom ologous</w>
he pt
estrogen -
en e.</w>
dat a.</w>
chemo kin
channel s.</w>
caus al</w>
asth matic</w>
Tr x
Syst emic</w>
Q )</w>
NAD (P)
B ),</w>
4- year-old</w>
spor adic</w>
schedul ed</w>
o rel
my cin
impair s</w>
fet uses</w>
erec tile</w>
ell ing</w>
conf ers</w>
catal ase,</w>
carcinogen icity</w>
anti- tumor</w>
DE -
B [a]
AB CC
9 8</w>
) -1-
week s)</w>
vasodi lation</w>
thorac ic</w>
platel ets</w>
par alysis</w>
hi sti
hemat ological</w>
glucocortico id
gamma ,</w>
deli ver
cran ial</w>
controver si
bi phenyl
ax is.</w>
andro st
acr yl
H er</w>
F our
B as
Angi otens
) =
( Z
xanth ine</w>
protec ting</w>
pow er
one- treated</w>
mo tility</w>
in sen
hypothe size</w>
hist ology</w>
grow ing</w>
glutam at
endothel in</w>
drug- resistant</w>
d itary</w>
cytokin es,</w>
al -induced</w>
E pi
CO X</w>
Bax ,</w>
4 0-
phen olic</w>
ore dox
o )</w>
n om
ine 's</w>
immun omod
group ).</w>
gr ap
elic it</w>
e z
dyst onia</w>
deli vered</w>
antipsycho tics</w>
am yl
adul ts.</w>
ac yclo
TGF- beta1</w>
ATION S:</w>
tim ul
re arrang
os ity</w>
orph in</w>
microgram /
ing est
i m</w>
erythro cytes</w>
epirub icin</w>
docum ent
con junction</w>
compoun d,</w>
chemo at
cath eter</w>
antidepress ants</w>
[ (3)
T yp
S SR
DNA -binding</w>
Compar ative</w>
CYP2B 6</w>
2 2.
1 -</w>
)- dependent</w>
termin ation</w>
s.c .</w>
ph ases</w>
paroxet ine</w>
p ra
micro vascular</w>
methyl prednisolone</w>
isch aemic</w>
interac ts</w>
immun ost
eth ambut
conf oun
colon y-
cit alopram</w>
cime tidine</w>
cer ul
backgro und</w>
asbest os</w>
S el
E A
C he
A si
6- year-old</w>
- H
( +/
ulcer ative</w>
st ates</w>
ran iti
open ia</w>
ongo ing</w>
lung ,</w>
id ase</w>
femal es.</w>
de tom
cyc le,</w>
be strol</w>
b ud
amelior ate</w>
MC s</w>
I T</w>
AL T</w>
toler ated.</w>
tech n
parox ys
ou gh</w>
osi ti
min ocycline</w>
lisin opril</w>
le ak
ketocon azole</w>
impair ment.</w>
ful l-
fo ot</w>
enhanc er</w>
deteri or
dele tions</w>
d d
com a</w>
al is</w>
adrenocept ors</w>
a defo
SM C</w>
N itro
1- year-old</w>
roten one</w>
re perfu
proced ures</w>
por cine</w>
p yl
kel et
in- like</w>
hepat otoxic</w>
ex ist</w>
ei gh
cysti tis.</w>
aden oma</w>
a reas
T L
LD L-
Jan uary</w>
I U/
GST P
CC R
0. 25</w>
) -1
(S )-
( at</w>
uter o</w>
ro ute</w>
reac tion,</w>
post ulated</w>
phosph odi
ph er
p5 3.</w>
p 27
mil li
me an
inten si
ing )</w>
imidaz o[
hypoxia- inducible</w>
hospit al
homeost asis.</w>
genotyp ing</w>
fl an
dis sociation</w>
de mograph
cortex .</w>
complex .</w>
andro genic</w>
alcoh ol
a uc
Sp 1</w>
Reg ulation</w>
C oca
( *
ver sion</w>
trigg ers</w>
techniqu es</w>
str ati
som at
progres sively</w>
preval ent</w>
p in
my c</w>
monit or</w>
los art
gl and
er t
contin ue</w>
clos ed</w>
b if
azol e.</w>
PAI -1</w>
Le vel
I P)</w>
HD L-
GST M
FK50 6</w>
Da y</w>
1A 2</w>
( control
v es,</w>
pregn ane</w>
mim ic</w>
me detom
long- lasting</w>
j ust</w>
io facial</w>
dy sp
diabet es,</w>
d ate</w>
W K
P e
MTH FR</w>
Ch E</w>
CI PA
(2 ).</w>
weigh t)</w>
tubulo interstitial</w>
sph ing
resist anc
require ments</w>
pod ocyte</w>
phen ol
other wise</w>
oc tre
myoclon us</w>
im ide</w>
if ost
hypokal emia</w>
famil y.</w>
f a
electrocardi ogram</w>
cytoplas m</w>
cult ure.</w>
c .</w>
block er,</w>
ator s.</w>
an -induced</w>
PGE (2)</w>
P MA
LY 29400
IC I</w>
F i
Experim ental</w>
2 B</w>
- 4-
y ond</w>
tumori genic</w>
tric yclic</w>
top ois
streptozotoc in</w>
senesc ence</w>
rifamp ic
p ene
onco gene</w>
obser ve</w>
n ACh
hom ogen
fenflur amine</w>
cyt osine</w>
becl ometh
ac tion,</w>
S equ
O .</w>
In flu
GS K-
D ).</w>
Assess ment</w>
vit al</w>
tobac co</w>
scaven ger</w>
haloperid ol.</w>
fl um
dose- limiting</w>
degener ation.</w>
cyclospor in</w>
compl ain
com patible</w>
cap sul
bro ad
brady kinin</w>
b it
ang u
ag re
act in
N-methyl-D- aspartate</w>
HaCa T</w>
GF R</w>
C x
5-HT (1
-1 ).</w>
sion -
r ation
on idine</w>
immun ocyt
immun ity</w>
ic al
gener ate</w>
discharg e</w>
der .</w>
de m</w>
con form
co enzyme</w>
cef triax
as sem
an ore
adip ocyte</w>
N P)</w>
MM P</w>
Level s</w>
Ikappa B
Hodg kin
CB Z</w>
7 5%</w>
20 35
2, 3-
- 3
(NS AID
( BP
val vular</w>
trans mis
strok e.</w>
rang e.</w>
p 6
ol one</w>
mon ocytic</w>
lif e.</w>
leng th
hippocamp us.</w>
hepat ocytes,</w>
h ind
e ].</w>
cor tic
chemoat tract
beta- blocker</w>
ac yl
Thir ty</w>
TCDD -induced</w>
O N</w>
Ne vertheless,</w>
E ),</w>
C >
3. 1</w>
(MAP K)</w>
threshol ds</w>
refle x
li th
l /
k eletal</w>
ine- resistant</w>
g/ d
el in</w>
effect or</w>
dom ains</w>
diet ,</w>
cardiomy ocyte</w>
bra ins</w>
and ed</w>
Invol vement</w>
H2O 2</w>
H MG
DN MT
Cad mium</w>
C PT
Addi tion</w>
9 7</w>
v ine</w>
typ es.</w>
poly (ADP-ribose)</w>
perid one</w>
not ed.</w>
ner ves</w>
l ing
j un
immortal ized</w>
cyt ometric</w>
cell s)</w>
calcitri ol</w>
age- matched</w>
acidi c</w>
acet am</w>
ac ,</w>
PPAR y</w>
H 2A
E N
D (3)</w>
A min
(M n
( Q
xenograf ts</w>
t ary</w>
retrospec tively</w>
practic e</w>
power ful</w>
peroxid ation,</w>
pene tr
ma ke</w>
lan sop
flu x</w>
cytos kelet
construc t</w>
concer n</w>
atax ia</w>
a ure
S S</w>
N on-
I R
AB CB1</w>
(Ah R)</w>
( an</w>
year .</w>
ve dil
u si
u f
scaveng ing</w>
sc an</w>
remark ably</w>
op tion</w>
onco genic</w>
nitros amine</w>
mutag ene
gu anine</w>
excl uded</w>
distri but
cop y</w>
ch ar
catalep tic</w>
bind ing.</w>
attac k</w>
ar abine</w>
amil or
Sr c</w>
P res
Inv estig
C a</w>
AKR 1C
3T 3-
(C O
yl ]
tic .</w>
repe at
paraox on
offsp r
obstruc tion</w>
minut es.</w>
metr onid
me t</w>
it y:</w>
investig ating</w>
hyp oglyc
exclu sively</w>
ex ci
dec i
cortico sterone</w>
chlor pyrif
ble ,</w>
S y
M orph
H F</w>
DE S</w>
D /
CYP1A 1,</w>
A h</w>
2. 2</w>
1. 6
1 3,</w>
0. 9</w>
. ).</w>
vascul ar
re adily</w>
precipit ated</w>
ondan setron</w>
mor ning</w>
ev o
eph edr
degrad ation.</w>
de v
cytos ol</w>
concomit antly</w>
colchic ine</w>
categ or
beta- adrenoceptor</w>
aor ta</w>
[(3) H]
R osi
MEASURE MENT
Ig G</w>
Hodgkin 's</w>
G W
Di ab
4 )
(5 )</w>
underli e</w>
t ardive</w>
stat e.</w>
phot o
omep razole</w>
k s.</w>
indina vir</w>
in :</w>
h ment</w>
cortis one</w>
casp ases</w>
apr ide</w>
PA -
IF N
C K</w>
3 B</w>
(P F
ur ate</w>
trache al</w>
thi ol</w>
st op</w>
nex in</w>
neuropath y,</w>
l ap
inv asi
ed ;</w>
disrup ted</w>
dec arboxyl
cycl ase</w>
consi der</w>
cerebro vascular</w>
bre ath
anti retroviral</w>
accum ulated</w>
GAD D
G N</w>
G -1</w>
Fif ty-
C an
B6C3 F1</w>
B- cell</w>
AL L</w>
3. 2</w>
( NF-kappa
t on</w>
sup ine</w>
stimul us</w>
ro un
person s</w>
per oxy
oste oc
intro n</w>
intracere bro
ine ].</w>
id .</w>
high- density</w>
hemod ynamics</w>
g et
epidemi ological</w>
des ensi
comple ment</w>
bas olateral</w>
analog u
an oid</w>
al idomide</w>
ag it
R T</w>
PD 980
PA H</w>
P ulmonary</w>
L ys
(COX -2)</w>
tric ho
thrombo embolic</w>
t es</w>
synucle in</w>
ni ght</w>
intrav ascular</w>
hyperalge sic</w>
hydro ph
haplotyp es</w>
ex change</w>
cran iofacial</w>
cont ent.</w>
care ful</w>
be d
amin obut
[ 4-
R L
K (m)</w>
ER a</w>
A sp
+ ,</w>
(p =0.0
ur sodeoxycholic</w>
tachycardi a,</w>
ste ad</w>
ro b
plas mid</w>
op lat
li ving</w>
h and</w>
facilit ated</w>
event ually</w>
efficac y,</w>
e ase</w>
catalep sy.</w>
bio activation</w>
be yond</w>
auth or
ator ,</w>
amitriptyl ine</w>
al ing</w>
aim s</w>
accumben s</w>
UD P-
U S</w>
N M
Mitochond rial</w>
K ore
y cin
week .</w>
uro thelial</w>
t un
sot alol</w>
orig in
on es.</w>
ogram s</w>
methylphen idate</w>
membran e.</w>
ine ),</w>
her bic
fibrill ation.</w>
distribut ed</w>
bo vine</w>
ar y.</w>
S ul
NAT 2</w>
MCF 7</w>
AR F</w>
( b)</w>
reli able</w>
radio therapy</w>
micro glial</w>
men .</w>
lys ine</w>
loc omo
immuno fluorescence</w>
hospit al.</w>
her oin</w>
glucocortico ids</w>
gemcit ab
expan sion</w>
dementi a</w>
contex t</w>
S il
Rep e
RA S</w>
R XR
K (+)</w>
Hyp ot
H O</w>
E GC
2 4.
ud g
tan dem</w>
spectro scop
some times</w>
si x
respectively ),</w>
phosph oin
particip ated</w>
p =0.0
osmo tic</w>
ol -treated</w>
occlu sive</w>
multic ent
ma king</w>
leuk ocytes</w>
is os
intoxic ation.</w>
gefit inib</w>
fill ing</w>
f ast</w>
eosin ophil</w>
ear ly-
don ors</w>
dis semin
depart ment</w>
day ),</w>
d ental</w>
blun ted</w>
al /
Th rom
P- treated</w>
L-NA ME
L ;</w>
GST T1</w>
7 %,</w>
1. 3
tramad ol</w>
th is,</w>
swell ing</w>
shorten ing</w>
self- administration</w>
sec tional</w>
rap amycin
ot opic</w>
ometr y</w>
monit or
mmHg ,</w>
man ip
load ed</w>
infer ior</w>
explan ation</w>
electrophore sis</w>
el ig
caspase- 9</w>
c ation</w>
Lith ium</w>
En d
CL L</w>
Be havi
ultras tructural</w>
uc ul
t ly,</w>
sensitiz es</w>
recor ds</w>
rat s:</w>
pre frontal</w>
pathophysi ological</w>
over dose.</w>
on ide</w>
manifest ation</w>
it rac
iso flur
inf requ
h ind</w>
exist s</w>
exhib iting</w>
examin ations</w>
cl es.</w>
cave ol
carbon yl</w>
bel ong
b ular</w>
at ech
ann exin</w>
all ergen
PATIENT S:</w>
PA ),</w>
D MB
Caucasi an</w>
C S</w>
7- year-old</w>
2. 4</w>
tw o
tion ;</w>
sal ine.</w>
ni gh
loc ally</w>
interac tions.</w>
in tran
in t
in sensitive</w>
fav our
bic arb
arrest ,</w>
an emia,</w>
Tam oxif
Pharmac ological</w>
OUTCO ME</w>
M ar
F em
B G</w>
Ak t/
6 0,</w>
tempor ary</w>
ot ax
ore s</w>
od ,</w>
oc om
mg/ day,</w>
lin king</w>
l ),</w>
integr in</w>
ifer in</w>
granul osa</w>
glutamat ergic</w>
gamma )</w>
ethan ol-induced</w>
ent -
cathep sin</w>
bri ef</w>
all op
all erg
aden os
abnormal ities,</w>
[ 2-
T d
NF kappaB</w>
N orm
Influ ence</w>
HT -2
G AT
D C</w>
CD DP</w>
3 ',
2 ',
.00 1).</w>
wor k,</w>
us ed,</w>
tend ency</w>
sper mat
progres sion,</w>
nal trex
mon ol
medic ine</w>
inter fe
id ylate</w>
i i)</w>
gra m</w>
fr am
fibro z
extr act
ex chang
em a</w>
electroly te</w>
e in</w>
d :</w>
Sur viv
S CC
P =
Me as
F ),</w>
Cr(V I)</w>
C/E BP
Ad ult</w>
-2 0</w>
- positive</w>
wom en
ver ified</w>
useful ness</w>
tri phosphate</w>
topois omerase</w>
spec ial</w>
repor ting</w>
reas on
prot otyp
poison ing.</w>
oxido reductase</w>
long- acting</w>
ir in
ing es
far nes
er ro
d ar
d ;</w>
cr yp
comple tion</w>
carb ox
c in</w>
ap i
and om</w>
TNF alpha</w>
S odium</w>
Ris k</w>
ye ast</w>
thi oredox
sul fam
stain ing,</w>
sha m</w>
secre tion,</w>
rob ust</w>
ro f
re ach</w>
ras h</w>
protec tion.</w>
osyl transferase</w>
nai ve</w>
me flo
lo vastatin</w>
ish es</w>
im ag
ic s,</w>
here ditary</w>
gen otoxicity</w>
experim ent,</w>
e ther</w>
ch ore
carri er</w>
bradycardi a.</w>
accumul ation.</w>
abol ism</w>
Wn t</w>
S BP</w>
H K
H A</w>
G er
CYP3A 5</w>
A beta</w>
(H UVEC
(-1 ))</w>
( p-
( 8</w>
zol edr
vit amin
u v
thyroidis m</w>
tetrac hlor
sp ite</w>
s ch
pir atory</w>
otom y</w>
ni ac
my co
lipid -
iso zym
in appropriate</w>
implant ation</w>
hallucin ations</w>
h ol
glycer ol</w>
flum azen
f .</w>
examin ing</w>
damag ing</w>
ad ec
abnormal ity</w>
I M
I AP</w>
E m
A no
3. 3</w>
.0 5).</w>
vasospas m</w>
u ous</w>
tryptoph an</w>
ti tive</w>
sal ine,</w>
rest ore</w>
record ings</w>
pyr rol
per in
paroxys mal</w>
p ,</w>
op last
m on</w>
interac tion.</w>
gen der</w>
determin ants</w>
co administration</w>
basel ine.</w>
aten ol
anaesthe tized</w>
aden ine</w>
TUNE L</w>
S A)</w>
Prolong ed</w>
Pre -
B U
AT F
x en</w>
vin yl</w>
synovi al</w>
suscepti bil
s par
ol g
nit rate</w>
metallothione in</w>
mes enteric</w>
is es</w>
i.p. ),</w>
headache ,</w>
fluoresce in</w>
fen adine</w>
dr y</w>
dep end</w>
com b
chloram phenic
cer amide</w>
cas e.</w>
bo x</w>
b /
anc es,</w>
T ro
In f
Gr ade</w>
G H</w>
G E</w>
E B
10 0,</w>
seg ments</w>
re generation</w>
po wer</w>
normal ,</w>
nic kel
labet alol</w>
in stead</w>
im at
gl auc
experim ents.</w>
ed :</w>
dog s,</w>
de methyl
cord ingly,</w>
chromat ograph
Previ ously,</w>
P RE
N S)</w>
M B</w>
F M
7 4
2. 1</w>
14 5</w>
1 2.5</w>
( all</w>
we an
un common</w>
stimul ant</w>
st one</w>
sion :</w>
retur n</w>
retin oids</w>
regul ation,</w>
pro ve</w>
p ip
ouab ain
o dr
monol ay
high light</w>
epileptic us.</w>
dou bl
conf er</w>
compreh ensive</w>
comp et
co- treatment</w>
acetaminophen -induced</w>
UGT1A 1</w>
PCB s</w>
O p
Indometh acin</w>
I Q
EP O</w>
2 6.
(AC E)</w>
( approximately</w>
vin blast
um ab</w>
therap ies.</w>
pro top
plic ation</w>
opi oids</w>
induc ers</w>
gangli a</w>
dyskine sia.</w>
cyt otoxicity,</w>
creatin ine,</w>
co valent</w>
cardi opulmonary</w>
at e)</w>
aldehy de,</w>
absor p
Pac litax
N ,
F T</w>
E E</w>
AID S</w>
1 1)</w>
transplant ed</w>
trans- retinoic</w>
tion :</w>
stand ardi
si ded</w>
picro toxin</w>
phenyleph r
p unc
orub ic
nic ardipine</w>
modul ators</w>
meta- analysis</w>
lymph ocytes.</w>
imidazo[ 4,5-
ibu prof
hypertroph y,</w>
hydr alazine</w>
erg ot
e icos
contrac tility</w>
cl omi
carb oplat
benzo[a] pyrene</w>
am p</w>
agonist s.</w>
Z ,</w>
TLR 4</w>
T op
Inc ub
Immunohist ochemical</w>
Ch lor
Ac cording</w>
9- year-old</w>
8 0,</w>
6 5
yl line</w>
ust rial</w>
striat um.</w>
stopp ing</w>
pre ference</w>
pect or
no tic
n mol
methyl ene
mE q/
iti n</w>
ind ustrial</w>
hyperprolact inemia</w>
glitaz one,</w>
fashi on.</w>
fascic ul
factor -1</w>
clin ic</w>
chemoattract ant</w>
at on
anc es.</w>
analy ses.</w>
age en
PL A
NF-k appa</w>
IS O</w>
Car vedilol</w>
A G</w>
3 7.
2 D3</w>
(5-FU )</w>
( GF
wor king</w>
weigh t.</w>
vag al</w>
swit ch</w>
supple ment
sor afenib</w>
slic es</w>
sh ap
retard ation</w>
pur pos
predic tion</w>
phenyl )-
parallel ed</w>
pa fen
op sy</w>
ne ede
inter individual</w>
exci sion</w>
dihydroxy vitamin</w>
da y-
bio transformation</w>
bin o</w>
ator vastatin</w>
antagon ize</w>
Xen op
Whe ther</w>
Uni versity</w>
S tr
S af
Not ably,</w>
N ife
N C
K n
Dec reased</w>
B MP
1. 9</w>
vin orel
ultim ately</w>
transpor ting</w>
thal idom
su ic
ste red</w>
protein uria,</w>
paren teral</w>
osyn cr
mis artan</w>
li gn
infec tions.</w>
frac tion
fluc tu
e a</w>
diethylstil bestrol</w>
cholest asis.</w>
children ,</w>
c ra
at -
as yst
ap l
amant adine</w>
X- linked</w>
S ou
G S</w>
Elev en</w>
6 0-
4- fold</w>
(1 5
x ameth
un its</w>
tim olol</w>
qu ar
pl ate</w>
ov ary</w>
oligonucle otide</w>
neuro genic</w>
neuro degeneration</w>
muscle .</w>
m arg
immun ological</w>
def ined.</w>
conduct ance</w>
az ine,</w>
al fentanil</w>
SOD 1</w>
S MA
P GF
O CT
LT )</w>
Cap sa
4 3
2 5.
vag inal</w>
psor iasis</w>
po ol
phosphoin ositi
per ind
occa sion
mimic ked</w>
metast asis.</w>
i k
flow ,</w>
c os
ar abin
allow s</w>
abil ities</w>
[ CI
S elective</w>
ER G</w>
E- cadherin</w>
D (2)</w>
BALB/ c</w>
AB C
A- I</w>
A O
1 a</w>
.00 0
(C R
ve get
uron ium</w>
sertr aline</w>
ris k,</w>
p ass
nigr a</w>
ne t</w>
melan oma.</w>
lung .</w>
ine- associated</w>
gamma- glutam
g radi
flavon oid
fail ure
dro p</w>
de red</w>
d- PGJ
chr ys
challeng e.</w>
candid ates</w>
c id
ator s,</w>
arrhythmi a.</w>
ap nea</w>
aminobut yric</w>
albumin uria</w>
Pre vention</w>
M P-
LD H</w>
I SO
Cl 2</w>
B D</w>
8 ;</w>
2. 3</w>
17 ,</w>
(H IF
up take.</w>
unc lear</w>
tr is
succinylchol ine</w>
sten osis</w>
st em
phospholip id</w>
organ ochlor
my ri
metr y</w>
metabol iz
loc ation</w>
ill ness</w>
flav opirid
fashi on</w>
e .g
duc t
d acarb
cyclophosph amide,</w>
c and
bodi es</w>
b red</w>
b an</w>
at ter
apomorph ine-induced</w>
aldo ster
U R
S P</w>
IL-1 b</w>
GSK- 3
CYP3A 4,</w>
BR CA1</w>
0.0 2).</w>
0 2</w>
-1 1</w>
(max )</w>
(1 )
( TH
ur ium</w>
u an
transfer ase,</w>
skin .</w>
separ ated</w>
ro t
r in,</w>
prog ram</w>
parathyro id</w>
pac ing</w>
out patients</w>
omer ic</w>
nitro fen
mo ve
mechanis m,</w>
hn 's</w>
form er</w>
et ary</w>
e asi
depri vation</w>
dec om
car vedil
calci um-
VE GF-
Un like</w>
Gen otyp
Fif teen</w>
BP ,</w>
(T B
(+ )
z ine</w>
un like</w>
tr active</w>
teste d,</w>
sple en</w>
sh am-
rever ses</w>
recomm end
proper ty</w>
posi tion.</w>
os es</w>
orth ostatic</w>
oper ation</w>
man .</w>
ju ven
heterogene ous</w>
gro s
f al
cri tically</w>
conjug ates</w>
confir ming</w>
con formation</w>
c- myc</w>
c och
br anc
behavi our
anti oxidative</w>
ag as
T T
SI AD
MK-80 1</w>
M en
IL -2
E F
D ys
CE :</w>
Adri amycin</w>
AB T-
3A 4</w>
(T GF-
spironolact one</w>
rhabdomy olysis</w>
re presented</w>
re present
pig s</w>
phen oxy
p im
ome g
ocyan ate</w>
ob tain</w>
ment ally</w>
ine ).</w>
gen ol</w>
du od
diaphrag matic</w>
dec id
conc ept</w>
cell- cycle</w>
bic ucul
b ene</w>
ather ogenic</w>
app ed</w>
administe red.</w>
T est
N D
G D</w>
Er b
DNA ,</w>
ATP7 B</w>
16 )</w>
* 3</w>
( -2
well .</w>
w ound</w>
saf et
ple ural</w>
parameter s,</w>
pap aver
non selective</w>
leuk aemia</w>
l in</w>
it abine</w>
inn ate</w>
infec tion,</w>
fem oral</w>
encoun tered</w>
electrophore tic</w>
e- dependent</w>
domin ant
cy pro
cas tr
aqu eous</w>
Xenop us</w>
Sup pression</w>
S H</w>
EGC G</w>
CYP 1
9 4</w>
5-aza- 2'-
2. 6</w>
(P =
(P -
(2 0
( CL
warr an
transfer rin</w>
til ity.</w>
there after
retin ol</w>
retin oblastoma</w>
nimesul ide</w>
napro xen</w>
malignanc ies</w>
iso thi
inhibitor )</w>
idi um</w>
heter ozygot
fol d.</w>
famoti dine</w>
end point</w>
dyskine tic</w>
cor ne
co incid
benz oic</w>
attenu ating</w>
acid s,</w>
Y -
S hor
P TH
P P</w>
Le ft</w>
K .</w>
Hg )</w>
D ose-
Cyt ochrome</w>
Cardi ovascular</w>
8 %,</w>
( 8-
z one</w>
y ch
thromb oxane</w>
ter ,</w>
ta ined.</w>
sen sus</w>
r andom</w>
preser ved</w>
or s,</w>
ogen icity</w>
o estrogen</w>
medull a</w>
m line</w>
lipopolysacch ari
he i
hap s</w>
end- stage</w>
cros s</w>
conclu sion</w>
catechol amines</w>
carbon ate</w>
allevi ated</w>
al lowing</w>
aff or
a ;</w>
S -1</w>
Res earch</w>
PG E1</w>
P Q
N uclear</w>
L RP
IF N</w>
Hist ological</w>
F an
CD 4</w>
Ac cordingly,</w>
0.00 1</w>
(50 0</w>
(3 00</w>
t ap
swit ched</w>
st s</w>
splic ing</w>
re presenting</w>
propion ate</w>
or in</w>
o k
mus cles</w>
migr ation.</w>
lithi um-induced</w>
hear t,</w>
guid el
four -
encephal opathy.</w>
e w
as e
adefo vir</w>
accept able</w>
abl ation</w>
V is
S P-
Nicot ine</w>
MD MA</w>
L abor
H R)</w>
Estro gen</w>
CYP1A 2,</w>
CYP 1B
6 %,</w>
1. 5
1 10</w>
(N MD
( 60</w>
w all
terat ogenic</w>
survi ved</w>
ri gh
rel im
re model
p 4
myel osup
micron ucle
mesotheli oma</w>
l -like</w>
ic ular</w>
guan osine</w>
estradi ol,</w>
echocardi ographic</w>
cit rate</w>
cin nam
c AMP-
ast e</w>
an s,</w>
Z in
U l
Toxic ity</w>
RT-PC R,</w>
N ar
MD R</w>
Cor onary</w>
Be fore</w>
Bas eline</w>
B C</w>
As(2)O (3
Amiod arone</w>
A 1,</w>
8 2
6 77
1. 2
(MAP )</w>
un saturated</w>
system atic</w>
side .</w>
remif entan
pris ingly,</w>
nucleoti d
na ire</w>
n mol</w>
myasth enia</w>
morph ine,</w>
mit ral</w>
malignanc ies.</w>
lip oxygenase</w>
lethal ity</w>
ju n</w>
ia sis.</w>
flow .</w>
er ic</w>
den er
de methylation</w>
convul sions.</w>
clon al</w>
but yr
at ely,</w>
accoun ted</w>
UDP- glucuron
TCD D-
PI3K/ Akt</w>
P i
O ut
HEK 293</w>
H PL
G T</w>
D E</w>
2 *
(4 ,
whe re
shor tly</w>
reser pine</w>
profi le.</w>
pollut ants</w>
pent obarbital</w>
or =
obarbit uric</w>
neurotransmit ter</w>
microsom es.</w>
ke phal
in- related</w>
imid azol
hyperglyc emia</w>
gene sis,</w>
fac e</w>
cross- over</w>
cl amp</w>
cell s;</w>
carr ageen
am bi
[ Ca(2+
V P</w>
S ta
N o
N /
M /
F act
3. 6</w>
traffic king</w>
tiz ing</w>
test s,</w>
tamoxif en
splic e</w>
progres sed</w>
polyphen ols</w>
par ad
ox ia</w>
morph ologic</w>
month s)</w>
investig ation.</w>
ing s.</w>
in one</w>
immunohistochemistr y.</w>
hemorrh age.</w>
haloperid ol,</w>
gener ating</w>
end oscop
diam eter
cord ance</w>
c ost</w>
ass et
alpha /
agonist s,</w>
age- related</w>
abstin ence</w>
P- 450</w>
INTERVEN TI
HIF-1 a</w>
Ex c
(P h
ur able</w>
u g
ti ous</w>
synthet ase</w>
stimul ation,</w>
set ting.</w>
psych omotor</w>
propyl thiourac
pl ants</w>
otri g
mixt ures</w>
men str
m ation</w>
le ster
hypercalc emia</w>
hel p
gal act
g/ kg</w>
for sk
diltiaz em
de t
construc ted</w>
clas sic</w>
[ 95%</w>
S C</w>
In sul
Fan con
Casp ase-
CD4 +</w>
BR CA
1, 4-
(N F
(C H
(1 2</w>
v ac
un g</w>
tim al</w>
so on</w>
rescu ed</w>
py raz
promot ers</w>
phen hydr
om ics</w>
mut ation,</w>
mark ers,</w>
kinas e/
hom olog
etom idate</w>
cataly zes</w>
bio availability</w>
an in</w>
accumul ation,</w>
III ,</w>
HB e
Con sider
Al l
ATI ON:</w>
17 )</w>
(SNP s)</w>
week -old</w>
vigabat rin</w>
vals artan</w>
sensitiv ity,</w>
rel ate</w>
produc ts.</w>
pren e
ost atin</w>
odi c</w>
neuro psychiatric</w>
ivaca ine</w>
ing :</w>
index ,</w>
implic ate</w>
grow n</w>
et ron</w>
embry o</w>
ec l
days ).</w>
compris ed</w>
ch am
cardi otoxic</w>
anti platelet</w>
all y-
Zin c</w>
Typ e</w>
S RE
Med ical</w>
HD AC</w>
9 ,
6 ;</w>
-L- arginine</w>
y r</w>
worsen ed</w>
volume ,</w>
ur i
tryp t
sur roun
reth ro
pup s</w>
part um</w>
mi tig
meto prol
kin ase.</w>
ifost ine</w>
hyper kal
en kephal
ell a</w>
compl ained</w>
com position</w>
block .</w>
bind ing,</w>
b und
amin ob
alum inum</w>
alpha-tocopher ol</w>
alpha ),</w>
agon istic</w>
T yr
PS A</w>
P ri
N RF
MC -
K e
II -
HCT 116</w>
E 2-
Comple te</w>
Com p
C entral</w>
(NS CL
( including</w>
to br
slow ly</w>
pre operative</w>
praz ol
popul ation
picro tox
per haps</w>
ozyg osity</w>
oxet ine</w>
mi RNAs</w>
keratin ocyte</w>
intr ad
indomethac in.</w>
im mature</w>
gener ation,</w>
form aldehyde</w>
calcineur in</w>
autophag ic</w>
adenocarcin omas</w>
ad ding</w>
a udi
TER T</w>
Pro po
Mcl -1</w>
In divid
Hydro xy
D ue</w>
CA ,</w>
Bra in</w>
Afr ic
3 5%</w>
transfer ase-
rig id
repor ted,</w>
protein uria.</w>
propor tional</w>
oz one</w>
over load</w>
ot otoxicity</w>
orig inal</w>
noc tur
nitro fen</w>
inte resting</w>
instil lation</w>
inser tion</w>
idi osyncr
fruct ose</w>
fi g
continu ation</w>
arb it
anser in</w>
am oxic
O (2)</w>
INTERVENTI ON
Four teen</w>
D SM-
A S)</w>
3. 8</w>
(P D)</w>
sul fo
see king</w>
salbutam ol</w>
rod ents</w>
respon der
reach ing</w>
progres s</w>
predis posing</w>
peri pher
my ot
meth amphet
ip )</w>
intra hepatic</w>
in activated</w>
id -
hypox ia.</w>
hospit alization</w>
gangli on</w>
g ated</w>
fol low</w>
flec ainide</w>
ell ate</w>
discontinu ing</w>
di al</w>
delt a-
de d,</w>
conjug ate</w>
cent er</w>
carb o
aug mentation</w>
ap tic</w>
al te
al bino</w>
ab rup
U ,</w>
Sub sequently,</w>
S D)</w>
Rever sible</w>
Q RS</w>
Incub ation</w>
F /
Develop ment</w>
D ic
CB F</w>
BP 1</w>
6- hydroxy
4. 0</w>
3 a</w>
2. 5
(6 )</w>
whi le,</w>
ver bal</w>
v is</w>
tumori genesis.</w>
trans dermal</w>
sub cellular</w>
ran k</w>
promot er,</w>
pres yn
physici ans</w>
og lit
monke ys.</w>
molecul e-1</w>
migr ation,</w>
mg/ L</w>
immunoglob ulin</w>
hepati tis,</w>
dominant -negative</w>
develop ed.</w>
coll ap
bra in-
S ep
Repe ated</w>
Phen y
O C</w>
M il
LVE F</w>
HT-2 9</w>
Dex amethasone</w>
5. 5</w>
1 30</w>
0. 0</w>
( up</w>
( as</w>
vesi cal</w>
un likely</w>
tumor .</w>
ter t-
sty rene</w>
res ection</w>
re :</w>
pyr uv
prog est
microg/ kg</w>
micro molar</w>
metalloprotein ases</w>
men ,</w>
medic ations.</w>
mechanism (s)</w>
indic ation</w>
in take.</w>
i.p. ,</w>
i bility</w>
hemoly sis</w>
follow s:</w>
excre tion.</w>
es are
end ocardi
ec oxi
ec hol</w>
ear ch
cG MP</w>
c asset
bi ologically</w>
ar ds</w>
app reci
acc ep
T ).</w>
Pati ent</w>
D 4</w>
B ar
A 1
(D A)</w>
(2 00
ur ine.</w>
tri am
thi obarbituric</w>
temozolom ide</w>
su xameth
pertur b
min al</w>
li poly
il ine</w>
hydroxy steroid</w>
gem fibroz
fas ter</w>
em ber</w>
e ther
det oxif
def er
cyclophosph amide-induced</w>
conjug ation</w>
co activator</w>
chang ing</w>
an ic</w>
L C-
Hep G
G n
10 .</w>
(i. e.</w>
( 9.
warran ted.</w>
un detectable</w>
toler ated,</w>
repress or</w>
region ,</w>
ou ter</w>
naph tho
n ol
mel phal
me -
li br
kin son</w>
hypothe sis,</w>
glut amine</w>
gall bladder</w>
g .</w>
fr u
fle x
ex ons</w>
evol ution</w>
esare an</w>
electro physiologic</w>
compli ance</w>
compart ment</w>
circul atory</w>
beclometh asone</w>
anore x
adolesc ents</w>
adip ocytes.</w>
S irt
R b</w>
PT H</w>
Mod ulation</w>
Drug -induced</w>
C57BL/ 6
+/ -2
(-1 ),</w>
z on
tr in</w>
tac rolim
stri king</w>
sep tic</w>
reduc ed,</w>
recover y.</w>
ration ale</w>
pro pafen
placeb o
phosphodi esterase</w>
mutag en
moi ety</w>
men tioned</w>
ir respective</w>
im p
glycol y
feed back</w>
easi ly</w>
e b
e IF
dissemin ated</w>
daun orubicin</w>
con sensus</w>
athi on</w>
[ A</w>
TNF- alpha,</w>
T 47
SB 2035
Rosi glitazone</w>
R andom
Pre gn
P lat
E :</w>
C- terminal</w>
Ano ther</w>
3 %),</w>
20 )</w>
19 -
(6 )-
(4 00</w>
wat er.</w>
thromb osis.</w>
test ing.</w>
super ficial</w>
standardi zed</w>
rat es.</w>
patient s:</w>
otroph ic</w>
multi ple
mi RNA
medetom idine</w>
k b</w>
ind olol</w>
i ent</w>
gen ital</w>
ga p</w>
decarboxyl ase</w>
cross- sectional</w>
con stitute</w>
cocaine- dependent</w>
blot .</w>
bl ack</w>
beta 2</w>
as par
an atom
affin ities</w>
[ Ca2+
W ar
ST Z</w>
R G
L T</w>
Kn ock
K- ras</w>
G AP
G (1)</w>
DP D</w>
3. 4</w>
200 0</w>
- opioid</w>
( BP)</w>
% );</w>
traum atic</w>
transcrip tion,</w>
resid u
recomm end</w>
prote olytic</w>
progres sion
p all
orb ide</w>
neph ritis.</w>
micro bial</w>
mg/m 2/
methyl- 6-
il -induced</w>
gyr us</w>
dis position</w>
conform ational</w>
co de
antioxid ant,</w>
allop urin
St atis
S h
S M</w>
Pharmac o
P ur
ME K
M et</w>
L A
H 4
G RP
Dec ember</w>
D et
3T3- L1</w>
(A R)</w>
(1 50</w>
( or</w>
ure- activity</w>
tr ast
stradi ol</w>
re placed</w>
pharmac eu
om et
o prost
myel ogenous</w>
my ocyte</w>
leb itis</w>
k a
in stability</w>
gene ic</w>
gab ap
for aph
flu v
epsil on
epid er
dys regulation</w>
des cending</w>
cytokin es.</w>
contrac tions</w>
comp ul
combin ation,</w>
com for
buty rate</w>
beli eve</w>
ar y-
ar ial</w>
X 1</w>
W or
Saf ety</w>
P ).</w>
NS AI
E P</w>
v ent
ta uro
small- cell</w>
ron ate</w>
publ ic</w>
ph e
or y,</w>
miner al
mi RNA</w>
ip ril</w>
initi s</w>
id one</w>
id ine.</w>
i v</w>
her bal</w>
he mi
har ve
growth -
furo semi
fel odipine</w>
exc eption</w>
em ent,</w>
disrup t</w>
coumar in</w>
colony- stimulating</w>
collag en
cle ft</w>
cancer :</w>
c- jun</w>
applic ations</w>
admini stering</w>
U .</w>
Tamoxif en</w>
Respon se</w>
P =0.00
N al
I s
Character ization</w>
A V</w>
3. 0
0.0 4
-1 3</w>
(G P
siz e,</w>
saf ely</w>
regul ated.</w>
pa w
or listat</w>
n ess
mon o-
le d.</w>
inf ants.</w>
inclu sion</w>
ic .</w>
grad ual</w>
f um
environ ment.</w>
derm ati
beta- blockers</w>
av es</w>
aspir in,</w>
al i
ab el
X R)</w>
Seiz ures</w>
NO -
M ang
Cis platin</w>
CRE B</w>
COX -1</w>
C ellular</w>
1, 000</w>
(L D
(A M
y le
studi ed,</w>
s one</w>
repair .</w>
p3 8
or in
nit ren
l avage</w>
kind led</w>
k ing.</w>
immun e-
ic hi
frag ments</w>
fe asi
facilit ates</w>
ex port</w>
emerg ing</w>
dyspla sia</w>
dy e</w>
correc tion</w>
aut om
anti- proliferative</w>
allel e.</w>
TC E</w>
M us
Inde ed,</w>
G row
Di etary</w>
Con tin
C B</w>
Ad en
2- year</w>
(W T)</w>
world w
ventric ul
tw ent
streptozotoc in-induced</w>
reac tions,</w>
ra re,</w>
pro ce
preferen tial</w>
platin um-
outcom es.</w>
omi metic</w>
olog ies</w>
off ers</w>
octre otide</w>
noctur nal</w>
mitoxantr one</w>
me gal
lac tic</w>
is ul
interval s.</w>
indic ations</w>
fl am
ethyl -
duc tal</w>
clon es</w>
chemic als.</w>
cat arac
cas ca
beta- D-
assess ments</w>
as y</w>
ag ne
[Ca2+ ]
U 0
TP 53</w>
T ac
Sta phylococc
P /d
IN R</w>
IC H</w>
I ).</w>
Hospit al</w>
HCT Z</w>
DC s</w>
CO MT</w>
A b</w>
2 7.
1 R</w>
0.0 1,</w>
vi able</w>
titr ation</w>
salicyl ic</w>
rod ents.</w>
repe titive</w>
prene oplastic</w>
por ph
perc utaneous</w>
p ine.</w>
olig od
ol og</w>
meth amphetamine-induced</w>
medull ary</w>
lob ular</w>
ir b
diarrhe a</w>
conside red.</w>
care fully</w>
bupren orphine</w>
be ats</w>
an k
ak athi
TR PA
Re duced</w>
Elev ated</w>
Con sequently,</w>
Con comit
15 )</w>
12 5
1. 9
weak ly</w>
vi ro
vehicle -treated</w>
van il
ta urine</w>
reas on</w>
pres ent.</w>
patient s;</w>
over t</w>
organo phosphorus</w>
organo phosphate</w>
neurolep tics</w>
l l
juven ile</w>
ir on-
inter -
indomethac in,</w>
hippocamp us,</w>
g old</w>
g ive</w>
exten sion</w>
eth inyl</w>
es us</w>
construc ts</w>
cartil age</w>
bus pir
az ide</w>
androgen s</w>
W R
T ors
Six ty-
PC R,</w>
L ung</w>
Glut athione</w>
Fem ale</w>
F os
De pression</w>
4- week</w>
3 6.
2 b</w>
2 8.
1 );</w>
+ -
weigh ted</w>
u xim
top ir
thym idylate</w>
te m</w>
steroid ogenic</w>
st ers</w>
st ellate</w>
sal iv
ra ise</w>
r ub
promp t</w>
progn osis.</w>
patient s).</w>
particul ate</w>
oxali platin</w>
nephro sis.</w>
myocl onic</w>
method s.</w>
malari a</w>
lo st
ling ual</w>
kill ing</w>
hypothalam ic</w>
hae mo
estim ates</w>
diure tics</w>
dic hlor
d or
co ated</w>
cirrho sis.</w>
chol angi
cas cad
aure us</w>
at ally</w>
appe ti
[Ca(2+ )]
T K
S ymptom
H b</w>
H SC
B 12</w>
3. 7</w>
14 )</w>
0- fold</w>
(N rf
tr azod
termin ated</w>
sulfam eth
rit on
propranol ol.</w>
polyp eptide</w>
ph ent
par ts</w>
mou se.</w>
m atic
ir lu
hyperther mia</w>
genotyp es.</w>
g ar
follow-up ,</w>
di phenhydr
di oxide</w>
di -
counter acted</w>
cir cu
a ic</w>
[ Acute</w>
War far
T n
P2 Y
P ren
L-DO PA-induced</w>
L o
L IC
Cere bral</w>
2 1-
(VEGF )</w>
(MAP K
(2) /
( b
transcript ase-
syncop e</w>
rever sing</w>
represent ative</w>
region s.</w>
procain amide</w>
p. o.</w>
over- expression</w>
ocyte -
necess it
man ic</w>
isos orbide</w>
ey es</w>
extr av
experiment ally</w>
drug -related</w>
dis appearance</w>
diagno sis.</w>
bra in
are a.</w>
arch it
T arg
Syn dro
SOD ,</w>
O ver</w>
N -induced</w>
MA )</w>
M er
I V)</w>
GM- CSF</w>
B CRP</w>
-2 00
-1 6
- 6</w>
) -1</w>
yiel d</w>
year s;</w>
u te
sion ;</w>
regurg itation</w>
ophthal m
occasion ally</w>
mitochondri a.</w>
mannit ol</w>
if i
hypoxi a-induced</w>
gamma- aminobutyric</w>
follic ular</w>
en erg
dys rhyth
dop amine-
con dens
chang e.</w>
break s</w>
as cit
arrest ed</w>
anti parkinsonian</w>
adjust ing</w>
accumul ate</w>
Twenty- four</w>
Th 2</w>
R as
P /
N CI
Leu k
LC A</w>
K E
Ig E</w>
F V
C hemo
B L
AS -2
A UC
7 ;</w>
3 -</w>
-2, 5-
(G AB
(+/ +)</w>
vulner ability</w>
tol cap
titr ated</w>
ti ze</w>
t ong
protop orph
prostagland ins</w>
par ac
ox ide
orth otopic</w>
nephro genic</w>
my opathy.</w>
my ocytes</w>
mitochondri a,</w>
mg/ day.</w>
lamivud ine-resistant</w>
in- associated</w>
hydroxyl ated</w>
heterogene ity</w>
ging iv
ger m</w>
evalu ation.</w>
disulf ide</w>
dis per
di ets</w>
de mic</w>
con sol
con ferred</w>
chemokin es</w>
ch os
centr ally</w>
c AMP
bud es
blocka de.</w>
bas ement</w>
asbest os
archit ect
ammon ia</w>
amin ation</w>
T PA</w>
P ol
Labor atory</w>
L- arginine</w>
Bis phenol</w>
B ac
2. 7</w>
- in</w>
(i ii)</w>
yohim bine</w>
vinorel bine</w>
transl ated</w>
tr ue</w>
to thec
si ve,</w>
resor uf
pro s
pre -</w>
p ,p'-
multicent er,</w>
methyl-4- phenyl
man ia</w>
lymph oma.</w>
lum inal</w>
leuko encephalopathy</w>
ic k
hyp om
exclu ded.</w>
docetax el
del ine
al ut
Z O
Throm b
TNF- alpha-induced</w>
Sur prisingly,</w>
R D
P OR
Grou p.</w>
G C</w>
Cro hn's</w>
AD .</w>
29 5
2 D</w>
tri ple</w>
thiop ent
techniqu e.</w>
sub acute</w>
st o
process es,</w>
p3 8,</w>
mutagene sis</w>
mut ational</w>
mar k</w>
lip ase</w>
lig and,</w>
ic h,</w>
h in
fing er</w>
enanti omers</w>
dismut ase,</w>
compromis ed</w>
ca dian</w>
br ile</w>
bio active</w>
anthrac yclin
Z .</w>
V P
T NB
Staphylococc us</w>
S wis
RA .</w>
Pro st
P Y
My c</w>
I C</w>
HIV- infected</w>
G al
Bcl-x L</w>
B o
AD HD</w>
2. 8</w>
10(- 6)</w>
(RA )</w>
(E T
( v
x yl
thrombo embolism</w>
surve y</w>
sit e,</w>
shi k
sensitiz ing</w>
retin oid
regimen s.</w>
plaqu e</w>
pent obarbit
patient -
oly sis.</w>
oc ul
neutr al</w>
ml )</w>
mit ogenic</w>
meth ane</w>
medi um.</w>
lam otrig
kine sia</w>
it ud
id ze
high- fat</w>
hepatocarcin ogenesis</w>
flush ing</w>
expec ted
ex tra
es ].</w>
dur ation,</w>
detec ting</w>
cryst al</w>
conscious ness</w>
connec tive</w>
chloro ethyl
chemo resistance</w>
carcinom as.</w>
bur den</w>
azol am</w>
author 's</w>
ang inal</w>
agre ement</w>
af il</w>
adolesc ent</w>
actin omycin</w>
acid )</w>
a emia.</w>
TCD D.</w>
Res veratro
PAH s</w>
O C
Nife dipine</w>
MP A</w>
I D</w>
G 0/
F r
E Na
Cur rent</w>
C ]
Bcl- X
15 3</w>
(i NOS)</w>
(C a
vir ,</w>
ult ural</w>
thes e,</w>
t rough</w>
suppor tive</w>
si r
sequ ently</w>
re bound</w>
py rethro
organ ization</w>
on es,</w>
nucle us.</w>
min ated</w>
mer cap
lif e
har m
h C
fore arm</w>
f os
experi encing</w>
elem ent
de vi
cyt es.</w>
compul sive</w>
com posed</w>
col itis.</w>
casset te</w>
benazep ril</w>
ap ar
S ch
Rec ur
M es
L R</w>
Inter national</w>
H /
D TI
C- reactive</w>
7 2
4 %,</w>
1 17
0.0 2</w>
(M P
(C I
wis e,</w>
uc l
s ors</w>
rib onucle
queti apine</w>
protein- coupled</w>
pharmac ologically</w>
ocycl ic</w>
oc rine</w>
moti f</w>
kain ic</w>
in es,</w>
in directly</w>
im ply</w>
flan king</w>
ene -induced</w>
en ol</w>
dom ain
dithi ocarb
dise qu
dipyridam ol
de myel
clear .</w>
azathi opr
aut ologous</w>
as sist
angi ogenesis.</w>
amy loid
amp tothec
addic tion</w>
V entricular</w>
R V
Pro pran
P ent
MP O</w>
M F
IMP LIC
H ),</w>
GAB A-
G PR
B ChE</w>
B ).</w>
(M RP
wor se</w>
w ing</w>
v ec
through put</w>
t ant</w>
surviv ing</w>
surve ill
res earch
raniti dine</w>
prolact in
pos it
pol lution</w>
pal mit
oligod endro
ole ic</w>
mor tem</w>
lor azepam</w>
ex ec
constric tion</w>
col i</w>
co- administration</w>
c- Fos</w>
but yl</w>
accep ted</w>
a ).</w>
PARP -1</w>
M UC
IL- 8,</w>
IGF -1</w>
GT P
F isch
Cop per</w>
CG RP</w>
C O</w>
9 6
(P PA
v ary</w>
ta u</w>
sulfameth ox
sil enced</w>
s lower</w>
review .</w>
reduct ase,</w>
pot encies</w>
omy el
od ys
mono therapy.</w>
l af
ische mia,</w>
indic ators</w>
id es.</w>
i.p. ).</w>
g insen
et a</w>
end- diastolic</w>
design .</w>
con e</w>
c m</w>
aspir in.</w>
antin ociception</w>
ana phyl
act able</w>
Val pro
V CAM-1</w>
Spec ific</w>
R af
R ATION
K (+)-
IkappaB alpha</w>
I M</w>
HS A</w>
H 9
Cl (2)</w>
C 6</w>
6. 5</w>
1 )
0.0 2)</w>
+/ -2.
(C A
( but</w>
yl )</w>
ves ti
un expected</w>
ton ic-
thic k
tail -
substr ates.</w>
stead y</w>
re f
pro st</w>
po ol</w>
p53- dependent</w>
ochrom ocyt
nitro -L-arginine</w>
nicot inamide</w>
neede d.</w>
lat ent</w>
initi ate</w>
im balance</w>
hyper ammon
hi l
he p
epti d
endotheli um</w>
corne al</w>
concer ns</w>
ca u
blind ed</w>
ble omycin
behavior ,</w>
ase- 1</w>
acid s.</w>
[ The</w>
S tro
Par kinson</w>
MS /
M i
LT B
Increas ing</w>
Contro l
Cd k
Ca ffe
4. 2</w>
1 -induced</w>
-1 6</w>
(IC 50</w>
(- )
ut es</w>
rat ings</w>
r ated</w>
protoc ols</w>
progression -free</w>
pro thrombin</w>
p yro
n M,</w>
malignanc y</w>
log ic</w>
insuffici ency.</w>
ing in</w>
induc ed,</w>
in es.</w>
ic k</w>
g ad
full- length</w>
expl or
en ox
din itro
demonstr ated.</w>
de trim
cor n</w>
complex ,</w>
comp uter
cholec yst
cas es)</w>
carcinom a,</w>
bu ff
b. w
az oc
attemp ted</w>
ap o</w>
amygdal a</w>
acet aldehyde</w>
Z -induced</w>
V ascular</w>
SC H</w>
Re duction</w>
RATION AL
RA R</w>
R i
In tra
II -induced</w>
AP O
5-HT 1A</w>
5 '</w>
29 .
2 E1</w>
13 )</w>
10 1</w>
0.0 3</w>
-1 7
(O R)</w>
(L PS
( 0,</w>
zoledr onic</w>
vari ance</w>
trans fu
tion /
succ ess</w>
sion )</w>
seg mental</w>
sampl es,</w>
question nai
polyphen olic</w>
pig ment</w>
per meth
och olic</w>
neg lig
myocardi tis</w>
menstr ual</w>
mater i
m apping</w>
invasi ven
femal es,</w>
expos ure
ex amp
diseas e:</w>
cryst all
consider ing</w>
bradycardi a,</w>
arsenit e-induced</w>
anti diuretic</w>
acet azol
S 6</w>
P S</w>
N AC
M o
L H</w>
Im pro
En alap
4 ',
0.9 %</w>
(e.g .</w>
(0. 3</w>
wh ich,</w>
us )</w>
tri als,</w>
thiazol -2-
th us,</w>
ten sive</w>
sh ar
ser um.</w>
sed ative</w>
s- -
s cin
prec eding</w>
pitu it
per fluoro
patter n
oid al</w>
of- function</w>
minut es,</w>
marro w
immunoblot ting</w>
hype re
favour able</w>
drug- drug</w>
dox azosin</w>
dextro meth
c ip
ascor b
as tem
ang in
] ).</w>
SP EC
P l
O 1</w>
M B-
In duced</w>
G s</w>
Fas L</w>
DO N</w>
Ap pro
9. 5</w>
9 ;</w>
5 3
4 80</w>
0.00 5).</w>
(SOD )</w>
(RT-PC R)</w>
(P< 0.05)</w>
(P E
(ERK )</w>
(AT RA)</w>
tamoxif en.</w>
t mann
surroun ding</w>
step s</w>
stabil ity.</w>
ro le.</w>
razol e,</w>
produc ts,</w>
pre- existing</w>
pod ocytes</w>
pi oglit
phen azine</w>
partic le</w>
ni gro
mmol/ L</w>
me d,</w>
mal es,</w>
m ec
lik eli
le i
j udg
io hex
invol ve
inter view
hy dant
gingiv al</w>
gener ation.</w>
g yn
end os
em ul
em pt
dos age.</w>
dat e,</w>
chemosensi tivity</w>
bus ulfan</w>
b um
ation ).</w>
at tractive</w>
anti convuls
achi e
ST- segment</w>
Pri or</w>
P2 X
Initi al</w>
Hg .</w>
Fi bro
A 3</w>
2- amino
)- treated</w>
(M C
( author's</w>
( <</w>
y- related</w>
trigg ering</w>
transl )].</w>
str um
repolar ization</w>
qu estion</w>
prol ine</w>
p ub
ophil ic</w>
neuro transmission</w>
naph th
multi plic
modul atory</w>
mitochondri a-
micromol/ L)</w>
mg/kg ;</w>
influ encing</w>
immunost aining</w>
hyponat remia</w>
fur an</w>
func tions,</w>
flur bi
extre mi
er atin</w>
emerg ed</w>
el as
e ma
dis opyr
depos its</w>
confir ms</w>
clozap ine.</w>
cerul oplas
bicarb onate</w>
baro reflex</w>
astem iz
aspir in-
arter y.</w>
arrhythmi as,</w>
aminoglyco side</w>
alpha -</w>
adul tho
TGF- beta
N F</w>
Meth otrex
JN K)</w>
J .</w>
IMPLIC ATIONS:</w>
Ev ans</w>
DR 5</w>
8. 5</w>
( both</w>
vir .</w>
vesi cular</w>
ut roph
trif luoro
transi tional</w>
strong est</w>
st ent</w>
skin ,</w>
single- nucleotide</w>
qual it
penicill in</w>
mo genic</w>
medul lo
kg -1,</w>
ind ap
indap amide</w>
hype remia</w>
glo bin
f resh
ephedr ine</w>
destruc tion</w>
derivati ve,</w>
con sequent</w>
con sequenc
compoun d.</w>
compa red.</w>
clinic ians</w>
cadmi um-induced</w>
benzo (a)
X IAP</w>
Up on</w>
Sing le</w>
O TA</w>
Meas ure
M ;</w>
I r
HCC .</w>
F ood</w>
F D
Experim ents</w>
ABC G2</w>
1/ *
- 0.
typ e,</w>
tonic- clonic</w>
thioredox in</w>
stabil ized</w>
si bl
re jection</w>
radi pine</w>
prom pt
poly phenol</w>
pla ying</w>
paraqu at
or rhe
opr im
opl asi
nor adrenergic</w>
nit rous</w>
neuro chemical</w>
mon key</w>
keratin ocytes.</w>
junc tional</w>
is omers</w>
irin otecan</w>
interval .</w>
in di
ific ation.</w>
hist ologically</w>
ger mline</w>
dig ox
di methyl</w>
def ini
contr al
chloramphenic ol</w>
check point</w>
anti mon
ann abin
Rec ept
Polymorph isms</w>
P G</w>
O at
O -induced</w>
Nit ric</w>
Knock down</w>
Fancon i</w>
D X
APA P-induced</w>
(H CC)</w>
year s).</w>
un tary</w>
typ e.</w>
ter ial</w>
sit es,</w>
ou pl
non- selective</w>
min eral</w>
macroph ages,</w>
interleukin- 8</w>
high- performance</w>
ha ir
g av
eu kary
ell ul
dos ing.</w>
differenti ate</w>
defect s.</w>
cytoskelet on</w>
contr a
alpha- synuclein</w>
all- trans-retinoic</w>
advant ages</w>
Ver apam
Trans f
Sub sequent</w>
Six teen</w>
Sim ult
R o</w>
PPAR- gamma</w>
P rom
P osi
LT C
Hypot ension</w>
5 alpha-
3. 9</w>
-2 '-
(N T
ud ing</w>
treatment s,</w>
traum a</w>
to id</w>
ti form</w>
tel misartan</w>
sub clinical</w>
sti ff
side- effect</w>
pool ed</w>
particip ation</w>
offspr ing.</w>
nodul es</w>
neutrop en
mo ther</w>
methotrex ate.</w>
intrac or
gros s</w>
ext ent,</w>
examin ation,</w>
er ul
effectiv e,</w>
constitu ents</w>
consider ation</w>
cat echol</w>
cal pain</w>
c ial</w>
bu terol</w>
branc h</w>
bal anced</w>
arter ies.</w>
anti hist
anaesthe tic</w>
adrenocor tical</w>
] ;</w>
WK Y</w>
SOD )</w>
Paclitax el</w>
In flam
Cy to
Cd -induced</w>
An dro
> =</w>
2. 9</w>
0. 5,</w>
- 4</w>
(TNF )-
(P =0.00
% -
vesi cles</w>
vascul itis.</w>
v on</w>
u -
tu res.</w>
transduc er</w>
tig raph
se en.</w>
ren ess</w>
r im
proced ure.</w>
pres sion.</w>
phy t
paclitaxel -induced</w>
open ing</w>
observ ational</w>
mol/ L</w>
lipo ph
ld en
ingest ed</w>
imi pr
il iary</w>
eosinophil s</w>
ent ly.</w>
ecl amp
d P/d
compens atory</w>
chemotherap y-induced</w>
ag ric
acyclo vir</w>
acc ess</w>
Transcri p
Therap eu
T er
S G</w>
RE )</w>
PM L</w>
MT X
DOX -induced</w>
Ca(2+ )-
Bi ochemical</w>
AB C</w>
5- Az
12 %</w>
1- methyl-4-phenyl
-2 ),</w>
(E P
(C G
(+/- )</w>
tri me
transport .</w>
tim ulation</w>
thiazol idine
tetrahydro folate</w>
syn chron
si lden
shorten ed</w>
ser a</w>
seiz ure
re di
r a</w>
pyr amidal</w>
pre treatment.</w>
population -based</w>
perg olide</w>
ox is
ow ing</w>
oper ativel
ocortico id</w>
new bor
neon ates</w>
need s</w>
mono phosphate</w>
met al-
leuk emi
leishman iasis</w>
lei omy
integr ated</w>
in- dependent</w>
hyp no
gentamic in-induced</w>
fragment ation,</w>
flavopirid ol</w>
examp le,</w>
ex ha
discharg ed</w>
di phenyl</w>
detrim ental</w>
cell ul
calcit onin</w>
ati ves</w>
RAR alpha</w>
R adi
O-de ethyl
L OX
Kore an</w>
Ke ap
K CN
Immunohist ochemistry</w>
H z</w>
F ).</w>
DD E</w>
Carb am
Angiotens in</w>
7 3
3- hydroxy-
2 8-
19 )</w>
(D N
vi ability.</w>
urac il</w>
ubiquit ous</w>
system s,</w>
strok e,</w>
st or
spectrometr y.</w>
ro om</w>
regar ded</w>
ra re.</w>
quin ine</w>
psych osis.</w>
protein )</w>
pir ide</w>
per si
peg ylated</w>
oxidi l</w>
olog ist
nit rit
likeli hood</w>
lig ase</w>
invol untary</w>
idiosyncr atic</w>
identifi ed,</w>
hemod ynam
h -
glutathion e,</w>
ferri tin</w>
equ i
elig ible</w>
c li
c es.</w>
av al
anomal ies</w>
androgen -independent</w>
anaesthe sia.</w>
VE C</w>
T rial</w>
SP 600
SAH A</w>
M s</w>
INTERVENTION S:</w>
High er</w>
F EV
EP S</w>
Consider ing</w>
C r</w>
Ah R-
A ra-
3 -induced</w>
10- fold</w>
(1 /
( NF-k
zaf irlu
z ole</w>
we re:</w>
ur ic
un ting
sub groups</w>
su sta
signific antly,</w>
sci atic</w>
reduc tion.</w>
re in
ran ul
pp ed</w>
po l</w>
phy ri
p in</w>
p 70
ox o
oligonucle oti
ol in
mt DNA</w>
meth icillin
mal es.</w>
lipos omal</w>
intr actable</w>
immunomod ulatory</w>
hyp omethyl
hom ology</w>
examin ation.</w>
electro my
effor t</w>
counter act</w>
cime tid
ain -
U .
Me an
ME K</w>
LO G
HC l</w>
Ch loro
CR C</w>
CA D</w>
A 4</w>
2 1,</w>
( CYP1A
z er
vis u
ver .</w>
treat ed,</w>
transf ec
stimul i.</w>
stabil izing</w>
si ve-
sensi tize</w>
recor ding</w>
quanti fy</w>
predic ts</w>
patient s),</w>
panc reas</w>
p et
omeg a-
ologic al,</w>
myel odys
mou se,</w>
monit ore
ml ,</w>
min -1</w>
l ist</w>
intracerebro ventricular</w>
insuffici ent</w>
injur ies</w>
improve ment.</w>
ic s.</w>
giv ing</w>
g ue</w>
g i
fibr onectin</w>
f un
constitu ent</w>
cardi over
capsaic in-
calc ification</w>
bron cho
benzodiazep ines</w>
b enc
al izing</w>
Therap y</w>
R H</w>
Pren atal</w>
M atri
H er
F R
Asi an</w>
A UC</w>
6- fold</w>
3 3%</w>
1- dependent</w>
(D OX
( 80</w>
vari ate</w>
ti ght</w>
ro le
ret ained</w>
quin oline</w>
prot on</w>
paraoxon ase</w>
pancre atitis</w>
pac ema
obvi ously</w>
mortal ity,</w>
month -old</w>
mmHg )</w>
micro lit
mg/kg/ day,</w>
mark ers.</w>
ma kes</w>
high- affinity</w>
flumazen il</w>
es cap
epsil on</w>
en ium</w>
dro perid
dacarb azine</w>
d ynamics</w>
d s.</w>
cy tic</w>
con focal</w>
chlorpyrif os</w>
c ure</w>
brain stem</w>
b. i.
ac onit
RATIONAL E:</w>
Par tic
NSAI D</w>
K m</w>
I OP</w>
HB I
GABA (A)</w>
FGF R
F low</w>
F GF</w>
Ev en</w>
Ep idemi
E MT</w>
Dis ease</w>
C e
B RA
4 50
10 5</w>
(MT X)</w>
(2 4</w>
( mRNA
urticar ia</w>
ud es</w>
transcrip tionally</w>
tr ained</w>
scre en
resul t,</w>
resembl ing</w>
reflec ting</w>
rate- limiting</w>
propranol ol,</w>
peak ed</w>
p 16</w>
oxy toc
oste oblast
or ith
ol factory</w>
nan om
myri state</w>
min ).</w>
mg/m 2,</w>
mg/d L</w>
medic ation,</w>
intra ocular</w>
insipid us</w>
ing redi
ine mia.</w>
ind ole</w>
granul ocyte</w>
gonad otrop
feno fibrate</w>
fe brile</w>
fati gu
ess entially</w>
eosinophil ic</w>
endometri um</w>
correc t</w>
comple mentary</w>
character ized.</w>
cell .</w>
benz brom
b and</w>
amin ophylline</w>
allo graft</w>
RE S</w>
Per oxis
O LOG
N S-
Mechan isms</w>
H S</w>
Enh anced</w>
D AT</w>
CYP2C 9,</w>
CA .</w>
C -1</w>
4 2
(1. 5</w>
(0. 2</w>
z o
y- based</w>
th .</w>
tab lets</w>
sim end
sha red</w>
sh are</w>
rh esus</w>
re plac
pre existing</w>
poly chlorinated</w>
phosphoinositi de</w>
ph ox
paras it
ox o-
oc cl
obes ity.</w>
o ocytes</w>
mos sy</w>
keto rol
in strum
hydrox y</w>
fif th</w>
f osfam
exclu sion</w>
dis plays</w>
datab ase</w>
commer cial</w>
carcin ogenesis,</w>
anesthe tics</w>
alg orith
MC )</w>
Los s</w>
HIV -1</w>
F XR</w>
ERK ,</w>
ELIS A.</w>
Di rec
ATP7 A</w>
8 ,
5-HT(1 A)</w>
3 8.
(S ):</w>
(N AC)</w>
(L )</w>
wash out</w>
valu es,</w>
ulc ers</w>
sul foraph
son 's</w>
similar ity</w>
s pro
risperid one.</w>
prov o
post ural</w>
phen ol-
pharmac ology</w>
oxif ylline</w>
op ent
odr ine</w>
neuro protection</w>
naltrex one</w>
month s).</w>
lithi asis</w>
labor ator
genotyp e,</w>
gen cy</w>
epitheli um.</w>
endotheli um-dependent</w>
disrup ts</w>
develop s</w>
dehydrogen ase,</w>
d ocking</w>
d ang
contral ateral</w>
clinic al,</w>
cir cadian</w>
c ally</w>
bil ater
ac hol</w>
Thir teen</w>
Therapeu tic</w>
T ric
Swis s</w>
SE .</w>
RE POR
R XR</w>
K v
G li
G G</w>
DE X</w>
D an
Cal ci
CT GF</w>
B ri
AS T</w>
A- treated</w>
5-aza-2'- deoxycytidine</w>
4 5%</w>
3 %).</w>
1 :</w>
(TNF- alpha)</w>
(NF-kappa B)</w>
(IL )-
(I GF
(H E
ur ine,</w>
th y
ter ti
sub lingual</w>
st ones</w>
signific ance.</w>
satur ation</w>
rou gh
quanti fication</w>
pr in
per idine</w>
ox y</w>
onc e-daily</w>
on ect
nar co
morph ine-
methyl-6- phenyl
mes na</w>
mater ial</w>
male ate</w>
inte rest
insul in,</w>
hi p</w>
headache .</w>
ethambut ol</w>
es -
diagno sis,</w>
contri bu
complic ations,</w>
bic alut
ati ve,</w>
at ript
antibodi es.</w>
am ifostine</w>
admis sion,</w>
accompan ying</w>
ac y
ab users</w>
V T
SMC s</w>
S O</w>
Ret ro
P s</w>
M S)</w>
Jun e</w>
JN K,</w>
I RS
G0/ G1</w>
Con centr
Bet ween</w>
BP .</w>
5- dimethyl
3- 4</w>
2 40</w>
0.0 3).</w>
0. 1%</w>
(B PA)</w>
( w
xen o
wat er-
them .</w>
ter ine</w>
sulf ide</w>
subjec t
som nol
si s;</w>
ser um,</w>
sc anning</w>
prescri ption</w>
poin ts.</w>
phys ostigmine</w>
pector is</w>
oxygen ation</w>
osteopo ro
onset ,</w>
occup ancy</w>
neph rin</w>
negati ve.</w>
n on</w>
milli on</w>
microgli a</w>
metronid azole</w>
larg e-
lansop razole</w>
ine ural</w>
individu ally</w>
ide mic</w>
hypother mia</w>
gamma .</w>
f f</w>
f all
f ,</w>
er up
epilep sy,</w>
dur al</w>
dis soci
di az
da idze
const ants</w>
con sti
be fore,</w>
al prazol
RA ,</w>
Qu in
P gp</w>
No vel</w>
NP Y</w>
MEASURE S:</w>
Hyper tension</w>
HM G-
H emat
GST T
G A
Cyclo phosph
Co x</w>
9 %,</w>
4 8-
10 4</w>
-1 00
( and</w>
warr anted</w>
w ind
volum es</w>
vir us
val idation</w>
v im
um /
surviv ors</w>
strati fied</w>
si s:</w>
s. c.
ro d</w>
rat es,</w>
r alg
pol y</w>
pneum onia</w>
physi ology</w>
p 27</w>
ow n</w>
organochlor ine</w>
ocic ept
micrograms/ kg/
method ,</w>
mT OR
l- DO
inter mediates</w>
indomethac in-induced</w>
immunosup press
hydr ate</w>
exten d</w>
degrad ation,</w>
day- old</w>
d UT
cri zot
convul sion</w>
com orb
caspase- 3.</w>
cann ab
cal modul
assem bly</w>
ac illin</w>
TA M</w>
St ates</w>
Re active</w>
P b</w>
O 6-
N in
M rp
CO 2</w>
AD R
6 7
25 )</w>
18 )</w>
1,25- (OH)
(HO -1)</w>
(C P
volt age</w>
treatment -
toler ance.</w>
s of
s at
reinfor c
receptor- gamma</w>
pyrid ox
port un
oste oblast</w>
ol es</w>
nitrofen -induced</w>
meflo quine</w>
leak age</w>
interven tion.</w>
in- releasing</w>
in ),</w>
highligh ts</w>
ep am</w>
dur ation.</w>
cipro floxac
anti- oxidant</w>
TRAIL -induced</w>
Symptom s</w>
Spec ific
SC N
R es</w>
PC 3</w>
M orphine</w>
E 2,</w>
B NP</w>
AN G</w>
-1- methyl-6-phenyl
( N-
zinc -
z -
tes tis</w>
ster ic</w>
shif ted</w>
selen i
ret ar
proc ess,</w>
presyn aptic</w>
presum ed</w>
omegal y</w>
n isol
mang iferin</w>
l d.</w>
in- 3-
in ogen</w>
hydro cortisone</w>
homozygot es</w>
histopath ology</w>
group ;</w>
diazep am,</w>
cyclophosph amide.</w>
ax im
analgesic s</w>
V /
R ac
Mut ation</w>
IL- 5</w>
HER 2</w>
Fir st,</w>
Differen ces</w>
As soci
Ad ren
A R-
9 3
2 R</w>
(N a
(+ )/
viol et</w>
ultras ound</w>
trast uz
tox ins</w>
si as</w>
selec tin</w>
se ar
pyrid inium</w>
pro ca
or ic
myel oma.</w>
methyl ation.</w>
life time</w>
le f
interfe res</w>
hemat oma</w>
flavon es</w>
disequ ilibrium</w>
dis comfor
c anal
ar ity</w>
anti- CD
aggrav ated</w>
abl es</w>
S )-
Grow th</w>
F orm
E gr
D XR</w>
B 1,</w>
A (2
1 C</w>
0.0 2
-2 4</w>
(LP S)</w>
(L V)</w>
(10 -
( 7</w>
withdraw al,</w>
w ine</w>
ud in</w>
tubul in</w>
tamoxif en,</w>
ser um-
sequel ae</w>
sept al</w>
repor t
rati o.</w>
qu ad
prost ac
predis position</w>
phor bol
paclitaxel ,</w>
oper atively</w>
on tal</w>
ocarcin oma</w>
na phthal
mg/d l</w>
judg ed</w>
in ergic</w>
hyper triglycer
emp fer
dis closed</w>
dichlor v
cor p
con fu
cl one</w>
b -induced</w>
asth matic
amiodar one.</w>
Tro glitazone</w>
Syndro me</w>
S we
R CC</w>
PD GF-
N ),</w>
N '-
Mean while,</w>
High -dose</w>
H2A X</w>
GS K3
Differen t</w>
CYP 1A</w>
CD 34
Alter ations</w>
AT M</w>
8 5
6 3
4. 6</w>
13 %</w>
1. 7
0.0 3
t aste</w>
su m</w>
si s)</w>
remifentan il</w>
r is</w>
r )</w>
question naire</w>
perind opril</w>
non specific</w>
micro tubule</w>
manag ed</w>
itrac onazole</w>
inter national</w>
increas e.</w>
ile t
hex achloro
glyco l</w>
g .
extrav as
ec st
di aly
criter ia.</w>
bi ology</w>
ant -induced</w>
amlo dip
TH C</w>
T ai
S CL
NAT 1</w>
M RS
IFN- alpha</w>
Hal operid
C PA</w>
B reas
9 4
1 %).</w>
1 %),</w>
(I )</w>
( JNK)</w>
vanil loid</w>
up take,</w>
unc ert
un known,</w>
un it
ucl ide</w>
tw ic
tu ally</w>
tot ally</w>
ti r
th an
sur fact
reas ons</w>
radi on
quantit atively</w>
proteas omal</w>
prol ong</w>
por tion</w>
ph os
oxy cycl
or id
neo adjuvant</w>
met ab
meas urable</w>
lymph oid</w>
locomo tion</w>
lat e-
laf ax
l and</w>
ine mia,</w>
icill in</w>
h eli
fl ud
e duc
dexamethas one,</w>
de af
cytometr y,</w>
chloram buc
carboxy lester
ca roten
beta 1-
anc estr
am -induced</w>
all ergy</w>
TCD D,</w>
RA NT
Li ke
Le w
Hy po
ED 50</w>
Dow n
COX -2,</w>
5 2
.0 5)</w>
)- positive</w>
(NSAID s)</w>
(B D
yo to</w>
trac ted</w>
ther .</w>
strain s.</w>
stat e,</w>
spl en
sour ces</w>
selen ite</w>
sco red</w>
quercet in.</w>
prote omic</w>
pro per</w>
practic e.</w>
pentylene tetr
param eter</w>
op tions</w>
op portun
mil rinone</w>
microg/m l</w>
methyl ation,</w>
mercur ic</w>
itud inal</w>
intub ation</w>
intro duc
hyp oplasia</w>
hybri d</w>
harm ful</w>
form alin</w>
ester one</w>
er ine</w>
dizzin ess</w>
den se</w>
demonstr ation</w>
del eted</w>
cycl es.</w>
cot reatment</w>
contamin ated</w>
chloro qu
che mistr
carr y</w>
but an
b allo
aug ments</w>
aor t
adriamycin -induced</w>
ad ic
ac ne</w>
Th alidomide</w>
Propran olol</w>
Posi tive</w>
P he
P M</w>
NO S,</w>
N CE:</w>
L am
Inhib it
HL A</w>
G V
F re
En viron
E /
DH T</w>
CYP2C 19
C H</w>
Breas t</w>
BACKGROUN D/
5-HT (2
5 %),</w>
10(- 5)</w>
(S E
(7 )</w>
( one</w>
( JNK
where by</w>
trans duced</w>
ti gh
thalam ic</w>
semi -
sam ple
posi tion,</w>
plas ma
oxi ous</w>
ox carb
os ens
meas ures.</w>
lidoca ine.</w>
kg(-1 ),</w>
is let</w>
illustr ates</w>
id in
h TERT</w>
gl ands</w>
g o-
exam ined,</w>
ex ilet
di l</w>
dev oid</w>
dec a
contracep tive</w>
bi phasic</w>
arth ralg
anti emetic</w>
analy ses,</w>
alpha 1-
achiev ing</w>
[ (1
Vis ual</w>
T ax
Re al-time</w>
P N</w>
K yoto</w>
HI T</w>
GST A
G as
Fl av
D MT
Bl ock
AB CG
2- week</w>
17 %</w>
10 ).</w>
(NMD A)</w>
ylchol inesterase</w>
unc oupl
tript yl
transform ation.</w>
se c</w>
psychos timul
peroxid ation.</w>
on ym
nifedip ine,</w>
mil dly</w>
mil d-
ly )</w>
limit ed.</w>
junc tiv
ide )</w>
harve sted</w>
guidel ines</w>
glomerul osclerosis</w>
flut ter</w>
extre me</w>
extr action</w>
eryth ema</w>
epilep tiform</w>
ed ul
depolar ization</w>
de d-release</w>
day time</w>
con s
compris ing</w>
channel s,</w>
bu tr
bis -
ari pip
analge sia.</w>
ab ove
S e</w>
Rel ative</w>
Prost agland
Peroxis ome</w>
PA T</w>
Here in,</w>
H cy</w>
CDK N
CD 11
BE AS-2
At ten
AB P</w>
(7 5</w>
(1 ),</w>
wor tmann
tol but
ti clop
tetrac ycline</w>
tetr adec
scin tigraph
ram ipril</w>
psor i
pressu re-
poly uria</w>
pig ment
pa e
p ide
ox ical</w>
ol s.</w>
occur .</w>
non- small-cell</w>
ng/m l)</w>
meth y
mac ular</w>
lor at
leuk emia,</w>
larg est</w>
l ar
inten s
ine- related</w>
immunosup pression</w>
ho t</w>
harb oring</w>
eukary otic</w>
dyst on
disease- free</w>
discontinu ation.</w>
di ver
cocaine- associated</w>
caud al</w>
cardiomy opathy,</w>
bro minated</w>
bi phenyl</w>
artic ular</w>
anxi olytic</w>
antigen s</w>
acryl amide</w>
ab ec
Ul tr
PC a</w>
M agne
I le
H z
Fisch er</w>
AP )</w>
AN CA</w>
AC TH
6. 0</w>
4. 1</w>
(ACh E)</w>
(3 ))</w>
un responsive</w>
un complicated</w>
transcriptase- polymerase</w>
toxic ology</w>
til ity,</w>
ticlop idine</w>
synth ase,</w>
spac e</w>
sec tion</w>
placent a</w>
physi ologically</w>
path y</w>
oxim es</w>
oxali plat
or i</w>
non sense</w>
n oxious</w>
n er</w>
myalg ia</w>
man u
low ,</w>
ligand s.</w>
insom nia</w>
hepar in-induced</w>
fati gue</w>
erythematos us</w>
duct us</w>
doxorubic in-
commun ication</w>
chemopreven tion</w>
blot ting,</w>
ati le</w>
anti fungal</w>
anesthe sia,</w>
amin es.</w>
amelior ation</w>
allevi ate</w>
al f
Te trac
ST )</w>
SE ,</w>
R ad
R V</w>
Not ch</w>
G- CSF</w>
CA 3</w>
A >
5 %).</w>
1 +/-
0. 15</w>
(P CB
up- regulate</w>
um in
tis m</w>
thereafter .</w>
surveill ance</w>
ste mic
sper m</w>
signific ant,</w>
shock .</w>
risperid one,</w>
qu ite</w>
pyruv ate</w>
prurit us</w>
proced ures.</w>
pr ide</w>
plic ations</w>
pic ture</w>
mimic king</w>
memor y,</w>
mal arial</w>
m 2</w>
l ;</w>
ish ment</w>
ina dequate</w>
implic ating</w>
im mobil
ic ity.</w>
high- grade</w>
here in</w>
h ).</w>
gall ate</w>
g il
discontinu ed,</w>
dilat ation</w>
diff ers</w>
demograph ic</w>
cri sis</w>
cour se.</w>
complic ation.</w>
cand esartan</w>
c im
b arbit
avail able.</w>
ar te
am idine</w>
T 3</w>
S ensi
RO S-
On c
Mor ris</w>
Mel atonin</w>
Like wise,</w>
K i-
IL-1 2</w>
I tal
Hist opathological</w>
GP x
E t
Ch k
Capsa icin</w>
AP P</w>
4. 3</w>
1. 8
- stimulated</w>
- 5
(P R
(MD A)</w>
( for</w>
utili zation</w>
ubiqu itin</w>
them ,</w>
te .</w>
silic a</w>
ris k
retin oin</w>
radion uclide</w>
phenyl alanine</w>
p ine-induced</w>
output ,</w>
ogen ously</w>
ochemic ally</w>
me ,</w>
l ens</w>
kg .</w>
ithro mycin
impl ying</w>
heter ocyclic</w>
glutathione- S-transferase</w>
glut ar
en es</w>
el f
dyst onic</w>
desensi tization</w>
contr ary,</w>
continu ing</w>
con currently</w>
cis apride</w>
chos en</w>
as sumed</w>
angi o
amilor ide</w>
all yl</w>
a e.</w>
a dequ
W AF
TRA IL-
N MD
LY29400 2</w>
HMG- CoA</w>
HK -2</w>
F atal</w>
Clinic ians</w>
Ah R
8- OH-
2 8,</w>
1 b</w>
-1 4
(c )</w>
(I N
(EGF R)</w>
(2) -induced</w>
( k
whi l
ultras on
ul a</w>
trypt amine</w>
transplant ation,</w>
tobr amycin</w>
throm bus</w>
ter med</w>
steat o
some what</w>
satis factory</w>
propafen one</w>
pre -treated</w>
poly neuropathy</w>
phenotyp e,</w>
osmol ality</w>
os in,</w>
och ro
och ol
nigro striatal</w>
mg/m 2)</w>
methoxy -
ip 1)</w>
ing s,</w>
import antly,</w>
hyperalge sia,</w>
hyper insul
hyper activity.</w>
help ful</w>
grad ed</w>
gen der,</w>
feat ures,</w>
excre ted</w>
diethyl nitrosamine</w>
cran i
biomar k
apoptosis- related</w>
agonist .</w>
aer os
aden ylate</w>
With draw
W )</w>
Second ary</w>
Recur rent</w>
Rec om
N ox
Mn -SOD</w>
GB M</w>
Di ag
D Z
D M</w>
B T
4. 0
.00 1)</w>
(S D)</w>
(D F
(1. 0</w>
year ,</w>
whil st</w>
vulner able</w>
ve tir
us age</w>
t ar
sulf oxim
sulf asalazine</w>
stit utes</w>
separ ately</w>
reversi bly</w>
rel in</w>
reas ,</w>
prop idium</w>
pos es</w>
pall id
p ter
nutri tional</w>
non invasive</w>
n ocicept
mon ocytes.</w>
lo op
lith ocholic</w>
le x
j e
isol e</w>
institu tion</w>
inges tion.</w>
in tolerance</w>
in take,</w>
histopath ologic</w>
formul ations</w>
for ce</w>
experim ent.</w>
excre tion,</w>
eth in
et ,</w>
curcum in,</w>
cult ures,</w>
co don
clu ster
ceftriax one</w>
c- Myc</w>
beta- block
aval ent</w>
ation -related</w>
ar ine</w>
aneurys m</w>
an )</w>
allo geneic</w>
ag ger
X- ray</w>
W om
V AD
Sevent y-
SC )</w>
S ter
Plat el
PC R-
O 3</w>
N a</w>
N HE
MDA- MB-
L S
J o
For ty</w>
Ex amination</w>
D AP
Cat al
CA R-
Al tered</w>
Al ph
9 7
8- hydroxy
295 R</w>
15 d-PGJ
- to-
( RP
weak er</w>
vehic le.</w>
v ic</w>
underg one</w>
un affected.</w>
ucle otide</w>
sur rog
s we
resveratrol -induced</w>
r ings</w>
plastic ity</w>
phe ochromocyt
pa in
ovari ectomized</w>
oun ds</w>
glucuron id
fore brain</w>
et y-
em por
d ol
cytos keletal</w>
controversi al.</w>
cohor ts</w>
clos ure</w>
chron otropic</w>
carb achol</w>
c-J un
broncho alveolar</w>
asth ma,</w>
ari es</w>
a id</w>
V as
Tai w
SULT 1A
SIGN IF
SIGNIF ICA
Propo fol</w>
NCI -H
L- dopa</w>
Inter leukin
Insul in</w>
Gl u</w>
ER R
Direc t</w>
Cycl in</w>
B PA
Ac cum
5 9,</w>
(mRNA )</w>
(T R
(M CP
(H ep
y an
wor th
w t</w>
vi si
u ation</w>
to- moderate</w>
struct ure-activity</w>
sta y</w>
sham- operated</w>
phosphat e-
papaver ine</w>
pa re
p ing</w>
oxid ation,</w>
os elective</w>
o protein</w>
ng/m L</w>
neuro peptide</w>
neuro behavioral</w>
myel in</w>
m u</w>
lit ter
ischemi a-
interven tions</w>
h ome</w>
feasi bility</w>
exacerb ate</w>
eth ane</w>
estrogen ,</w>
el ast
dom ain.</w>
desi pramine</w>
dam s</w>
con sequently</w>
clonid ine.</w>
clar ithromycin</w>
blood ,</w>
b ot
angi oplast
am ik
abl ing</w>
SIGNIFICA NCE:</w>
OATP 1B
Inc idence</w>
Impro vement</w>
Com mon</w>
C 2</w>
B one</w>
B -induced</w>
7. 4</w>
4. 8</w>
4. 4</w>
1- 2</w>
(HB V)</w>
( two</w>
ym pathetic</w>
ycl in</w>
w al
vastat in,</w>
to ols</w>
te a</w>
spec troph
sever ity.</w>
ros ophil
rof ecoxib</w>
ro w</w>
recipi ents.</w>
propofol .</w>
pen icillin
parathyro idis
over l
monitor ing.</w>
le g</w>
immunob lot</w>
hydroxy urea</w>
geran yl
distingu ish</w>
di stress</w>
dap sone</w>
cyt arabine</w>
chondro cytes</w>
caspase- dependent</w>
b os
b ond</w>
ap on
allopurin ol</w>
all y)</w>
adjunc t</w>
Wom en</w>
Th ose</w>
Partic ip
Over all</w>
Inter action</w>
HUVEC s</w>
Eigh teen</w>
D ox</w>
D ist
An nexin</w>
3 1,</w>
1A ,</w>
- a</w>
(C I)</w>
(2 50</w>
yl- CoA</w>
xenobio tics</w>
worldw ide.</w>
utili zing</w>
tong ue</w>
th eli
tetrachlor ide</w>
sulf hydr
seve re,</w>
sco re,</w>
ra ises</w>
pyr imid
profi le,</w>
orig in.</w>
o- occlusive</w>
mi metic</w>
mang anes
kg ),</w>
ind ing</w>
hear ts.</w>
he mis
haemat ological</w>
group ),</w>
fail ing</w>
enc e-
e en</w>
e at
dyskinesi as.</w>
complain ts</w>
collec ting</w>
cholester ol.</w>
chaper one</w>
cell s/
bund le</w>
br id
at omic</w>
at RA</w>
arteri os
RP E</w>
P LC
Na +</w>
K ine
Iso proteren
F LT
D rosophil
CO L
C las
Au g
AD P</w>
7 50</w>
5 )
4 0,</w>
2- adrenoceptor</w>
14 0
10 9
1 (-/-)</w>
.0 1).</w>
-1, 2,3,
(R R</w>
(E 2)</w>
( with</w>
( siRNA
ym ph
treatment -related</w>
str ych
sin us
respir ation</w>
propylthiourac il</w>
prob es</w>
pl an
phorbol -1
per form</w>
pa ir</w>
p ens
os ing</w>
nitro -
nifedip ine.</w>
n as
micro tubul
mg ),</w>
lithi um-
k ept</w>
intra operative</w>
in form
hydro quinone</w>
hemat uria</w>
hab it
h ERG</w>
glucos amin
feat ures.</w>
en ough</w>
differenti ating</w>
cyto static</w>
con flic
carbamazep ine.</w>
arabin oside</w>
am ni
altern ate</w>
alter ations.</w>
aggreg ates</w>
ag itation</w>
ac tions.</w>
Surviv al</w>
Phosph or
PK C-
PF OS</w>
NAD(P) H
METHOD OLOG
M axim
CXCR 4</w>
C57BL/6 J</w>
C ir
AV P</w>
8 %),</w>
7 0-
3 5.
3 00
1 50
+/ +</w>
(A K
(* )
( medi
yl) -1-
vent ro
thre onine</w>
susceptibil ity.</w>
sub mitted</w>
solu tions</w>
scler osis.</w>
re tin</w>
radio immuno
protoc ol.</w>
peroxis omal</w>
path ogenesis.</w>
parallel -
ostig m
oin t
not ably</w>
nanom olar</w>
micro angi
l oci
irt az
intrav entricular</w>
interleukin -1</w>
incid ent</w>
in complete</w>
implic ation</w>
ile ut
hyper parathyroidis
hal ogen
h ),</w>
fur ant
fung ic
form .</w>
fibroblast s,</w>
end points</w>
enc our
elic its</w>
drug- metabolizing</w>
di piv
di g</w>
de phosphorylation</w>
common ,</w>
clear ance,</w>
cent ri
cell- based</w>
bar ic</w>
avoid ed</w>
as eptic</w>
areas .</w>
alop ec
acetyl transferase</w>
Warfar in</w>
P 2</w>
N T-
K idne
HSP 70</w>
G SH-
F S</w>
Dop amine</w>
Cl onidine</w>
Ar g</w>
6. 2</w>
4, 4'-
30 )</w>
2- mediated</w>
2 C</w>
(E L
(A I
( 6-
vesti bular</w>
tal k</w>
stat es.</w>
ser ves</w>
second s</w>
salic ylate</w>
ro str
resistanc e-associated</w>
process ed</w>
perin atal</w>
particip ates</w>
ob ses
no vel
manu fact
manag ement.</w>
ishe d,</w>
is ed,</w>
individu als,</w>
hom olog</w>
g/m 2</w>
ex piratory</w>
er t</w>
dro pped</w>
dex medetomidine</w>
deoxy nucleotid
degener ation,</w>
consist s</w>
chel ator</w>
carboxyl ic</w>
c amptothec
beta -induced</w>
at r
achi al</w>
Wist ar-
U preg
RP E
REPOR T:</w>
NO S
M ater
M SCs</w>
L P</w>
Gen ome-wide</w>
Ex tr
ENa C</w>
D ou
Ar terial</w>
ATP- binding</w>
AR NT</w>
AM -
8 5%</w>
6 2
13 5</w>
/ kg</w>
-1 8
(N QO
(IL )-1
( L-
un stable</w>
um )</w>
trunc ated</w>
transpor ted</w>
trac e</w>
throm bin
resuscit ation</w>
requi red.</w>
pseud o
pro jec
posi tions</w>
p =
oste oblastic</w>
ost at</w>
must ard</w>
muscle ,</w>
mic tur
le pt
inclu ded.</w>
hydroph obic</w>
h ence</w>
exce eded</w>
dehy dr
defic its.</w>
correspon ded</w>
comparison s</w>
clo fibrate</w>
chromatograph y-
breath ing</w>
aug ment</w>
appea red.</w>
ambi ent</w>
[ Effect</w>
XR CC1</w>
Vari ous</w>
V A</w>
TRPA 1</w>
T >
Micro array</w>
MC P
HgCl 2</w>
HU VEC</w>
H ).</w>
DD P</w>
Cyp 1a
AR E</w>
AP 1</w>
7 0,</w>
3 90</w>
17 b-
12 .</w>
(P G
(10 0
( control</w>
wor ks</w>
verapam il,</w>
transporter ,</w>
sy stemic
streng th</w>
simend an</w>
rout in
rein stat
pi rox
phenomen a</w>
oxid ation.</w>
ou se</w>
oter ol</w>
oste oblasts</w>
omer ular</w>
ol s,</w>
molecul es,</w>
mod al
memor y.</w>
me val
inter nal
gest ation.</w>
gen icity</w>
gabap entin</w>
famil ies.</w>
expec ted,</w>
et .</w>
em ents</w>
ec ta
e tr
dex tr
decom pens
cl es,</w>
chemot actic</w>
canc erous</w>
aw a</w>
approach .</w>
administr ated</w>
Withdraw al</w>
W D</w>
T47 D</w>
T re
T issue</w>
S ud
Ris peridone</w>
PF OA</w>
ME T</w>
MAP K,</w>
Los artan</w>
I shik
GT N</w>
DE HP</w>
D obut
CD -1</w>
B 6</w>
AKR 1B
14 %</w>
10 ),</w>
( q
( J
typ es,</w>
trimeth oprim
tion ).</w>
ti es.</w>
syndrom es.</w>
swit ching</w>
supernat ants</w>
sig ma
seg reg
rib osomal</w>
retro grade</w>
ple x
phosphon ates</w>
peroxid es</w>
perme able</w>
paren ts</w>
paradig m</w>
og luc
methyl dopa</w>
mel aton
medic ations,</w>
me peridine</w>
low ers</w>
literat ure,</w>
infec tious</w>
impro ved.</w>
hydroxy cholesterol</w>
hr .</w>
gu t</w>
fin ally</w>
eth nic</w>
diclofen ac
cogn i
chlor ide,</w>
capsaic in.</w>
c DNA
bl ast</w>
ammon ium</w>
alte red.</w>
V SMC</w>
SI GN</w>
S- phase</w>
PPAR a</w>
N- acetyl</w>
L C</w>
Ho ech
CR F</w>
A 4
(A MP
(1 7
treatment ;</w>
ten sin</w>
t agg
synerg y</w>
su pr
sep sis</w>
s en</w>
re tri
rang e:</w>
put am
pro drug</w>
previ ously.</w>
p3 00</w>
oxid ants</w>
os til
oro facial</w>
onym ous</w>
nar ingin</w>
ka empfer
k en</w>
isch aemia</w>
irb esartan</w>
intrad ermal</w>
inflam ed</w>
in oc
imidazo[4,5- b]
illustr ate</w>
ic l
ia :</w>
histor y,</w>
gyn ec
gradi ent</w>
glucos amine</w>
exten ded-release</w>
explo red.</w>
eu genol</w>
es el</w>
ent an</w>
enalap ril
diarr ho
cataly ze</w>
blo od.</w>
b oun
aqu ap
addres sed</w>
ac etin</w>
U V</w>
TI CIPA
T ime</w>
Ser ot
SC s)</w>
PAR TICIPA
N 1</w>
L 2</w>
I fosfam
Ho wever</w>
DAT A</w>
Calci um</w>
Behavi oral</w>
B -dependent</w>
AN P</w>
A ff
3 9.
13 2</w>
(D D
(C d
(1 ,</w>
up- regulates</w>
tro glitaz
tolcap one</w>
ter fenadine</w>
substitu tions</w>
st age,</w>
regimen ,</w>
promis e</w>
prolifer ator</w>
proble m.</w>
pilocarp ine.</w>
p ant
p 16
on to</w>
ol d,</w>
objec tives</w>
ob tained.</w>
no tion</w>
neph rectom
morph ology,</w>
mo re
iv )</w>
insectic ides</w>
haemorrh age</w>
gli benc
geniste in,</w>
gener al,</w>
fl are</w>
evalu ations</w>
ev ent.</w>
estrogen -induced</w>
defici ency,</w>
co st-
chro mi
ch or
cap ability</w>
biphenyl s</w>
anxiet y,</w>
androst ane</w>
alk yl</w>
al opr
a ine</w>
Wil son's</w>
Transf ection</w>
T -induced</w>
S timulation</w>
RE -
PARTICIPA NT
P- glyco
Ox y
Not ch
L D</w>
HT )</w>
H ET
G ra
Enalap ril</w>
DE SIGN</w>
Contin uous</w>
Child ren</w>
C ox
An t
Am ph
AR S</w>
4. 9</w>
3 50</w>
2- amino-
y dig</w>
v ill
tum oral</w>
transmis sion.</w>
toler ance,</w>
therap y:</w>
spl enic</w>
sensor ineural</w>
s low-
rosi glitaz
reser ve</w>
ren dered</w>
protoporph yrin</w>
prob uc
prescri bing</w>
phenyl propan
pericardi al</w>
pal ate</w>
n ociception</w>
myel o
mo fe
min (-1)</w>
microscop y,</w>
microg/ kg/
mg/m 2.</w>
mat ch</w>
mal e,</w>
iz ations</w>
investig ates</w>
in -</w>
im ages</w>
i p</w>
hyper lipidemia</w>
h /
f m
ex agger
escap e</w>
ep ez
en ol
em ide</w>
deoxy -
cyste ine,</w>
cycl ing</w>
consump tion,</w>
con junctiv
common .</w>
bif id
at raz
arthri tis,</w>
ar ab
angi ographic</w>
angi ogenesis,</w>
adjunc tive</w>
addic tion.</w>
Ser tol
R s)</w>
R )-
P HT</w>
I Q</w>
He modynamic</w>
HPL C</w>
F -1</w>
Appro ximately</w>
An esthe
Ab normal</w>
5-FU .</w>
40 )</w>
3 C</w>
3 )
3 '
26 4.7</w>
2 1)</w>
16 %</w>
10(- 7)</w>
0.00 1,</w>
(GST )</w>
vir tually</w>
verapam il.</w>
us ers,</w>
typ e-
techniqu es.</w>
schizophren ia,</w>
s cor
pur pur
opoi e
ol im
oc alization</w>
nitros ourea</w>
me .</w>
man ,</w>
lidoca ine,</w>
label ,</w>
lab or</w>
kinas es,</w>
ke to</w>
k ne
invasiven ess</w>
inflammat ory,</w>
in tolerant</w>
if ep
ifep rist
hepat otoxicity,</w>
elf ina
dyn orphin</w>
dihydro pyridine</w>
dic h
di ed.</w>
di benzo
deoxynucleotid yl</w>
d oxycycl
cre am</w>
clon ogenic</w>
bronch odi
awa reness</w>
aut opsy</w>
aut ocrine</w>
as ked</w>
appeti te</w>
anthrac ycl
androgen -
amiodar one,</w>
adeno virus</w>
ad versely</w>
ach lor</w>
V F</w>
U. S.</w>
T o
SH R.</w>
SE )</w>
S tre
S or
RA NK
PD GF
P en
O u
M V
L ocal</w>
H ol
Gen er
Environ mental</w>
Caffe ine</w>
CON T
C L</w>
B A</w>
AD )</w>
5. 3</w>
4 %),</w>
2 3.
(p< 0.05).</w>
(1 6
zidov ud
ven lafax
vaso active</w>
ub icin</w>
to o</w>
sul piride</w>
spectroph ot
smok ing,</w>
polymorphis m.</w>
ouabain -induced</w>
non- Hodgkin's</w>
m apped</w>
iso prost
im azole</w>
hemat oc
fill ed</w>
epirub ic
eng ine
emphasi ze</w>
emo tional</w>
electroph ilic</w>
contracep tives</w>
cat at
c up
at t
ar ms</w>
amin es,</w>
TRP M
T oxic</w>
Suc cess
Psy chiatric</w>
Pregn ant</w>
Pot ential</w>
PM A</w>
Intr athecal</w>
Er yth
E l
DH A</w>
Cyt otoxicity</w>
Ch rom
Cd c
CYP1 1B
Bu t</w>
An aly
5- year</w>
2, 7
2 7,</w>
2 3-
0. 1,</w>
(P ON
(O R,</w>
(3 0
z y
vincrist ine,</w>
tri ge
toxic ants</w>
tetradec ano
tauro chol
supple ment</w>
si rolim
sh un
routin ely</w>
res h</w>
re absorption</w>
pra vastatin</w>
patter n.</w>
p2 1,</w>
over load
necro tizing</w>
metabol ize</w>
mem ant
manif est</w>
lipo ic</w>
ligand s,</w>
leuc ov
ketorol ac</w>
is radipine</w>
inva sion,</w>
intr at
interferon- gamma</w>
in nerv
immunoprecip it
fibro genic</w>
fibrin ogen</w>
extr insic</w>
estrogen s.</w>
er tain</w>
endometri osis</w>
consump tion.</w>
col or</w>
bis (2-
beta- HS
at e/
ast atin</w>
assist ed</w>
aro se</w>
anthrac ene</w>
allel e,</w>
ag on</w>
ac cordance</w>
St ates.</w>
Retin oic</w>
Re sist
Ph IP
O lan
H ap
F U</w>
E T</w>
DR G</w>
CCl 4</w>
Al together,</w>
AD V</w>
A ustr
A 27
6- week</w>
3- (4,
10 (9
1 c
/ PR
(r =
(V PA)</w>
(C u
( i.p.)</w>
( Y
well- tolerated</w>
we dg
ti um</w>
tetr am
substr ate,</w>
sub family</w>
steroid s.</w>
rou ght</w>
reflec ts</w>
receptor- alpha</w>
promp ted</w>
poin t.</w>
phyto estrogens</w>
p21 (W
on ical</w>
om ing</w>
ol e,</w>
ob ac
nACh R</w>
lo g</w>
is omer
is etron</w>
ine d-release</w>
ic ul
hemorrh age,</w>
fluv oxamine</w>
explor atory</w>
distur bed</w>
depress ant</w>
corticosteroid s.</w>
ceruloplas min</w>
casca de.</w>
b ),</w>
ax ial</w>
anil ide</w>
U rine</w>
U A</w>
Sp ont
Le ydig</w>
L X
K/ ERK</w>
K 3</w>
H 2
ER CC
D MS
CTR 1</w>
6. 1</w>
6- phosphate</w>
-1 9</w>
(RO S),</w>
un controlled</w>
ul ating</w>
tin nit
testoster one,</w>
te -
tak es</w>
system atically</w>
steroid ogenesis</w>
similar ities</w>
sig ma</w>
scal e.</w>
rheum atic</w>
repeat edly</w>
re distribution</w>
r hiz
pub er
protein uric</w>
pro chlor
pollut ant</w>
phenyto in,</w>
oxid ase,</w>
os al</w>
oly sis,</w>
mucos a.</w>
min oxidil</w>
m exilet
knock -
kidne ys.</w>
it inib</w>
immunohistochemistr y,</w>
identi ty</w>
homeost asis,</w>
health .</w>
graf ts</w>
glutam ic</w>
gen ce</w>
fragment ation.</w>
ene di
down- regulate</w>
con fusion</w>
coch lear</w>
clopidog rel
cerebell um</w>
calci um,</w>
buspir one</w>
ble omycin</w>
b rought</w>
b ar</w>
art an,</w>
ap lasia</w>
an g</w>
a ].</w>
Y )</w>
Verapam il</w>
TS A</w>
Success ful</w>
SRE BP
Pheny to
PM L-
Norm al</w>
NA )</w>
Methotrex ate</w>
M X
II A</w>
IGF BP-
ICA L</w>
Eigh ty-
ERK 1/2,</w>
EGF R-
De x</w>
D T
B ilateral</w>
AT ),</w>
2 :</w>
18 %</w>
1 1%</w>
00 0
(M R
(C NS)</w>
yl phenol</w>
ur ation</w>
ul tra
troph oblast</w>
thiop ental</w>
terti ary</w>
t 's</w>
susp ic
supplement ation.</w>
substr ate.</w>
striat um,</w>
sp ind
sil ent</w>
s pread</w>
resul tant</w>
rest ores</w>
psych otropic</w>
predis pose</w>
platelet -derived</w>
phen anth
pen ile</w>
ol abel
ochrom es</w>
nitren dipine</w>
nisol dipine</w>
nic k</w>
neuro toxicity,</w>
neuro blast
myocardi um.</w>
medic ated</w>
mGlu R
ligand -binding</w>
levo floxacin</w>
kg -1.
intra vesical</w>
intr agas
hyper activity,</w>
glyc ation</w>
fluc onazole</w>
exercis e.</w>
escal ating</w>
epinephr ine-induced</w>
end otoxin</w>
end otox
el usi
el ong
dis ability</w>
coordin ation</w>
contamin ant</w>
consol idation</w>
condi tional</w>
complex es.</w>
blot ,</w>
bi ologic</w>
beta (2)-
au terine</w>
atript an</w>
ap ne
[ S
Z ),</w>
Ultr as
SI S:</w>
PTH r
PK A</w>
OH d
N GF</w>
MT ,</w>
L it
K ir
Increas es</w>
IL-1 beta,</w>
H9 c2</w>
H unting
BEAS-2 B</w>
Austr al
AB CB
6 8
5- lipoxygenase</w>
2 2%</w>
-1 4</w>
w an
v ap
ureth ane</w>
upregul ates</w>
un translated</w>
sulph ate</w>
sal ine-treated</w>
rostr al</w>
regul ated,</w>
regi stered</w>
quar tile</w>
prompt ly</w>
prec ed
peroxy nitrite</w>
pancre ati
ol d
od y</w>
nucle us,</w>
nitro gen
moti f
metabolis m
me g
l er
kind ling</w>
iz ine</w>
in ed</w>
gall oc
fol ded</w>
fluor ide</w>
e us</w>
draw n</w>
dizzin ess,</w>
deple tion.</w>
dec ano
con serv
col um
clozap ine,</w>
can onical</w>
can di
ca vity</w>
bu thi
b atter
ator .</w>
antibodi es,</w>
anti d
antagonist )</w>
ann ed</w>
analyz ing</w>
aberr ations</w>
Z IP
Th rough</w>
TC A</w>
Resveratro l,</w>
PC )</w>
P u
P seud
Met abolic</w>
M HC</w>
L- dop
L arg
High -
F ail
D- penicill
C F</w>
B id</w>
13 3</w>
0.000 1),</w>
(C s
(A LT)</w>
( total</w>
wat er,</w>
two- dimensional</w>
topir amate</w>
to genesis</w>
sup ply</w>
st av
solv ent</w>
ri t</w>
post partum</w>
point es.</w>
phosph ate,</w>
phenobarbit al,</w>
par i
paclitaxel .</w>
om a-
nicot ine.</w>
neglig ible</w>
mus cim
month ly</w>
membran e,</w>
lin ing</w>
injec tions.</w>
ini b,</w>
ing 's</w>
in ability</w>
impair ment,</w>
ichi a</w>
histi dine</w>
flurbi profen</w>
fet us</w>
ethoxy resoruf
epi galloc
enlarg ement</w>
eme sis</w>
duod enal</w>
derivati ves,</w>
condi tion,</w>
con sumed</w>
comp ut
circul ation.</w>
catarac t</w>
an j
Post -
NF-kappa B.</w>
NF )</w>
Mater nal</w>
M G-
Inhib itory</w>
III -
I k
EP H
Diab et
Car cin
B[a] P</w>
AMP- activated</w>
A N</w>
A ED
= .0
6-hydroxy dopamine</w>
6 5%</w>
4 8,</w>
27 %</w>
2 1%</w>
17 5</w>
0.0 4</w>
0 1</w>
(As 2O
(4 )
un co
u ren
tri ple
toler able</w>
tab let</w>
sulf ate,</w>
stor age</w>
sid ase</w>
sh rin
sco res,</w>
r t
qu ick
pregnanc y,</w>
por phyri
pharmaceu tical</w>
person al</w>
pent amidine</w>
oxy cod
od ine</w>
o ffic
new er</w>
my ome
icardi al</w>
gland ular</w>
frequ ency,</w>
fe a
exam ple</w>
erg oline</w>
ed )</w>
dys morph
dos e)</w>
dipiv ox
di el
defin ite</w>
cult ure,</w>
bro w
beta- caten
aver aged</w>
are a,</w>
amin ase</w>
aden yl
accur ate</w>
T el
T RE
Syst olic</w>
Stud y.</w>
S AP
Recept or</w>
N MR</w>
N G</w>
MEASUREMENT S</w>
L ev
Ishik awa</w>
In di
B E</w>
7 90
6- month</w>
3 2,</w>
24 %</w>
(T RA
(T GF
(PD ).</w>
(B a
( alpha-
warr ants</w>
vi gil
ul y</w>
uc h
trop onin</w>
tot al,</w>
thir d-
su fentanil</w>
stopp ed.</w>
stabil ity,</w>
sodi um,</w>
r in-
pro pos
path ogenetic</w>
p ock
p indolol</w>
p )</w>
oxytoc in</w>
nod al</w>
monitore d.</w>
mild- to-moderate</w>
melphal an</w>
libr ary</w>
leuk openia</w>
iohex ol</w>
intran asal</w>
interrup tion</w>
hypox ia,</w>
hyperten si
hyp oplastic</w>
fruct ose-
f ro
dexamethas one.</w>
cop i
bleed ing.</w>
as e/
an ion
am ip
al .,</w>
adren o
acceler ate</w>
We e
T AC
Specific ally,</w>
Sertol i</w>
Ser ial</w>
S100 A
Prog esterone</w>
NF-kappa B,</w>
NAD H</w>
MM C</w>
M LC
Intrac ellular</w>
IL-1 8</w>
H 295R</w>
F etal</w>
Ep id
EC )</w>
E ch
Del a
CP P</w>
B inding</w>
Americ ans</w>
Al a
5-Az a-
3 '</w>
2, 2-
2 %).</w>
-2'- deoxy
-2 00</w>
-1-methyl-6-phenyl imidazo[4,5-b]
(H R
(A Z
( SI
verte bral</w>
uro spor
transporter s,</w>
test ).</w>
t us
susta ined-release</w>
sulf ur</w>
separ ation</w>
ril e</w>
reversi ble.</w>
repor ts,</w>
relap se.</w>
re war
psor iasis.</w>
produc t,</w>
post- treatment</w>
phenol ate</w>
pepti de,</w>
pair s</w>
ox an</w>
out side</w>
os molar</w>
nucleoti des</w>
nor triptyl
neutr alizing</w>
neuro developmental</w>
nephropath y,</w>
myelodys plastic</w>
mutagen icity</w>
minim ize</w>
mg ).</w>
it on
i.c.v .</w>
gene- related</w>
gemfibroz il</w>
g ent</w>
g e</w>
fluoro quinol
exp anded</w>
estradi ol
esc ence</w>
en ded.</w>
diphenhydr amine</w>
cri bed</w>
copper ,</w>
confoun ding</w>
con stituted</w>
com et</w>
catech ol-
budes onide</w>
ba x</w>
ation ),</w>
ar ising</w>
ar a-
applic ation.</w>
anti malarial</w>
anesthe si
Wn t/
VKOR C
U p-
S cre
Pro l
PD980 59</w>
PC s</w>
P o
OD )</w>
NS- 39
N NK</w>
Med ic
LPS- stimulated</w>
L id
IN H</w>
H GF</w>
G G1</w>
Fail ure</w>
D s</w>
Cr(V I
CYP2E 1,</w>
B cr
AZ A</w>
AN OV
6. 7</w>
34 35
3 2%</w>
2 2)</w>
18 0
10(- 8
(L V
vehic le,</w>
ult ured</w>
therapeu tics</w>
spectroscop y</w>
sp ina</w>
side- effects.</w>
selec t</w>
reduc tion,</w>
py ri
precur sor
pre ferred</w>
pirox ic
pharmac ogenetic</w>
pat ent</w>
organ s.</w>
miR-2 1</w>
marg inal</w>
m us</w>
lute in
lu men</w>
low .</w>
lipid- lowering</w>
kind s</w>
k s,</w>
intracor onary</w>
halogen ated</w>
flut amide</w>
es ulf
ergot amine</w>
epigalloc atech
endocardi tis</w>
des ferri
dela ys</w>
defect s,</w>
dam ages</w>
d s,</w>
clear ance.</w>
c IAP
bec omes</w>
awa ke</w>
anti microbial</w>
af lat
acetyl salicylic</w>
acetyl ated</w>
Z e
U CP
T 2</w>
Pro spective</w>
P D-
M id
I A</w>
HD .</w>
Drosophil a</w>
C ys</w>
Afric an-
8- fold</w>
7- fold</w>
29 ,</w>
2. 5,</w>
(T RP
(P< 0.01).</w>
(P- gp
(3 ),</w>
ys til
transf ect
til ide</w>
t- PA</w>
syn onymous</w>
sive- compulsive</w>
similar .</w>
sh RNA</w>
rul ed</w>
rever se-
relax ant</w>
pres ent,</w>
predic table</w>
plas ma,</w>
pioglit azone</w>
phent olamine</w>
phenomen on.</w>
persist ence</w>
peri odic</w>
p ation</w>
os al
or adi
opath ology</w>
ol ol,</w>
nor adrenal
multi focal</w>
microarra ys</w>
methyl dop
mel it
m and
low- up</w>
long itudinal</w>
iter pen
ing ;</w>
in bred</w>
im pul
ic /
hydrox amic</w>
hex a
haz ards</w>
giv en.</w>
gener ates</w>
fore stomach</w>
factor- a</w>
enrol led.</w>
end o
ell ite</w>
ell ed</w>
down regulates</w>
document ed.</w>
depri v
cra ving</w>
com es</w>
code ine</w>
cere br
carcinogen ,</w>
bor der
b ond
ation ].</w>
af in
Transcrip tional</w>
TIMP -1</w>
Sevent een</w>
SU B
S oci
RO S,</w>
P450 s</w>
Na Cl</w>
NT E</w>
N 2</w>
Mechan ism</w>
MATERI AL</w>
In stitute</w>
IV ,</w>
HT 29</w>
EC 50</w>
Da ily</w>
CC N
CA R
BM I</w>
6 7%</w>
2C 9</w>
2 2,</w>
2 %),</w>
12 3</w>
10 2</w>
1. 0,</w>
1 13</w>
-2,5- diphenyl
-1, 3-
(L VE
(I V)</w>
(C o
( i.v.)</w>
z ip
x ine</w>
tw it
tricho statin</w>
transport ,</w>
tom y</w>
tim ing</w>
thre e
sens ation</w>
ro cur
rec ti
re d-
prost ate-
phen ol,</w>
ox ide-induced</w>
ou s.</w>
neuro psychological</w>
ne vir
mit ogen</w>
methotrex ate,</w>
mat ory</w>
junc tions</w>
frequ enc
fibrin olytic</w>
factor- kappa</w>
f resh</w>
epitheli al-
ent or
ectom y.</w>
diff ering</w>
depend ence,</w>
de )</w>
characteris ed</w>
caveol in-1</w>
autophag y.</w>
ation -specific</w>
as alaz
an k</w>
amph i
act ual</w>
[ Effects</w>
V al</w>
There fore</w>
Ta q
Stro ke</w>
SUB JEC
Rho A</w>
R em
PARTICIPANT S:</w>
MP TP</w>
MMP -1</w>
Lip id</w>
L- type</w>
KE Y</w>
IC P</w>
H om
F I
ER alpha-
DB A/
Clo zapine</w>
CYP3A 4.</w>
CD 3
B ody</w>
AM I</w>
3 8%</w>
26 %</w>
24 )</w>
12 ).</w>
1 alpha,
1 10
0 %,</w>
) ],</w>
) .
(IF N-
(H R)</w>
(C h
(C M
(B )</w>
( +/-</w>
warfar in.</w>
utroph il</w>
ul es</w>
two fold</w>
tremor ,</w>
to- treat</w>
tel u
target s.</w>
sulforaph ane</w>
s lowing</w>
remodel ing.</w>
reli eved</w>
recur red</w>
poin t,</w>
phen e</w>
parkinson ism.</w>
open- label,</w>
op posed</w>
oblas toid</w>
o il
mon telu
modifi es</w>
mac hin
las mic</w>
je jun
is omer</w>
irrit ation</w>
iod ine</w>
inf anti
incre ment</w>
in 's</w>
im otor</w>
i dipine</w>
hum oral</w>
graph ic</w>
fraction ated</w>
foun d,</w>
form ,</w>
fold ),</w>
fact ,</w>
excit ability</w>
escal ation</w>
eosinophil ia</w>
endoc r
dis h</w>
countri es.</w>
chlor ide.</w>
catalep sy,</w>
an aplastic</w>
activ ely</w>
abrup t</w>
Z D</w>
T -2</w>
Statis tical</w>
Psy ch
O ),</w>
NF kB</w>
J A
Hodg kin</w>
Fol low-up</w>
Concomit ant</w>
Cl (-)</w>
Ca MK
AD M</w>
> or=
( methyl
( "
vetir acetam</w>
ver ify</w>
vasoconstric tor</w>
trazod one</w>
tar tr
synthe siz
stres sed</w>
sl ope</w>
sev ent
sch er
ret e</w>
prostac yclin</w>
pro to-
pro arrhythmic</w>
peptid ase</w>
parad oxical</w>
os c
non- specific</w>
nitro furant
mus cul
molecul es.</w>
mis oprost
metab otropic</w>
line age</w>
hour s)</w>
fibrill ary</w>
fascicul ations</w>
examin es</w>
es hi
en su
en able</w>
echocardi ography.</w>
dystroph y</w>
down- regulates</w>
diure sis</w>
differen tly</w>
dextrometh orphan</w>
copi es/
ci lost
child ho
bi ogenesis</w>
aminob i
activ e.</w>
] ),</w>
Top ical</w>
SL E</w>
Particip ants</w>
K(+)- ATPase</w>
I sol
I CAM
Hep a
H 2-
ER CC1</w>
D u
D il
D ig
Br ady
A LT
4 8.
29 %</w>
19 %</w>
1- year</w>
-1 a</w>
-1 H-
- 3,</w>
(SOD ),</w>
(N AC
(D el
(1 99
weigh t
week s).</w>
volume .</w>
vari ants,</w>
trin itro
tr abec
thiazol-2- yl)
supernat ant</w>
stom ach
sot al
som an</w>
sir tu
single- agent</w>
set ting
sensitiz ation.</w>
scher ichia</w>
sc ans</w>
rest oring</w>
re flux</w>
prophyl axis.</w>
physici an</w>
out ,</w>
ou ma
opo si
onit oring</w>
on ly,</w>
om on
ologic ally,</w>
nephro toxicity,</w>
machin er
le pro
lat encies</w>
k ing,</w>
in o
i op
hemo globin
fram eshi
est ers</w>
ere s</w>
en one</w>
diab e
design ated</w>
cyt ochromes</w>
cor ro
connec ted</w>
congen ers</w>
classi fication</w>
chol anth
chemistr y</w>
cat abolism</w>
carcinogen s.</w>
canc er-
br achial</w>
both .</w>
bl asts</w>
bi ot
benzo[a] pyren
at ed-
as tic</w>
arti ficial</w>
anti angiogenic</w>
angi ography.</w>
amne sic</w>
alkal oid</w>
adipo genesis</w>
Syn erg
S 1
Rh o</w>
RB C</w>
Org an
O (6)-
Na +/
NS ).</w>
Mus cle</w>
Low -dose</w>
L K
K i</w>
H L</w>
Gn RH</w>
F e</w>
CA M</w>
C- 0
80 .</w>
5. 6</w>
27 )</w>
25 ).</w>
15 ).</w>
10 3</w>
-1 8</w>
(S NP)</w>
(PK C)</w>
(M e
(H C
(G R)</w>
( less</w>
w aves</w>
vomit ing.</w>
treat ed.</w>
transfer red</w>
thym ic</w>
t y.</w>
synerg ism</w>
susp ension</w>
sup pl
sign at
recommend ations</w>
re pres
polymorphis ms.</w>
po t</w>
plas ma.</w>
perc eption</w>
os e
n M),</w>
mon ocyte
mellit us.</w>
m argin
lipoph ilic</w>
lat er
intoxic ated</w>
insectic ide</w>
ine- based</w>
in ;</w>
i a-
fel b
fea sible</w>
es tin</w>
enti rely</w>
ens ity</w>
dro w
dos age,</w>
dimin ish</w>
dUT P</w>
cyclohex imide</w>
cot inine</w>
contribu tions</w>
chromat ography.</w>
cel ecoxi
c oc
but ylated</w>
b w
anatom ical</w>
allo steric</w>
adenocarcin oma.</w>
accoun ting</w>
ab sc
X ),</w>
Upreg ulation</w>
TNF- a,</w>
SK- N-
S ulf
Retro spective</w>
RANT ES</w>
PR T</w>
P F</w>
Nor th</w>
Nal ox
Mul tivariate</w>
Investig ation</w>
I F</w>
Hoech st</w>
HL 60</w>
H Q</w>
H NF
F s</w>
D o
Cd R</w>
CB P</w>
C av
C 3</w>
B V
AMP A</w>
AE s</w>
17 0</w>
10(- 8)</w>
0.00 5)</w>
- up</w>
- fed</w>
- 3-
(S E)</w>
(IC (50)</w>
(H R</w>
(ERK 1/
zol pide
vessel s.</w>
un de
thiaz ide</w>
suxameth onium</w>
super family</w>
roten one-induced</w>
rit odrine</w>
rifamp in</w>
ri z
r s</w>
pro mo
phen acetin</w>
oxcarb azepine</w>
otox ins</w>
os elec
or n
ophthal mic</w>
ograph ically</w>
oc tan
nitro tyrosine</w>
neuro endocrine</w>
ne oplasia</w>
mod es</w>
mod ality</w>
mineral ocorticoid</w>
migra ine.</w>
micro g)</w>
membrane- bound</w>
m ir
m /
lo vir</w>
leg s</w>
lamotrig ine</w>
kg(-1 ))</w>
it es</w>
ine teen</w>
im pot
hyper lipide
hydro peroxide</w>
hy pol
gra vis</w>
fresh ly</w>
fav or</w>
en demic</w>
ec to
dri ve</w>
dihydro pyrimidine</w>
difficul ty</w>
di is
dextr an</w>
dexamethas one-induced</w>
derivati ves.</w>
dar k</w>
complic ating</w>
characteris tics.</w>
cascad es</w>
ca re.</w>
bl ind,</w>
az ine.</w>
ax on
as sum
arth ro
api genin</w>
aminonucle o
ad ine,</w>
ac illin
S- transferases</w>
S J
R o
Q U
Prostagland in</w>
Prol ifer
PRE T
PB MCs</w>
M ac
INTER PRET
I kappaB</w>
I S</w>
GSH ,</w>
FAN FT</w>
Dow n-
C as
Acet aminophen</w>
Ab err
AC S</w>
5. 8</w>
5 5%</w>
3 3.
2 1.
-- ></w>
(R )-
(P< 0.001).</w>
(P M
(N R
(N =
(L DH)</w>
(I CAM
(EL IS
(E E
(A PA
( 9</w>
y top
weigh t/
vitamin s</w>
vinblast ine</w>
val bum
transporter s.</w>
thrombocytopen ia,</w>
tetr ab
sub chronic</w>
solu tion.</w>
si al
ser ies.</w>
sal t-
riton avir</w>
replic ated</w>
rac emic</w>
r -
psych o
prim ed</w>
possess ing</w>
period s.</w>
pent oxifylline</w>
p 7
overl apping</w>
m irtaz
m ap
lymph oblastoid</w>
lign ocaine</w>
l angu
kin j
k )</w>
induc ibility</w>
incorpor ated</w>
ic yl
headach es</w>
glob ul
ethan ol.</w>
environ mentally</w>
elusi ve.</w>
down- regulating</w>
dog .</w>
diazep am.</w>
di azin
dener v
coupl ing</w>
centri lobular</w>
carcinom as,</w>
cap ec
bur st</w>
bezaf ib
anti diabetic</w>
anj o</w>
an and
akathi sia</w>
addi tionally</w>
ad op
ac to
Wistar- Kyoto</w>
Tol l-like</w>
Six ty</w>
S B</w>
Recom bin
Pre- treatment</w>
PB DE
MT .</w>
MCF -10
M yc
L O</w>
I ron</w>
Hepati tis</w>
G 6
FOX O
En zym
E scherichia</w>
DTI C</w>
CYP s</w>
C RP
Bax /
Adri amycin
8 4
5. 1</w>
12- O-
10 0-
1 13
(p< 0.05)</w>
y el
un altered</w>
ultra violet</w>
trige minal</w>
tri atal</w>
the sis</w>
sp in
rop ivacaine</w>
retard ation,</w>
qu i
polymorph onuclear</w>
path ogen
paren chymal</w>
oste ogenic</w>
om as
ocy n
o sides</w>
mictur ition</w>
maxim ally</w>
lipo proteins</w>
lin ks</w>
lif e,</w>
kinj e</w>
kg ).</w>
k le</w>
it y;</w>
interferon- alpha</w>
i as</w>
hyp ocal
hy pos
high- throughput</w>
g ain,</w>
expos ures.</w>
esc ent</w>
epilep togenic</w>
discharg es</w>
dipivox il</w>
din itrate</w>
day ;</w>
cholin erg
chemot axis</w>
characteris tics,</w>
ca v
azol e-induced</w>
ation ic</w>
angi ecta
ane ously,</w>
amphet amine.</w>
am isul
acu ity</w>
acetazol amide</w>
TS H</w>
Sep tem
SOD 2</w>
SH )</w>
Pro state</w>
PF O
PD ,</w>
NK 1</w>
NA G-1</w>
N-acetyl -L-
N CT
METH -induced</w>
G C-
F requ
Down regulation</w>
Diabet es</w>
CC K-
C P-
Br d
B ut
Ak t
5. 2</w>
10 ,
1 -2
0. 2%</w>
) -2-
(PI 3
(D M
(AT P)</w>
( which</w>
yst ag
y ron
wa y.</w>
transloc ation,</w>
transferase- mediated</w>
trans fusion</w>
tiv ity.</w>
syndrome :</w>
stre ptom
stand ar
sta urospor
squ are</w>
speci es
sp ent</w>
sodi um-
sign ature</w>
sensor imotor</w>
schedul es</w>
safet y,</w>
repair ,</w>
ren ew
reinstat ement</w>
pentylene tetrazol
o ,p'-
mim ics</w>
metalloproteinase- 9</w>
medic inal</w>
lap aro
isopren aline</w>
intr auterine</w>
intr ath
imid azole</w>
i pr
hyper baric</w>
hyp og
fur an
for ward</w>
extr ap
exagger ated</w>
ethyl hex
en ec
doubl ed</w>
disopyr amide</w>
discomfor t</w>
cre ated</w>
conf ined</w>
co efficient</w>
chemic als,</w>
carbamazep ine,</w>
car must
broad -
at ase</w>
anti thrombotic</w>
alpha- adrenergic</w>
acet ate,</w>
a emia,</w>
V i
TGF- alpha</w>
SC -
Rap id</w>
PG C-1
PC 12</w>
PA R</w>
P rec
Nar anjo</w>
Methyl ation</w>
M arch</w>
K ),</w>
II I)</w>
H OX
H 3K
GAB AA</w>
G ).</w>
E c
C NS
Al so</w>
: quinone</w>
4 6.
34 %</w>
3, 5-
- ,</w>
+/- 0.0
( 0-
un explained</w>
tro pine</w>
trime ster</w>
toxic ity:</w>
toxic ant</w>
tetrac ycl
termin als</w>
siz e.</w>
scor ing</w>
respon si
regul in</w>
reac ted</w>
raz oxane</w>
progester one,</w>
prepar ations.</w>
perform ance.</w>
path ology.</w>
parallel ,</w>
par at
pacema ker</w>
ov ine</w>
osteopo rosis</w>
or ic</w>
on azole,</w>
oc il
o fo
non toxic</w>
mmHg .</w>
min ),</w>
mil d,</w>
medi um,</w>
medi ated,</w>
m dr
li ke
lev am
isot retinoin</w>
inflamm as
fluoxet ine.</w>
fix ed-
fatigu e,</w>
estradi ol.</w>
entr e</w>
end s</w>
emerg ent</w>
el ia</w>
di esel</w>
defer oxamine</w>
d re
chel ation</w>
ax is,</w>
av ing</w>
arrhythmi a,</w>
alpha- hydroxylase</w>
ag e)</w>
acro megal
Sm all</w>
STAT 1</w>
R U
R R
Pur kinje</w>
Nephro toxicity</w>
K A</w>
HN E</w>
GST -
GP x</w>
Ep o</w>
DE P</w>
D eter
D R</w>
CD DP
Block ade</w>
9 %),</w>
50 %.</w>
4 2%</w>
19 7
1,25- dihydroxyvitamin</w>
* 2</w>
(PI 3K
( adjusted</w>
work ers.</w>
trastuz umab</w>
trans gene</w>
th at
sit ting</w>
sed ation,</w>
sar cop
rabb its.</w>
preser vation</w>
pren atally</w>
pre fer
potenti ating</w>
ple i
pim oz
phospholip ids</w>
phenyl but
peroxid ase,</w>
paras ympathetic</w>
one ;</w>
oc ap
nim odipine</w>
neutrophil s.</w>
multiplic ity</w>
ml .</w>
mi g
m L
j mal
ip si
inva sion.</w>
inher it
infrequ ent</w>
in- 2</w>
in effective.</w>
imat inib</w>
im er
ifi ed.</w>
ide a</w>
id az
ham ster
hall mark</w>
encephal y</w>
e able</w>
distingu ish
concentration- time</w>
con cent
comparison ,</w>
clomi pramine</w>
cephal ospor
cap ill
canal icular</w>
butr amine</w>
bri ef
blad der.</w>
atrac he
ar s
ap it
antagon izes</w>
al is
[ 3-
UDP-glucuron osyltransferase</w>
S chi
Q ,</w>
PT U</w>
Na (+)</w>
MD D</w>
Kidne y</w>
K56 2/
In dian</w>
HB s
H )-
G astro
Cx 43</w>
CL IN
CI )</w>
C s)</w>
Bet a-
B ru
B en
AI A</w>
A )-
4 %).</w>
3T 3</w>
2 3,</w>
0 ),</w>
/ =
(S R
(NF-k B)</w>
(C S
(+/- )-
( phox
world wide</w>
w k.</w>
ventil ated</w>
uter us</w>
tur n,</w>
top otecan</w>
t ate</w>
sympath omimetic</w>
succin ate</w>
s "</w>
rs 2
propion ic</w>
precur sors</w>
por e</w>
particip ating</w>
ous tic</w>
osc ill
oph ore</w>
olig o
og u
obses sive-compulsive</w>
obes ity,</w>
non competitive</w>
n ival
n ig
mon omethyl
medi a.</w>
lim bs</w>
lim b
interleukin-1 beta</w>
infarc ted</w>
incid ence,</w>
in contin
in activating</w>
hypo thyroidism</w>
hypercholesterol emia</w>
hei gh
exha ust</w>
epi andro
em pir
elucid ated</w>
ed s</w>
e.g .</w>
dr in</w>
dis sol
deple tion,</w>
concentration -</w>
commer ci
chang e,</w>
cent ers</w>
carcinogen .</w>
c is</w>
bicucul line</w>
batter y</w>
b erb
arteri olar</w>
af ine</w>
SPEC T</w>
Recombin ant</w>
R at</w>
Post operative</w>
PP 2A</w>
PC NA</w>
Onc ology</w>
N ).</w>
Mer cur
L ig
Immun ob
G olg
ER )</w>
Dep art
Da ys</w>
D N</w>
Cyp 2
Co gn
CLIN ICAL</w>
Ara- C</w>
A ro
2 8%</w>
- sulfamethox
- onset</w>
( Zn
zafirlu kast</w>
wedg e</w>
we t</w>
vancom ycin
ubiquit ination</w>
tis :</w>
tetrahydro cannabin
symptom at
sulfhydr yl</w>
suic ide</w>
sol ely</w>
sequenc ing.</w>
seiz ure.</w>
secre ting</w>
se di
s car
prov oc
pig s.</w>
pan -
pae diatric</w>
over production</w>
oste op
month .</w>
micrograms/ kg)</w>
mg/ day).</w>
mg. kg-1</w>
malignanc y.</w>
m ers</w>
lik re
intramus cul
infanti le</w>
im ine</w>
gh ,</w>
g ained</w>
fun dam
fib ers.</w>
factor- kB</w>
es mol
eptid ase</w>
ent ation</w>
endoscop ic</w>
empor al</w>
em bed
e- directed</w>
dys lipidemia</w>
de tac
d ine,</w>
channel .</w>
c esarean</w>
azol ine</w>
azoc ine</w>
agric ultural</w>
affor ded</w>
admis sion.</w>
ad ver
XR CC
T SC
ST ,</w>
R an
NO ,</w>
N OX
Meth amphetamine</w>
MA ,</w>
Long -
Kine tic</w>
IL-1 2
II a</w>
Hep 3B</w>
H a-
F ul
ERK 1/
DE N</w>
D ose</w>
Cyclophosph amide</w>
C CA
Anim al</w>
AR ,</w>
9 00</w>
80 )</w>
14 .</w>
12-O- tetradecano
10 8</w>
(NSCL C)</w>
(A n
( non-
vascular ization</w>
twent y-
thick ening</w>
st .</w>
spro uting</w>
slow ed</w>
sil ver</w>
sex es</w>
ser i
sco re.</w>
sat ellite</w>
reperfu sion.</w>
ren e,</w>
reci proc
rat oxin</w>
r ational</w>
prop ensity</w>
prop ag
pressu re
pharmacod ynamics</w>
par a-
p amid
oligonucleoti des</w>
o hex
necess ary.</w>
mobil ization</w>
minim ally</w>
mg/ d)</w>
medullo blastoma</w>
medi ation</w>
lep tic</w>
it r
irradi ated</w>
influ enz
hepat oprotective</w>
gluc agon</w>
glauc oma</w>
fin aster
enkephal in</w>
endos ulfan</w>
dithiocarb amate</w>
discrimin ation</w>
dil ation</w>
desi r
degrad ed</w>
de b
daun orubic
cour se,</w>
coun t,</w>
cor d.</w>
cl aud
cholester ol-
cd k
biop sy.</w>
beta- estradiol</w>
be sides</w>
astrocyt es.</w>
arthri tic</w>
arrhyth mogenic</w>
antibod y.</w>
an es</w>
ad d</w>
accid ental</w>
W T1</w>
V inc
Up- regulation</w>
Th 1</w>
T A-
R g
P b
O AT
NSCL C.</w>
N- methyl
N umerous</w>
Lam iv
L uc
J uly</w>
IGF BP
He p</w>
He ad
GD C-0
Endo thelial</w>
Dobut amine</w>
Dela yed</w>
BP ),</w>
Alzheim er</w>
Aden osine</w>
9 %).</w>
6. 4</w>
4- di
3 H-
(F GF
(AP L)</w>
( hazard</w>
( f
( Al
zy mograph
w as
vect ors</w>
vec uronium</w>
vari ants.</w>
u ve
tumour s.</w>
trin itrate</w>
tiz an
ti es,</w>
tas k.</w>
sulf oxide</w>
sp ray</w>
somat ostatin</w>
silden afil</w>
reve aling</w>
reproduc ible</w>
repress es</w>
random ised,</w>
proble ms.</w>
prim ing</w>
pre medication</w>
polymorphis ms,</w>
pel vic</w>
par anoid</w>
ocyto sis.</w>
ocyto sis,</w>
nicot ine,</w>
neurolep tic-induced</w>
micro injection</w>
lymph ocytes,</w>
ischemi a/
index .</w>
hyper plastic</w>
heterodi mer</w>
g/m l</w>
g adol
exc ep
enalap ril,</w>
emplo ying</w>
eff u
early- onset</w>
defini tive</w>
d ).</w>
cyclo -
cit alopr
chi meric</w>
block ,</w>
benz ene,</w>
belong s</w>
atic ,</w>
ascit es</w>
ap parat
anth ra
ane ously.</w>
aldehy de.</w>
acetyl -
acet amide</w>
Zn -
Tol er
TP MT</w>
Stat 3</w>
St and
S kin</w>
RA -
Prom ot
Prog res
PB MC</w>
N-acetyl transferase</w>
M CL
LP L</w>
IN CIPA
INCIPA L</w>
IC R</w>
H s
Gl yc
Gl c
Genotyp ing</w>
G B</w>
E 3</w>
DL IN
DF O</w>
Cur ren
C ases</w>
Bru gad
BB B</w>
B N
Al l-
A I</w>
A H</w>
= 1.
7 %),</w>
6 %),</w>
(D R
( relative</w>
( RE
( L-NAME
yr id
y ed.</w>
vincrist ine-induced</w>
valu e.</w>
val idate</w>
un exposed</w>
tren ds</w>
the ore
surrog ate</w>
surfact ant</w>
simvastat in,</w>
ri tis,</w>
ri bo
rever ted</w>
pyl ori</w>
pi perid
per ic
opath ies</w>
min ute
micro dialysis</w>
mic e:</w>
membran ous</w>
intest ine.</w>
increas e,</w>
in completely</w>
idemi a,</w>
heter ozygosity</w>
h sp
h s
guan ine-
g over
forsk olin</w>
filam ent</w>
exacerb ates</w>
endoc annabin
elev ated.</w>
dist ance</w>
diarrhe a,</w>
descri ption</w>
clon ing</w>
cleav age.</w>
cell ,</w>
c- f
break down</w>
brain- derived</w>
benzbrom arone</w>
baro receptor</w>
ba ical
ag ement</w>
ac oustic</w>
T reat
Protec tion</w>
Per sistent</w>
P t
O R,</w>
Nin ety-
NF-kappa B-
MP )</w>
LP S.</w>
Isoproteren ol</w>
Er k
Epidemi ological</w>
E2 -induced</w>
Down- regulation</w>
D 2
CHO P</w>
CH F.</w>
BACKGROUND/ AIMS:</w>
6 %).</w>
5. 4</w>
29 )</w>
(T E
(S er
(PGE 2)</w>
(P L
(M DR
(Hep G
(2) ),</w>
( day</w>
( UGT
upregul ate</w>
transcri ptom
ter m,</w>
sub sets</w>
st al
st age.</w>
sid es,</w>
sen sing</w>
scal e,</w>
s- of-function</w>
relim inary</w>
regurg it
ra sid
quin april</w>
psy chi
promot er-
proca ine</w>
ph il
parac rine</w>
p3 8-
oxygenase- 2</w>
ot um
osteo arthritis</w>
oste ocal
occur red,</w>
o ffered</w>
ne u</w>
n af
myot ub
microsom es,</w>
mic rom</w>
me an,</w>
lithi um.</w>
lipoly sis</w>
ket one</w>
ir on,</w>
in uria</w>
haem olytic</w>
gli omas</w>
gli oblast
expres ses</w>
dichlorv os</w>
develop ed,</w>
del u
coun ter</w>
cou gh</w>
cl av
chrom osomes</w>
cham ber</w>
but ,</w>
brow n</w>
bor ne</w>
auto antibodies</w>
anti cip
analog ,</w>
adrenocor tic
activ e,</w>
TGF- b</w>
Simult aneous</w>
SC s.</w>
S ma
R ifamp
P reliminary</w>
Ne on
NADP H-
N at
Ma j
M uc
Hepat ocellular</w>
H b
G em
CH O</w>
CB 2</w>
C NT
B io
50 %,</w>
2- 3</w>
2 3%</w>
12 5,</w>
10 A</w>
1. 25</w>
/ P
, "</w>
(IL- 6)</w>
(AT O)</w>
(A DH
(3- pyrid
(0. 25</w>
uncoupl ing</w>
um -treated</w>
thi orid
t ly.</w>
sulfoxim ine</w>
sulfon yl
st ac
sp ots</w>
rup ture</w>
regul arly</w>
region s,</w>
re feren
quick ly</w>
prolong ing</w>
polymorphis m,</w>
polym y
peri operative</w>
ox ide-
over la
ot otoxic</w>
n ocicep
mmol/ l</w>
macro scopic</w>
ly sis</w>
lit er
le an</w>
lac ks</w>
hydant oin</w>
glycer yl</w>
gal acto
fol ding</w>
etopo side,</w>
dop amine,</w>
dihydro testosterone</w>
desir able</w>
des methyl
deliver y.</w>
curcum in.</w>
countri es</w>
conc ept
con struct
competi tion</w>
coll ection</w>
captop ril,</w>
cal cin
beats/ min</w>
awa k
ation -dependent</w>
architect ure</w>
antioxid ants,</w>
al an
[ 14
T g
ON O
Na +
N ec
M IP
JAK 2</w>
Hg ;</w>
GLUT 1</w>
G> A</w>
Flu oxetine</w>
Ci pro
Chol est
Che mical</w>
CYP3A 5
CYP2 6
B PA,</w>
Al co
AS 3
A trial</w>
2 )
10 7</w>
-1 3
(IC (50
(4- hydroxy
( LT
year s),</w>
w anted</w>
ves '</w>
to ,</w>
th r
ter one</w>
techn ology</w>
suffici ently</w>
sti n</w>
stereotyp ed</w>
spec ulate</w>
siven ess</w>
silic o</w>
sign s,</w>
ser ine/
scal es</w>
retar ded</w>
prostate- specific</w>
pren olol</w>
plaqu es</w>
phosphatidyl serine</w>
ov an
other .</w>
oth yron
one- associated</w>
oc ur
myel inated</w>
mis match</w>
microgram s)</w>
mas s,</w>
lute olin</w>
li stat
it y
in- 3</w>
ide mia</w>
hem angi
hand ling</w>
gluc o
genotyp es,</w>
frac tion,</w>
fl ame</w>
factor- beta</w>
estrogen s,</w>
engine ered</w>
end ,</w>
e "</w>
dermati tis.</w>
depend ed</w>
con flu
cid ol
beta- blocking</w>
az id
auto immunity</w>
as cending</w>
ari um</w>
amy otrophic</w>
ag ranul
activit y;</w>
accur acy</w>
Y M
V C</w>
TGF- b
Sever ity</w>
Serot onin</w>
Septem ber</w>
Repor t</w>
Re verse</w>
PG I
P y
P anc
O ste
LO X</w>
J E
Im pac
H Y
G CL
F E
D PAT</w>
Con tr
CD )</w>
C ef
B SE
B F
Amph et
Ac tivity</w>
A E</w>
7 %).</w>
6- tetrahydro
3-(4, 5-dimethyl
2. 5%</w>
(TB AR
(T LR
(PA RP)</w>
(5-HT )</w>
(10 ,</w>
wh y</w>
ven o-occlusive</w>
var ic
us h</w>
treatment :</w>
there after</w>
termin us</w>
strateg ies.</w>
stiff ness</w>
steroid s,</w>
sal ts</w>
recomm ended.</w>
rati o
princ i
poly amine</w>
oxi diz
out flow</w>
ol d)</w>
ob enz
mec amyl
lef t-
iso enzyme</w>
interpre tation</w>
inde ed</w>
imag ing.</w>
ill ic
i ver
haemo globin</w>
for tun
expected ly,</w>
en flurane</w>
embed ded</w>
ed ar
disper sion</w>
di mer</w>
crizot inib</w>
contamin ants</w>
clinic .</w>
chlor thal
caud ate</w>
calcul ated.</w>
c idin</w>
c ationic</w>
beta /
benzo [
az ot
ascorb ate</w>
an hydr
aflat oxin</w>
administe red,</w>
acceler ation</w>
VAD -
Un der
UT R</w>
U ),</w>
Td P</w>
T AM
SO )</w>
R en
PE X
O pi
N G-
ME DLIN
IC U</w>
Haloperid ol</w>
HBI G</w>
Gra ves'</w>
Gl omerular</w>
G I</w>
Fif ty</w>
F AS
Eth anol</w>
Egr -1</w>
DO CA-
Coca ine-induced</w>
CONT EX
CO PD</w>
CB (1)</w>
B up
Aberr ant</w>
AR T</w>
AD R-
8. 0</w>
7. 1</w>
5. 0
4 7%</w>
1, 1-
-1 7</w>
(+ ),</w>
" .</w>
yn uren
y lo
v a
therap y].</w>
struct ure.</w>
smok ers.</w>
res the
remis sion.</w>
re produced</w>
r af
prog estin</w>
plas mid
phorbol-1 3-
panc ytop
p urine</w>
ox on</w>
ori s.</w>
onset .</w>
non enal</w>
n ystag
n ous</w>
min ocycl
microgram s.
methyl ene</w>
met for
lorat adine</w>
lear n
l ine-induced</w>
iodi x
interpre ted</w>
infiltr ation,</w>
hyperpla sia,</w>
homogen ates</w>
glucos e.</w>
fo ot
fen amic</w>
f oci
excl uding</w>
eti ological</w>
equi potent</w>
epidemi ologic</w>
encod e</w>
embry os.</w>
electroencephal ogram</w>
e- related</w>
droperid ol</w>
cyclophosph amide
comorb id</w>
commerci ally</w>
c ab
bu il
assess ment.</w>
ari a</w>
antibod y,</w>
anorex ia</w>
amid oph
adap tation</w>
[Ca2+] i</w>
Y ,</w>
Resist ance</w>
R G</w>
Platel et</w>
Physi ci
Neuro logical</w>
Na (+)/
NI S</w>
N ineteen</w>
N MS</w>
Lit tle</w>
Li ke</w>
K i
J Q
Ig M</w>
He ter
Dis rup
D oc
D ip
2 10</w>
15 .</w>
0.0 8</w>
(S H
(1 .0
yl- L-
vasodil atory</w>
v in</w>
uro theli
tumor ,</w>
tolbut amide</w>
ti clopid
them sel
terat ogen
st ain</w>
sp ine</w>
sca ff
rec re
re ma
razol e.</w>
posi tive,</w>
pol ys
pilocarp ine,</w>
phosphat ase,</w>
phenyto in.</w>
par ab
p s.</w>
oscop y</w>
os ulf
op tical</w>
omycin -
olig uric</w>
nitroprus side-induced</w>
myelosup pression</w>
month s;</w>
mode stly</w>
methicillin -resistant</w>
mening itis.</w>
mark eting</w>
m ).</w>
lys osom
lymph omas</w>
le sion.</w>
kal likre
kain ate</w>
intra- arterial</w>
ine- containing</w>
im age</w>
he avi
ge ho
flu phenazine</w>
fe ed</w>
facilit ating</w>
element -binding</w>
drow sin
dis playing</w>
di propionate</w>
determin es</w>
depress or</w>
decid u
d- amphetamine</w>
d p
cycl opent
convul sions,</w>
cardi ogenic</w>
but adi
bio assay</w>
attemp ts</w>
atrac urium</w>
ar ise</w>
approach ,</w>
aneurys ms</w>
ane diol</w>
anch or
amne sia.</w>
amik acin</w>
al buterol</w>
aggres sion</w>
afin il</w>
af 1/
acetyl ator</w>
Y or
Spont aneous</w>
Signific antly</w>
R ot
Q T-
Pre dic
PT )</w>
MEASUREMENT S:</w>
I X</w>
Gen eral</w>
G ly</w>
G 1/
Ech ocardi
ER OD</w>
E mer
Dis ulfir
Dis continuation</w>
DU 145</w>
DN R</w>
D S</w>
Cycl ospor
CYP 17</w>
C> T</w>
C 1
Bcl -2.</w>
BRA F</w>
As (III)</w>
AC h</w>
7. 8</w>
5-hydroxy tryptamine</w>
5 A</w>
2 +
16 ).</w>
10. 0</w>
10 9</w>
10 /
0.0 6</w>
- 8
(T r
(H SP
x 2</w>
wil d
tel angiecta
stabil ize</w>
sever ity,</w>
ses sion</w>
sear ched</w>
recogn ize</w>
propor tions</w>
possi bil
popul ations,</w>
poly cystic</w>
p =0.00
overla p</w>
otyp ic</w>
ot ep
oste osarcom
os p
orn ith
oposi tive</w>
nar row</w>
nalox one.</w>
n elfina
micro sph
ment ing</w>
ma de.</w>
m ass
litter mat
kill er</w>
issu es</w>
is lets</w>
iod othyron
intrath ec
intest ine,</w>
interleukin -2</w>
induc ed.</w>
ind ustr
ific ation,</w>
ifeprist one</w>
he at-
form al
flic k</w>
fibrill ar</w>
eth idine</w>
enalap ril.</w>
days ),</w>
corro bor
clonid ine,</w>
chol inester
c Tn
butyr ylcholinesterase</w>
both ,</w>
border line</w>
bec oming</w>
be ,</w>
at tained</w>
astemiz ole</w>
aripip razole</w>
amin ophyl
alprazol am</w>
alpha 2-
allel es.</w>
al as
W -
V max</w>
U GT</w>
SW 480</w>
PE T</w>
O F</w>
N V
My el
MA O-
M SH
L QT
Inhibit ors</w>
Individ u
Impac t</w>
Hist one</w>
HU S</w>
HBe Ag</w>
F 50
DE )</w>
Chin a.</w>
Carbam azepine</w>
AF B
A ;</w>
5. 7</w>
4 3%</w>
4 -induced</w>
3-methyl cholanth
3 b</w>
2/ 3</w>
2- chloro
2 :
1 %.</w>
0.00 2).</w>
0. 75</w>
(P V
(C AT)</w>
( greater</w>
z ileut
yme tri
yl) -2-
w as,</w>
viro logical</w>
u sible</w>
tript an</w>
transloc ation.</w>
tract .</w>
tab le
supple mental</w>
substr ates,</w>
substr ate-
specific ,</w>
spar ing</w>
sol e</w>
sequenc e.</w>
sequ enced</w>
saliv ary</w>
r ut
purpos e,</w>
pu er
psori atic</w>
poly po
per azine</w>
par aly
p ep
oche mo
n ia.</w>
mod elling</w>
me dro
li ve</w>
leuk emia
hyper calci
hydr ation</w>
h u
granul omatous</w>
gamma-glutam yl
fo am</w>
flav one,</w>
f ate</w>
f action</w>
extravas ation</w>
episod es.</w>
epi did
ep icardial</w>
enc ap
down regulating</w>
don epez
commun ic
cogn ition</w>
co oper
co al</w>
co administered</w>
bu ffered</w>
blad der,</w>
anti- angiogenic</w>
anim als
amphet amine,</w>
Rec over
R est
P H</w>
NAD(P)H :quinone</w>
NA ,</w>
MC A</w>
M 3</w>
IT C</w>
IC RF
H ex
Depart ment</w>
DNA- damaging</w>
Aug ust</w>
Ak t.</w>
4- methyl
3'- di
29 3
23 390</w>
14 ).</w>
13- acetate</w>
12 2</w>
10(- 4)</w>
1 15</w>
1 12</w>
- /-</w>
(H L
(1 1</w>
( STAT
week s;</w>
w t
variabl es.</w>
ul ph
triam te
thiazolidine di
supple ments</w>
sulfo transferase</w>
suggest ed.</w>
stereotyp y</w>
st art
ses sions</w>
saf e,</w>
rout es</w>
rel ated,</w>
re jec
ras h,</w>
prof oun
pri on</w>
pharmaco therapy</w>
persi st</w>
perfor med,</w>
osal icyl
od ynamic</w>
numb er,</w>
not able</w>
n ur
metabolit e.</w>
metabol ically</w>
me trex
lung s.</w>
langu age</w>
kinas es.</w>
isol ates</w>
iso propyl
inosit ol-
ine- mediated</w>
hyper polar
hO CT
gl and,</w>
fundam ental</w>
frameshi ft</w>
facil itation</w>
expres sions.</w>
exchang er</w>
emul sion</w>
electroencephal ographic</w>
dro ple
distribu tion,</w>
distinguish able</w>
di mer
demyel in
corp us</w>
contracep tiv
compens ated</w>
com posite</w>
cl im
carbon yl
bupivaca ine.</w>
bilater ally</w>
beta (1)-
atheroscler osis,</w>
at inib</w>
as cribed</w>
as certain</w>
analogu e,</w>
allergen s</w>
air ways</w>
adi pos
Th en,</w>
TM Z</w>
Scre ening</w>
S ol
P- mediated</w>
Oc to
N i</w>
Mic ha
MAPK s</w>
LD L
L L
HS C</w>
HB V-
F ren
E GF-
Diab etic</w>
Cu -
Cogn itive</w>
CONTEX T:</w>
CM L</w>
B Q
Ah R.</w>
A/ J</w>
9, 10-
8- week</w>
3- week</w>
2, 5-
2 +/-
12 0
1,25(OH) 2D3</w>
-1-methyl-6-phenylimidazo[4,5-b] pyridine</w>
(PA H
(O P)</w>
ver ing</w>
vari es</w>
ust ine</w>
ubiquit in-
transcript ome</w>
ton 's</w>
tissu e-specific</w>
tim es.</w>
three fold</w>
the -
that :</w>
suff er</w>
star ted.</w>
stabil iz
simil ar,</w>
sic kle</w>
ri de,</w>
ren oprotective</w>
regener ative</w>
recurren ce.</w>
protein /
plei otropic</w>
pect oris.</w>
pe metrex
output .</w>
ore r</w>
or ally,</w>
one ),</w>
ol ;</w>
oder ma</w>
necess arily</w>
micro RNA</w>
mesoth elial</w>
men adi
ma y,</w>
l amide</w>
isoproteren ol.</w>
ipsi lateral</w>
involve ment.</w>
investig ation,</w>
in s
hypomethyl ation</w>
hyper homocyste
human ized</w>
gen der
expl ants</w>
eti ology.</w>
er o
ep iso
elder ly.</w>
don ors.</w>
din ucleotide</w>
depend ency</w>
daidze in</w>
collap se</w>
co factor</w>
clon azepam</w>
circum st
char t</w>
catechol- O-
carbam ate</w>
capac ity,</w>
cannab is</w>
bro mi
bis ulf
av one</w>
aut oradi
as ym
art an
anthracyclin es</w>
amil ton</w>
all yl
alcoh ol,</w>
album in,</w>
aggreg ation.</w>
adul ts,</w>
act ually</w>
a p</w>
Tors ades</w>
Th ym
T im
T M</w>
T DI
T 4</w>
Shor t
S ym
Ra yn
Pr P
PTHr P</w>
P or
O HE
Ni acin</w>
N im
N eg
Maj or</w>
MS A</w>
MMP- 9,</w>
M em
L im
I RF
I .
H G
F uture</w>
E F</w>
Drug s</w>
Del e
Comp ound</w>
CYP2D 6*
A RE
5 8.
5 5,
48 6</w>
4 5,</w>
1 14</w>
0.0 4).</w>
-1 alpha</w>
(e NOS)</w>
(S SR
(PA RP
(Nrf 2)</w>
(H CC
(A D)</w>
(3 )-
(1 4</w>
( 7-
zym os
z en</w>
vis its</w>
top ically</w>
thromb osis,</w>
temperat ure,</w>
t in,</w>
spas tic
simvastat in.</w>
seiz ures
reason able</w>
r id
platinum- based</w>
pituit ary-
ph enter
pal pit
om edul
ol e.</w>
n ary</w>
mu -opioid</w>
methylene tetrahydrofolate</w>
memant ine</w>
manip ulation</w>
mal formation</w>
leuc ine</w>
is land</w>
iod o
intr atrache
intr ap
interac ted</w>
in in</w>
impa i
ic tal</w>
hypoglyc emia</w>
hae mod
hO AT
guine a-
group s;</w>
glomerul oscler
gir l
fr ame</w>
fol inic</w>
fibrill ation,</w>
fibr in</w>
experi ences</w>
ex ome</w>
ep oxy
e o
dr on
di phosphate</w>
di e</w>
conduc ted.</w>
com ing</w>
clav ul
capac ity.</w>
biosynthe sis.</w>
benzo(a) pyrene</w>
belong ing</w>
bal ance.</w>
b y-
alpha (1)-
agon ism</w>
acy tidine</w>
ach e</w>
abstin ent</w>
a u</w>
V OD</w>
U0 126</w>
Twenty- one</w>
Sirt 1</w>
P ER
Measure ments</w>
M S.</w>
J 2</w>
HSP 27</w>
F AS</w>
Eryth ro
E ).</w>
CYP2D 6,</w>
CYP1B 1,</w>
CD4 (+)</w>
Be sides</w>
B- CLL</w>
B raz
ACE I</w>
7. 3</w>
6-OHD A</w>
6 -</w>
5-fluorourac il,</w>
5-HT 2A</w>
3 6%</w>
3 1%</w>
2, 6-
14 4</w>
10 6</w>
-1,2,3, 6-tetrahydro
- 6
(S ER
(M M
(COX )</w>
(A PL
(3-pyrid yl)-1-
(-1 ).</w>
yle stradiol</w>
yan odine</w>
week s'</w>
voltage- dependent</w>
vi sible</w>
v o
understo od</w>
understo od,</w>
ty ph
tryp sin</w>
tic ally,</w>
thromb oph
tachy arrhythmias</w>
struct ure,</w>
ster nal</w>
spi ke</w>
rel ated.</w>
prop yl</w>
permeth rin</w>
par s</w>
pap er,</w>
ove m
or =</w>
o esophageal</w>
notic ed</w>
nod ular</w>
no des</w>
nmol )</w>
nic ardi
n m</w>
n M.</w>
midd le-
metaboliz ers</w>
mercap to
m oun
m M,</w>
kg -1)</w>
illic it</w>
ill ness
hype rex
her nia</w>
heli x</w>
hae modi
fib rate,</w>
estrogen- responsive</w>
estr one</w>
enric hment</w>
dissec ted</w>
deterior ated</w>
co vari
ch lor</w>
ch al
cell -mediated</w>
benz yl</w>
behavior s.</w>
antid ot
accoun ts</w>
VEGF R
V an
TR H</w>
T S:</w>
T D</w>
S ot
S L</w>
Neon atal</w>
Neg ative</w>
M -induced</w>
LC 3-
Hem e</w>
HI F-
F X
Ex trac
Electro n</w>
DSM- IV</w>
Cl ar
B W
A4 31</w>
A- mediated</w>
A l</w>
A R)</w>
7. 2</w>
6. 3</w>
50 6</w>
5-F luoro
.0 1)</w>
- cell</w>
- 8</w>
( to</w>
( [
w it
vac cin
us -induced</w>
up- regulating</w>
two- stage</w>
tremor s</w>
transporter .</w>
to p</w>
tissu e-
therap y;</w>
te re
sy -
stead ,</w>
sm all,</w>
se e</w>
satis faction</w>
resor ption</w>
reduc tive</w>
re d
prob enec
possess ed</w>
phyt ochemic
phy se
pa resthe
oxid ase-
os amine</w>
ol ive</w>
occ ip
no l</w>
nam ely,</w>
myc otoxin</w>
mou se
mic ,</w>
metast ases.</w>
losart an,</w>
ish .</w>
in ).</w>
ic )</w>
hypol ip
hypo thes
hydrochlor ide,</w>
h ot
gl and.</w>
foc using</w>
factor ial</w>
f is
extr a-
etom id
et -
equ iv
equ ilibrium</w>
embol ism.</w>
eff usion</w>
e.g .,</w>
drug- free</w>
distinc tive</w>
dissec tion</w>
computer ized</w>
cohor t.</w>
chlorambuc il</w>
ch eno
cell- derived</w>
c res
arsenic .</w>
amoxic illin
alter ations,</w>
alpha 1</w>
alkyl ation</w>
ag nes
absor bed</w>
ab led</w>
Wil son</w>
VEGF ,</w>
T ou
T MP
Synerg istic</w>
Sul ind
St res
SB2035 80</w>
Respon ses</w>
Rap amycin</w>
R os
P D)</w>
NRF 2</w>
NF kappa
Mil d</w>
L in
Hyp oxia</w>
Gen iste
G J
F C</w>
E B</w>
Cl -</w>
C E</w>
Ap plication</w>
AT /
ALDH 2</w>
AL F</w>
9 0,</w>
677 T</w>
1 -1.
-2,5-diphenyl tetrazolium</w>
)- 2</w>
(D MA
(A A)</w>
(4 ),</w>
vasodilat ation</w>
uron al</w>
undergo es</w>
tus sis</w>
triglycer ides,</w>
tim es,</w>
thrombocytopen ia.</w>
therapeu tically</w>
test es</w>
suc rose</w>
stimul i,</w>
so y</w>
second- line</w>
respon d
repor ts.</w>
re fer
pre eclamp
po orer</w>
phosph oro
olg us</w>
olanzap ine,</w>
occa sional</w>
o quin
neur ite</w>
n um
myco phenolate</w>
month ,</w>
mono therapy,</w>
mexilet ine</w>
metast asi
mar ine</w>
m o</w>
low- grade</w>
ligh t-
ligand -activated</w>
lay ers</w>
land s</w>
it y)</w>
it raz
iop amid
id -induced</w>
hyper sensitivity.</w>
hy al
heterozygot es</w>
hep cidin</w>
hel per</w>
glut aryl</w>
gh relin</w>
gel at
fib res</w>
effor ts</w>
dri ving</w>
depri ved</w>
d b
cyc le
cortic otrop
continu es</w>
coincid ed</w>
cat s</w>
capsul e</w>
cannabin oids</w>
broad- spectrum</w>
ax on</w>
attac ks.</w>
ati ve
ast .</w>
antipsycho tics.</w>
amphet amine-
amoxic illin</w>
adipo genic</w>
W i
U -induced</w>
TR PC
TH E
Sp inal</w>
SP600 125</w>
SL CO
SIAD H</w>
S tructural</w>
Random ized</w>
RA R-
PT X</w>
N ovem
N N
M onitoring</w>
M odi
M ei
INTERPRET ATION:</w>
III .</w>
G re
F P</w>
Extr apyramidal</w>
E 2.</w>
CPT -11</w>
C ip
Bri ef</w>
B 4</w>
8 3
8 %).</w>
7. 0</w>
6 3%</w>
5. 9</w>
3-hydroxy- 3-methyl
3 2.
10 (6)</w>
1- null</w>
/ \
(TRA IL
(S t
(MD R)</w>
(As (2)O
(1 4.
( di
( d)</w>
tri azol
te g
sph er
sinus oidal</w>
signal s.</w>
sh ed</w>
s cho
res um
res tim
recipi ent</w>
prescri p
ph lebitis</w>
p mol</w>
ori metric</w>
opath ologic</w>
onucle ase</w>
non- competitive</w>
nitro -2-
newbor ns</w>
ne oin
n M).</w>
morph one</w>
moder ate-
medic ine.</w>
leucov orin</w>
iso flavones</w>
ini b.</w>
ine mic</w>
impl ies</w>
immun ity.</w>
ic a</w>
ham sters</w>
gli omas.</w>
fo relim
fluorourac il</w>
flu ids</w>
f azod
f ]
extra hepatic</w>
erythropoi e
er lot
en comp
ec h</w>
doxycycl ine</w>
dimethyl benz
dec itabine</w>
conserv ative</w>
connec tion</w>
con stitutes</w>
competi tively</w>
breas t,</w>
benz en
be it</w>
be hind</w>
appear ing</w>
ampl es</w>
ab use,</w>
TNF a</w>
SULT 1A1</w>
Rever sal</w>
R ed</w>
PPAR- y</w>
PBDE s</w>
O S
NT G</w>
MY C</w>
METHODOLOG Y
ME K/ERK</w>
M IC
L evo
H amilton</w>
Gl n</w>
Fe w</w>
Epi genetic</w>
E po
Con sist
Cl on
B HT</w>
Ar yl</w>
AD P-rib
4- HP
2 20</w>
1A 1,</w>
13 ).</w>
1 R
1 18
00 /
(M A
(2 5-
( 80
' ,</w>
xenograf ts.</w>
vascul ature</w>
tub ocur
thym us</w>
thi otep
th imer
systemic ally</w>
stress- related</w>
step -
sp ut
semi quantitative</w>
s );</w>
rs 10
roph yl
radi al</w>
post- transcriptional</w>
posit ron</w>
porph yrin</w>
pla usible</w>
pa di
organ isms</w>
n adi
min ;</w>
membran es.</w>
m c
lidoca ine-induced</w>
isozym es</w>
isothi ocyanate</w>
is amide</w>
interac tions,</w>
inter- individual</w>
id s,</w>
hypno tic</w>
hydr alaz
follic les</w>
fluctu ations</w>
fi ve-
epith elia</w>
elimin ate</w>
ecst asy</w>
e ver
dos ing,</w>
detoxif ying</w>
deline ate</w>
defici enc
cy r
capsaic in,</w>
c ame</w>
block ers,</w>
beta ),</w>
backgro un
atraz ine</w>
aqu ine</w>
appl ying</w>
anti estrogen</w>
anti androgenic</w>
am ide-
alpha ).</w>
adv anc
adhe rence</w>
adeno viral</w>
activator ,</w>
acet ate.</w>
Twenty- two</w>
Th en</w>
Test o
TB ARS</w>
T g</w>
SH BG</w>
S N-
Recover y</w>
R B</w>
Physici ans</w>
O-deethyl ase</w>
Nalox one</w>
MD S</w>
L DH
Hol ter</w>
GSK-3 beta</w>
G ene
FEV 1</w>
E s
E S
DC M</w>
Concentr ations</w>
Cap top
CYP4 F2</w>
C enter</w>
BD P</w>
Ah R,</w>
Ab out</w>
AD H
A ther
3 20</w>
2 alpha</w>
2 3)</w>
13 .</w>
0.0 3)</w>
- matched</w>
(RT-PC R).</w>
(Mn SOD)</w>
(IF N
(As2O 3)</w>
( 0.00
% ]</w>
venlafax ine</w>
upregul ating</w>
ul inic</w>
tr us
terbut al
sel eg
ri ol</w>
resor p
reli ev
reflex es</w>
radi osensi
radi ological</w>
ques tions</w>
quanti ty</w>
poin ts,</w>
plat form</w>
phyto al
perform ing</w>
p70 S6
p og
ot ane</w>
onect in,</w>
one :</w>
on yl</w>
ogu anine</w>
ob iliary</w>
nitros amino
ni a,</w>
ng/m l,</w>
ne oplasi
mil k</w>
margin ally</w>
lute al</w>
liver s.</w>
lin oleic</w>
isol ation</w>
ip p
insuffici ency,</w>
incre mental</w>
in formed</w>
in activation.</w>
ill us</w>
ifer ous</w>
gonad al</w>
eo ful
each .</w>
dis abling</w>
differen t.</w>
differen ces.</w>
de regulation</w>
cyt otoxic
cryp t</w>
cl amp
c- FL
but yl-
bicalut amide</w>
bac lofen
appro xim
androgen -dependent</w>
an ionic</w>
aldehy des</w>
after ,</w>
adequ ately</w>
ad ine.</w>
acceler ates</w>
ac in
Th ough</w>
ST AT</w>
SR L</w>
S- nitros
RXR alpha</w>
RB V</w>
PC A</w>
P rophyl
Or listat</w>
NO .</w>
NAD(P) H</w>
N-nitros odi
N an
MR P</w>
ML H1</w>
I GF</w>
HN SCC</w>
G H
DMS O</w>
CYP -induced</w>
CCl (4)</w>
C tr
C d-
C G</w>
Brugad a</w>
BU N</w>
BA Y</w>
Ac role
A beta
A RPE
7. 6</w>
5 50</w>
3 5,</w>
11 b-
0 33
- deficient</w>
(p =0.00
(i. c.v
(PI3 K)</w>
(GSH ),</w>
(D O
(D H
(1 2.
( three</w>
ymetri x</w>
y- like</w>
x ),</w>
warr ant</w>
us p
uni variate</w>
un event
uan idine</w>
tremor .</w>
streng th
sco res.</w>
sarcop lasmic</w>
saf er</w>
profil es.</w>
pro convulsant</w>
placebo- treated</w>
phosph ates</w>
phenylephr ine-induced</w>
pa in-
onco genes</w>
olanzap ine.</w>
objec t</w>
ob sc
o virus</w>
neuro genesis</w>
napro xen
n d</w>
micro mol</w>
micro gram</w>
le n</w>
ischemia- reperfusion</w>
initi ated.</w>
ine- rich</w>
in timal</w>
in ess</w>
il lo
i. m.</w>
hypothalam us</w>
hydro las
hor n</w>
granul es</w>
glutam ate-
gener al
gas trin</w>
frac tion.</w>
extrem ity</w>
extrap ol
exc itation</w>
ex plant
epiandro sterone</w>
en tic</w>
en sis</w>
elec tric</w>
e b</w>
dys regulated</w>
docum ent</w>
cytok ine-induced</w>
cyto genetic</w>
clar ified.</w>
cl ass
cd c
cardiomy ocytes.</w>
br y
block age</w>
benz ene-induced</w>
ballo on</w>
bacter ia</w>
b ing
aster n</w>
ar ubicin</w>
ang le</w>
an al</w>
an abolic</w>
al end
ag e-</w>
aden omatous</w>
a rec
Yor k</w>
V (max)</w>
Sal mon
S .
R b
R aloxif
Phosphor ylation</w>
Phenyto in</w>
PC P</w>
P lac
Neuro toxicity</w>
M D</w>
L XR
K +-
I U</w>
HC )</w>
Glu R
G I
Fren ch</w>
Flu o
FGF- 23</w>
E SCC</w>
CC .</w>
CA P</w>
CA ),</w>
C -induced</w>
B ro
B ang
B B</w>
Ad ju
AS P</w>
6. 6</w>
5-FU ,</w>
5 8%</w>
3 7%</w>
3 2)</w>
2 E
2 6,</w>
18 2,7
12- week</w>
1 1).</w>
- 4
(siRNA )</w>
(p =
(PPAR gamma)</w>
(OR =
verapam il
ver s</w>
us :</w>
tr uc
sw im
sud den
succ essive</w>
sub tle</w>
spind le</w>
spe ed</w>
senesc ent</w>
se as
rigid ity,</w>
re act</w>
qu en
prototyp ical</w>
pl anned</w>
phen ols</w>
or ders</w>
oid s,</w>
occur ren
nor mo
no dos
narco tic</w>
nar in
nam ed</w>
mou th</w>
mid -
l aryngeal</w>
insul in.</w>
hyper -
glycoly tic</w>
g ar</w>
frequ ency.</w>
fold ).</w>
fail s</w>
f ut
exp ect
ethan ol,</w>
estradi ol-induced</w>
erro r</w>
enti ty</w>
endotheli um-
endocr ine-
end ocardial</w>
di valent</w>
defic its,</w>
dec re
de trus
dat e.</w>
cyclohex im
cy nom
condens ation</w>
concent rating</w>
challeng es</w>
b ox
b id
asyst ole</w>
associ ation.</w>
as se
ar ate</w>
ant -
analog ous</w>
alum in
adenyl yl</w>
ac cess
ab le
Su stained</w>
SC H
S o
Octo ber</w>
Novem ber</w>
N ur
N ex
Met abolism</w>
MMP s</w>
METHODOLOGY /PR
METHODOLOGY/PR INCIPAL</w>
MC .</w>
K u
J )</w>
Inter fer
IL-1 b,</w>
IK K
GLUT 4</w>
G 1-
Fact ors</w>
Dox orubic
Can did
CP T</w>
CD8 +</w>
C K-
C 4
AR B</w>
AR .</w>
AC H
A MT
8 +/-
5 HT
5 AC</w>
5 6%</w>
4 9.
1. 5%</w>
1- receptor</w>
1- 3</w>
.00 1),</w>
(MT T)</w>
(M G
wind ow</w>
wat er
ure a,</w>
unclear ,</w>
uc ine</w>
ub ular</w>
u PA</w>
suspic ion</w>
sti b
stib ogluc
sal me
ris es</w>
reli eve</w>
pter ostil
posi tiv
plat e
phys ostigm
phosph ate.</w>
p21 (C
p- nitro
oxycod one</w>
ox azol
one ).</w>
oglob in</w>
ochemic al,</w>
occupati on
no ea</w>
nitros ative</w>
neuro degeneration.</w>
nar row
mat ching</w>
macroph age-
lipopolysacchari de-induced</w>
lig and.</w>
injec ting</w>
ing /
ind es
in patient</w>
id s.</w>
hyperpla sia.</w>
hyperex cit
hydrox ystil
hydr oneph
herbic ide</w>
hematoc rit</w>
hap lo
flun ar
failure :</w>
f used</w>
er oyl
enlarg ed</w>
emphasi zes</w>
do fe
dist ant</w>
describe d,</w>
dem and</w>
cypro terone</w>
cu t</w>
cro cidol
coordin ated</w>
control s)</w>
confir mation</w>
compromis e</w>
cer vi
cap s
caffe ine.</w>
avail able,</w>
antidepress ants.</w>
an is
amelior ating</w>
administr ations</w>
ad ing</w>
ac yl</w>
[CI ],</w>
UGT2B 7</w>
TNF- alpha.</w>
T AS
SSR I</w>
S truct
S le
S ,
RA D
PC .</w>
P T</w>
O l
Na (+)-
MPP (+)</w>
M N</w>
L ong</w>
L ack</w>
L U
JE G-
Individu als</w>
Individ ual</w>
Hunting ton's</w>
Ha- ras</w>
HP LC
HB E</w>
F ind
Deter min
Consist ently,</w>
Caspase- 3</w>
CR H</w>
CD 36</w>
C ent
Be zaf
B M</w>
5- amin
5 3%</w>
4 8%</w>
4 4%</w>
4 -</w>
3/ 7</w>
2 A,</w>
1. 5-
1 11</w>
(A N
(1 3</w>
weigh ing</w>
wan n</w>
vincrist ine.</w>
vi de
us ti
un mas
um ab
tri valent</w>
tri methyl
tr ain
suppres sion.</w>
speci men</w>
ro l</w>
res ected</w>
recre ational</w>
provo ke</w>
prim ate</w>
pri l</w>
pres sion,</w>
predis posed</w>
ph ere
paraquat -induced</w>
otum or</w>
organ is
on tin</w>
o estradiol</w>
my ocytes.</w>
morb id
mg/kg/ d</w>
m ),</w>
lymph o
log -
lipid s,</w>
le a
keto profen</w>
ja w</w>
ith iasis</w>
ia /
i.v .,</w>
i tic</w>
geranyl geran
gen in,</w>
form e</w>
floxac in,</w>
fa il</w>
f ine</w>
eti ologic</w>
est rel</w>
esophag us</w>
er ate</w>
enanti omer</w>
dysrhyth mi
dissol ved</w>
discrimin ate</w>
dip loid</w>
dig ital</w>
diet -induced</w>
devi ation</w>
design ,</w>
describ ing</w>
demethyl ating</w>
deci sion</w>
de ad</w>
d ),</w>
chrys in</w>
atro pine,</w>
atri zo
atenol ol,</w>
astro cyte</w>
assess able</w>
anxi ogenic</w>
anti- inflammatory,</w>
anc ic
amino )
am ine)</w>
aden osyl
ad aic</w>
a- 2</w>
[ OR
Wh ite</w>
S a
Prec linical</w>
Pe ak</w>
Olan zapine</w>
NK 4
L F
L 6</w>
Intrac ere
Ig G
I (K
Gen omic</w>
G M</w>
G 9
CONCLUSION S</w>
Au tism</w>
ATP ,</w>
AC E-
5 %
2. 7
2. 6
2- dependent</w>
2 25</w>
1. 73</w>
1 D</w>
1 18</w>
033 29
- L
)-1- (3-pyridyl)-1-
(S HR)</w>
(S BP)</w>
(H ER
(C T
(A S
(10 )</w>
(1 9
( UD
zolpide m</w>
y t
worth y</w>
well- established</w>
ver tig
tw elve</w>
tw ard</w>
tryp tam
triam cin
the mo
taurochol ate</w>
ster ols</w>
stal k</w>
spectr al</w>
sof tw
set t
repe ats</w>
regres sion.</w>
r in.</w>
prof en,</w>
potassi um,</w>
ph edr
p ene</w>
ox a
otyp e</w>
ornith ine</w>
origin ally</w>
ole- 3-
ogr am.</w>
nat ur
mo ving</w>
micro cephal
meval onate</w>
measure ments.</w>
lox acin</w>
inc i
in ].</w>
impair ing</w>
il s</w>
if orm
id ine-induced</w>
hypos padi
homolog ue</w>
hepat otoxic
h inal</w>
gran ular</w>
glutathion e.</w>
glucosamin idase</w>
gluc one
geho g</w>
forsk ol
fi er</w>
factor- related</w>
eroyl anilide</w>
ene m</w>
el eg
ec onomic</w>
dro ps</w>
cirrho sis,</w>
ci par
che wing</w>
carvedil ol,</w>
biosyn thetic</w>
atro genic</w>
al beit</w>
affec ted,</w>
ad ,</w>
ac ne
ac en
abol ish</w>
[3H] -
T ME
St AR</w>
Short -term</w>
Salmon ella</w>
RO S.</w>
RNA .</w>
PA ).</w>
NA G</w>
N-acetyl-L- cysteine</w>
Mal ign
Ma y</w>
MP O-
Lew is</w>
Le ishman
Jo hn
Hsp 70</w>
Hep ar
H an</w>
Fe br
F K</w>
E -induced</w>
D eli
D J
Cys LT
CF TR
ATP- dependent</w>
AKR1C 3</w>
A ne
A B</w>
A 2A</w>
5 -</w>
4 a</w>
4 3-
4 1%</w>
12-O-tetradecano yl
1 b
. i.
(R B
(I V
(4 5</w>
( 0</w>
yiel ding</w>
xy progesterone</w>
visi t</w>
vasodil ating</w>
v age</w>
to ur
tic ular</w>
thal lium</w>
tempor ally</w>
sep sis.</w>
s a</w>
run -in</w>
reversi ble,</w>
reversi bility</w>
retin a</w>
ret ard</w>
receptor- dependent</w>
rang es</w>
radi ation.</w>
pul s
post- translational</w>
polyp s</w>
p. m.</w>
ox yp
one uro
omorph ic</w>
ocytopen ia</w>
neuro troph
natriure sis</w>
modifi er</w>
meth an
mark s</w>
m sec</w>
leth arg
lad es
j usti
irradi ation.</w>
interrup ted</w>
internal ization</w>
interac tion,</w>
ingredi ent</w>
in -1,</w>
ill ness.</w>
i an
hypom agnes
hydroxy vitamin</w>
hei ght</w>
gly ca
fal cipar
ex tub
establ ishment</w>
epinephr ine,</w>
epidid ym
el et
e- treated</w>
duc ts</w>
diz ocil
diltiazem ,</w>
digit alis</w>
determ ined,</w>
deple ting</w>
de l</w>
con fig
cleav age,</w>
cisplatin- resistant</w>
cholecyst o
chel ating</w>
carri ers.</w>
bu propion
bre ak</w>
blocka de,</w>
bifid a</w>
benzo ate</w>
atroph y.</w>
atenol ol.</w>
ar sin
apo A-I</w>
ap ocyn
amip ex
aldehy de-
al ive</w>
ag le</w>
ad d-
[ 1,
Z ip
Y .</w>
Wn t
Un fortun
Sch wann</w>
S 3</w>
Quer cet
P LD
Me Hg</w>
Lamiv udine</w>
LI D</w>
Inflam matory</w>
I bu
HE K</w>
H 4</w>
H -induced</w>
Golg i</w>
F 34
Endo thel
ESR D</w>
ER- positive</w>
E s</w>
E MG</w>
DMB A</w>
Control led</w>
Con current</w>
CD 9
B row
AT O-induced</w>
AP C</w>
95 %
9- fold</w>
8. 7</w>
34 )</w>
2,3,7,8- Tetrac
13 0
12- myristate</w>
12 8</w>
1 st</w>
1 '-
(control )</w>
(TRP V
(T T
(T P
(S V
(S P
(NF )-
v )</w>
uron i
un differentiated</w>
tu res,</w>
trimethoprim -sulfamethox
tic -like</w>
tetrahydrocannabin ol</w>
t az
sulph asalazine</w>
spectr a</w>
specimen s.</w>
situ ation</w>
sion /
single- dose</w>
shock ,</w>
rocur onium</w>
respon der</w>
resi stin</w>
report ].</w>
propor tion
progester one.</w>
prec l
pg/m l</w>
path olog
pari etal</w>
pal li
pa f
osteoc las
osalicyl ic</w>
ologist s</w>
ofo vir</w>
occip ital</w>
non- toxic</w>
non ionic</w>
neoplas ms.</w>
n u
n ally</w>
morph ogenetic</w>
monolay er</w>
mo id</w>
misoprost ol</w>
meth amidoph
man ia.</w>
lutein izing</w>
lin k
kne e</w>
k ynuren
isopren al
ir udin</w>
infec tions,</w>
indic ated.</w>
id yl</w>
hyp op
h es
gamma-glutam yl</w>
flun itraz
fer ul
felb amate</w>
exce eding</w>
eth nic
et oric
er ve</w>
ent u
electro de</w>
deacetyl ation</w>
de ep
cynom olgus</w>
confu sion,</w>
co sts</w>
cancer -related</w>
c resc
bur ning</w>
bis (
aud 's</w>
areas ,</w>
amiodar one-induced</w>
W HO</w>
Twenty- six</w>
THE SIS:</w>
T x
T est</w>
Scal e,</w>
Rec ently</w>
RE M</w>
R I</w>
PI K3
PC OS</w>
P< 0.05).</w>
O T</w>
O P-
NSAID s.</w>
Morph ological</w>
Men kes</w>
MT X.</w>
L ymph
HBe Ag
Fas /
Experim ent</w>
Euro p
ER ,</w>
EC s.</w>
E stradiol</w>
DH EA</w>
D 3,</w>
Ch ro
B DE-
Aff ymetrix</w>
AC C</w>
8-OH- DPAT</w>
7 1%</w>
57 %</w>
4, 6-
12 /
(TCD D),</w>
(B AL
(2 0%)</w>
( also</w>
( alpha
vir t
ur ide</w>
tigh tly</w>
tic /
ti ter</w>
test ing,</w>
success ful
steato hepatitis</w>
shap e</w>
sertr al
ser g
rod ents,</w>
reli ably</w>
rec apit
r yanodine</w>
pre treatment,</w>
pir iform</w>
phenol- A</w>
pericardi tis</w>
par athion</w>
outcom e,</w>
os in.</w>
orrhe a</w>
ol :</w>
norepinephr ine,</w>
non alcoholic</w>
ne sted</w>
ne ocor
ne ar-
kidne ys,</w>
ir on
impac ts</w>
he at
glyc emic</w>
gi ant</w>
fract ure</w>
ex o
et in,</w>
equ im
ep it
elev ate</w>
diseas ed</w>
dihydro -
detrus or</w>
d .)</w>
clea red</w>
channel ,</w>
castr ated</w>
carri es</w>
cardi otoxicity,</w>
carb id
break through</w>
beta- end
benzo quinone</w>
azep am,</w>
ator ial</w>
ath et
atax ia,</w>
arsen ic,</w>
ap ine,</w>
angin a.</w>
am ine-treated</w>
ag e:</w>
acet one</w>
a re,</w>
W A
The ophylline</w>
T Y
Swe dish</w>
S elec
R y
P- g
Met oclopr
MC s)</w>
K (i)</w>
Isol ated</w>
Head ache</w>
G- ->
F ish
Estro gen
E2- related</w>
D ON
Cardi otoxicity</w>
CYP2C 8</w>
CYP 1</w>
CP F</w>
CP -induced</w>
CD 95</w>
C ultured</w>
C 677T</w>
Bang lades
B AL</w>
A pril</w>
A -1</w>
54 %</w>
50 ;</w>
4', 5-
2- related</w>
17 ).</w>
16 5</w>
1-methyl-4-phenyl -1,2,3,6-tetrahydro
1, 0
-2 1</w>
-- a</w>
(M MP-
(H g
(G B
(C F
(0. 4</w>
( no</w>
( TI
zip rasid
ym er
wall .</w>
vim entin</w>
ver age</w>
v oid
toxic ities.</w>
ten e</w>
t rou
sulf onate</w>
sub sided</w>
struc tures.</w>
sk elet
sion -induced</w>
single- blind</w>
self- reported</w>
ros ine</w>
rigid ity.</w>
rec t
rac l
promot er
perturb ation</w>
pent achloro
pati bility</w>
pamid ronate</w>
p27 (K
p es</w>
off -
neur itis</w>
net works</w>
multi forme</w>
micronucle us</w>
mac rol
los s-of-function</w>
lithi um,</w>
le vetiracetam</w>
j er
isoflur ane-induced</w>
ion izing</w>
intr as
insul t</w>
immuno fluoresc
immun ologic</w>
id ine-
hypocal c
hyper sensitive</w>
hom ogene
histor ies</w>
gra y</w>
gr is
gen om
end azole</w>
earli est</w>
do dec
direc tion</w>
did an
diclofen ac,</w>
di pl
di methoxy
dep th</w>
deliri um.</w>
clu stering</w>
chondro cytes.</w>
chol ang
buthi onine</w>
but olol</w>
b ands</w>
ap sig
adultho od.</w>
ach lor
acc es
Z )-induced</w>
V AS</w>
Un expectedly,</w>
Sou th</w>
S NA
Reg ion
Rayn aud's</w>
Qu es
Par tial</w>
PA N-
Na As
MI M</w>
M ouse</w>
L at
Keap 1</w>
In formation</w>
ISO -induced</w>
INTERVEN TION:</w>
IL-1 3</w>
II ),</w>
HER -2</w>
Gl n
GT P</w>
GF )</w>
E ML
D Q
Co Cl
Clas s</w>
Cl -
CI N</w>
B ad</w>
Apopto tic</w>
ATF 3</w>
AS D</w>
A 2
8 3%</w>
8 0-
6. 9</w>
6. 0
6 4%</w>
3 5-
14 17
12 98
12 00</w>
- keto</w>
(W K
(A E
( cat
( age</w>
( TIMP
wor ld</w>
week )</w>
uni versity</w>
uni ver
tour niqu
ti tis</w>
thyro xine</w>
thiopent one</w>
therapeu tics.</w>
si x-
si butramine</w>
sampl ing</w>
sal ine-
retri ev
res ec
reduct ase.</w>
re mor
ra ising</w>
r d</w>
qualit ative</w>
profoun dly</w>
pp m)</w>
post ulate</w>
plex us</w>
ple mentation</w>
phen o
percent ages</w>
par ano
p.o .,</w>
osteoporo sis.</w>
opath y:</w>
ol mes
ococc al</w>
nival enol</w>
muscim ol</w>
mofe til</w>
microg/ kg)</w>
micro satellite</w>
micro -
m om
lethal ity.</w>
j i</w>
isothi ocyan
isoform s,</w>
intensi ties</w>
integr al</w>
in- converting</w>
ic ity,</w>
her it
haloth ane-
glucos e-induced</w>
for ti
flav in</w>
ff er</w>
femal e,</w>
evol u
estim ation</w>
ester ol</w>
establ ishing</w>
end ocytosis</w>
dys function
dur ations</w>
difficul ties</w>
dener vation</w>
defic it
de regulated</w>
dant rol
counter par
commun ity</w>
co val
cilost azol</w>
chel ators</w>
charg e</w>
cell- cell</w>
catheter ization</w>
cat abol
carbo hydrate</w>
bod y.</w>
blind ness</w>
bis phosphonates</w>
biosynthe sis,</w>
ax ons</w>
astro cytic</w>
aspec t</w>
as cer
algorith m</w>
adhe sion,</w>
acetaminophen ,</w>
absorp tion.</w>
ab users.</w>
ab normally</w>
ab et
[CI ]</w>
Toge ther</w>
Targ eting</w>
TO R)</w>
Sulind ac</w>
Sor afenib</w>
Sel enium</w>
S n
S AM
Rel ationshi
RS V
Q ),</w>
Promot er</w>
PT Z</w>
P 1)</w>
NF-k B,</w>
Meth ad
Mang anese</w>
Malign ant</w>
MD )</w>
Intr aperitone
In jection</w>
Im paired</w>
IGF -1
I DH
I CI
HB -
H cy
GST s</w>
Flu oro
F at
ESR 1</w>
Dou ble-
Diag nos
DNMT 1</w>
D oses</w>
Curren tly,</w>
C ho
C ET
B 1*
Analy ses</w>
An d</w>
AP ,</w>
A d-
9. 3</w>
9 0-
8. 3</w>
7 5,</w>
3 -1
29 -
200 ,</w>
20 1</w>
2 2-
19 0</w>
16 .</w>
1 1),</w>
-1 000</w>
(PC R)</w>
(M M)</w>
(C R)</w>
(B CN
(AM L)</w>
(1 7.
( average</w>
women )</w>
weak ness,</w>
water- soluble</w>
warfar in,</w>
unchang ed,</w>
trichloro ethylene</w>
tri oxide.</w>
transloc ator</w>
therap ies,</w>
t ains</w>
stav udine</w>
sph inc
sor afen
sil enc
shar p</w>
sequ entially</w>
rh initis</w>
responder s.</w>
ren 's</w>
reli ef
quin one,</w>
pre pro
post translational</w>
poly clonal</w>
platelet -
phenyl -
per tussis</w>
paraox on</w>
pant op
p 47
over night</w>
opportun ity</w>
operativel y.</w>
oper ation.</w>
om a:</w>
o vul
microg/m L</w>
metast asis,</w>
measure d,</w>
m p
m mol</w>
levo simendan</w>
lab elled</w>
itsel f.</w>
investig ators</w>
investig ated,</w>
intra renal</w>
infiltr ation.</w>
hyper thyroidism</w>
hepatocarcin ogenesis.</w>
hepat o
heavi ly</w>
gris eoful
finaster ide</w>
exercis e-induced</w>
encephal ic</w>
emph asis</w>
electro shock</w>
disc rete</w>
di hydroxy-
depolar izing</w>
deoxycy tid
decompens ated</w>
de x</w>
control )</w>
cirrho tic</w>
chic ken</w>
camptothec in</w>
beta- amyloid</w>
az ithromycin</w>
approach es.</w>
anti estrogenic</w>
angiotens inogen</w>
anchor age-
an i
adrenocept ors.</w>
adrenal ine-induced</w>
ac in,</w>
[a ,
Valpro ic</w>
UV B</w>
Th yro
TNF- alpha-
SM A</w>
RA W</w>
R ,
Min ocycline</w>
MP ,</w>
MM A</w>
MD M2</w>
MCF-10 A</w>
M O</w>
Lid ocaine</w>
L og
L i</w>
Inde x</w>
IL-1 0,</w>
I ]
Hu h
HLA- DR
GADD 45
Febr uary</w>
Enh anc
En gl
DH E
CYP2B 6,</w>
CA PE</w>
B SA</w>
B 3</w>
B (a)
ATRA -induced</w>
AT R</w>
AMP H</w>
AB CA1</w>
A(2 A)</w>
A M)</w>
8. 9</w>
4 6%</w>
3- 3</w>
3 4.
20 .</w>
15 4</w>
15 1</w>
12 ),</w>
1 h</w>
(m TOR)</w>
(T UNE
( range:</w>
( iv)</w>
wor k.</w>
voltage- gated</w>
vol atile</w>
vigil ance</w>
ur ban</w>
top ic</w>
toler ate</w>
til mic
thi x
target .</w>
t yr
sper m
shif ts</w>
serine/ threonine</w>
secret ase</w>
second- generation</w>
scaveng ers</w>
righ t-
reten tion.</w>
ret initis</w>
receptor- positive</w>
rec over</w>
rat ory</w>
pyrethro id</w>
punc ture</w>
prolong ation.</w>
profil es,</w>
possi ble.</w>
period ontal</w>
perform ance,</w>
percent )</w>
per -
pattern s.</w>
patter n,</w>
p als
pals y</w>
ot ting</w>
op e
olabel ed</w>
negati ve,</w>
n t
mit te
mg ;</w>
methoxy chlor</w>
los an</w>
le tro
isoform s.</w>
inst ances</w>
inhibit ed.</w>
in tended</w>
immune- mediated</w>
id oxime</w>
i.v .),</w>
hydroxy proline</w>
hydroxy chloroquine</w>
high ,</w>
hepat obiliary</w>
hair pin</w>
guan fac
glyc os
glucose- 6-phosphate</w>
exec utive</w>
ex cis
eu than
epinephr ine.</w>
doubl ing</w>
dom ain,</w>
dis appeared.</w>
din it
diff usion</w>
diaphrag m</w>
di atrizo
dex razoxane</w>
desferri oxamine</w>
der ing</w>
cross- linking</w>
cr y
control s).</w>
contribut or</w>
compon ents.</w>
col on,</w>
cocaine- related</w>
chrom osom
cDNA s</w>
bir th.</w>
beta- cell</w>
be at</w>
ated ;</w>
at ely.</w>
asbestos -induced</w>
arter ies,</w>
antibio tics.</w>
anti anginal</w>
ant ar</w>
and -
amin opyr
adju v
accumul ates</w>
Unfortun ately,</w>
TD I</w>
T ra
S R-
R un
Ques tion
Q 10</w>
PI3 K-
OV CAR-
N U
N B</w>
MS C</w>
MM F</w>
MI ,</w>
MC T</w>
Lith i
L if
Ket amine</w>
IV S
IN K
HF E</w>
HF D</w>
H ME
Gen es</w>
Fre y</w>
ER b</w>
Dep le
DOCA- salt</w>
D RE
D G</w>
CYP2 7
CONCLUSION S/
CCl (4
As (III
Anti oxidant</w>
Andro gen</w>
AT ,</w>
APO E</w>
AD ,</w>
A A)</w>
A :</w>
7 00</w>
5-fluorourac il
4 7,</w>
4 3.
39 %</w>
2 1.</w>
10 ,000</w>
1/ CI
1 15
0. 12</w>
(PF O
(MMP )</w>
(M TH
(HIF -1
(CD K
(5- nitro-2-
y- dependent</w>
un folded</w>
tumor- bearing</w>
tri gu
transamin ases</w>
tr un
tinnit us</w>
surg ically</w>
sequel ae.</w>
review s</w>
retin opathy</w>
reciproc al</w>
re constituted</w>
radic als.</w>
pyri meth
prop ane</w>
present ation,</w>
precipit ate</w>
phorbol-13- acetate</w>
parallel- group</w>
par aff
out growth</w>
optim ized</w>
on ate,</w>
o therapy</w>
novel ,</w>
nitrosamino )-1-(3-pyridyl)-1-
need le</w>
ne fazod
multi drug-resistant</w>
muc us</w>
ml/ min/
mil l</w>
micrograms/ ml</w>
micro globulin</w>
mg/ 100</w>
m ess
ly ase</w>
kin d</w>
is omerase</w>
is ite</w>
iodothyron ine</w>
instil led</w>
inser ted</w>
inflammas ome</w>
index es</w>
if ying</w>
ide al</w>
i.v .).</w>
i ox
hyperkal emia</w>
hil ar</w>
grap e</w>
glibenc lamide</w>
gel dan
factor- beta1</w>
ext ent.</w>
epileptic us,</w>
ep ri
entr ant</w>
encephal opathy,</w>
effect ors</w>
do m</w>
disc re
dig estion</w>
deoxy corticosterone</w>
d ynam
d h
conver ts</w>
con sul
comple mentation</w>
chemo -
categor ies</w>
caspase- 9,</w>
carmust ine</w>
carboxylester ase</w>
buff er</w>
block ers.</w>
bio tin</w>
b ab
autophag y,</w>
ati ve-
arsenit e.</w>
ar act
apsig arg
appl i
anc oz
an ions</w>
amp icillin
al ert</w>
activ in</w>
Tw o-
S er</w>
S c
Par aqu
PC -
P PI
MRS A</w>
J W
Ifosfam ide</w>
I l
I 1</w>
I -induced</w>
Hap lotyp
HUVEC s.</w>
HC V-
F O
ERK /
Disulfir am</w>
D ap
D D</w>
Cu /
Con vul
Co- administration</w>
Cl ,</w>
CYP2C 19,</w>
CD 40
An xi
A )
9- cis-
7, 12-
6. 8</w>
5- methyl
5, 7-
5'- flanking</w>
4 3,</w>
3- kinase/
25- dihydroxyvitamin</w>
23 1</w>
23 18
20 5</w>
2 -1
199 9</w>
18 ).</w>
0.0 2),</w>
0. 5-
(RO S).</w>
(NO S)</w>
(2- ethylhex
(1 8</w>
weigh t-
ventil ation.</w>
uncert ain.</w>
unc ture</w>
ulcer ation</w>
tol l-like</w>
ter -
swit ch
surviv in,</w>
sulf ation</w>
subtyp es.</w>
sty ren
strateg y.</w>
st ret
somnol ence</w>
sit e-directed</w>
shap ed</w>
sensi tis
rol ,</w>
retard ation.</w>
resid ents</w>
rec all</w>
re ward</w>
prop yl-
probuc ol</w>
polypo sis</w>
patch -
p ass</w>
out -
op ril
ol ),</w>
oint ment</w>
o stat
nitroglycer in-induced</w>
necessit ating</w>
nan o-
motif s</w>
mon ocytes,</w>
mid brain</w>
methyl ation-specific</w>
meth ach
loc us.</w>
lo bin
level s;</w>
k ast,</w>
it ab
interval s,</w>
incub ations</w>
i.c.v .)</w>
histor ical</w>
hemodi alysis.</w>
granul ocyte-
g ancic
ex ud
ev ent,</w>
estrogen .</w>
erythro mycin</w>
epitheli um,</w>
e fferen
dysp nea</w>
diox in-like</w>
diagnos es</w>
di methyl-
di alysis.</w>
dementi a.</w>
decano ate</w>
cytoplas m.</w>
cross- talk</w>
conjunctiv al</w>
cheno deoxycholic</w>
cham b
calmodul in</w>
barri er.</w>
atro ban</w>
aspir in-induced</w>
antibio tics,</w>
anil ine</w>
angioplast y</w>
ane )</w>
an te
adap t
acu te,</w>
U C)</w>
Tors ade</w>
Testo sterone</w>
Tac rolimus</w>
T- treated</w>
S- adenosyl
Rh abdomy
Res piratory</w>
RNA ,</w>
Prote inuria</w>
PN D</w>
P il
N eu
M t
John son</w>
J -
IL- 4,</w>
III a</w>
Hsp 90</w>
G entam
Fox O
FA K</w>
F am
EC (50)</w>
E u
Dele tion</w>
C RA
B rom
B O
B AP
Az athi
A 1)</w>
8. 4</w>
8 8%</w>
60 )</w>
5 -1
3- hydroxy
3 +/-
1A 2,</w>
19 ).</w>
12 1</w>
10(9 )/
1- 5</w>
/d b</w>
(v )
(S AH
(I NK4
(H F
(DOX )</w>
(C I),</w>
(C Cl
(C )</w>
(50 %)</w>
(5-nitro-2- fur
( chi
" )</w>
zinc ,</w>
yl methyl
yl ]-
xenobio tic-
vasopres s
un recognized</w>
treatment )</w>
tre ad
transfer ase.</w>
trans m
threshol d.</w>
sub- G1</w>
streptom ycin</w>
str anded</w>
steat osis.</w>
sp ens
shrin kage</w>
sar co
sal vage</w>
safet y.</w>
rhyth m.</w>
rema ind
re challenge</w>
radi ographic</w>
protein -2</w>
porphyri a</w>
phosphoryl ase</w>
persist ing</w>
perme ability,</w>
patient- controlled</w>
pare sis</w>
p21(W AF
p H
oxi dil
osi s-
olim bic</w>
ob al
montelu kast</w>
mellit us,</w>
meg ak
megak ary
medro xyprogesterone</w>
mar mos
manip ul
lac ked</w>
l es
ket o-
jaundic e.</w>
iso flavone</w>
iso enzymes</w>
iodix anol</w>
interval :</w>
import ant.</w>
immunocyt ochemistry</w>
immunoblot ting.</w>
immun o-
hyponat re
hyperglyc emia,</w>
hyper tonic</w>
hormon es,</w>
hepar an</w>
h ou
guanine- DNA</w>
giv es</w>
fen retin
f ec
elas tin</w>
eg ,</w>
eat an
eatan nol</w>
duod en
distingu ished</w>
cyt es,</w>
cyste ine.</w>
conflic ting</w>
ch ori
carboplat in,</w>
caffe ine,</w>
cadmi um,</w>
c DNA-
brief ly</w>
bet we
barbit ur
ation s:</w>
astro glial</w>
as e),</w>
apar t</w>
antihist amines</w>
ant en
ane ous
amp icillin</w>
amino transferase,</w>
aggra vation</w>
acid osis,</w>
achie ved.</w>
Twenty- three</w>
Twenty- five</w>
TH P</w>
Sequ ential</w>
SS F
SA H</w>
Physi cal</w>
P im
P (
NS-39 8</w>
NO S),</w>
N- [4-
MEDLIN E</w>
M 1,</w>
Low er</w>
L p
K K
K I</w>
JEG- 3</w>
Intraperitone al</w>
IP ),</w>
Hepa RG</w>
GSTP 1-1</w>
F34 4/
End ogenous</w>
Disrup tion</w>
Det ection</w>
Cd Cl
CD 40</w>
CA -induced</w>
C R)</w>
C N</w>
B DE
As2O 3-induced</w>
Alter n
ATP ase,</w>
AKR1B 10</w>
A (2)</w>
9. 2</w>
9 1
8- OHd
6 8%</w>
4 50)</w>
30 4</w>
3/ 4</w>
3-(4,5-dimethyl thiazol-2-yl)
3 5)</w>
2, 000</w>
(T D
(LPS )-induced</w>
(HD AC
(D I
(C V
(A r
(A HR)</w>
(9 )-
(4- chloro
( grade</w>
wh it
w asting</w>
ver -
tro glitazone,</w>
tri ed</w>
thi ols</w>
thalidom ide.</w>
ten ed</w>
tam sul
sup port
spas ms</w>
six th</w>
si lym
semin al</w>
sed ation.</w>
se tr
s c</w>
read ing</w>
re str
re combination</w>
re b
rat e-induced</w>
r d
puber tal</w>
protoc ol,</w>
proteas ome-
progres sing</w>
pran dial</w>
pot ent,</w>
po real</w>
peri vascular</w>
perc enti
pentylenetetr azol</w>
p ed
oxi redox
op a</w>
og lobin
ocyste ine</w>
occupation ally</w>
oc alized</w>
non- diabetic</w>
nigh t
ner ve.</w>
n ose</w>
muc in</w>
mod afinil</w>
mi t</w>
meth anol</w>
le d,</w>
lac king.</w>
iso prolol</w>
intragas tric</w>
intrac aver
integr ation</w>
inhibitor -1</w>
ill s</w>
ibuprof en,</w>
hypothes es</w>
hyperten sion:</w>
hyper uric
heter ologous</w>
haemorrh agic</w>
gu ide</w>
gran ulation</w>
g out</w>
g ),</w>
fu z
fiel ds</w>
fic i
fentanyl .</w>
far ,</w>
f ast
erec tion</w>
er ti
equim olar</w>
environ ment,</w>
endometri otic</w>
electromy ographic</w>
ectom y,</w>
e otax
dyston ia.</w>
dig estive</w>
detec tab
dermat omy
db /db</w>
cu ff</w>
coval ently</w>
concentration- dependently</w>
col on.</w>
cholest asis,</w>
cat aract
carb onic</w>
c /
blad ders</w>
bacter i
astrocyt oma</w>
appreci able</w>
anti thrombin</w>
a jmal
Zn T
Vinc rist
Raloxif ene</w>
RO S
RA ),</w>
R he
R am
Prolifer ation</w>
PD TC</w>
PA /
NP ,</w>
NO S-
NA c</w>
MS/ MS</w>
M oder
L S</w>
Inter actions</w>
ICRF -1
I son
H +</w>
Fact or</w>
FGF- 2</w>
E H</w>
D DP
Captop ril</w>
CYP2A 6,</w>
CYP11B 2</w>
C 4</w>
Am lo
AhR -dependent</w>
AN IT</w>
AI F</w>
A s)</w>
A di
99 mT
7. 7</w>
7 8,</w>
7 40
5 2%</w>
5 +/-
4 2,</w>
4 +/-
20 ).</w>
2. 8
2-amino -1-methyl-6-phenylimidazo[4,5-b]pyridine</w>
2 28</w>
199 8</w>
17b- estradiol</w>
0.0 7</w>
-1 16</w>
* 1/*
)- stimulated</w>
(MP O)</w>
(MC F-
wortmann in</w>
wom an,</w>
withdraw n.</w>
up ffer</w>
tubercul osis.</w>
transloc ated</w>
tra it</w>
thir ds</w>
t -induced</w>
sub stitute</w>
stric t</w>
solub il
si an</w>
short- acting</w>
schiz o
sample .</w>
s acch
rosi glitazone,</w>
resembl ed</w>
radio active</w>
pro- oxidant</w>
prac tical</w>
posi tive.</w>
pl uri
phenotyp es.</w>
perox ide.</w>
papill omas</w>
osteop ontin</w>
os uxim
on o
occlu sion.</w>
oc lastic</w>
neutropen ia,</w>
naphtho flavone</w>
microg/m l)</w>
mg/d l,</w>
mg/ d,</w>
met als,</w>
lab ile</w>
it em
intramuscul arly</w>
incub ation.</w>
immuno therapy</w>
ific ations</w>
ic h
i ble.</w>
hyper bilirub
hex iline</w>
granul omat
glo bus</w>
fur ther
food -
follic le</w>
fol ate-
fle x</w>
expl oration</w>
establ ished,</w>
er a</w>
ep ic
encap sul
empt y</w>
ell ar</w>
dos e:</w>
disrup tor
dihydroxy phenyl
dens ity,</w>
delt ameth
de methoxy
d act
cho w</w>
chemotherap y-
cell s).</w>
caspase- 3-
c ock
bradycardi c</w>
beta- caroten
az oxy
autom ated</w>
ativel y,</w>
arterios us</w>
amisul pride</w>
agonist -induced</w>
achiev able</w>
Sprag ue</w>
Seiz ure</w>
SF N</w>
R UN
R N
Pharmaco kinetic</w>
PPAR gamma
PP I</w>
PL D</w>
PKC delta</w>
P RA</w>
P L</w>
MLC K</w>
Jap an.</w>
Jan us</w>
Hist amine</w>
Find ings</w>
Di azepam</w>
D er
Comp ounds</w>
CS A</w>
CG P</w>
CC ,</w>
CA ).</w>
Brady cardia</w>
BM P-
B W</w>
9. 0</w>
6 -induced</w>
5 3,</w>
3 1.
24 h.</w>
2. 5-
19 2</w>
14 2</w>
12 ,
1 -10</w>
0.05 ;</w>
(R S
(P< 0.01)</w>
(D C
(0. 5-
wor ld.</w>
vir us-
ventil atory</w>
vel oci
tom ycin</w>
ti tion
th apsigarg
terat ogenicity</w>
tal ity</w>
subst ances.</w>
semi- quantitative</w>
seiz ure,</w>
scintigraph y</w>
ribavir in.</w>
remis sions</w>
rearrang ement</w>
quanti ties</w>
putam en</w>
poison ing,</w>
pl us-
pin acidi
phosphatidyl inositol-
phosphati dic</w>
par ap
p i</w>
p Rb</w>
oxid ase.</w>
orth o-
organ s,</w>
opioid -induced</w>
on om
olog ic,</w>
ogen ,</w>
ocom patibility</w>
occa sions</w>
oc ro
muc ositis</w>
mo triptan</w>
mo tiv
min/ mg</w>
mil der</w>
middle- aged</w>
mg/ day),</w>
methylphen id
methylene di
mechanism -based</w>
mas s.</w>
m ifepristone</w>
lip idemia,</w>
limit ations</w>
large- scale</w>
l ic</w>
l es.</w>
l ary</w>
k eratin</w>
int ell
ina emia</w>
in- binding</w>
in ver
immun ocom
im mobility</w>
idaz oxan</w>
i ar</w>
hydroly zed</w>
human ,</w>
highligh ted</w>
hepat omegaly</w>
group :</w>
g ).</w>
flu id.</w>
expl aining</w>
ex ual</w>
es '</w>
endotheli um.</w>
end omy
electro convulsive</w>
dyskine sia,</w>
dys functions</w>
du plication</w>
dipyridamol e-induced</w>
di vision</w>
deaf ness</w>
cytok eratin</w>
cyst in-
cypro hept
complex ity</w>
compet ent</w>
co sis</w>
cell- specific</w>
cardiover sion</w>
c e-
bronchodi lat
br ate</w>
bo ys</w>
bilirub in,</w>
b one-
autis m,</w>
atic s</w>
at e:</w>
aryn g
arsen ate</w>
anand amide</w>
allerg en</w>
ac it
W /
Syn thesis</w>
Sub st
Sil encing</w>
Second ,</w>
R X
Parkinson ism</w>
PM N</w>
N LRP
Met allo
Ison iaz
Inf arc
In duc
Ig A</w>
I G
HC H</w>
Cal ifor
CYP 19</w>
CDK 2</w>
CD 13
C um
C ros
B or
B ene
B Z
Associ ations</w>
Amiod ar
AED s</w>
70 )</w>
60 /
6 6%</w>
5-fluorourac il.</w>
5- day</w>
4 2)</w>
4 -1
3 beta-
3 75</w>
2 6-
15 ),</w>
14 ,
13 ),</w>
0. 3,</w>
(P< 0.05),</w>
(H CT
(G T
(ED 50</w>
(Del ta
(AD ).</w>
( serum</w>
( human</w>
ze tim
xenobio tics.</w>
wean ing</w>
ultim ate</w>
ti tan
tetrac hloro
tax ol</w>
sw im</w>
sulf ate.</w>
sulf adi
sub scale</w>
stri k
so y
situ ations</w>
sin o
ser ies,</w>
seiz ure-
sci enti
scaveng er,</w>
resem ble</w>
quin ones</w>
py el
prote oglyc
poly unsaturated</w>
phosphor ib
pathophysi ologic</w>
panc uronium</w>
p mol
p H,</w>
overexpres sion.</w>
orb ital</w>
ob stac
morph ologically</w>
malform ations.</w>
m :</w>
lamin in</w>
labet al
l es,</w>
k head</w>
isozym e</w>
is le
insulin- dependent</w>
in distinguishable</w>
implic ations.</w>
hr ,</w>
hormon e,</w>
he d
gran isetron</w>
glomeruloneph ritis.</w>
gentamic in.</w>
g ri
fir ing</w>
fet us
extremi ties</w>
end ogenously</w>
elev ated,</w>
elem ent.</w>
distribu tion.</w>
diethyl nitros
dic hlorodi
days ;</w>
dan azol</w>
cyste inyl</w>
cur ative</w>
cryst al
cr amp
cop ies</w>
clonid ine-induced</w>
charg ed</w>
categor ized</w>
c-f os,</w>
bronchi olar</w>
brady kin
bio avail
ati ve.</w>
ated )</w>
at ric
associ ate</w>
aro x
ar m.</w>
ar is
aquap or
antidepress ants,</w>
anti- HB
anti tumour</w>
ann -
am ine/
agit ation,</w>
aggrav ate</w>
adip ocytes,</w>
a i</w>
V SMCs</w>
T f
ST ),</w>
S- related</w>
Region al</w>
RA SSF
R E</w>
Q .</w>
Previ ously</w>
PU FA</w>
PQ -induced</w>
Ob jec
O T
Micha el
MI .</w>
MD MA
I s)</w>
HgCl (2)</w>
HT R
H or
H c
G1/ S</w>
G (2)/
En doc
Em bry
EGF R,</w>
EC .</w>
Deple tion</w>
D (1)</w>
Cor relation</w>
Com put
CYP1A 1.</w>
Bezaf ibrate</w>
Benz ene</w>
Bcl -2/
Ak t-
Accum ulation</w>
9. 4</w>
8. 2</w>
7 +/-
3 1)</w>
3 +</w>
10(- 9)</w>
1- adrenoceptor</w>
(T ax
(C RE
(6 00</w>
(1 6</w>
(1 ))</w>
(-/- ))</w>
( p.
( mean,</w>
yr -old</w>
yl cy
x in</w>
vi ron</w>
vari ant.</w>
vari ability.</w>
uz ole</w>
tumori genicity</w>
tocopher ol</w>
time- course</w>
thyroidis m.</w>
th en
tagg ed</w>
t BH
subun it,</w>
strain s,</w>
ster ile</w>
step wise</w>
sp anning</w>
sign s.</w>
sibl ings</w>
se ed</w>
schizo affective</w>
rup t
recover y,</w>
publ ic
prototyp e</w>
prost ate.</w>
program s</w>
proced ure,</w>
picrotox in-induced</w>
perox ide,</w>
ouma rol</w>
other s.</w>
osi s:</w>
or listat
ocyt oclastic</w>
na il</w>
molecul e,</w>
method s,</w>
meth imazole</w>
mercur y-induced</w>
mecamyl amine</w>
manag ing</w>
main tains</w>
mac ul
losart an.</w>
lipos omes</w>
ligand -dependent</w>
ligand -
la ev
ketocon azole,</w>
intrat um
injec tions,</w>
ing -induced</w>
infiltr ating</w>
in put</w>
in ol</w>
in he
in ate</w>
idi l</w>
ic in,</w>
ibuprof en.</w>
i a)</w>
hyperglyc emic</w>
hormon es.</w>
hepatocarcin oma</w>
group ed</w>
grad es</w>
gra vi
g/ kg/
fro zen</w>
expl oring</w>
erythematos us.</w>
ep sy</w>
ens ure</w>
endro flu
efferen t</w>
du al-
diaph or
denerv ated</w>
cr ude</w>
consequenc es.</w>
conclu sions</w>
compon ents,</w>
chondro cyte</w>
chloro form</w>
chel ator,</w>
cephal oth
casp as
carvedil ol.</w>
bupren orph
bos entan</w>
b.i. d.</w>
assi st</w>
amni otic</w>
amid es</w>
admini ster</w>
add- on</w>
ach ing</w>
acetaminophen .</w>
a e,</w>
[Ca(2+)] (i)</w>
Y oun
W I
Syst em
ST S</w>
SH ,</w>
S cop
S ci
S ]
Pro -
PA F</w>
On ce</w>
O H)</w>
O F
Ne w
N NA
MUC 5AC</w>
MC- 77
L E</w>
Ital ian</w>
In stead,</w>
I/ R</w>
His panic</w>
HLA- B
GAP DH</w>
F 2
F -induced</w>
Ex ogenous</w>
En viron</w>
EC M</w>
Doc etax
Di hydro
DP Y
D ar
Co operative</w>
CYP 7
CS F)</w>
Acrole in</w>
AP PRO
A P-
7 6%</w>
5 FU</w>
5 -10</w>
4 E-
3 :</w>
15 2</w>
1 500</w>
0.0 9</w>
-10 (-
-1 2
(PPA R-
(PA I
(G W
(1 3.
( miRNA
ys in</w>
yl)-2- thiazol
well- characterized</w>
vesi cle</w>
ventro lateral</w>
valpro ate,</w>
v acc
underli es</w>
un favorable</w>
th s</w>
tend on</w>
te tro
sudden ly</w>
sub cortical</w>
su s-
strain .</w>
sten osis.</w>
st ores</w>
specific .</w>
s. (ABSTRACT</w>
ri um</w>
resol ve</w>
reac tion-
rat s].</w>
rat s;</w>
prote ases</w>
progenit ors</w>
present ation.</w>
precipit ating</w>
pre conditioning</w>
pre adipocytes</w>
post mortem</w>
phytochemic als</w>
paras ite</w>
p ts</w>
ogr am,</w>
nucle i.</w>
non fatal</w>
more over,</w>
mirtaz apine</w>
mg/m l</w>
me tics</w>
me themo
mark er,</w>
m PGE
li bit
larg e,</w>
ke ep
kaempfer ol</w>
it u
inter neurons</w>
injec tion
inhibitor ),</w>
hex ameth
h t
guid ed</w>
gel atin</w>
follow s</w>
fol lowe
flud arabine</w>
fib rates</w>
est rous</w>
er y
er adic
en flur
electro retin
dis placement</w>
diabet es
correspon ds</w>
contr ast
consti pati
collag en,</w>
cho ic
chic k</w>
chec ked</w>
catat onia</w>
carb ach
cadmi um.</w>
c ing
berb erine</w>
bell ar</w>
be fore
b order</w>
b FGF</w>
associ ates</w>
aspir ation</w>
arte mis
ar ri
anxiet y.</w>
an oids</w>
alas in</w>
activ e-
a etiology</w>
Tax ol</w>
TME M
T OR
Sensi tivity</w>
SM MC-77
Ra f</w>
RNA i</w>
Mul tic
Magne tic</w>
M u
J ,</w>
Im pres
IP ,</w>
I NS
HO -1,</w>
Gluc ocortico
G AL
Emer gency</w>
DH ),</w>
D DE
D AD
C ri
Brow n</w>
Bl ocking</w>
Bl ad
Benz o
Ba P-induced</w>
B D)</w>
Atten uation</w>
Anti- inflammatory</w>
AD Rs</w>
A II</w>
8 )
5 1%</w>
46 8</w>
4- mediated</w>
3 7,</w>
20 2
2,3,7,8-Tetrac hlorodibenzo-p-dioxin</w>
14 6</w>
1 1.</w>
1 1,
-2, 3-
-2 4
- 30
, 00
(V D
(V )</w>
(P-gp )</w>
(N AT
(M PT
(HUVEC s)</w>
(C T)</w>
(C HO
(4 ))</w>
(10 %)</w>
( beta-
( QT
( ATP
" ,</w>
yohim b
yl transferase</w>
yel low</w>
vacuol ization</w>
urg ent</w>
un iform</w>
theore tical</w>
th eta</w>
testoster one.</w>
tert- butyl
ta ined,</w>
swim ming</w>
suxameth oni
start le</w>
siz es</w>
signat ures</w>
serum- free</w>
sequ estr
schedul e.</w>
rosiglitaz one.</w>
regres sed</w>
rec ycl
raloxif ene,</w>
radi olabeled</w>
radi ation-induced</w>
pyrrol idine</w>
prote olysis</w>
prost ate,</w>
propofol ,</w>
pock et</w>
phosphatidyl choline</w>
pheny leth
pestic ides.</w>
perturb ations</w>
per spec
per m
patch es</w>
part ner</w>
p 75
p 73</w>
overexpres s</w>
ou mar
ot remor
osteocal cin</w>
osarcom as</w>
nortriptyl ine</w>
nephro calcin
move ments.</w>
miR- 34
metoprol ol.</w>
methotrex ate-induced</w>
melan oma,</w>
me eting</w>
m Ab</w>
lys o
lofen ac</w>
lamin a</w>
intrathec ally</w>
insulin- stimulated</w>
inclu de
implant ation.</w>
ic ally.</w>
high- frequency</w>
high er,</w>
hic cup
h PXR</w>
h ;</w>
gu n</w>
gangli onic</w>
fl up
fe ar</w>
evalu ation,</w>
ethoxyresoruf in</w>
eth yn
erup tion</w>
ent )</w>
el ,</w>
dist or
dehydro epiandrosterone</w>
cyclin s</w>
coun ting</w>
complex es,</w>
coch le
chloroethyl )-1-
ch ains</w>
biop sy,</w>
benzen esulf
bas es</w>
as ymptom
ap arin</w>
ann ual</w>
amplit u
amin op
am ine-</w>
am ate,</w>
allevi ates</w>
allel es,</w>
al :</w>
acr yn
acid osis.</w>
Y MDD</w>
Sing le-
RA GE</w>
Per iod
Pen icill
PI )</w>
PA X
P K</w>
P 4</w>
Out come</w>
Mor tality</w>
Mar ked</w>
MAPK .</w>
K upffer</w>
K apl
In fusion</w>
HDL- C</w>
E PA</w>
Dil tiaz
Cyclo oxygenase-2</w>
Com plications</w>
BSE P</w>
BCL -2</w>
B asal</w>
Al do
AS3 MT</w>
AQP 3</w>
AC R</w>
A s-
9. 8</w>
5, 000</w>
4 2.
2- h</w>
14 7</w>
10(- 6
1- fold</w>
0. 10</w>
-2 ).</w>
(P R)</w>
(D MB
(C r
(9 5</w>
(2) D(3)</w>
( eg,</w>
( beta
zer o</w>
z ox
ylcy prom
ver sus-
vas omotor</w>
ur red</w>
um :</w>
typh im
tox in,</w>
ted ly</w>
techniqu e,</w>
sur al</w>
sub lethal</w>
str y</w>
s ?</w>
rest en
research .</w>
repres s</w>
reliev ing</w>
relationshi p.</w>
reinforc ing</w>
reduct ases</w>
rectom y</w>
re strain
re organization</w>
radio therapy.</w>
prurit us,</w>
propos ed.</w>
promot ers.</w>
prolactin oma</w>
prof es
pre menopausal</w>
post transcriptional</w>
pog relate</w>
pneumon ia
phyto estrogen</w>
phot osensi
phospho kinase</w>
oxic am</w>
ox -
os pec
or ally.</w>
one /
ometr y.</w>
move ments,</w>
mon oxide</w>
mol/ L)</w>
m sec
lys ates</w>
li es</w>
isoproteren ol,</w>
is o-
inf ants,</w>
ind o
in ity</w>
in adver
hist ology,</w>
hepar in,</w>
growth- inhibitory</w>
gadol inium</w>
g ating</w>
fluoxet ine,</w>
fashi on,</w>
etoric oxib</w>
disturb ances.</w>
detec ted,</w>
deca y</w>
cytos ol,</w>
comm enc
cinnam aldehyde</w>
capec itabine</w>
benz ene
arra ys</w>
ar k
anticip ated</w>
aminobi phenyl</w>
al ip
al 's</w>
ac yl-CoA</w>
ac .</w>
absorp tion,</w>
Tr p</w>
Tr p-
T V
Stand ard</w>
SUBJEC TS:</w>
S us
PG s</w>
PG HS
PD980 59,</w>
N a-
N GF
My co
Met o
Met formin</w>
MT- 3</w>
MP T
Li Cl</w>
LP S,</w>
LP A</w>
L is
L an
I/ II</w>
I sche
HT ,</w>
H D-
GF P</w>
G(2)/ M</w>
E DCs</w>
Diagnos tic</w>
DO PA
DMA B</w>
CYP3A5 *
CI =
CH D</w>
CD H
B K</w>
ARPE -19</w>
A ER
7 3%</w>
5, 6-
3 beta</w>
3 8,</w>
17 2</w>
0.00 2)</w>
-1, 4-
(medi an,</w>
(MTH F
(DE S)</w>
(C /
(2 5%)</w>
( 7.5</w>
( -2)</w>
zinc .</w>
y rene</w>
whole- cell</w>
we re,</w>
vari ant,</w>
valpro ate.</w>
utili z
under took</w>
twent y</w>
transmis sion,</w>
tr ap
tion ing</w>
thromb olytic</w>
the- counter</w>
surfac e.</w>
super sensitivity</w>
sul fi
suic idal</w>
su nit
strik ingly</w>
stil bene</w>
sput um</w>
sper mine</w>
solu tion,</w>
sevo flur
rough ly</w>
rof ecoxi
rh initi
resol ved.</w>
pyridox ine</w>
prob ands</w>
pro collagen</w>
por ter</w>
per iton
pemetrex ed</w>
pass age</w>
p ith
os a
opres sin</w>
op posing</w>
ok adaic</w>
oid ,</w>
non synonymous</w>
ne tilmic
metoprol ol,</w>
mes ylate</w>
mes alazine</w>
ma -
m ari
levodop a.</w>
lat ano
k an
ischemia/ reperfusion</w>
ir regular</w>
initi ates</w>
ing ),</w>
in- based</w>
in patients</w>
improve ment,</w>
implic ates</w>
immunosuppress ant</w>
ic ally,</w>
hypokal emia.</w>
hypoglyc emic</w>
hypertriglycer idemia</w>
hr s</w>
hour ly</w>
hormone- dependent</w>
hlorodibenzo-p- diox
high .</w>
hemat opoie
hear ts,</w>
h abil
ga it</w>
form amide</w>
fentanyl -induced</w>
falcipar um</w>
ex on
ethyl ene
esmol ol</w>
endocannabin oid</w>
ei ved</w>
down .</w>
dimethyl arsin
des m
def ens
cyt omegal
crocidol ite</w>
consti pation</w>
con nexin</w>
co erul
co effici
caspase- 8,</w>
cas es].</w>
bupivaca ine,</w>
benef it.</w>
be d.</w>
at tri
astrocyt es,</w>
arter y,</w>
ap onin</w>
anti bacterial</w>
anch nic</w>
an oic</w>
all ic</w>
al- mediated</w>
aggreg ation,</w>
ag ene
adv ances</w>
adreno receptor</w>
acyl glycerol</w>
acryn ic</w>
accur ately</w>
a- like</w>
[14 C]
Zn 2+</w>
X RE
U ro
Twenty- eight</w>
TGF- b1</w>
Stres s</w>
Ser ious</w>
ST Z-
ST X
S ar
S Q
PM L/
P s)</w>
P PA</w>
O (2)
N, N-
M W
Immuno fluorescence</w>
IL-1 beta-induced</w>
IGF- II</w>
IF O</w>
Hem orrh
GST A1</w>
G i
F DA</w>
ED TA</w>
Cr(VI )-induced</w>
C reat
Bax/ Bcl-2</w>
Activ ated</w>
AT 2</w>
A P-2</w>
9 66
78 8</w>
7 5-
5-Fluoro uracil</w>
3- year</w>
3 60</w>
26 6</w>
26 ).</w>
10(- 9
. "</w>
-2 6</w>
-- >
(V SMC
(PAH s)</w>
(P XR)</w>
(JNK ),</w>
(B B
(A Q
(A DR
(2 0-
yl in</w>
xeno estrogens</w>
with dre
un it.</w>
tubercul ous</w>
tri azolam</w>
tread mill</w>
transplant .</w>
tran dr
toxic ,</w>
ti bial</w>
themsel ves</w>
t one.</w>
stabil izes</w>
spas m.</w>
sp ond
si s).</w>
sha res</w>
sett ings</w>
sequenc e,</w>
responsiven ess.</w>
reser pine-induced</w>
remaind er</w>
rel ating</w>
recor d</w>
rec ently,</w>
reat h</w>
rapamycin ,</w>
radic als,</w>
radi olig
pyr ro
pseud ol
pro tracted</w>
press ed</w>
prednisol one,</w>
pre incubation</w>
poly -
poin ted</w>
phytoal exin</w>
ph leb
p53- independent</w>
p 50</w>
ox otremor
ox anth
orin ostat</w>
op leg
op ia</w>
olig omer
nitrosamino)-1-(3-pyridyl)-1- butan
nig ra
mus cles.</w>
mu M</w>
morph ogenesis</w>
mono oxygenase</w>
ml/ min</w>
mit osis</w>
mir ro
mg/ L)</w>
melit tin</w>
m ur
l c
ion ization</w>
intraven ously.</w>
inherit ance</w>
immunocyt ochemistr
ic idal</w>
hybridiz ation.</w>
hepar in.</w>
graf t-
gl um
forelim b</w>
fer ric</w>
evid ences</w>
er ol</w>
ent ec
ent ac
endocrine- disrupting</w>
e zetim
dr as
double- strand</w>
disrup tor</w>
discre panc
dimin ishes</w>
de vic
de form
cre ate</w>
co ffe
clozap ine-induced</w>
cli oquin
chro mo
chi ld.</w>
cerebr i</w>
caus e.</w>
catechol-O- methyltransferase</w>
cardio protection</w>
bl ac
atroph y,</w>
ar ding</w>
anti- oxidative</w>
ant )</w>
an- Mei
alg ia</w>
al istic</w>
al ;</w>
ag en</w>
activit y)</w>
X PC</w>
W o</w>
V ir
V PA-induced</w>
Under standing</w>
U K</w>
U F
T GF</w>
Sma d</w>
S P)</w>
Ri bavir
R 1,</w>
Phen yl
P< 0.01).</w>
P< 0.001).</w>
P neum
O vari
O ne
Neuro leptic</w>
NH L</w>
NF AT
Mn SOD
MM R</w>
MA -
M -1</w>
Leishman ia</w>
LD 50</w>
L- N
IB D</w>
HCC s</w>
Ex er
Er k</w>
Cyp1a 1</w>
Cir cul
Chrom atin</w>
CD11 b</w>
CD H.</w>
C/E BP</w>
C/ T</w>
C it
Bax .</w>
BM D</w>
B SO</w>
ATRA .</w>
A ra
A gg
A 2318
> 0.05).</w>
8. 1</w>
3. 6
200 2</w>
2 nd</w>
13 6</w>
1. 5,</w>
1 16
0 ).</w>
-2 93</w>
-1 45</w>
-1 -induced</w>
(EC G)</w>
(C d)</w>
(C AT),</w>
(2 2</w>
( after</w>
zon isamide</w>
yiel ds</w>
ventric le.</w>
vascul at
v indes
us er</w>
un iform
un desirable</w>
u ate</w>
tiv ely.</w>
theophyl line.</w>
theophyl line,</w>
telangiecta sia</w>
t ent
smok ing.</w>
rest ,</w>
res ect
re min
program ming</w>
princip ally</w>
pent azocine</w>
p S2</w>
oz o
ot o
os um</w>
organ ell
or dial</w>
optim um</w>
ont ine</w>
omycin ,</w>
om ere</w>
observ ations,</w>
neutrop enic</w>
neuro tensin</w>
nalox one,</w>
mix ed-
mg/d L,</w>
membran es,</w>
me pivaca
matri x-
man age</w>
m ;</w>
loci .</w>
iter pene</w>
ir on.</w>
ion s,</w>
in ally</w>
i. t.</w>
hyperther mia.</w>
hemodi aly
ha m</w>
h old</w>
gre l</w>
gonadotrop in</w>
fructose- fed</w>
fru it</w>
fl ash
fibr ic</w>
fer tili
famil ies,</w>
fall s</w>
fac itinib</w>
extrac ellul
ester ,</w>
es cul
end- systolic</w>
en ing.</w>
diis ocyanate</w>
diameter s</w>
di le
des atur
defin ing</w>
def ence</w>
de br
cytos ol.</w>
cryst als</w>
criter ia,</w>
concentr ated</w>
compet e</w>
clo trim
c- Src</w>
bisulf ite</w>
beta- lact
ba sis.</w>
azathiopr ine.</w>
atten tion-
attac hment</w>
ar .</w>
ap one</w>
antimon y</w>
anti hyperalgesic</w>
angio edema.</w>
analy se</w>
amplit udes</w>
alkal oids</w>
al og
adduc ts.</w>
acc entu
ac tions,</w>
Zn (2+)</w>
X ).</w>
W Y
U V-
U 87
TH )</w>
T TP</w>
Sur ve
St ar
SH R,</w>
SCL C</w>
S um
S GC
Relationshi p</w>
Rac 1</w>
NP C</w>
MT X,</w>
M F</w>
Larg e</w>
LR R
L M</w>
HMG B1</w>
HC F
GS SG</w>
Epid ermal</w>
Caucasi ans</w>
CL )</w>
CCA AT/
CA G</w>
C ot
C och
B us
As p</w>
AM L
AB L</w>
A ten
90 )</w>
8. 6</w>
8- ox
8 6%</w>
8 4%</w>
8 2%</w>
7. 9</w>
7 9%</w>
7 2%</w>
6 1%</w>
5 9%</w>
5 00
4- (methyl
4 T</w>
3- mediated</w>
3 rd</w>
2D 6</w>
23 5</w>
2- 4</w>
16 A</w>
16 8</w>
15 6</w>
1. 0%</w>
1,25-(OH) 2D3</w>
(PA N)</w>
(P< 0.001)</w>
(P O
(I GF-
(EE G)</w>
(CS F)</w>
(AP -1)</w>
(2+ ),</w>
(1 1
(0.0 5</w>
( SIRT
( 5,</w>
ventric les</w>
val erate</w>
ureth ral</w>
un less</w>
uc cin
transm ural</w>
trans- resveratrol</w>
tourniqu et</w>
tizan idine</w>
tas ks</w>
tac tile</w>
stibogluc onate</w>
simul ated</w>
sensitiz ers</w>
ro ta
quantit ated</w>
qualit atively</w>
psych osis,</w>
preven tion.</w>
preser v
piroxic am</w>
phosphat ases</w>
phosph onate</w>
phen ir
ph ox</w>
pestic ides,</w>
perfu sion.</w>
p21 WAF
over dose,</w>
osmol al
or bi
oph asic</w>
oper ating</w>
on org
on a
ol ev
of ,</w>
neutropen ia.</w>
n ab
morph olin
mig ratory</w>
micro g,</w>
mg/ 24</w>
machiner y</w>
m ox
m osph
m ad
lys osomes</w>
low- level</w>
lab elling</w>
l-DO PA</w>
k g/m
jug ular</w>
inhibit or-
imidazo[4,5- f]
im prin
im ip
hypo phosphat
hydr azine</w>
glucocorticoid -induced</w>
g ain.</w>
form s.</w>
fle xi
fic ient</w>
fe el
f osin
f mol/
escal ated</w>
epti des</w>
entor hinal</w>
elucid ating</w>
elic iting</w>
elem ents.</w>
eIF 4
drug 's</w>
disturb ances,</w>
dissoci ated</w>
differen ce,</w>
di bular</w>
cortico ster
coagul ant</w>
cholecysto kinin</w>
cent er.</w>
capsul es</w>
cap ture</w>
c- jun
bic yc
beta- receptor</w>
avoid ing</w>
at um</w>
arteri oles</w>
antagon izing</w>
alopec ia</w>
ag arose</w>
adolesc ents.</w>
ac compl
a- mediated</w>
a 1</w>
X IAP
W T
V ol
V PA
U0 12
Reg i
Pot enti
OD C</w>
Nrf 2,</w>
Non steroidal</w>
NT /
NT )</w>
N Y
Me IQ
Mac roph
MT ),</w>
MCF 10A</w>
Ikappa B-
ICRF-1 87</w>
HD ,</w>
Geniste in</w>
Exc essive</w>
ET A</w>
Chemo therapy</w>
COX -2.</w>
CD34 +</w>
CB R1</w>
B N</w>
Amlo dipine</w>
African- American</w>
ATRA ,</w>
A cr
< /
7- day</w>
7,12- dimethylbenz
3- O-
3 2-
2 A1</w>
17 .</w>
13 9</w>
12 7</w>
1 L</w>
0.0 5%</w>
/ w
. go
-2 7
-1, 2-
(TUNE L)</w>
(S HR
(MR I)</w>
(As(2)O (3))</w>
(AL DH
(1 5-
(1 20</w>
(1 2.5</w>
( c.
y li
vis ed</w>
vir us.</w>
vastat in.</w>
vasopres sor</w>
vacu olar</w>
usp id</w>
unde restim
tyros inase</w>
twic e-daily</w>
tubul es.</w>
triamcin olone</w>
trans peptidase</w>
til t</w>
ter bin
target s,</w>
tachycardi as</w>
synth ase.</w>
sub eroylanilide</w>
ste d.</w>
si um</w>
sc rat
sc )</w>
ru tin</w>
res our
re entrant</w>
produc t.</w>
pregnanc ies</w>
pp m,</w>
perme abil
peri portal</w>
or d
oph aryngeal</w>
operativel y,</w>
onc ology</w>
ol ol.</w>
oid s.</w>
ococc us</w>
ochemo therapy</w>
non- alcoholic</w>
nit rates</w>
neuro surgical</w>
mut ant,</w>
mo tility,</w>
mil umin
malignanc ies,</w>
leuk open
late- onset</w>
labor .</w>
jaundic e,</w>
iti dine</w>
isol ate</w>
ir rig
ion ophore</w>
inde d,</w>
incre ments</w>
ill ness,</w>
if ith
hear t-
genotyp e-
gall ic</w>
formul a</w>
fib rous</w>
far .</w>
f low-
f ic</w>
excit otoxic</w>
ev ening</w>
ethan ol-
ep o
enrol l
encephal itis</w>
en ess</w>
electro graphic</w>
echocardi ography,</w>
dras tically</w>
dom peridone</w>
di methyl-4-
di bromo
dang erous</w>
d ensi
d ]
compa res</w>
commun ity-
chloro -
cat abolic</w>
carbox amide</w>
captop ril.</w>
captop ril
cal ca
bal ance,</w>
b reath</w>
b endroflu
arsenit e,</w>
arboxyl ic</w>
applic able</w>
antioxid ants.</w>
antine utrophil</w>
ane di
an a</w>
am ine
aldo -keto</w>
ail ed</w>
Z ol
Z E
W est</w>
V CM</w>
Un til</w>
T AT
ST Z-induced</w>
S in
S ens
Rem ark
Reg arding</w>
Re duc
Ra ji</w>
RA -induced</w>
PF S</w>
PC R)</w>
P al
P SC
P MS
OP N</w>
Nrf 2/
Neuro logic</w>
NF-kappa B-dependent</w>
M g</w>
M MC
K -1</w>
He at</w>
HER 2-
HBs Ag</w>
Gem cit
F g
F MO
Enhanc ement</w>
E2 F1</w>
Deli rium</w>
D L-
Co administration</w>
C b
BP /
B PA.</w>
Aut ophag
Anesthe sia</w>
Amin o
Alph a-
Al a-
APPRO ACH
APPROACH :</w>
AP L.</w>
AA G</w>
A part</w>
9 +/-
7 8%</w>
6 43</w>
50 /
5-FU -induced</w>
5 1
4 th</w>
4 5.
3 6,</w>
28 .</w>
20 %,</w>
18 .</w>
0. 35</w>
- 9,</w>
(i e,</w>
(V K
(TNF- a)</w>
(S LC
(S D</w>
(R F
(H (2)O
(E )-
(D BP)</w>
(C HF
(AR F)</w>
(5-nitro-2-fur yl)-2-thiazol
(1 6.
(1 2
( METH
( CYP3A
valbum in</w>
ultrason ography</w>
ub i
tri oxide-induced</w>
tobac co
therap y-
ter ic</w>
temperat ure.</w>
tak en.</w>
syndro mic</w>
syn cy
strych n
stimul ants</w>
sta phylococc
sphinc ter</w>
spas tic</w>
small- molecule</w>
sleep .</w>
sleep -
si li
setting s.</w>
seleg iline</w>
ros ace
rifampic in,</w>
resveratro l-
requ isite</w>
ren one</w>
rel ations</w>
regener ation.</w>
recogn ised</w>
re aring</w>
rat )</w>
random ization</w>
pyrrol idin
py razol
provoc ation</w>
program .</w>
preser ve</w>
predis poses</w>
pr ick</w>
pr amipex
posi tivity</w>
pla y
phen el
ph ase-
person ality</w>
oxy -
over- the-counter</w>
osteoc last</w>
osa hexa
os e,</w>
omedul lin</w>
om ain</w>
ne ostigmine</w>
nadi r</w>
morph ology.</w>
molecul ar-
modal ities</w>
min oxidil
medi ators.</w>
mal athion</w>
los ses</w>
lo zol
lim itation</w>
len alidomide</w>
le ak</w>
laev is</w>
ket anserin</w>
itsel f,</w>
inter feren
in- resistant</w>
in ulin</w>
in ous</w>
i As</w>
hyperten sion
hyal uron
hor iz
glycosyl ation</w>
glyco gen
fi ed.</w>
exist ed</w>
exam ic</w>
eu gen
ethyl amine</w>
epis odic</w>
ent in,</w>
endomy ocardial</w>
endometri um.</w>
elong ation</w>
disrup tors</w>
dis continue</w>
diarrho ea</w>
di- n-
der ang
defici encies</w>
defect .</w>
d B</w>
cyr rhiz
criter ion</w>
cra v
cortis ol,</w>
conver t</w>
co st
ce ment</w>
cardi ac
cAMP- dependent</w>
c illin</w>
c es,</w>
c ations</w>
bromocript ine.</w>
bleed ing,</w>
beta- oxidation</w>
ber g</w>
aut op
ation -associated</w>
assem bl
assa y)</w>
arter io
arsenic als</w>
anti cholinerg
anti cataleptic</w>
anhydr ase</w>
an of
am s</w>
all- cause</w>
alend ronate</w>
aldehy de-induced</w>
al fuz
agonist )</w>
affin ity.</w>
aer obic</w>
abund antly</w>
a esthe
X 2</w>
V D</w>
Ur sodeoxycholic</w>
Toxic ology</w>
TNF -induced</w>
Stat us</w>
Sou thern</w>
Sle ep</w>
SGC 790
RS F
R -induced</w>
P raz
P an
Oat p
Nex t,</w>
Man agement</w>
M ex
M U
Kapl an-Mei
Inc .</w>
IL- 6-
II ).</w>
Hyp oxi
Here in</w>
GSH- P
Fir st</w>
F AD
E M</w>
DF P</w>
DBA/ 2</w>
D LD
Ca re
CXCR 2</w>
CET P</w>
C ush
C o</w>
Blad der</w>
B ile</w>
Alco hol</w>
ALT ,</w>
A qu
A paf
A 2,</w>
9. 1</w>
3-methylcholanth rene</w>
3- month</w>
2- hydroxy
19 90</w>
16 2</w>
1- /-</w>
1,25(OH) 2D
0.05 );</w>
(phox )</w>
(PCB s)</w>
(P B)</w>
(M I)</w>
(HD L)</w>
(GAB A)</w>
(C X
(B UN
(A H
(5 %)</w>
(1 1.
(1 -1
(-1 )).</w>
( vitamin</w>
' .</w>
ym ic</w>
withdre w</w>
volun tary</w>
verte b
variabl es,</w>
ubiquit ously</w>
twit ch</w>
tumori genesis,</w>
treatment ].</w>
tran ylcyprom
tract ,</w>
tr iterpen
tr apping</w>
tiv e-
thromboph lebitis</w>
the ory</w>
th -
tail- flick</w>
symptomat ology</w>
sulf one</w>
sphing osine</w>
spe ech</w>
spastic ity</w>
sho ul
sensitiv ities</w>
sens or</w>
sc at
s o-
rest ar
reperfu sion,</w>
ren al,</w>
relap se
recti fier</w>
recogn ized.</w>
rearrang ements</w>
rapid ,</w>
pterostil bene</w>
po doc
phag ocytosis</w>
peripher ally</w>
palli ative</w>
oph armac
one- third</w>
ondan setr
ol ine,</w>
o in.</w>
nystag mus</w>
non responders</w>
neurotransmit ters</w>
nerv es.</w>
n t</w>
mitig ated</w>
micronucle i</w>
micro M;</w>
m is</w>
m M).</w>
m M),</w>
log ram</w>
lo oked</w>
li z
leukotri enes</w>
leuk emo
leng th,</w>
lamivud ine.</w>
lact ation</w>
knock- out</w>
kinas e)</w>
ki logram</w>
is -M
is-M ent
iopamid ol</w>
intracerebro ventricul
interleukin- 4</w>
interfe red</w>
ing ).</w>
imp ed
im plant</w>
ia sis,</w>
hyperparathyroidis m</w>
hydrox yc
heter olog
gram s</w>
follow ing:</w>
flav an
fas ted</w>
excl ude</w>
estrogen -dependent</w>
erro rs</w>
er s:</w>
epithelial- mesenchymal</w>
en em
dr onate</w>
dou b
donepez il</w>
direc tional</w>
dev ice</w>
determin ations</w>
cyto kine
cros stalk</w>
counter acts</w>
coun ts,</w>
correspon d</w>
contr ary</w>
combin atorial</w>
codon s</w>
chron ic,</w>
chore a</w>
chang ed.</w>
ch ain,</w>
cathe ters</w>
carrageen an-induced</w>
c- myc
c ne
c ]
br and</w>
betwe en-
benz ene.</w>
benz ene-
be gun</w>
azep am.</w>
aspar tic</w>
antigen ,</w>
antagon ism.</w>
anchorage- independent</w>
analge sia,</w>
alpha- 2</w>
allevi ating</w>
aldoster on
abrog ates</w>
abol ishes</w>
a il</w>
[ 1-
U 2O
T OP
Su peroxide</w>
S mo
RANK L</w>
Pro gram</w>
Phen obarbital</w>
PX R.</w>
PPAR- alpha</w>
PD E</w>
O PI
O 2)</w>
NR TI
NADP H
N s</w>
Mechan is
Maxim al</w>
MA G
MA ),</w>
LDL- C</w>
K D</w>
IV .</w>
IL-1 7</w>
I P-
Hist ologic</w>
HSP 90</w>
HCT -116</w>
Gas tric</w>
GRP 78</w>
Extrac ellular</w>
Exc ept</w>
Erb B2</w>
End ome
E T-
DMT 1</w>
DAT S</w>
D 2,</w>
Cu ,
Cd (2+)</w>
C oun
An th
AM ,</w>
AG T</w>
AC .</w>
7 )
6 2%</w>
6 -1
0.000 0
0.0 1;</w>
0. 50</w>
- beta</w>
- S
(T NB
(S L
(NAC ),</w>
(CH F)</w>
(A ng</w>
(A LT
(6 %)</w>
(3 +)</w>
ve str
un fractionated</w>
tric losan</w>
tr action</w>
tis ].</w>
tetr ap
test inal</w>
tacrolim us.</w>
tac rine</w>
t .)</w>
sul pi
subst ances,</w>
sple en,</w>
smok e,</w>
si s/
sarcom a.</w>
roten one,</w>
res sion</w>
remis sion,</w>
re habil
prolong s</w>
proce dural</w>
pro pri
princi ple</w>
pre malignant</w>
post treatment</w>
pop ular</w>
poly ethylene</w>
piper azin
per oxiredox
pentylenetetr azole</w>
peak s</w>
pal atal</w>
oxygen .</w>
ox amine,</w>
ot otoxicity.</w>
ot onic</w>
ost om
orth olog
opath ies.</w>
omega- 3</w>
o il,</w>
nutri ent</w>
num er
no -
neuro toxin</w>
nephro lithiasis</w>
nelfina vir</w>
naphth yl
mul tivari
micro l</w>
methyl mercury</w>
met an
mer captop
men th
mark et</w>
lymph oma,</w>
li er</w>
it ol</w>
is-Ment en</w>
ir reversibly</w>
in dependent.</w>
imag ing,</w>
il ed</w>
if ug
hypothalam ic-
hypertroph ied</w>
hist ocompatibility</w>
hap ten
gest ation,</w>
gene tics</w>
g/ L</w>
g all</w>
fut ure.</w>
fluor anth
filam ents</w>
fentanyl ,</w>
expos ing</w>
expl ains</w>
eth osuxim
en abled</w>
ec ho
dysp ep
disor i
dex fenfluramine</w>
des flurane</w>
coun sel
clinic opathological</w>
clar ithromycin
challeng e,</w>
ber ate</w>
benzo(a) pyren
b y
b im
az april</w>
atroph ic</w>
ath ymic</w>
ass ing</w>
arterio venous</w>
anticonvuls ants</w>
anten atal</w>
analy sed.</w>
aminob enz
am o
acen oc
a uro
Thirty- six</w>
Thirty- five</w>
TCDD- mediated</w>
T CP
Sub cutaneous</w>
Soci ety</w>
Si rolimus</w>
SI -
S- treated</w>
R ab
PA P</w>
P- selectin</w>
OP s</w>
O cular</w>
Nor way</w>
Ne uronal</w>
NSAID s,</w>
M ental</w>
Inte gr
IGFBP- 3</w>
H2O 2-induced</w>
H -2
G (0
Exer cis
Elec troph
E ar
E Z
E GR
Diltiaz em</w>
DI M</w>
D G
Cl )</w>
Cd Cl2</w>
COX 2</w>
Bar r</w>
B S</w>
Ather osclerosis</w>
Ap c
Al a</w>
ABT- 7
A uro
A )-induced</w>
= .00
9. 6</w>
8. 8</w>
7 7%</w>
7 61</w>
6 9%</w>
5 4.
39 )</w>
15 -1
13 8</w>
12 9</w>
1 alpha</w>
1 17</w>
.000 1).</w>
-1 A</w>
- a-
(i.c.v .)</w>
(T G)</w>
(T C
(NQO 1)</w>
(MMP s)</w>
(I D
(B M
(AC E
(A 54
( normal</w>
y n</w>
y "</w>
with in-
whe reas,</w>
vi sion,</w>
van ad
vacuol es</w>
ur nal</w>
tric hlor
tri als
transi ent,</w>
th ing</w>
tetr ak
teg mental</w>
techniqu es,</w>
sw ol
suspec ted.</w>
sulf ated</w>
su n
specific ity.</w>
spec ulated</w>
sirtu in</w>
sim ply</w>
sim ple
si vity</w>
sh inone</w>
ser ocon
sar col
reten tion,</w>
r ,</w>
precip itation</w>
porph yr
pharmacokine tics.</w>
persist s</w>
par g
pa ins</w>
p tive</w>
p 70</w>
osi tis.</w>
osens ory</w>
osahexa enoic</w>
obstruc tion.</w>
o )
nic k-
ng/m l.</w>
neuron es</w>
neph ritis,</w>
n in
mucos a,</w>
morb id</w>
monitor ing,</w>
min us</w>
microangi opathy</w>
micro environment</w>
me perid
mas ter</w>
mac rom
m ectin</w>
m U/
li ved</w>
lev onorg
irrit ant</w>
invol ved,</w>
inter active</w>
in- stimulated</w>
ide -treated</w>
i NOS,</w>
hist ochemical</w>
hear t
he n</w>
haloth ane.</w>
h ard
graft- versus-
gly ox
gentamic in,</w>
galacto sidase</w>
g ing</w>
flavonoid s,</w>
exce ed</w>
ec k
e jac
diltiazem .</w>
diazin on</w>
diagnos ed.</w>
di allyl</w>
demyel ination</w>
de bil
dP/d t
cyt ochro
cycl es,</w>
correl ating</w>
col orimetric</w>
co- administered</w>
cing ulate</w>
ciga ret
cho ro
chlor zox
catalep togenic</w>
carcinogen s,</w>
cap t
ca ver
c- Myc
butadi ene</w>
beta ine</w>
b- caten
b ax
atic .</w>
an :</w>
aminonucleo side-induced</w>
age- dependent</w>
adrenocept or-
ad sor
Ze al
Wor ld</w>
VT E</w>
V PA.</w>
V ),</w>
U RO
S K</w>
S A),</w>
RA W
Q- T</w>
Org ano
NO S.</w>
NF AT</w>
N C</w>
Measure ment</w>
MMP -2,</w>
M c
Log istic</w>
Jap an</w>
In organic</w>
IL- 6.</w>
IC )</w>
HCF C-1
H elic
Ger man</w>
GF AP</w>
Fluo resc
ELIS A,</w>
Do es</w>
Con di
Can ad
CYP2C9* 3</w>
CYP2C9* 2</w>
COX -2-
CONCLUSIONS/ SIGNIFICANCE:</w>
C utaneous</w>
Brom ocript
Angiotens in-converting</w>
Ah R-mediated</w>
AL P</w>
AK T/
AG E</w>
A x
A A,</w>
A .
5-az acytidine</w>
4 35
3- day</w>
3 6)</w>
3 1-
17 alpha-
15 8</w>
14 3</w>
13 4</w>
12 99</w>
12 9
1, 8-
0. 8%</w>
0. 17</w>
-1 5
- D
- 5</w>
(p< 0.001).</w>
(TGF- beta
(P XR
(P )</w>
(LVE F)</w>
(LD L)</w>
(Cs A)</w>
(CYP1A 1)</w>
(B PA),</w>
(AD R)</w>
(A G
(3 5</w>
(10 00</w>
( five</w>
volunte ers,</w>
ve ins</w>
uxim ab</w>
urotheli um</w>
un common.</w>
ultr a-
tryp an</w>
trifluoro methyl
trans ver
trans plants</w>
tid al</w>
test )</w>
ten d</w>
tel omere</w>
synthe size</w>
st ages.</w>
smok ers,</w>
sleep ,</w>
sic kn
s ac
rul e</w>
ri de.</w>
retro vir
re ple
purpur a</w>
pum ps</w>
psychostimul ant</w>
protec tion,</w>
pith ed</w>
pheochromocyt oma</w>
phenyl) -2-
pancytop enia</w>
oz ym
osteoblast s.</w>
ol d.</w>
obac ter</w>
not ,</w>
nor thern</w>
non significant</w>
non diabetic</w>
nitrofurant oin</w>
ng/m L)</w>
neutrophil s,</w>
mut ants.</w>
multic entre</w>
mit ting</w>
microscop e</w>
micron utri
mg/ l</w>
met ol
meflo qu
materi als</w>
map s</w>
manifest ations.</w>
mE H</w>
lif es
levam isole</w>
letro zole</w>
intub ation.</w>
intr onic</w>
inter im</w>
intens ity,</w>
intell ect
ingest ing</w>
immunocyt ochemical</w>
illustr ated</w>
hypolip idemic</w>
hypercholesterol emic</w>
hyp oplasi
heter o
herbic ides</w>
hemorrh ages</w>
haz ard
genotyp ic</w>
g/ kg)</w>
g an
furosemi de,</w>
food s</w>
f exo
excis ed</w>
elev ation.</w>
dop amine.</w>
desi pr
dep ren
degrad ing</w>
dail y),</w>
d ine.</w>
cour ses.</w>
control s;</w>
consec u
co -treated</w>
childho od.</w>
che milumin
caus es.</w>
cataly sed</w>
catal ase.</w>
caspase- 2</w>
bronch ospas
bronch opulmonary</w>
be ating</w>
be agle</w>
asthmatic s</w>
asp inal</w>
applic ations.</w>
allodyn ia.</w>
air wa
aeros ol</w>
addic ts</w>
acin ar</w>
access ory</w>
abrog ate</w>
a ec
[ 35
Wi ley</w>
V PA,</w>
UGT1A 1,</w>
Trans forming</w>
Thyro id</w>
Thirty- two</w>
SER T</w>
S ymptomatic</w>
RS G</w>
RNA -
PD GF</w>
PA NC
P in
P 53</w>
O V-
Nrf 2.</w>
Moder ate</w>
Mn -induced</w>
Michael is-Menten</w>
Matri x</w>
MK K
MI F</w>
ME HP</w>
Li ght</w>
L- argin
Kaplan-Mei er</w>
JQ 1</w>
J ak
Inc rease</w>
In haled</w>
IT S</w>
Hg ).</w>
Gluc ose</w>
GW 966
F344/ N</w>
F c
F LD
EGF -induced</w>
D- amphetamine</w>
D 1.</w>
Ci me
Casp ase</w>
CM F</w>
C p</w>
C hem
Be sides,</w>
AL I</w>
AK T,</w>
A gr
A ED</w>
7. 5%</w>
34 1</w>
3. 9
26 8</w>
25 1</w>
24 ).</w>
200 1</w>
20 ),</w>
2 8)</w>
2 30</w>
199 7</w>
14 ),</w>
/- )</w>
-2 5</w>
- type</w>
) -1,</w>
(WK Y)</w>
(S N
(PPA R)</w>
(P N
(M PP
(IL- 8)</w>
(I SO
(H A
(3) H-
(2 3</w>
(1 7</w>
(1 5.
(1 2)</w>
( mean
( Th
( 6-OHD
wor sen</w>
vinblast ine,</w>
verte brate</w>
unc ertain</w>
un toward</w>
un predictable</w>
u ed</w>
u PAR</w>
trimeth aph
ti ters</w>
thalam us</w>
tel li
tachy kinin</w>
sy n</w>
strych nine</w>
strok es</w>
stres s
sti s</w>
spi ro
spens able</w>
silym arin</w>
short -</w>
second ,</w>
sar in</w>
s ure</w>
s r
s pre
riton a
ris ing</w>
resembl es</w>
redox -sensitive</w>
re modelling</w>
pimoz ide</w>
physi cally</w>
per son</w>
os yl</w>
os per
ore tic</w>
ologic ally.</w>
ol itis</w>
og lut
ocy stis</w>
o yl</w>
o b</w>
norepinephr ine.</w>
nanop arti
multiple x</w>
metr y.</w>
mat ous</w>
mark eted</w>
m M.</w>
los amide</w>
les sen
le aves</w>
lar v
l er</w>
kg(-1 ).
ion s.</w>
intraven ous
intoxic ation,</w>
inter play</w>
inoc ulated</w>
infiltr ate</w>
infer tility</w>
incontin ence</w>
il ian</w>
if en
i atrogenic</w>
hyperammon emia</w>
hydrochlor ide.</w>
homeost atic</w>
heterozygot e</w>
glauc oma.</w>
gastro protective</w>
g/ day</w>
fol i
fm k</w>
flunar izine</w>
flavonoid ,</w>
fib ers,</w>
f uc
ezetim i
expres sion;</w>
ex encephaly</w>
eth acrynic</w>
erythro cytes.</w>
endometri osis.</w>
edar avone</w>
e osin</w>
down regulate</w>
distribu tions</w>
detec tion.</w>
de toxic
capsaicin- sensitive</w>
cal ori
cal ce
c- IAP
bupivaca ine-induced</w>
bi vol
bi ased</w>
beta-end orphin</w>
attac ks,</w>
aort a.</w>
anxiet y-like</w>
al- like</w>
adv oc
ac up
a .
[ odds</w>
ZO L</w>
V enous</w>
V SMC
V L
V I</w>
TRPM 8</w>
T PA-induced</w>
Sequ ence</w>
S ox
S DF
RG Z</w>
Prophyl actic</w>
P P)</w>
Nim esul
Nephro tic</w>
NO 2</w>
NH 2-
NA FL
N-nitros ourea</w>
Mrp 2</w>
Me di
Maxim um</w>
Le u</w>
L-dop a-induced</w>
L u
L ei
KG F</w>
K T
IN )</w>
GTP ase</w>
GSTM 1,</w>
GSH .</w>
G- protein</w>
F entan
Electro cardi
ENT 1</w>
Cis plat
Ca P</w>
CS F.</w>
CS F,</w>
CS E</w>
CG RP
CB D</w>
C U
B MP</w>
Aro cl
Ab l</w>
AP -1,</w>
AMP K
AD AM
ACh E.</w>
A A-
9. 7</w>
6 17
4 A</w>
3- hour</w>
3, 2'-
2- adrenergic</w>
1: 1</w>
199 3</w>
1 1B
1 1.5</w>
0. 20</w>
0 ;</w>
-1 20</w>
(S F
(R XR
(P G)</w>
(M T)</w>
(M N
(HD AC)</w>
(G )-
(EGF )</w>
(E D)</w>
(AMP K)</w>
(A UC)</w>
(A ST)</w>
(3 3%)</w>
(1 ).</w>
( rh
yrid am
year -
wal king</w>
w k,</w>
w ine,</w>
viro logic</w>
vasoconstric tion.</w>
us cular</w>
ure ly</w>
tubocur arine</w>
tric uspid</w>
triamte rene</w>
til es</w>
third- generation</w>
th ys
t .i.
subun its,</w>
subtyp es,</w>
stopp ed,</w>
steroid -induced</w>
sodi um.</w>
sl ice</w>
sist er</w>
single- strand</w>
shun t</w>
she ar</w>
seve re.</w>
sarcom as</w>
sarcol em
rifampic in.</w>
relap ses</w>
refer ral</w>
receptor /
r y</w>
r .</w>
quin idine,</w>
questionnai res</w>
pro tr
post- operative</w>
polar ized</w>
pneumon ia.</w>
ple thys
perg ol
perc eived</w>
par tur
pancreati tis.</w>
p38 MAPK</w>
or )</w>
onit rile</w>
ol ic,</w>
ogen omic</w>
ob taining</w>
ob ia</w>
o in,</w>
non- invasive</w>
myome tri
monolay ers</w>
mmol/ kg</w>
mitte e</w>
mit otane</w>
mg/m (2))</w>
mercur y,</w>
mechan ically</w>
meas ures,</w>
mean ing
malform ations,</w>
kin es</w>
ketocon azole.</w>
k ill</w>
isoflur ane.</w>
ir ac
intest in
inter quartile</w>
initi ation.</w>
in osine</w>
ile um</w>
i lo
hypot on
hypokal emic</w>
hy ste
ho c</w>
heterolog ously</w>
her pes</w>
hallucin ations,</w>
haemod ynamics</w>
h MLH1</w>
grap es</w>
glycosyl ase</w>
gli a</w>
gen y</w>
fre e-
for ty-
flec ain
ext ends</w>
expres sed.</w>
experi ence.</w>
ep tin</w>
ep le
enox aparin</w>
encapsul ated</w>
elev ation,</w>
elev ating</w>
electrophore sis.</w>
electr onic</w>
el uting</w>
dose- depend
dis si
di valpro
d es.</w>
d .
cyclohex ane</w>
cyan ide</w>
col itis,</w>
cne mi
cl otting</w>
cisplatin- based</w>
chori ocarcinoma</w>
chlorthal idone</w>
cell- free</w>
cef otax
caus ality</w>
cataly zing</w>
br anch
bleomycin -induced</w>
biop sy-
benz amide</w>
basel ine)</w>
az one,</w>
atten tion.</w>
atten tion,</w>
atro pine.</w>
ati d</w>
ated :</w>
as )</w>
arter itis</w>
aro tene</w>
ar is</w>
ap ine.</w>
anti convulsive</w>
an emic</w>
aggres siveness</w>
adv ised</w>
addic tive</w>
ad .</w>
V ig
V D-
Ultras tructural</w>
Trans genic</w>
TC C</w>
T- 47
T O</w>
SSR Is</w>
SIRT 1,</w>
S o</w>
S k
S PAR
ROS- mediated</w>
RA L</w>
Parkinson ian</w>
P- 450
P arox
Oc cu
NH (2)-
Ket ocon
K ip
In s
IC (50
I mi
Hypo kal
HEK -293</w>
H CA
Ex tensive</w>
Enzym e</w>
Electro physiological</w>
E2 F
E K
Dip yridam
Differen ti
D MA</w>
Cholest atic</w>
CDK 4</w>
CC K</w>
C3 H/
C s.</w>
C in
C .
Brd U</w>
Bcl-X L</w>
Anti hypertensive</w>
Agr ic
Ag e</w>
ATP- sensitive</w>
AS ,</w>
AC 1</w>
9 2%</w>
8 A</w>
8 1%</w>
7 '-
27 ).</w>
2 (-/-)</w>
17 ),</w>
0.00 3).</w>
(V CAM
(MD A),</w>
(M O
(EP S)</w>
(BD NF)</w>
(A O
(3 ).</w>
(1 5%)</w>
(0. 3
( OD
zileut on</w>
y 's</w>
x 1</w>
w t)</w>
visu alized</w>
ver tical</w>
ure teral</w>
unc tional</w>
un identified</w>
tur meric</w>
transform ation,</w>
tho rough</w>
ta u
ta ,</w>
t y,</w>
struc tures,</w>
stress- activated</w>
strat um</w>
spac e.</w>
ser vic
sequenc ing,</w>
salme terol</w>
redox -
prednisol one.</w>
prac tition
pow der</w>
phot on</w>
phen acet
paracetam ol-induced</w>
p. p.m.</w>
p g</w>
p g/
p 450</w>
ox amine.</w>
os erti
or ally)</w>
open- field</w>
olip id</w>
octan oic</w>
observ ation,</w>
obser ve
o athet
ng/ kg</w>
nevir apine</w>
neuro physiological</w>
ne bul
mon ocro
micromol/ l</w>
methylenedi oxy
memb ers,</w>
marg in</w>
ma p</w>
lung s,</w>
lipo genesis</w>
ligand -induced</w>
k 1</w>
isot ope</w>
intrac i
inter n
intellect ual</w>
instil l
ini b-
ine a</w>
impro ved,</w>
ifosfam ide-induced</w>
hydroxyl ation,</w>
hour .</w>
highligh ting</w>
her b</w>
h CE
fre ely</w>
fir st,</w>
fibro sarcoma</w>
factor -2</w>
f )</w>
evo ke</w>
evalu ates</w>
estim ating</w>
epilep to
epigallocatech in</w>
ent ory</w>
electro des</w>
du plic
dose- effect</w>
dis cer
dip ine,</w>
dimin ution</w>
dil uted</w>
diethylstil best
dec ad
de granulation</w>
cyt arab
cysti tis,</w>
crystall ine</w>
cross- resistance</w>
copper .</w>
comput ational</w>
com a.</w>
col lateral</w>
clear ances</w>
character izing</w>
calci um.</w>
caffe ic</w>
br an
bi val
b 2</w>
at ing,</w>
apl antar</w>
antin uclear</w>
anti histamine</w>
anti androgen</w>
anthra quinone</w>
ank le</w>
all .</w>
W eight</w>
W IN</w>
W BC</w>
Twenty- seven</w>
T ur
T B</w>
T A)</w>
SK F</w>
Rhabdomy olysis</w>
RESULT S</w>
R u
Pil ocar
Paraqu at</w>
Panc re
PA NS
P ap
Occu pati
OVCAR- 3</w>
O t
N 2
Mercur y</w>
MP M</w>
MMA (III)</w>
MM .</w>
M CA
Long- Evans</w>
L- Dop
K- ATPase</w>
J un</w>
IF )</w>
I 3C</w>
H4 60</w>
H 1-
Further more</w>
F el
EC ,</w>
DP H</w>
D AC</w>
Con stitu
Circul ating</w>
Cipro floxacin</w>
Care ful</w>
CD .</w>
CA A</w>
Br -
Ba k</w>
Anxi ety</w>
Ang II</w>
All- trans</w>
All el
AL K-
AG S</w>
A -</w>
6 7,</w>
5- LO</w>
5 a</w>
4 4.
3 %;</w>
28- day</w>
25 ),</w>
20 3</w>
1. 1-
0. 16</w>
)- based</w>
(T d
(T S)</w>
(T M
(PI3K )/
(P H
(K (i)</w>
(F L
( t-
( in
( encoding</w>
( about</w>
y le</w>
vit y,</w>
ven s-
vens- Johnson</w>
veget abl
val idity</w>
uro kinase</w>
un il
ultras truc
typhim urium</w>
transfect ants</w>
thiotep a</w>
thal asse
ter s.</w>
t ung
spl anchnic</w>
sp ong
si ve.</w>
sh ut
sensi tive,</w>
scienti fic</w>
sampl ed</w>
ro mo
ro le,</w>
ribonucle ic</w>
retriev al</w>
pyro phosphate</w>
pro to
prepar ation.</w>
pot ency.</w>
plate au</w>
phenoxy benz
ph a
persist ently</w>
param e
omyel itis</w>
o floxacin</w>
not e
neuropath ological</w>
nes tic</w>
myotub es</w>
my o-
multi factorial</w>
monocyte -derived</w>
molecul e.</w>
midazol am,</w>
microtubul e-associated</w>
me ter</w>
manifest ing</w>
mac aqu
lit er</w>
li ves</w>
ist s</w>
inhe rent</w>
infu sions.</w>
infiltr ates</w>
inf ra
ine- dependent</w>
in kg
in activate</w>
im port</w>
ill ic</w>
il -
ifosfam ide.</w>
ifith rin-
icl op
hyperammon emic</w>
hydroxyl ase,</w>
hydrox yp
hall marks</w>
hO GG1</w>
granulocyte- macrophage</w>
ful vestr
fic ation.</w>
fi st
fel t</w>
f und
f light</w>
f ecal</w>
exercis e,</w>
evid ent.</w>
epri dil</w>
en se</w>
drug s:</w>
dp /d
dor sol
discus sion</w>
diphenyl hydantoin</w>
diox in-
digit oxin</w>
des og
depres sion
deoxy guanosine</w>
decreas e.</w>
debil it
de aminase</w>
d in</w>
clu sters</w>
clavul anic</w>
che mor
ce ti
carboxyl ate</w>
cal f</w>
bur n</w>
bu ph
bro mod
behaviour .</w>
bas ophil
atri a</w>
aspar ag
as e).</w>
arabin o
ar m,</w>
aqu atic</w>
antipsycho tics,</w>
anti- epileptic</w>
anti thyroid</w>
ane up
anaphyl actic</w>
analgesic s.</w>
an ia</w>
alpha 2
al cit
adv is
accumul ating</w>
V CR</w>
V ).</w>
There after,</w>
T iclop
T em
Sym ptom</w>
Ster oid</w>
Ste vens-Johnson</w>
St able</w>
SOD ),</w>
S e-
PPAR gamma,</w>
PMA -induced</w>
PC ,</w>
Over -
Organ ization</w>
NAD (+)</w>
N utri
My D
Metallo thione
Met abol
Matri gel</w>
MPP (+
MMP -13</w>
MD B
MC L</w>
MA O</w>
M ass
L XR</w>
L N</w>
JN K/
Haplotyp e</w>
Ha e
HT .</w>
HM OX
HET E</w>
HC B</w>
H V
H G</w>
GV HD</w>
G O</w>
F ocal</w>
F e-
ER .</w>
EA E</w>
Cum ulative</w>
Con genital</w>
Combin ing</w>
Cef triax
Cardi omy
CDK 4/
C ertain</w>
C 1)</w>
B I</w>
B 2,</w>
Arsen ite</w>
Ang io
Agric ultural</w>
Ab s
AT 1R</w>
AC ,</w>
A typical</w>
A dip
A F-
80 1</w>
5 %.</w>
46 6
4- nitro
4 3)</w>
4 2-
38 9</w>
3. 8
3 R</w>
26 77
200 -
11 beta-
10(-1 0
1- week</w>
1 1/
0. 6%</w>
0. 11</w>
(TNF )</w>
(TGF )-
(NSCL C).</w>
(MCP -1)</w>
(E SR
(D B
(C ys
(APL ).</w>
(2) D
(2) ).</w>
(2 1</w>
work ers,</w>
w orm
volunte er</w>
un methylated</w>
ul inum</w>
ubiquit in
type- 2</w>
tra vel
three- dimensional</w>
thiazolidine dione</w>
ther mo
suppres sed.</w>
strain ,</w>
staphylococc al</w>
sevent h</w>
senesc ence.</w>
restr ained</w>
replic ation.</w>
replac ement.</w>
renew al</w>
ren ovascular</w>
remodel ing,</w>
regimen s,</w>
re a</w>
radio activity</w>
pu st
proxim ity</w>
pro ficient</w>
preced es</w>
poin ting</w>
phenobarbit al.</w>
perfluoro oct
penetr ation</w>
pe di
paraff in-
p,p'- DDE</w>
ox prenolol</w>
orig in,</w>
or der
or an
optim ization</w>
oper able</w>
op ril,</w>
observ ations.</w>
ob i
nutri tion</w>
norm oxic</w>
nephro n</w>
n -3</w>
mumol/ L</w>
mon ocyt
modi um</w>
micro M
mic e)</w>
methamidoph os</w>
maz epam</w>
matur ation.</w>
mat osis</w>
mari ju
m V</w>
lymph aden
lo th
leuk ocytes.</w>
le sion,</w>
lac tin</w>
ket amine.</w>
it e,</w>
inten tional</w>
insul ts</w>
innerv ation</w>
infu sion
in significant</w>
ic als,</w>
he me
gastro cnemi
flunitraz epam</w>
fibr e</w>
ff ic</w>
fer ro
favor ably</w>
extr a</w>
es un
es --
erlot inib</w>
end onuclease</w>
ect op
dys lipide
dis c</w>
diaz oxide</w>
di acetate</w>
deficit /
deficit/ hyperactivity</w>
dap tomycin</w>
d l-
cor por
con gener
cohor t,</w>
cocaine- seeking</w>
cis ap
chemor adi
celecoxi b,</w>
cas es),</w>
cardio respiratory</w>
carcinogen icity.</w>
cDNA- expressed</w>
benzo yl
art esun
applic ators</w>
anticoagul ation.</w>
angin a,</w>
amygdal a,</w>
alf a-
album in.</w>
act in,</w>
absc ess</w>
abrog ation</w>
Wee k</w>
U 87</w>
S ed
S S)</w>
R Y
R 1)</w>
Pro lactin</w>
Pheny leph
Ou ab
Occupati onal</w>
OP G</w>
O G</w>
Na use
NAFL D</w>
N-acetyl- beta-D-
N-[4- (5-nitro-2-furyl)-2-thiazol
My ocl
MT D</w>
M otor</w>
M ain
Lev odop
LTB 4</w>
In testinal</w>
Im pair
Huh 7</w>
HBV- DNA</w>
H E</w>
FLT 3</w>
FGF 23</w>
Epi lep
ER -negative</w>
EPH X1</w>
DJ -1</w>
D LC
D 2-
Con tri
Col chic
Co- treatment</w>
Clo zap
Chol esterol</w>
Cell s.</w>
CH E</w>
Be Wo</w>
Bar ret
As(2)O(3 )-induced</w>
As sa
Amphet amine</w>
Alter ation</w>
AH R
9. 9</w>
9 3%</w>
55, 2
5-amin osalicylic</w>
5- fluoro
4-(methyl nitrosamino)-1-(3-pyridyl)-1-butan
3-hydroxy-3-methyl glutaryl</w>
200 4</w>
200 3</w>
1- 4</w>
1 C1</w>
03329 91</w>
0.00 1;</w>
-10 )</w>
(R T
(I g
(I R)</w>
(G -
(ET -1)</w>
(A c
(A ED
(3 +
( anti-
( aged</w>
( SIAD
( CYP2E
vol emic</w>
void ing</w>
viv o
vessel s,</w>
veloci ties</w>
veget ables</w>
val id</w>
transi t</w>
trabec ular</w>
tis ed</w>
ter s,</w>
ten ofovir</w>
swol len</w>
struct ured</w>
stop -
steat osis,</w>
st asis</w>
slic es.</w>
side )</w>
si RNAs</w>
scaven ger
sarco id
ro bu
resect able</w>
recurren ces</w>
radi ation,</w>
prost anoid</w>
prochlor perazine</w>
pri ap
preser ving</w>
praz osin,</w>
phot er
period s,</w>
per hexiline</w>
path ologies</w>
oxyl in</w>
oxim one</w>
ox azole</w>
over weight</w>
opre gn
op ene</w>
ol- 3-
nocicept ors</w>
nitroglycer in.</w>
nick- end</w>
new -onset</w>
myocardi tis.</w>
myo fibrillar</w>
my ric
mg/kg/ day.</w>
metoclopr amide.</w>
methamphet amine.</w>
methamphet amine-
meth ohex
metalloproteinase- 2</w>
medi ators,</w>
lipo protein
lamivud ine,</w>
lam b
k a</w>
isoniaz id,</w>
intratrache al</w>
intermedi ate-
interest .</w>
injur ious</w>
initi ator</w>
infrequ ently</w>
indi rub
immun opositive</w>
imipr amine,</w>
ide :</w>
ide /
hydrochlor ic</w>
hospital ization.</w>
hi r
hemoglobin ,</w>
heigh tened</w>
he re,</w>
glycosyl ated</w>
glomeruloscler osis.</w>
gemcitab ine,</w>
geldan amycin</w>
gall stone</w>
gal ect
g ap
foc uses</w>
fibrin olysis</w>
ext ending</w>
evolu tion
ether s</w>
eth el
erg ic,</w>
epilep sy
epi genetically</w>
ep tive</w>
ep in</w>
electroly tes</w>
ecto dermal</w>
ear al
e asy</w>
disrup tive</w>
dimin ishing</w>
diameter ,</w>
des or
deoxy nivalenol</w>
dens ity.</w>
dend rit
de position.</w>
days /
cyto protection</w>
cros sed</w>
concer n.</w>
con sequently,</w>
comple ting</w>
comm encing</w>
combin ations.</w>
ciprofloxac in,</w>
cil iary</w>
chromatography- mass</w>
ch y
centr e</w>
catechol aminergic</w>
caspase- independent</w>
carbid opa</w>
c ured</w>
c epti
bul bar</w>
br ush</w>
bis phenol-A</w>
be ha
b ret
b ).</w>
az o
ascer tained</w>
ar ic</w>
ap noea</w>
antin ocicep
antidepress ant
amphi regulin</w>
amlodip ine,</w>
altern ating</w>
alge sia</w>
al c
ain- of-function</w>
adhe ren
adduc ts,</w>
acr idine</w>
Twenty- nine</w>
T 2D</w>
T 2-
Sign aling</w>
SB2035 80,</w>
RP 1</w>
R IN
Quercet in,</w>
Pre incubation</w>
Period icals,</w>
PTE N-
P- type</w>
P g
P at
N DR
N DE
Magne sium</w>
M Z
Luc iferase</w>
LD L,</w>
K (ATP)</w>
HR H</w>
H2- receptor</w>
H ar
H U</w>
F amil
F SH</w>
E ph
D om
D MP
Cor tico
Control s</w>
Ch est</w>
CYP2A 13</w>
C ig
C Y</w>
Bcr -
B R</w>
Am photer
AT O.</w>
AM L.</w>
ADR -induced</w>
A O</w>
A 10</w>
: 00</w>
9 41</w>
9 2
8-OHd G</w>
6, 7-
6 5)</w>
6 +/-
4 1,</w>
30 ).</w>
3,2'- dimethyl-4-
3 3,</w>
3 3)</w>
3 00,</w>
293 T</w>
1B ,</w>
17 ,
16 7</w>
16 3</w>
15- deoxy-
15 /
10 5
1 19
0. 14</w>
-1 ;</w>
- 0.6
(ICAM -1)</w>
(HepG 2)</w>
(H sp
(H T
(G L
(B [a]
(B E
(4 /
(3, 4-
(0.0 1</w>
(0. 5
( sh
( gamma-
vi sion.</w>
two- fold</w>
tw o,</w>
transl ation.</w>
transduc tion.</w>
trans mitted</w>
thiop urine</w>
th ous
ter fen
tas k,</w>
tamsul osin</w>
tac r
synap t
swell ing,</w>
susp en
succinylchol ine.</w>
su gar</w>
stric tly</w>
simult aneously.</w>
seizure -induced</w>
scopol amine.</w>
rs 7
rota rod</w>
respon ds</w>
residu es.</w>
ren ders</w>
rele ases</w>
relap sing</w>
reac tion
quinol one</w>
quen ching</w>
prote omics</w>
progn osis,</w>
pro of</w>
poison ed</w>
pl en
pinacidi l</w>
phthal ates</w>
person -
oselec tivity</w>
on ly
olev ulinic</w>
neph ron
naphthal ene</w>
myel in
my oglobin
min g
mil d.</w>
micro RNAs</w>
methy serg
measure ments,</w>
max )</w>
macrol ide</w>
low er,</w>
load .</w>
lif est
l one</w>
keratin ocytes,</w>
k y</w>
is lands</w>
intracaver nous</w>
inclu sions</w>
ic in-induced</w>
hypercalc emia.</w>
horiz ontal</w>
high er.</w>
health y,</w>
haloth ane,</w>
guinea- pig</w>
guanfac ine</w>
graft-versus- host</w>
gp 91
go- go-
glyc opyr
gener 's</w>
fluo rene</w>
fixed- dose</w>
fi ve
femal es)</w>
fe ver.</w>
explo ited</w>
expected ly</w>
eti ologies</w>
epilep togenesis</w>
epider mis</w>
entr y.</w>
el s</w>
e- mediated</w>
doxorubic in-treated</w>
double-bl ind
don or,</w>
diure tics.</w>
dichlorodi phenyl
di urnal</w>
di morph
di meth
detectab le.</w>
delta ,</w>
del li
coun ted</w>
contex t,</w>
confir med.</w>
co transporter</w>
clu es</w>
chemopreven tion.</w>
chemo resistant</w>
ch ain.</w>
c illin
c at</w>
c 1</w>
bi ochemical,</w>
beta- blockade</w>
bel ong</w>
bcl -2,</w>
bcl -
b isoprolol</w>
appropri ately</w>
amycin ,</w>
am en
allevi ation</w>
agranul ocytosis</w>
affin ity,</w>
ad s</w>
ad rib
aconit ine</w>
ace a
a kinesia</w>
[ Severe</w>
Wil le
We gener's</w>
V al-
TO F</w>
Sus cepti
St age</w>
Smad 3</w>
S pir
S mac
Repor ts</w>
R- 3</w>
Path ological</w>
PI 3-
PB DE</w>
P O</w>
Ou t</w>
Or th
NH(2)- terminal</w>
Mic ros
Mechan istic</w>
ME L</w>
MD L</w>
L oc
L ac
L abet
L F</w>
K I
K B</w>
IRS -1</w>
IP 1</w>
HepG 2,</w>
HI F</w>
H h</w>
G el
G ef
G ab
Flav on
Fat ty</w>
Dic lofenac</w>
Dec reas
DU -145</w>
D T-
CNS .</w>
CD 14</w>
C alu
B le
Ane mia</w>
Acet yl
AM D</w>
AL A-
ADP-rib ose</w>
AD H</w>
A tor
A AP</w>
> /=
8 9%</w>
7,8- dihydro
7 4%</w>
50 .</w>
5 4-year-old</w>
5 2.
4- 6</w>
30 .</w>
3- 5</w>
3- 3
3, 3',
3 alpha-
2A 6</w>
28 ).</w>
25 3</w>
20 4
2 +,</w>
17 7</w>
16 /
14 8</w>
13 1</w>
1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine</w>
1- deficient</w>
1 ].</w>
0.00 5),</w>
0.0 4)</w>
+/ -2</w>
(TBAR S)</w>
(ST Z)-induced</w>
(P r
(O S)</w>
(N H
(N E)</w>
(ERK1/ 2)</w>
(C AR
(APA P)</w>
(2 5
(2 /
(1 9%)</w>
well ing</w>
week s),</w>
w oun
van adi
val vul
ureth ane-
ur ap
tri iodothyronine</w>
tradi tionally</w>
thir ty-
thiorid azine</w>
te tan
t s:</w>
steroid -
stere ois
st ones.</w>
specific ity,</w>
sept um</w>
s.c. ).</w>
s.c .,</w>
s pot</w>
re mot
re act
radioimmuno assay.</w>
quad r
propyl ene</w>
pro coagulant</w>
post prandial</w>
perc nt
pe dig
p t</w>
oxygen ases</w>
oxid ant
on ate.</w>
om el
och ratoxin</w>
occur s.</w>
nause a/
nalox one-
myoclon us.</w>
month s),</w>
mon ophasic</w>
modul ation.</w>
mode oxy
metabol izes</w>
mess age</w>
mes olimbic</w>
mer its</w>
manufact ure
mand atory</w>
list ed</w>
leuk aemia.</w>
kg ;</w>
ket amine,</w>
is obut
instrum ented</w>
inhibitor -induced</w>
in dependent,</w>
in ase-
impai red.</w>
i atric</w>
hypothalamic- pituitary-
hypercalci uria</w>
hydroneph rosis</w>
histor y.</w>
hel d</w>
function ing.</w>
fru its</w>
fram e
form ulated</w>
fav our</w>
extract .</w>
event ual</w>
ess enti
es sively</w>
erg ot</w>
endo tracheal</w>
en olone</w>
ell agic</w>
effect s:</w>
dro p
dizocil pine</w>
dimen sions</w>
dimen sion</w>
densi ties</w>
decreas e,</w>
death s.</w>
corticosteroid s,</w>
cor d,</w>
controversi al</w>
consum ing</w>
confoun der
coincid ent</w>
coca ine's</w>
co vering</w>
co operative</w>
cir cular</w>
cathep s
cann ul
c rest</w>
c ast
ba sis,</w>
ba sil
az ine-induced</w>
attac hed</w>
ate tra
ar )</w>
amide )</w>
am nestic</w>
alkal in
al motriptan</w>
ag ing.</w>
ab used</w>
ab aca
a -</w>
_ percnt
Youn g</w>
X L
X /
Wnt/ b-catenin</w>
V LDL</w>
V GB</w>
Th r</w>
T- cells</w>
Statis tically</w>
SMMC-77 21</w>
S ;</w>
Rho -
Remark ably,</w>
RASSF 1A</w>
Q -induced</w>
Par aox
Par ad
P2Y 12</w>
P S-
Out comes</w>
OR =
ONO O
NH2- terminal</w>
MD A,</w>
MCF- 7/
L- positive</w>
L 3</w>
Inflam mation</w>
In activation</w>
H ipp
H GF
GSTT 1,</w>
G LP
FK BP
F 3</w>
ERK .</w>
E M
Det ailed</w>
DH FR</w>
Cu (2+)</w>
Cox -2</w>
Chloro quine</w>
Cat ech
CYP1A 2.</w>
CD 44</w>
C V</w>
B s</w>
B ron
B el
B Q</w>
Asp -
Am B</w>
Ac qu
Ac -
AR CH</w>
AP ),</w>
AF 1</w>
ABCC 2</w>
8 7%</w>
6 6.
4 9%</w>
34 2</w>
20 /
2- ,</w>
14 9</w>
12-O-tetradecanoyl phorbol-13-acetate</w>
12 4</w>
1 19</w>
1 %;</w>
0.000 1</w>
0.00 4).</w>
0.00 1);</w>
0. 3%</w>
)- related</w>
(L C
(HC V)</w>
(GF R)</w>
(D EX
(4 8</w>
( increased</w>
( four</w>
vacu ous</w>
v ice</w>
under score</w>
un wanted</w>
tubul es,</w>
tricho thec
transfu sions</w>
trans epithelial</w>
titan ium</w>
tion- to-treat</w>
synap ses</w>
sulf asalaz
sugg estion</w>
su me</w>
stress- mediated</w>
stimul us.</w>
stil ben
so- called</w>
slow- release</w>
she d
scopol amine,</w>
sco re
ro ots</w>
refract orin
pup il</w>
punc t
proc ou
pro meth
pres ently</w>
prednis one.</w>
pre mat
plasma phere
pilocarp ine-treated</w>
phenylbut azone</w>
perme ability.</w>
patch- clamp</w>
paraffin- embedded</w>
p an</w>
oxidiz ing</w>
oxid es</w>
over coming</w>
outcom es,</w>
ou ts</w>
os tin</w>
ors '</w>
or poreal</w>
opioid s.</w>
omycin .</w>
omep razole,</w>
omegal y,</w>
olmes artan</w>
ol dop
o ide
nucle i,</w>
myome trial</w>
myelo proliferative</w>
my ositis</w>
mul tin
molecular- weight</w>
moder ate,</w>
mitochondria- dependent</w>
mil i
micro m)</w>
mic arb
metaboliz er</w>
me tric
mammal s</w>
mammal s.</w>
m L)</w>
lum in
leg e</w>
le aving</w>
latano prost</w>
kallikre in</w>
interven tions.</w>
insul t.</w>
immunohist ochemically</w>
ifosfam ide,</w>
i al,</w>
hypere mic</w>
hemodynam ics,</w>
gamma ),</w>
g/d L</w>
g ains</w>
flu vastatin</w>
ff -
fer ring</w>
fen oldop
fat al
farnes yl</w>
farnes oid</w>
expres sions,</w>
euthan ized</w>
er ad
erad ication</w>
epsil on-
entec avir</w>
enanti omer
en ing,</w>
en -induced</w>
ed arone</w>
e h
dorsol ateral</w>
di lution</w>
detail s</w>
de gu
dail y).</w>
cytomegal ovirus</w>
cyclo- oxygenase</w>
curren ts.</w>
cresc entic</w>
conflu ent</w>
conduc t</w>
comparison .</w>
colum n</w>
cogn ate</w>
categ ory</w>
cat as
cas es).</w>
carb aryl</w>
car bin
c lip
bi lob
aur a</w>
att ending</w>
atri um</w>
at e;</w>
ast ine</w>
ase- 2</w>
arthralg ia</w>
ant ec
anaphyl axis</w>
analyz ed,</w>
anaesthe tised</w>
an olic</w>
alpha- 1</w>
al fentan
ag ar</w>
adv ance</w>
aden omas.</w>
acrole in,</w>
Zn O</w>
Z ).</w>
V 1</w>
Tum ors</w>
TNF alpha-induced</w>
T LP
T J</w>
SU MO
SLC 6
SE ARCH</w>
S D,</w>
R ib
Praz osin</w>
P s
Oc t
O GG1</w>
Nitro glycer
NS ),</w>
NCT 00
N- de
Methad one</w>
MS ).</w>
MMP- 3</w>
Li po
L ate</w>
K+- ATPase</w>
K Cl</w>
Im proved</w>
Im medi
IL- 6
HDL- cholesterol</w>
GT )</w>
ER K-
E- selectin</w>
E RE
Develop mental</w>
DPY D</w>
D ual</w>
Cot reatment</w>
Catal epsy</w>
Candid a</w>
CYP3A 4
CYP2E 1.</w>
CR ,</w>
CP ,</w>
C elec
C U</w>
B alb
B G-1</w>
B AG
Apo E</w>
Amphoter icin</w>
Ac id</w>
AT -
? ].</w>
99mT c-
8 2/
8 -1
5 5-
40 %,</w>
3A ,</w>
23 39
199 5</w>
18 ),</w>
12- month</w>
11. 2</w>
1 a,</w>
1 12
0. 13</w>
/ T
-2, 4-
-2'-deoxy guanosine</w>
-2 8</w>
- S-
(m t
(T G
(S RE
(S D
(P 450)</w>
(G SH-
(F K
(D -
(B cl
(A ML
(9 5%
(4 0
(2. 0</w>
(1 :
(1 8.
(1 -10</w>
(0. 1,</w>
( u
ziprasid one</w>
z yme
ve ter
urk it
un reported</w>
un bound</w>
un acceptable</w>
tro meth
trimethoprim-sulfamethox azole</w>
tri hydroxystil
transcrip tion
trans verse</w>
trans activation.</w>
tran examic</w>
tiv ity,</w>
ti t
thiazolidinedi ones</w>
th emia</w>
tetram ethyl
t ler
t ently</w>
suppres sion,</w>
subtyp e.</w>
spi k
sp in</w>
sp an</w>
siRNA -mediated</w>
si ve
shed ding</w>
sensitiz ation,</w>
satis factor
rhabdomy olysis.</w>
resid ential</w>
resid ent</w>
regul ations</w>
re tain</w>
puer arin</w>
prop yl)
probenec id</w>
pro ti
pro -</w>
prepar ations,</w>
pre medicated</w>
posi tional</w>
plethys mograph
plant ar</w>
piper azine</w>
pic t
phenomen on,</w>
pharmaceu tic
oxal ate</w>
overload .</w>
os keletal</w>
origin ating</w>
om er.</w>
od ol
och anin</w>
obstac le</w>
obsc ure.</w>
note worthy</w>
non- treated</w>
non human</w>
nitros oure
nicot ine-
nicot in
nephro sis,</w>
neoin timal</w>
nas opharyngeal</w>
mmHg ;</w>
mesotheli oma.</w>
me glum
lox acillin</w>
long- chain</w>
li p</w>
levodop a-
l av
k (cat
j um
it em</w>
intratum oral</w>
interview ed</w>
integr ity.</w>
insec t</w>
injur ies.</w>
inhibit ed,</w>
indol yl
indo or</w>
in- containing</w>
in stability.</w>
in oids</w>
imipr amine.</w>
ic al,</w>
hypokal emia,</w>
hydroxyl ation.</w>
hormon e.</w>
glutam ate,</w>
ginsen g</w>
fal se</w>
ex -
ethin ylestradiol</w>
episod es,</w>
enhanc er
empt ying</w>
empir ical</w>
electro chemical</w>
el .</w>
e ating</w>
dobut amine-induced</w>
diver gent</w>
dis par
di lu
deoxychol ate</w>
d m
d amine</w>
cytochro me-
cult ure
creatin ine.</w>
conven ient</w>
contrac tility.</w>
complet ely.</w>
co vered</w>
clomi pr
cl ind
circum flex</w>
circu it</w>
cinnam ic</w>
cervi x</w>
cell s].</w>
but yric</w>
bu ter
bis(2- chloroethyl)-1-
biomark ers.</w>
beg in</w>
b abo
ative /
ation s;</w>
as sign
arsenic -
ap op
ancestr y</w>
am rinone</w>
alpha 7</w>
allel e-specific</w>
aggrav ates</w>
ag al
adhe sive</w>
Zn -SOD</w>
Zeal and</w>
Z uc
Wille brand</w>
Wh it
W S</w>
Valpro ate</w>
V P)</w>
V E</w>
U87 MG</w>
U2O S</w>
Tou ret
Toler ance</w>
Th 17</w>
T TF
Sequ encing</w>
STAT 5</w>
SO UR
SH RS
SE M)</w>
SD S-
S AL</w>
Rifamp icin</w>
RE T</w>
R S)</w>
Pneum ocystis</w>
PI3K/ Akt/
P oin
P R)</w>
Nic kel</w>
Ne ther
NAS H</w>
N OD
MRP 1,</w>
MP H</w>
LOX -1</w>
L EC
K RAS</w>
K C</w>
ICAM -1,</w>
Hydro x
Hepat otoxicity</w>
Helic obacter</w>
H4 II
H P)</w>
Gastro intestinal</w>
GST A2</w>
G y</w>
G am
G 3
F F
ER s</w>
EGF ,</w>
E qu
DR 4</w>
DE VD-
DD T,</w>
Cush ing's</w>
Cros s-
C57B l/
C oc
C 1,</w>
BC R-
B ak
Aten olol</w>
Associ ated</w>
As cor
AN IT
AMP )</w>
AL L.</w>
AC F</w>
A AA</w>
70 .</w>
6- thi
50 %)</w>
5-aza- CdR</w>
4 5-
4 1.
30 ),</w>
25 8</w>
19 .</w>
18 27
13- cis-
12- 2</w>
100 ,000</w>
10(- 3)</w>
10 %,</w>
1- expressing</w>
0. 25,</w>
- T
) %</w>
(TNF)- alpha</w>
(T -
(S B
(RA ).</w>
(PON 1)</w>
(IC 50
(H IV
(GP x)</w>
(D HE
(C E
(6 0
(3 2</w>
(2 6</w>
( t</w>
( such</w>
( maximum</w>
( apo
x er
wat er)</w>
vinc lozol
ventil ation,</w>
valu e,</w>
trichloro ethane</w>
transfer ases.</w>
tra ffic</w>
toxic .</w>
to remif
ting -
tel e
t ari
sup posed</w>
spermat ogenesis</w>
set ting,</w>
rit er
ri zine</w>
retard ants</w>
resveratrol -treated</w>
restrain t</w>
rat e)</w>
radi ologic</w>
pul p</w>
proto- oncogene</w>
propo s</w>
pro- survival</w>
pre requisite</w>
por tin</w>
platelet s.</w>
placent a.</w>
phenylpropan olamine</w>
phenylpropan ol
phenyl )</w>
phenotyp ing</w>
pantop razole</w>
pallid us</w>
ous -
oper ation,</w>
no sis</w>
neuropath ies</w>
neuro -
neon ates.</w>
myocardi um,</w>
mu star
mu -
mon onit
mmol/ L)</w>
micromol/ L,</w>
microarra y.</w>
micro vessel</w>
m s)</w>
lithium- pilocarpine</w>
limb s.</w>
li t</w>
lepro sy</w>
lad der</w>
l ing.</w>
intraven ously,</w>
intensi fied</w>
injec table</w>
initi ation,</w>
ine ar</w>
industr y</w>
individu alized</w>
indina vir
incorpor ating</w>
in tim
impot ence</w>
impl ants</w>
immedi ate-
if ens
hyperther mia,</w>
hyperlipide mic</w>
hyp oper
hydroxy toluene</w>
hom ozygosity</w>
hist ology.</w>
hex y
hemo static</w>
hard ly</w>
h elic
go-go- related</w>
glucocorticoid s.</w>
gene- environment</w>
gar lic</w>
gancic lovir</w>
g ic</w>
g aug
g ain-of-function</w>
floxac in-induced</w>
fig ures</w>
ex ogenously</w>
eth idium</w>
est ed</w>
ent a
endos ulf
embry onal</w>
eigh t-
diure tics,</w>
diox ins</w>
destruc tive</w>
desi red</w>
dermati tis,</w>
deli berate</w>
defin ition</w>
de tail</w>
d ust</w>
cytok ine,</w>
counterpar ts.</w>
control ).</w>
contra indicated</w>
compon ent.</w>
comp rise</w>
col ocalized</w>
co- exposure</w>
clu sion</w>
cimetid ine.</w>
chromatograph y/
chrom atid</w>
chor ionic</w>
children :</w>
ce ph
caspase- 1</w>
cardiomy ocytes,</w>
c ach
ben ser
avi ren
auth ors'</w>
attac k.</w>
assess ment,</w>
artic le,</w>
aro usal</w>
ari s.</w>
arg atroban</w>
ar n
apyr idine</w>
angu in
ana emia.</w>
aminog uanidine</w>
adriamycin ,</w>
adenocarcin omas.</w>
acid ),</w>
acetylchol inester
abstin ence.</w>
a w</w>
W at
V in
V en
Tri als</w>
Targ eted</w>
TH E</w>
Sur g
SO 4</w>
SER CA
S ph
Ribavir in</w>
Re view</w>
RESULT :</w>
RAW 264.7</w>
R ates</w>
PX R-
PX R,</w>
PGF (2
PB C</w>
NT R</w>
NE T</w>
N K-
Multic enter</w>
Mechanis tically,</w>
MCP -1,</w>
M an</w>
M am
M ad
Lo vastatin</w>
LY29400 2,</w>
LT D
LRR K2</w>
L s</w>
L et
L ast
Ki- ras</w>
K im
Impair ment</w>
Im pression</w>
IFN- y</w>
Hyper tensive</w>
Hg (2+)</w>
H I</w>
Gl y-
GP X
G(0 )/
G o
G DF
Fibro blast</w>
F IC
F ACS</w>
Ep ith
Electroph oretic</w>
Effec tive</w>
ER- alpha</w>
EGF R/
E st
E astern</w>
Docetax el</w>
DOX .</w>
D IL
Cu (II)</w>
Co PP</w>
Child ren's</w>
Cd Cl(2)</w>
Car ri
CXCL 8</w>
CXCL 12</w>
CD D
B K
B F</w>
B ER</w>
Azathi oprine</w>
Ar g/
Anti tumor</w>
Anti convulsant</w>
Anti arrhythmic</w>
ATP ases</w>
AQP 2</w>
ANOV A</w>
A verage</w>
A v
A U
A (4)</w>
9 4%</w>
6 h</w>
5 6.
4 7.
4 5-year-old</w>
39 3</w>
38 9
3 40</w>
3 00-
27- hydroxycholesterol</w>
2. 5-fold</w>
2 6)</w>
13 9
-1 c</w>
+ .</w>
)- -
(control ),</w>
(IFN )-
(ER alpha)</w>
(4 '-
( high</w>
( a-
y lium</w>
xim e</w>
wild type</w>
whole- genome</w>
who ,</w>
wa ke</w>
vul gar
vascul itis,</w>
v .</w>
uch en
transcriptom ic</w>
trac er</w>
time- dependently</w>
thou gh,</w>
th rin</w>
te 's</w>
tab un</w>
synchron ized</w>
sumatript an.</w>
spi kes</w>
sorafen ib
solub ility</w>
sino atrial</w>
si vel
sex -matched</w>
selec tive,</w>
screen ing.</w>
rh in
review ,</w>
reser p
remo ving</w>
rem n
re ated</w>
radiolig and</w>
r one</w>
pur inergic</w>
pseud otumor</w>
pl ified</w>
pim ec
pic eatannol</w>
phenter mine</w>
per mitted</w>
pel lets</w>
par alysis.</w>
p4 4/
p4 2/
p eptic</w>
over growth</w>
ot et
os etron</w>
os -
or ies</w>
one ].</w>
ol ).</w>
ocyte -specific</w>
oc hi
observ ation.</w>
o king</w>
nitrogen ,</w>
nimesul ide,</w>
neurolep tics.</w>
neuroblast oma.</w>
nephrectom y</w>
nal buph
myo fibroblast</w>
my opathy,</w>
mon omer</w>
micro mol
mg/ d.</w>
metr ical</w>
medi ated.</w>
meaning ful</w>
m 1</w>
loid y</w>
kine tics,</w>
kine sia,</w>
isot onic</w>
ion ,</w>
investig ations.</w>
int act
insom nia,</w>
in- vitro</w>
immunoglob ul
immobil ized</w>
ili ated</w>
hyperlipide mia.</w>
hyperexcit ability</w>
hyper glyca
human .</w>
hospit als</w>
hom odi
heat- shock</w>
he aled</w>
hamster s.</w>
griseoful vin</w>
gluc agon
gland s.</w>
fungic ide</w>
fr us
form oterol</w>
find ing,</w>
fav oring</w>
factor- alpha,</w>
expos ure-
etopo side.</w>
est rel
es citalopram</w>
er arch
enzym ic</w>
ent ering</w>
energ e
enc ycl
el aic</w>
e ye
dysrhythmi as</w>
dys plastic</w>
dur ing,</w>
drowsin ess</w>
divalpro ex</w>
distur b</w>
dela y
de fibrill
dantrol ene</w>
dP/d t</w>
d /
cul tiv
correc tly</w>
correc ted
contr adic
cont act
clo fib
circul ation,</w>
cil azapril</w>
cholangi ocarcinoma</w>
chol el
chaper ones</w>
challeng ing</w>
ch ance</w>
cephal or
cataly tically</w>
c a</w>
benzo yl</w>
benzenesulf onic</w>
av oide
as e;</w>
arteri oscler
appro val</w>
apparat us</w>
apocyn in</w>
analy tical</w>
an ol
aminoglyco sides</w>
al ize</w>
al dose</w>
ag en
adrenal ectomized</w>
adi an</w>
activ ations</w>
ace butolol</w>
V e
V R1</w>
V IP</w>
V I
V CAM
U -2
Transcri ption</w>
Tr p
Ti O(2)</w>
Taiw an.</w>
TR I
T MS</w>
T MA</w>
SC ID</w>
Re f
Pro pyl
Potenti ation</w>
PP H</w>
PON 1
PK B</w>
PGI 2</w>
PGE 2,</w>
PCB 126</w>
PB DE-
P450 ,</w>
One -
Objec tive</w>
O PRT</w>
O CT</w>
NT D</w>
NF ,</w>
NE P</w>
MT ).</w>
MG- 63</w>
MC ,</w>
Last ly,</w>
IS H</w>
IFN- gamma,</w>
I U
Hospit al,</w>
HS PA
G 2-
Flav opirid
F- actin</w>
Exercis e</w>
De ath</w>
DN MT</w>
D os
D VT</w>
Co Cl2</w>
Cig a
CCL 2</w>
C ;</w>
C 2
Bcl-x L,</w>
BP DE</w>
B1* 0
B urkit
As perg
Abs ence</w>
AF .</w>
A A.</w>
6 beta-
6 '-
5-aza- d
5- LOX</w>
5 5.
5 000</w>
3435 T</w>
34 ).</w>
33 3</w>
33 ).</w>
24 .</w>
20- fold</w>
15 8
1 ]</w>
0. 4%</w>
0. 19</w>
-2 7</w>
- out</w>
(P< 0.01),</w>
(MTHF R)</w>
(HUVEC )</w>
(E DC
(D ex
(C P)</w>
(AB C)</w>
(8 %)</w>
(50 %</w>
(1 7%)</w>
(1 4%)</w>
( not</w>
z ir
z eta</w>
y rosine</w>
val ence</w>
vacc ine</w>
unil ater
un expectedly</w>
ultras oun
ul ture</w>
transpor ts</w>
transcript s.</w>
trans placental</w>
tran dol
tox in.</w>
tic )</w>
thi ol-
ter azosin</w>
t p
survi ve</w>
sur pris
sub optimal</w>
sphing omyel
solv ents</w>
siRNA .</w>
sequenc es.</w>
ro om
rewar ding</w>
reverse- transcription</w>
rest less
receptor -1</w>
re agent</w>
rat :</w>
raph e</w>
quin pi
pyrid o[
propofol -induced</w>
press ing</w>
post operatively</w>
pol lu
point es,</w>
photo receptor</w>
pg/m l,</w>
pepti de
pent amid
pe red</w>
parame tric</w>
p70S6 K</w>
p16 (INK4
ox azepam</w>
ovul atory</w>
overexpres sion,</w>
oti fen</w>
oth re
oserti b</w>
op es</w>
one- mediated</w>
on ase</w>
on 's</w>
ogene tics</w>
og as
oci al</w>
oblast s.</w>
nucle osomal</w>
non- cytotoxic</w>
non coding</w>
nic oran
necess ity</w>
my dri
minut es)</w>
min ority</w>
mi anserin</w>
methyl guanine-DNA</w>
methad one.</w>
medullo blast
me phedr
malondi aldehyde,</w>
main stay</w>
lig ated</w>
le x</w>
k now</w>
k er
ish ,</w>
is ometric</w>
iox ag
insipid us.</w>
induc er,</w>
incub ation,</w>
in ward</w>
immunost ain
hypothe sis.</w>
hypo album
hypertensi ves</w>
hyper responsiveness</w>
hou se
homozygot e</w>
home ob
hex avalent</w>
guan ylate</w>
grad u
glomerul i.</w>
furosemi de.</w>
fruct os
frac tions.</w>
fo etal</w>
fic ially</w>
fav ored</w>
f air
ext inc
expres sed,</w>
evid ence,</w>
ether -a-
estrogen -related</w>
estrogen -like</w>
episo de.</w>
ent 's</w>
encour aging</w>
elucid ation</w>
elev en</w>
electr on-
ecst as
dys arthri
domain s.</w>
disorder :</w>
discharg e.</w>
dis ul
dis proportion
diarrho e
di versity</w>
di ethyl</w>
demonstr ated,</w>
contrac ted</w>
cont acts</w>
consum er</w>
con vol
con ferring</w>
commenc ement</w>
clioquin ol</w>
chloro benzene</w>
chi l
chemic al-induced</w>
chec k</w>
cell s),</w>
cat aton
carrageen an</w>
ca re,</w>
but anol</w>
budes on
bromo -
bol one</w>
bod y,</w>
bing e</w>
beta-caroten e</w>
bac tere
b one.</w>
auto regulation</w>
auto phosphorylation</w>
atax ia.</w>
approxim ate</w>
anti carcinogenic</w>
anth ine</w>
aneurys mal</w>
aminog lyc
alpha- smooth</w>
al idom
afferen ts</w>
adultho od</w>
adap ted</w>
acr al</w>
acqu ire</w>
acid- reactive</w>
abs ent.</w>
ab str
a- 1</w>
a ,
Zuc ker</w>
Zn T-
X L</w>
Wh ole-
V 79</w>
U/ L</w>
Thirty- one</w>
TB T</w>
T W
Sh h</w>
SR 1417
Random ized,</w>
RA RA</w>
R alpha</w>
R GS
Pre dn
Pharmaco kinetics</w>
PhIP -induced</w>
Pe diatric</w>
Par t</w>
PK G</w>
P ul
P B,</w>
O X</w>
Nat ural</w>
NI DD
NA DH
MTX -induced</w>
MCF- 7
Lew y</w>
L- carnitine</w>
K now
K IF
Immunob lot
Immedi ately</w>
HPLC .</w>
HC .</w>
Gentam icin</w>
GPR 109
GADD 153</w>
G ranul
G ER
Fl t
F ree</w>
E -1</w>
Diag nosis</w>
D F</w>
D 5
D -2</w>
Concomit antly,</w>
Ciga rette</w>
Ch r
Cav -1</w>
CYP2 C</w>
C obal
Balb /
As n
Arocl or</w>
Am ant
AR NT
A27 80</w>
A AG
6 5.
6 4,</w>
5 9.
5 9)</w>
5 8-year-old</w>
5 7.
4-HP R</w>
4 60</w>
3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium</w>
3- [
3', 5'-
3 G</w>
2 q
2 )-
182,7 80</w>
17 4</w>
16 ),</w>
13 /
1, 25
1 0.0
0. 24</w>
0. 1
.0 1),</w>
(V I)</w>
(UGT )</w>
(S M
(R R
(M R)</w>
(F D
(A ST),</w>
(A RE
(1 4)
(1 1%)</w>
(-1 )
( non
( measured</w>
( defined</w>
yl ,</w>
weigh ed</w>
vascul ar,</w>
v a</w>
ure tic</w>
un necessary</w>
tro pic
treatment- emergent</w>
tre tin
threshol d,</w>
th ro
ter in</w>
tempor arily</w>
tel eph
t ain
sum mary</w>
succinylchol ine-induced</w>
sti tial</w>
st able,</w>
spectroscop y.</w>
sleep ing</w>
si bility</w>
ser ving</w>
sequestr ation</w>
self- administered</w>
seleni um-
secret e</w>
seas onal</w>
se mis
sc ap
sar pogrelate</w>
rop ium</w>
reinfor cement</w>
re activated</w>
rat s)</w>
quercet in-induced</w>
pur ification</w>
pros thetic</w>
pran lu
practic e,</w>
pr al
pos tis
parkinson ism,</w>
paren chym
pa uc
p< 0.05).</w>
p6 5,</w>
oth yro
organis ms.</w>
organ ism</w>
open ,</w>
op ac
ol -</w>
oc el
non- Hodgkin</w>
ng/m L,</w>
neuro cognitive</w>
multivari able</w>
muc ous</w>
monke ys,</w>
ml ).</w>
min (-1),</w>
methach oline</w>
medull a.</w>
medi um-
matri x.</w>
m O
liver -
leiomy oma</w>
kerat osis</w>
keep ing</w>
ju ice</w>
inv ari
intras triatal</w>
ind u
immunosup pression.</w>
immuno assay</w>
id arubicin</w>
ic ot
hyperpla si
hyper phosphorylation</w>
hyper locomotion</w>
hexy phen
hemoly sis.</w>
he min</w>
haemodi alysis</w>
habit ual</w>
gu ai
go rous</w>
go ing</w>
gastro esophageal</w>
g/m l)</w>
g/d l</w>
function ality</w>
ful filled</w>
for khead</w>
flun om
flex ible</w>
fer rit
exp on
epididym al</w>
en graf
emph ig
emia :</w>
electr ically</w>
el u
eicos atetra
efflu x.</w>
e- based</w>
dyspla sia.</w>
dur able</w>
down- regulated.</w>
double-blind ed</w>
dos ages.</w>
doc osahexaenoic</w>
distinc tly</w>
diet )</w>
dich ro
diazep am
diaphor ase</w>
develop ment
deliver y,</w>
dat as
d ated</w>
cytok ine-
cystin- LR</w>
cut ane
corticotrop in-releasing</w>
cord ant</w>
contr act
compens ate</w>
comp any</w>
com promising</w>
colon ies</w>
coerul eus</w>
co activator
clin ics</w>
circum feren
cholester yl</w>
chol ic</w>
capsaicin- evoked</w>
bu metan
broad er</w>
bodi es.</w>
bodi es,</w>
blot s</w>
bleomycin ,</w>
biot in
benz tropine</w>
behavior s,</w>
be f
basil ar</w>
avi an</w>
aver age,</w>
aur anof
attem pt
ation ally</w>
astro gli
app ly</w>
aort as</w>
anorex ia,</w>
anes ulf
alpha, beta-
al- related</w>
al- based</w>
addic ted</w>
ac yl-
X -induced</w>
Trx R1</w>
Ti me-
Th at</w>
Tac hy
TP O</w>
TOP 2A</w>
TI ON</w>
TB BPA</w>
T TR</w>
T 24</w>
T 2
Suscepti bility</w>
Stat ins</w>
Scop olamine</w>
Scal e.</w>
SN- 38</w>
SH Rs</w>
SC D</w>
S amples</w>
S -</w>
Rad 51</w>
Prote omic</w>
Progres sive</w>
P i</w>
P ax
P -1
NA T</w>
N-acetyl cysteine,</w>
N NK
N (G)-
MP .</w>
MA C</w>
M L-
Labet alol</w>
L R-
L AM</w>
L -1</w>
K CC
Intracere bro
Intr a-
Inter stitial</w>
IL -2,</w>
IGF-1 R</w>
Hyper sensitivity</w>
Hy dr
Hemorrh agic</w>
HS D</w>
H SCs</w>
GAT A-
GAT A
G- protein-coupled</w>
G p
F luc
Determin ation</w>
Delta 9-
Clin ically</w>
Clar a</w>
Ca )</w>
C :</w>
Bene ficial</w>
BC RP
BA X</w>
Al um
ACh R</w>
AA -induced</w>
9 00
7 2,</w>
3 D</w>
3 4-
3 000</w>
20 3
199 6</w>
15d-PGJ (2)</w>
14- day</w>
1-methyl-4-phenyl pyridinium</w>
0. 30</w>
0. 18</w>
-1/ 2</w>
+ +</w>
(T )</w>
(P <</w>
(L ),</w>
(HE K
(H IV)</w>
(G D)</w>
(F F
(D TI
(ALT ),</w>
(7 5%)</w>
(5 ,
( low</w>
( '
zon a</w>
well- documented</w>
wean ling</w>
war ds</w>
v ocal</w>
us ate</w>
uniqu ely</w>
trunc ation</w>
tri -
tis h</w>
thr ice</w>
thi ourea</w>
thi en
tetro d
t os
sulfadi azine</w>
subcut aneous
strok e-
stomach ,</w>
stem -like</w>
staurospor ine</w>
sp ot
silden af
signall ing.</w>
serv ice</w>
ser ological</w>
sec tions.</w>
scaff old</w>
sacch arin</w>
s.c. ),</w>
s lit</w>
rest .</w>
remot e</w>
remo val
reg im
re activate</w>
qu it
q RT-PCR</w>
prote ome</w>
promo tion.</w>
prim ates</w>
prednis one,</w>
pot ency,</w>
pollut ants.</w>
po )</w>
placebo ).</w>
placeb o)</w>
pla sia</w>
pig mentation</w>
phosphoryl ate</w>
phent ol
pharmacokine tics,</w>
phag ocytic</w>
pertur bed</w>
peg interferon</w>
path ologically</w>
particip ants.</w>
parano ia</w>
papill oma</w>
osteosarcom a.</w>
orph anol</w>
or ang
om b
oder m</w>
octre oti
occl uded</w>
o edema.</w>
norepinephr ine-induced</w>
neoplasi a.</w>
ne y</w>
mul tiv
morbid ity.</w>
mon grel</w>
mo re.</w>
mm )</w>
minim izing</w>
min d</w>
migra ineur
microg/ L</w>
met als.</w>
mesen chym
medi um
m ancoz
low- risk</w>
local ize</w>
lipid s.</w>
line zol
line )</w>
ligand -independent</w>
libit um</w>
li ability</w>
lev ob
len tiviral</w>
irin otec
intra arterial</w>
intens ity.</w>
ing ent</w>
indu stri
in soluble</w>
im ple
hyperprolact inemia.</w>
hyp ocap
high- resolution</w>
heterodi mer
hemis ph
he mic
harb ored</w>
hC tr
h E
glut aminase</w>
giv en,</w>
frame work</w>
fluor inated</w>
flu tic
fat al.</w>
ey es.</w>
ex foli
et h</w>
er ian</w>
epic atech
emplo yed.</w>
el en
ef aviren
e zing</w>
dose- dependent,</w>
dofe tilide</w>
diff u
diel drin</w>
diel dr
didan osine</w>
dextro se</w>
defic it.</w>
decid ed</w>
corrobor ated</w>
control ;</w>
comput er</w>
com bus
collec ted.</w>
clim bing</w>
cholec ys
calci um-dependent</w>
cAMP ,</w>
c ity</w>
bro modeoxy
block er.</w>
bir th,</w>
bio inform
bio available</w>
bin ary</w>
bi as</w>
beta2- adrenergic</w>
beta 3</w>
b ol</w>
auto immunity.</w>
at re
aspar tam
arsen ical</w>
ap eptide</w>
antigen -
antibod y-
anti- tumour</w>
ann ex
and ing</w>
an atomic</w>
an 's</w>
am ong
alpha 1
ali ph
albumin uria,</w>
al -dependent</w>
adren omedullin</w>
abs orb
ab at
[a] anthracene</w>
[35 S]
[ Clinical</w>
[ A
Ver y</w>
VEGF .</w>
V als
UGT 1A</w>
UDP-glucuron osyl
TG Z</w>
T> C</w>
T or
T SP
T 3
Sy stem</w>
Subjec tive</w>
S qu
S ir
S OX
S N</w>
S ASP</w>
RO CK</w>
R v
R CA
Propo fol
Plas modium</w>
PP ),</w>
PA N-induced</w>
PA M</w>
P450 sc
P estic
P XR
P 3</w>
NLRP 3</w>
N r
N )-induced</w>
Metoclopr amide</w>
MX C</w>
MCF- 7,</w>
M as
L ys</w>
L en
L EV
KCN Q
K ing
Ir b
Inv entory</w>
Initi ally,</w>
I RE
H AS
H 1299</w>
GSTP 1
GSK3 beta</w>
GDC-0 941</w>
G st
ER alpha.</w>
EG CG
EC s)</w>
EC G,</w>
E 1,</w>
D-penicill amine.</w>
D uration</w>
D on
D og
Cyt otoxic</w>
Contri bution</w>
Co Cl(2)</w>
Ch E)</w>
Cere bro
Carbam azep
Ca ution</w>
Bi om
BN IP
BAL F</w>
An nex
AR C</w>
AD AMT
A ST,</w>
7 th</w>
60 .</w>
6 8.
4 4,</w>
3 30
23 ).</w>
2 ]</w>
19 1</w>
18 3</w>
10 6
1. 4%</w>
1- h</w>
) %,</w>
(TNF- alpha),</w>
(RA ),</w>
(NO ),</w>
(K i</w>
(H 2O
(G M-
(E G
(E C</w>
(C AP
(A F
(9 %)</w>
(6 /
% /
wid er</w>
weigh ts,</w>
vir uses</w>
ult ures</w>
two -</w>
trinitro benzenesulfonic</w>
toler ability.</w>
tion ].</w>
thyroidis m,</w>
thyro trop
thickn ess,</w>
te aching</w>
tax ane</w>
target ,</w>
sunit inib</w>
strom a</w>
stit uting</w>
sten otic</w>
somat osensory</w>
smo ked</w>
sleep iness</w>
selen o
sed ated</w>
sample ,</w>
salt- sensitive</w>
ro ot
rest less</w>
ren der</w>
regar ds</w>
recycl ing</w>
recove red.</w>
reaction- restriction</w>
re ticular</w>
q 13.
pseud o-
pro ic</w>
pro drugs</w>
pre incubated</w>
pp b</w>
potenti als.</w>
poly cy
pol l
picrotox in,</w>
peptid es,</w>
p 40</w>
ori entation</w>
org as
ophysi cal</w>
op in
onid azole</w>
omal ac
ol in,</w>
ol ate</w>
offic e</w>
och oline</w>
occl ud
o uring</w>
nucle ic</w>
not e</w>
non ylphenol</w>
non en
nitr ation</w>
nat ure.</w>
myoclon us,</w>
myo- inositol</w>
multi functional</w>
morph ometric</w>
ml .
micrograms/ kg,</w>
mg. kg-1.
mercur y.</w>
manifest ations,</w>
manganes e-
man ual</w>
mag n
loci ,</w>
local ization,</w>
lis uride</w>
lifest yle</w>
li bid
length ening</w>
larv ae</w>
laborator y.</w>
l amin</w>
isoprost ane</w>
is ob
interven tion,</w>
inte g
ini um-
in-3- gallate</w>
hr )</w>
histopath ology,</w>
hel ps</w>
headach es.</w>
haplo insufficiency</w>
granul ocytic</w>
glycoly sis</w>
gas tr
fosin opril</w>
fl or
exter nal
excit otoxicity</w>
er s)</w>
er obic</w>
epsilon 4</w>
ent :</w>
em physe
e mod
dis ed</w>
dihydro folate</w>
detoxic ation</w>
deple te</w>
demyelin ating</w>
dela y,</w>
de stro
concentration- response</w>
con nex
compar atively</w>
com pression</w>
collec tively</w>
collag en.</w>
cle f
cimetid ine,</w>
chlor diazep
chlor al
cephaloth in</w>
cau ti
boun d
biopsi es.</w>
bab ies</w>
b on
at om</w>
asth ma
assum ption</w>
antidot e</w>
anti leukemic</w>
anthracycl ine-induced</w>
an /
among st</w>
alpha- adrenoceptor</w>
alpha (2)-
aldoster one,</w>
alcoh ol-induced</w>
ajmal ine</w>
ad olol</w>
accompl ished</w>
above .</w>
Z NF
Vincrist ine</w>
Sy ri
Surg ical</w>
Sud den</w>
Stre pto
Se x</w>
S tri
Rel A</w>
RL S</w>
RF LP</w>
PL C</w>
PE G-
P )-induced</w>
O-de methylation</w>
Multi drug</w>
Man ia</w>
MDA-MB- 468</w>
M ont
M H</w>
Leu -
LD LR</w>
L BD</w>
J 82/
In din
Immunob lot</w>
IL- 8.</w>
IK K</w>
HLA-B *
HER -2/
H R,</w>
GF P-
G P</w>
G ITS</w>
G -induced</w>
FOXO 3a</w>
FAN F
F uro
F as,</w>
F N</w>
F 1,</w>
Erk 1/2</w>
Endoc rine</w>
Ei ther</w>
Ec topic</w>
EZ H2</w>
E- cadher
E .
Di ethyl
DNA )</w>
DD P)</w>
D 3
Co A)</w>
CYP26 A1</w>
CP Z</w>
CP .</w>
CCl 4-induced</w>
C- 5</w>
C- 3</w>
C ong
C er
Am elior
AT G
AB CA
4-hydroxy tamoxifen</w>
3', 4'-
3 7)</w>
3 4,</w>
26 1</w>
24 ,
20 2</w>
2, 2',
2 80</w>
18 1</w>
16 4</w>
10 (5)</w>
0.0 3,</w>
0. 22</w>
-20 1</w>
(RT-PC R),</w>
(R ,
(PR L)</w>
(P (
(MMP- 9)</w>
(IN R)</w>
(G CL
(F I
(F A)</w>
(D ox
(D SM-
(BCN U)</w>
(B rd
(3 0%)</w>
(2 .0
(1 9</w>
( six</w>
( A</w>
zol e,</w>
z ed.</w>
well ,</w>
vindes ine</w>
ven a</w>
vasodil ation.</w>
us ;</w>
urticar ia.</w>
unit s/
ug inos
u e,</w>
tumor- promoting</w>
thrombocytopen ic</w>
thrombo embolism.</w>
termin ating</w>
tachy arrhythmia</w>
t es,</w>
syndrom es,</w>
su fentan
struct ure
sto ichi
standar d-
st able.</w>
so il</w>
side- effects,</w>
ser vation</w>
scler osis,</w>
s apon
remo ve</w>
rel atives</w>
refle x.</w>
reac he
r ane</w>
propag ation</w>
prop oxy
prol yl</w>
prec ordial</w>
post operatively.</w>
por ide</w>
pir one</w>
period on
pepti de.</w>
pel le
path ology,</w>
paroxet ine.</w>
paraqu at,</w>
pa id</w>
p27 Kip
p indol
or ac
optim ize</w>
opi ates</w>
ope dic</w>
op ri
on ec
on ad
oligodendro cyte</w>
off set</w>
neutrophil ic</w>
neuro peptides</w>
neon ate</w>
nei gh
mutag en</w>
mouse )</w>
mixt ure.</w>
min -1)</w>
microarra ys.</w>
mic e;</w>
methemo glob
met a
memb ers.</w>
mel amine</w>
maz e.</w>
marrow -derived</w>
m oxif
loc us,</w>
load ,</w>
liver s,</w>
lign oca
lex y</w>
leukemi as</w>
le andom
kn ock</w>
ki lo
isul ind</w>
ion ized</w>
inter view</w>
infer tility.</w>
ine ous</w>
in- 4</w>
in side</w>
in otrop
import ant,</w>
immun ity,</w>
ifer a</w>
hydroph ilic</w>
hybridiz ation,</w>
hospital ization,</w>
hom ovan
hi t</w>
hexameth onium</w>
hazard ous</w>
haloth ane-induced</w>
gal ant
fore ign</w>
extrac orporeal</w>
exp end
expend it
eti l</w>
et odol
epider mi
ent ;</w>
enedi amine</w>
ene dione</w>
emplo y
effect s;</w>
echocardi ograph
ear s</w>
e (s)</w>
dystroph y.</w>
disturb ance,</w>
diseas e].</w>
dimethylarsin ic</w>
detox ification.</w>
detac hment</w>
dehydrogen ase.</w>
dec lines</w>
debilit ating</w>
de vast
de activation</w>
cyst s</w>
cos metic</w>
copper -binding</w>
coordin ate</w>
conver ting-
con cordance</w>
compart ments</w>
co infected</w>
ci glitazone</w>
chrys oti
chemo resistance.</w>
char ts</w>
char coal</w>
cerebell um.</w>
cer iv
c ue</w>
br u
bivol ol</w>
bio activated</w>
bi osens
bet amethasone</w>
baical ein</w>
ax illary</w>
at mosph
at able</w>
asth enia</w>
appea red,</w>
anti- metastatic</w>
anti tumoral</w>
an isole</w>
alcoh ol.</w>
ag glut
ag e;</w>
aer uginos
adenocarcin oma,</w>
adap tor</w>
acu te-
activ ated.</w>
acetyl ators</w>
accept or</w>
a- associated</w>
[(1 4)
Z idov
Y -2
UV A</w>
UV -induced</w>
T urk
T U
T BP
T 98
Stud y,</w>
Sed ation</w>
S wit
Reg ression</w>
Pro gram
Pres ent</w>
Pr inc
Per fluoro
Par acetam
Pa ren
PT P</w>
PRO CE
PROCE DU
PROCEDU RE
PPAR gamma-
PI -
PG )</w>
P< 0.001)</w>
P F-
P 1-1</w>
Org anic</w>
O 2,</w>
O (3)</w>
N- (4-hydroxy
N Q
N MDA-
N ER</w>
Mn SOD,</w>
Meto prolol</w>
MI BG</w>
ME D
MDR 3</w>
MA LD
Le ad</w>
LT .</w>
L Y</w>
K inase</w>
K d</w>
Immun ocyt
Ik B
IP ).</w>
Hypoxi a-
Hor mon
HIV- positive</w>
H2O 2.</w>
H PR
Glucocortico ids</w>
F K-
F ABP</w>
Dis e
Dig oxin</w>
Cu 2+</w>
Catal ase</w>
CO M
CD34 (+)</w>
C/EBP beta</w>
C riter
Bcl 2</w>
B S
B PA-induced</w>
At g
AL DH</w>
AD HD.</w>
A or
9 8%</w>
57 1</w>
5-FU -based</w>
5- ASA</w>
5 3.
36 ).</w>
3- 6</w>
3 9,</w>
25 )
25 %,</w>
24 ),</w>
200 5</w>
17beta- estradiol,</w>
16 0
14 1</w>
10- year</w>
10 0-fold</w>
1,3- bis(2-chloroethyl)-1-
0.0 2,</w>
0 ,
. ;</w>
-2- methyl
- 8,</w>
- 0.4
)- associated</w>
(m TOR
(VK OR
(VEGF ),</w>
(TRPV 1)</w>
(TRAIL )</w>
(P MA)</w>
(M RS
(H PL
(D )</w>
(C K
(Ah R).</w>
(4 0%)</w>
(3 0-
(3 /
(2 2%)</w>
(1 4
(1 )/
( trans-
z earal
youn g,</w>
yle stradi
war m</w>
vesi cles.</w>
vag ina</w>
urap idil</w>
upregul ation.</w>
uniform ly</w>
uc h</w>
trunc ating</w>
triple -negative</w>
trandr ine</w>
tom ographic</w>
thimer osal</w>
thereafter ,</w>
tetrab en
ter rit
ta p</w>
sulf in
suc h,</w>
subst anc
sub population</w>
star v
st ent
spec ially</w>
sili bin
sex es.</w>
ses qu
selen oprotein</w>
selec tin,</w>
scop y</w>
s essive</w>
resc ues</w>
record s.</w>
recipi ents,</w>
re acting</w>
rate- pressure</w>
rat ropium</w>
ram ipr
r ing
question ed</w>
qu ater
q PCR</w>
pyel oneph
py re
propofol -
proble m,</w>
present ations</w>
prec au
polymer ization</w>
pmol/ mg</w>
phen procou
ph encycl
per chlor
pent agas
pel vis</w>
parad oxic
p- chloro
p s,</w>
p ifithrin-
other s,</w>
ospec ific</w>
orth opedic</w>
ono ki
ometr y,</w>
occlu sion,</w>
oc lob
oc in</w>
nur sing</w>
now ,</w>
nom ifens
nmol/ L</w>
niac in.</w>
narin genin</w>
ml/ kg</w>
mitig ate</w>
mit omycin-
microscop e.</w>
mg/m (2),</w>
meth i
mes encephalic</w>
medi ast
me phenytoin</w>
me et</w>
mark ed
mal a
lum irac
lo ok</w>
lipo genic</w>
la g</w>
l ine-
ki ren</w>
iz er</w>
intraperitone ally)</w>
intrac ellul
intr al
inten tion-to-treat</w>
i x
hypother mic</w>
hypercalc emic</w>
hom o
hepat ectomy</w>
he me-
h ard</w>
gr al</w>
girl s</w>
general ised</w>
gastro -
gall stones</w>
g o</w>
fo od.</w>
fluoresc ence-
flu id,</w>
fiel d.</w>
fic ation,</w>
fexo fenadine</w>
fer tility</w>
f an</w>
exacerb ations</w>
er in</w>
embr ane</w>
echocardi ogram</w>
dysmorph ic</w>
drople ts</w>
dipyridam ole-
dimer ization</w>
digox in,</w>
devast ating</w>
deoxy glucose</w>
daun omycin</w>
datab ases</w>
d G</w>
cr ack</w>
cost- effectiveness</w>
conscious ness.</w>
com a,</w>
co he
citalopr am.</w>
ch ain
ce ased</w>
cab ergoline</w>
c ure
c n
beta- 1</w>
aut o-
ate- treated</w>
at e),</w>
ast at
apomorph ine.</w>
anticoagul ants</w>
anth ocyan
anomal ies.</w>
anomal ies,</w>
angi ographically</w>
ana emia,</w>
amne sia,</w>
am ox
am odi
alve olar
agene sis</w>
affor d</w>
advant age
aden omas,</w>
acrole in.</w>
above -
Y 1</w>
Wil m
WR N</w>
UGT1A 9</w>
Trx R</w>
TY MS</w>
TUNE L-positive</w>
Syri an</w>
Stre pt
SV CT
SOUR CE
SNP ,</w>
SK- Hep
SH .</w>
S V</w>
S PA
Ras /
ROS -dependent</w>
R 2
R 18
Pro spec
Pre ven
Ph e</w>
PT GS
PKC alpha</w>
PD A</w>
PANS S</w>
P- 43</w>
Ob es
NT P</w>
NQO 1,</w>
N D</w>
Mem ory</w>
MT X-
MD .</w>
MB F</w>
MA .</w>
M s)</w>
Lp (a)</w>
LE V</w>
L ind
L IN
L -induced</w>
K 2,</w>
J 77
Intracerebro ventricular</w>
Inter vention</w>
HY PO
HLA- G</w>
H g/
H PA</w>
H ER</w>
GSH /
G(0)/ G(1)</w>
G 1,</w>
F U
Ep inephrine</w>
Endome trial</w>
En dos
Eigh ty</w>
ER beta.</w>
ER alpha,</w>
E MB
E BP
DM SO
D A-
CM V</w>
CH )</w>
CD C
CCR 5</w>
CB )</w>
C 5
Bromocript ine</w>
Bcl-x (L)</w>
BE T</w>
BCL 2</w>
B -1</w>
Autophag y</w>
Austral ian</w>
As 3
Angio edema</w>
Ag NPs</w>
Accum ulating</w>
AR F.</w>
AC A</w>
9- cis</w>
8. 0
8 9,</w>
6 th</w>
6 5-year-old</w>
5 th</w>
5 1,</w>
5 );</w>
30- min</w>
3 26
15 7</w>
10 ;</w>
10 -1
1- nitro
1- ,</w>
1, 2,3-
- -</w>
(n ACh
(TCD D).</w>
(MAPK s)</w>
(M B
(G S
(F EV
(EC )</w>
(E 2),</w>
(CA R)</w>
(AK R
(5 /
(4 %)</w>
(2) =
(2 3.
(1. 2</w>
(1 2,
(0. 1-
ym panic</w>
ye 's</w>
y et.</w>
x ic</w>
vac iz
uro n</w>
unco vered</w>
un treated,</w>
turno ver.</w>
tur ned</w>
traum a.</w>
transloc ations</w>
transamin ase,</w>
tp :
tp: /
toxic ants.</w>
tiv eness</w>
thromb omod
thromb i</w>
thre at</w>
thi azole</w>
tert- butyl</w>
tagg ing</w>
t ag
synovi ocytes</w>
syncop e.</w>
syncop al</w>
super family,</w>
subun it.</w>
stres ses</w>
splic ed</w>
softw are</w>
scre ens</w>
scler oder
scho ol</w>
s ac</w>
rs 17
riz atriptan</w>
ric -
restric tive</w>
rehabil itation</w>
reg ained</w>
ra emia</w>
r ural</w>
r ane
promaz ine</w>
prolong ation,</w>
prolact inemia</w>
pregn enolone</w>
pl ates</w>
phosphoryl ates</w>
phenotyp es,</w>
phenobarbit one</w>
ph ases.</w>
ph aryngeal</w>
perid ol</w>
pentobarbit al-
pel let</w>
par av
ox acillin</w>
otom y.</w>
osi tis,</w>
os ed</w>
ophthalm ologic</w>
on ab
om e.</w>
oligo deoxy
ole-3- carbin
och alasin</w>
ob liter
o yl-
o il.</w>
notic eable</w>
normal ize</w>
nitroprus side,</w>
nickel -induced</w>
necess ary,</w>
myel omon
my ogenic</w>
mut ant.</w>
mmHg ).</w>
mix tures.</w>
mg/d l.</w>
metr y,</w>
mening i
men )</w>
medic ines</w>
manag ement,</w>
mT OR,</w>
mRNA s.</w>
mPGE S-1</w>
m (-2)</w>
lyc opene</w>
log- rank</w>
lithi um-treated</w>
lept in,</w>
isoniaz id.</w>
isoniaz id-induced</w>
irradi ation,</w>
ir acetam</w>
ip in</w>
intr aplantar</w>
inter face</w>
ini i</w>
inhal ation.</w>
ingredi ents</w>
inflamm ation-related</w>
inf ant.</w>
in- A</w>
import ance.</w>
immunomod ul
hour ,</w>
hospit al,</w>
homogene ous</w>
hil us</w>
hed gehog</w>
ham pered</w>
gr as
gg ul
gas tri
g/m L</w>
g ang
g -
fur ther.</w>
four fold</w>
find ing.</w>
exp and</w>
evalu ated,</w>
eti ology,</w>
erythropoie sis</w>
epo etin</w>
ep idemic</w>
ensu ing</w>
enhanc ed.</w>
enhanc ed,</w>
en ever</w>
elem ents,</w>
e uro
dithi othre
dile val
di fluoro
dextrometh orph
demonstr able</w>
dd C</w>
counter acting</w>
cot reated</w>
converting- enzyme</w>
control ),</w>
contamin ation</w>
consequenc e,</w>
config uration</w>
comb ined,</w>
comb ine
co w
clas s,</w>
chromatography- tandem</w>
chi ral</w>
chemic al,</w>
character izes</w>
ch ow
ce furo
catat onic</w>
cardi o-
can al</w>
bilob a</w>
ber yl
benzbrom ar
be vaciz
barri er,</w>
av en
at tracted</w>
aryl amine</w>
ardi ac</w>
arac ter</w>
ar s</w>
apl asi
ap o-
ano rec
ann- Whit
anesthe tics.</w>
analogu es.</w>
analog s.</w>
alpha- methyldop
alpha 2</w>
aliph atic</w>
alge sic</w>
after load</w>
acup uncture</w>
acetyl ation,</w>
abnormal ity.</w>
a ]
[ corrected
[ 6
Z 1</w>
With out</w>
U p</w>
Treat ments</w>
Tr x</w>
Touret te's</w>
TRAIL .</w>
T ub
T f</w>
T c
T UDCA</w>
T 1,</w>
Su per
Schi z
SLCO 1B1</w>
SC I</w>
S6 K1</w>
S pan
S AL
R s.</w>
R at
Question naire</w>
Propyl thiourac
Plac eb
Path way</w>
PA O</w>
PA H-
P450 1A1</w>
O ).</w>
NP ),</w>
N SC
N PC
Me tr
MEK 1/2</w>
MAP K-
Low -
Lithi um-induced</w>
LC3- II</w>
LC 3</w>
K 1,</w>
IL-1 beta-
IL 6</w>
Hz )</w>
His -
Hep arin</w>
Heal th
Hae modynamic</w>
HYPO THESIS:</w>
H ]</w>
H AM-
G 4
F us
F ibr
F T)</w>
ERK1/ 2.</w>
E W
Dose- response</w>
Dose- dependent</w>
Del ta</w>
DS S</w>
DP ),</w>
DF S</w>
DC F</w>
D 3.</w>
Convul sions</w>
Com mittee</w>
Col lege</w>
Ca2+ -
CO PD.</w>
CHO -
CH F,</w>
CA SE:</w>
Bi m</w>
Bcl-2/ Bax</w>
B L</w>
B -mediated</w>
An tin
Ad v
ATP .</w>
AQP 9</w>
AN I
AK T1</w>
AH R-
ACh E,</w>
9- hydroxy
9 9%</w>
9 -1
82 26</w>
8 th</w>
8 q
6 4.
4- OH-
3- phosphate</w>
29 ).</w>
200 2.</w>
2 16
2 1/
1alpha, 25-dihydroxyvitamin</w>
19 8</w>
125 I-
12 ;</w>
1- adrenergic</w>
1 50,</w>
0.000 1,</w>
0. 40</w>
0. 26</w>
0. 2,</w>
-2, 2-
-2 2</w>
- selective</w>
- 7</w>
- )</w>
(P I)</w>
(P DE
(N I
(M S)</w>
(L Y
(EC M)</w>
(DE N)</w>
(Ba P)</w>
(Ah R),</w>
(50 ,</w>
( s).</w>
zymograph y</w>
week ly.</w>
w ri
vertig o</w>
venti lat
ven om</w>
vect or.</w>
vari able.</w>
us -like</w>
ultrastruc ture</w>
troglitaz one.</w>
tri phosphatase</w>
toxic ities,</w>
thio acetamide</w>
th enium</w>
terbin afine</w>
tend s</w>
ted ;</w>
tartr ate</w>
tamoxifen -induced</w>
ta ke
ta g</w>
subun its.</w>
substanti ated</w>
su reth
sol eus</w>
sensitiz er</w>
semis yn
se b
se arch
rs 4
rot tler
ron tal</w>
retro peritoneal</w>
ren o
relief .</w>
recruit ed.</w>
receptor )</w>
rati os.</w>
rat e/
rac e</w>
r ice</w>
pyrid ine-
pro carb
potassi um-
post transplant</w>
possibil ities</w>
poly p</w>
pod ocytes.</w>
peroxy nitrit
per mit</w>
parti cles.</w>
pa i
oxygen ,</w>
ox ine</w>
over- expressed</w>
osteoc last
ost ri
or al,</w>
oni um,</w>
on us</w>
on )</w>
og lyco
off ending</w>
numb er.</w>
non- malignant</w>
non malignant</w>
nitroprus side.</w>
ni ff
neuro active</w>
necessit ated</w>
ne omycin</w>
n s.</w>
mou th,</w>
mograph ic</w>
microgram s,</w>
microg/ kg,</w>
mg/ K
meth anesulf
medic ine,</w>
maz e,</w>
mas k</w>
marrow ,</w>
manner s.</w>
m L,</w>
loth o</w>
liver -specific</w>
limit ed,</w>
ligand ed</w>
l -induced</w>
kine tics.</w>
ket amine-induced</w>
iter rane
ison s</w>
inver ted</w>
in- sensitive</w>
in spir
in activation,</w>
impl ied</w>
il le
hyperglyc emia.</w>
hydrochlorothiaz ide,</w>
hormone- binding</w>
hind limb</w>
h os
h CTR1</w>
go als</w>
glycos aminoglyc
ger iatric</w>
form yl
fair ly</w>
extract s.</w>
exp ensive</w>
exercis ed</w>
exclu sive</w>
est riol</w>
ery the
ep oprost
encomp assing</w>
en ia,</w>
en i
en ari
emia -induced</w>
elev ates</w>
electro physiology</w>
educ ation</w>
ec gon
eIF4 E</w>
dyskinesi as,</w>
down ,</w>
disturb ance.</w>
disrup tion.</w>
discus sed,</w>
dis til
diatrizo ate</w>
detail .</w>
den at
den afil</w>
defin it
de -binding</w>
damag e-
cytoplas m,</w>
cost- effective</w>
convol uted</w>
consecu tively</w>
conduc ting</w>
cock tail</w>
cl adrib
ciprofloxac in.</w>
chore oathet
cholest yr
chlorzox azone</w>
chlor prop
chlor ine</w>
ch ose</w>
caus ally</w>
cathe ter.</w>
casp ases,</w>
cardi oselective</w>
car nos
car inii</w>
can av
calcul ate</w>
c I
but yn
br ucine</w>
bi ochemically</w>
beta- galactosidase</w>
beta- carb
beta 3-
beta -</w>
benzyl oxy
behaviour s</w>
before .</w>
bef radi
bacter ium</w>
b li
b id</w>
azot emia</w>
ati l
at op
anxi oly
amphet amines</w>
altern atives</w>
alfuz osin</w>
alf a</w>
al ),</w>
adop ted</w>
adenocarcin omas,</w>
acet o
ab use
] :</w>
X PD</w>
Wnt/ beta-catenin</w>
Treat ment
Ta king</w>
Smac /
SPAR C</w>
S om
Re ye's</w>
RU 486</w>
RNA )</w>
R 3</w>
Pro b
PT PN
PD ),</w>
P R,</w>
On set</w>
O d
O ST
O P)</w>
NT S</w>
NP .</w>
NO -induced</w>
NAT 2*
NA FLD
N-acetyl- l-
N ore
N erve</w>
N av
N Z
Min im
MPO- ANCA</w>
MC s.</w>
MAP K/
M acro
M BP</w>
Levo simendan</w>
LP O</w>
JN K-
Ig G1</w>
II alpha</w>
I V-
Hepar in-induced</w>
HepG 2.</w>
H en
Ger man
GSTP 1,</w>
GS K
GC s</w>
G a
F FA</w>
E stim
E osin
Dog s</w>
DS F</w>
Cyto kine</w>
Cyclospor ine</w>
Con focal</w>
Comput ed</w>
Cac o
CYP2 J2</w>
CPT -1
CP 2</w>
CA SP
Bu propion</w>
Braz ilian</w>
BRCA 2</w>
B ud
B AD
Alum inum</w>
Activ ities</w>
AS ),</w>
A tropine</w>
A c</w>
A SC
< =</w>
8 5.
7 A</w>
6 3.
5 '
46 ).</w>
4-hydroxy nonenal</w>
4-(methylnitrosamino)-1-(3-pyridyl)-1-butan one</w>
4 %;</w>
37 ).</w>
35 ).</w>
3, 2-
3 5-year-old</w>
3 1
29 2</w>
28 7
2. 9
2, 2'-
2 %;</w>
16 6</w>
14 th</w>
1- NP</w>
1 0.5</w>
0. 21</w>
0 19
(p< 0.01)</w>
(p< 0.001)</w>
(RA S)</w>
(RA R
(R R)</w>
(NT R)</w>
(I /
(H P
(GSH- P
(ER OD)</w>
(ELIS A).</w>
(E S
(CG RP)</w>
(CB Z)</w>
(C C
(7 0</w>
(4- methyl
(2-ethylhex yl)</w>
(1 2%)</w>
( un
( except</w>
( R</w>
yst roph
with ,</w>
well- recognized</w>
wa y,</w>
virt ue</w>
vi z
verthel ess</w>
vasospas m.</w>
vasodilat ors</w>
vag otomy</w>
un stimulated</w>
u te,</w>
transi tion.</w>
transfec tion.</w>
transduc tion,</w>
toxic osis</w>
to facitinib</w>
tic in</w>
ti a</w>
thyro id
theophyl line-induced</w>
th in</w>
ten ance</w>
t s)</w>
t ),</w>
synthesiz ing</w>
sympath o
sureth ral</w>
sur ge
support .</w>
sulfonyl urea</w>
substitu ents</w>
stop- exposure</w>
stitu tion</w>
st en</w>
spectro scopic</w>
specimen s,</w>
species -specific</w>
speci alized</w>
spec ified</w>
significant ).</w>
signal .</w>
signal -
ser ially</w>
sel dom</w>
se en,</w>
righ ting</w>
rever sion</w>
residu es,</w>
reproduc i
repor tedly</w>
relax ations</w>
ras H2</w>
radioimmuno assay</w>
rac em
r 1</w>
quinol ones</w>
quin oxal
pul mon
psychos ocial</w>
psycho active</w>
protein ).</w>
previ ously,</w>
prec i
pre- clinical</w>
phosphati d
phenylephr ine.</w>
peroxid es,</w>
permeth rin,</w>
perc ent,</w>
per oxidative</w>
pep per
pathogen s</w>
pat er
parav entricular</w>
p emphig
organo phosphates</w>
omet asone</w>
ocyte -derived</w>
obes ity-
o sid
nigr al</w>
niac in,</w>
new ,</w>
nefazod one</w>
nause a.</w>
narrow ing</w>
n ing,</w>
miner alization</w>
midazol am.</w>
micrograms. kg-1.
micro tubules</w>
micro circulation</w>
mg/kg/ d)</w>
mg/d L)</w>
methoxy phenyl)
meth im
met allic</w>
mes yl
menadi one</w>
mat ine</w>
local ization.</w>
littermat es</w>
levob up
leishman iasis.</w>
k /
item s</w>
ist er</w>
is or
is ocyan
irrit ability</w>
irb es
intracerebroventricul arly</w>
inges tion,</w>
in takes</w>
immuno deficient</w>
il li
ic opl
ic ari
hypospadi as</w>
hyperinsul inemia</w>
hyper calca
hydroxy methyl
hydro gen
hs p</w>
hiccup s</w>
hem ochro
half- lives</w>
guan os
gro und
graf ting</w>
gr and</w>
gluc oside</w>
gest od
gangli a.</w>
galact ose</w>
fur ther,</w>
flud arab
factor- I</w>
ezetimi be</w>
ey e.</w>
extremi ties.</w>
examin ations.</w>
eu phor
establ ishes</w>
erythro id
eple renone</w>
electrophore sis,</w>
electrocardi ograms</w>
efficac ies</w>
du e,</w>
dron edarone</w>
down- regulation.</w>
domin ated</w>
disturb ing</w>
diseas e;</w>
digox in.</w>
diclofenac .</w>
diag nose</w>
di os
desm opressin</w>
de ma</w>
de duced</w>
day (-1)</w>
dang er</w>
countri es,</w>
concer t</w>
col iti
coffe e</w>
chlor phenir
chi ll
chal cone</w>
cess ation.</w>
cel i
castr ation</w>
cas e].</w>
cardi otoxic
carboplat in.</w>
candi dat
c ocul
c lob
c ).</w>
bot ulinum</w>
bif unctional</w>
bi ochanin</w>
beclometh as
be an</w>
b y,</w>
b w</w>
b erg
arteri ography</w>
art an.</w>
ar ises</w>
antr al</w>
antioxid ant
anti muscarinic</w>
anti atherogenic</w>
antagon ised</w>
angu ineous</w>
an olone</w>
an -treated</w>
amygdal oid</w>
amycin .</w>
amitriptyl ine,</w>
altern atively</w>
adjust ments</w>
adi one</w>
adenos ine,</w>
activit y:</w>
activator s.</w>
Z NS</w>
X O</w>
W y
V NTR</w>
U 37
TNF ,</w>
TC /
Strepto zotoc
St ate</w>
Sr c,</w>
SO CS
SO (4)</w>
SG LT
S b
S PI
Repor ter</w>
RNA -mediated</w>
R e</w>
Par ticul
Pancre atic</w>
PO ),</w>
PLA (2)</w>
P si
OD N</w>
OATP1B 3</w>
O CD</w>
NS ,</w>
NR 2B</w>
NF- E2-related</w>
NAC .</w>
NA D</w>
NA -
N-nitrosodi ethylamine</w>
N- ethyl-
N- (2-
N, N
N ig
N VP</w>
N MB
Mon o
Mid azolam</w>
Main tenance</w>
MRP 3</w>
M dr
Lif e-
LTC (4)</w>
LNCa P-
LC- MS/MS</w>
JN K1</w>
Isoniaz id</w>
Interfer on</w>
IL-1 beta.</w>
IL-1 R
IFN gamma</w>
Hipp ocamp
Hem olytic</w>
HO -
HB- EGF</w>
GJ IC</w>
GG T</w>
GC S</w>
G old
Forty- two</w>
Fas -
Ex peri
E O
Dox -induced</w>
Dan ish</w>
Cs A.</w>
Col l
Coca ine-
Cobal t</w>
Cdc 25
Ca M</w>
CV D</w>
CE S
CD CA</w>
C annabin
C a-
C 6
Bor tezomi
Bi ol.</w>
Barret t's</w>
Bac lofen</w>
Ba y</w>
BP H</w>
B MT</w>
Ascor bic</w>
As th
Americ ans.</w>
AS ).</w>
AL A</w>
AK I</w>
AA H</w>
A tox
A s.</w>
9 26</w>
9 1%</w>
7 %;</w>
5 3-
5 %;</w>
48 ;</w>
4 7)</w>
3 6-
3 25</w>
27 0</w>
27 .</w>
2, 4,6-
2 );</w>
1B 1,</w>
1A )</w>
14- year-old</w>
12 6
10 q
10 -20</w>
1, 500</w>
1, 5-
1, 00
1 q
1 G</w>
0. 23</w>
.go v</w>
-10 1</w>
-1 9
(i NOS),</w>
(S -
(Ph IP)</w>
(PC NA)</w>
(P 450
(II )-
(H U
(CI ):</w>
(AL L)</w>
(ADH D)</w>
(A UC
(3 3.
(2, 4-
(1 9.
( OX
wind ow
ventric le,</w>
vec uroni
vastat in-induced</w>
up .</w>
unevent ful</w>
under -
un altered.</w>
ubiquit inated</w>
typ e-1</w>
two- hybrid</w>
tro leandom
tri phenyl
transcription- PCR</w>
tiz ed,</w>
tion ),</w>
thyro id-
thi azine</w>
tes tis,</w>
tap ering</w>
tap ered</w>
suppress ors</w>
sul fur
sub thalamic</w>
sub dural</w>
strati fication</w>
steroid ogenesis.</w>
step- through</w>
st ored</w>
spermat ozo
sim ulation</w>
si fication</w>
serocon version</w>
semisyn thetic</w>
scal p</w>
ro und</w>
rid delli
ri ti
ri es</w>
reser ved</w>
reinfor ced</w>
reac ts</w>
r t-PA</w>
r Hu
qui escent</w>
protoc ols.</w>
protec tive.</w>
progest ins</w>
proble ms,</w>
pressu res,</w>
preced e</w>
pr o</w>
por tions</w>
polymy ositis</w>
phag ia</w>
per tin
pathophysi ology.</w>
partur i
parenchym a</w>
paradig m.</w>
par kin</w>
pair -fed</w>
p53- mediated</w>
p ontine</w>
p ine
ovari es</w>
osteo arthritis.</w>
organ otypic</w>
op id
on ine-
omethyl )
ol ochi
oca proic</w>
o ocytes.</w>
non- significant</w>
netilmic in</w>
ne a,</w>
myc otoxins</w>
mut ants,</w>
moderate- to-
mm 3</w>
micro injections</w>
mg/m2/ day</w>
method ology</w>
meta- analysis.</w>
met aplasia</w>
me tin</w>
me fenamic</w>
marrow .</w>
mainten ance.</w>
low -</w>
literat ure
lipoly tic</w>
lig ation.</w>
li ber
leuk ocytoclastic</w>
lact one</w>
kappa -
issu e,</w>
iod inated</w>
intrav it
intr ag
interleukin- 6,</w>
ine mi
ind ole
in telli
immuno fluorescent</w>
hyperther mic</w>
hyper thyroid</w>
hyper active</w>
hydroxy ethyl
hydro peroxides</w>
hot -
hormone- refractory</w>
homeob ox</w>
gyr us.</w>
gra de,</w>
glyco sides</w>
glutam ate-induced</w>
glibenc lam
ge ometric</w>
g ;</w>
fet us.</w>
fenflur amine,</w>
exten sor</w>
experi enc
exist .</w>
estr us</w>
er :</w>
epi -
eosinophil ia,</w>
entac apone</w>
ent- to-treat</w>
ent ary</w>
ence :</w>
en sed</w>
en ables</w>
eleg ans</w>
electroph il
earli er.</w>
dr aw</w>
dox az
disul fi
differen ce.</w>
di glyc
design ing</w>
depriv ation.</w>
depren yl</w>
deoxy uridine</w>
degener ating</w>
d um
cycl os
cop e</w>
controver sy</w>
computer -
compon ent,</w>
com ycin</w>
colony- forming</w>
clo t</w>
circu itr
ch aracter</w>
calmodul in-dependent</w>
cal bind
caffe ine-induced</w>
cTn T</w>
c-myc ,</w>
c ent.</w>
bis phosphon
beta-caten in,</w>
beta 1,</w>
bed time</w>
be than
bas ophilic</w>
b ath
applic ation,</w>
antibio tic,</w>
anc erous</w>
anaesthe sia,</w>
an eth
am orph
alve ol
alpha- methyl-
alpha- mediated</w>
alpha (1
all opregn
aldehy de
acne .</w>
acetyl amino
acenoc oumarol</w>
a- az
a y</w>
a ren
XR E</w>
W NT
V DR
Thirty- three</w>
TX N
T Q</w>
Ste ad
St .</w>
Simult aneously,</w>
SV R</w>
STUD Y:</w>
STAT 3,</w>
SP- B</w>
SOURCE S:</w>
SNP s,</w>
SF -1</w>
S I</w>
Rhe um
Ras -
RE SEARCH</w>
R NF
Pu er
Pot assi
Poly chlorinated</w>
PON V</w>
PML- RARalpha</w>
PL A2</w>
PI3 K,</w>
Over- expression</w>
Ovari an</w>
Oc tre
Ob serv
O me
O SCC</w>
O 2-
Nrf2- null</w>
Na+ ,
NS D1</w>
N-acetyl-beta-D- glucosaminidase</w>
Meth oxy
Med iterrane
MK N
MC D</w>
MATERI AL
M b</w>
L- 02</w>
L or
K LF
Irb esartan</w>
Investig ations</w>
Immunoblot ting</w>
IT PA</w>
I -1
Hu R</w>
Hal oth
HCFC-1 23</w>
HA ART</w>
H2O 2,</w>
H(2)O (2)-induced</w>
Gemcit abine</w>
GSK3 b</w>
GSK-3 b</w>
GS K3</w>
G cl
G Y
Form ation</w>
Flavon oids</w>
Famil ial</w>
FGF R1</w>
F H
Ex acerb
Dist inc
DO -
Cyt os
Coch rane</w>
Ch ina</w>
Celec oxib</w>
CYP3A 4/
CYP2C 8
CX C</w>
CR /
CI P</w>
CH E
CD K</w>
CA P
C- ->
C d.</w>
C ST
Bi ological</w>
BH A</w>
B Z</w>
Ator vastatin</w>
Asperg illus</w>
Anth rac
Acqu ired</w>
AT O
AC E2</w>
ABT- 88
A my
A bl
7 5.
6- mercaptop
50 ),</w>
5, 4'-
5 5,</w>
4 90</w>
3 ]</w>
3 70</w>
27- hydroxylase</w>
200 0.</w>
20 %.</w>
2,3,7,8-tetrac hlorodibenzo-p-diox
2 50
19 6
19 4</w>
15 9</w>
14 /
13 7</w>
11b- HS
11 beta-HS
0.00 6).</w>
-2 B</w>
(VD R)</w>
(T L
(P C)</w>
(M MA
(M L
(HO -1),</w>
(GST M
(G D
(F AN
(E (2))</w>
(COX )-2</w>
(C y
(C DH)</w>
(A F)</w>
(80 %)</w>
(7 0%)</w>
(1 8%)</w>
( cumulative</w>
( cases)</w>
( 8)</w>
yclin es</w>
y a</w>
xenograf ts,</w>
weak ness.</w>
vul g
vir -induced</w>
view ed</w>
vegetabl es,</w>
vasospas tic</w>
v orinostat</w>
ur y</w>
univer sal</w>
u ,</w>
tri hexyphen
transcri bed</w>
tra its</w>
toler ability,</w>
tim ulatory</w>
thix ol</w>
teleph one</w>
tab un
surfac e,</w>
supr aspinal</w>
subun it
stres sor
st u
spectro metric</w>
sp ra
siRNA ,</w>
shar ply</w>
sen ile</w>
selec ting</w>
seizure -like</w>
sec tion.</w>
sc enari
sa quin
s n
s in,</w>
rou te.</w>
ris k-
ribonucle otide</w>
ribavir in-induced</w>
ret ory</w>
relapse -free</w>
reas .</w>
raph ic</w>
pyrethro ids</w>
protein- protein</w>
protein ase</w>
prop anol</w>
pro thrombotic</w>
pressure- lowering</w>
pp m.</w>
poly dip
pluri potent</w>
piperid in
pic olin
phosphon o
phen ethyl</w>
pent avalent</w>
patholog ies.</w>
path ogenesis,</w>
pant oth
pa x
p21 Cip
p 1</w>
ox az
os es.</w>
onco protein</w>
om no
ol ab
ogen s</w>
og uan
occup ied</w>
ob tained,</w>
o dex
non treated</w>
non sustained</w>
neuro kinin</w>
nerv es,</w>
nephrocalcin osis</w>
nephro lithi
neo vascularization</w>
naproxen ,</w>
myelomon ocytic</w>
multicent re,</w>
month s'</w>
mon os
moi et
mod al</w>
mitochondria- mediated</w>
micrograms/ ml)</w>
micro bi
mic -
mg/kg/ day).</w>
metr if
mes n
m m,</w>
lympho proliferative</w>
low er.</w>
loc ations</w>
l- NA
l aryng
l ]
knock ed</w>
kinase- type</w>
is s
insen oside</w>
infarc tions</w>
inf ant
induc ers.</w>
il it
if ies</w>
ide ),</w>
ical cit
hyper coagul
homovan illic</w>
heterodi mers</w>
hemat uria.</w>
head -up</w>
hallucin ations.</w>
half- maximal</w>
gemcitab ine.</w>
g in</w>
fold ;</w>
fol ds</w>
flan k</w>
fenretin ide</w>
expos ures,</w>
examin ations,</w>
ex it</w>
evol ved</w>
eth ion
escul etin</w>
erythro mycin
enzym atically</w>
enhancer -binding</w>
eicosatetra enoic</w>
ed /
dys phor
dog ,</w>
document ation</w>
disor gan
dialy s
diabe tics</w>
deri ve</w>
degu elin</w>
dec ade</w>
de pot</w>
cyt ochalasin</w>
cy st</w>
curren t.</w>
cres ol</w>
coun ts.</w>
copper- transporting</w>
cop lan
consci ous,</w>
cons anguineous</w>
concer ned</w>
comp eting</w>
co ol
clu stered</w>
clinic ian</w>
cholang itis</w>
catech in</w>
casca de,</w>
ca ven
c- F
c DNA.</w>
c ),</w>
bur st
bromodeoxy uridine</w>
bod y
biopsy- proven</w>
benzodiazep ines,</w>
be ver
bas e-
atr an</w>
ather ogenesis.</w>
at oxin</w>
astro l</w>
arteri ol
arec oline</w>
ar son
antigen .</w>
anti- arrhythmic</w>
anore xi
androst enedione</w>
ana erobic</w>
amid o
am ine:</w>
al kine</w>
admis sions</w>
adhe sion.</w>
adapt ations</w>
ac ar
[(3)H] -
Z -treated</w>
Wilm s'</w>
Wil c
W ol
W er
V TA</w>
V II</w>
UGT s</w>
U012 6,</w>
U tili
U SP
Tel misartan</w>
Taq Man</w>
TRA F
TM P-
TMP- SM
T an
T GR
T AA</w>
Sud an</w>
Sign al</w>
SM N</w>
SK-N- SH</w>
S core</w>
Retin oids</w>
Pharmac ologic</w>
PR DX
PDE 4
P450 c
P- gp
OATP 1B1</w>
O S.</w>
N ucle
MMP- 9.</w>
MMP -1,</w>
M ass</w>
Lis in
L ess</w>
L AM
K R-
K B-
K 1)</w>
Iso flurane</w>
IC H.</w>
H (1)</w>
Fos B</w>
Forty- eight</w>
Fentan yl</w>
FT R)</w>
F en
F L</w>
F G
ED (50)</w>
E 6</w>
Dep end
Da h
DI AB
D 18</w>
Cr -
Cor tical</w>
Chro mium</w>
Chlor am
Can adian</w>
Califor nia</w>
CP K</w>
CI -
CG I-
C max</w>
C SCs</w>
All ergic</w>
AR s</w>
AKR 1C1</w>
AIM s</w>
9 %;</w>
80 3</w>
7'- dichloro
6 7.
6 5-
49 ;</w>
4 h</w>
4 1
3 8-
29 8</w>
20 9</w>
2 15</w>
198 7</w>
13. 5</w>
11 ;</w>
1. 2,</w>
0. 45</w>
-2 H-
-1 -dependent</w>
- inducing</w>
)- 3-
) -2,</w>
(m ))</w>
(PK C
(PB MCs)</w>
(P CR
(O A)</w>
(N E
(METH )</w>
(IL- 6),</w>
(HCC ).</w>
(H SC
(GW AS)</w>
(G 6
(C AS</w>
(10(- 6)</w>
(1, 2-
(1 6%)</w>
(1 25</w>
(0. 5,</w>
(0. 15</w>
(+ ))</w>
( at
( CYP2C
( 90</w>
ys :</w>
wom an.</w>
wall s</w>
w k
virus -mediated</w>
vehic le-
urin alysis</w>
um ;</w>
ul us</w>
ubiquitin- proteasome</w>
tyros ine-
tumour s,</w>
treatment ).</w>
trache a</w>
top o</w>
thromb olysis</w>
thre e,</w>
therapeu tical</w>
thalam us,</w>
tel mis
techn ical</w>
suppl ied</w>
sulf atase</w>
sub set
sub mucosal</w>
stro ke
stat ins,</w>
sp ic
simul ations</w>
sens ations</w>
self- renewal</w>
sedi mentation</w>
scat tered</w>
s niff
s anguin
relationshi p,</w>
qu adri
proti line</w>
protein ;</w>
process ing.</w>
prob e.</w>
prim idone</w>
pre pulse</w>
poly drug</w>
poly acrylamide</w>
pl ast
pig mented</w>
phosphodi ester
per il
pe tic</w>
pe ti
pai red-
p75 (NTR)</w>
p38- MAPK</w>
p.o .),</w>
p em
osom al-
orbi di
orb it
opyr idine</w>
opr ide</w>
opid og
one 's</w>
ona dis
on to
on azole.</w>
omep razole.</w>
om yl</w>
om a
oid -induced</w>
od -
occup anc
non ischemic</w>
neuro transmission.</w>
neuro biological</w>
necro p
ne d.</w>
naf cillin</w>
n- hex
my oglobin</w>
muscul oskeletal</w>
moi eti
micromol/ l)</w>
mg/m (2)/
metfor min.</w>
melaton in.</w>
mammal s,</w>
ma kal
long ev
length s</w>
l ess.</w>
knock- down</w>
kinase- 1</w>
isol ated,</w>
iso quinol
is oc
investig ator</w>
investig ational</w>
intraci sternal</w>
interv als
ing "</w>
ine -1
indic a</w>
indi spensable</w>
incid ence.</w>
inc ap
inadver tent</w>
in- 4-
in struc
in k</w>
immuno assay.</w>
imidazol e-
ifi ed,</w>
ibu tilide</w>
i. m
hypop ar
hypopar athyro
hist amine,</w>
hi g
har m</w>
hal ation</w>
gynec ologic</w>
guan idine</w>
gly cin
glucuron ides</w>
fraction ation</w>
fing er
fif ty-
f ish.</w>
f 1</w>
explant s.</w>
ester ified</w>
equiv oc
energ etic</w>
elder ly,</w>
el se
early- stage</w>
distingu ishing</w>
distil led</w>
disease- modifying</w>
di ed,</w>
des cent</w>
dela ying</w>
defin es</w>
dd I</w>
d one.</w>
cyclohex yl
cre ating</w>
cong es
comm enced</w>
collagen ase</w>
co repressor</w>
co expression</w>
clopidogrel .</w>
clinic ally.</w>
clar ified</w>
chi mer
ch es</w>
cand es
bus ulf
bul ky</w>
bp m</w>
bod y-
blun t</w>
bival irudin</w>
bezafib rate,</w>
beta- adrenoceptors</w>
barbit urate</w>
bar k</w>
b ones</w>
b epridil</w>
azid o-
av anc
auto antibody</w>
aut onom
ator y,</w>
ather ogenesis</w>
arsenic -exposed</w>
ars onic</w>
aro tid</w>
ara- C</w>
ar ms.</w>
ar ides</w>
antipsycho tic-induced</w>
ann ot
amitriptyl ine.</w>
am )</w>
alcohol ism</w>
agg rec
af 1</w>
activ iti
activ ated,</w>
acet oxy
[ SD
ZO -1</w>
Y et,</w>
Turk ish</w>
Tric hloro
Tre ating</w>
Tr yp
TRAIL ,</w>
TK 6</w>
T2- weighted</w>
T yr</w>
T PE
T AC</w>
Struct ure-activity</w>
Star ting</w>
St ates,</w>
Ser tr
SS c</w>
SI N
SC r</w>
RS ,</w>
R el</w>
R ;</w>
R 2)</w>
Poly cyclic</w>
PPAR gamma.</w>
PO X</w>
PIK3 CA</w>
PE .</w>
PDE 4</w>
PCB s,</w>
P rac
P ic
Op tic</w>
O Cs</w>
O ATP-
Notch 1</w>
Na+/ H+</w>
NY HA</w>
N- desmethyl
N CX
MG 132</w>
ME F
ME )</w>
MDR -1</w>
MAP ,</w>
LT G</w>
L ute
L AD</w>
L 5</w>
L 1,</w>
K ap
In dependent</w>
IL-1 alpha</w>
II b/
IFN- gamma
I D)</w>
Hg ),</w>
HSD 17
HO -1.</w>
HC T</w>
HC -
H VA</w>
G inkg
G MP</w>
G M
Ful minant</w>
Forty- five</w>
F ac
Em erg
Ear lier</w>
ER R</w>
ER BB
E2 F</w>
Dis co
Di ff
De fec
DSM- III-
D uchen
Constitu tive</w>
Clinic ally,</w>
Cl opidog
Cl 2)</w>
Cin nam
CYP1 1B1</w>
CR F
CL A</w>
CDK4/ 6</w>
CD 38</w>
CC -
C lu
BL M</w>
B T</w>
B ;</w>
As2O 3.</w>
As2O 3,</w>
As(2)O(3 ).</w>
Aldo sterone</w>
Ag )</w>
Ac tive</w>
AN CE:</w>
AID S-related</w>
A G)</w>
6 50</w>
5-HT 3</w>
5 2,</w>
5 00,</w>
48 h</w>
4- 2</w>
4 1)</w>
3- treated</w>
2C 19</w>
200 6</w>
2- methoxy
2', 3'-di
18 2</w>
17 ;</w>
16 ,
15 5</w>
12- lead</w>
10 00
1- like</w>
019 10.
0.5 5</w>
0.00 8).</w>
0.0 4,</w>
0.0 25).</w>
0.0 %</w>
.00 1</w>
- square</w>
- Arg
(p< 0.01).</w>
(miRNA s)</w>
(h ER
(S )</w>
(R V
(P ro
(N P
(MT D)</w>
(III )
(C FTR)</w>
(B C
(3 8.
(2 2.
(1 3
( days</w>
( beta</w>
yl ation,</w>
y ol
whole- body</w>
wh enever</w>
ven tional</w>
valpro ate-induced</w>
ut lin
up- regulated.</w>
up ,</w>
un usually</w>
un common,</w>
trun k</w>
trihydroxystil bene
treatment -resistant</w>
treat able</w>
tran surethral</w>
termin ally</w>
ten -
suspec t</w>
susp ended</w>
sulf onic</w>
sub toxic</w>
sub populations</w>
str ai
sit e-specific</w>
si sed</w>
she ep</w>
sh ell
sex .</w>
semin iferous</w>
seg ments.</w>
scler oderma</w>
schedul e,</w>
ribo flavin</w>
reviewe d,</w>
res in</w>
repress ing</w>
replic ate</w>
renin- angiotensin-
rac e,</w>
r =
quin azol
quin ap
questionnai re.</w>
quater nary</w>
pyren e,</w>
prim ates.</w>
predomin ance</w>
prec ancerous</w>
pre- eclamp
pr il
postis che
possi ble,</w>
ple ur
platelet s,</w>
plasma -
plan ar</w>
pimec rolimus</w>
phenyl ]
persi sted.</w>
perin uclear</w>
per phenazine</w>
parg yl
palmit ate</w>
oxaliplat in,</w>
over activity</w>
op eptide</w>
omon as</w>
olochi c</w>
ol ].</w>
od es</w>
ob ste
o ther,</w>
o edema,</w>
not ed,</w>
normal -
nor dihydro
nitroglycer in,</w>
natur alistic</w>
n adolol</w>
mut ation
mononit rate</w>
mil rin
micromol/ L),</w>
micrograms/kg/ min</w>
micro dissected</w>
melan ocytes</w>
melan in</w>
medic ally</w>
mechanis tically</w>
mdr 1</w>
mal athion
m ast
long est</w>
local izes</w>
lesion al</w>
le )</w>
l on</w>
l a</w>
ip ratropium</w>
ing -related</w>
inflammat or
in- O-deethylase</w>
in active.</w>
immunofluoresc ence.</w>
identifi able</w>
id ene
hyper oxia</w>
hydroxy- 3-
hol ds</w>
hi ther
heterodi meric</w>
h ands</w>
gyr us,</w>
gynec ological</w>
gener ational</w>
gen u
gaug e</w>
gastrocnemi us</w>
foci .</w>
fluoranth ene</w>
ferul ic</w>
fail ures</w>
f ai
extract ,</w>
explan ations</w>
expl ant</w>
ex em
eti d
ethel ess,</w>
es in</w>
equiv ocal</w>
eosinophil s.</w>
entr y,</w>
enti ty.</w>
en oximone</w>
emphasi zed</w>
elas tic</w>
e ren
e meto
dyston ia,</w>
dri ves</w>
dis solution</w>
dexamethas one-treated</w>
des er
dementi a,</w>
dec ades</w>
datab ase.</w>
cy ano
contrac tion.</w>
cont ext
conclu sive</w>
compl aining</w>
com orbidi
co activators</w>
clas s.</w>
ceti rizine</w>
cef otet
caud ate-
catechol amines.</w>
cardiomy opath
capill aries</w>
behavior al,</w>
bal anc
b are
b FGF
az one.</w>
at us</w>
asym metric</w>
aspirin- intolerant</w>
artesun ate</w>
are tic</w>
aquap orin</w>
approach es,</w>
ap art
anti rheumatic</w>
anti pyre
anti globulin</w>
anti fibrotic</w>
ant i</w>
anser in,</w>
anorec tic</w>
ann-Whit ney</w>
androgen- responsive</w>
analog s,</w>
an ol,</w>
alpha1- adrenoceptor</w>
all- trans-
ak ed</w>
adhe rent</w>
aconit ase</w>
[OR ]</w>
Z R-
VKORC 1,</w>
UGT1A 6</w>
UC N-
U K
U 266</w>
TI M
T c-
T 1
Strept ococcus</w>
SU 54
ST N</w>
S ide-
Re sid
R W
Pharmac eu
PP ,</w>
PGE 2.</w>
PGC-1 a</w>
P< 0.01)</w>
P-glyco protein,</w>
P-g p.</w>
P ro</w>
P op
OX )</w>
ON )</w>
Nause a</w>
NF-kappaB- regulated</w>
N- treated</w>
N ot</w>
N et
More over</w>
Mn TB
MI ),</w>
MDR 1,</w>
MDB GN</w>
M at
M K</w>
LPS- treated</w>
L eptin</w>
L ang
L a
L B
Ketocon azole</w>
Inter leukin</w>
Inc id
In jec
In d
INK 4
IL- 5,</w>
I di
HT ),</w>
H ed
H V</w>
H AL
Gef itinib</w>
GL U
GCL C</w>
G AD</w>
Engl ish</w>
Echocardi ography</w>
ERR gamma</w>
ER /
EC P</w>
Dec rease</w>
DP .</w>
DOPA C</w>
DLD -1</w>
D V
D SC
D 1/
Contr ary</w>
Con cer
Chin es
CYP3A 5,</w>
CT ,</w>
CR .</w>
CD40 L</w>
CC ).</w>
C/ C</w>
C Q</w>
B x
B (2)</w>
Aut opsy</w>
Amiodar one-induced</w>
Adju vant</w>
Ad nab
AT O,</w>
AF B1</w>
ABT-7 37</w>
A27 80
A s,</w>
A plastic</w>
A mit
A 5</w>
: 1</w>
9 6,</w>
9 1,</w>
7 9.
7 5)</w>
6- mediated</w>
6 7-year-old</w>
5 6,</w>
5 59
4, 4',5-
4 9-year-old</w>
4 5)</w>
4 1-
27 5</w>
200 5.</w>
1c 7</w>
16 1</w>
14 )-
12 3
1. 3%</w>
0.05 .</w>
0.0 3),</w>
0 3</w>
- J
(UD CA)</w>
(Tr x
(SIAD H)</w>
(S CL
(RS V)</w>
(PC R-
(P P
(O V
(K O)</w>
(H R),</w>
(H M
(H I
(E x
(BB B)</w>
(B MP
(B H
(5. 0</w>
(5- 20</w>
(4- fluoro
(3 6%)</w>
(3 ,</w>
(2+ ).</w>
(2 3%)</w>
(1 98
(- ),</w>
( especially</w>
( SULT
( JAK
yr ,</w>
y sen
wor th</w>
wash -out</w>
w t/
w ol
vaso relaxation</w>
vasculat ure.</w>
vap or</w>
uter o.</w>
ur an
un ra
typ e)</w>
tro pon
transduc ers</w>
transcript s,</w>
trans version</w>
time- of-
tic- uremic</w>
ter m.</w>
tamoxifen -resistant</w>
sy l</w>
summar ize</w>
sulfon amide</w>
stimul ator</w>
stat e-
specific ally,</w>
somnol ence,</w>
sodi um-dependent</w>
sl udg
sir tin
simul ate</w>
sic k</w>
sh am
self- administration.</w>
sel f</w>
sed ating</w>
scler osing</w>
s ati
rhyth ms</w>
rhyth m,</w>
rhiniti s.</w>
resten osis</w>
replic ation,</w>
relax ation.</w>
regurgit ation.</w>
raloxif ene.</w>
radi ograph
rab ep
quin one-
quantit ation</w>
pyrimeth amine</w>
protoporph yr
prefer able</w>
pr act
pollut ants,</w>
plasmid s</w>
ph lor
perman ently</w>
patient s].</w>
parac ellular</w>
par asi
p R
ozym e</w>
oxy sterols</w>
or /
op ril.</w>
ol ized</w>
ochol ester
oc utaneous</w>
o,p'- DDT</w>
o ocyte</w>
nucle olar</w>
not e,</w>
nodos um</w>
night time</w>
ng/ d
neoplas m</w>
myasth enic</w>
mon omorphic</w>
model ed</w>
microsph eres</w>
mg/m l)</w>
mg/d l)</w>
methyl transferases</w>
methyl selen
melaton in,</w>
meglum ine</w>
man n</w>
man 's</w>
lymph omas.</w>
lymph atic</w>
lum azen
long- term,</w>
lipo protein-
lev othyro
lead ,</w>
l-DO PA-induced</w>
l- arginine</w>
ke ep</w>
kaempfer ol,</w>
k i</w>
jejun um</w>
itrac onazole,</w>
irrig ation</w>
intr amy
insulin- resistant</w>
influenz a</w>
induc ed-
indina vir.</w>
ind apam
inc o
in stituted</w>
imip enem
im mer
ic -like</w>
ia ;</w>
hypoparathyro idis
hypog onadis
hypo thyroid</w>
hyper lipidemia,</w>
hydro cortis
hydro cephal
hom ozyg
hemi paresis</w>
gro w</w>
gli oma.</w>
g m</w>
ful ness</w>
foci ,</w>
flow s</w>
five fold</w>
fetus es.</w>
fer tile</w>
fer rous</w>
fat ,</w>
famil y-based</w>
factor- kappa
ethyl ]-
estradiol -17
ent ally</w>
ede ma
e NOS,</w>
dum m
docetaxel ,</w>
dig it</w>
differen t,</w>
diethylstilbest rol
di en
depolar izations</w>
dela y.</w>
dehydr ation</w>
d .,</w>
cyprohept adine</w>
cyc le-
cul min
consol id
congen er</w>
compli ance.</w>
cobal amin</w>
co ded</w>
ch it
catas troph
casp ases.</w>
carcinogen -induced</w>
cach ex
bis phosphonate</w>
beta-block ers.</w>
bet ax
ballo on
baclofen .</w>
aver sive</w>
auth or</w>
ati dine</w>
at ab
ars ine</w>
argin ine-
applic ability</w>
ap re
aor ta,</w>
antioxid ant.</w>
anti proteinuric</w>
antec ed
an astro
an ase</w>
amin ocaproic</w>
ambi gu
al ).</w>
ag ly
advantage ous</w>
adrenocortic otropic</w>
accentu ated</w>
Wil ms</w>
W F</w>
Vari ation</w>
VEGF- A</w>
V s</w>
V L</w>
Thirty- four</w>
TP .</w>
TIM P-2</w>
TGF beta1</w>
T C)</w>
Sup plementation</w>
SLC 22
S AR</w>
Reg ular</w>
Raf -1</w>
R IP
Pre valence</w>
Potassi um</w>
PI NK1</w>
PD T</w>
OV- 3</w>
O A.</w>
Nimesul ide</w>
NAT 1*
N- oxide</w>
N,N ',
N -</w>
Mut ant</w>
Methyl phen
Meth od
Mediterrane an</w>
MS 1</w>
MS -2
MS ),</w>
MRP 4</w>
MN U</w>
ME K1</w>
MC ),</w>
MAG E-
M X</w>
M MT
LO H</w>
LC- PK
L-Dop a</w>
L- C)</w>
Ki- 67</w>
K562/ A
Intr alip
In tensive</w>
In j
Ibu profen</w>
II /
Hypoxia- inducible</w>
Hydro gen</w>
Hsp 27</w>
HPL C-
HLA- DR</w>
HC ,</w>
H (2)</w>
GE M</w>
G all
G S-
G O
G E)</w>
G DNF</w>
Fish er</w>
Fg f
Fas -mediated</w>
F lumazen
F ib
F a
F S
F AAH</w>
Exacerb ation</w>
Effec tiveness</w>
ET -1,</w>
EC s,</w>
E MMP
Doxorubic in-induced</w>
Disco very</w>
Dipyridam ole</w>
Decreas es</w>
DN .</w>
DE S-
D BP
D 21</w>
D -1</w>
Con clu
Compar isons</w>
Colchic ine</w>
Chem opreven
Cdk 2</w>
Carri ers</w>
Carb on</w>
CYP 450</w>
CD4 4
CC R2</w>
CC K
CB (2)</w>
CAT ,</w>
CA R,</w>
C> T,</w>
C SC
C 8
C 3435T</w>
B 1)</w>
Aor tic</w>
Adi po
AT F-
AT (1)</w>
AP OB
AP -1.</w>
AN F</w>
AD R.</w>
ACE i</w>
A ffec
9 37</w>
88 6</w>
8 4.
77 9</w>
7 -1
60 %,</w>
6 9.
6 8-year-old</w>
6 2.
5 4,</w>
4 6,</w>
4 20</w>
35 .</w>
30 %,</w>
3- h</w>
3'- untranslated</w>
3 9-year-old</w>
3 8)</w>
25 6</w>
23 /
2 12</w>
2 1),</w>
18 5</w>
14. 5</w>
1. 1.
1. 00
1- positive</w>
0.5 2</w>
0 7</w>
-2 9
) 2</w>
(p H</w>
(i ))</w>
(S O
(N S)</w>
(N N
(N HE
(N B
(M A)</w>
(L-NAME )</w>
(L N
(IL-1 beta)</w>
(H MG
(ELIS A)</w>
(E MT)</w>
(E )</w>
(C PT
(C D)</w>
(AZ T)</w>
(AL P)</w>
(6 0%)</w>
(3 5.
(2 7.
(10 -100</w>
(1 3%)</w>
(+/ +
( more</w>
( mal
( alpha</w>
( SU
( F</w>
( CY
zym e</w>
y ou
wor d</w>
we ar</w>
w w
vulgar is</w>
vic tim
vect or-
ve )</w>
va sive</w>
up dated</w>
trou bl
troglitaz one-induced</w>
til l</w>
ti m</w>
ti bolone</w>
thromb ocy
thic k</w>
tetra ethyl
te icopl
tan shinone</w>
syncy ti
surviv in.</w>
sub threshold</w>
sub lines</w>
sub endocardial</w>
ste ine</w>
star vation</w>
sotal ol,</w>
silenc ing.</w>
ser ine-
selen it
selec tivity.</w>
screen ing,</w>
s wee
run -
risperid one-induced</w>
rig osertib</w>
rhabdomy olysis,</w>
responder s,</w>
repa ired</w>
ren dering</w>
remin is
reminis cent</w>
recur ring</w>
recogn i
re pressive</w>
re mitted</w>
rapamycin .</w>
quanti fied.</w>
quad rup
pul sed</w>
projec t</w>
preser ves</w>
prescrip tions</w>
prec is
pot enc
polymorph ous</w>
poly amines</w>
poly (ADP-ribos
ple as
phot odynamic</w>
pheno thiaz
ph asi
perid in</w>
peri ventricular</w>
peri metry</w>
perfu sion,</w>
per zine</w>
per mis
parti cles,</w>
panc reas,</w>
pan- caspase</w>
p27(K ip1)</w>
p o</w>
p ethidine</w>
p ed</w>
p S
oxi me
ou tward</w>
ot es</w>
or aph
opri m</w>
omycin -induced</w>
olog ist</w>
ol -mediated</w>
offic in
odi stri
occur ,</w>
oc r
ob idoxime</w>
o da
non- responders</w>
nanop article</w>
myalg ia.</w>
mu M)</w>
monocyt es/
mono -</w>
molecul e-
minim ized</w>
micromol/ L.</w>
micrograms/ ml,</w>
microg/m L)</w>
microcephal y</w>
micro L</w>
mg/m L</w>
mg/kg/ day),</w>
methyl ation-
methy leth
metabolis ing</w>
mercur y-
me da
me at</w>
matrix- assisted</w>
mGluR 5</w>
m asses</w>
ly tic</w>
low- affinity</w>
limit ing.</w>
lim its.</w>
li um
lea f</w>
lansop razole,</w>
kal a-az
it ch
involve ment,</w>
interleukin-1 b</w>
interfer on
infu sion)</w>
inf ancy</w>
incub ating</w>
in stability,</w>
in direc
in activates</w>
ili br
ide ;</w>
hypokal aemia</w>
hypocalc emia</w>
hyperpla sias</w>
hither to</w>
histopath ology.</w>
hist ones</w>
hist amine-
health ,</w>
harb or</w>
h ER
h (-1)</w>
gravi s.</w>
graph y</w>
fu sions</w>
fluoroquinol one</w>
fif teen</w>
fiel d,</w>
feel ing</w>
factor -1alpha</w>
evo kes</w>
elimin ating</w>
ec z
eb sel
double- stranded</w>
dose- dependent.</w>
dos ages,</w>
divid ing</w>
discrimin ative</w>
dis placed</w>
di a</w>
dehydrogen ases</w>
deacetyl ases</w>
de position,</w>
de granul
de grade</w>
cyclooxygenase- 1</w>
cur ve.</w>
cou gh
coplan ar</w>
contraceptiv es.</w>
contra indications</w>
consider ations</w>
cong estion</w>
complic ation,</w>
complex ed</w>
comp act
col ocalization</w>
coeffici ents</w>
co oked</w>
cl ock</w>
cisplat in/
cerebell um,</w>
cauti ously</w>
cas ein</w>
carri ers,</w>
candi di
c-Jun ,</w>
c am
butyr yl</w>
broad ly</w>
biomark ers,</w>
bio assays</w>
bicucul line,</w>
beta- hydroxy
beats/ min,</w>
azoxy methane</w>
az elaic</w>
attention- deficit/hyperactivity</w>
at .</w>
as :</w>
arsenic -related</w>
ari es.</w>
are .</w>
app end
antigen s.</w>
anti tuberculosis</w>
amin olevulinic</w>
am ate.</w>
alpha 4
alcoh ols</w>
again .</w>
a 2</w>
[ 125
Y-2 76
UGT1A 1*
U TR
Tr k
Thirty- eight</w>
TNF- a-induced</w>
TNF RSF
TB I</w>
T C,</w>
T 1)</w>
Suc cin
Sot os</w>
Simil arly</w>
SI )</w>
S exual</w>
S (+)-
Ret inal</w>
Raf /
R s,</w>
R it
R ati
Pu bl
Pro gn
Preven tive</w>
Parox et
PU F
PON 2</w>
P< 0.05)</w>
P od
P ase</w>
P ak
P IL
P HE
P )-
OD .</w>
Nitroglycer in</w>
NO V
NK X
N I</w>
Modi fication</w>
Mitochond ri
Me Hg
Mang iferin</w>
MY CN</w>
MRP 2,</w>
MN K</w>
MC P</w>
LV H</w>
L y
L 4</w>
Intrac ranial</w>
IL-1 ra</w>
I kB</w>
I a</w>
Hear ing</w>
Hb A1
HS F1</w>
HER 2/
HCC ,</w>
H2 O</w>
H(2)O (2),</w>
G rad
G d
Fox O1</w>
FAS N</w>
EC -SOD</w>
E lig
DM F</w>
DE H
Curcum a</w>
Creat inine</w>
Che m.</w>
CYP3A 7</w>
CYP2D6* 10</w>
CYP27 A1</w>
CYP2 B1</w>
CK D</w>
CB Z,</w>
C are</w>
C S-
C HI
Bup ren
Bo NT/
Biom ar
Bcl -2-
BRCA -1</w>
BR D4</w>
BAP TA-
B SO
B :</w>
Amant adine</w>
Altern atively,</w>
Al bum
Ag -
AQ P1</w>
AG ,</w>
AA I</w>
9 6%</w>
8 8.
6- keto-
50- year-old</w>
50 ).</w>
5-hydroxy tryptam
5-HT TLP
40 %.</w>
4 7-
4 6-year-old</w>
35 9</w>
33 342</w>
3-kinase/ Akt</w>
3- nitro
3 80</w>
2C 9,</w>
25- hydroxyvitamin</w>
24- week</w>
24 3</w>
200 7</w>
2- hour</w>
2- 2</w>
2 h</w>
2 50,</w>
19 ),</w>
17 1</w>
10(- 7
1/ 2)</w>
1, 8
.0 5</w>
-2, 4-di
-2 50</w>
-2 3</w>
-1 50</w>
- operated</w>
- 7
(d d
(T X
(SRE BP
(SHR ).</w>
(PD 980
(PD ),</w>
(PB MC)</w>
(PA H)</w>
(OR s)</w>
(Mn )</w>
(IC 50)</w>
(I P
(H MG-
(E MS
(COX -2),</w>
(AB CC
(6-OHD A)</w>
(6 4)
(50 )=
(5-FU ),</w>
(2 6.
(2 4%)</w>
(2 1%)</w>
(2 ,</w>
( type</w>
( s.c.)</w>
( 0)</w>
zidovud ine.</w>
y e</w>
xenobiotic- metabolizing</w>
wild- type,</w>
was hed</w>
ventro medial</w>
uve al</w>
utili ze</w>
up- regulation.</w>
up -</w>
trigu ingly,</w>
tri ad</w>
tranylcyprom ine</w>
trans itory</w>
tr y</w>
tox ins,</w>
tox in-induced</w>
thi one</w>
thi ab
therap y)</w>
ter nary</w>
tamoxifen -treated</w>
synerg izes</w>
synerg ized</w>
supplement ation,</w>
supple mentary</w>
stud y;</w>
spond yli
spectrophot ometric</w>
sor ting</w>
show n.</w>
sensitiv e.</w>
scal es.</w>
ru n</w>
ro tation</w>
reproduc ibility</w>
reperfu sion-induced</w>
renin-angiotensin- aldosterone</w>
ren e.</w>
regres sion,</w>
re production</w>
re fin
rap h</w>
punc tate</w>
pum p.</w>
pul ses</w>
puber ty</w>
protein -1,</w>
prophyl ac
promot ers,</w>
pro l</w>
prim e</w>
pres sions</w>
prepar ation,</w>
preg ab
pramipex ole</w>
post- training</w>
poly brominated</w>
polar ization</w>
plus- maze</w>
placebo ;</w>
pigment osa</w>
phenylephr ine,</w>
peripher y</w>
peri -
peptid es.</w>
pauc ity</w>
pattern s,</w>
paradig ms</w>
pap ille
p2 1.</w>
oxygen ase,</w>
ov ary,</w>
otroph oblast</w>
origin ate</w>
on yl
ome ga
om es.</w>
ol ymer
ol d-
offspr ing,</w>
ocyt es:</w>
oct ylphenol</w>
ob lig
o hum
normal izes</w>
no reth
no otropic</w>
neoplas ms,</w>
multiple -
mono- OH-
modific ation.</w>
microg/ g</w>
mg/ day;</w>
meth oxy</w>
meth iaz
metal- binding</w>
mesoth elin</w>
mes alaz
medi a,</w>
manipul ations</w>
malignanc y,</w>
male imide</w>
malari a.</w>
main tained.</w>
macroph ag
macrom olec
m t</w>
m oclob
lob es</w>
line arly</w>
li ve
levodop a,</w>
levam isol
leuk ocytes,</w>
l ing,</w>
iver mectin</w>
iso propyl</w>
intersti tium</w>
inter cal
inhibitor s:</w>
infer red</w>
include d:</w>
inci sion</w>
in- V</w>
in formation.</w>
immunoprecipit ated</w>
immunocytochemistr y.</w>
id el
ic v</w>
hyperparathyroidis m.</w>
hypercholesterol emia.</w>
hyper thyroidism.</w>
hyper sensitivity,</w>
hydralaz ine,</w>
homogen ate</w>
hist ochemistry</w>
hex am
heter ozyg
hepati tis
h app
h TER
glycer aldehyde-
gland s,</w>
ginsen oside</w>
gen otoxic
gangli a,</w>
galact os
gal lium</w>
gal anin</w>
four teen</w>
fol ate,</w>
flutic asone</w>
fluoro -
fen oterol</w>
exist ent</w>
ethosuxim ide</w>
ethin ylo
enroll ment</w>
endoc rin
encoun te
emp tive</w>
embol ism,</w>
eg reg
edul lary</w>
e '</w>
dyspep sia</w>
dys functional</w>
dy es</w>
dop amin
document ed,</w>
disco ver</w>
dipyridamol e.</w>
diglyc idyl</w>
dibenzo [a,
desensi tiz
deltameth rin</w>
d- tubocurarine</w>
d- aspartate</w>
controlle d-release</w>
continu ed.</w>
concentr ate</w>
combus tion</w>
com mis
cluster in</w>
cit rul
circum v
choro idal</w>
capac ities</w>
buty rate,</w>
but anediol</w>
bret ylium</w>
break s.</w>
bi ology.</w>
benzodiazep ines.</w>
b in</w>
avoide d.</w>
aug menting</w>
asses sed,</w>
arri val</w>
appli ed.</w>
apne a.</w>
anti- hypertensive</w>
anti myco
anti estrogens</w>
an ec
am il</w>
alcoh ol-
ag ing,</w>
af iltr
adipos ity</w>
adip onectin,</w>
ad ds</w>
achie vement</w>
acet am,</w>
acch aro
ac cr
abil ities.</w>
W a
V 617
UGT2B 15</w>
U N</w>
Tol cap
TSC 2</w>
TRE AT
T- ALL</w>
T MP</w>
Sp 3</w>
Sin us</w>
Shor t</w>
Sev o
SN U-
SLC 30
S-adenosyl methionine</w>
S it
Rheum at
R es.</w>
R 2,</w>
R (+)-
Qu ality</w>
Q u</w>
Pb (2+)</w>
PT 1</w>
PL X
PF C</w>
PARP ,</w>
P yr
Opi oid</w>
Nox a</w>
Nan o-
NS .</w>
NP s)</w>
N-acetyl cysteine.</w>
N o.</w>
Micro scopic</w>
Mi x
MT S</w>
ML L</w>
MK N-
ME P</w>
MB C</w>
M is
M en</w>
Leuk otri
Lei den</w>
LT P</w>
LD L)</w>
L act
K W-
Inter mit
In ten
Ig G,</w>
IS T</w>
I TC
Hypokal emia</w>
Hemat ologic</w>
HB V.</w>
H (2)
Glut amate</w>
Glc N</w>
GPR 30</w>
GADD 15
GAB A,</w>
Forty- six</w>
Fol ate</w>
Flavopirid ol</w>
FK 228</w>
F eno
Elev ation</w>
EG b</w>
E g
Dis orders</w>
Delta (9)-
DMB A-
D A,</w>
Comple x</w>
Chk 1</w>
CYP2 B</w>
CD8 6</w>
CC S</w>
CA LU
Benzo [a]
Bec lin
B (1)</w>
Apo 2
AUC (0
ACh E-
A .,</w>
8 8,</w>
8 3.
8 23</w>
7 20</w>
50- fold</w>
5-F u</w>
5 7-year-old</w>
5 5-year-old</w>
4- year</w>
4- aminopyr
4 7-year-old</w>
4 6)</w>
4 4)</w>
30- year-old</w>
3 b-
3 17
25- (OH)
200 3.</w>
2, 0
2 =
2 8-year-old</w>
2 1).</w>
18 6</w>
14- 3-3
12 0,</w>
100 %,</w>
1. 5-fold</w>
.0 5),</w>
-1 0-
)/ K
) .(ABSTRACT</w>
(T F)</w>
(S S
(PGE (2))</w>
(PA )</w>
(O CT
(NS AI
(I R
(H(2)O (2))</w>
(C O)</w>
(C AD)</w>
(AQ P
(7 /
(3. 0</w>
(2, 6-
(2 5,</w>
(1/ 2)</w>
z ones</w>
z ine,</w>
yl amine</w>
y no
well- defined</w>
wal k</w>
vulg aris.</w>
vari able,</w>
uron s</w>
uro kinase-type</w>
urg ently</w>
unco ver</w>
un conjugated</w>
ul l</w>
ucle ated</w>
two- thirds</w>
tri oxide
trap ib</w>
transmit ter</w>
trans cranial</w>
toxic o
thrombomod ulin</w>
three- fold</w>
therap y-induced</w>
thalasse mia</w>
ter :</w>
te d)</w>
taz idi
tachy arrhythmias.</w>
sym metrical</w>
susceptibil ity,</w>
surpris ingly</w>
sulph asalaz
sulind ac,</w>
sub line</w>
su perim
streng then</w>
spro ut
splen ocytes</w>
smok e.</w>
sit y-
self- report</w>
sear ching</w>
satur able</w>
s me
run ning</w>
rop ini
ris ks.</w>
right- sided</w>
retro bulbar</w>
retin amide</w>
regi str
reg ime</w>
re place</w>
ran ked</w>
queti apine,</w>
py razole</w>
puro mycin
proteoglyc an</w>
pro survival</w>
prim itive</w>
polys omno
polymer ase.</w>
pir acetam</w>
phenyl ]-
phenomen a.</w>
pertin ent</w>
pea king</w>
par a
pa in:</w>
p3 8.</w>
p2 2
oxy l</w>
oxi me,</w>
ox ins</w>
oumar in</w>
osteo arthritic</w>
ose micarb
oscop ic</w>
os sy
orth olog</w>
on ych
omy cosis</w>
od ystroph
od al</w>
ocor tical</w>
o .
nucleoti de-binding</w>
nor mother
non linear</w>
nic losamide</w>
neurotroph in</w>
nar col
nalbuph ine</w>
n ers</w>
n ar</w>
n M
my ocytes,</w>
my ces</w>
moxif loxacin</w>
mot one
modifi ed.</w>
mmol/ l)</w>
mid line</w>
micro l/
mg/ g</w>
metol achlor</w>
methamphet amine,</w>
mepivaca ine</w>
menth ol</w>
learn ing,</w>
kg(-1 )
it ari
ip ),</w>
ion ine</w>
int ent-to-treat</w>
ini b-induced</w>
in operable</w>
immunoblot ting,</w>
imidazol ine</w>
illness es</w>
ili ac</w>
hyper secretion</w>
hyper reflex
hyper cap
hydroly sis.</w>
hemat otoxicity</w>
he mag
har mal
ha em</w>
hC G</w>
granul ocytes</w>
glyc emia</w>
glucose- 6-
gen es:</w>
function ing,</w>
fract alkine</w>
femal e.</w>
fam cic
f atin</w>
ey es,</w>
extr asyst
expec ted.</w>
equ ol</w>
epitheli a.</w>
eosinophil s,</w>
en abling</w>
emphasi zed.</w>
electrocardi ography</w>
elast ase</w>
each )</w>
e u</w>
don ors,</w>
dis ability.</w>
dimin ished.</w>
di isopropyl
detac h
depart ment.</w>
dendrit es</w>
delta 9-
de uter
d m2</w>
d es,</w>
cros ses</w>
copper /
contrast -induced</w>
contrac tility,</w>
construc tion</w>
con es</w>
coagul opathy</w>
co- incubation</w>
co fil
co existing</w>
cholesterol- lowering</w>
chol ine-
chlorpromaz ine,</w>
chlor dec
chemilumin escence</w>
centr ifug
cav ity.</w>
carbamazep ine-induced</w>
cancer ;</w>
c-FL IP
c DDP</w>
bur sts</w>
buc cal</w>
bromocript ine,</w>
breas t-
branch es</w>
bos entan
bioavail ability.</w>
benser azide</w>
backgroun d.</w>
bac ul
auranof in</w>
atrac uri
ation al,</w>
ation -resistant</w>
asi s:</w>
arc uate</w>
ap enta
anti- invasive</w>
anti trypsin</w>
anti serum</w>
anti cholinesterase</w>
analogu es,</w>
am ine].</w>
am b
alpha- synucle
alpha- methyl
all y-induced</w>
alkal i</w>
accharo myces</w>
ac in-induced</w>
aberr antly</w>
a kinetic</w>
[ N-
ZD V</w>
X -1</w>
WA Y
Vig abat
Vari ants</w>
V G
V C
U ).</w>
Toler ability</w>
Te tr
T X</w>
T 2D
Spir onolact
Sel f-
SU LT</w>
SP600 125,</w>
RB Cs</w>
R ed
R IN</w>
Q X</w>
Prospec tive,</w>
PU .
PR L-
PLX 40
PI3K/ AKT</w>
PI -3
PB O</w>
P-glyco protein.</w>
Ouab ain</w>
O HT</w>
Nore p
Nin ety</w>
NSAID -induced</w>
NR 1
NO x</w>
NAC ,</w>
N RA
N KG
MUC 1</w>
MR S</w>
MA R
M UT
M S-
M OR</w>
M G)</w>
M 204
K a
K B
JA K</w>
Intermit tent</w>
In halation</w>
IL- 5
IL K</w>
IGF- IR</w>
HSD 11B
H- ras</w>
GL I
GE C</w>
GC L</w>
GABA (B)</w>
G/ G</w>
G add
G LC
G A-
Frequ ency</w>
Europ e</w>
Epid ural</w>
Ep ste
E IF
E (2),</w>
E (-/-)</w>
Duchen ne</w>
Double- blind</w>
De oxy
DN CB</w>
DMT U</w>
DAD S</w>
D eg
D -induced</w>
Cu ,</w>
Cong estive</w>
Compar ing</w>
Che mic
Cal cit
CYP1B 1.</w>
CTR 2</w>
C ase-
Bcr- Abl</w>
Banglades h.</w>
B [
B Ch
B 1-
As best
Ang -
Adriamycin -induced</w>
AE A</w>
AA F</w>
A SI
A AP
A AD
A 9</w>
> or=</w>
9 5.
8 %;</w>
7 2)</w>
7 -</w>
60 9</w>
6 8,</w>
6 3-year-old</w>
6 20</w>
5-HT 2</w>
5 80</w>
5 6-year-old</w>
5 3-year-old</w>
49 ).</w>
48 ).</w>
4- HNE</w>
4- 5</w>
4- 4</w>
4, 3-
4 2-year-old</w>
36 ),</w>
33 258</w>
3 a,</w>
29 3-
29 ),</w>
22 q
20 4</w>
2- 5</w>
2,4- dinitro
2 B1</w>
19 4
18 9</w>
18 8</w>
18 7</w>
10 th</w>
1/ WAF
1 -100</w>
0.5 6</w>
0.00 5</w>
0.0 6
0. 1-
-1 -mediated</w>
) s</w>
) (2)</w>
(X IAP
(V T)</w>
(T F
(ST Z)</w>
(PC NA
(PAI -1)</w>
(P< 0.001),</w>
(P SA)</w>
(G SK-
(G SK
(E E)</w>
(D AT)</w>
(D A
(CM L)</w>
(CHF ).</w>
(C A)</w>
(B A
(8- OHd
(8 /
(5 7%)</w>
(4 5%)</w>
(4 0-
(3 %)</w>
(2 9</w>
(10 0-
(- ))</w>
( without</w>
( stage</w>
( primary</w>
( VE
z ep
yl osing</w>
y tic</w>
wortmann in,</w>
worldw ide,</w>
week ly,</w>
war f
vasodil ation,</w>
vasoconstric tion,</w>
vas tig
val ves</w>
v -
ure )</w>
ur icos
up- regulated,</w>
up right</w>
unilater ally</w>
uni polar</w>
under taken.</w>
un it,</w>
u )</w>
tung sten</w>
trif l
transver sions</w>
toc ainide</w>
ti bi
th yl
tetrak is
tamoxif en-
t ory</w>
superi ority</w>
super family.</w>
su stain</w>
strepto z
stre pt
stat ins.</w>
squ ir
spre ading</w>
sple en.</w>
speci al
si es</w>
seve re
seroton in,</w>
separ ately.</w>
ru thenium</w>
rs 37
ri vastig
reve al
retin opathy.</w>
reticul um.</w>
research ,</w>
re- expression</w>
rati o)</w>
quanti fying</w>
pu ts</w>
proper ty.</w>
promin ently</w>
prol ide</w>
profes sion
prof en.</w>
pro vi
pro kinetic</w>
predic tions</w>
podoc in</w>
plaqu es.</w>
phyt ochemical</w>
physostigm ine.</w>
person alized</w>
peroxiredox in</w>
period ically</w>
perc ep
part ner
paraquat .</w>
palmit oyl
pa in-related</w>
p21(C IP
p 3</w>
oxygen -
over dosage</w>
over all,</w>
otyp es</w>
oth rom
orbit of
orac ic</w>
oplas tin</w>
oper oxidase</w>
oper amide</w>
onc e-
om eter</w>
ogr ade</w>
oc cul
o- interstitial</w>
nor floxacin</w>
non- neoplastic</w>
nickel ,</w>
neuro sph
neuro protection.</w>
neuro filament</w>
myel opathy</w>
myalg i
mul tim
mox onidine</w>
monocro tal
metoclopr amide,</w>
methad one,</w>
mercap tur
mang ifer
macro cephal
mL/ min</w>
mGlu R</w>
low- molecular-weight</w>
loop s</w>
leukemia :</w>
len tivir
kappa -opioid</w>
k it.</w>
k ]
isch aemia.</w>
is oxazol
is ogenic</w>
intrac arotid</w>
intra hippocampal</w>
interest ,</w>
insulin- sensitizing</w>
inspir atory</w>
ing ual</w>
ing ].</w>
inf in
im el
hypothalamic-pituitary- adrenal</w>
hyper methylated</w>
hydroly ze</w>
hydroly tic</w>
ht tp:/
heal ing.</w>
he re.</w>
haemorrh age.</w>
h p
grap es,</w>
gly oxal
gluc onate</w>
ger bil
gal ang
g et</w>
fum ig
floxac in.</w>
fl ap</w>
fibro genesis</w>
fel odi
fall ing</w>
f us
extinc tion</w>
ex isulind</w>
ether-a- go-go-related</w>
et c.</w>
esophag itis</w>
erg on
er /
epoprost enol</w>
epider moid</w>
enter oc
enox acin</w>
end- point</w>
el y-
effici encies</w>
effectiven ess.</w>
dystroph in</w>
drug ;</w>
dr astic</w>
dr ain
diseas e)</w>
discontinu ation,</w>
dinit rop
diabetes -induced</w>
desog estrel</w>
depos its.</w>
dep olymer
def ensive</w>
day (-1))</w>
daidze in,</w>
d- type</w>
cyst atin</w>
cy tidine</w>
cro ton
connec ting</w>
com mod
com mit
com at
coll icul
cocaine- exposed</w>
coca ine-</w>
co des</w>
clon es.</w>
circum ference</w>
chromat ographic</w>
chr ysen
choic e.</w>
chloroqu ine-induced</w>
chi ef</w>
chemo therapeutics</w>
cent er,</w>
cefotax ime</w>
caus e,</w>
cataly ses</w>
carboxy l</w>
carbo furan</w>
calc ification.</w>
byp as
br ing</w>
br ac
b- cell</w>
b ath</w>
atten tional</w>
ation -mediated</w>
artan /
anti- Fas</w>
anti eme
anim al.</w>
anesthe tized,</w>
amino )-
altern ation</w>
alpha- lipoic</w>
all ucin
al er
ad ded.</w>
acu ity,</w>
activator .</w>
acromegal ic</w>
ac yclic</w>
abor tion</w>
abl ated</w>
a- smooth</w>
XIAP ,</w>
W al
Tri meth
Tri als
Tr am
Thirty- nine</w>
TRAIL- mediated</w>
TNB S</w>
TNB S-induced</w>
TCDD -treated</w>
Side- effects</w>
Selec ted</w>
ST ).</w>
SK-N- MC</w>
SE LEC
SDS- PA
S AP</w>
S AC</w>
Res er
RP P-
R- 4</w>
R b1</w>
R KO</w>
R D</w>
Pro c
Pent oxifylline</w>
PG ,</w>
Obes ity</w>
NF k
N- hydroxy-
N- ethyl
N R</w>
N R1</w>
Mut ational</w>
Mn -
MS I</w>
MCF- 7.</w>
M 6
M .,</w>
Leuk emia</w>
L ID
L HRH</w>
L :</w>
L 1-
Ki 67</w>
K562/A 02</w>
K Y
JNK .</w>
Im plications</w>
IkappaB- alpha</w>
I- II</w>
I s.</w>
Hal f</w>
HIV /
H 3
Ginkg o</w>
Gener alized</w>
GSH-P x</w>
GPx -1</w>
G e
Fus arium</w>
Frequ ent</w>
Forty- one</w>
Fl ur
FM K</w>
F olic</w>
F lec
F ar
Et OH</w>
EGF R.</w>
E (2)
DC s.</w>
D X</w>
D U</w>
Cu/ Zn</w>
Conver sion</w>
Com et</w>
Chi p</w>
Ch eck
Ch IP</w>
CYP3A 4-
CYP2C 9.</w>
CS C</w>
CP O</w>
CK II</w>
CA S</w>
C/EBP alpha</w>
C d,</w>
C M)</w>
Behavi or</w>
Balb/ c</w>
B- ME
B art
B H</w>
B AP1</w>
At p7
As -induced</w>
An aesthe
AT .</w>
AP E1</w>
AL S.</w>
AI M</w>
A defo
90 7</w>
90 .</w>
70- year-old</w>
70 6</w>
7. 5,</w>
7 q
7 6,</w>
55,2 12-2</w>
5-HT (2)</w>
5- bromo
5 F</w>
5 9-year-old</w>
47 3</w>
4 1-year-old</w>
4 '
30 %.</w>
3 %.</w>
29 8
27 ),</w>
24 h,</w>
2. 0%</w>
2 19</w>
2 %.</w>
18 /
17 9</w>
15-deoxy- Delta
15 ;</w>
13 ,
12. 5,</w>
10 -</w>
1 14
0. 36</w>
/ day</w>
-1. 0</w>
-1,3- prop
-1 7-
(TNF- a),</w>
(T O
(P gp
(P TH
(P TE
(P =0.
(O P
(MAPK ),</w>
(M K-
(HUVEC s).</w>
(G lu
(G SS
(G AD
(E 2
(DR G)</w>
(C DDP)</w>
(3 3</w>
(3 1.
(2+ ))</w>
(2 8.
(10 /
(0. 8</w>
(-1 )),</w>
( PAR
( L-DO
' )</w>
zinc -induced</w>
yol k</w>
x es</w>
w av
v af
us ).</w>
uro logical</w>
tript olide</w>
tox ins.</w>
toc olytic</w>
thyroid- stimulating</w>
thromb oplastin</w>
thapsigarg in</w>
tBH Q</w>
syndrome )</w>
substitu ent</w>
stud y:</w>
sp ired</w>
sor bit
son -
sol itary</w>
smo oth
six ty-
side d.</w>
sibl ing</w>
si s].</w>
saf e.</w>
s- like</w>
s -1</w>
ro su
rhyth mic</w>
resol u
reser vo
reser pine,</w>
remn ant</w>
reli es</w>
rectom ized</w>
receptor- independent</w>
rearrang ed</w>
re appeared</w>
ras h.</w>
qu asi
pyrid in
pyraz in
pyl ori
pur su
pto sis</w>
pseudol ithiasis</w>
protr u
proper ly</w>
prolifer ate</w>
proble matic</w>
prob and</w>
prescri bed.</w>
post ure</w>
placent a,</w>
pil l</w>
phospho protein</w>
phosphat ase.</w>
person s.</w>
perm its</w>
pedig re
pec ul
parti ally,</w>
pac ing.</w>
p21(W af1/
p21 (w
p lo
oxidi ze</w>
oxi pride</w>
ov o</w>
ot op
osteoclas ts</w>
osteoblast -like</w>
ost er</w>
osp ond
oplast y</w>
oper ations</w>
op tions.</w>
op orph
onoki ol</w>
oid -
oc alin</w>
observ able</w>
o him
norm oxia</w>
nit ric-
nevir ap
neurolep tics,</w>
nalox one-induced</w>
n ap
my opathic</w>
monocyte /
metalloproteinase- 1</w>
met al-induced</w>
mening eal</w>
mas pin</w>
mO sm
mEq/ L</w>
m 2,</w>
lumirac oxib</w>
lipoph il
limb s,</w>
like wise</w>
leuko encephalopathy.</w>
letharg y,</w>
learn ing.</w>
lear ned</w>
labor ative</w>
l ess,</w>
knock down.</w>
kine sia.</w>
kg/ min</w>
k it</w>
k P
ju x
interview s</w>
interven tional</w>
interac tion
inter ictal</w>
inten tion</w>
injec tion)</w>
infra red</w>
infer i
indic es.</w>
inco ordin
in consistent</w>
ile al</w>
hypothalam us,</w>
hypere mia.</w>
hyperbilirub inemia</w>
hyperalge si
high- level</w>
hap t
h en
gri p</w>
graf ts.</w>
glyco side</w>
glucuronid ation.</w>
glucone ogenesis</w>
globul in,</w>
gl ab
gener ic</w>
g ut
g t
g out.</w>
frequ ent,</w>
fract ures</w>
formal in-induced</w>
flut ter.</w>
flu id
fil tered</w>
fen valerate</w>
extrapol ated</w>
expres sion
expan sion,</w>
exer ting</w>
ex arotene</w>
et uses</w>
estradi ol-
er ),</w>
ep im
emeto genic</w>
embry os,</w>
e .
double-bl inded,</w>
dos e),</w>
disori ent
discus ses</w>
disco ver
diphenyl hydant
dileval ol</w>
diis ocyan
dihydroxy phenylalanine</w>
diet s.</w>
di as
dermat ological</w>
deliri um,</w>
decidu alization</w>
de stabilization</w>
cyste ines</w>
cyclohexim ide,</w>
cutane a</w>
constitu tion</w>
conscious ness,</w>
circumst ances</w>
chrysoti le</w>
chromo ph
chromat ography,</w>
chor io
cholinester ases</w>
cd c2</w>
carcin oid</w>
car te
cadmi um-
c- Ha-ras</w>
c ine
bu f
bronch oconstric
bir th
bi os
behaviour ,</w>
ate ].</w>
associ ation,</w>
ase 2</w>
as e:</w>
arthro plast
artemis inin</w>
arson ous</w>
arrest s</w>
api genin,</w>
anti- oxid
anti- diabetic</w>
anti retrovir
anti dyskinetic</w>
antagonist ),</w>
ano ik
ancestr y.</w>
allodyn ia,</w>
airwa ys.</w>
agre ed</w>
agit ated</w>
ag inal</w>
administr ation;</w>
addi tives</w>
addi tive.</w>
ad ol</w>
a- synuclein</w>
a res</w>
a emi
[3H] thymidine</w>
Y ohim
U -1
Toxic ol</w>
Thirty- seven</w>
Th ai</w>
TC E-induced</w>
TA 15
T opir
T emporal</w>
T ZD
Span ish</w>
Sevent y</w>
SI ON</w>
SER Ms</w>
SD ).</w>
SCC .</w>
S- 7</w>
S timul
Run x2</w>
Rec ogn
RP MI</w>
RA S
R iton
Phenyleph rine</w>
PA )-induced</w>
P CD
Op timal</w>
OV 3</w>
O-deethyl ation</w>
Nrf2- dependent</w>
Nic ardipine</w>
Ne ural</w>
NV P-
N-[4-(5-nitro-2-furyl)-2-thiazol yl]
Min or</w>
Mex ic
Met ast
MT -1
MRP 1.</w>
MI T
Lo V
LN G</w>
LDL- cholesterol</w>
L- FABP</w>
Jap an,</w>
JW A</w>
In dic
III ).</w>
Ho w</w>
Heter ozygous</w>
HDAC i</w>
HC Q</w>
H PRT</w>
H MC
H F.</w>
G2- M</w>
G 3</w>
Fluoresc ence</w>
F SG
F OL
F O</w>
F ITC</w>
Experi ence</w>
Erythro poi
Endothel in-1</w>
EP C</w>
E w
E -mediated</w>
Dah l</w>
DR D2</w>
DO CA</w>
DD VP</w>
DC B</w>
D en
D atab
Cyclospor in</w>
Con ventional</w>
Clon ing</w>
Cere bellar</w>
Carb oplatin</w>
CO S-7</w>
CO RT</w>
CH 2
CD8 (+)</w>
CCK- 8</w>
CA 1,</w>
C- peptide</w>
C re
B 1.</w>
As(2)O(3 ),</w>
Ar ray</w>
Anti oxidants</w>
Alph a</w>
AZ A-
APOB EC
AI N</w>
AF P</w>
A EC</w>
A 1.</w>
9 5,</w>
86 44</w>
80 ).</w>
80 %,</w>
8 6.
7 6.
60- year-old</w>
60 ).</w>
6. 25</w>
6 1-year-old</w>
57 )</w>
5-aza-2'- deoxycytid
5-HT(2 C)</w>
5-HT(2 A)</w>
5-Aza- 2'-
5 HT</w>
5 7,</w>
40 7</w>
4. 8
4-hydroxy -2-
4 8)</w>
3 alpha,
28 2
23 ),</w>
200 2,</w>
2 R
199 4</w>
17- year-old</w>
17- AAG</w>
17 beta
17 /
15 %,</w>
12 0-
10 (4)</w>
1/ 2-
1. 2-
1- hour</w>
1,3-bis(2-chloroethyl)-1- nitrosourea</w>
1, 2,3,
1 )-
0.00 3)</w>
0. 39</w>
0. 32</w>
0. 29</w>
0. 28</w>
0 7
0 6</w>
/ cm
/ B
-2- (
- responsive</w>
)- containing</w>
(TH )</w>
(S K
(PGE 1)</w>
(PD GF
(P CO
(N PY
(II ),</w>
(I T
(HPL C)</w>
(HMG- CoA)</w>
(F A
(ER ),</w>
(D MT
(CYP )-induced</w>
(C M)</w>
(A beta)</w>
(9 9
(7 %)</w>
(4 3%)</w>
(3, 5-
(2 4.
(12, 14)-
( systolic</w>
( re
( /
zymos an</w>
xyl ene</w>
women ;</w>
vis it,</w>
vi br
ve in.</w>
vari ant
vanadi um</w>
val erat
vag in
ure sis</w>
un resectable</w>
triple -
tri met
tretin oin</w>
traum a,</w>
trastuz umab
trandol april</w>
tract us</w>
tr ical</w>
toremif ene</w>
ton sil
tolu ene,</w>
time-of- flight</w>
thi o-
thalidom ide,</w>
tax if
syndrome ].</w>
syncop e,</w>
successful .</w>
sub groups.</w>
studi ed:</w>
stere oselective</w>
ste adily</w>
stav ud
star ted,</w>
stabil ization.</w>
st ents</w>
st af
squir rel</w>
sol itari
simul ating</w>
si s),</w>
sex ually</w>
ses sions.</w>
ser ous</w>
sep tic
secre tin</w>
sc hist
s an
rub ber</w>
rs 18
roten one.</w>
rho damine</w>
rhabdomy osarcoma</w>
replic ative</w>
re ds</w>
ra u
py rex
proteasome- dependent</w>
pronoun c
prolact in-
priap ism</w>
premat urely</w>
praz osin.</w>
po ols</w>
pneumon ia,</w>
pil sic
picolin ate</w>
physe al</w>
pheno thiazine</w>
pg/m L</w>
pentobarbital- anesthetized</w>
penetr ance</w>
parasit es</w>
pain- free</w>
p a</w>
oxy butyn
over comes</w>
ouab ain.</w>
otroph in</w>
oth ym
ord inary</w>
opyr an
om e,</w>
om a)</w>
oligodendro cytes</w>
oid es</w>
ogen omics</w>
of il
nutri ents</w>
nitrit e/
neuro imaging</w>
neuro degeneration,</w>
nACh Rs</w>
mono aminergic</w>
moderate-to- severe</w>
mo tility.</w>
ml/ kg)</w>
mitochondri al-
mirro red</w>
micrograms/ ml.</w>
micro albuminuria</w>
miR-1 8
methyserg ide</w>
me al</w>
max ,</w>
matri x,</w>
mat ter.</w>
man dibular</w>
mTOR /
m s:</w>
m mol
lum ina</w>
lip tic
lifes pan</w>
las go
lasgo w</w>
kg(-1 ).</w>
k ingly,</w>
isoform ,</w>
intra -</w>
insom nia.</w>
insi di
infer tile</w>
in- deficient</w>
in version</w>
iden tic
ide- sensitive</w>
i um,</w>
hypercalc emia,</w>
hydro morphone</w>
hour s;</w>
high -</w>
hi erarch
hexachloro cyclohexane</w>
hepati c,</w>
hepar in
hemat oxylin</w>
headach es,</w>
h op
h GST
guai aretic</w>
gre w</w>
go t</w>
gh t
g/ kg,</w>
fulvestr ant</w>
frus emide</w>
fron t
four- hour</w>
fluoroquinol ones</w>
flex ion</w>
fascic ulation</w>
f 2</w>
exce eds</w>
etr on,</w>
etomid ate.</w>
eti olog
ethyl )-
equ ilibr
equ ation</w>
epirubic in,</w>
entr ic</w>
engraf t
emergen c
elem ent,</w>
electro physi
effec ted</w>
ear ly,</w>
e- derived</w>
drug -treated</w>
dro g
down regulated.</w>
dismut ase.</w>
discharg e,</w>
dimethyl imidazo[4,5-f]
dihydroxyphenyl acetic</w>
diam m
dermatomy ositis</w>
demograph ics,</w>
deli ver</w>
death s,</w>
de :</w>
d ation</w>
cyst athion
crani otomy</w>
covari ates</w>
cortic es</w>
correspon d
copies/ mL</w>
conven i
controlle d.</w>
control s),</w>
contribut ory</w>
contrac tion,</w>
construct .</w>
constipati on,</w>
consi st</w>
condens ation,</w>
compris es</w>
comb ined.</w>
comb at</w>
chromi um
chi al</w>
catechol amine-induced</w>
cataly sis</w>
carbox yp
canav alin</w>
can idipine</w>
cal oric</w>
c aly
bur d
bronchodilat or</w>
break s,</w>
bicyc le</w>
befradi l</w>
bacter icidal</w>
azathiopr ine,</w>
as ted</w>
arrest ing</w>
apopto sis;</w>
anti- androgen</w>
anti malari
anthracyclin es.</w>
ante l</w>
ane /
androgen s.</w>
amplitu de,</w>
ampl ify</w>
amino hipp
alpha- 2b</w>
allopregn anolone</w>
allodyn ic</w>
allo grafts</w>
all ed</w>
al ep
al ene</w>
aggres siven
ag al</w>
af1/ cip
acyl glycer
acid :</w>
acetyl cysteine</w>
accompan ies</w>
[ HR
Z ym
Z A</w>
We b
W e,</w>
W DR
URO t
To oth</w>
Ticlop idine</w>
Thromb otic</w>
TL R</w>
T- mediated</w>
T en
Stri kingly,</w>
Sens ory</w>
Schiz ophren
ST I
SM RT</w>
S che
RE ,</w>
Pseud omonas</w>
Polymorph ism</w>
PT P
PK C,</w>
PE PC
PE ITC</w>
P R-
Od ds</w>
Nur 77</w>
Nitro prus
Ne ut
Na ,
Na +-
NIDD M</w>
N,N', N'-
Mes na</w>
Mel an
Man nit
MPT P-treated</w>
MO LT
MD M
MA L
M- mode</w>
M SC
LRP T</w>
LP ),</w>
L-NAME ,</w>
K +
Inhib iting</w>
Indi a.</w>
Immun e</w>
IL-2 R</w>
IGFBP -1</w>
I (
Hypot ensive</w>
Hyp onat
HT 10
HBeAg -positive</w>
H NS
H 3-
GSH/ GSSG</w>
G> A,</w>
G reat
G R.</w>
Furo semide</w>
Fr uct
FLT 3-
FL S</w>
FD A-
F lut
F er
F 2-
Eu genol</w>
El der
EC G.</w>
Dou ble</w>
Dex amethas
DDE ,</w>
D s.</w>
D am
Cl .</w>
Cl (2))</w>
Cime tidine</w>
Chang e</w>
Cd 2+</w>
CYP2C19 *
CO (2)</w>
CFTR .</w>
CDKN 2A</w>
CDDP -induced</w>
CD 95
C AC
C -treated</w>
Bo y
B al
Ar rhyth
Ant agonism</w>
Am ifostine</w>
Ag on
Adefo vir</w>
APA P.</w>
ANIT -induced</w>
AMP K-
ALK- positive</w>
AID S.</w>
AG 14
A propos</w>
A ir
A PC
A :
A 375</w>
= .
; q
: C</w>
9 5-
9 3.
8 9.
7 5-year-old</w>
7 4-year-old</w>
6 35</w>
5 3)</w>
5 2-year-old</w>
48- h</w>
40- year-old</w>
4 9,</w>
4 3-year-old</w>
38 ).</w>
3- dependent</w>
3 B,</w>
3 2),</w>
3 10</w>
2. 0,</w>
2 a,</w>
199 2</w>
17 3</w>
16- year-old</w>
15 ,
12 th</w>
11- 70
1. 3-
1, 200</w>
00- fold</w>
0.8 5</w>
0.5 1</w>
0.4 4</w>
0.000 5).</w>
0. 65</w>
/ day)</w>
-1 46
(V AS)</w>
(Td P)</w>
(TCD D
(S P)</w>
(S C
(PPAR )-
(PK A)</w>
(P Q)</w>
(P GC
(M et
(L i
(L DH),</w>
(GP x),</w>
(ERK ),</w>
(ER )-
(E r
(DN MT
(D HT)</w>
(CO MT)</w>
(BP ),</w>
(B L
(9 /
(4 1%)</w>
(3 5%)</w>
(3 4</w>
(2 7%)</w>
(10(- 5)</w>
(0. 1-1</w>
( compared</w>
yl ]</w>
y- associated</w>
y- -
y ly</w>
xenobio tics,</w>
whole- exome</w>
where in</w>
war d.</w>
w all,</w>
visc osity</w>
vir us,</w>
vinclozol in</w>
vari ability,</w>
uve itis</w>
uncert ain
u til
u t</w>
tur mer
tric h
tri azine</w>
tren d)</w>
transi tions</w>
tran qu
train ing.</w>
tr al</w>
toxic ity;</w>
tor ce
thym ocytes</w>
tho roughly</w>
thimer os
ter i
ter 's</w>
tel omer
te eth</w>
tacrolim us
t.i. d.</w>
t- butyl
sym metric</w>
swee t</w>
stri ps</w>
strength ened</w>
st ages,</w>
sphing olipid</w>
specific ities</w>
sou thern</w>
soci o
situ ation.</w>
sit e)</w>
sing ly</w>
sh el
ses sion,</w>
ser opositive</w>
se a</w>
sc ram
sc ra
s PLA
rupt ured</w>
rom e</w>
rom ate</w>
ribavir in,</w>
reticul ocyte</w>
require ments.</w>
rejec tion.</w>
regul ators,</w>
refractorin ess</w>
refle x,</w>
re produce</w>
re pression.</w>
radic ul
quar tiles</w>
psychos es</w>
provo kes</w>
protein ),</w>
proced ures,</w>
prim aquine</w>
poly neuropathy.</w>
play er</w>
picrotox in.</w>
phosphatid yl</w>
peri den</w>
pector is,</w>
par athion
palpit ations</w>
p H.</w>
oxy morphone</w>
oxic ity</w>
ox acin</w>
osup pression</w>
osmolal ity,</w>
os entan</w>
oro tate</w>
organell es</w>
one- half</w>
om un
ol ine.</w>
og raph</w>
numer ical</w>
normal ised</w>
noradrenal ine.</w>
noradrenal ine,</w>
non- coding</w>
non hematologic</w>
non genotoxic</w>
ng/m l).</w>
neuro protec
neuro hormonal</w>
ne ostri
n m)</w>
n g)</w>
mus cles,</w>
mumol/ kg</w>
mother s.</w>
mon omeric</w>
micromol/ kg</w>
micro l)</w>
mic .</w>
mi st
mg/m 2).</w>
metast ases,</w>
mes al
manifest s</w>
mRNA s,</w>
long- standing</w>
load ing.</w>
lim on
lik ely.</w>
lat ency,</w>
laparo scopic</w>
kinas e
kan amycin</w>
j o
isle ts.</w>
ion .</w>
intub ation,</w>
interleukin -10</w>
insul ts.</w>
ine- sensitive</w>
induc i
induc ers,</w>
indirub in</w>
in spired</w>
in depend
impul sivity</w>
immun ized</w>
ib og
hydro quin
hol o
histopath ologically</w>
hist omorph
hemag glut
h GSTA
group s).</w>
gros s
glyox al</w>
glutar yl-
glomerul opathy</w>
gener ations</w>
gav aged</w>
fund us</w>
form s,</w>
fl at</w>
fil gras
fibroblast -like</w>
fibr onectin,</w>
fer r
famil iar</w>
fac e,</w>
experi ence,</w>
ex pla
estrogen icity</w>
essenti al.</w>
equival ents</w>
epilepto genesis.</w>
en or
en il
en ail</w>
elimin ation.</w>
ede matous</w>
ecgon ine</w>
dyslipide mia.</w>
dy scra
duoden um</w>
dp/d t
down regulation.</w>
dobut amine.</w>
discontinu ance</w>
dis plac
dis ci
disci pl
differen ces,</w>
diclofenac -induced</w>
di um</w>
develop mentally</w>
detoxif y</w>
depression -like</w>
decre ment</w>
dec lining</w>
d le</w>
crystal log
counter parts</w>
cooper ate</w>
concentr ic</w>
con vinc
compart ment.</w>
cochle a</w>
clo fibrate,</w>
cli p</w>
classi cally</w>
chlorthal id
chloro phenyl)
chlor ide-induced</w>
ch -
cef tazidi
carbon ate.</w>
capec itab
c- Met</w>
c RA</w>
c .)</w>
brid ge</w>
beta ).</w>
beta (3)-
bac eous</w>
aug ment
ascit es,</w>
are sis</w>
arc ot
approach ed</w>
apomorph ine,</w>
apo B</w>
apenta enoic</w>
antidepress ant,</w>
anter ograde</w>
anteced ent</w>
ank ylosing</w>
androgen ,</w>
an y,</w>
amodi aquine</w>
am ifost
alum inal</w>
al is,</w>
al im
al buter
air borne</w>
air .</w>
adipo genesis.</w>
addic ts.</w>
acy tid
acit retin</w>
acetylchol ine,</w>
accumben s.</w>
accid ent</w>
acceler ating</w>
above- mentioned</w>
abaca vir</w>
ab using</w>
ab ated</w>
a x</w>
[corrected ]</w>
W ,</w>
V alu
V R
Up take</w>
U- 937</w>
Ti O2</w>
Thym idylate</w>
Th re
TNB C</w>
TH P
TA -induced</w>
T98 G</w>
T ;</w>
Str ong</w>
Sim p
SOD -1</w>
SNP s.</w>
SM S</w>
S- transferase,</w>
S AM</w>
Rot enone</w>
Rg 1</w>
RP MI
RE LEV
R- R</w>
R K
Pr P</w>
Pol ymer
Paraox onase</w>
PA N.</w>
P ET
P <</w>
P 27
O m
O 2
O (2))</w>
Non etheless,</w>
NT Ds</w>
NMD AR</w>
NF ),</w>
NADPH- cytochrome</w>
Micro RNAs</w>
Metallothione in</w>
Met a-
MP 1</w>
MN NG</w>
MC- LR</w>
MC ).</w>
MALD I-
MA T</w>
MA -induced</w>
M U</w>
Lim ited</w>
Let ter:</w>
LC T</w>
L L</w>
L I</w>
Jap anes
In triguingly,</w>
IB D.</w>
Hist ologically,</w>
Hepat ocyte</w>
HP ),</w>
H- pyrido[
GT ,</w>
GAD 67</w>
FGFR 3</w>
Eth ambut
Elder ly</w>
ET B</w>
ER E</w>
EP I</w>
E MSA</w>
E 4</w>
Distinc t</w>
Der mat
D em
D SE</w>
Cyp2 e
Ctr 1</w>
Clopidog rel</w>
CYP4 F
CI S</w>
CC s</w>
C PD
BM P-2</w>
BI D</w>
BDE- 47</w>
BCL -
B im
B c
Ar ach
Am -
Ah r</w>
Adv anced</w>
AT ).</w>
AP .</w>
ACTH -induced</w>
A str
A 3,</w>
9 L</w>
9 6-
80 ),</w>
7 8.
7 8)</w>
6 90
50- mg</w>
50 ,
5 24
45 3</w>
4 35</w>
32 P-
30 8</w>
3. 0,</w>
3 4-year-old</w>
25- year-old</w>
200 6.</w>
2- receptor</w>
2 2-year-old</w>
1c 1c7</w>
1B /
199 1</w>
17 q
15- PG
14 %,</w>
13- week</w>
10 (-2
1,25(OH) (2)D(3)</w>
1, 6-
1, 6
1 b,</w>
0 -1
-1 4,
- inhibited</w>
- P
- 7,</w>
+ ).</w>
(R L
(PB DE
(P S
(P >0.05).</w>
(P =</w>
(NSAI D)</w>
(NF-kappa B),</w>
(NF)- kappaB</w>
(N i
(MG MT)</w>
(M n-
(M F
(M )</w>
(L CA)</w>
(I P)</w>
(HIF -1)</w>
(GP x
(GL UT
(C DH
(B ChE)</w>
(A ra-
(A d
(5-FU ).</w>
(4 4%)</w>
(2 8%)</w>
(2 4-
( mainly</w>
zidovud ine,</w>
yr )</w>
x /
worm s</w>
weight ).</w>
war ds.</w>
vis it.</w>
vis fatin</w>
vas t</w>
uter us.</w>
us ed:</w>
uricos uric</w>
under line</w>
un ineph
un diagnosed</w>
um -</w>
ulf ide</w>
ulcer s.</w>
tw o.</w>
tris phosphate</w>
trif lu
to sis</w>
tion -induced</w>
tim es)</w>
tico ag
th en,</w>
tend er
temozolom ide.</w>
te remia</w>
t one,</w>
t g
synchron ous</w>
syn geneic</w>
stret ch</w>
str on
str ate</w>
stereotyp ic</w>
stat es,</w>
stat e-dependent</w>
st ath
spi per
sotal ol.</w>
skelet on</w>
six teen</w>
sis- related</w>
sirolim us,</w>
shoul der</w>
short ness</w>
shock -induced</w>
sh ell</w>
sal t
s- associated</w>
rim onab
rig id</w>
resum ption</w>
resum ed</w>
resi ding</w>
replac ing</w>
rel y,</w>
reduc ed-
recover ing</w>
recogn ized,</w>
rapid ly.</w>
r if
pyrid yl
pup s.</w>
pup illary</w>
psor iasis,</w>
prote ger
prot amine</w>
pro dynorphin</w>
pressure ;</w>
precursor ,</w>
practition ers</w>
post- transplant</w>
poor .</w>
poly uria.</w>
pneumonia e</w>
ple g
pl es</w>
physi c
phosphoryl ation/
phenyto in-induced</w>
phenter m
perox ide-induced</w>
perfluorooct ane</w>
perf ec
percenti le</w>
per vasive</w>
per t</w>
peop le.</w>
penicill amine.</w>
particip ant</w>
p53- deficient</w>
p5 3/
p,p'- DDT</w>
p 62</w>
oxantr one</w>
ox acillin
over- expressing</w>
over doses</w>
ov al</w>
otox in,</w>
ori ent
op ap
oni poride</w>
oneuro pathy</w>
on azol
olig omeric</w>
ole-3-carbin ol</w>
odi lat
od enal</w>
obstruc tion,</w>
ob let</w>
o ate</w>
normot ensi
non- human</w>
nocicep tion.</w>
nmol/ L)</w>
nitric- oxide</w>
nim odi
nicoran dil</w>
neuropath y:</w>
nephro protective</w>
ne bivolol</w>
n il
n g.
n NOS</w>
mum ol</w>
mol/ L,</w>
minute )</w>
min ute,</w>
min -1,</w>
mil l
migra ine,</w>
micro RNA
mg/m 2),</w>
mg. kg(-1).
methad one-
mephedr one</w>
mening itis,</w>
mL/ min/
m er.</w>
lox acillin
low- frequency</w>
los por
littermat es.</w>
lipid ,</w>
lin es:</w>
leuc ocyte</w>
lat e,</w>
lap atinib</w>
l om
kynuren ine</w>
kinase- dependent</w>
kidne y-
ket otifen</w>
kappa B)</w>
k en
k D</w>
iz yg
it rile</w>
isob olog
is ed.</w>
ioxag late</w>
intub ated</w>
intravit real</w>
intermedi ary</w>
interleukin- 5</w>
integr ity,</w>
inst ance</w>
increas es.</w>
ina dequ
in trigu
in nov
impair ments.</w>
im il
ic -induced</w>
hypomagnes emia</w>
hyperprolact inaemia</w>
hour s).</w>
her ni
hepar in-
hemodynam ically</w>
hemat uria,</w>
gross ly</w>
granulomat osis</w>
gover ning</w>
go it
glyceraldehyde- 3-phosphate</w>
glucose- regulated</w>
ger y</w>
galant amine</w>
further more,</w>
filam ent
feed ing.</w>
exposure :</w>
event -free</w>
ethyl )
er s;</w>
er h
ep oxy</w>
endothel in
endocardi tis.</w>
end ritic</w>
encephal omyelitis</w>
emis sions</w>
electroencephal ography</w>
e- 7,8-
dos e).</w>
domain s,</w>
dom inal</w>
dodec yl</w>
dis place</w>
dihydro chloride</w>
dich romate</w>
dialy sis,</w>
di tis</w>
di meric</w>
deterior ation.</w>
deser ves</w>
delu sions</w>
degre e.</w>
dact yly</w>
cur rence</w>
cu stom
cortis ol-induced</w>
cor on
copper -dependent</w>
copper (II)</w>
conjug ating</w>
compli ance,</w>
com position,</w>
com bine</w>
collag en-
co vit
clotrim azole</w>
clind amycin</w>
chloroqu ine.</w>
children 's</w>
chemokin es,</w>
cephalor idine</w>
cent res</w>
cell- permeable</w>
cau tion.</w>
cardio vascular,</w>
calcul i</w>
calcium- channel</w>
calc ifications</w>
bo ost
benzo furan</w>
be d,</w>
basel ine).</w>
bal ances</w>
b arium</w>
b am
autom atic</w>
aut osomal-
aur in</w>
atur ation</w>
atro p
ati ves.</w>
ase- positive</w>
arsenit e-
arrhyth mo
arbit r
ar il
anomal y</w>
angi ography,</w>
amyloid -beta</w>
ampl ification.</w>
alum ina</w>
akathi sia,</w>
ail s</w>
adriamycin .</w>
adrenocept ors,</w>
adrenal ine,</w>
acet ate-
accid ents</w>
ac company</w>
a- dependent</w>
ZD 18
X AF1</w>
Wil d-type</w>
Vals artan</w>
V CM
V (max
Uni variate</w>
Un it</w>
UN EL
Te mozolom
TR P</w>
TR 1</w>
TI A</w>
TGF-beta 1,</w>
T MT</w>
T CB
Sub stitution</w>
Sot alol</w>
Ser -
ST .</w>
SR C
SAM e</w>
S1 P</w>
S od
S nail</w>
S co
Res ol
RF C</w>
R ing
R ev
R emission</w>
Q 19
Pro toc
Pro jec
Pro duction</w>
Phosph ati
PN S</w>
PAH s.</w>
P erg
Ox carb
Ox ali
Octre otide</w>
O RA
O H.</w>
Neut rop
NF-k B.</w>
NDE A</w>
NC X</w>
NA .</w>
N-methyl- d-aspartate</w>
N, N,N',N'-
N asal</w>
N (
Myco bacterium</w>
MnTB AP</w>
MR I.</w>
M ini
M ann-Whitney</w>
Li -
LP S/
LI D.</w>
LDL -induced</w>
L-DO PA.</w>
L inear</w>
JA K-
In -
IT D</w>
IIb/ IIIa</w>
I :</w>
Hyper calc
Hum ans</w>
Hed gehog</w>
HM 74
HC O
H ir
H a</w>
H T-
H 7</w>
Gr am
Gn R
Genotyp es</w>
GT P-
G 0</w>
Flumazen il</w>
Fish er's</w>
Fifty- two</w>
Fe wer</w>
Fam ily</w>
FOX O1</w>
FMO 3</w>
F c</w>
Epith elial</w>
ET V</w>
ER beta-
EML A</w>
E- deficient</w>
E wing</w>
E top
Di methyl
Dep ending</w>
De pressive</w>
De fici
DOX ,</w>
Cor tis
Cad mi
Ca(2+ )-dependent</w>
CYP2C 8,</w>
CP P
CO R
CG P
CC I-
C3 H</w>
C- mediated</w>
C ip1)</w>
C entre</w>
C and
C anc
Bri tish</w>
Ba P.</w>
B u</w>
B X
Az a-
Ap parent</w>
An ticoag
Al most</w>
Ab normal
Ab dominal</w>
ATF 4</w>
AS .</w>
AK T.</w>
90 13
8- oxo-
7 3.
600 2</w>
60 %.</w>
6 5,</w>
5-HT (3)</w>
5 4)</w>
4- tetrahydro
4 alpha</w>
4 %.</w>
3A 4,</w>
37 ;</w>
37 .</w>
35 8</w>
3,2'-dimethyl-4- aminobiphenyl</w>
3, 4,
3 1-year-old</w>
2C 12</w>
200 4.</w>
11 %,</w>
10(9 )</w>
10 %.</w>
1. 00</w>
1- transfected</w>
0.6 1</w>
0 4</w>
/ K
- transfected</w>
- 0.7
)- like</w>
) M</w>
(rs 2
(c AMP)</w>
(SE ).</w>
(S R)</w>
(P< 0.05</w>
(P RA)</w>
(N M
(H F)</w>
(G R),</w>
(FK 50
(EDC s)</w>
(CG I-
(C TGF
(C K)</w>
(Brd U)</w>
(AT RA
(AT F
(8 5</w>
(8 00</w>
(5 ),</w>
(3 6.
(2. 5-
(2 9%)</w>
(2 8</w>
(1. 6</w>
(1 3)
( within</w>
( plasma</w>
( [Ca(2+)]
( Thr
% ])</w>
ylchol ine</w>
wei gh</w>
wean ed</w>
w rit
w /
vis ited</w>
virt ual</w>
vigabat rin.</w>
vasodilat ation.</w>
vari ation.</w>
vancomycin .</w>
valu es)</w>
un selected</w>
un remark
ud itory</w>
ubi quinone</w>
u gh
tubul o-interstitial</w>
tris -
trimeth oprim</w>
tri hydroxy-
transfer .</w>
trac ts</w>
tr ically</w>
tion al,</w>
thir teen</w>
tetrac aine</w>
temperat ures</w>
tel avanc
tail- cuff</w>
t Hcy</w>
surfac es</w>
sulind ac.</w>
sulf ad
subsequ ently,</w>
sub o</w>
stres sors</w>
sion- weighted</w>
signal s,</w>
side- chain</w>
segreg ated</w>
rot ational</w>
ro modi
ro lip
rolip ram</w>
ril men
res equ
regul ar
receptor- y</w>
reache d.</w>
re flu
re d;</w>
re activity.</w>
ras h
radi o-
rabb its,</w>
ra x
pyridox al</w>
purpos es</w>
psychi atr
prototyp ic</w>
proce eded</w>
procain amide.</w>
pro hib
pro arrhythmia</w>
prevent ative</w>
preh ensive</w>
pr e</w>
polymer ase-1</w>
pol ysacch
pneumon itis</w>
platelet- activating</w>
pi ren
pheochromocyt oma.</w>
phenotyp ically</w>
phenel zine</w>
pharmac ophore</w>
ph in
perind opril
par icalcit
p2 7,</w>
p ills</w>
p ill
overload ,</w>
over use</w>
ov ulation</w>
oto acoustic</w>
organo phosphat
orbitof rontal</w>
opleg ia</w>
open- chest</w>
one -</w>
ois son</w>
nucle ar-
noreth ind
non genomic</w>
nickel -
neuro inflammation</w>
neur algia</w>
nat ure,</w>
n or-
n ano
my x
multi system</w>
mu g</w>
morphine- dependent</w>
mon onucle
mit o
min s</w>
microgli a.</w>
microarra y,</w>
microangi opathic</w>
mi me
methylenedioxy methamphetamine</w>
melan omas</w>
melan ogenesis</w>
mel oxicam</w>
mark er.</w>
mancoz eb</w>
lup us-like</w>
levonorg estrel</w>
leuc openia</w>
le ver</w>
le flunom
le as
k u
k ly</w>
k il
j apon
isoprenal ine-induced</w>
isoform .</w>
isoflur ane,</w>
is al</w>
irrit able</w>
invari ably</w>
intern alized</w>
inter nucleosomal</w>
inoc ulation</w>
inhibi tions</w>
inf anc
ine- 3-
induc tively</w>
individu al's</w>
inc urable</w>
in tolerance.</w>
immunocom pet
icari in</w>
i ome
i als</w>
hypothalam us.</w>
hospit al-based</w>
hex idine</w>
hemangi osarcomas</w>
hab ditis</w>
h ous
guan yl
gram -negative</w>
glutamate- cysteine</w>
gen s</w>
gemcitab ine-induced</w>
gav age.</w>
gas es</w>
gamma-glutamyl cysteine</w>
g ers</w>
formul ation,</w>
flush ing,</w>
flexi bility</w>
fil ter</w>
ffici ent</w>
fertili zation</w>
fenoldop am</w>
far m</w>
factor -induced</w>
f issu
exp ense</w>
ex amples</w>
ev odi
ethoxyresoruf in-O-deethylase</w>
et in.</w>
erythropoi etic</w>
epit ope</w>
enter ocytes</w>
enrol led,</w>
enor habditis</w>
ell we
eli osis</w>
electrocardi ogram.</w>
electro spray</w>
eigh th</w>
eicos anoid</w>
each ,</w>
e gg
e ?</w>
dyspla sia,</w>
doxorubicin- resistant</w>
down- regulated,</w>
double- dumm
docetaxel .</w>
discrepanc y</w>
dis elen
difficul t.</w>
di ol
di d.</w>
di benzo-p-
des erve</w>
defen ses</w>
da ugh
d a</w>
d -induced</w>
cys tic
cruc iferous</w>
copper- zinc</w>
contrac tions.</w>
contr asted</w>
cont ents,</w>
conside red,</w>
condition ing.</w>
comp elling</w>
common est</w>
combine d)</w>
co inc
clopidogrel ,</w>
clob az
clinic opathologic</w>
clinic ally,</w>
chrom ate</w>
ch ratoxin</w>
cere visi
cent ers.</w>
cat ch
cas es;</w>
carbo hydr
c-jun ,</w>
c all</w>
bond s</w>
bil iver
beta-block ers,</w>
bare ly</w>
azep ine,</w>
attenu ated.</w>
ator vastatin,</w>
at ing.</w>
asymptom atic.</w>
aster ix
arterioscler otic</w>
arterios us.</w>
arcot -M
arcot-M ari
aph thal
anti-CD 3</w>
anti- neoplastic</w>
amyl ase</w>
amilor ide,</w>
aly tic</w>
alkal osis</w>
alc ifer
al ert
al achlor</w>
al "</w>
aggreg ate</w>
ag oraph
ad j
achlor ,</w>
acces sible</w>
a way</w>
a sia</w>
a pro
a C</w>
[125 I]
[ Treatment</w>
Z ellwe
Wilc oxon</w>
Wh ole</w>
Wester n-
Vigabat rin</w>
V MAT
Un ilateral</w>
UGT1A 3</w>
UDP-glucuronosyl transferases</w>
Tric ho
Tre ated</w>
TNF alpha,</w>
TN P-
TDI -induced</w>
TC S</w>
T- wave</w>
T reg
T radi
T RO
T L</w>
T K</w>
T CH
Str uc
Ste re
Sr c-
Smac/ DIAB
Sertr aline</w>
SY N
SUBJEC TS</w>
SP ,</w>
SIRT 1.</w>
SHRS P</w>
SE N
S Z</w>
Ris perid
RP 2</w>
Q ).</w>
Polymer ase</w>
Poin tes</w>
Per in
PR K
PL C-
PK c
PCR- RFLP</w>
PCB 153</w>
PBDE- 47</w>
PANC -1</w>
PAN- treated</w>
PA -treated</w>
P oisson</w>
P hi
P eg
P 1
Olan zap
OH C</w>
OCT 1</w>
O ther
O phthal
O chratoxin</w>
Nrf2- mediated</w>
Neuro protective</w>
Nar ingin</w>
Na, K-ATPase</w>
Na (v)
ND I</w>
N- nitro-L-arginine</w>
N Q</w>
N MRI</w>
MP ),</w>
MK-80 1,</w>
METHODOLOG Y:</w>
MCF 7/
Lind ane</w>
LD (50)</w>
LC /
L LC-PK
K ).</w>
Jun D</w>
Infarc tion</w>
Ig E,</w>
IN VE
IDH 1</w>
I B-ME
Hist opathology</w>
Hippocamp al</w>
HSP 72</w>
H EC
Great er</w>
Ger mline</w>
GW AS</w>
G9 a</w>
G HR
G AG</w>
F asting</w>
F ab
ER -mediated</w>
EN U</w>
EMMP RIN</w>
EE G.</w>
E x</w>
E G</w>
Dose- related</w>
DC s,</w>
DAP I</w>
D Y
D PA
D ME
D AS</w>
Chk 2</w>
Character is
Ch ang</w>
Cd c2</w>
CYP3A4 *
CT X</w>
CT P</w>
CP R</w>
COM MD
CH B</w>
CCAAT/ enhancer</w>
C a-2</w>
BP DE-
BP ).</w>
BD E</w>
BC L</w>
B re
B ad,</w>
B PA-
Arach id
Ang el
Amit riptyl
Ad ding</w>
AS E</w>
ALDH 3A
AC -
A> G</w>
A2318 7</w>
A S-
A AI
A 2)</w>
9 9.
9 7%</w>
7 3-year-old</w>
6 7)</w>
6 2-year-old</w>
6 %;</w>
56 2</w>
45 ).</w>
40 ),</w>
4- OHE
4 A1</w>
39 9
39 ).</w>
3 6-year-old</w>
26 .</w>
200 6,</w>
200 4,</w>
200 0,</w>
2 60</w>
2 11</w>
2 ))</w>
19 A1</w>
19 6</w>
17. 5</w>
17 6</w>
15- year-old</w>
12. 2</w>
11. 1</w>
11- year-old</w>
10- day</w>
10(-1 0)</w>
10(- 4
10 (3)</w>
1* 2</w>
1 +
0.8 4</w>
0.5 3</w>
0.00 7).</w>
0.0 1);</w>
0. 4,</w>
0. 34</w>
0. 33</w>
-2'-deoxy uridine</w>
-1. 5</w>
(q RT-PC
(Ph Se
(P a
(OR :</w>
(O C)</w>
(N TD
(MDR 1)</w>
(I BD
(HER G)</w>
(HB s
(H D)</w>
(GST s)</w>
(GB M)</w>
(G E
(ER -
(E GC
(D L
(CB F)</w>
(3 7.
(2 %)</w>
(1. 8</w>
(1 %</w>
(0.0 3</w>
( sal
( anti
( .
zinc- deficient</w>
zebraf ish.</w>
yl) methyl
y z
xenograf ted</w>
wri thing</w>
wo od</w>
w est</w>
w ast
vill i</w>
vag otom
ur aemic</w>
um inal</w>
um -mediated</w>
ulcer ogenic</w>
ulc er.</w>
triglycer ide,</w>
trichloro ethyl
tri oxide,</w>
treatment -induced</w>
toge ther.</w>
tissue- type</w>
tic s:</w>
tetrachlor ide-induced</w>
tetrab romo
temozolom ide,</w>
tem pol</w>
tax anes</w>
t in.</w>
t ang
sub maximal</w>
sten osis,</w>
st ated</w>
spir al</w>
sirolim us.</w>
sickn ess</w>
ses sion.</w>
seroton inergic</w>
seroton in-
ser ologic</w>
selec ted.</w>
scrat ching</w>
salicyl ate,</w>
s EH</w>
ril uzole</w>
retri eved</w>
resol ving</w>
require d,</w>
relap se,</w>
recru it</w>
reas on,</w>
rau wol
ratio :</w>
radio therapy,</w>
r us
quadr ant</w>
publ ished.</w>
prolact in,</w>
pro jection</w>
pressure- volume</w>
pres cho
pranlu kast</w>
post- mortem</w>
po fung
plant s.</w>
plant s,</w>
plant ation</w>
piper az
piper acillin</w>
pigment os
phosphorib osyltransferase</w>
phil us</w>
periton itis</w>
per phen
per one
per mitting</w>
pent azoc
part ly,</w>
parallel- group,</w>
paclitaxel -
pacema k
p.o .).</w>
p s
p 2</w>
oxotremor ine</w>
over view</w>
out i</w>
osyl ation</w>
osteo proteger
ori ented</w>
or che
oplas mo
opioid -
oper ate</w>
open- angle</w>
on s.</w>
ometr ically</w>
ograph ical</w>
occur s,</w>
occl udin</w>
o,p'- DD
o y</w>
numb ers,</w>
nucle osides</w>
non- enzymatic</w>
non enzymatic</w>
noc oda
no ise</w>
net work.</w>
nar ing
naphtho flavone,</w>
n ish</w>
myometri um</w>
myelosup pression,</w>
myalg ias</w>
multi- drug</w>
mono amines</w>
modul ators.</w>
mod ell
mili eu</w>
microtubul e-
microgli a,</w>
microg/ paw
micro vesicular</w>
mic e).</w>
mi th
mg/d L.</w>
mg/ (
megakary ocytic</w>
me rely</w>
mat che
manner ;</w>
mal ian</w>
magnit u
mTOR C1</w>
ly ;</w>
luc ifer
locomo tion,</w>
lo x</w>
lium -201</w>
lipopolysacchari de-
linezol id</w>
leu prolide</w>
lessen ed</w>
le -induced</w>
lat ter.</w>
lat ency.</w>
l ock
kinase- 3beta</w>
kD a)</w>
iz ol
it y/
ish -
intr insi
injur y:</w>
inform ative</w>
influenz ae</w>
infec tive</w>
ine dichloro
ine -1-
implic ated.</w>
implant able</w>
immun otoxic</w>
im per
hyperhomocyste inemia</w>
hot- plate</w>
herit able</w>
haem olysis</w>
h ence,</w>
h ERalpha</w>
glob ally</w>
genotype- phenotype</w>
gen dor
g oblet</w>
fur fur
forti fication</w>
formul ation.</w>
fluoxet ine-induced</w>
first- episode</w>
factor -1a</w>
fac ility</w>
exc retory</w>
ethin ylestradi
estradiol -17</w>
est ri
epidemi ology</w>
endothelium- independent</w>
endotheli um,</w>
en y
elem ental</w>
electrocardi ogram,</w>
efaviren z</w>
dom perid
dofe tili
docum ents</w>
dip ine.</w>
dic um
diarrhe a.</w>
depriv ation,</w>
depres s</w>
depolar iz
demethyl ase</w>
delay ed-
degre e,</w>
deci sion-
days '</w>
da -
d "</w>
cyt olytic</w>
crani os
counsel ing</w>
cou gh,</w>
copper -induced</w>
control :</w>
con canavalin</w>
colchic ine-induced</w>
col loid
coagul ation,</w>
co factors</w>
clear -
cir cl
chlor d
chi p</w>
character ized,</w>
ch in
ch i</w>
cent ros
cent ro
cellul ose</w>
cel astrol</w>
caspase- 3/7</w>
cas ts</w>
cas t</w>
carcinom a:</w>
carb on-
car i
calce in</w>
cTn I</w>
buthi onine-
bus ulph
bur den
brid ging</w>
bran ched</w>
bi g</w>
bi allelic</w>
beta-HS D</w>
beta- actin</w>
benzyl guanine</w>
bac teremia</w>
b and
ate- resistant</w>
at e).</w>
arg ue</w>
arcot-Mari e-
ar ub
anti tumorigenic</w>
analgesic ,</w>
anaesthe tics</w>
amygdal a.</w>
aminobi phenyl
amino- acid</w>
amino ]
amelior ative</w>
alte red,</w>
alpha- syn</w>
allerg y.</w>
agonist ),</w>
agit ation.</w>
aggres sion,</w>
aggreg ated</w>
age ing</w>
aeros olized</w>
adrenoceptor- mediated</w>
addi tively</w>
acute- phase</w>
ac commod
[ C
Zidov udine</w>
Z- VAD-
X 1,</w>
W ell
W all
V HL</w>
UCP 2</w>
U PD
Tum our</w>
Tolcap one</w>
Th 2-
Tachy cardia</w>
TP ,</w>
TC R</w>
TC F
T- lymphocyte</w>
T rem
T S,</w>
T E</w>
T 17
Surviv in</w>
Squ ib
Smad 4</w>
Sensi tization</w>
SYN THESIS:</w>
SR D5
SE M</w>
S100 B</w>
S ult
S ham
S F</w>
S 1,</w>
Rest ing</w>
RELEV ANCE:</w>
Pro found</w>
Per son
Penicill amine</w>
Paracetam ol</w>
PPAR alpha-
PB S</w>
P-g p-
P d
P =0.
O P,</w>
Nutri tion</w>
Neuro pathy</w>
NP Y
Myocl onus</w>
My ers</w>
Mechan ical</w>
Mcl -1,</w>
Mam malian</w>
MT F-1</w>
MR C-5</w>
MPP(+ )-induced</w>
MPP +</w>
MP T</w>
MM T</w>
MD A
M ol
M S,</w>
M CD
Le sions</w>
Lang erh
L H-
L (-1)</w>
Is radipine</w>
Is ra
Inf ants</w>
Indin avir</w>
Immun oprecip
IT C-
I le</w>
High ly</w>
HepG 2-
Ha emo
HSD 3
H4II E</w>
G6 PD</w>
G/ A</w>
G h
G end
Fc epsilon
F ri
F X</w>
F P
Exc ess</w>
Ex pl
Estrogen s</w>
Erb B
En ter
ERK 2</w>
ER beta,</w>
ER -dependent</w>
E SC
Dow n</w>
Dic hloro
DSM-III- R</w>
DRE SS</w>
DP ,</w>
D ynamic</w>
D SB
Cy A</w>
Curcum in,</w>
Criter ia</w>
Cr )</w>
Clin ic</w>
Cardiomy opathy</w>
Ca enorhabditis</w>
CT /
CT .</w>
CP ),</w>
CO ,</w>
CD 25
CCN U</w>
C ann
C 5</w>
C 2C12</w>
Bl ue</w>
Bet a</w>
B[a] P-
BP RS</w>
BAG 3</w>
B- type</w>
B(a) P</w>
B rist
B ic
Abnormal ities</w>
AT O-
AR ID
AO M</w>
AN CA-
AM .</w>
ALDH 2*
A uditory</w>
A gency</w>
A K</w>
A (1)</w>
< or=</w>
99 m</w>
8 7.
8 5-
8 2,</w>
70 %,</w>
6 4-year-old</w>
6 1.
5. 8
5. 0,</w>
5-HTTLP R</w>
5- HI
5 F
5 5)</w>
5 5%,</w>
5 1.
40 .</w>
39 8</w>
38 ),</w>
30- fold</w>
3, 000</w>
3'- deoxy
3 7-year-old</w>
3 7-
29 1</w>
29 0</w>
28 ),</w>
20 ,000</w>
2. 1,</w>
2- treated</w>
2- (4-
2 A/
2 -2
1alpha, 25(OH)
1a 1</w>
1A -
19 7</w>
19 5</w>
16 HBE</w>
10(- 3
1/ *3</w>
1 -2.
0.5 7</w>
0.4 7</w>
0.00 2),</w>
0.0 5-
0. 80</w>
0. 8,</w>
0. 48</w>
0. 125</w>
- clavulanic</w>
+/ -1</w>
(TNF alpha)</w>
(T PA)</w>
(SOD 1)</w>
(PT U)</w>
(P MA
(N K
(M K
(ISO )-induced</w>
(IFN- gamma)</w>
(I OP)</w>
(GST ),</w>
(D PD)</w>
(C yp
(BM I)</w>
(B -
(AT 1)</w>
(A54 9)</w>
(A RF
(7 3%)</w>
(4 )-
(3 8%)</w>
(3 2.
(2+ )-induced</w>
(14) C-
(10 0%)</w>
(1 1/
(1 -100</w>
(0. 75</w>
( pre
( RNA
( 0/
ys ;</w>
y -</w>
wa ist</w>
vim entin,</w>
uro genital</w>
tw in</w>
tumori gen
tribut yl
transplant able</w>
transfec ting</w>
trans form</w>
tranqu il
to oth</w>
tic oline</w>
thromb ospond
thi osemicarb
tacrolim us,</w>
sulind ac
sulfo transferases</w>
sugg es
ste d,</w>
spironolact one,</w>
spas ms.</w>
sour ces.</w>
sof t-
sludg e</w>
sk y</w>
situ ations.</w>
single- cell</w>
si s-induced</w>
secre tions</w>
scaff ol
s one-induced</w>
s ent</w>
rs 3
romodi phenyl</w>
ril at</w>
resveratrol -mediated</w>
resul t.</w>
respir ation,</w>
reinfor ce</w>
regener ating</w>
recru iting</w>
re programming</w>
re introduction</w>
re alg
rag yn
r ing,</w>
quinpi role</w>
quercet in-
qu arter
promis ed</w>
prol idase</w>
pract olol</w>
pleas ant</w>
physic ochemical</w>
phyl axis</w>
phlor iz
ph on
perspec tives</w>
pepti de-
pe an
path y.</w>
pass ed</w>
paradoxic ally</w>
par valbumin</w>
papill a</w>
panc uroni
pal ate.</w>
pal ate,</w>
p 14
oxy )
ox pren
ox on
over lap
ous ness</w>
ot em
osom es.</w>
os e)</w>
or ial</w>
or f
onec rosis</w>
ometh yl</w>
omat osis</w>
ol- Myers</w>
ol umin
off ering</w>
off "</w>
o roph
o prost</w>
o ocytes,</w>
numb ness</w>
non transgenic</w>
nocicep tion,</w>
no e
nit rate/
ni dipine</w>
ner ve,</w>
nephrectom ized</w>
myot onia</w>
mmol/ L,</w>
mmHg ),</w>
ml (-1)</w>
mixt ure,</w>
microgram/ kg</w>
mg/kg );</w>
methoxy flurane</w>
methoxy chlor
met al.</w>
megal oblastic</w>
measure ment.</w>
mass eter</w>
mas ked</w>
manag eable</w>
man eb</w>
magnesi um,</w>
lumb os
low- osmolar</w>
low er
lor azepam.</w>
lip ocalin</w>
leukemi as.</w>
lat enc
land scap
lact ating</w>
laborator y,</w>
knock -in</w>
ke 's</w>
it y).</w>
is in</w>
is ation.</w>
intrigu ing</w>
intraperitone ally,</w>
intragas trically</w>
interval )</w>
intermedi ates.</w>
inter strand</w>
innov ative</w>
inhal ational</w>
ind welling</w>
i ol</w>
i As(III)</w>
hypoper fusion</w>
hyper lipid
hydroxy progesterone</w>
hydr az
hy d
hormone- related</w>
hemodi lution</w>
h ouse</w>
guan ethidine</w>
group s)</w>
gro und</w>
gonadotrop in-releasing</w>
glioblast oma.</w>
gen otoxicity.</w>
gad odi
g ed</w>
frequ ently,</w>
four ,</w>
fluoro pyrimid
fluoresc ence,</w>
fluctu ating</w>
flavonoid s.</w>
fl uro
fibrin ogen,</w>
fer rox
feno fibrate,</w>
failure ;</w>
ey e,</w>
extub ation</w>
exacerb ating</w>
eti opath
estro l</w>
estim ated.</w>
end op
el e
e res.</w>
e 's</w>
dul oxetine</w>
drug- resistance</w>
dri ver</w>
dipyridamol e,</w>
detec tion,</w>
des loratadine</w>
depolar ization,</w>
denat uring</w>
definit ely</w>
def ined,</w>
decad es,</w>
d- amphetamine-induced</w>
cyclospor ine.</w>
cyclospor ine,</w>
coun t.</w>
cos egreg
convul sing</w>
contex t.</w>
cohor ts.</w>
co transfected</w>
cit r
cin nar
chemo k
cefuro xime</w>
caver nos
catechol amines,</w>
cast or</w>
car d
cancer ].</w>
cad aver
ca 8
cAMP .</w>
c-Myc ,</w>
bul im
breas t.</w>
bi us</w>
bi ochemistry</w>
bi le.</w>
between- group</w>
betax olol</w>
beta-lact am</w>
beta-D- glucuronide</w>
bas ed,</w>
b.i. d.)</w>
b 1,</w>
awak ening</w>
autophag osome</w>
aur icular</w>
att ain
ate br
asthmatic s.</w>
aspartam e</w>
asbestos -related</w>
as cic
aryl hydrocarbon</w>
arcot-Marie- Tooth</w>
ap racl
anti phospholipid</w>
anti al</w>
anion -
aneth ole</w>
anesthe tic.</w>
androgen s,</w>
an ic
amlodip ine.</w>
amino -2-
amine- associated</w>
alleng e</w>
al one;</w>
ak i</w>
age- specific</w>
adul t-
aden oma.</w>
adduc ted</w>
addres sing</w>
activator s,</w>
acea e)</w>
ac ac
ab us
Zellwe ger</w>
Y- maze</w>
Web ster</w>
V III</w>
V -related</w>
Utili zing</w>
UV B-induced</w>
U/ m
U PR</w>
U P-
U B
U 8
Trans port</w>
Tou rette</w>
Te tra
TTF -1</w>
TB Z</w>
T-47 D</w>
T- lymphocytes</w>
T ubular</w>
T oc
T c</w>
T ET
SS AT</w>
SI M</w>
S triatal</w>
S W</w>
S 9</w>
S )-induced</w>
Repor ted</w>
Re actions</w>
Ran itidine</w>
RUN X
R ig
QT c
Pr x</w>
Perin atal</w>
PT U-induced</w>
PS P</w>
PE ,</w>
P= 0.000
P450sc c</w>
P450 -
P HD
Ol der</w>
O ,
Nicot inic</w>
Neuro psychiatric</w>
Net work</w>
NO X</w>
NO -mediated</w>
NI H</w>
NG- nitro-L-arginine</w>
N- cadherin</w>
N G,</w>
N EC</w>
Men i
MT -1</w>
ML P</w>
MI C</w>
MG ,</w>
MD R-
MAO- A</w>
MA O
M ec
M LP
Lisin opril</w>
Life- threatening</w>
K s</w>
Ische mic</w>
IP .</w>
II :</w>
IF ,</w>
Hist opathologic</w>
He mo
HT10 80</w>
HLA- DQ
HL M</w>
HIF-1 alpha,</w>
HIF-1 a,</w>
HI ST
HI -
H allucin
Gluc osamine</w>
Gab ap
GS S
GPR109 A</w>
GP T</w>
GLUT 5</w>
G lasgow</w>
G R,</w>
Func tion</w>
Flu oxet
Flec ainide</w>
Fas/ FasL</w>
FDA- approved</w>
F ISH</w>
F HL
Ew ing's</w>
En cephal
ET (A)</w>
EML 4-
E pig
E ll
E ast</w>
E OC</w>
DT- diaphorase</w>
DO PA</w>
D y
Com prehensive</w>
Com pan
Clinic al,</w>
CXCR 1</w>
CR C.</w>
CG ),</w>
CALU X</w>
C SE
C HC
Bupren orphine</w>
Bup ivacaine</w>
Boy den</w>
Bis phosphonates</w>
Bcl-X (L)</w>
BV -2</w>
BB R</w>
B iliary</w>
B -</w>
Ap omorph
An tic
Alter native</w>
Adnab -9</w>
Ac t
AN CA
AL )</w>
A- 8
A 2.</w>
< or=
< =
90 %.</w>
9 8,</w>
9 )
7- nitro
7- hydroxylation</w>
7 7,</w>
7 6-year-old</w>
6-thi oguanine</w>
6- 8</w>
6 25</w>
5-Aza- CdR</w>
5- mediated</w>
48 8
47 ).</w>
40 3</w>
40 ).</w>
4- day</w>
4 8-year-old</w>
39 ),</w>
3/ *3</w>
3-methyl adenine</w>
3- ,</w>
3, 8-
3 h</w>
29 5</w>
25 /
25 .</w>
21- day</w>
200 8</w>
2, 4
1A /
19 /
18 4</w>
15 q
10- min</w>
10(- 5)
1. 6,</w>
1,25-(OH) 2D
1 beta</w>
1 0.3</w>
0. 7%</w>
0. 38</w>
0 5
0 2
/ =</w>
.0 2).</w>
-1- methyl
(r 2</w>
(VCAM -1)</w>
(TGF- beta)</w>
(RP E)</w>
(PXR ),</w>
(PA NS
(P S)</w>
(P E)</w>
(H b)</w>
(H S
(H NS
(H Be
(ERK1/ 2),</w>
(CYP2E 1)</w>
(BUN )</w>
(AB CB
(A po
(8 6%)</w>
(4 ,</w>
(3) ),</w>
(3 7%)</w>
(3 6</w>
(2. 5,</w>
(2 7</w>
(2 6%)</w>
(2 0%</w>
(1 8
(1 60</w>
( seven</w>
( s),</w>
( protein</w>
( on</w>
( groups</w>
( CYP2D
( ATP7
zafirlu kast,</w>
z oster</w>
yr .</w>
well- differentiated</w>
volume tric</w>
ve red.</w>
val ine</w>
vacuol ation</w>
uxim ab
um ).</w>
tyros ine,</w>
tri azole</w>
transi ent.</w>
trans glutaminase</w>
trans generational</w>
tor .</w>
ti p</w>
tetra acetic</w>
t s
t i</w>
t amp
suxamethoni um.</w>
subtyp e,</w>
su mo
su b</w>
stomach .</w>
staf f</w>
stabil ization,</w>
spe ech
sor al
sol id-
sk ip
sing le,</w>
separ ately,</w>
self- injurious</w>
second arily</w>
se baceous</w>
s aponin</w>
rox ylin</w>
riddelli ine</w>
retur ning</w>
resist ant.</w>
repolar ization.</w>
receptor- associated</w>
receptor -2</w>
re constitution</w>
re activators</w>
rauwol sc
rang es.</w>
racl opride</w>
ra ys</w>
pyrro lo
provid ers</w>
protein- bound</w>
prost adi
prometh azine</w>
prof en
produc tive</w>
produc ed.</w>
pro fibrotic</w>
prim ers</w>
pril ocaine</w>
postische mic</w>
pol i
plastic ity.</w>
piper idine</w>
phosph ot
perfor ant</w>
perfluoro octanoic</w>
per spective</w>
pentobarbit al.</w>
patter ning</w>
p tion/
p e</w>
oxif yl
ox LDL</w>
out patients.</w>
osteoporo tic</w>
orin ostat
omeg a</w>
om y</w>
olig uria</w>
ol enic</w>
og uanidine</w>
occul t</w>
ob sessive</w>
o sterol</w>
o ster
o rol
nucle ophilic</w>
normal ized.</w>
nordihydro guaiaretic</w>
non- insulin-dependent</w>
non- cancer</w>
no ur
nmol/ l</w>
nigra .</w>
ng/m L.</w>
neuro humoral</w>
ne o-
n m
n )</w>
mum ol
monomethyl arsonic</w>
mon ocarb
moieti es</w>
modul ator,</w>
ml ),</w>
min -induced</w>
methyl ating</w>
medull a,</w>
mediast inal</w>
me ter
mat ric
mal onic</w>
lumbos acral</w>
lob ul
lethal ity,</w>
leas on</w>
lay er.</w>
labetal ol.</w>
l ich</w>
k y
k o
join ts</w>
ip ,</w>
intestin al,</w>
intermedi ate.</w>
intermedi ate,</w>
insul in-induced</w>
inst em
ini b
influ enc
ine- evoked</w>
ine d:</w>
induc tive</w>
indic es,</w>
impai red,</w>
im pulse</w>
hypo vol
hyper phosphat
hyper oxic</w>
hyper kinetic</w>
hyp oxic
hydroxy ure
hydr amni
hy gi
hospital izations</w>
hir su
hind paw</w>
hemoly sis,</w>
hem izyg
help ed</w>
haemat opoietic</w>
h ens</w>
h CAR</w>
gu ggul
glucuron osyltransferase</w>
gl icl
ginsen osides</w>
gestod ene</w>
gen der.</w>
g/ 24</w>
fungic ides</w>
ful .</w>
fu sion.</w>
fructos e-induced</w>
fos f
form er
flup irt
fluoro metric</w>
fluoresc ence.</w>
flex or</w>
fist ula</w>
f ine-
expres sion:</w>
ex haled</w>
et on,</w>
erb B2</w>
episo de,</w>
epigallocatech in-3-gallate</w>
ep am,</w>
environ ment
ent- onset</w>
ent ine</w>
eng agement</w>
end- tidal</w>
electroly tes,</w>
ei v
eff ac
echocardi ograms</w>
ear ,</w>
each ).</w>
e ut
e gr
dys lipid
drug- seeking</w>
dose- dense</w>
docetaxel -induced</w>
diure tic,</w>
di-n- propyl
dex tran
desatur ase</w>
demethoxy curcumin</w>
decre ments</w>
dap son
d- up</w>
cyto sis</w>
cross- links</w>
cros sing</w>
counter part</w>
con servation</w>
con genic</w>
cobal t,</w>
ci ster
chondro cytes,</w>
chemotherap y:</w>
ce as
caspase- 8.</w>
carcinogen -
carbon yl-
cancer -associated</w>
can th
calcul ations</w>
calcium- binding</w>
ca erul
c ent,</w>
c c
c amph
bw )</w>
but orphanol</w>
bul l
bromod omain</w>
bra instem
bra ins.</w>
bortezomi b,</w>
bo w
blun ting</w>
bl u
bios caven
bil ity.</w>
bil ity,</w>
bi ophysical</w>
bi ochemotherapy</w>
bi -
beta- HCH</w>
barbitur ates</w>
b cr
azid othym
az osulf
autoradi ography</w>
audi ogenic</w>
atom s</w>
atax ic</w>
asp ect
asbestos -exposed</w>
ari st
appro x.</w>
appreci ated</w>
antipyre tic</w>
anti tuberculous</w>
ana x</w>
alpha- fet
alpha 4</w>
alkyl ated</w>
albumin uria.</w>
album in-
agonist /
agne tic</w>
ag atran</w>
advanc ed,</w>
adenos ine-
addres sed.</w>
acyclo vir.</w>
activit y).</w>
acetylamino fluorene</w>
abrup tly</w>
[SD ]</w>
Z ileut
VP -16</w>
VEGF- C</w>
UCN- 01</w>
U/ L,</w>
U M-
Tran s-
Toxic ities</w>
Ti me
Th ail
Test s</w>
TRPV 4</w>
TO F-
TGF beta
T/ T</w>
T ob
T at</w>
Syn thetic</w>
Sum atriptan</w>
Sevo flurane</w>
ST IG
SB -2
S keletal</w>
Re al</w>
R- treated</w>
R elev
R e-
R C</w>
R 1.</w>
Progn ostic</w>
Princ eton,</w>
Pot ent</w>
Post mortem</w>
Phy s
Par allel</w>
Pa CO2</w>
PT C</w>
PT ,</w>
PGF 2</w>
P< 0.001),</w>
P2X 7</w>
P ub
P it
P atter
P IC
Oatp 1b
O lig
O PR
Nec rosis</w>
Na ph
ND GA</w>
NADPH -dependent</w>
N-acetyl-l- cysteine</w>
Minim al</w>
MeIQ x</w>
MMP 9</w>
METH .</w>
MEASURE :</w>
ME C</w>
M sh
M ain</w>
Lu c</w>
Lip opolysacch
Kv 1.5</w>
K O)</w>
K L
K IT</w>
Intracere bral</w>
Inhibit or</w>
ISO -treated</w>
INVE STIG
HL- 60/
HBI g</w>
H(2)O (2).</w>
H S-
H H</w>
Gluc ocorticoid</w>
GW966 2</w>
GF ,</w>
G ood</w>
G CS
Est abl
Elig ible</w>
EC Gs</w>
E rec
E H
E F-
E D.</w>
Differenti ation</w>
Deg u
Dap sone</w>
DIL I</w>
DH C</w>
DH ,</w>
DD S</w>
DBA/ 2
Com mun
Ci lost
Ch arcot-Marie-Tooth</w>
Ceftriax one</w>
Carcin oma</w>
Calu -3</w>
Cal c
Ca ++</w>
CYP2 6</w>
CYP 17
CG I</w>
CD 8</w>
CD 28</w>
CA R.</w>
Brist ol-Myers</w>
Bi opsy</w>
Benzo[a] pyrene</w>
Ben ign</w>
Ba P,</w>
BP s</w>
BH 3-
BCN U,</w>
B z
Apaf -1</w>
Am mon
All- trans-retinoic</w>
Ah r
ATI ON</w>
AN T</w>
AI CAR</w>
AD ).</w>
A stro
< 0.05).</w>
8-ox od
6 J</w>
6 1,</w>
6 -12</w>
5-HT 2C</w>
5, 10-
5 40</w>
48 /
4- phenyl
4- (
38 /
30 %)</w>
3- amino
2B 6</w>
2: 1</w>
29 ;</w>
29 9</w>
200 1.</w>
200 1,</w>
20 ;</w>
2- microglobulin</w>
199 9,</w>
17 %,</w>
15-PG DH</w>
13 ;</w>
12- year-old</w>
11. 8</w>
109 203
100 )</w>
10(- 8),</w>
1/ 2.</w>
1. 0-
1- chloro
0.6 8</w>
0.5 8</w>
0.000 5)</w>
0.00 6)</w>
0.00 4)</w>
0. 70</w>
0. 6,</w>
0. 31</w>
, 5
) (2)
(rs 10
(p R
(m Glu
(S p
(S W
(MMP )-
(M I).</w>
(IC(50 )=
(H a
(F B
(E R</w>
(DEX )</w>
(Ch IP)</w>
(CR C)</w>
(B SO
(B CRP
(A SA)</w>
(A )
(> =</w>
(5 8%)</w>
(5 3%)</w>
(2+ )-
( si
( peak</w>
zol e.</w>
z- VAD-
youn g
yn chron
war ning</w>
vitamin osis</w>
vinorel b
vesti bul
uro lithiasis</w>
urin ol</w>
ung ent</w>
un modified</w>
un detectable.</w>
tyr amine</w>
troph oblasts</w>
treat ed)</w>
ti um-
tech ne
ta ilo
survi ved.</w>
suppress ants</w>
supple ments.</w>
superim posed</w>
suit ability</w>
substitu tion,</w>
subject s:</w>
sten oses</w>
st ains</w>
sphingomyel inase</w>
sperm idine</w>
spas m,</w>
skip ping</w>
skin -
si s
sex -
sequenc es,</w>
sep sis,</w>
sensitis ation</w>
selec tiv
schizophren ia:</w>
scaveng e</w>
sc an.</w>
s oun
s and
robu stly</w>
reverse- transcriptase</w>
retinoid s,</w>
ret ains</w>
resuscit ated</w>
rest ore
rest or
reser pine.</w>
repe ti
relax ation,</w>
rel ates</w>
recti fying</w>
recommend ation</w>
receptor s)</w>
rec ur</w>
re oxygenation</w>
re medi
re challenged</w>
rat ax
r as,</w>
quinol inic</w>
quin ox
quin idine.</w>
qual ity-
psychostimul ants</w>
psych opathology</w>
prot on-
progres ses</w>
program ,</w>
process ing,</w>
pro bed</w>
present ed,</w>
precis ely</w>
prec oci
pre- test</w>
pral idoxime</w>
pol ic
plas min</w>
plas matic</w>
phen ous</w>
perone al</w>
pecul iar</w>
particip ants,</w>
p27 (k
p entan
p al</w>
p M</w>
p /
oxy acetic</w>
ou red</w>
oth al
ot an</w>
osp inal</w>
osi 's</w>
or rho
op anc
onect in.</w>
ol us</w>
ocel e</w>
norethind rone</w>
non- ionic</w>
non cytotoxic</w>
nomifens ine</w>
nmol/ mg</w>
ng/m l),</w>
neuropath ology</w>
net work
ne vertheless</w>
ne mat
nausea/ vomiting</w>
naphtho quinone</w>
n ame</w>
myel oma,</w>
myalg ia,</w>
modific ation,</w>
modi alysis</w>
migraineur s</w>
microg/m l,</w>
mic e].</w>
methemoglob inemia</w>
metallo id</w>
metabolis ed</w>
mesenchym e</w>
mefloqu ine.</w>
me iotic</w>
matur ation,</w>
mariju ana</w>
man ic-
makal im</w>
macul opap
macro scop
ma protiline</w>
m d
loop -
literature ].</w>
lisin opril,</w>
lic ensed</w>
leukopen ia,</w>
len ses</w>
left- ventricular</w>
left- sided</w>
le ptom
lat ter,</w>
lat est</w>
las er-
laparo tomy</w>
lact ate,</w>
l ose</w>
k ling</w>
itu itary</w>
it ching</w>
iso flavon
ischemi a-induced</w>
is one</w>
intrac ardiac</w>
inte restingly,</w>
inst ance,</w>
inhibitor ).</w>
infu sions,</w>
ind azole</w>
increas e)</w>
inc r
in- Barr</w>
in born</w>
impair ment
immun ization</w>
imat oprost</w>
ic ter
i e,</w>
i 's</w>
hyperpolar ization</w>
hyper nat
hyper kinesia</w>
hydroxyl ase.</w>
hydro quinone,</w>
homocyste ine,</w>
her nia.</w>
hepat oblastoma</w>
hemoly tic-uremic</w>
hemodynam ics.</w>
h ope</w>
h MSCs</w>
great er.</w>
glyc ated</w>
gly bur
glucuron ide,</w>
glomerul i,</w>
gl ass</w>
gav age,</w>
g ent
frac tions,</w>
fos car
former ly</w>
for mon
food ,</w>
fol ates</w>
fl atten
fl as
fil l</w>
fibro genesis.</w>
fatigu e.</w>
famoti dine,</w>
f its</w>
extremi ties,</w>
extr usion</w>
expect ancy</w>
ex changes</w>
ew es</w>
ev en
estr am
ere bellar</w>
ere 's</w>
eotax in</w>
ell ag
effici ency,</w>
e- like</w>
doxorubic in/
domin antly</w>
domain -containing</w>
do or</w>
disrup tion,</w>
discipl inary</w>
dis ap
dioxin- responsive</w>
dichloro ethylene</w>
dic arb
di amin
detoxif ied</w>
deple tes</w>
depart ments</w>
dele tions.</w>
de ad
dan azol
d ying</w>
d up
d (-1)</w>
cu e-induced</w>
crystall in</w>
cross- reactivity</w>
contr asting</w>
config ur
compreh ensi
complain t</w>
collagen -induced</w>
co- localized</w>
clo dronate</w>
clear- cut</w>
cis- diamm
circu its</w>
cin ,</w>
cic lospor
cholecyst ectomy</w>
chlorpromaz ine.</w>
chlordiazep oxide</w>
ceftriax one.</w>
cdk 2</w>
catabol ism.</w>
cascad es.</w>
capac it
calci um/
c-FL IP</w>
bumetan ide</w>
bronchi tis</w>
br a</w>
bi periden</w>
bi odistri
bezafib rate.</w>
benzo phen
benz imidazole</w>
az ab
atri enoic</w>
atil ity</w>
at a,</w>
as sume</w>
arsenic -treated</w>
arachid on
ar ith
appreci ably</w>
apop lexy</w>
antipsycho tic,</w>
anoik is</w>
ano ate</w>
angioplast y.</w>
angi ograph
ane dione</w>
an -1</w>
aminophyl line,</w>
all idal</w>
alcohol ism.</w>
al- derived</w>
agent -induced</w>
ag e).</w>
addi tion.</w>
acyl transferase</w>
act am</w>
acidi fication</w>
aca demic</w>
ac in.</w>
ac cord
a de
[ P
Yohim bine</w>
Wee kly</w>
W IN
Ve hic
V- FITC</w>
V im
V 2</w>
UN ,</w>
Trans dermal</w>
Throm bo
Thre e-
Thi op
TRAIL /
TGF b</w>
TF AP
TC P</w>
T R-
T FA</w>
System atic</w>
Spironolact one</w>
Soci al</w>
Sil denafil</w>
Seventy- five</w>
SV T</w>
SNP .</w>
SMC s.</w>
SH ),</w>
SAH .</w>
Recogn ition</w>
Re mo
RN ase</w>
RA P</w>
R P-
Pur ified</w>
Placeb o</w>
Pin 1</w>
Phy to
Parkinson -
PU MA</w>
PI ,</w>
PD 15
P uro
On tari
OL T</w>
O s
O TA-induced</w>
O G
Nec ro
NP s.</w>
NF-kappa B/
N2 O</w>
N- (
N od
N EC
My opathy</w>
Mon ocyte</w>
Mo del</w>
Mit omycin</w>
Min oxidil</w>
Mg (2+)</w>
Meni ere's</w>
Macroph ages</w>
MT- III</w>
MN NG
MI A</w>
MG 63</w>
MD ,</w>
MAO- B</w>
Le uc
Lan gendor
LX A(4)</w>
L-NAME .</w>
Kap osi's</w>
K lotho</w>
K ar
K 4</w>
J .,</w>
IM R-
III A</w>
II b</w>
IGF- I,</w>
ID 50</w>
Hormon al</w>
HR T</w>
HP V</w>
HO S</w>
HIV -1-
HB CD</w>
HB )</w>
Gly cyrrhiz
Genotyp e</w>
GR P</w>
GABA B</w>
G yn
G el</w>
G R-
FSG S</w>
FK50 6.</w>
FD G</w>
F G</w>
F AC
Epig alloc
E L</w>
Del t
Dar by</w>
DON -induced</w>
D ut
Cy clin
Cri zot
Cr yst
Cholest asis</w>
Chin a,</w>
Caucasi ans.</w>
Ca ki
CYP2A 6.</w>
COX -2
CI -10
CH X</w>
CF U-
CD9 5/
CD 3</w>
CD 18</w>
CD ,</w>
CA D.</w>
C EP
Bec lin</w>
BD L</w>
B id,</w>
B erb
Aut o
Atox 1</w>
An y</w>
Adip onectin</w>
Ad eno
AZ T/
AT L</w>
AD ORA
A54 9,</w>
A/ G</w>
A- ->
A 3
A 1-1</w>
90 %,</w>
9 706</w>
89 7</w>
8 2.
8 -2
7- ket
7- NI</w>
7 80</w>
7 7.
7 2-year-old</w>
7 %.</w>
50 mg/kg</w>
50 ,000</w>
5-F U/
5-Aza-2'- deoxycytidine</w>
5 q
5 1-year-old</w>
5 1)</w>
4E- BP1</w>
4 R</w>
4 70</w>
4 12</w>
4 1).</w>
38 4</w>
37 8
35 ),</w>
3- NB
3 a
3 1).</w>
3 -2
28 6</w>
24 ;</w>
20- year-old</w>
20 :
2- deficient</w>
2- adrenoceptors</w>
2 500</w>
1A 3</w>
19 9</w>
17 8</w>
14 ;</w>
14 2
10. 6</w>
10(- 5
1. 75</w>
1-1 6
0.6 6</w>
0. 90</w>
0. 37</w>
0. 25%</w>
/ protein</w>
.0 3).</w>
-2 10</w>
-16 39
-10 ,
-1 0,</w>
(p =0.
(T AM)</w>
(T /
(R R,</w>
(PPAR y)</w>
(P CA)</w>
(M V
(L A)</w>
(IL)- 6</w>
(I SO)</w>
(H V
(H BI
(GSK- 3
(F AK
(D P
(C x
(AC TH)</w>
(A RE)</w>
(A NOV
(7 2</w>
(50 ))</w>
(3 '-
(2. 4</w>
(2 9.
(2 5.
(1. 25</w>
(1- 7)</w>
(1 80</w>
(0. 25-
( using</w>
( superoxide</w>
( left</w>
( either</w>
( each</w>
( dose</w>
( cytochrome</w>
( acute</w>
' t</w>
zoledr onate</w>
z in</w>
y rate</w>
worsen s</w>
ventricul ography</w>
vascular ization.</w>
us age.</w>
us ),</w>
ur so
upregul ated.</w>
up- regulation,</w>
ultrason ography.</w>
ul ates</w>
udi l</w>
tumor- suppressor</w>
troph oblastic</w>
tre e</w>
trans thoracic</w>
tobac co-
to enail</w>
thou gh
terat ogenesis</w>
tel omeric</w>
te trandrine</w>
t- time</w>
t inea</w>
syst olic,</w>
suppress ant</w>
summar ized</w>
sulph ate,</w>
stereotyp ies</w>
st yr
spin y</w>
spher oid</w>
spectrometr y,</w>
som e,</w>
single- blind,</w>
sin usi
si al</w>
shut t
short- lived</w>
short- chain</w>
sev en-
seri ously</w>
scram bl
sc ar</w>
satis fac
sacrific e</w>
sa phenous</w>
rot ations</w>
ros covit
rifampic in-induced</w>
responsiven ess,</w>
res tin</w>
regener ation,</w>
record ings.</w>
recor ded,</w>
recipi ent.</w>
reason ably</w>
re organ
re infection</w>
raz ox
rati os,</w>
r ing.</w>
quar ter</w>
qu am
putam en,</w>
psychi at
prote ase-
prostagland ins,</w>
prolifer ators</w>
pro geny</w>
pri v
pri or
pregab alin</w>
preeclamp sia.</w>
precursor s.</w>
pre load</w>
post- synaptic</w>
polyp eptides</w>
poli po
pmol/ min/
platin um
plasmaphere sis</w>
pl ification</w>
pig s,</w>
phosphoro thio
phospholip ids,</w>
phenyl alan
pharmac ogenetics</w>
peak -dose</w>
partic i
part ners</w>
parab ens</w>
panc reas.</w>
paired- pulse</w>
pac k
p21(C ip
p-nitro phenol</w>
oxid ases</w>
ouab ain,</w>
ot ed</w>
osteoporo sis,</w>
osper mia</w>
ore mentioned</w>
order :</w>
or um</w>
opioid s,</w>
opin ion</w>
ophil ia</w>
on asal</w>
omethyl) -1,3-prop
olabel ing</w>
ol ti
ol ine-induced</w>
ogram s,</w>
ocor tic
ochemistr y,</w>
ob /
o[ 3,2-
o estrogenic</w>
o A</w>
nmol ),</w>
nicot ine-treated</w>
nicardi pine,</w>
nic ergoline</w>
neuro transmission,</w>
neocor tical</w>
neigh b
mutagene sis.</w>
mut ual</w>
multiple -dose</w>
monitore d,</w>
modifi ers</w>
mis sing</w>
minocycl ine.</w>
microcephal y,</w>
micro injected</w>
micro cystin-LR</w>
mg/m2/ d</w>
metrif onate</w>
methohex it
mes o
men ;</w>
melan ogas
me f
mas tec
marmos et</w>
m ated</w>
m M
lute in</w>
log y</w>
li zation</w>
level s)</w>
leg al</w>
lec ith
lead -induced</w>
l ect
isoc itrate</w>
iso quinoline</w>
irrit ants</w>
iod o-
introduc e</w>
intral e
intermit tently</w>
integr ins</w>
inn oc
ind ol</w>
in- vivo</w>
in- derived</w>
in tolerable</w>
imprin ted</w>
impot ence.</w>
immunore activity.</w>
immobil ization</w>
ig ra
ian -like</w>
hyponatre mia.</w>
hypo thyroidism.</w>
hypere mia,</w>
hydroxy anisole</w>
hydrolas es</w>
hormon ally</w>
hist amine.</w>
her bs</w>
haemod ynam
hO AT1</w>
h -1</w>
gynec omas
gyn aec
growth- promoting</w>
glyc id
glucosamin id
glomerul us</w>
ging erol</w>
gastro enter
g ossy
further more</w>
frag mented</w>
forskol in,</w>
formal in-
flup en
f ain
extract s,</w>
extracellul ar-
expos ed,</w>
exp anding</w>
ethyl ation</w>
ethnic ity</w>
estrogen -regulated</w>
erythro leukemia</w>
energe tics</w>
end- organ</w>
end points.</w>
end ocytic</w>
en tion</w>
elig ible.</w>
el -
effici ency.</w>
dy drog
drin k</w>
dr al</w>
dos es)</w>
dithiocarb am
dissec t</w>
dis pos
diff us
diff er.</w>
di amine</w>
desor ption/
desi re</w>
decid ual</w>
dap amide</w>
dact yl
d it
cyste ine-
cycl ase,</w>
curren tly,</w>
cri sis.</w>
cou me
conjug ates.</w>
conf used</w>
conc ep
comple te.</w>
comple menting</w>
compa red,</w>
com mitted</w>
collag ens</w>
co operation</w>
cisplat in-treated</w>
circuitr y</w>
child 's</w>
ceriv astatin</w>
cer vic
cer tain
cell- surface</w>
cef azol
catarac ts</w>
carri age</w>
cardiover sion.</w>
cardi ac,</w>
ca esarean</w>
c- MYC</w>
but ane</w>
brom omethyl)-1,3-prop
block er)</w>
bl urred</w>
biosens or</w>
bil ay
beta/ delta</w>
beta- naphthoflavone</w>
beta(2)- adrenoceptor</w>
benef its.</w>
ben oxa
behavi orally</w>
beha ved</w>
beats/ min.</w>
bcl- x
balloon ing</w>
back bone</w>
b un
b one,</w>
b is</w>
az ithromycin
at tend
at o</w>
assi vely</w>
assess ments.</w>
ar in,</w>
ar chi
apo B
ap se</w>
anti- fibrotic</w>
anti- apoptosis</w>
anesthe tic,</w>
anc e)</w>
an us</w>
aminop eptidase</w>
amino transferases</w>
amin ept
alpha- amino-
alpha,beta- unsaturated</w>
aldoster one.</w>
al es</w>
aim ing</w>
agit tal</w>
af orementioned</w>
adriamycin -treated</w>
administr ation:</w>
ad duction</w>
ad amant
activ ation)</w>
ace ph
abl y.</w>
abdom en</w>
a- derived</w>
a id
[(14) C]
Zn SOD</w>
W H</w>
V eter
V IIa</w>
V 600
Un treated</w>
UROt sa</w>
UGT 1</w>
U G
Trem or</w>
Tr kB</w>
TLR 2</w>
TC .</w>
T ript
T l
T ardive</w>
T ZD</w>
Str at
Smad 2</w>
Signific antly,</w>
SR C-1</w>
SOD .</w>
SH P</w>
SCN N
SAP K/
S pati
Resol ution</w>
Remo val</w>
Re action</w>
RB 59
R NP</w>
R CC.</w>
QT- prolonging</w>
Q D</w>
Ph thal
Pestic ide</w>
Paroxet ine</w>
Pa Ca-2</w>
PV N</w>
PO MC</w>
PN D
PK R</w>
PDGF- B</w>
PCR- based</w>
PC NA,</w>
PC ).</w>
PB L</w>
P2X (7)</w>
P ir
P OR</w>
P =</w>
Out patient</w>
OCT N2</w>
O- glucuronide</w>
O zone</w>
O SC
O E
O 2-</w>
Non- steroidal</w>
Ne utrophil</w>
Ne utroph
N- demethylation</w>
N 6
N (6)-
Muc h</w>
Mas sive</w>
Mar kers</w>
MTH F
MT 1
MT -2</w>
MPT P-
MG C-
MENT :</w>
MD CK</w>
M s.</w>
Loc omotor</w>
LT D4</w>
LA PC
Kim -1</w>
K- Ras</w>
K erat
JAK /
Infarc t</w>
In tro
In dapamide</w>
IT B</w>
IS P</w>
IL-1 2,</w>
III B</w>
IC V</w>
I R,</w>
Hyper prolactinemia</w>
HP -induced</w>
HI PK
H(2)O (2)-
H NF-
H H
H 1,</w>
Gener ation</w>
Gabap entin</w>
GLP -1</w>
G (1)-
Fos -
For ced</w>
Fluoro -J
FM D</w>
FB M</w>
FAN CD
Epste in-Barr</w>
Epigalloc atech
Epi leptic</w>
Emerg ing</w>
E2 F-1</w>
E GT
Drug -
DOX -treated</w>
DMB A-induced</w>
DL BCL</w>
DE NA</w>
DA RPP-
D yst
D e</w>
D HC
Cu (I)</w>
Coll agen</w>
Clozap ine-induced</w>
Characteris tics</w>
Carbamazep ine-induced</w>
Ca(2+ )/
CP T-
CE ES</w>
C s,</w>
C ath
C at</w>
C K,</w>
C (max)</w>
Biomar kers</w>
Ben azep
Be as
BP DE
BNIP 3</w>
BAD GE</w>
B GC-
Asth ma</w>
An tim
Al though,</w>
Ac tin
AMP K,</w>
AI )</w>
AH R.</w>
AD R,</w>
A(2 A)
A polipo
A 6</w>
A 2-
= 2.
95% CI</w>
9 T</w>
9 9,</w>
9 8.
9 6.
9 2.
8- oxo
70 ),</w>
7 1,</w>
6 3,</w>
5-HT(2 B)</w>
5- (
5 2)</w>
400 ,</w>
40 %)</w>
4. 5%</w>
4- hydroxylation</w>
4- fold,</w>
4 S
4 :</w>
4 30</w>
4 3).</w>
4 -1.
35 ;</w>
34 4
34 ),</w>
28 2</w>
27- year-old</w>
25 2</w>
24- year-old</w>
24 /
23 2</w>
200 3,</w>
2- mercapto
2 K
2 2).</w>
199 8,</w>
19 3</w>
15- 45
12. 6</w>
12 54</w>
11 q
1- treated</w>
1 ],</w>
1 )/
0.9 2</w>
0.7 5%</w>
0.6 3</w>
0.6 2</w>
0.4 6</w>
0. 27</w>
0 8
0 6
0 %).</w>
.0 2)</w>
- 3.</w>
) ,
(p< 0.05),</w>
(max ))</w>
(VKOR C1)</w>
(T AC
(SIRT 1)</w>
(R, S)-
(R G
(PI3K)/ Akt</w>
(PCR- RF
(M CF
(LP S),</w>
(IL)- 6,</w>
(III ),</w>
(H K
(F as
(F T
(EP O)</w>
(EC (50)</w>
(E F
(E -
(DMB A)</w>
(C N
(ACh )</w>
(A V)</w>
(A HR
(A GE
(6 4%)</w>
(4 6%)</w>
(3 9%)</w>
(3 8</w>
(2 4
(2 1.
(1 1)</w>
(1 %)</w>
(0. 6</w>
( placebo</w>
( p38</w>
( heart</w>
( g
( before</w>
( LTB
z omep
z imel
y- specific</w>
y leth
x- ray</w>
we d,</w>
wa ke
vinc a</w>
vanad ate</w>
v /
uscit ation</w>
und 's</w>
un myelinated</w>
ultras onic</w>
typ e-specific</w>
tun ic
tro phy
trihexyphen idyl</w>
tri az
treat .</w>
traffic king.</w>
tra p</w>
tom ography,</w>
tol metin</w>
to- mesenchymal</w>
til ,</w>
tic- pharmacodynamic</w>
ti ag
thio phen
th imide</w>
terbutal ine.</w>
ter tile</w>
techn ology.</w>
tailo red</w>
t ard
syst ole</w>
sym porter</w>
surve yed</w>
suppress or.</w>
sumatript an,</w>
subcutaneous ly)</w>
sub total</w>
struct ure-
step- down</w>
stat e)</w>
stand ards</w>
st ore
st ane</w>
splic e-
spectroscop y,</w>
sil ence</w>
si dom
self- administer</w>
satis fied</w>
sarcom a,</w>
sanguin arine</w>
rout es.</w>
rosu vastatin</w>
rofecoxi b,</w>
rib ose</w>
rho dop
restar ted</w>
resec tion.</w>
renew ed</w>
reli ability</w>
recogn izing</w>
re ri
re al
rang e)</w>
quinox aline</w>
pur ity</w>
puls atile</w>
protoc ols,</w>
pron il</w>
prolactin omas</w>
progres sive,</w>
pro ton
pro of-
pro monocytic</w>
pro angiogenic</w>
preeclamp sia</w>
por ted</w>
polymer ase,</w>
poly therapy</w>
poll uted</w>
plant -derived</w>
pit ant</w>
piren zep
phenyl) -1-
phencycl idine</w>
pharmac y</w>
ph i</w>
pg/m l)</w>
permeabil ization</w>
percent ),</w>
per it
pe floxacin</w>
paw .</w>
path om
pathom echan
paren chy
p53- null</w>
p21(WAF 1/CI
p- H
p ungent</w>
p un
p razole</w>
oxygen ation.</w>
oxaliplat in-induced</w>
ouabain -treated</w>
oti tis</w>
othrom b
orrhe a,</w>
or der.</w>
oph or
oph o
omo tion</w>
ome ter.</w>
om es,</w>
o rous</w>
non neoplastic</w>
non depolarizing</w>
net work,</w>
neon atally</w>
naloxone- precipitated</w>
n iz
n ;</w>
myri state-
myo fibroblasts</w>
multi for
motiv ation</w>
mom ent</w>
moder n</w>
minute .</w>
mineral ocortico
min g.</w>
min (-1))</w>
mil itary</w>
mg. /
methamphetamine- dependent</w>
metallothione in-
mes angi
melan ocytes.</w>
medi ator,</w>
maculopap ular</w>
m ect
lys ate</w>
lu c</w>
log (10)</w>
locomo tion.</w>
lit ters</w>
lind ane,</w>
lin olenic</w>
li gam
levobup ivacaine</w>
lay er,</w>
kg .
ka olin</w>
k Hz</w>
jum ping</w>
join ing</w>
iz ation-
isoniaz id
irrit ability,</w>
intra epithelial</w>
inter ventricular</w>
induc tions</w>
in- positive</w>
in ti
in s)</w>
imple mented</w>
immunostain ing.</w>
im posed</w>
id a
ic um</w>
i i</w>
hypox emia</w>
hypother mia.</w>
hypothe tical</w>
hypoplasi a.</w>
hyperglyc emia-induced</w>
hypercholesterol emia,</w>
hyper trophy
hydrocarbon s,</w>
hom e.</w>
hippocamp i</w>
high- salt</w>
hexa hydro
hes peridin</w>
hCtr 1</w>
h amne
hamne tin</w>
h N
h MSH
graf ted</w>
grad ing</w>
gly cyrrhiz
glutaryl- coenzyme</w>
g um</w>
g out
four- week</w>
form ance</w>
form al</w>
follic ul
fluc loxacillin</w>
flu ids.</w>
first- pass</w>
first- degree</w>
fibrin ogen
failure ].</w>
fai led.</w>
f s
extr as
expres sion/
exec ution</w>
es "</w>
erythe ma,</w>
enti ties</w>
eng aged</w>
endoscop y</w>
encephal on</w>
em ed</w>
eli an</w>
el liptic
el le</w>
eg g</w>
effu sion.</w>
efflu x,</w>
ed ge</w>
ec to-
e di
e b,</w>
dro ph
dri ed</w>
dn /P
dithiothre itol</w>
disulf onic</w>
dissi pation</w>
disease- related</w>
discer ni
dis odium</w>
dis appeared,</w>
direc t-
diaphrag ms</w>
dialys ate</w>
di ary</w>
dexamethas one-
dermat ologic</w>
deliver ing</w>
deline ated</w>
dehydr atase</w>
deep er</w>
decompens ation</w>
d s
d as
cytochrome- c</w>
cyt open
cyclooxygenase- 2,</w>
cyan id
cour ses,</w>
cot in
conver sion.</w>
contribut ors</w>
continu ous-
congen it
compar able.</w>
coca ethylene</w>
coag ulated</w>
co- activator</w>
clomi phene</w>
cle an
clamp ing</w>
cladrib ine</w>
chromi um,</w>
cholel ithiasis</w>
cholecys titis</w>
chlordec one</w>
chemic al.</w>
caus es,</w>
cataton ia.</w>
catalep sy
caspase- 12</w>
caspas es-
carb imazole</w>
cann ula</w>
ca vity,</w>
cG MP-
c us</w>
c ox
bupropion .</w>
biopsi es,</w>
beta- AR</w>
beta- 2</w>
beta 2
beryl lium</w>
bacter ia.</w>
b end
attri bute</w>
ation s)</w>
at- risk</w>
asyst ole.</w>
assum p
as es:</w>
as es
ari an</w>
anti- hyperalgesic</w>
anti- estrogen</w>
anti microbi
ant le</w>
angi ograms</w>
angi ogram</w>
andro lone</w>
anastro zole</w>
analge si
an uric</w>
amp ut
amisul pri
alpha- methyldopa</w>
alpha (2
alkalin ization</w>
alb ic
al o
aggrav ating</w>
advoc ated</w>
adrenal ine.</w>
ad ural</w>
acrole in-induced</w>
acid /
acid -treated</w>
accept ability</w>
ac anth
_percnt ;</w>
[6 ]-
Zol edr
ZnT -1</w>
Y S</w>
Wn t-
V H</w>
U 466
Tri al.</w>
Ta urine</w>
TRAIL- resistant</w>
TP MT
TC ),</w>
TB X
TB AR
T ex
T et
T ca8
T J
Surve y</w>
Sulf asalazine</w>
Stud ent's</w>
SV 40</w>
ST E
SNP -induced</w>
SH B
SGC790 1/
SG C-
SGC- 790
S emi
S em
S Z
S CA
Riton avir</w>
Rest oration</w>
Ra ther,</w>
RT V</w>
RT .</w>
RP -1</w>
RO S/
RE CK</w>
RANT E
R F</w>
Quin idine</w>
Progres sion</w>
Polymorph ic</w>
Phe -
PT PR
PROCEDURE :</w>
PM 2.5</w>
PI 3</w>
PGHS -2</w>
PDGF R
PA CAP</w>
P W
P KG
P ;</w>
P .
On dan
Ome prazole</w>
OUTCO ME
O pen
O H,</w>
O GD</w>
Nrf2/ ARE</w>
Nal trex
Na Cl
NF-k B-
NAFLD .</w>
NAD +</w>
N-acetyl ation</w>
N- methyl</w>
Methylphen idate</w>
MT 2A</w>
MT 1</w>
MM ,</w>
MEASURE (S):</w>
ME NT</w>
ME D</w>
MCF 10
M l
M LN
M 4</w>
LoV o</w>
Lin kage</w>
Leukotri ene</w>
LS 180</w>
LS 17
LDH ,</w>
L AT
L 12
L );</w>
J a
Interleukin -6</w>
Insul in-like</w>
Inj ury</w>
Il lumina</w>
IkB a</w>
IU/ L</w>
IL-2 2</w>
IL-1 1</w>
I g</w>
I b
Hospit al.</w>
Hom ozygous</w>
HgCl 2-induced</w>
HU S.</w>
HS A.</w>
HER-2/ neu</w>
H3K 9</w>
H x
H tr
H ox
H D)</w>
H -1</w>
Gu ill
Gre en</w>
GF R,</w>
GAB RA
FOX O</w>
FK- 506</w>
F CC
F 10</w>
Estro genic</w>
Endothel in</w>
EC V
EC T</w>
E MS
E DN
Di phenyl
De mographic</w>
DC P</w>
D XR
D IC
D AM
Cann ab
Cand esartan</w>
CYP2D 6.</w>
CYP 3
CO S-1</w>
CD H1</w>
CD 34</w>
CD 1</w>
CCl(4 )-induced</w>
CC A</w>
C T-
C Q
C 1-
Bortezomi b</w>
B ir
B W)</w>
B LA</w>
B DCM</w>
B 16</w>
B 1/
Auro ra-
Astr agal
Aro mat
Ar nt</w>
Anti sense</w>
Ang us</w>
Amin oglyco
Am bul
Al k
Akt/ mTOR</w>
Ag e,</w>
ATP ase.</w>
AS A-
A -dependent</w>
9 7.
9 %.</w>
8- mediated</w>
8- Br-
7 3,</w>
60 2</w>
6 9-year-old</w>
6 6,</w>
50 s</w>
44 ;</w>
43- 900
4 10</w>
33 ),</w>
3- (
3, 4,5-
3 3-
3 27</w>
3 1),</w>
28 ;</w>
24 8</w>
23 7</w>
23 4</w>
2 17</w>
2 16</w>
2 13</w>
2 +)</w>
199 6.</w>
19 ;</w>
1827 80</w>
18 8
15d-PGJ 2</w>
14 C-
14 0/
13- year-old</w>
117 3
1- specific</w>
1- selective</w>
1, 1,1-
1 c</w>
1 R)</w>
1 +</w>
1 (+/+)</w>
0.6 9</w>
0.5 9</w>
0.0 4),</w>
0. 56
0. 43</w>
-1- yl)
) alpha</w>
(r =0.
(V DR
(S G
(R I
(PPAR s)</w>
(PN D)</w>
(PE T)</w>
(PA N)-induced</w>
(P M)</w>
(O ATP
(NA )</w>
(N MS)</w>
(L QT
(I RS
(H N
(G n
(G V
(F GF-
(E N
(CX CL
(C RP)</w>
(BAL )</w>
(B ax
(Ah R
(A k
(A P)</w>
(50 -
(5 )
(4 2%)</w>
(3. 5</w>
(3 2%)</w>
(2) ;</w>
(15 ;
(10 0,</w>
(10 -20</w>
(10 %</w>
(1 A)</w>
(0. 8
(0. 1-10</w>
( sodium</w>
( p53
yr in
yno st
ycin ,</w>
xyl azine</w>
work place</w>
wor st</w>
wid ening</w>
wh el
war d,</w>
valvul opathy</w>
v an</w>
ur b
upregul ated,</w>
ung aro
underestim ated</w>
un successful</w>
un restrained</w>
un biased</w>
trimethaph an</w>
trichothec ene</w>
tric ycl
tri hydroxy
treatment ),</w>
transplant ation:</w>
transl ate</w>
trans activation,</w>
tox oplasmo
to :</w>
tim ely</w>
ti de</w>
thyro id,</w>
thal lium-201</w>
tetrac hlorodibenzo-p-dioxin</w>
testoster one-
test es.</w>
terat ogen</w>
tard a</w>
t ures</w>
t osyl
sulfi de,</w>
suc cum
subst ance.</w>
sub micromolar</w>
sub divided</w>
stom atitis</w>
ster one,</w>
stand ard
spik e-
sive -like</w>
sing le
shrin k
sex u
seroton in.</w>
sequ est
senesc ence,</w>
senesc enc
sen se,</w>
sen se
see k</w>
second s.</w>
schedul es.</w>
s arc
rop ivaca
rop ipr
rit uximab</w>
risk :</w>
retrospec tively.</w>
retinoid s.</w>
reticul ata</w>
reple te</w>
remo ves</w>
relev ance.</w>
reduct ase-
recapit ulated</w>
re agents</w>
re activation.</w>
pyraz one</w>
psych opharmac
pseudo ephedrine</w>
profil ing.</w>
profil ed</w>
prim er</w>
pri ate</w>
presum ptive</w>
pressu res.</w>
prefer ring</w>
pre- incubation</w>
pre pubertal</w>
potassi um.</w>
post- traumatic</w>
post- menopausal</w>
post marketing</w>
polyphen ol,</w>
polym er</w>
polycy themia</w>
poly cyst
pla usi
pine al</w>
pifithrin- alpha</w>
phosphor amid
perchlor ate</w>
pentagas trin</w>
pentachloro biphenyl</w>
patient -derived</w>
paroxet ine,</w>
parap leg
pal mi
pH i</w>
p< 0.001).</w>
p6 5.</w>
p 44</w>
p 110
oxid ative/
ox in,</w>
ox adi
over flow</w>
ot subo</w>
ot on
os ine,</w>
or y.</w>
or ice</w>
or chi
opoie sis</w>
opi ate-
op enem</w>
one g
on fer
omegal y.</w>
ome tric
ol der,</w>
ohum ol</w>
ogram s.</w>
occurren ces</w>
occurren ce.</w>
occa sions.</w>
objec tively</w>
normother mic</w>
non- synonymous</w>
non- pregnant</w>
non- genotoxic</w>
non- fatal</w>
non- NMDA</w>
no de-
nitro- N-nitros
neuro ectodermal</w>
ner ve-
neglig ible.</w>
naphthyl isothiocyanate</w>
myric etin</w>
mumol/ l</w>
monomethyl arsonous</w>
moly b
mol/ l</w>
mol/ l)</w>
mo od,</w>
mm ;</w>
min g,</w>
microg/kg/ min</w>
mi befradil</w>
mg/d L;</w>
mg/ m</w>
mg/ L,</w>
methyl guanine</w>
metabolism -related</w>
mes oporph
mening iti
medic am
meas ure.</w>
maxim ize</w>
materi al.</w>
mala is
mal es)</w>
lys ozyme</w>
ly ca
low er-
long term</w>
lip oper
lic king</w>
li xim
leucov or
length .</w>
lad der
l -1</w>
k k
k ed,</w>
jer ks</w>
iz ole</w>
ip al</w>
investig ations,</w>
introduc ed.</w>
intraperitone ally.</w>
instrum ental</w>
institu tion.</w>
initi ated,</w>
influ x.</w>
in consist
in ase,</w>
immunocompet ent</w>
immunocom promised</w>
im pression</w>
im pregn
idi xic</w>
idi c</w>
id osis</w>
i NOS.</w>
hyste rectomy</w>
hypot onic</w>
hypom ania</w>
hyperten sive,</w>
hyper lip
hsp 70</w>
hr lich</w>
hormon e-induced</w>
hepatocarcin ogenesis,</w>
hepar anase</w>
h unting
h id
gran zyme</w>
gly phos
geniste in.</w>
gelat inase</w>
gel -
ful min
ful l
fron t</w>
frequenc ies.</w>
fl oun
fi es</w>
feno fib
fenflur amine.</w>
fe et</w>
fav ors</w>
f otem
exposure- response</w>
exc ited</w>
ex ocytosis</w>
evolution arily</w>
evol ving</w>
evid ently</w>
eu sia</w>
et retin
ero sive</w>
erg ometr
erec tions</w>
epicatech in</w>
epi gastric</w>
ent in.</w>
endometri um,</w>
end osomal</w>
end elian</w>
encour age</w>
emerg e</w>
electroretin ogram</w>
efficac i
ed ical</w>
ed ),</w>
ech n
e ther,</w>
e in,</w>
dys functions.</w>
duc ts.</w>
drug s;</w>
drowsin ess,</w>
drain age</w>
dose-depend ently.</w>
don ovan
dobut amine,</w>
disorient ation,</w>
dis position.</w>
dis ability,</w>
dinitro benzene</w>
dimethyl hydrazine</w>
dimethyl amino
di butyryl</w>
di acylglycerol</w>
dex medetom
deri an</w>
dele tion,</w>
defen se.</w>
def eren
dec line.</w>
de iod
de emed</w>
d y</w>
cyclohexim ide.</w>
cycl op
curren t,</w>
cross- lin
cramp s</w>
convul sion.</w>
conflic t</w>
concept us</w>
concentration -related</w>
conc eiv
con den
comprehensi vely</w>
compar ator</w>
communic ation,</w>
comat ose</w>
col our</w>
col ic</w>
co- expression</w>
co repress
co incubation</w>
ci lex
chondro sarcoma</w>
cholec alcifer
chlorothiaz ide</w>
cent ur
cells/ mm
cell -like</w>
celecoxi b.</w>
catheter ization.</w>
catechol amine-
c ues</w>
bronchospas m</w>
bro ther</w>
bra z
ble b
beta-caten in/
beta(1)- adrenergic</w>
ben ign
ba by</w>
b.w .</w>
ati p
ati cal</w>
at e-</w>
asbest os.</w>
as perg
architect ure.</w>
ar yl-
appear ance,</w>
apparen t.</w>
apparat us.</w>
apart .</w>
anomal ous</w>
androgen -sensitive</w>
amino- terminal</w>
amide ),</w>
amant adine.</w>
am oxy
alopec ia,</w>
al prostadi
ag o,</w>
aff iliated</w>
adsor ption</w>
adrenal ectomy</w>
adip ocyto
addic tion,</w>
act u
acrole in-
acid- base</w>
accoun t,</w>
ac itidine</w>
a phen
a king</w>
[ Study</w>
W P
Val /
V LDL-
Topir amate</w>
Taiw anese</w>
TV X</w>
TP T</w>
TLR 3</w>
TI VE</w>
TGF beta</w>
T yrosine</w>
T it
T -</w>
Squib b</w>
SULT 1
STX 140</w>
SK OV-3</w>
SIRT 3</w>
SC ),</w>
S ha
Reg ulatory</w>
Ref -1</w>
Re activation</w>
Rati o</w>
R out
R are</w>
R AP
Pseud otumor</w>
Predic tors</w>
Physi ological</w>
Phosphati dyl
Pharmac ogenetic</w>
Per fusion</w>
Parkinson- White</w>
PU. 1</w>
PT E</w>
PPAR delta</w>
PM s</w>
PM Ns</w>
PLX40 32</w>
PD ).</w>
PCB 12
PA N,</w>
PA H.</w>
P-gp ,</w>
P- 3</w>
P t</w>
P ituitary</w>
P ERK</w>
OR s</w>
Neutrop enia</w>
Na +,</w>
NR 4
NKX 3.1</w>
N-methyl- N-nitrosourea</w>
N(G)- nitro-L-arginine</w>
N p6
N L
My asthenia</w>
MT C</w>
ME K-
MAP K)</w>
M s
M er</w>
M (-1)</w>
Le vetiracetam</w>
LTC 4</w>
LT ,</w>
LD L.</w>
L-DO PA,</w>
L- 740
L .,</w>
Keap 1-
K -dependent</w>
Inter view</w>
Induc ible</w>
IT GB
IS DN</w>
IQ GAP
INS -1</w>
IL- 3</w>
IF -1</w>
ID /
IAP s</w>
I- converting</w>
I(K r)</w>
I ran
I DP
Hu H-
Ha emat
HSP 70,</w>
HSD11B 2</w>
HD ).</w>
H ill</w>
H am
H PA
H AT</w>
Gu an
Gram -negative</w>
Gener ally,</w>
Gen ome</w>
GSTA 1-1</w>
G leason</w>
G ar
G U
G SI
G NA
Fre und's</w>
Fin nish</w>
Fam oti
FK50 6,</w>
F E</w>
Erythropoi etin</w>
Electro physiologic</w>
Echocardi ographic</w>
ET V
ET (B)</w>
EP 1</w>
EGF P</w>
EB V</w>
E ti
E hrlich</w>
E I
E ACA</w>
Dut ch</w>
Dose- limiting</w>
Dex medetomidine</w>
De si
Dam age</w>
DSC R1</w>
DR E</w>
DNA- PKc
DI -
DE S.</w>
DA ergic</w>
D- glucose</w>
D l
D acarb
D T</w>
D 3-
D .
Cor rec
Chlor pyrif
Cerebro spinal</w>
Cb l</w>
CYP2C9* 1/*
CYP2C19 *2</w>
CYP -treated</w>
CRE B,</w>
CR L
CONCLUSION (S):</w>
CO UP-
CCAAT/ enhancer-binding</w>
CB DCA</w>
CA -treated</w>
C T)</w>
Benz odi
Bec k</w>
Ba y
BP 1,</w>
BMP- 4</w>
BMP R2</w>
BD NF,</w>
BC G</w>
B SP</w>
B D.</w>
Appro priate</w>
Ap c</w>
An algesic</w>
Americ ans,</w>
Al fentanil</w>
Acet aminophen
ANCA- positive</w>
AH RR</w>
AH R,</w>
AH )</w>
AD P-induced</w>
AB CC1</w>
AB )</w>
A ri
A 1298
< 0.001).</w>
9 9)</w>
80 %.</w>
80 %)</w>
7 2.
60 ;</w>
60 %)</w>
6 :</w>
6 77</w>
6 30</w>
6 )
57 8
5-HI AA</w>
5 8)</w>
5 00-
48- hour</w>
48 5</w>
30 1</w>
3- kinase,</w>
3 24</w>
2C 19,</w>
29 3)</w>
26 ),</w>
24- 48</w>
24 6</w>
200 7.</w>
20 6</w>
2,2- bis(
2', 7'-dichloro
2 3-year-old</w>
2 26</w>
17 G</w>
16 alpha-
15-1 788</w>
13-cis- retinoic</w>
12- week,</w>
12 h</w>
10(9)/ L</w>
10 -2
10 -15</w>
10 (7)</w>
1.0 5</w>
1. 8-
1- overexpressing</w>
1- associated</w>
00 0/
0.6 25</w>
0.5 4</w>
0.5 %,</w>
0. 2-
0. 12
-2- yl)
-2 ',
- G</w>
* 2,</w>
(n ine</w>
(i. t.)</w>
(W B
(V I
(TGF-beta 1)</w>
(T yr
(T S
(T P)</w>
(T C)</w>
(SSR Is)</w>
(SE M)</w>
(S H-
(S 6
(N GF)</w>
(M IP
(L C-
(H PA)</w>
(GSH-P x)</w>
(G I
(DTI C)</w>
(D V
(D AT
(CRE B)</w>
(C l
(A s)</w>
(9 0%)</w>
(5 6%)</w>
(5 2%)</w>
(4 7</w>
(3 1%)</w>
(2, 3-
(12,14)- prostaglandin</w>
(+)- dependent</w>
( week</w>
( l
( delta</w>
( blood</w>
( [Ca2+]
( UGT1A
yl ation.</w>
y aw
writ ten</w>
withdraw al-induced</w>
weak ened</w>
warfar in-associated</w>
warf are</w>
w ide-
vit re
vesi c
ver ine</w>
vasoconstric tive</w>
valu e
val dec
v ity.</w>
up ward</w>
unmas ked</w>
un described</w>
un affected,</w>
ul ts</w>
ul ations</w>
two- year</w>
two- step</w>
tumor- associated</w>
troubl es
tren d
transl ation,</w>
trans- Golgi</w>
trans well</w>
trans peptid
train ing,</w>
traffic -related</w>
tom ography.</w>
tim a</w>
tic ally.</w>
thous ands</w>
thi on
thi ol
the red</w>
thalidom ide-induced</w>
th et
tetrap leg
tes tis.</w>
termin ate</w>
terbutal ine,</w>
ten sion,</w>
tas ks.</w>
tachycardi c</w>
t :</w>
t (15;
synap ses.</w>
synap se</w>
surviv ors.</w>
supra -
sulf ate-
substrate- 1</w>
su staining</w>
stroke- prone</w>
streptozotoc in.</w>
streptozotoc in-
strateg y,</w>
stil bestrol</w>
stereotyp y,</w>
ster .</w>
stath min</w>
stat in,</w>
slic es,</w>
sk ill
sivel y,</w>
simple x</w>
silic a-induced</w>
sig mo
show ,</w>
sevent y-
sertral ine.</w>
senescenc e-associated</w>
second- order</w>
se men</w>
sc ot
sc ab
sapon ins</w>
s agittal</w>
s abel
s ICAM-1</w>
s (-1)</w>
rs 16
rosace a</w>
ropini role</w>
rit ,</w>
ris t</w>
ri de-induced</w>
resuscit ation.</w>
resist ances</w>
rescu e.</w>
removal .</w>
remo ved.</w>
rem oxipride</w>
relationshi ps.</w>
rejec tion,</w>
regurgit ation,</w>
recurren ce-
re traction</w>
re med
re challenge.</w>
rat 's</w>
radic al-
qu ant
pust ular</w>
protein -mediated</w>
prostac yclin
prost at
prophylac tically</w>
prog uan
profession als</w>
pro be,</w>
preserv ative</w>
pren ylation</w>
precau tions</w>
pre ovulatory</w>
pofung in</w>
pneum ococcal</w>
pmol/ min/mg</w>
pl ots</w>
physi ology.</w>
phenoxybenz amine</w>
pharmaceutic als</w>
ph ases,</w>
perfor ation</w>
pent oxifyl
pem oline</w>
pe titive</w>
pat h</w>
param agnetic</w>
paraly sis,</w>
par then
pancreati tis,</w>
p< 0.01).</w>
p53 +/-</w>
p27Kip 1</w>
p =0.
p 24</w>
p 16,</w>
oxy ster
ovari an,</w>
ov aqu
otrop in</w>
oste omalac
oste ogenesis</w>
ost asis</w>
osi s)</w>
osarcom a.</w>
os an</w>
orrhe a.</w>
or al)</w>
onfer ron
onco gene,</w>
omega )-
om ic
olar yn
ocyte .</w>
ocor tin</w>
ocardi tis</w>
obser ving</w>
o vi
o -</w>
normal izing</w>
non responders.</w>
nmol/ min/
nitros amines</w>
nitrogen -containing</w>
nigra ,</w>
nigh t.</w>
ni ghts</w>
neur alg
neede d,</w>
nec k,</w>
nebul ized</w>
ne v
nanoparti cles.</w>
modific ations.</w>
mini -
mil lis
millis ec
micronutri ent</w>
micromol/ kg,</w>
microgram/ ml</w>
micro vessels</w>
micro environment.</w>
mi osis</w>
mg/m (2).</w>
mg /</w>
membran e-associated</w>
melphal an,</w>
me te
mat ter,</w>
manic- depressive</w>
m app
m L.</w>
m Glu</w>
lysosom es.</w>
lyso phosphatidic</w>
lymph oblasts</w>
lo vastatin,</w>
lip oxin</w>
li press
leuc yl-
leishman ial</w>
le af
landscap e</w>
lam ellar</w>
lact ation.</w>
lac Z</w>
lab our
ke ts</w>
iz ers</w>
it y-induced</w>
it us</w>
iso pro
introduc ing</w>
intran e
intrad u
intr aluminal</w>
interleukin-1 alpha</w>
insuffici enc
insectic ides,</w>
inib- resistant</w>
inhal er</w>
infu sional</w>
influ x,</w>
infarc tion:</w>
ind ol-3-
increas es,</w>
im put
il )</w>
ifen pro
ic us</w>
ic idin</w>
ibuprof en
i um
hydroneph ro
hydro peroxy
hi al</w>
hepat otox
hep cid
hemisph ere</w>
heli x-
health care</w>
h NIS</w>
go ro
geranylgeran yl</w>
gentamic in-treated</w>
gene tic,</w>
gene :</w>
gen omics</w>
g/m 2/
fu sion,</w>
fre e,</w>
form yl-
for med.</w>
followe d.</w>
fix ed,</w>
fit ting</w>
ff- Parkinson-White</w>
fatal ities</w>
facilit atory</w>
f ratax
excre tions</w>
exchang e.</w>
excep tional</w>
etopo side-induced</w>
ethyl ]
esophag us.</w>
es tic</w>
ergon ovine</w>
erg oline,</w>
er s'</w>
equival ence</w>
epsilon- aminocaproic</w>
epidermi s.</w>
ep s</w>
ep oxides</w>
ent eral</w>
enox apar
end- of-
end ur
encounte red.</w>
en ei
emod in</w>
el ta</w>
eicos anoids</w>
effectiven ess,</w>
educ ation,</w>
e )
dysp nea,</w>
dyn orph
drug- associated</w>
dox epin</w>
dou ble
dos e;</w>
dil ,</w>
diethyl -
diet -fed</w>
dichro ism</w>
dias tere
di aldehyde</w>
develop .</w>
des min</w>
derivati ve.</w>
den ied</w>
defibrill ator</w>
de methylated</w>
de amin
damag e-induced</w>
d res
d 1</w>
cystic er
cycle -related</w>
cyan amide</w>
cranios ynost
cortis ol.</w>
correc ts</w>
corp uscular</w>
convuls ants</w>
construct s,</w>
constric ted</w>
constitu tional</w>
const ant.</w>
conjug ate.</w>
complic ate</w>
compar ably</w>
compact a</w>
comorb idity</w>
combin es</w>
cocul ture</w>
co regulator</w>
co exposure</w>
cin onide</w>
cigaret tes</w>
chromatography/ mass</w>
cholestyr amine</w>
chlorprop amide</w>
chlorphenir amine</w>
chloral ose</w>
cephalospor in</w>
cau tious</w>
catheps ins</w>
cat s.</w>
caspas es
carte olol</w>
carnos ine</w>
card inal</w>
carboxylester ases</w>
carbon ylation</w>
carb azole</w>
c-Jun -
c ili
c RNA</w>
but yl)
break point</w>
brady kinesia</w>
br uc
both ).</w>
blad der
bi olumin
beta- hydroxylase</w>
beta- cells</w>
benzo[a]pyren e,</w>
bax ,</w>
backgroun d,</w>
b endazole</w>
az imil
ax anth
at ovaqu
aspirin- tolerant</w>
arist olochic</w>
aqu e
apopto genic</w>
aph th
ap ir
antigen s,</w>
anti- emetic</w>
anti- androgenic</w>
anthracycl ine-based</w>
ampl ification,</w>
aminoglyco side-induced</w>
am enable</w>
alpha 2b</w>
all y),</w>
alis kiren</w>
air -
ain- of-
ag rel
adren erg
addres ses</w>
addi tive,</w>
ad in
active- site</w>
absorb ance</w>
a- -
a red</w>
[ n</w>
Z P</w>
Vin orel
V it</w>
UC P-2</w>
U/ ml</w>
U RB59
Typ ical</w>
Trans mission</w>
Top otecan</w>
Test ing</w>
TR I</w>
TNF AI
T rop
T l</w>
Subst ance</w>
Sub acute</w>
Strat eg
Stead y-state</w>
Sol ub
Sign s</w>
Second ly,</w>
ST -1</w>
SP- D</w>
SO (2)</w>
SMA D4</w>
SIAD H.</w>
SDF -1</w>
SD ),</w>
SB 202
S-nitros ylation</w>
S mith
S lc
S SC
Run x
Rho- kinase</w>
Regi stry</w>
Reg ard
RV LM</w>
RU 48
RP P</w>
RAR alpha,</w>
RAD 51</w>
R oles</w>
R M</w>
Pul se</w>
Prolong ation</w>
Pilocar pine</w>
Phenyl propan
Perg olide</w>
Paclitax el
PX R-mediated</w>
PRE SE
PPAR s</w>
PLC /PR
PL P</w>
PCB s.</w>
PC T</w>
PC B-
PC 2</w>
PA F-
P< 0.05</w>
P< 0.05),</w>
P B-
P 1,</w>
O R)</w>
Norep inephrine</w>
Na(+)/ K(+)-ATPase</w>
NS F</w>
NP -induced</w>
NOS 3</w>
NO S2</w>
N- [
N J)</w>
N CC
N +
My o
Mitochondri a</w>
Me CP2</w>
ML T</w>
MGC- 803</w>
MG .</w>
ME K/
M mp
M Z</w>
M SCs.</w>
M H
LI MIT
L G</w>
L .
JNK 1/2</w>
Intra operative</w>
Injec tions</w>
Inf ection</w>
III /
I 3
Hypercalc emia</w>
Hallucin ations</w>
Ha em
HUVEC .</w>
HSP s</w>
HS G</w>
HP T</w>
HNF 4a</w>
HL Ms</w>
H an
H A)</w>
H (2)-
Gluc uron
Glu R1</w>
Glu -
GTP ases</w>
GST ,</w>
GSH P
GH B</w>
G--> A</w>
FGF- 9</w>
Ex pressions</w>
Ex cit
Epo R</w>
Epidemi ologic</w>
EG R1</w>
E tom
E sc
E pir
E PCs</w>
Defici ency</w>
De ep</w>
Da un
DMP S</w>
DE X
DB A</w>
D PC
D .,</w>
Cp G-
Cortis ol</w>
Cop per
Compan y,</w>
Com petitive</w>
Col on</w>
Ca (v)
CYP2C19 .</w>
CRA BP-
CR E</w>
CHE K2</w>
CG S</w>
CD 45
CCN D1</w>
CCI- 779</w>
C on</w>
C oma</w>
C lear
C 282
Ble eding</w>
BI S</w>
BH3- only</w>
BCN U.</w>
B ur
B lack</w>
B er
B ach
B 2
Arachid onic</w>
Ar te
Apolipo protein</w>
Amitriptyl ine</w>
Ambul atory</w>
Al ong</w>
Ag ents</w>
Ag e-related</w>
Adren ocept
Ad he
Activ ating</w>
ATRA -
ATP -induced</w>
AS A.</w>
APA P-
AP L,</w>
AN )</w>
ABT-88 8</w>
A RA-
> /=</w>
9-hydroxy risperidone</w>
8 -</w>
78 ),</w>
7- ethoxyresorufin</w>
7,12-dimethylbenz [a]anthracene</w>
7 alpha-hydroxylase</w>
7 alpha-
7 1-year-old</w>
6-keto- PGF
59 .</w>
5-aza-d C</w>
5-aza- Cd
5, 5'-
5 a-
5 B</w>
5 30</w>
5 25
4 :
4 9)</w>
4 36</w>
4 000</w>
3alpha, 5alpha-
38 .</w>
34 3</w>
30 ;</w>
30 6</w>
3 8-year-old</w>
3 3-year-old</w>
3 1.</w>
2D 6,</w>
27 7</w>
25 5</w>
24 1</w>
22 ;</w>
200 7,</w>
200 5,</w>
2,3,7,8-tetrac hlorodi
2 3.</w>
2 2),</w>
1B 1)</w>
199 9.</w>
199 9
19 80</w>
12. 1</w>
10. 9</w>
10. 8</w>
10 86
1/ W
1-nitro pyrene</w>
1- 6</w>
1 alpha-hydroxylase</w>
1 a/
1 1.0</w>
1 ))</w>
00 0,</w>
0.9 3</w>
0.8 9</w>
0.8 3</w>
0.0 1%</w>
0. 7,</w>
0. 3-
0 12
0 %),</w>
- 5-
+/- 4.
* 1</w>
)/ K(m)</w>
) n</w>
(e IF
(b FGF
(TC E)</w>
(T UNEL
(S NA
(R SV
(PBDE s)</w>
(P= .0
(P P2
(MRS A)</w>
(MRP 1)</w>
(M o
(M AL
(IL)- 8</w>
(IL -1</w>
(IGF- I)</w>
(IC(50 ))</w>
(HCT Z)</w>
(FAN FT)</w>
(F e
(Ex perim
(ERK )
(EGC G)</w>
(E t
(DE HP)</w>
(D T
(D S
(C S)</w>
(Ba P),</w>
(BE AS-2
(BAL F)</w>
(B SO)</w>
(AED s)</w>
(AD ),</w>
(A dri
(A DP
(5 5</w>
(5 5%)</w>
(4 4.
(4 ).</w>
(3 4.
(3 )/
(2-ethylhex yl)
(10- 50</w>
(10(- 8)</w>
(10(- 7)</w>
(1) R</w>
(1 7-
( low
( first</w>
( UC
( R-
yohimb ine.</w>
year s
xim el
x am
wor ds</w>
withdraw n,</w>
wa iting</w>
vill ous</w>
vancomycin ,</w>
vals artan,</w>
vaf loxacin</w>
vacuol ization,</w>
vaccin ation</w>
urethane- anesthetized</w>
ures :</w>
ur s
ur ines</w>
un suspected</w>
ulcer s,</w>
ul ose</w>
uccin ate</w>
tubercul osis,</w>
trypt ase</w>
trop ane</w>
trim oxazole</w>
triflu oper
tri ol</w>
tri acylglycerol</w>
tre mul
trabec ul
top otec
toc occ
tis -like</w>
tim olol.</w>
tim es/
ti tis.</w>
thi omal
thi ocholine</w>
thi am
tetraben azine</w>
te ar</w>
t ann
t ;</w>
synthesiz ed,</w>
synerg ize</w>
surve y.</w>
sur pr
super vised</w>
sulfamethox azole</w>
subtyp e-
substanti ate</w>
subjec t.</w>
sub- chronic</w>
sub tractive</w>
struct ur
strai ght</w>
step ,</w>
stabiliz ers</w>
st ly,</w>
st am
sorbit ol</w>
sleep- wake</w>
sl er</w>
sirtin ol</w>
sing ,</w>
simple ,</w>
sigma (1)</w>
sial ic</w>
shor test</w>
setting s,</w>
servic es</w>
selec tion.</w>
seg ment
secret ag
second s,</w>
se stam
se al
sc atter
sarcolem mal</w>
s av
rop ic</w>
rol ate</w>
ro line</w>
rit odr
rever t</w>
retin aldehyde</w>
restric tion.</w>
resour ce</w>
resid es</w>
resid ence</w>
research ers</w>
require ment.</w>
rel oc
rectom y.</w>
receptor- a</w>
rearrang em
read -
re vascularization</w>
re plen
re per
rat s).</w>
radio iodine</w>
rac ial</w>
r ing-
pyrazol o[
pul sive</w>
public ations</w>
psych ometric</w>
prurit us.</w>
prostagland in-
prop en
promot or</w>
prob es.</w>
pro x
princi ples</w>
prevent ed.</w>
predic t
precoci ous</w>
pre operatively</w>
praz iqu
prac tically</w>
pot ent.</w>
post transplantation</w>
polyphen ols,</w>
poly uria,</w>
plac e.</w>
pl an</w>
phorbol-1 2-
phenprocou mon</w>
phen ad
phal loid
ph lo
person- years</w>
period )</w>
pemphig us</w>
pe retin</w>
path ogen</w>
pass ages</w>
parkinson ian-like</w>
parallel s</w>
paracetam ol.</w>
parab en</w>
pac ked</w>
pa rous</w>
pa in)</w>
p2 1-
p r</w>
p ),</w>
oxygen ase.</w>
oxy sterol</w>
ox ,</w>
ov ary.</w>
ot e
osmol arity</w>
oscill ations</w>
orlistat ,</w>
ore sis</w>
orang e</w>
or ide</w>
opportun istic</w>
ophthalm ological</w>
oper ant</w>
one- carbon</w>
om ot
ol 's</w>
ob/ ob</w>
nod es.</w>
nicardi pine.</w>
neutr alized</w>
nephrolithi asis.</w>
neon ate.</w>
necrop sy</w>
ne op
n s,</w>
n ing.</w>
myelosup pression.</w>
muc ocutaneous</w>
moun t</w>
mos aic</w>
modal ities.</w>
mmol/ l,</w>
ml/ min,</w>
mitig ates</w>
mit ript
mis sed</w>
minim al.</w>
ming ly</w>
midazol am
microg/m L,</w>
micro g
mi vac
mg/ 70</w>
methion ine-
methion ine,</w>
meth icillin</w>
mercaptur ic</w>
me q/
maxim um-
mal aox
mad elta</w>
ma y
m m.</w>
m 2)</w>
m .
lidoca ine-
leuk aemic</w>
ler canidipine</w>
length ened</w>
le t-
late- stage</w>
lact ational</w>
lact ac
l op
l omerular</w>
kinase- mediated</w>
kill ing.</w>
kg -1.</w>
kD a.</w>
k av
justi fy</w>
jejun al</w>
it -
isoform -specific</w>
is radi
ir ud
io prom
intratrache ally</w>
intrag enic</w>
intelli gence</w>
individu als
indic ations.</w>
in- Darby</w>
in- 7-
in formation,</w>
im pressive</w>
im ages.</w>
ib i</w>
ia- like</w>
i. pl
i gral</w>
i ),</w>
hypothe sised</w>
hypocap nia</w>
hypo uric
hyper dynamic</w>
hyper acetylation</w>
hydrochlorothiaz ide.</w>
hydralaz ine.</w>
hu perzine</w>
homogen ates.</w>
histi d
high er-
hemochro matosis</w>
hematopoie sis</w>
hel ical</w>
he mot
haplotyp e,</w>
hand -
haloperid ol-treated</w>
half- life,</w>
h onokiol</w>
h RF
h ENT1</w>
glyc it
glyc ine,</w>
glucuronid ated</w>
glucocorticoid s,</w>
glioblast omas</w>
gene )</w>
gamma- secretase</w>
g es</w>
g ation</w>
frequ ently.</w>
fr ank</w>
form aldehyde.</w>
flush ing.</w>
fluoro pyrimidine</w>
flu -like</w>
filgras tim</w>
fibr ils</w>
fer rin</w>
fast -
f ri
expon ential</w>
excep tionally</w>
etodol ac</w>
ess ation</w>
erythropoie sis.</w>
erythro cytes,</w>
epit opes</w>
ep ome
environ ments</w>
enei od
encephal y,</w>
eme sis.</w>
eicos atrienoic</w>
eicos apentaenoic</w>
ed "</w>
ebsel en</w>
ear .</w>
e- exposed</w>
e- -
dysrhyth mia</w>
dys lipidemia,</w>
drin k
do steine</w>
discerni ble</w>
dilat ation,</w>
dihydro diol</w>
diethylnitros amine-induced</w>
di s</w>
di ol-
di flun
des -Arg
dep ot
delu sional</w>
defect ,</w>
d ol</w>
d enti
cytok ine.</w>
cyste ine-rich</w>
cyclopent yl
crystall uria</w>
crav ing,</w>
cons ent</w>
confu sional</w>
conden sed</w>
con formation.</w>
comple ment
complain ts.</w>
commit ment</w>
col or
col later
co expressed</w>
clear ,</w>
cl ue</w>
citalopr am,</w>
chrys in,</w>
chi as
chemosensi tization</w>
chemosensi tiz
cephalospor ins</w>
cellul arity</w>
cell s'</w>
calori e</w>
ca pro
cIAP 2</w>
c ages</w>
bu d</w>
bol uses</w>
block ed.</w>
bl y,</w>
bit ter</w>
bendroflu methiaz
b ungaro
b at
b all
azol es</w>
autom atic
as -
arti ficially</w>
arthri tis:</w>
arra y.</w>
arbitr ary</w>
ar ms,</w>
apopto sis)</w>
aph asia</w>
ap ati
antigen- presenting</w>
antigen -specific</w>
anti- parkinsonian</w>
anti- HIV</w>
ano ther.</w>
ane ),</w>
an um</w>
an es,</w>
amb ulation</w>
amant adine,</w>
am ine;</w>
allergen -induced</w>
alep lon</w>
aldosteron ism</w>
al- specific</w>
al iz
al -treated</w>
aggrec an</w>
age- adjusted</w>
afiltr ation</w>
aeruginos a</w>
ad just</w>
activit y),</w>
acetylchol ine.</w>
acetyl ation.</w>
acet aldehyde.</w>
acet aldehyde,</w>
acces sibility</w>
Wol ff-Parkinson-White</w>
Wat er</w>
WK Y.</w>
W T-
Vari ations</w>
Van comycin</w>
VEGF -induced</w>
VD R.</w>
V617 F</w>
V X</w>
V X-
Ur d</w>
US A</w>
Transcri ptom
Temozolom ide</w>
Td P.</w>
Taiw an</w>
TNF- a.</w>
TDI -
TD P-43</w>
TCP OB
T sc
Sur gery</w>
Sup por
Sul ph
Sul foraph
Sn ail
Sir tu
SR S</w>
SH R-
SGLT 1</w>
SD S</w>
SCH 23390</w>
S- adenos
S accharomyces</w>
S NA</w>
Rel ease</w>
Reduc tions</w>
Ram ipril</w>
RL IP
RESULT (S):</w>
RD X</w>
RA S,</w>
R II</w>
Question nai
Puro mycin</w>
Propofol -
Predn isol
PhIP .</w>
Per formance</w>
Penicill amine-induced</w>
PRO G</w>
PRESE NT
PM N
PLD 1</w>
PK B/
PE -induced</w>
PAH s,</w>
P450 -dependent</w>
P dn/P
P HS
Oxcarb azepine</w>
OX C</w>
O wing</w>
O PC
O 2.</w>
O /
Nether land
NT 1</w>
NR 2
NH E</w>
NDR G1</w>
N-methyl- N'-
N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide</w>
N iss
Mit ogen
Mil rinone</w>
Mg SO4</w>
Meth yl</w>
Met -
Melan oma</w>
MS-2 75</w>
MG MT-
ME F</w>
MDA-MB- 435</w>
MB )</w>
M ed</w>
Lig and</w>
Levodop a-induced</w>
Langerh ans</w>
LY29400 2.</w>
LP S
L ovo</w>
L ear
L a</w>
L P)</w>
L G
L AQ
KW- 6002</w>
Jo hn's</w>
Intra vesical</w>
Intr am
Interfer on-
In stitu
Idi opathic</w>
IV ).</w>
INVESTIG ATIONS:</w>
INTERVENTION (S):</w>
IL-1 0.</w>
I cel
I HC</w>
I H</w>
Ho e</w>
Hist ology</w>
Hex avalent</w>
Hepat ocytes</w>
Hep a-1</w>
Haloperid ol-induced</w>
HT -induced</w>
HR V</w>
HR G</w>
HO Cl</w>
HN E-
HMOX 1</w>
HEK 293-
HBs Ag
H- associated</w>
H- Ras</w>
H ip
H 2,</w>
H (+)</w>
Guill ain-
Gli oblastoma</w>
Gem fibroz
GY KI</w>
GPx 1</w>
G- 6-
G est
G as</w>
G 4</w>
Ful l</w>
Form aldehyde</w>
Fluc onazole</w>
Fibro blasts</w>
FL IP</w>
F yn</w>
F o
F etuses</w>
F RE
F A-
Ev ent</w>
Endo theli
ERK s</w>
ECV 304</w>
EA .
E- selectin,</w>
E dar
E b
E O</w>
Don epez
Dis opyr
DZ P</w>
DU SP
D TC</w>
D N-
Cytos olic</w>
Cyto kines</w>
Cri tical</w>
Con sor
Co omb
Clinic al
Catech ol
Ca ro
CYP2B 6.</w>
CXCL 10</w>
CS F
CR F-
COMMD 1</w>
CL DN
CH (3)
CCR 3</w>
C3H/ He
C/E BP-
C ou
C essation</w>
C ]-
BM SCs</w>
BE Z
BE L-740
BCL 2
B max</w>
B AD</w>
Au th
Asi ans</w>
Aromat ase</w>
Ara C</w>
Antin ociceptive</w>
Anti psychotic</w>
Anti bodies</w>
Ak athi
Acet ylcholinesterase</w>
Ab c
Ab )</w>
AZ T-induced</w>
AT M
AS K1</w>
AMP K/
AM ),</w>
AKR 1C</w>
AG E
AFB (1)</w>
AC ).</w>
8-OH- DP
8 4,</w>
7 9-
7 9)</w>
7 7-year-old</w>
7 4,</w>
6-mercaptop urine</w>
6, 7,8-
6 6-year-old</w>
59 3</w>
5/ 6</w>
5- 6</w>
5 29</w>
44 %,</w>
4. 6
4- ,</w>
4, 5,
4 S</w>
4 4-year-old</w>
35 %,</w>
30 2</w>
3' UTR</w>
3 q
3 20
26 S</w>
24 %,</w>
2339 0,</w>
23 %,</w>
2- fold,</w>
2- day</w>
2 14</w>
199 8.</w>
198 9</w>
198 6</w>
17 p
150 2</w>
15. 0</w>
14 8
10(-8 )).</w>
1. 2%</w>
1- naphth
1,3- butadiene</w>
1, 4,5-
1 8-year-old</w>
0.8 6</w>
0.4 2</w>
0.00 3),</w>
0. 25
.0 1</w>
-10, 11-
-1- phenyl
- C</w>
- 3.
) >
(c d
(Z O
(V T
(T S),</w>
(T CA)</w>
(STAT 3)</w>
(SL E)</w>
(S AP
(R XR)</w>
(PF S)</w>
(P TH)</w>
(P Ca)</w>
(N RF
(N D
(Me IQ
(MPT P)</w>
(LPS ).</w>
(L O
(K (i
(IL)-1 beta</w>
(I BD)</w>
(HIF-1 alpha)</w>
(HE K)</w>
(H PLC
(H L-
(GAB A
(G RP
(G C
(E MG)</w>
(E B
(Cu )</w>
(C F)</w>
(C CN
(B R
(A V
(A FB
(6 7%)</w>
(5 -10</w>
(4 2.
(1. 5-
(1-1 3)</w>
(1 8)
(0. 7</w>
( positive</w>
( ip)</w>
( Res
( 9-
zymos an-induced</w>
zomep ir
zir am</w>
z oniporide</w>
ycin -induced</w>
y ne
y et,</w>
withdraw ing</w>
withdraw als</w>
weight/ body</w>
week -
vir /
vic inity</w>
verteb rates</w>
vect or,</w>
v as</w>
utlin -3</w>
uni vers
un anesthetized</w>
um ].</w>
tubocur ar
tub erous</w>
tub e.</w>
troubles ome</w>
tri phasic</w>
tri acylglycer
transporter -1</w>
transi tion,</w>
tobacco -related</w>
tic um</w>
thrombin -
thir ty</w>
thio acetam
thi s.</w>
thi gh</w>
thi amine</w>
tetracycl ine,</w>
termin als.</w>
terfen adine,</w>
telavanc in</w>
taxif olin</w>
t c
t ad
t RNA</w>
t 1</w>
t ).</w>
surg e</w>
summar izes</w>
succ ess.</w>
stud y].</w>
stres sor</w>
stereois omers</w>
steato hepatitis.</w>
soy bean</w>
sorafenib .</w>
somat ostat
soft- tissue</w>
small est</w>
shif ting</w>
sh aring</w>
sex es,</w>
sex -specific</w>
sertral ine,</w>
sarcoid osis</w>
s- related</w>
s lid
rs 6
rimonab ant</w>
reticul in</w>
response ;</w>
resoruf in</w>
resorp tion.</w>
reproduci bly</w>
repair ing</w>
relief ,</w>
red und
re par
re entry</w>
re ar
rate- treated</w>
rat e;</w>
rapid -
ra ,</w>
r CBF</w>
quin ine.</w>
ques tion,</w>
pul l-
proto oncogene</w>
protein ur
prostagland ins.</w>
promis cu
procain amide,</w>
pro ven
pro caspase-3</w>
post infarction</w>
polar ity</w>
poison ing].</w>
phthal ate,</w>
phox ,</w>
phenylpropanol amine.</w>
phenyl)- 4-
phenanth rene</w>
patient ).</w>
parti tion</w>
parasi tic</w>
palmi tic</w>
pa d</w>
p3 5</w>
p21WAF 1</w>
p21WAF 1/CI
p21(Waf1/ Cip1)</w>
p eliosis</w>
p ast
p 44
p 130</w>
oxygenase- 1,</w>
osteoproteger in</w>
ost aining</w>
osom es,</w>
os oma</w>
oroph aryngeal</w>
optim izing</w>
optim ally</w>
onco genesis</w>
on aphthal
omun yl</w>
oligomer ization</w>
olaryn g
ol eth
og onin</w>
od e</w>
ocyte ,</w>
ocyt es;</w>
ocholester ol
ocar b</w>
oc ta
oc er
o- nitro
non smokers</w>
non convulsive</w>
non cardiac</w>
nitrite/ nitrate</w>
nitrate/ nitrite</w>
nin ety-
nigh t,</w>
niac in-induced</w>
ner 's</w>
neoin tima</w>
myel oblastic</w>
morph ine-treated</w>
monolay ers.</w>
monocarb oxyl
moclob emide</w>
mo ,</w>
mini ature</w>
millisec ond
migr ate</w>
microlit ers</w>
micro m,</w>
miR- 49
mg/kg )-induced</w>
methylphenid ate,</w>
meth oxyl
metfor min,</w>
metabol ic,</w>
memor fan</w>
me pyr
mannit ol,</w>
man son
m er,</w>
m ally</w>
m T</w>
m (-2
ly :</w>
lute olin,</w>
longev ity</w>
lo reth
lo os
lithi um/
lit ter</w>
lip ase,</w>
li pr
levonorg estrel
level s:</w>
ledg e</w>
le- stimulating</w>
le 's</w>
laborator ies</w>
kala-az ar</w>
iz able</w>
isol e
iso zyme
ip ).</w>
ion toph
invasi vely</w>
intravenous ly)</w>
intest ines</w>
inter rog
intensi fication</w>
insul in
inst ances,</w>
inhibi tion)</w>
ing ham</w>
infor m</w>
inferi ority</w>
infec tion
induc er.</w>
incorpor ation.</w>
incorpor ate</w>
inclu ded,</w>
in apar
imped ance</w>
immunofluoresc ence,</w>
imidazole- 4-
im plementation</w>
il /
i.v .
i riti
i b,</w>
hypother mia,</w>
hypo activity</w>
hypercalca emia</w>
hydroxy cholesterol,</w>
hydroly zing</w>
hydrocarbon s.</w>
hybri di
hist amine-induced</w>
her o
hemat oma.</w>
heigh t,</w>
haplotyp es.</w>
haplotyp e.</w>
hamster s,</w>
halothane- anesthetized</w>
hal o
guidel ines.</w>
gp t</w>
glycopyr rolate</w>
gluco sidase</w>
gam madelta</w>
fum arate</w>
ful ly.</w>
fu si
fresh water</w>
followe d-up</w>
fis etin</w>
ferrit in,</w>
feed ing,</w>
fat al,</w>
famoti dine.</w>
fac e.</w>
f ish,</w>
external ization</w>
exposure ;</w>
exem plified</w>
ex port
ever olim
eut opic</w>
eugen ol,</w>
ethyn ylestradiol</w>
estr ag
ester ases</w>
erul oplas
ent s:</w>
encephal opathy:</w>
embry o.</w>
eigh ty-
effac ement</w>
ed om</w>
ed ).</w>
ech o</w>
e droph
dram atic
dos e/
dizzin ess.</w>
distor tion</w>
dist ension</w>
disrup tions</w>
disopyr amide.</w>
discharg es.</w>
dis ulph
diphenhydr amine,</w>
digit alis
di qu
di deoxy
dex trin</w>
descri ptive</w>
der gic</w>
del phin
deci sions</w>
debr is</w>
de al</w>
dail y;</w>
da m</w>
d f</w>
d ,
cyto st
cyan o-
cut off</w>
cut -
cry op
cow s</w>
cool ing</w>
contraceptiv es,</w>
cont ain
construc t,</w>
constitu ents,</w>
confounder s.</w>
confoun ders</w>
confir med,</w>
conduc tion.</w>
con cordant</w>
comp eted</w>
co transfection</w>
co propor
cm /
classi fy</w>
cl um
cl oxacillin</w>
circumv ent</w>
cipro fibrate</w>
chlorpyrif os,</w>
childho od
cere bri
cent ered</w>
cell- type</w>
cdc 25
cardi olip
carbach ol-induced</w>
captopril -treated</w>
caps ular</w>
calc ific
cI AP-2</w>
c age</w>
bypas s.</w>
bupropion ,</w>
bro mazepam</w>
break age</w>
bradykin in,</w>
bol us,</w>
block er
bleomycin .</w>
bl inded,</w>
bis (p-
bioavail ability,</w>
beta1- adrenergic</w>
benzo thiazole</w>
benz yl-
be red</w>
basophil s</w>
b.w .)</w>
azol e-
auto receptors</w>
aure us.</w>
ase- mediated</w>
asbest os,</w>
as tr
arrest in
arra ys.</w>
ar ization</w>
appropri ate.</w>
apo A-
ap ath
anti migraine</w>
anti depressive</w>
anti arrhyth
angi itis</w>
ang er</w>
andro sten
anatom y</w>
an ous</w>
an om
aminophyl line.</w>
am auro
als o,</w>
alpha-tocopher ol.</w>
alpha (2)
algorith ms</w>
al in,</w>
al ign
ai k
ag o</w>
advis able</w>
adenos ine.</w>
acid -binding</w>
acet onide</w>
abl ative</w>
a 5</w>
[ 4,5-
W .</w>
VKORC 1-16
V T.</w>
Un ified</w>
UT I</w>
U s
U T-
Twenty- four-hour</w>
Trx 1</w>
Treatment -related</w>
Tram adol</w>
Th y
Targ et</w>
TR AC
TPE N</w>
TP M</w>
T ACE</w>
T -1</w>
Smo king</w>
Shor tly</w>
Semi quantitative</w>
SULT 2A1</w>
ST 2</w>
SS G</w>
SN S</w>
SN F</w>
SMA RCA
SM ase</w>
SIRT 1-
SH P-1</w>
S w
S cler
S al</w>
S 100</w>
S .,</w>
Rheumat oid</w>
Rel ation</w>
Regard less</w>
RS ),</w>
RA MP
Proc ain
Pro xim
PhIP ,</w>
Pa O2</w>
PT Z-induced</w>
PS C</w>
PKC a</w>
PI G
PI C</w>
PG E</w>
PD15 30
PD -1
PC ),</w>
P ra
P icro
P 3
Ophthal m
On co
OV A</w>
OP -induced</w>
O6- methylguanine-DNA</w>
O le
Nitroprus side</w>
Neuro blastoma</w>
NaAs O2</w>
NSCL C,</w>
NR G1</w>
NQO 2</w>
NO S).</w>
NKG 2D</w>
NK 2</w>
NADP H,</w>
N-methyl-N'- nitro-N-nitros
N U</w>
Mo vement</w>
Methyl -
Man ual</w>
Mad in-Darby</w>
MT X)</w>
MP EP</w>
MMP 2</w>
MMP -1
MM I</w>
MI P-2</w>
ME L
M urine</w>
M os
M in</w>
M etal</w>
M embrane</w>
M e-
Lif e</w>
Li pos
Lan sop
LO S</w>
L os</w>
K C
K .,</w>
Ja undic
Intralip id</w>
In tran
Impres sions</w>
Im mediate</w>
IV ),</w>
IU GR</w>
IFN- gamma.</w>
IC D</w>
I R)</w>
Hz ,</w>
Hyponat remia</w>
Haloth ane</w>
HT G</w>
HO MA-
HO E</w>
HO -2</w>
HMC -1</w>
HG -induced</w>
HC BD</w>
HC A</w>
H s</w>
GTP gamma
GM- CSF,</w>
GF R.</w>
GF ),</w>
G alpha
G GC
G (2)</w>
Fifty- five</w>
Feno fibrate</w>
FIC Z</w>
FHL 2</w>
Erec tile</w>
Embry onic</w>
Em plo
Electro my
Electro encephal
ER a,</w>
ER ),</w>
EC E-1</w>
Di os
DZ R</w>
DS S-induced</w>
DM U-2
DM H</w>
DE S,</w>
DE N-
DE B</w>
D-penicill amine-induced</w>
D ro
D MC
D 28
D 2/
Cyp2 b
Cyp 3a
Cyclo oxygenase</w>
Cr (2)O
Cor responding</w>
Coca ine-associated</w>
Co hor
Cl 3</w>
Chlorpyrif os</w>
Caro lin
CYP1A 1/
CK 2</w>
CDK 6</w>
CDD P-
CD 14
CC ),</w>
C- fiber</w>
C am
Bus ulfan</w>
Benazep ril</w>
Ba P-
BCN U
B ow
B eg
B U</w>
Ar e</w>
Ap pl
Amelior ation</w>
Adren ergic</w>
Ac celer
ALDH 1A1</w>
AL K
AKR1C 2</w>
AH R/
ABT- 0
A- V</w>
A do
A NA
A MD
9-cis- retinoic</w>
9 -1.
8- week,</w>
8- M
8 5)</w>
8 -induced</w>
78 0,</w>
7, 8,
7 B</w>
7 6)</w>
7 4.
6 q
6 9)</w>
6 7-
5-fluorourac il-induced</w>
5 2%,</w>
48 2
47 ;</w>
45 ;</w>
45 7</w>
4- h</w>
4'- hydroxylation</w>
4 C</w>
4 3),</w>
4 18</w>
34 8</w>
30- day</w>
3. 5%</w>
3- (2-
3'- UTR</w>
3 MC</w>
3 2-year-old</w>
2E 1.</w>
2E 1,</w>
2C 9
2B 6,</w>
26 /
24 4</w>
2-amino- 3-methyl
2, 500</w>
2 24</w>
2 -2.
198 8</w>
17- beta-estradiol</w>
17, 20-
15- min</w>
13 %,</w>
12 %,</w>
10. 4</w>
1-1. 0</w>
1, 2,4-
0.00 4</w>
.000 1)</w>
.00 2).</w>
.00 1,</w>
-2 4-
- B</w>
) 1</w>
(mt DNA)</w>
(e )
(c Tn
(X RE
(V ),</w>
(U CP
(TLR 4)</w>
(S C)</w>
(Ph IP),</w>
(PPAR alpha)</w>
(PFO A)</w>
(NA G)</w>
(N K)</w>
(MK- 80
(MCP -1),</w>
(M I
(M CA
(L XR
(L D)</w>
(IGF BP
(I Q
(I K
(H e
(G- CSF)</w>
(Experim ent</w>
(ER CC
(ER )-positive</w>
(EGF R),</w>
(D ani
(D EP
(B AD
(Ar g
(AL S)</w>
(> or=
(6 6.
(6 1%)</w>
(5 '-
(4 1</w>
(3 2)
(2) Cr(2)O
(15 d-PGJ
(1. 4</w>
(1 3/
( glutathione</w>
( CYP2A
yohimb ine,</w>
yn e</w>
xen oestrogen</w>
x .
warfar in-related</w>
wall s.</w>
w /w
ver a</w>
varic eal</w>
v il
v et
us nic</w>
unde rex
un transfected</w>
un pleasant</w>
un favourable</w>
ultr afine</w>
two- way</w>
two- sided.</w>
turno ver,</w>
trou t</w>
trop isetron</w>
trop ical</w>
tris ulfide</w>
tremor s,</w>
transfec tion,</w>
trans esophageal</w>
ticlopid ine.</w>
ti tu
thyrotrop in</w>
therapeu tics,</w>
tetrod otoxin</w>
tetr ameth
termin ation.</w>
tem sirolimus</w>
tem plate</w>
tel ome
tail- tremor</w>
tail ed</w>
table ts.</w>
surger y:</w>
sur amin</w>
suppres sed,</w>
sum mation</w>
sulpi ride,</w>
suggest ed,</w>
sugges tions</w>
sub stituting</w>
stud ents</w>
stres sing</w>
sto res.</w>
sto ol</w>
stil bene
stere otax
standard- dose</w>
st ore</w>
st ones,</w>
st ing
splic ing.</w>
spin al-
spermatozo a</w>
speci es-
sodi um/
slow s</w>
sleep in
sirolim us
sion ).</w>
signific ance,</w>
sid es.</w>
sev en
ser s</w>
self- administration,</w>
seleni um,</w>
segreg ating</w>
scopol amine-treated</w>
sche me</w>
sc ann
saquin avir</w>
s cl
ro lipr
rivastig mine</w>
rilmen idine</w>
retin ol-
resist ant,</w>
reserp ine-treated</w>
ren aline</w>
ren al-
recurren ce,</w>
rec ent-onset</w>
re- exposure</w>
raz od
rang e
rabep razole</w>
quin one
q o
publ ication</w>
psych ogenic</w>
protec tive,</w>
prop ic
proof- of-
prolifer ative,</w>
prolact in.</w>
pro oxidant</w>
pro cycl
precl uded</w>
pre- treatment.</w>
pre hospital</w>
potenti als,</w>
post- exposure</w>
post traumatic</w>
pollu tion.</w>
po re-
piper onyl</w>
piper acillin
pilsic ainide</w>
pigment osum</w>
pi ec
phot oph
phosphoryl ating</w>
phentol amine,</w>
ph aro
pg/m L,</w>
pentylenetetrazol -induced</w>
patient ),</w>
pa the
p3 8/
p- cresol</w>
p 19
oxygen ated</w>
oxy met
oxid ant-induced</w>
oxaliplat in.</w>
ox ystil
ox )</w>
over whel
over active</w>
out weigh</w>
out bred</w>
ot emporal</w>
os se
orig inated</w>
ondansetr on.</w>
onco gene.</w>
on ly)</w>
on line</w>
omy osin</w>
omel an
oly b
olig omers</w>
og insenoside</w>
oca ine,</w>
obes e,</w>
o roxylin</w>
o estrogens</w>
nucle ase</w>
normal isation</w>
non- cancerous</w>
non oliguric</w>
nit ro</w>
nigh t-time</w>
nicot ine's</w>
neighb oring</w>
ne o</w>
mydri asis</w>
myco phenolic</w>
mus ,</w>
mu g/
mou th
morpholin o</w>
monos odium</w>
mmol/ kg,</w>
mmol/ kg)</w>
ml -1</w>
mis folding</w>
mis folded</w>
mill ilit
micromol/ kg)</w>
microg/m l.</w>
micro dissection</w>
miR-2 00
mer it</w>
melan omas.</w>
meda ka</w>
manufact uring</w>
lymph om
ly ).</w>
lob ar</w>
lik e,</w>
ligh t,</w>
levothyro xine</w>
letharg y</w>
lec tin</w>
lamotrig ine,</w>
lamivud ine-
labetal ol,</w>
label ing,</w>
l-NA ME</w>
l ined.</w>
kind ling.</w>
issu e.</w>
isopren oid</w>
is th
iron -induced</w>
ion otropic</w>
ion euro
ioneuro tic</w>
intradu odenal</w>
interleukin-1 2</w>
inter act
integr in-
insidi ous</w>
indina vir,</w>
inde red</w>
ind omet
incorpor ation,</w>
incontin ence.</w>
in- hospital</w>
in- ,</w>
in puts</w>
in olol</w>
in ocul
in dependence</w>
immunosuppress ed</w>
immediate- release</w>
il ing</w>
if lum
if l
ic yclo
ic ally-
hyponatre mia,</w>
hypog lyca
hypo diploid</w>
hyper oxal
hyper motility</w>
hyper keratosis</w>
hydroxy zine</w>
hydrox ide</w>
hydroly zes</w>
human -
home od
hn RNP</w>
hist ologically.</w>
hex ose</w>
hemo stasis</w>
hem op
he ating</w>
hapt oglobin</w>
h indered</w>
gran is
go od.</w>
glucuron idase</w>
gl yp
gastro- intestinal</w>
gas tric
galect in-3</w>
galact osamine</w>
g/m 2)</w>
g/ L)</w>
function al,</w>
fron t-
fre e.</w>
for ces</w>
flu phen
flow- mediated</w>
flecain ide.</w>
flavan one</w>
finger prin
fif ty</w>
fertili z
ferrox idase</w>
fat ality</w>
famcic lovir</w>
factor- b</w>
fa ec
explo res</w>
ex tran
ex on-
evolution ary</w>
ethyl enediamine</w>
esophag us,</w>
erythemat ous</w>
er v
ent s'</w>
enol pyruvate</w>
endotox in-induced</w>
endothel in-1,</w>
end point.</w>
en ia.</w>
embry ogenesis</w>
elimin ates</w>
effu sion,</w>
efflu ent</w>
ed ic
ect omy
eIF 2alpha</w>
dys esthe
drug -dependent</w>
down- regulation,</w>
dn ess,</w>
disor dered</w>
diselen ide</w>
discontinu ous</w>
diffu sion-weighted</w>
diameter .</w>
diagnos ing</w>
diagnos ed,</w>
di propion
di ones</w>
dex amphetamine</w>
destruc tion.</w>
des flur
depos ited</w>
dens it
defic it,</w>
decision- making</w>
deb ate</w>
deb ate.</w>
de d-
cum ene</w>
cr ac
corticoster one,</w>
cortico striatal</w>
cor ds</w>
controversi al,</w>
contamin ants.</w>
conjug ates,</w>
confounder s,</w>
confir m
con su
comple ted.</w>
comparison s.</w>
combin ations,</w>
coincid ing</w>
cogni tion.</w>
coca ine-treated</w>
coc ultured</w>
co- expressed</w>
co oking</w>
co de</w>
clarithromycin .</w>
citr us</w>
cis-diamm inedichloro
cil astatin</w>
chy mo
chondro genic</w>
chol ine,</w>
chlorpromaz ine-induced</w>
chi -square</w>
chemokin es.</w>
caspase-3- like</w>
cascad es,</w>
cardiac -
cardi otonic</w>
carb im
carb ap
calcitri ol.</w>
c yl
c m-
but oxy
bu fur
bo ard</w>
bir ds</w>
biodistri bution</w>
bi ogenic</w>
bevaciz umab</w>
beta2- adrenoceptor</w>
beta- adrenoreceptor</w>
beta 4</w>
beta (1)</w>
benzo[ k]
benzene- exposed</w>
benz opyr
bene fici
benazep ril
beg un
be ds</w>
be am</w>
b] indole</w>
b imatoprost</w>
b ia</w>
b (5)</w>
azido- 3'-deoxy
avail ability.</w>
autophag osomes</w>
attenu ated,</w>
ation "</w>
ascic ular</w>
aro l</w>
aril y,</w>
argin ine,</w>
arachidon oyl
apr ind
apoptosis- associated</w>
apopto tic,</w>
anxiet y-related</w>
antibio tic.</w>
anti- estrogenic</w>
anti pyr
anti coagulated</w>
anti ci
aneup loidy</w>
androgen -induced</w>
an x
an uria</w>
amplitu de.</w>
amip ide</w>
amino ]-
amin ,</w>
am pros
alter ation.</w>
alpha-fet oprotein</w>
alpha- subunit</w>
all y;</w>
all ant
aldehy des.</w>
al th</w>
adv enti
act in.</w>
acid uria</w>
acetylcholinester ase.</w>
accept ance</w>
absc ess
ab is
[ I
[ 1.
Zn- superoxide</w>
Y M-
XRCC 3</w>
Wnt 5a</w>
W B
Vas cul
Val- Ala-
Val 66
VMAT 2</w>
V SD</w>
U/ kg</w>
Trimeth oprim
Trials .gov</w>
Tre g</w>
Thi azol
Th rough
Ter but
TZD s</w>
TK I</w>
TI S
TH P1</w>
TAC -101</w>
T razod
T empor
T CC
T AK
T +
Sp 1,</w>
Sma c</w>
Sche dul
STAT 6</w>
SPEC TIVE
SN CA</w>
S ch</w>
Ri ght</w>
Ret t</w>
Rep lic
Reduc ing</w>
Radi x</w>
RP ),</w>
RIN G</w>
R -</w>
Qu eti
QO L</w>
Pro fil
Plac ental</w>
Phys ostigmine</w>
Phen otypic</w>
Ph IP-
PT CA</w>
PT .</w>
PP 2</w>
PP .</w>
PMA ,</w>
PLC/PR F/
PI s</w>
PI ),</w>
PG S</w>
PG .</w>
PF 4</w>
PER SPECTIVE
PDGF -induced</w>
PD CD4</w>
P ten</w>
P anax</w>
P O)</w>
P -</w>
O-de methyl
O R-
O K
Ni O</w>
Nephro genic</w>
Naltrex one</w>
Na (+)
NS-39 8,</w>
NP s,</w>
NO AR
NO )</w>
NF 1</w>
N-nitros oure
N, N'-
N p
N ET
N DI
N 2O
N 1-
Mn (2+)</w>
Mit otane</w>
Met ,</w>
MRP 1-mediated</w>
MP O,</w>
MDA-MB 231</w>
MD I</w>
MC s,</w>
M -1
LT s</w>
LPS- mediated</w>
LD A</w>
L/ min/
L eth
L 02</w>
Know ledge</w>
King dom</w>
K L-
K (+
J oin
Inv a
Integr ated</w>
In dex
Immunocyt ochemical</w>
Immun ostaining</w>
Im aging</w>
Identi fying</w>
IRF -1</w>
IL-12 p40</w>
IL-1 7
III ),</w>
I ll
I RA
Hyper methylation</w>
His pan
Hir sch
Here ditary</w>
HUVEC s,</w>
HS P</w>
HO )</w>
HIST OR
HI -6</w>
HD L
H u</w>
H ic
H el
Gyn ec
GN )</w>
GE ,</w>
G> C</w>
G lyco
G OT</w>
G A,</w>
Fel odipine</w>
FOX A1</w>
FGF 21</w>
F50 8</w>
F rac
F AM
F A.</w>
Epilep sy</w>
Encephal opathy</w>
Electrocardi ographic</w>
ERK -dependent</w>
ER a-
EGR -1</w>
EE G,</w>
EE ,</w>
E S)</w>
E E2</w>
E E-
E 1.</w>
Dys regulation</w>
Dop aminergic</w>
Dex trometh
DO C</w>
DLC s</w>
DESIGN ,</w>
DES- exposed</w>
DE P-induced</w>
DC ,</w>
DB C</w>
D A)</w>
Cu, Zn-SOD</w>
Cs A-induced</w>
Cr e</w>
Cor respond
Con tact</w>
Combin ations</w>
Col laborative</w>
Child hood</w>
Caucasi ans,</w>
CYP2 4</w>
CYP .</w>
CT N</w>
CT N
CO C</w>
CNS ,</w>
CN S-
CK- MB</w>
CHO P,</w>
CE S1</w>
CDDP .</w>
CD DO-
C57Bl/ 6</w>
C ost
Behavi oural</w>
Bcl-x L.</w>
BV 2</w>
BT X</w>
BR CA</w>
BP C</w>
BCR- ABL</w>
B onferron
B ZD</w>
B MI
B CHE</w>
Auro ra</w>
Atten tion</w>
Asbest os</w>
Arg ent
Al b</w>
Air way</w>
Ah R/
Acet azol
ATP 13
AT F2</w>
AS A,</w>
AP LP
AM B</w>
AKR 7
AB C-
A/ A</w>
A wa
A ir</w>
A R-mediated</w>
< .05).</w>
; -
8-hydroxy deoxyguanosine</w>
8-hydroxy -2'-deoxyguanosine</w>
8 33</w>
75 %,</w>
7- OH-
7 -1.
6 a</w>
57 1,</w>
5 6)</w>
45 ),</w>
40 /
4, 4',
4 a
4 4-
38 393</w>
33 ;</w>
30 9</w>
3 30</w>
3 17</w>
3 12</w>
23 6</w>
23 3</w>
20 8</w>
2. 0-
2- 6</w>
2,5- hex
2, 1-
2 a)</w>
2 R/
2 A)</w>
2 30
2 '
199 4,</w>
198 5</w>
16 HB
16 9</w>
16 6
16 %,</w>
14. 4</w>
13. 3</w>
12. 0</w>
12 33
11beta- hydroxysteroid</w>
11. 7</w>
10. 7</w>
10- phenanth
10 89</w>
10 2
1.0 6</w>
1. 8,</w>
1. 6-
1. 4,</w>
1- amino
1, 9
1 H-
1 0.2</w>
1 0.1</w>
0.9 5</w>
0.8 2</w>
0.4 1</w>
0. 60</w>
0. 1)</w>
/ bronchiolar</w>
-2,4-di bromo
-2 0-
-10 .</w>
-1 3.
-1 .0
- enhanced</w>
)- resistant</w>
)- binding</w>
) (q
(w t)</w>
(phox ),</w>
(Tax ol;</w>
(T G),</w>
(SP EC
(R CC)</w>
(PGC -1
(PG I
(P RO
(O r
(O TA)</w>
(O PR
(NPY )</w>
(N NK
(ME K)</w>
(M PA)</w>
(M MC)</w>
(M M).</w>
(LN Ca
(IN H)</w>
(IF N)</w>
(H cy
(H AM-
(GM- CSF)</w>
(EC 50</w>
(Dani o</w>
(CYP2C 9)</w>
(C lin
(B MI),</w>
(AR NT)</w>
(AC )</w>
(A PO
(A IM
(5 2.
(4- benzoic</w>
(4 5.
(4 2</w>
(4 0%</w>
(3 0%</w>
(200 0)</w>
(1 25)
(1 2/
(0. 25,</w>
(-1 );</w>
( x
( tumor</w>
( selective</w>
( phase</w>
( b-
( ZD
zol mitript
zearal enone</w>
z et
z atebr
yl)- 5-
yl phenol,</w>
yl ase</w>
y- H2AX</w>
x. do
x.do i.
x.doi. or
x.doi.or g/
wor m</w>
wor ked</w>
wh ites</w>
week ),</w>
was :</w>
vis cer
virus- infected</w>
vi remia</w>
vi an</w>
veget able</w>
vap t
van ishing</w>
vag us</w>
use :</w>
us s</w>
uran ium</w>
upregul ation,</w>
unra vel</w>
uncert ain,</w>
un n</w>
umb ar</w>
ulcer ation.</w>
tumor- derived</w>
tumor s/
transfer ases,</w>
trac king</w>
tr ast</w>
tr apped</w>
tr ain-of-
toxic ologic</w>
tor ,</w>
toc otri
tobacco ,</w>
time -related</w>
ti tin</w>
ti ated</w>
thromboph leb
threshol ds.</w>
thio phene</w>
thiazol-2- yl]
th ink</w>
ten sion-
suc ro
subject s)</w>
sub cl
su gar
strepto kinase</w>
spiper one</w>
solubil ized</w>
solu tions.</w>
softw are.</w>
sligh tly.</w>
single- stranded</w>
sidom ine</w>
si as,</w>
she ath</w>
sesqu iterpene</w>
seleni um.</w>
scavenger s,</w>
scar ce.</w>
scal es,</w>
sand w
sac rine</w>
s ]</w>
ropipr ant</w>
ri gorous</w>
retin a.</w>
reticul um,</w>
ret aining</w>
resol ved,</w>
requ ested</w>
relax ing</w>
relax ants</w>
refl ection</w>
redox- active</w>
recurrence- free</w>
reason s,</w>
re appearance</w>
rat s'</w>
radi ocon
quasi -
qu oti
pyeloneph ritis</w>
provoc ative</w>
profes sional</w>
pro til
priv ate</w>
preser ved.</w>
preferen ce.</w>
pre- operative</w>
pre defined</w>
pre contracted</w>
possibil ity,</w>
possi bly,</w>
pop lit
pollut ant,</w>
po uch</w>
plas mac
placent as</w>
placebo :</w>
pl anning</w>
pin prick</w>
physostigm ine,</w>
phospho rous</w>
phenyl)- 5-
phenol s,</w>
pharmac ology,</w>
pertur b</w>
peroxid ase.</w>
perfor med
perf usate</w>
pepti dergic</w>
paresthe sia</w>
paraox on,</w>
p44/ 42</w>
p lot</w>
p K
p H-
oxide /
oxanth in</w>
our s</w>
ot inib</w>
oste olytic</w>
osi s].</w>
os e.</w>
os )</w>
organochlor ines</w>
ore active</w>
or der,</w>
open s</w>
onto geny</w>
on s,</w>
omy co
ochemistr y.</w>
och loro
occa sions,</w>
o valbumin</w>
nos e,</w>
non- peptide</w>
non- genomic</w>
non small</w>
non pregnant</w>
nodul es,</w>
nit ri
ng/m l;</w>
ng/ L</w>
nex t-
neuropath ies.</w>
neurolep tic
neuro toxins</w>
neuro toxicity:</w>
neuro hypo
necessit ate</w>
myocardi tis,</w>
myel ography</w>
mutag ens</w>
multi stage</w>
mono phosphate-
mon ni
ml ;</w>
mitoxantr one.</w>
mil lim
micronucle ated</w>
microlit er</w>
micrograms/ kg),</w>
micro some</w>
micro phthal
micro g.</w>
mi R</w>
methylphenid ate.</w>
methyl prednisolone.</w>
meth oxamine</w>
meth ox
metabol omic</w>
mesal amine</w>
mer openem</w>
medi an,</w>
mechan ics</w>
max illary</w>
matur ity</w>
mater n
macromolec ules</w>
mL (-1)</w>
lop ina
loc ation,</w>
lit er,</w>
lisin opril.</w>
lipress in</w>
lipopolysaccharide- stimulated</w>
lin ,</w>
ligam ent</w>
li pot
lad el
ladel ph
lac rim
l- THP</w>
l ucid
kynuren ic</w>
kain ate-induced</w>
k- alkali</w>
k ),</w>
j aw
ison icot
ir is</w>
intram olecular</w>
interven ing</w>
interrup ting</w>
institu tions</w>
insectic ide,</w>
inf lixim
indole acetic</w>
in- B</w>
in olytic</w>
impul sive</w>
imprin ting</w>
impac ted</w>
immunocytochemistr y,</w>
immuno allergic</w>
if ensive</w>
identifi ed:</w>
id azole</w>
ia ].</w>
i As
hypo thyroidism,</w>
hypo phosphorylation</w>
hypertension ].</w>
hypercoagul able</w>
hydroxyl amine</w>
hybridi zed</w>
hy brid
hy 926</w>
http:/ /d
http://d x.doi.org/
hr s.</w>
house hold</w>
hepati tis:</w>
hemo sider
habit uation</w>
hab its</w>
hOAT 3</w>
h s-
h as
gynaec ological</w>
guid ance</w>
guan ylin</w>
grap e
gradi ents</w>
goro us
glyoxal ase</w>
glutam ate.</w>
gluc opyran
genit o
gabap entin,</w>
function ;</w>
fru its,</w>
frag ments.</w>
four .</w>
foun dation</w>
forti fied</w>
form )</w>
food s.</w>
follic les.</w>
fmol/ mg</w>
fluctu ations.</w>
flu fenamic</w>
fiel ds.</w>
ferro portin</w>
fer tility.</w>
fam and
fac i
ey el
exud ative</w>
extrapol ation</w>
extr adural</w>
expendit ure</w>
exist ,</w>
excit ability.</w>
ex eme
ever y
ethambut ol.</w>
erro r
erb al</w>
environ ments.</w>
ent ers</w>
end- labeling</w>
end point,</w>
end ings</w>
ence- based</w>
enc ainide</w>
enantiomer s.</w>
en s,</w>
en anth
elem ent-
el ch
ectop ically</w>
dys men
dyn es/
doxorubicin- based</w>
dis infection</w>
dis abled</w>
dieldr in,</w>
dic arboxylic</w>
dic arboxyl
diazep am-induced</w>
di vi
di stress,</w>
di propyl
di buc
di acetyl
dex razox
deterior ation,</w>
descri p
depres sive-like</w>
depres sions</w>
demograph ic,</w>
dele tion.</w>
dec oy</w>
dec itab
deacetyl ase,</w>
datab ase,</w>
d (-1))</w>
cyst ine</w>
cut ell
curcum inoids</w>
cri ption</w>
coordin ately</w>
conver sely,</w>
contradic tory</w>
continu ously.</w>
cont ingent</w>
constipati on.</w>
const ell
const antly</w>
const ant,</w>
conges tion,</w>
conduc tion,</w>
compart ment
colloid al</w>
collec ted,</w>
col labor
col i,</w>
coagul ation.</w>
clozap ine-treated</w>
clo bet
clavul an
class es,</w>
cit rate,</w>
chloroqu ine,</w>
chel eryth
check points</w>
ch ing,</w>
cells/ micro
caver nous</w>
caspase- mediated</w>
carnit ine,</w>
carboxyl ase</w>
carbam oyl
caps azepine</w>
cap abilities</w>
cancer -specific</w>
ca .</w>
c rises</w>
c DNA,</w>
by- products</w>
busulph an</w>
buprenorph ine.</w>
bungaro toxin</w>
bronchodi lation</w>
bromi de
bro ther
blac ks</w>
bio assay.</w>
bio activity</w>
bicyc lol</w>
ben e,</w>
beclomethas one,</w>
azidothym idine</w>
atro b
atmosph eric</w>
at ran
asterix is</w>
ast om
arthralg ia,</w>
artemis in
ar idin</w>
apopto sis:</w>
api gen
antidepressant -like</w>
antidepress ant.</w>
anti- viral</w>
anti- platelet</w>
anti folate</w>
anthracyclin es,</w>
anion ,</w>
angi ogene
an sam
an s
an emia
amygdal a-
amid ino
am ine),</w>
alpha 3</w>
alopec ia.</w>
allergen s.</w>
al one)</w>
al ised</w>
agric ulture</w>
aggres sion.</w>
affor ds</w>
adul t.</w>
activit y-
acromegal y.</w>
acr ylate</w>
achie ved,</w>
accumul ations</w>
accoun t.</w>
ac knowledg
abl ation.</w>
a z</w>
a vir,</w>
[ P</w>
[ 11
[ (3
[ (2-
ZE N</w>
Z on
W T.</w>
V OD.</w>
V -induced</w>
UR AT1</w>
UPD RS</w>
UGT1A1* 28</w>
UGT1A 4</w>
U BE
U 251</w>
Trans well</w>
Thromb ocytopenia</w>
Thi oredox
TXN IP</w>
TRPV 6</w>
TRPM 7</w>
TLR 4,</w>
TK Is</w>
TF PI</w>
TAS 2R
T/ C</w>
T- cadherin</w>
T S-
T E-
T (H
Subst antial</w>
Six -
Serot on
Sem i-
ST K
SR- BI</w>
SR C-3</w>
SGC790 1</w>
SGC-790 1</w>
SC O
SC ).</w>
S-nitros o-
S per
S an</w>
S XR</w>
Rout ine</w>
Reser pine</w>
Recom m
RX R-
RUN X2</w>
RSV L</w>
RAR- beta</w>
RAR beta</w>
RA B
R PA
R -2
Qu al
Q o
Prote ins</w>
Prote as
Prom pt</w>
Predic tion</w>
Pi per
Phi ladelph
Per spec
Parad oxical</w>
PTE N/
PTE N,</w>
PMS F</w>
PL Z
PI TX
PGJ 2</w>
PGF(2 alpha)</w>
PB N</w>
PB A</w>
PATIENT (S):</w>
P< 0.01),</w>
P450 2E1</w>
P ]
P V</w>
P NP</w>
Ox idation</w>
Ot otoxicity</w>
Op tim
Observ ations</w>
Nether lands</w>
NT A</w>
NS C</w>
NNA L-
NI H
NHE -1</w>
NG AL</w>
N( omega)-
N early</w>
Mitogen -activated</w>
Meta- analysis</w>
Med ication</w>
MUT Z
MI -
ME Cs</w>
MAP K/ERK</w>
M eg
M dm2</w>
M -2</w>
M (2)</w>
M (1)</w>
Long itudinal</w>
Lear ning</w>
Le vel</w>
Larg er</w>
LLC-PK 1</w>
LK B1</w>
L P-
L 2,</w>
K/ Akt</w>
K Br
K (d)</w>
J M
In k
In clusion</w>
Impres sion
Immunoprecip itation</w>
Ig E-mediated</w>
IP P</w>
IL-1R a</w>
IGF -1,</w>
I sot
I NF
Hz .</w>
Haemo philus</w>
HS F
HS ,</w>
HMG CR</w>
H es
H AL</w>
H -2</w>
Gas 6</w>
GST O1</w>
GS PE</w>
GS .</w>
GLUT 2</w>
GLU T</w>
GDC-0 94
GC /
GADD 45</w>
G/ C</w>
G ri
G RE
G K</w>
G AP</w>
Fr ance</w>
Forty- three</w>
Fir st-
FT Y
F u
F ]
F OS</w>
F C
Ex ome</w>
Ep is
Enzym atic</w>
Engl ish-
EX TRAC
ER- alpha
ER P</w>
EP R</w>
EP 3</w>
EP ,</w>
EML4- ALK</w>
EC ).</w>
E (2)-
De fer
DN )</w>
DI C</w>
DH -
D O</w>
D CB
Cyclo hex
Cs A,</w>
Crizot inib</w>
Con sum
Con fir
Col o
Co w
Cho re
Case- control</w>
Carb oxy
CXCL 1</w>
CS ,</w>
COX -
CM V-
CL .</w>
CD4 (+)
CB D
C yst
C c
C 57</w>
Bx PC-3</w>
Burkit t</w>
Beg inning</w>
Beas -2B</w>
Bart ter's</w>
BPDE- DNA</w>
B R-3</w>
B CR
B BP</w>
Austral ia.</w>
As3 MT</w>
As eptic</w>
Arg -
Apo E(-/-)</w>
Antic ancer</w>
Ant ine
Al ve
Al dh
Akathi sia</w>
Affec ted</w>
ATP7 B.</w>
AT A</w>
AR T
AR F,</w>
AN .</w>
AN ,</w>
AI R</w>
AF ,</w>
AB VD</w>
A> C</w>
A pp
A mis
A cyclo
A alpha
A 6
> 50%</w>
9 7,</w>
80 /
8-M OP</w>
8 8)</w>
7- hydroxy-
7 3)</w>
6 56
6 4)</w>
54 ).</w>
50 =
5-HT 4</w>
5, 8,
5 10</w>
5 1-
5 -1.
45 %,</w>
4-aminopyr idine</w>
4- hydroxy-
4 6-
4 31</w>
4 25</w>
39 6</w>
3. 1.1.
3- fold)</w>
3- (4-
3,4- methylenedioxymethamphetamine</w>
3,4- dihydroxyphenylalanine</w>
3 9-
3 13
3 );</w>
29- year-old</w>
28 8</w>
28 %,</w>
25 %.</w>
24 7</w>
24 5</w>
20 %)</w>
2- deoxyglucose</w>
2- DG</w>
2 R)</w>
2 35
2 29</w>
2 1-year-old</w>
199 7.</w>
18. 5</w>
18 %,</w>
17,20- lyase</w>
16 ;</w>
16 00</w>
15- fold</w>
14. 3</w>
12 5)</w>
12 -24</w>
11. 9</w>
11. 4</w>
1.0 4</w>
1. 7%</w>
1. 1,</w>
1- month</w>
1,2,3- trichloro
1 alpha-
01910. Na</w>
0.9 6</w>
0.8 1</w>
0.7 3</w>
0.6 4</w>
0. 1).</w>
. /
- evoked</w>
- blocking</w>
* 3,</w>
(TBAR S),</w>
(T SA)</w>
(R T)</w>
(PARP ),</w>
(O AT
(Nrf 2),</w>
(NSAID s).</w>
(NF-k B),</w>
(NA FL
(MD A-
(MAP ),</w>
(M P)</w>
(M DS)</w>
(LY 29400
(L BD)</w>
(IL)-1 beta,</w>
(IL -2)</w>
(I/ R)</w>
(I CH)</w>
(HIF-1 a)</w>
(HBI G)</w>
(H SA)</w>
(H ME
(H -2
(G S)</w>
(FK50 6)</w>
(ER a)</w>
(E T)</w>
(E F)</w>
(Dex )</w>
(DM SO
(D CF
(Cd ),</w>
(CYP3A 4)</w>
(CL L)</w>
(CG I)</w>
(C/ EBP
(C TR
(An g
(A RB
(A R),</w>
(7 1%)</w>
(6 5</w>
(6 2%)</w>
(4 7%)</w>
(4 6.
(3,4- dichloro
(1 -3</w>
(0.0 2</w>
(0.0 1-
(+ 3</w>
( reduced</w>
( overall</w>
( UV
( R)</w>
( LT)</w>
( %
" ).</w>
z alcit
ys )</w>
y ros
y ?</w>
wor l
worl d,</w>
women ).</w>
wild life</w>
wid th</w>
viol ent</w>
vide o-
vi gorous</w>
vi d</w>
verteb rates.</w>
vent ing</w>
vasospas m,</w>
vasodilat or,</w>
uter us,</w>
under scores</w>
ul nar</w>
u g</w>
two- week</w>
tum orous</w>
tropic amide</w>
triterpen oid</w>
trinitro benzene</w>
tre s</w>
transi ents</w>
transf used</w>
train-of- four</w>
tot al)</w>
torce trapib</w>
tim ed</w>
tigh t
thyro x
threshol ds,</w>
tetr alin</w>
test ),</w>
te t
tacrolim us-induced</w>
t s;</w>
t s/
syndrome ).</w>
syn ergic</w>
sym bol</w>
sy ring
swe ating</w>
suspec ted,</w>
surfac e-
super oxide.</w>
succin yl
substitu tion.</w>
su pran
su ited</w>
stress ful</w>
spermat ogenesis.</w>
speech ,</w>
sin o-
silibin in</w>
si ly
shorten ing,</w>
sestam ibi</w>
ser ine,</w>
sensor y-
seizures :</w>
segreg ation</w>
see mingly</w>
sed entary</w>
sec )</w>
se d-
scler otic</w>
salme ter
sacrific e.</w>
rs 9
retinol- binding</w>
retinoid ,</w>
retin opathy,</w>
restric t</w>
respectively ].</w>
resor cin
reser ve.</w>
reser pin
relax in</w>
receptor- selective</w>
re al-
re activity,</w>
rauwolsc ine</w>
raniti dine,</w>
r ar
pyraz ine</w>
pyraz inamide</w>
proto- oncogenes</w>
promoter- driven</w>
prolong ed,</w>
progester one-
proce ed</w>
pro- arrhythmic</w>
preci sion</w>
practic es</w>
posi tioned</w>
poplit eal</w>
polyp epti
pol e</w>
pleg ia</w>
ple x</w>
plas tics</w>
plaqu es,</w>
pioglit azone,</w>
phyto hemagglut
physici ans.</w>
phenyl arsine</w>
phenoxy )
pet ro
permis sive</w>
penicill amine-induced</w>
pater nal</w>
pat ed.</w>
particul arly,</w>
paricalcit ol</w>
paraoxon ase-1</w>
paraly zed</w>
par ag
papille dema</w>
papill oma
pal p
pac ing,</w>
p47 (phox)</w>
p en</w>
p ellag
p I</w>
oxid ative-
ox on,</w>
osup pressive</w>
os in-
orche str
opioid -dependent</w>
op tion.</w>
op posit
op allidal</w>
one- year</w>
ondansetr on,</w>
omy elin</w>
oligodeoxy nucleotides</w>
og on
occa sion</w>
observe d;</w>
nour ished</w>
normot en
non- tumor</w>
non- protein</w>
non smoking</w>
nom inal</w>
nod es,</w>
nocicept ors.</w>
no .</w>
newbor n.</w>
neurolog ically</w>
negati ve
naproxen .</w>
n ac
myeloper oxidase,</w>
myel ination</w>
my oblasts</w>
mut ually</w>
multiv it
morbid ity,</w>
monocyte/ macrophage</w>
mono hydrate</w>
mon omers</w>
model ing.</w>
model :</w>
mit e</w>
mist ak
mis use</w>
mis onidazole</w>
microgram s.</w>
miR-34 a</w>
mi stri
mi metics</w>
mg/kg/ min</w>
mg/d ).</w>
mg/ l)</w>
meth oxyp
meth iodide</w>
metabolism :</w>
mepyr amine</w>
meperid ine,</w>
mechan o-
mater nally</w>
marmos ets</w>
manufact ure</w>
mal e)</w>
mainten ance,</w>
mL/ kg</w>
mE q</w>
m s).</w>
m A</w>
liver ;</w>
list s</w>
lipo prote
line :</w>
lig ustr
life- threat
leukemia ].</w>
le t
lan d.</w>
lamb da</w>
lab our</w>
l end</w>
iz otan</w>
it y].</w>
isot retin
iriti genin</w>
intrap ulmonary</w>
intermedi ates,</w>
inter patient</w>
intact .</w>
instrum ent</w>
insipid us,</w>
innoc uous</w>
ine vit
in take
in ert</w>
in ase.</w>
in appropriately</w>
import antly</w>
implant ation,</w>
immuno regulatory</w>
immun ologically</w>
imid april</w>
im balance.</w>
il :</w>
iflum ic</w>
ide mia.</w>
ic- coated</w>
ia ).</w>
i g</w>
hypoplasi a,</w>
hyperuric emia</w>
hypertensi ves.</w>
hyperkal aemia</w>
hyper sensitiv
hyper methylation.</w>
hyper androgen
hygi ene</w>
hydroxy tyros
hydroxy -2-
hydroly sis,</w>
hydrocephal us</w>
hy aline</w>
human s:</w>
http://dx.doi.org/ 10.
hs a-
hind brain</w>
high- pressure</w>
hex o
hepat omegaly,</w>
hemodialy sis,</w>
hemizyg ous</w>
head -
half- life.</w>
grape fruit</w>
granulomat osis.</w>
granul os
granul oma</w>
glutam yl</w>
glomeruloscler osis,</w>
glomeruloneph ritis,</w>
gli oma,</w>
genom e.</w>
gener al.</w>
gene- gene</w>
gen ous</w>
gemfibroz il,</w>
gas eous</w>
g/m L)</w>
g/ d</w>
furosemi de-induced</w>
fur in</w>
foscar net</w>
fore stomach,</w>
food s,</w>
follic le-stimulating</w>
flurbi profen,</w>
fluorescence- activated</w>
flumazen il.</w>
floun der</w>
femal es;</w>
factor- a,</w>
f 9</w>
extrasyst oles</w>
excit otoxicity.</w>
exc essively</w>
event s:</w>
ethan olic</w>
er c
ep ist
ent ).</w>
end otoxic</w>
en ing
emphyse ma</w>
embry otoxic</w>
elucid ated,</w>
electroph ile</w>
electr on
eigh teen</w>
edar av
e- weekly</w>
e- to-
e quin
e ol</w>
e k</w>
dr yn
dose- responsive</w>
don or.</w>
dom estic</w>
distinc tion</w>
dispos al</w>
disease- causing</w>
diseas e-associated</w>
diphenyl eneiod
dibenzo fur
di hydroxy</w>
depend ant</w>
demethyl ation.</w>
delta- aminolevulinic</w>
defini tively</w>
daunorubic in-induced</w>
cytoskelet on.</w>
cultiv ated</w>
cult uring</w>
cos timulatory</w>
correc ting</w>
contracep tion</w>
construct s.</w>
constric tion.</w>
consist ency</w>
compli ant</w>
col ocal
col o
coinc ides</w>
cofil in</w>
clos er</w>
clomipr amine.</w>
ci ticoline</w>
cholest asi
chloro genic</w>
chemosensi tizing</w>
ch ain-
cell -dependent</w>
ce fac
caveol ae</w>
cav a</w>
castr ation-resistant</w>
carri er
carcinom at
carbonyl s</w>
carbam ates</w>
carb aryl
capsaic in-treated</w>
calc ulation</w>
calc emic</w>
cadmi um-treated</w>
ca p</w>
bull ous</w>
bul k</w>
bronchi ol
brady arrhythmia</w>
bor rel
bond ing</w>
blun ts</w>
bl ing</w>
bioinform atics</w>
bio activation.</w>
bi weekly</w>
bi phasi
bi directional</w>
beta-carb ol
benzo fur
benz imidazol
benazep ril,</w>
beats/ min)</w>
be t</w>
b- adrenergic</w>
b exarotene</w>
b 5</w>
azol ,</w>
az e</w>
ax etil</w>
autophag y-related</w>
ator y.</w>
ation- inducing</w>
at um
at tended</w>
at tain</w>
asymptom atic,</w>
associ ations.</w>
associ ating</w>
assa y;</w>
arthralg ias</w>
ar restin</w>
ar ly.</w>
ar /
appli ed,</w>
appear ance.</w>
antidot es</w>
anticonvuls ant,</w>
anti- atherogenic</w>
anti ulcer</w>
anti mycin</w>
anti metastatic</w>
anti genic</w>
animals ;</w>
anesthe tic-induced</w>
analy sing</w>
an- 4-
an ),</w>
amyloid osis</w>
amptothec in</w>
aminohipp urate</w>
amide -treated</w>
am e
alpha2- adrenergic</w>
alph ostin</w>
alkal oid,</w>
alfa- 2a</w>
al ity.</w>
age- associated</w>
adi en
ach ite</w>
acetyl ators.</w>
ab domin
a prost</w>
[ [
[ N
[ CI,</w>
[ 2.
Y-276 32</w>
X Y</w>
X BP1</w>
Valu es</w>
U U
U -2</w>
Tol u
Thiazol idine
TSP -1</w>
TREAT MENT</w>
T- ->
T u
T b
T T,</w>
T P-
Sub sequently</w>
Sou th
Sel en
Schizophren ia</w>
Schi ff</w>
Sc hist
Sa os
SREBP -1</w>
SO (2)-
SNA P</w>
SM F</w>
SLC 2A
SL U
SH- SY5
SERCA 2</w>
SC F</w>
SAP K</w>
S, 3
S V-
S -1
Ros i</w>
Resid ual</w>
Recur rence</w>
Rab b
RO S-induced</w>
RAR beta2</w>
R X</w>
R U</w>
R AC
R :</w>
Quanti fication</w>
QT- interval</w>
Q /
Psych osis</w>
Projec t</w>
Pres sure</w>
Post natal</w>
Poly brominated</w>
Phosphor ylated</w>
Pdn/P d
Path ologic</w>
Particul arly,</w>
PS 1</w>
PRESENT ATION:</w>
PPAR alpha,</w>
PP P</w>
PML/ RARalpha</w>
PD K1</w>
PD CD
PC s)</w>
PC E</w>
PARP .</w>
PA H,</w>
PA CAP
P ol</w>
P ick</w>
OV CA</w>
O-de alkylation</w>
O Z
O AB</w>
Notch -1</w>
Neutroph ils</w>
Neu tr
Nephro pathy</w>
NRTI s</w>
NO TCH
NK -1</w>
N6 AMT
N- OH-
N d
N H</w>
Multi focal</w>
Mannit ol</w>
MIP -1</w>
MG -1
MC T/
MAP .</w>
M un
M ast</w>
M ancoz
M V</w>
M AC
Lipopolysacch aride</w>
LQT S</w>
LP .</w>
LO ,</w>
L-dop a.</w>
L- tryptophan</w>
L ]</w>
L BP</w>
L A-
L -2
K -2
Jaundic e</w>
JAK- STAT</w>
Ische mia</w>
Intra hepatic</w>
Imi pramine</w>
IR I</w>
IL-12 p70</w>
IL- 4
IK r</w>
IB-ME CA</w>
I sop
I R.</w>
I HD</w>
I ET
I B</w>
Hydr alazine</w>
Hu h-
He av
HL .</w>
HIV-1- infected</w>
HEK 293T</w>
HE K-
H 3,</w>
H -treated</w>
GT S</w>
GSTM 1
GF 109203
G d-
G RO
G LT
G 2677
Forty- nine</w>
Fifty- four</w>
Fe eding</w>
Far nes
FV B/
FR 17
FL LL
FB S</w>
F x
F ram
F inal</w>
F enflur
F H</w>
Es s
English- language</w>
Emplo ying</w>
Ec st
ERR alpha</w>
ERK 1</w>
ERK )</w>
ERCC 2</w>
EP 2</w>
E S:</w>
E NT</w>
E 3
E 2/
Dys function</w>
Depend ent</w>
DN ase</w>
D K
D I</w>
D 2R</w>
Correspond ingly,</w>
Co Q10</w>
Cinnam aldehyde</w>
Chrom osomal</w>
Calc ineur
CYP2 S1</w>
CP S</w>
CL Z</w>
CL P</w>
CI =1.
CI ),</w>
CFTR ,</w>
CE S2</w>
CD44 v
C> A</w>
C3H/ He</w>
C282 Y</w>
C ock
C WR
C M,</w>
C -2</w>
BoNT/ A</w>
BAPTA- AM</w>
B y
B ub
B mi
B aro
B MS
B CK
B As</w>
B 2)</w>
Awa reness</w>
Ar th
Ang ina</w>
Anesthe si
An alog
An a
Allel ic</w>
Af ter
AZ A-1</w>
ATP7 B,</w>
AS A)</w>
AP 1,</w>
AO AA</w>
AKR 1B1</w>
AB A</w>
A54 9/
A mil
A fl
A E)</w>
A AT</w>
A +
> 50</w>
: 1)</w>
90 ).</w>
90 %)</w>
9 5)</w>
9 4.
8-oxod G</w>
6-OHD A-
6 9,</w>
5- week</w>
5- min</w>
5 -15</w>
4-hydroxy-2- nonenal</w>
4- positive</w>
4- fold)</w>
4 49</w>
36 %,</w>
34 ;</w>
32 %,</w>
3 2.</w>
29 9
28 9</w>
24- hydroxylase</w>
20 7</w>
2. 4,</w>
2,4- D</w>
199 7,</w>
182,7 80.</w>
18 ;</w>
15 4
10(-8 ))</w>
1.0 8</w>
1.0 2</w>
1. 6%</w>
1 D
1 0.6
00 )</w>
0.7 8</w>
0.7 6</w>
0.00 2</w>
0.0 3%</w>
0.0 1-
0 5</w>
-1,2,3, 4-tetrahydro
-1 1-
, 0
(r (2)</w>
(n= 8)</w>
(V PA),</w>
(TGF- b
(S e)</w>
(RB C)</w>
(R V)</w>
(PB ),</w>
(P TP
(NO ).</w>
(NAT 2)</w>
(N TR
(ME K
(M HC)</w>
(LPS )-stimulated</w>
(LP O)</w>
(L ID)</w>
(L ID
(IL- 8),</w>
(I le
(I M)</w>
(H b
(H R,</w>
(H NF
(G R
(G I)</w>
(F V
(F S)</w>
(F R
(D HF
(CR F)</w>
(CL )</w>
(CI s)</w>
(C PK
(C OP
(B NP)</w>
(B CL
(AT RA),</w>
(AL L).</w>
(A m
(A h)</w>
(A S)</w>
(A NP)</w>
(9 5%)</w>
(8 5%)</w>
(8 4%)</w>
(8 1%)</w>
(50 -100</w>
(5 5.
(3 1</w>
(2 0,</w>
(1- 5</w>
(1- 42)</w>
(1) H</w>
(-1 .
(-1 ).
(-/- )
( stat
( maximal</w>
( encoded</w>
( e)</w>
( creatinine</w>
( combined</w>
( case</w>
( c-
zymograph y.</w>
zinc -binding</w>
z ,</w>
year s'</w>
year )</w>
work -up</w>
warfar in-
w t,</w>
w ann
w alk
w ,</w>
vis its.</w>
vis it
view ,</w>
vide o</w>
veter inary</w>
ver y-
utili zes</w>
us e-dependent</w>
urticar ia/
ureth ane-induced</w>
unremark able.</w>
unmas king</w>
univers ally</w>
under lines</w>
un ve
un its.</w>
un infected</w>
un equivoc
un ambigu
um ),</w>
ul l
tur ning</w>
tubul e.</w>
tryp s
troph y</w>
trichlor f
transloc ate</w>
transfu sion.</w>
transcriptom ics</w>
trans activated</w>
toler ated;</w>
titr e</w>
tit ude</w>
tic tal</w>
ti um.</w>
thrombin -induced</w>
thro at</w>
thre on
thiopent al,</w>
thick ened</w>
thiab endazole</w>
tetrahydro -
tetracycl ine-
testoster one-induced</w>
tert- butyl-
ten tion</w>
te mazepam</w>
tachy kin
t rough
t n
t RA</w>
t PA</w>
synthesiz ed.</w>
symptom atic,</w>
sym pathe
surroun ded</w>
surpr ising</w>
super vision</w>
sup pos
sulf oxide,</w>
sulf ates</w>
sub normal</w>
sub epithelial</w>
stud y).</w>
stu ff
store -operated</w>
stimul us,</w>
steroid -dependent</w>
ste red.</w>
stat in-induced</w>
st un
sr c</w>
spironolact one.</w>
sphing omyelin</w>
soy as
son ,</w>
smo ke
simult aneously,</w>
signall ing,</w>
side- out</w>
si cal</w>
sho ga
seri ous,</w>
sequenc ed.</w>
sens ors</w>
sen ger</w>
seizure -related</w>
sedi ment</w>
sec tions,</w>
sc an,</w>
satisfactor ily</w>
saliv a</w>
salicyl ates</w>
s pa
s ke
rt M204
rottler in</w>
rifamp in.</w>
reveal ed.</w>
retar ding</w>
resol ves</w>
residu e.</w>
report :</w>
replic ating</w>
reinforc ement.</w>
regi stry</w>
recruit ment.</w>
re presentation</w>
ras -
raniti dine.</w>
raf ts</w>
queti apine.</w>
quantit ate</w>
pyrid ostigmine</w>
purpos es.</w>
puls atility</w>
psychiat rist
provo king</w>
propyl ]
prophyl axis,</w>
promo tion,</w>
prolactin oma.</w>
projec tions</w>
prog ab
produc ed,</w>
prochlor per
prob able.</w>
pro- angiogenic</w>
preven tion,</w>
pren ylated</w>
pr ic
post ul
post labeling</w>
poly arteritis</w>
po ol.</w>
po ison</w>
photosensi tivity</w>
phot oc
phosphoryl ated-
phospho enolpyruvate</w>
phos gene</w>
pg/m l;</w>
pestic ide,</w>
peril ipin</w>
peptid yl</w>
pent etr
paw -
parathyro id
parap aresis</w>
par an
p42/ 44</w>
p3 00/
p21(w af1/cip
p- X
p- Akt</w>
p g
p RB</w>
oz one-induced</w>
oxygenase- 1.</w>
oxi dised</w>
ox ia,</w>
ov agal</w>
out- patients</w>
osi s;</w>
os el
org e</w>
or/ and</w>
or y-
opportun ities</w>
open ia,</w>
open ed</w>
oni um.</w>
onco genesis.</w>
on :</w>
on /
on -induced</w>
om in
ole anolic</w>
olanzap ine-treated</w>
od or</w>
ocon vul
ocholesterol emic</w>
oc rit</w>
ob id
ob end
nucle ophil
novel ty</w>
norepinephr ine-
non responsive</w>
nom inally</w>
no re
nickel .</w>
neutr alization</w>
neuro kin
neuro inflammatory</w>
nephro toxic
nal idixic</w>
n 't</w>
multi kinase</w>
month )</w>
mono amine-
monke y.</w>
modul e</w>
mmol/ L.</w>
ml/min/ 1.73</w>
mit ot
minoxidil .</w>
mid odrine</w>
micronutri ents</w>
micro g),</w>
mg/ week</w>
mg/ l,</w>
mg. kg-1)</w>
methyldop a,</w>
methyl )
methohex ital</w>
met allop
messen gers</w>
may be</w>
mat ing</w>
marked ly.</w>
mariju an
mannit ol.</w>
man idipine</w>
ma them
mGlu Rs</w>
lys osome</w>
long standing</w>
load s</w>
lipopolysacchari de.</w>
libid o</w>
li ability.</w>
leuk ocytosis</w>
lac to
l ers</w>
l aryn
l 2</w>
knock ing</w>
kinase- 3</w>
kD a,</w>
isor hamnetin</w>
ioprom ide</w>
ion omycin</w>
ion -
intrat ympanic</w>
intran as
interferen ce.</w>
instill ation.</w>
innerv ated</w>
injur y;</w>
infiltr ated</w>
individu al.</w>
incr imin
in war
in spec
in activator</w>
imip enem</w>
ifosfam ide
if lor
if entan
idi zed</w>
ide ].</w>
idaz ox
ic ol
i um.</w>
i pro
i es:</w>
hyponat raemia</w>
hypoglyc emia.</w>
hyper for
hyaluron ic</w>
hyaluron an</w>
homozygot es.</w>
homocyste ine-induced</w>
high- sensitivity</w>
her b
hept achlor</w>
hepar in-binding</w>
hemat ology</w>
hem oper
helic ase</w>
hRF I</w>
h and.</w>
granul ocytopenia</w>
gout y</w>
glucos yl
glucocorticoid -
glibenclam ide,</w>
gli osis</w>
gl u
gel sol
gamma ).</w>
galang in</w>
gadol inium-
g/m 2,</w>
g old
g all-
g ain
furosemi de
furan osyl
fur azol
ful le
ful filling</w>
fre ezing</w>
form aldehyde,</w>
flupirt ine</w>
first- generation</w>
filament ous</w>
fib ril</w>
feno profen</w>
factor )</w>
explant ed</w>
exon s,</w>
ex plic
evid ence.</w>
ethan ol-treated</w>
estram ustine</w>
equ ine</w>
epirubic in.</w>
entor ial</w>
engraft ment</w>
endothelium- derived</w>
endop eptidase</w>
encephal opath
en il</w>
empt y
embry opathy</w>
electromy ography</w>
ejac ulation</w>
eIF 2a</w>
e- matched</w>
e min
e ased</w>
e NOS-
doxaz osin,</w>
dose- finding</w>
dose- escalation</w>
disulfir am.</w>
disproportion ate</w>
disorder s:</w>
dimorph ic</w>
dihydro fluorescein</w>
dichloro fluorescein</w>
deter gent</w>
detec ts</w>
depend ence
dem ecl
dele tions,</w>
decad es.</w>
dec el
deaf ness.</w>
day -1</w>
cycl ing.</w>
cy permethrin</w>
cro cin</w>
correl ation.</w>
corpor a</w>
cop ic</w>
contamin ant,</w>
concentration )</w>
con spic
compoun d-
com plain</w>
collap sed</w>
colchic ine.</w>
col d-
co- cultured</w>
co- culture</w>
clon ogenicity</w>
clin ic,</w>
clarithromycin ,</w>
cl org
citrul line</w>
circl ing</w>
characteris tically</w>
chamb ers</w>
cet uximab</w>
carboxy -
capt ured</w>
calc ification,</w>
caerul ein</w>
c- My
c ub
but oxide</w>
buil t</w>
bu hal
bromomethyl)-1,3-prop anediol</w>
bortezomi b-induced</w>
bifid a.</w>
bi le,</w>
beta- tubulin</w>
berb er
benzoyl ecgonine</w>
benzo[a]pyren e.</w>
benzo thiazol
bendroflu azide</w>
ben omyl</w>
beha ves</w>
be ar</w>
babo ons</w>
az ide,</w>
ax is
aw as
atre sia</w>
assembl ed</w>
asp an</w>
arra y,</w>
are flex
aque ductal</w>
apracl onidine</w>
ap ram</w>
antigen -induced</w>
antid otal</w>
anti- rheumatic</w>
anti- nociceptive</w>
anth ran
anter i
ane- treated</w>
an emi
ampl ifications</w>
amoxy cillin
amoxicillin -clavulanic</w>
alveolar /bronchiolar</w>
als alaz
aldoster one-
ail ing</w>
ai od
ag outi</w>
af luoro
adult- onset</w>
adul t,</w>
adenos ine-induced</w>
adeno virus-mediated</w>
aden osis</w>
aden o-
addi tiv
activ ation-induced</w>
acromegal y</w>
acid ;</w>
acid -mediated</w>
acetyl- CoA</w>
ace ous</w>
ac ic
absorp tive</w>
abs ent,</w>
aberr ation</w>
a ys</w>
a V
_ alpha
Y B-1</w>
X PA</w>
Wil li
W I</w>
Veter ans</w>
Val66 Met</w>
VSMC s.</w>
VP 16</w>
VEGFR -1</w>
VEGF R2</w>
VD AC1</w>
VCAM -1,</w>
V/ PI</w>
URB59 7</w>
Tradi tional</w>
Through out</w>
Thir d,</w>
Th alidom
Tempor ary</w>
TRPV 1,</w>
TP P</w>
TP /
TNF a,</w>
TIMP -1,</w>
TBP S</w>
TB I.</w>
T opo
T erat
T TS</w>
T D.</w>
Sur face</w>
Specific ity</w>
Spec i
Simp son-
Si butramine</w>
Si Ha</w>
SN U
SMA )</w>
SM -induced</w>
SI ,</w>
SH ).</w>
SETTI NG,</w>
SC -5
SB2035 80.</w>
S100 P</w>
S til
S cutell
S AS
S 2
Ry R2</w>
Ring er's</w>
Resveratro l-induced</w>
Repe at</w>
Rec or
Rb 2/
RS V.</w>
RP ,</w>
R as,</w>
Q Ds</w>
Proxim al</w>
Protoc ol</w>
Propylthiourac il</w>
Pro buc
Pres ence</w>
PrP (C)</w>
Post operatively,</w>
Pop ulation</w>
Pharmaceu tic
Pharmac ology</w>
Ph ot
Per man
Pat ch</w>
Parad oxic
PY Y</w>
PR I
PQ .</w>
PPI s</w>
PI3 K
PI AS
PGE 2-induced</w>
PAI -2</w>
P yrid
Oxali platin</w>
OP P</w>
O il</w>
O S-
O MIM</w>
O HC
O (4)
Nox 4</w>
Ni (II)</w>
Ne vir
NT 69
NT ),</w>
NNA L</w>
NH 4
NF 2</w>
N6AMT 1</w>
N og
N a,</w>
N (2)-
Multi -
Min ocycl
Micros omal</w>
Micro injection</w>
Mes senger</w>
Mem ant
Mang ifera</w>
MS/ MS.</w>
MPTP- lesioned</w>
MDA- MB</w>
MA A</w>
M ood</w>
M ag
Li br
LTD (4)</w>
LS17 4T</w>
LNCa P,</w>
LC 3
LAPC -4</w>
L n
L PA
L IF
L 180
K (i
Join t</w>
Japanes e.</w>
Intram uscular</w>
Incid ences</w>
Impression s-
IV M</w>
IC S</w>
I ;</w>
Hg -
Hex achloro
Hear ts</w>
HS P-
H ormone</w>
Gadd 45
GRP 78,</w>
GABA- ergic</w>
GAB A.</w>
G1- phase</w>
G unn</w>
G AC</w>
G 20
Fas -associated</w>
Famoti dine</w>
FX R-
FL X</w>
F50 8-
F- treated</w>
F s)</w>
F ab</w>
F ITC-
Etop oside</w>
Ess ential</w>
Erb B</w>
En dop
En d-
Elec trical</w>
ERK 5</w>
ER b
ER alpha
ED S</w>
EC S</w>
EC -
E X</w>
E SI-
E ;</w>
E -</w>
Dox azosin</w>
Diff use</w>
Dex razoxane</w>
De hydro
Datab ase</w>
DS B</w>
DP ).</w>
DNMT 3A</w>
DNA- repair</w>
DNA- encoded</w>
DN P</w>
DC E</w>
DARPP- 32</w>
D s,</w>
D PD
Concentr ation</w>
Com pu
Cime tid
Cilost azol</w>
Chloram phenic
Cd- treated</w>
Car vedil
Capsa icin-induced</w>
Candid ate</w>
CaMK II</w>
Ca (+
CYP3A5* 1</w>
CYP2C9* 1</w>
CYP -mediated</w>
CT s</w>
CT A</w>
CL S</w>
CL O
CL L.</w>
CDK 4,</w>
CD 133</w>
CB Z-
C57 /
C yclic</w>
C il
C HD
C .,</w>
Bi polar</w>
BU P</w>
BP 1)</w>
BI R
BGC- 823</w>
B- 4</w>
B NI
As c</w>
Arg inine</w>
Am- 80</w>
Al prazol
Al -
Ad dic
Acetyl cysteine</w>
Ac tion</w>
Ab solute</w>
AS M</w>
AP P
ANCA -associated</w>
AL AD</w>
AK I.</w>
AG Es</w>
AC T
AA S</w>
A(2A) R</w>
A symptomatic</w>
A stem
A dr
A As</w>
A 1),</w>
< .001)</w>
89 /
8-ox oguanine</w>
8 58
8 1)</w>
77 7</w>
70 %.</w>
7 70
7 2-
600 -
6- h</w>
5-hydroxy indoleacetic</w>
5-FU -resistant</w>
5- lip
5 8,</w>
5 3.</w>
45 8</w>
400 -
40 ;</w>
4- dependent</w>
4- aminobiphenyl</w>
38 ;</w>
37 ),</w>
35 1</w>
33 4</w>
33 %,</w>
3-1 99
3- methyl-
3- fold,</w>
3, 7-
3 35</w>
3 2).</w>
3 11</w>
27 6</w>
27 %,</w>
25 6
24- hr</w>
22 %,</w>
20 15</w>
20 1
2- arachidonoyl
2, 4,5-
2 u-
2 22</w>
2 2.</w>
199 5.</w>
19- year-old</w>
17 8
16 8
15. 5</w>
15-45 13</w>
15 6
14- 3-3</w>
13. 7</w>
13 1
12. 4</w>
12. 3</w>
12, 14-
11b-HS D1</w>
11 6,</w>
10- year-old</w>
10 mg/kg</w>
10 -12</w>
10 (8)</w>
1,8- cine
1,25(OH) (2)D
1 p3
00 4</w>
00 2</w>
0.9 9</w>
0.9 8</w>
0.8 %)</w>
0.5 %)</w>
0.00 5,</w>
.0 5,</w>
-1, 2,4-
-1 98
- susceptible</w>
- O
- 4.
, 8
* 2/
)- derived</w>
(trans- 3,
(mean +/-
(m GluR
(V PA).</w>
(T ZD
(T N
(SB 2035
(RA NK
(QT c)</w>
(PFO S)</w>
(PC P)</w>
(P N)</w>
(O (2)
(NN K)</w>
(NF kappaB)</w>
(NAFL D)</w>
(N e
(N C
(M LC
(M C)</w>
(L E
(K m</w>
(K CN
(K (m)</w>
(III ))</w>
(ICAM -1),</w>
(IBD ).</w>
(Ha Ca
(HU S)</w>
(H2O 2)</w>
(H CA
(H A)</w>
(G PX
(G J
(G GT
(G G
(F C
(DO PA
(D RE
(CYP )
(CTGF )</w>
(CO ),</w>
(C CL
(C BD
(C -
(BUN ),</w>
(B T
(APL ),</w>
(AP P)</w>
(AE D)</w>
(ACE I)</w>
(A LP),</w>
(A /
(8 3%)</w>
(8 2%)</w>
(6 2.
(6 %),</w>
(5 8.
(4 3.
(3 7</w>
(2-ethylhexyl) phthalate</w>
(2, 3,
(2 %</w>
(10 0%</w>
(10 %).</w>
(1, 3-
( interquartile</w>
( increase</w>
( eight</w>
( difference</w>
( cyclin</w>
( alpha)</w>
( NADP
( 8%</w>
zo fen
z onal</w>
ym ph</w>
yl ine</w>
yl ene</w>
year- old,</w>
y H2AX</w>
y .
xer ostom
xanth one</w>
xam oterol</w>
wh ole,</w>
weight ),</w>
week ).</w>
w aste</w>
vincrist ine-treated</w>
vehicle )</w>
vascul opathy</w>
vascul iti
vari ance.</w>
v ,</w>
us es.</w>
urs olic</w>
uro logic</w>
urg -S
urg-S tra
urg-Stra uss</w>
ure ter</w>
ure mia</w>
ure as</w>
under p
uncertain ty</w>
un responsiveness</w>
un defined.</w>
umb ell
ul d,</w>
ul ation.</w>
udi oxon
u pro
trimeth adione</w>
triglycer ides.</w>
tri tiated</w>
tri os</w>
transform ants</w>
transfec tions</w>
transamin ases,</w>
trans thy
tramad ol.</w>
tramad ol,</w>
tr it
tot emporal</w>
tom y.</w>
toler anc
ti an</w>
the ast</w>
tetrak is</w>
tetrac a
ten as
telmis artan,</w>
teicopl anin</w>
te in</w>
te )</w>
t- related</w>
t le,</w>
syndrome ;</w>
swe at</w>
suspen sions</w>
sul prost
successful ly.</w>
substr at
sub groups,</w>
stereotyp y.</w>
step .</w>
stat in-
st ag
spl it</w>
spher oids</w>
small .</w>
si ed</w>
shell fish</w>
sha kes</w>
set ,</w>
sequest ered</w>
selen ocysteine</w>
seizures ;</w>
sed :</w>
search es</w>
scintigraph ic</w>
sch wann
scaveng ed</w>
scar ring</w>
scal e)</w>
sacrific ed.</w>
s E-
rs 13
rs 12
rit anserin</w>
ric kets</w>
retin oblast
retard ant</w>
restric tion,</w>
response )</w>
reservo ir</w>
remo ph
rel y.</w>
regul ators.</w>
regar d,</w>
ref used</w>
rect al,</w>
receptor- related</w>
receptor- negative</w>
receptor s;</w>
re alized</w>
radiosensi tivity</w>
radi olab
radi ochemotherapy</w>
r- Hu
qual ified</w>
qu e</w>
purpos e.</w>
psychiatr y</w>
psych ot
psych opathological</w>
prur itic</w>
protec tor</w>
proteasome- mediated</w>
prote olysis.</w>
prost anoids</w>
promoter- luciferase</w>
prolong ed.</w>
program m
progest ogen</w>
proce eds</w>
pro enkephalin</w>
prim id
pres enil
pre adipocyte</w>
pra vastatin,</w>
pr ud
pp m),</w>
posi tioning</w>
poly(ADP-ribos e)
pod ocytes,</w>
pluri potency</w>
piv al
pituit ary.</w>
pit av
pic a</w>
phy lo
phosphorib osyl</w>
pher ic</w>
pentobarbit al-induced</w>
pentobarbit al,</w>
pent ose</w>
pent a
patch y</w>
paresthe sias</w>
pal sy.</w>
p< 0.05)</w>
p6 5-
p5 3)</w>
p3 00,</w>
p- hydroxy
p ies</w>
p ial</w>
ow a</w>
ot etr
osse ous</w>
oscop y.</w>
orth o
organ ized</w>
or phenad
or dered</w>
opoi etin</w>
op indolol</w>
on isin</w>
om yc
ol ol-induced</w>
oglut arate</w>
ogen ic,</w>
odystroph y</w>
odi phenyl
ocy clo
oc tion</w>
o- like</w>
o in-induced</w>
normot ension</w>
non- obese</w>
non- Hispanic</w>
nocicept or</w>
noc ifensive</w>
nmol/ L,</w>
nimesul ide.</w>
neuroblast oma,</w>
neocor tex</w>
ne vertheless,</w>
ne ar
n- butyl</w>
n m.</w>
n M;</w>
myotub es.</w>
myelosup pressive</w>
myel otoxicity</w>
my ris
multin ucleated</w>
multi potent</w>
mon oter
mon omer
ml/ kg/
ml (-1))</w>
mitomycin- C</w>
mitig ating</w>
mis e</w>
mini pum
min ing</w>
milli ons</w>
micromol/ L).</w>
microg/m L.</w>
mic s</w>
miR -10
mi thr
mi as</w>
mg/ min</w>
metronid azole-induced</w>
methion ine.</w>
metallothione ins</w>
met al,</w>
mening o
medulloblast oma.</w>
me z
maximum- tolerated</w>
matche d,</w>
man eu
male im
macroscop ically</w>
machiner y.</w>
ma- media</w>
m ate</w>
m AChR</w>
ly syl</w>
log 10</w>
lob e.</w>
lit er)</w>
lipos ome</w>
lipophil icity</w>
line age.</w>
lig ation,</w>
li v
lester ase</w>
leiomy omas</w>
le ast,</w>
l ax
ket otic</w>
kav a</w>
isomer ization</w>
iso flav
isle ts,</w>
ir idin
ipp ed</w>
intramy ocardial</w>
intrale sional</w>
inti ma-media</w>
intens ely</w>
integr in,</w>
integr ative</w>
integr ate</w>
institu tional</w>
inflamm ation-induced</w>
ine- like</w>
industr y.</w>
indomethac in-treated</w>
in tolerance,</w>
in sensitivity</w>
in effective,</w>
impul si
immunoprecipit ation.</w>
immunoprecipit ation,</w>
immer sion</w>
idi ol</w>
id ol</w>
ich thy
ic ted</w>
ibog aine</w>
i. t
hypoxi a/
hyperprolact inemia,</w>
hyperkal emia.</w>
hyperinsul inemic</w>
hyper ton
hyper oxi
hydroxy cholesterol.</w>
hydroph ob
hydrochlor ide)</w>
hex yl
hemis phe
hematopoie sis.</w>
hOCT 2</w>
h its</w>
guanyl yl</w>
guan eth
gran in</w>
gra vity</w>
gorous ly</w>
glycoly sis,</w>
glucuron ide.</w>
genito urinary</w>
gene ;</w>
gel .</w>
gastri tis</w>
g/m l.</w>
fusi dic</w>
frequ ent.</w>
foun der</w>
formul ations.</w>
foot prin
fm k,</w>
fluv oxamine.</w>
flupen thixol</w>
fluoro methyl
flunar iz
flu thrin</w>
flavon ols</w>
fl us
fis sion</w>
fi pronil</w>
femal e)</w>
farnes ol</w>
factor- alpha-induced</w>
f ly</w>
extr am
ext ents</w>
expan sion.</w>
exha us
exfoli ative</w>
exc iting</w>
exc ess.</w>
ex osomes</w>
ex onic</w>
ex ocrine</w>
evodi amine</w>
ethan e-
erb B
epome diol</w>
epilep tics</w>
enteroc olitis</w>
enlarg ement,</w>
endur ance</w>
endosulf an,</w>
end onucle
enalapril -treated</w>
embr anous</w>
electro -
eat ann
eIF 2
dyst oni
dyscra sias</w>
dysarthri a,</w>
drug- sensitive</w>
drug- eluting</w>
drople t</w>
droperid ol.</w>
diure sis.</w>
disulfir am,</w>
disper sed</w>
discontinu ations</w>
disco vered.</w>
dis cour
dis appear</w>
direc tly.</w>
dipl opia</w>
dimorph ism</w>
dihydro -5
di sp
di mers</w>
develop s.</w>
deoxy guanos
deficienc y:</w>
decel er
de afferen
dd i</w>
dUT P-
d- Chi
d iterpen
cytotoxic ,</w>
cyste in
cyst in
cy haloth
curcum in-induced</w>
cum ul
culmin ating</w>
cou ple
corticotrop in</w>
context ual</w>
cont ents.</w>
connex in
congener s,</w>
con ve
con du
complet ely,</w>
community- acquired</w>
com position.</w>
collec t</w>
colchic ine,</w>
cohe rence</w>
clos ure.</w>
clos ed-
cl aims</w>
cin ac
chym ase</w>
chromat in-
chol ere
chlor hexidine</w>
chemo prophylaxis</w>
chem oconvul
characteris e</w>
ch ase</w>
cerevisi ae</w>
cent rom
cent )</w>
ce )</w>
caudate- putamen</w>
catch ard</w>
cataly st</w>
cas pofungin</w>
cann ulation</w>
candidi asis</w>
candidat es.</w>
calci um-induced</w>
ca ro
cG MP,</w>
cAMP /
c-F os,</w>
burden s</w>
buil ding</w>
bran ching</w>
brac hy
bortezomi b.</w>
blot s.</w>
bl astic</w>
biop terin</w>
beta- mediated</w>
beta- hydroxysteroid</w>
benzbromar one,</w>
benef it,</w>
beg ins</w>
bec tomy</w>
bas e,</w>
baclofen ,</w>
b ing,</w>
b 2
b /</w>
axon s.</w>
awak en
aven ue</w>
autoradi ographic</w>
audi ometry</w>
atri a,</w>
ator in</w>
ati b
ather othromb
at ures</w>
at a.</w>
astemiz ole,</w>
ascit es.</w>
arteri osclerosis</w>
artan/ HCTZ</w>
arr e</w>
apne ic</w>
apne a,</w>
aplasi a.</w>
anx ious</w>
anti- ischemic</w>
antagon ism,</w>
angiotensin- converting-enzyme</w>
angiotens in
anesthesi a].</w>
androst enedi
an y
amyl in</w>
amphi regul
aminog lute
amino- 5-
alumin um-
alpha-methyl- p-
alpha-amino- 3-hydroxy-
alpha- naphthoflavone</w>
alpha- actin
alpha(1)- adrenergic</w>
alpha 5</w>
albic ans</w>
al one).</w>
al dox
agly cone</w>
again ,</w>
ag o.</w>
ag li
after depolarizations</w>
aff lic
af il
aden oma,</w>
activ ation;</w>
acid ].</w>
accumben s,</w>
abol ished.</w>
abil ities,</w>
ab users,</w>
ab le-
a etiological</w>
_percnt ;
_alpha ;-
[HR ]</w>
[2- (
[ mean</w>
Zileut on</w>
X PF</w>
WI 38</w>
WA Y</w>
W C-
Vis c
V max
V T,</w>
V S</w>
V AD</w>
UC B</w>
U/ ml)</w>
Tricho statin</w>
Top o</w>
Tim m</w>
Tg -
Tem pol</w>
TRPV 1.</w>
TRPC 1</w>
TR X</w>
TP -induced</w>
TGF-b 1,</w>
TB TO</w>
T- type</w>
T rac
T G,</w>
T AT</w>
Sy n</w>
Swit zer
Swe d
Sub -
Streptozotoc in</w>
St yrene</w>
Spec ial</w>
Solub le</w>
Seventy- two</w>
Schist osoma</w>
SU N</w>
ST- T</w>
SREBP -1c</w>
SP- A</w>
SO 2</w>
SM T</w>
SK OV3</w>
SJ W</w>
SE LE
SE ).</w>
SC-5 60</w>
S100 A4</w>
S- mephenytoin</w>
S s</w>
S ham</w>
S catchard</w>
S aline</w>
S PR
S BP,</w>
S B-
Rho /
Retin ol</w>
Rel ated</w>
Re elin</w>
RNA -binding</w>
RI F</w>
RF S</w>
RE- luciferase</w>
R ob
R ech
R 115
Q19 2R</w>
Prednisol one</w>
Pre operative</w>
Prac tic
Paradoxic ally,</w>
PV C</w>
PTGS 2</w>
PT SD</w>
PT M
PP D</w>
PIL O</w>
PH A-
PG P</w>
PE G</w>
PD 0332991</w>
PD 0
PCB -1
PA P
P450 .</w>
P- R</w>
P ure</w>
P R.</w>
P NP
P 38</w>
Orth ostatic</w>
Oc currence</w>
OH ),</w>
O(2) (-)</w>
O k
O ddi</w>
O GG
O AT1</w>
Norm alized</w>
Ni em
Ni SO(4)</w>
Na(+)- K(+)-ATPase</w>
NT CP</w>
NR H</w>
NK CC
NHE K</w>
N-nitros omorph
N-nitros omethyl
N-acetyl- cysteine</w>
N- terminus</w>
N x</w>
N isol
N elfina
N ONO
Mit oxantrone</w>
Mercur ic</w>
Medic ines</w>
Medi ated</w>
MTX -treated</w>
MT s</w>
MT F
MT 1-
MMT V-
ME ,</w>
MD Z</w>
MA MP</w>
M R-
M 5</w>
M -2
Lymph ocyte</w>
Lipo ic</w>
Le ber</w>
LPS- activated</w>
LIMIT ATIONS:</w>
L-argin ine,</w>
L Z
L IV
Kine tics</w>
KI AA
K562/ ADM</w>
K o
K awas
K as
K 18</w>
K 0
K (2)Cr(2)O
In stitutes</w>
In cl
Ill ness</w>
IQ ,</w>
INK 4a</w>
IN P</w>
IN D</w>
IL-1 3,</w>
IC G</w>
I trac
I mat
I NP
I MP</w>
Hyper algesia</w>
Hyp oxic</w>
HuH- 7</w>
Hep a</w>
Heav y</w>
HOX A10</w>
HM F</w>
H 6
GT F2
GS NO</w>
GP X</w>
GE N</w>
G M-induced</w>
G ;</w>
G 2,</w>
Func tionally,</w>
Fruct ose</w>
Fluoro-J ade</w>
Fifty- seven</w>
Fifty- one</w>
Fel b
FK50 6-induced</w>
FGF 9</w>
FAS ,</w>
F- mediated</w>
F ore
F hit</w>
F XR
F TI
F SH
F DH</w>
Europ e.</w>
Ethambut ol</w>
Endos ulfan</w>
Endop lasmic</w>
El ucid
EXTRAC TION:</w>
ET S</w>
EP S.</w>
Di hydroxyvitamin</w>
Degu elin</w>
Dacarb azine</w>
DN ,</w>
DHE A-
DH P</w>
DH E</w>
D MI</w>
D B</w>
D A.</w>
Cys -
Cyclophosph amide-induced</w>
Cy pro
Cx 32</w>
Cu (II
Cs A-
Cr ,</w>
Con sec
Coc E</w>
Clo fibrate</w>
Cit alopram</w>
Chlor promazine</w>
Ch ondro
Ch el
Cell -
Cd A</w>
Cannabin oids</w>
Ca2 +/
Ca esarean</w>
CXCR 3</w>
CRP ,</w>
CR T</w>
CL /
CE M</w>
CDDP ,</w>
CA s</w>
C 3,</w>
Bis phenol-A</w>
Bcl-x l</w>
Bak ,</w>
BP -induced</w>
BEZ 235</w>
BCL- X
B Q-
B MI,</w>
B E,</w>
Astragal us</w>
Assess ing</w>
Aqu ap
Ap gar</w>
Alco h
Ag ing</w>
Ad ap
Ab str
AZ T,</w>
ANA LY
AM s</w>
AM L,</w>
AKR7 A2</w>
AD A</w>
AC I</w>
ABCG 2.</w>
A ur
A ST
A 20</w>
A 1/
< .001).</w>
9- tetrahydrocannabinol</w>
9 40</w>
9 4,</w>
8 5,</w>
72 h</w>
7 8-year-old</w>
7 4)</w>
6 2,</w>
6 1-
58 %,</w>
54 ),</w>
50 8</w>
50 5</w>
5-hydroxytryptam ine
5-HT(1 B)</w>
5-HT T</w>
5-HT 1B</w>
5- nitro
5- AZA-
5'- untranslated</w>
5 A1</w>
46 ),</w>
36 57</w>
35 7</w>
34 .</w>
3. 0-
3- nitrotyrosine</w>
3,3', 4,4',5-
3 36</w>
3 -1.
28 7</w>
27 9</w>
27 6
27 3</w>
26 ;</w>
26 5</w>
24 5
23 9
200 0
20 th</w>
2- null</w>
1B 1.</w>
199 5,</w>
18 :
17 0
13 0/
12- fold</w>
11. 3</w>
10 (6
1. 3,</w>
1-chloro -2,4-
1- related</w>
1- (2-
00 1</w>
0.4 9</w>
0.00 9).</w>
0. 77
0. 70
0. 18
-10 ),</w>
- linked</w>
- 0.8
, t-
+/- 5</w>
+/- 4</w>
* 4</w>
* 10(-
) +
(control s)</w>
(at RA)</w>
(UGT s)</w>
(TNF)- alpha,</w>
(TD I)</w>
(T i
(T 2D
(SAH A)</w>
(PPAR- gamma)</w>
(PL D)</w>
(P RA),</w>
(P LA
(O PI
(Na As
(NS ).</w>
(NR TI
(NO S
(MM R)</w>
(M RP)</w>
(IL-1 b)</w>
(IL )
(I C</w>
(H SF
(H C)</w>
(GSK 3
(G C)</w>
(EG CG),</w>
(E Na
(D ON)</w>
(D C)</w>
(D AP
(CR C).</w>
(CPT -1
(CHO )</w>
(C I</w>
(B[a] P)</w>
(B- CL
(B N)</w>
(B F
(Ara- C)</w>
(Adri amycin
(A g
(A IF)</w>
(A A
(8 8%)</w>
(7 6%)</w>
(6 8%)</w>
(5 6.
(5 3.
(5 )-
(4-chloro phenyl)
(4 6</w>
(3 4%)</w>
(2. 5
(1. 7</w>
(1 H-
(1 75</w>
(-)- epigallocatechin</w>
( ~
( exon</w>
( baseline</w>
( CYP2C9
( 0.05
zol d-
ys mal</w>
xenobiotic- responsive</w>
week s:</w>
war n
war m
w ounds</w>
w k)</w>
w af
volum ic</w>
vitro :</w>
vin yl
victim s</w>
veloc ity,</w>
vasculat ure,</w>
vanil loid
v oric
utiliz ation.</w>
ush ing</w>
urticar ial</w>
unequivoc ally</w>
un its,</w>
u ing</w>
tw ins</w>
tubul in,</w>
troleandom ycin</w>
trazod one.</w>
transplant s.</w>
transplant ,</w>
transloc ates</w>
trans endothelial</w>
trans activates</w>
trabec ted
toxic ogenomic</w>
toc olysis</w>
tobacco- specific</w>
tis m,</w>
tion ary</w>
tinnit us.</w>
time ;</w>
ti tres</w>
ti apride</w>
thrombin ,</w>
thre e-</w>
thous and</w>
thiomal ate</w>
th )</w>
test ;</w>
temperat ure
te a,</w>
t ext
symptomat ology.</w>
sympath o-
surve ys</w>
super oxide,</w>
super -
sup raph
subcut aneously,</w>
sub therapeutic</w>
stress- responsive</w>
streptoz oc
streng th,</w>
str abis
stimul ated,</w>
steroid ,</w>
ster il
stat ure</w>
spor ad
spermat ocytes</w>
spac es</w>
son ography</w>
sol ar</w>
sity- affiliated</w>
single- photon</w>
signal -related</w>
si es.</w>
ses sions,</w>
sensitiz ers.</w>
sens ation.</w>
sec ur
scenari o</w>
sc rap
sc oli
satur ation,</w>
sarcom as.</w>
sarcolem ma</w>
saline- injected</w>
salbutam ol.</w>
sal ine;</w>
s onic</w>
s o.</w>
s aving</w>
rut in,</w>
rut in
run s</w>
rou te,</w>
riz z
rhodop sin</w>
rewar d.</w>
reticul ocytes</w>
restless ness,</w>
responsi vity</w>
respond ing.</w>
respon s
reper to
reno protection</w>
relap sed
regi stered.</w>
record ings,</w>
rec umb
re- uptake</w>
re mic</w>
rat t
rat entorial</w>
radio frequency</w>
rabb it.</w>
q 22.
pull- down</w>
pul se-
pseud ochol
provi ded.</w>
protru sions</w>
proteas ome.</w>
propranol ol-induced</w>
proper ty,</w>
proguan il</w>
produc tion;</w>
pro pol
pro myel
pro carcinogens</w>
pri ori</w>
prepar ative</w>
predn ison
predic tab
precursor s,</w>
precl ude</w>
pre- training</w>
pre optic</w>
post- treatment.</w>
post nat
post injection</w>
pos tictal</w>
popul arity</w>
pock et.</w>
ple uro
platinum- resistant</w>
pimoz ide,</w>
pig mentary</w>
pide m</w>
physici an's</w>
phy g
phthal ein</w>
phot o-
phosphatidylinositol- 3</w>
phorbol-12- myristate-
pharmacokine tic-pharmacodynamic</w>
pharmac ology.</w>
pet role
pertur bs</w>
person nel</w>
perindopril /
pergol ide,</w>
per pet
pentylenetetrazol e-induced</w>
penetr ate</w>
pedi atric
pax illin</w>
patient :</w>
particip ant
par valbum
pac ed</w>
pa inf
p70 (s
p21 CI
p16(INK4 a)</w>
p- glycoprotein</w>
p si
p cDNA
oz ide</w>
oxyl in-
oxid atively</w>
ox ia.</w>
ow ed</w>
otop ically</w>
ot olaryng
ot ,</w>
ostigm ine,</w>
oste omyelitis</w>
orth opa
organ elle</w>
ore activity</w>
opoi et
opioid ergic</w>
opi omelan
omi metics</w>
omi me
omet abolic</w>
omer ul
oil s</w>
officin alis</w>
of- life</w>
od ular</w>
od am
ochemic ally.</w>
ochemic ally,</w>
ocal c
oc upro
oc idal</w>
oc eptive</w>
oc e
obac ter
ob is
ob ia,</w>
nucle o
notic e
nore thi
non- apoptotic</w>
non exposed</w>
non atopic</w>
nodul e</w>
nival en
nit raz
nit rate.</w>
neuro vascular</w>
neuro development</w>
neph ros
necro psy
necro lysis</w>
naphthal en
nan ot
n-hex ane</w>
n is
my ostatin</w>
monke y,</w>
mon omethyl</w>
molecul arly</w>
mol ind
moiet y.</w>
mix ing</w>
minocycl ine,</w>
millim olar</w>
microg/ L)</w>
micro n</w>
methyldop a.</w>
methyl )-
methoxyl ated</w>
mes enter
ment )</w>
measure ment,</w>
mas ked,</w>
man -
macro cytic</w>
m us.</w>
m s;</w>
m .)</w>
m )
lymph oma-
lum en.</w>
lucifer ase-
luc i
long itud
log arith
lipoprotein- cholesterol</w>
lip ocal
line ages.</w>
lind ane.</w>
lin ker</w>
levodop a/
leak age,</w>
le ural</w>
label ing.</w>
lab yrin
l ag
knock down,</w>
kg/ day</w>
kary otyp
kappa B-
junc tions.</w>
izol astine</w>
ity- related</w>
it ting</w>
it e-
isoproteren ol-
isoprost anes</w>
isol ated.</w>
iso electric</w>
iome prol</w>
intran igral</w>
interest ed</w>
instruc ted</w>
inhibitor s)</w>
inhal ation,</w>
ingu inal</w>
inf using</w>
ine- ,</w>
indic ations,</w>
ind ole-
incap able</w>
inadver tently</w>
in put
im balances</w>
if ene</w>
id in,</w>
ic ide</w>
ib er
i.c.v .),</w>
i. t.)</w>
i NOS-
hypoton ia,</w>
hypogonadis m</w>
hypoglyc emia,</w>
hypo -
hyperten sion;</w>
hyperinsul inemia,</w>
hyper activation</w>
hydrolas e,</w>
hy br
hous ed</w>
hormone- independent</w>
hi m</w>
hex yl</w>
hepato protection</w>
hepati tis].</w>
hepat o-
hematoc rit,</w>
helix- loop-
heal ing,</w>
ham art
h ML
h CG
growth -related</w>
graf ting.</w>
go od,</w>
glutathion -S-
glucose-6- phosphatase</w>
glicl azide</w>
gli omas,</w>
gene- specific</w>
gefit inib,</w>
ge ographic</w>
gastro intestinal,</w>
gas es,</w>
gancic lo
gamma-glutamyl transpeptidase</w>
gamma- hydroxy
gall- bladder</w>
g/ day)</w>
frequenc y-
fotem ustine</w>
for ,</w>
follow up</w>
fluoro genic</w>
fl acc
fist ul
fir stly</w>
fil ter
fil m</w>
ff in</w>
fen bu
feel ings</w>
fat -
fascicul ations.</w>
f osine</w>
f in</w>
extrac ranial</w>
ex qu
evalu ations.</w>
euphor ia</w>
eu glycemic</w>
etomid ate,</w>
et 's</w>
estr one-
erythromycin ,</w>
er ;</w>
er -term</w>
equilibr ative</w>
equ ip
equ ilibri
epithelial- to-mesenchymal</w>
ephedr ine.</w>
entric ul
enter ic-coated</w>
energ ies</w>
end ocytosis,</w>
en velop
en ig
en ate</w>
en am
en )</w>
else where</w>
electromy ogram</w>
e up
dysrhyth mic</w>
dysfunction :</w>
dys phagia</w>
dro p-
dri p</w>
double-dumm y,</w>
dos e
disturb s</w>
dispar ate</w>
disori entation</w>
discrepanc ies</w>
dis similar</w>
dis k</w>
diox ide,</w>
dihydro pyridine-
didan os
dichlorodiphenyl trichloroethane</w>
devic es</w>
determin ation.</w>
desorption/ ionization</w>
desipr amine.</w>
des cent.</w>
degranul ation.</w>
deci ph
dec ong
death -inducing</w>
de phosphorylated</w>
de differentiation</w>
d 4
cystathion ine</w>
cyclo dextrin</w>
cur ves.</w>
cryop reserved</w>
cro makalim</w>
cres yl</w>
copper- deficient</w>
consum ers</w>
consul tation</w>
constell ation</w>
confu sion.</w>
concer ted</w>
conc eption</w>
con sume</w>
community- based</w>
code ine,</w>
co il</w>
clos ing</w>
clon azepam,</w>
clobaz am</w>
clinic i
clinic al
cli ent</w>
cleav es</w>
cl ock
chore iform</w>
chol era</w>
cho osing</w>
cho ose</w>
chloro phenyl
chloro -4-
chemoradi otherapy</w>
chemok ine,</w>
chemo protective</w>
ch all
cerul e
cer amid
cefazol in</w>
ce famand
carnit ine.</w>
cardiolip in</w>
carcinogen ic,</w>
carcin ogene
carb en
car v
cG MP
cAMP -induced</w>
c row
c PLA
buspir one,</w>
bur g</w>
brom o</w>
break points</w>
bp )</w>
bleed s</w>
bl ue-
biot in-
beta- agonist</w>
benzodiazep ine,</w>
benzo[a]pyren e-
be have</w>
be ad
b- oxidation</w>
b are</w>
autosomal- dominant</w>
autonom ous</w>
attac k
ation -</w>
ati ves,</w>
assa y),</w>
as tig
arthri tis
ardi zed</w>
ar ity,</w>
ar ic
ar ap
ap aro
antinocicep tion,</w>
antimon i
antihist amin
anticholinerg ics</w>
anti- obesity</w>
anti- amnesic</w>
anti fibrinolytic</w>
anti dopaminergic</w>
anth el
ann- Pick</w>
animals '</w>
analy sis).</w>
aminept ine</w>
am i
alumin um-induced</w>
alpha-tocopher ol,</w>
allel e)</w>
alfentan il.</w>
alert ness</w>
alcohol ics</w>
al -</w>
agonist/ antagonist</w>
aff ir
advanc ing</w>
adheren s</w>
adap t</w>
acetazol amide,</w>
acet aldehyde-induced</w>
ac cord</w>
above ,</w>
abnormal ity,</w>
abnormal iti
able ;</w>
a/ b</w>
a- related</w>
[a, l]
[3H] TCDD</w>
[35S] TBPS</w>
[3 H]</w>
[ Myocardial</w>
[ Efficacy</w>
[ Cr(VI
[ 5-
Z EA</w>
Z )-
Y a
Vir al</w>
Ven o-occlusive</w>
Val idation</w>
V orinostat</w>
V 4
UGT2B 17</w>
U terine</w>
U P</w>
U M</w>
Trichloro ethylene</w>
Th 1-
TT P-
TRI AL</w>
TP R</w>
TO CP</w>
TNF a-induced</w>
TNF SF
TMP y
TGR 5</w>
TC F</w>
T esticular</w>
T U</w>
T DP</w>
T Ap
Syn cope</w>
Spont aneously</w>
Smad 7</w>
STAT 3-
SP ),</w>
SDS-PA GE</w>
SCN 5A</w>
S t</w>
S pi
S p</w>
S and
S SE
S D.</w>
Rep lac
Red ox</w>
RT ,</w>
RI ),</w>
RE GI
REGI STR
RE .</w>
RB 2</w>
R TI
R HO
R BP</w>
Queti apine</w>
Qu inine</w>
Pregn ancy</w>
Pic eatannol</w>
Parkinson ism.</w>
PSC A</w>
PO ).</w>
PMA .</w>
PKC epsilon</w>
PERSPECTIVE :</w>
PE PT1</w>
PE F</w>
PD980 59.</w>
PD X-1</w>
PC -3,</w>
P X</w>
P RA,</w>
P :
Oxy gen</w>
Op en</w>
Ondan setron</w>
Ob ese</w>
O v
O E</w>
O 2*
O 2),</w>
Niem ann-Pick</w>
Ni aspan</w>
New ly</w>
Neuro lep
NO /
NIH 3T3</w>
N g
N DMA
N Co
Mont elu
Ml h
Me flo
Me SO(2)-
Macroph age</w>
MPP +
ML- 7</w>
MI TF</w>
MG 13
ME .</w>
MCP -1.</w>
MATERIAL S:</w>
MAPK s.</w>
M6 G</w>
M s,</w>
M endelian</w>
M 3G</w>
M 1)</w>
Lute olin</w>
Lev am
LM WH</w>
L u</w>
L H
L -</w>
Kerat in
K ing's</w>
K A-induced</w>
K 1.</w>
JAK 2
J AR</w>
Inter ference</w>
Inf ec
IP -10</w>
IF ),</w>
IET D-
Hydro cortisone</w>
Health y</w>
Hcy -induced</w>
HbA1 c</w>
HT ).</w>
HSC R</w>
HP V-
HIPK 2</w>
HIF -1.</w>
HA E</w>
H b,</w>
H PM
H N</w>
H B</w>
Glycyrrhiz a</w>
Gl omerul
Gen e-
Gam ma-
GS ,</w>
GP x,</w>
GN MT</w>
GN .</w>
GGC X</w>
GAT A4</w>
G d</w>
G H-
Fifty- three</w>
FK50 6-
FG D1</w>
FEV (1)</w>
F n</w>
F U)</w>
F HF</w>
F AK
F ;</w>
Embry os</w>
El k
ED T
EC s).</w>
E-cadher in,</w>
Dis order</w>
Dig it
Di uretic</w>
Delta Psi
DSB s</w>
DP I</w>
DE N-induced</w>
DE B-induced</w>
DC C</w>
DC .</w>
DBA/2 J</w>
D- mediated</w>
D- dimer</w>
Cortico steroids</w>
Contin ued</w>
Consec utive</w>
Compar able</w>
CoCl (2)-induced</w>
Co (2+)</w>
Chemopreven tive</w>
Ch urg-Strauss</w>
Ca SR</w>
CYP3A5 *3</w>
CV -1</w>
CS B</w>
CRE B-
CO S</w>
CL ,</w>
CDK 2,</w>
CD -
CCL 2,</w>
CB R3</w>
CB F
CA R/
C PA,</w>
C ER</w>
BRCA 1,</w>
BR R</w>
BD NF
BA X,</w>
B osentan</w>
B O</w>
B LM
B D,</w>
B CAR
B 16
Azathi opr
Auth ors</w>
Aut osomal</w>
Atg 5</w>
Ari pip
Arg 389
Ap ocyn
Ap o</w>
Angi ogenesis</w>
Andro graph
An tiviral</w>
Amin o-
Allel e</w>
Adju sted</w>
Ad .
Actin omycin</w>
AZ T-
AT M,</w>
AT 1-receptor</w>
AS P
AQP 4</w>
AL C</w>
AG R2</w>
AD P-ribos
AC D</w>
ABCC 11</w>
A- II</w>
A udi
A b-
A HCC</w>
< 10</w>
90 9</w>
9 8)</w>
9 2,</w>
8- bromo-
8 7,</w>
8 1,</w>
75- 1</w>
70 /
7- hydroxy
7 1)</w>
60 ),</w>
6 %.</w>
59 4</w>
57 ;</w>
55 2
54 ;</w>
5- 7</w>
5 beta-
5 48</w>
48 ),</w>
46 ;</w>
40 5</w>
4. 5
4 O
4 N</w>
4 1),</w>
3T C</w>
39 ;</w>
39 9</w>
38 8</w>
37 /
35 %.</w>
33 9</w>
3- sulfate</w>
3 x
3 p</w>
3 26</w>
3 (+)</w>
2D G</w>
2A 6,</w>
24 9</w>
23 ;</w>
23 8</w>
20 15.</w>
2. 4-fold</w>
2. 3,</w>
2- OH-
2+ .</w>
2 6-year-old</w>
2 -1.
19 0
18. 0</w>
18 5
14- fold</w>
14 5
13. 9</w>
13. 6</w>
13. 4</w>
12 -</w>
100 %.</w>
1. 8%</w>
1. 6-fold</w>
1. 23</w>
1. 1%</w>
1,3- butanediol</w>
1 b1</w>
1 +/-0.
0.4 %,</w>
0.00 3</w>
0. 8-
0. 72</w>
0. 5)</w>
0 9013
0 %;</w>
-2 .0
-1 beta</w>
- 9.</w>
- 6,</w>
- 0.5
, 9
+/- 3</w>
* 3
* *
)- exposed</w>
(Zn )</w>
(V OD)</w>
(U -
(S J
(RA R)</w>
(PT Z)</w>
(PARP ).</w>
(P= 0.000
(P R),</w>
(P PI)</w>
(P HT)</w>
(O S
(O R),</w>
(NT E)</w>
(NA G
(N Y
(MAL DI-
(IL-1 beta),</w>
(HI T)</w>
(HD L-C)</w>
(HA AR
(G AP
(F XR)</w>
(E S)</w>
(E RE
(DF S)</w>
(D XR)</w>
(D M)</w>
(D IL
(B A)</w>
(AL K)</w>
(AE s)</w>
(AC TH
(A A),</w>
(7 6.
(6 3%)</w>
(6 )
(4. 0</w>
(4 8%)</w>
(4 1.
(2. 3</w>
(2- pyrid
(0.0 1,</w>
( via</w>
( study</w>
( standard</w>
( phen
( p53-
( ox
( incidence</w>
( determined</w>
( body</w>
( area</w>
( C</w>
( %</w>
" in</w>
zold- J
you ths</w>
ym y
ylmethyl )
y 2</w>
y '</w>
wor t</w>
wor ker</w>
with /
with/ without</w>
well- controlled</w>
week ly)</w>
wa ve
w ished</w>
vesi cle
ven o
vecuroni um.</w>
ve mur
vasopress in.</w>
vari ably</w>
ure ter
unc ular</w>
un treated.</w>
un intentional</w>
un explored.</w>
un determined</w>
umbell ifer
ultr arap
ultrarap id</w>
ulf ite</w>
ul ob
ulob uter
ul es.</w>
ucle oti
u ated</w>
typ ing</w>
twenty- four</w>
tumor- specific</w>
trihydroxystilbene )</w>
trihydroxy- trans-
tremul ous</w>
trans migration</w>
topir amate.</w>
tolbut amide,</w>
ticlopid ine-induced</w>
thyro idi
thi oure
therap y-related</w>
ther mia</w>
theore tically</w>
thalam us.</w>
tetr as
ter bu
ten ing</w>
te eth
tamp on
tampon ade</w>
tak en,</w>
t(15; 17)</w>
t ase</w>
syst ol
symptom s;</w>
switch es</w>
swell ing.</w>
swe et
susceptibil ities</w>
sur prisingly,</w>
suppress or,</w>
suc kling</w>
sub scales</w>
strom el
strat a</w>
stimul ations</w>
statis tics</w>
stand er</w>
stabiliz er</w>
st roph
st )</w>
spont aneously.</w>
spong e</w>
spondyli tis</w>
spectr um,</w>
spar floxacin</w>
sp ines</w>
sp ice</w>
sm el
sligh tly,</w>
sk ills</w>
simvastat in-induced</w>
sildenaf il,</w>
short- lasting</w>
shor t,</w>
ser oneg
seleg il
second- degree</w>
sa id</w>
s n-
s als
rus k
rs 46
row th</w>
rofecoxi b.</w>
ritona vir,</w>
ric ket
rib osome</w>
rex ol</w>
review ing</w>
rever sal
respon sive,</w>
resorp tive</w>
residu e,</w>
resequ encing</w>
require ments,</w>
remo ved,</w>
remed y</w>
relax ed</w>
regres sions</w>
reflex es.</w>
refin ed</w>
ref ly</w>
recogn izes</w>
receptor :</w>
recapit ulate</w>
read- through</w>
re alistic</w>
ras ag
r ine,</w>
quin ine-induced</w>
questionnai re,</w>
quercet in-treated</w>
pyrimid in
pyrid ine,</w>
pyl or
put resc
put atively</w>
pum p,</w>
pub ert
propafen one.</w>
prolifer ator
progester one-induced</w>
prochlor az</w>
pro fibrogenic</w>
pro anthocyan
prior iti
pressure )</w>
pren yl
preferen ce,</w>
pon der
pon atinib</w>
poly uric</w>
poly radicul
poly neuropathy,</w>
poly carbonate</w>
pneum ocytes</w>
pmol )</w>
pl ane</w>
phyri a</w>
phosphor amide</w>
phosphoinositi de-
phosphat e-induced</w>
phenacet in,</w>
phen ol.</w>
pericardi tis,</w>
perfec t</w>
per s</w>
pentamid ine.</w>
pen is</w>
peg -
patient s);</w>
pathwa y
paradig m,</w>
paracetam ol,</w>
pantoth enic</w>
pal i
painf ul
pacemak er.</w>
p< 0.05),</w>
p< 0.001)</w>
p70(s 6
p47 phox</w>
p21(WAF 1)</w>
p. Gly
p urely</w>
p ing,</w>
p end
oxybutyn in</w>
oxide )</w>
over .</w>
out- patient</w>
ot ere</w>
ositi de</w>
osarcom a,</w>
organ -specific</w>
ore .</w>
ont ology</w>
one- way</w>
omet rexol</w>
om is
ologist .</w>
ole oyl
oil )</w>
oid .</w>
of :</w>
odi lation</w>
oce phal
obstruc ted</w>
o. d.</w>
o encephalopathy</w>
o dex</w>
non- exposed</w>
non sedating</w>
non peptide</w>
non functional</w>
nitr ated</w>
nephros cler
nephrectom y.</w>
neon ates,</w>
neocor tex
narin genin,</w>
mus h
multic entric</w>
multi organ</w>
mul tis
muc inous</w>
move ment,</w>
more over</w>
mono-OH- M</w>
mon otonic</w>
mol )</w>
modul ations</w>
modific ations,</w>
moder ate.</w>
model s:</w>
mode ,</w>
mobil ization,</w>
mini pumps</w>
mig rating</w>
microsph ere</w>
microgram/ kg/
mi x</w>
mg/d L).</w>
mg/d L),</w>
mg/K g</w>
mg (-1)</w>
metronid azole.</w>
methyl malonic</w>
methyl ,</w>
method ological</w>
methadone- maintained</w>
metabol omics</w>
mechanism s:</w>
mark ed,</w>
man ia,</w>
mal e.</w>
macrophage- like</w>
macaqu e</w>
ma protil
m ock
m as</w>
lymph omas,</w>
lor n
long a</w>
local isation</w>
lin es;</w>
ligand )</w>
lif el
lifel ong</w>
levo floxacin,</w>
levamisol e.</w>
leuk ocyt
len alidom
leflunom ide</w>
lam ell
lact ulose</w>
labor ,</w>
l us
kine sias</w>
kind red</w>
kin et
kill s</w>
k cal
k ast.</w>
ith iasis.</w>
isozym es.</w>
isot op
iso enzymes.</w>
ir regular
iodi c</w>
inwar dly</w>
intracellul arly</w>
intoxic ations</w>
intervals )</w>
integ rating</w>
insectic ides.</w>
injur y-induced</w>
injec ted.</w>
ing er</w>
infl ation</w>
inf inity</w>
indic ated,</w>
ind ole-3-carbinol</w>
includ ing:</w>
inapar sin</w>
inadequ ately</w>
in- 5-
in z
imp eded</w>
immunore activities</w>
immunoglobul ins</w>
immun otoxicity</w>
il ast</w>
ic hloro
i o</w>
i ).</w>
hypot onia</w>
http://dx.doi.org/10. 12
http://dx.doi.org/10.12 89/
hour )</w>
hospit als.</w>
hom ocy
heterogene ity.</w>
her bim
hemodynam ic,</w>
hemis pheric</w>
heav y-
health -
he at,</w>
harb ouring</w>
haplotyp es,</w>
hand ic
haloperid ol-
haemo globin
h i</w>
gro un
griseoful v
gradu ally.</w>
glycyrrhiz in</w>
glycer ol-induced</w>
glyc an</w>
glybur ide</w>
globul in.</w>
gh t,</w>
gh rel
genom e,</w>
gen us</w>
gefit inib.</w>
g allo
g al</w>
g aining</w>
g -1</w>
frequenc ies,</w>
forskol in-stimulated</w>
follic les,</w>
flut amide.</w>
flut amide,</w>
flash back
fit ted</w>
fibrill atory</w>
fibr il
fe ver
fe et,</w>
f op
f MLP
exposure )</w>
exha ust
exclu ded,</w>
excit ability,</w>
exchang e,</w>
ex act
ethinylo estradiol</w>
estrogen -mediated</w>
est s</w>
es ti
es es</w>
es .
erythematos us,</w>
eradic ate</w>
er yp
entr ance</w>
enrol le
enanth ate</w>
enalapril at</w>
empir ic</w>
emphasi zing</w>
embol ization</w>
el ess</w>
egr -1</w>
educ ational</w>
ecto der
ear man</w>
e dic</w>
dysarthri a</w>
dynam ically</w>
dy ne
duc ts,</w>
dro mic</w>
drin kers</w>
down ward</w>
dop amine-induced</w>
donovan i</w>
dom oic</w>
direc tly,</w>
diox o
dihydro-5 H-
diazep am-
diabet ogenic</w>
detox ification,</w>
desor ption</w>
degrad es</w>
dec hloro
dec apit
deb ated.</w>
de stabilizing</w>
day (-1),</w>
d ine-induced</w>
d ac
cytokine /
cys LT
cy p
cut- off</w>
cur ve,</w>
cross- resistant</w>
criter ia)</w>
cor nea</w>
copper/ zinc</w>
copies/ ml</w>
cooper ates</w>
contra indication</w>
continuous- infusion</w>
consul ted</w>
constric tive</w>
conduc ted,</w>
comorbidi ties</w>
col i.</w>
cogni tion,</w>
codon .</w>
cod one</w>
co- localization</w>
clon us</w>
cl ometasone</w>
cisap ride,</w>
chromosom e-
chromi um-
chromat in.</w>
chemosensi tivity.</w>
chemic ally-induced</w>
challeng es.</w>
chal con
ch l
catheps in-
categ ori
casp ase
caroten oids</w>
carbox yl-
cann ulated</w>
call osum</w>
calcitri ol,</w>
calcit on
cadaver ic</w>
but anedi
bronchodi l
bronchoconstric tion</w>
bromocript ine-induced</w>
breas t
bosentan ,</w>
biom edical</w>
bio assays.</w>
bio assay,</w>
bilirub in.</w>
beta2- AR</w>
beta1- adrenoceptor</w>
beta- cells.</w>
be st-
basel ine),</w>
axon opathy</w>
awa iting</w>
aver sion</w>
ati vity</w>
ati tis,</w>
associ ated,</w>
assa yed.</w>
aspect s.</w>
ase- deficient</w>
as e-induced</w>
arub icin,</w>
arrhythmi as
aris ch</w>
arg atrob
arb ox
arabino side.</w>
ar ylation</w>
ar i</w>
ap ril
anticoagul ation,</w>
anti- ulcer</w>
anti- atherosclerotic</w>
anti secretory</w>
anthrac ene,</w>
antagonist s:</w>
ann u
angli onic</w>
aneurys m.</w>
ane ph
ancestr al</w>
an- American</w>
an z
an swe
amoun ted</w>
amin idase</w>
am ple</w>
am ates</w>
am alg
amalg am</w>
alum inium</w>
altern ans</w>
alprostadi l</w>
alpha1- adrenergic</w>
alpha- bungarotoxin</w>
alpha 7-
alpha 2-adrenoceptor</w>
allerg ies</w>
alfa- 2b</w>
alcohol -dependent</w>
al t
akathi sia.</w>
air s</w>
agranul ocytosis.</w>
aff initi
adv ise</w>
adultho od,</w>
adreno receptors</w>
adolesc ence</w>
adequ acy</w>
adduc tor</w>
adduc t.</w>
actu arial</w>
act in-
acetylchol ine-induced</w>
accur ac
acarb ose</w>
ab l</w>
a ic
a 7</w>
[OR ],</w>
[(1 25)
[ T
[ 3.
ZD18 39</w>
Z inc
Z /
Y et</w>
Y Y1</w>
Y N</w>
Y ),</w>
X X
WK Y,</w>
Val )</w>
VEGFR -2</w>
VD R-
V F
Uni vers
Un expected</w>
UT R)</w>
UC P-3</w>
U/ g</w>
U L-
U 25
U 13
Toc opher
Thromb osis</w>
Th 1/
Ter fenadine</w>
Tca8 113</w>
Tac rolim
TMP RS
TL E</w>
TI MI</w>
TCDD -dependent</w>
T- cells.</w>
T ris
T et</w>
Sup ple
Sulforaph ane</w>
Strateg ies</w>
Som atic</w>
SULT 2A
SP s</w>
SLC22 A
SL E.</w>
SK F
SF RP
SELEC TION:</w>
SE MA
S pl
S pas
S lu
S ho
S he
S NO
S 9
Relev ant</w>
Regi str
Rech allenge</w>
RO C</w>
RNA i
RLIP 76</w>
RE SV</w>
R estr
Q C</w>
Pt d
Psy chi
Prostagland ins</w>
Prophyl axis</w>
Poly (ADP-ribose)</w>
Pilocar pine-induced</w>
Perspec t</w>
PUF As</w>
PTP 1B</w>
PON 3</w>
PLC/PRF/ 5</w>
PL A</w>
PGC-1 alpha</w>
PG D(2)</w>
PD I</w>
PC -induced</w>
PB .</w>
PAR -1</w>
P< 0.00
P450c 17</w>
P450 s.</w>
P r</w>
P c</w>
P anic</w>
P RA
P H.</w>
Organo phosphate</w>
Oct 4</w>
O TC</w>
O SA</w>
O OH</w>
O LT.</w>
Na+, K+-ATPase</w>
Na pro
NR1 I
NQO 1.</w>
NK- 92
NI H-
NGF I-
NFkappa B.</w>
NCT D</w>
NAT 2,</w>
NAD (+)-dependent</w>
NA PQ
NA IP</w>
N CO
N CAM</w>
N 2a</w>
Myel osuppression</w>
Myco phenolate</w>
Mod el
Meth y
Meth ionine</w>
Metabol ites</w>
Mes oth
Mel it
Medic ine</w>
MV D</w>
MD ),</w>
MB s</w>
M ethylene</w>
M I)</w>
M GST
M 2-
Low ering</w>
Lansop razole</w>
LT A</w>
LS D1</w>
LP ).</w>
LO D</w>
LAQ 8
L- treated</w>
L- asparag
L um
L ab
L VD
L O)</w>
L MP1</w>
Ke y</w>
K ras</w>
K it
K F
K (+)
JAK 3</w>
J u
J e
J (2)</w>
Intr insic</w>
IkappaB alpha,</w>
Ik B-
Icel an
IR -induced</w>
IP 2</w>
IND O</w>
IN 1</w>
IL- 6/
IL 1B</w>
III c</w>
II B</w>
IGF 1</w>
IFN- beta</w>
I so</w>
I owa</w>
I MT</w>
Hs p</w>
Hom ocysteine</w>
Hep G2/
HeL a,</w>
He modialysis</w>
HP V
HOX D
HL- 60,</w>
HC l,</w>
H MB
H CA-
H A-
H 10
Guillain- Barr</w>
Glyc er
Gli 1</w>
Gcl m
GTPgamma S</w>
GER D</w>
GABA- A</w>
G PI
G H3</w>
G CD
G AA</w>
G 55
G 12
Flu v
Fibro sis</w>
Fem ales</w>
Fancon i's</w>
FTY 720</w>
FGF R</w>
FGF R2</w>
FB X
F h
F AP</w>
F ALS</w>
Es ophag
Erythro cyte</w>
Epis odes</w>
Epir ubicin</w>
En zyme
En gland</w>
Emer gence</w>
EV I1</w>
ERK/ MAPK</w>
ER +/
EC H-associated</w>
EB V-
E specially</w>
E U
E AR</w>
Dyst onia</w>
Dys kinesia</w>
Dos age</w>
Di az
Defec ts</w>
De fic
DE ),</w>
DAP M</w>
D- like</w>
D n
D S.</w>
D MC</w>
D IS
D ;</w>
Con currently,</w>
Col orectal</w>
Cohor t</w>
Clu ster</w>
Clar ithromycin</w>
Cl onid
Cir rho
Chines e.</w>
Cardi oprotective</w>
Ca(2+ ),</w>
Ca ve
Ca M-
CYP7 A1</w>
CYP 17,</w>
CYP -
CTR 1,</w>
CP B</w>
CL PTM
CD4 4,</w>
CD4 +
CA L
C- terminus</w>
C ultures</w>
C J
Burkit t's</w>
Bu ChE</w>
Br O
Bio inform
BD 10
BCh E.</w>
B CC</w>
B (12)</w>
Az A</w>
At tem
Assa y</w>
As berg</w>
As V</w>
Ar f
Aqu eous</w>
Ap nea</w>
Anaesthe sia</w>
Amil oride</w>
Am ne
Adrenocept or</w>
Acr yl
Abeta 42</w>
Ab s</w>
AZ T.</w>
ATRA -treated</w>
ATP13 A2</w>
AT M/
AS D.</w>
AP 2</w>
ANI MAL
AI MS/
AC E,</w>
AB R</w>
AA M</w>
A1298 C</w>
A/ D</w>
A pi
A jmal
A GT
A EC
A 1*
= 1</w>
< /=
9 3,</w>
8 %.</w>
7 9,</w>
7 2-h</w>
6-hydroxy dopamine-
6-OHDA- lesioned</w>
6- methyl
6 8)</w>
6 6-
59 ).</w>
59 ),</w>
54 .</w>
5-hydroxy tryptophan</w>
5-az acytid
5- 8</w>
5,7- dihydroxy
5 b</w>
5 60</w>
5 20</w>
48 %,</w>
47 .</w>
4 4).</w>
4 );</w>
38 %,</w>
36 ;</w>
36 2</w>
30 min</w>
3. 5,</w>
3. 3,</w>
3, 6-
3, 3'-di
3 beta-HSD</w>
3 22</w>
29 4</w>
29 /
29 %,</w>
28 B</w>
25 %)</w>
24 9
22 Rv
20- HETE</w>
2- acetylaminofluorene</w>
2- PAM</w>
2- OHE
2 B)</w>
2 50-
2 1.1</w>
2 +-
199 3,</w>
19. 2</w>
19 2
17beta- estradiol.</w>
15- 30</w>
13. 1</w>
12 9/
100 ,00
10(-7 )).</w>
10(-6 )
1.0 3</w>
1. 26</w>
1. 11</w>
1-amino -2,4-dibromo
1- day</w>
1'- hydroxylation</w>
0.7 %,</w>
0.6 7</w>
0.5 ).</w>
0.00 7)</w>
0.0 16).</w>
0.0 13).</w>
/ SM
/ D
.00 5).</w>
-2- one</w>
-2- hydroxy
-1 5.
-1 200</w>
-1 (-/-)</w>
- 4,</w>
- 0.9
(v )</w>
(qRT-PC R)</w>
(p ,p'-
(miRNA )</w>
(mean :</w>
(chi 2</w>
(VSMC )</w>
(U V)</w>
(U PD
(TM Z)</w>
(T D)</w>
(T C),</w>
(SSR I)</w>
(S n
(S ,
(RT )-
(Pgp )</w>
(PTE N)</w>
(M T-
(M S
(M N)</w>
(L- N
(JNK ).</w>
(I L)</w>
(HCC ),</w>
(H SD
(H -
(H )</w>
(Gn R
(GSS G)</w>
(GSH ).</w>
(GF AP)</w>
(G A)</w>
(F ig
(F AC
(E O
(E 2).</w>
(DOX )-induced</w>
(DE S),</w>
(DD T)</w>
(D MP
(COP D)</w>
(CHF ),</w>
(CB Z),</w>
(C on
(B HT)</w>
(B D)</w>
(An g)</w>
(AZ A)</w>
(AT M)</w>
(AS 3
(AR B)</w>
(ALDH 2)</w>
(A VP)</w>
(99 m)
(8-OHd G)</w>
(8- OH-
(6 5%)</w>
(6 ),</w>
(5. 5</w>
(5- hydroxy
(5 4.
(4 4</w>
(3. 2</w>
(3- phenyl
(3 9</w>
(3 9.
(2 7
(2 40</w>
(10 (-1
(1 3-
(1 0.0</w>
(0.0 3-
( y
( pro
( nuclear</w>
( diastolic</w>
( cell</w>
( age,</w>
( M</w>
zon ula</w>
zomepir ac</w>
zold-J arisch</w>
zileut on,</w>
z op
ylchol ine-induced</w>
yl -2-
ye ast.</w>
yc no
ximel agatran</w>
work up</w>
women ),</w>
well- being</w>
weight/ day)</w>
war ds,</w>
wa ys.</w>
vis ually</w>
vir -
vesi cles,</w>
vasopress in,</w>
vaso depressor</w>
vari ation,</w>
van ill
valdec oxib</w>
val ve.</w>
v orinostat
urticar ia,</w>
uro epithelial</w>
ure teric</w>
un dul
um i
ul op
ud y</w>
ubiquitin ation,</w>
u tility.</w>
twic e,</w>
tumour .</w>
tubercul in</w>
tript ol
trimethoprim /
tributyl tin</w>
tre c
trast -induced</w>
transl uminal</w>
transfer ase)</w>
transcript .</w>
traffic king,</w>
toxico kinetics</w>
to uc
time )</w>
ticlopid ine,</w>
throm el
thio )
tetraethyl ammonium</w>
territ ory</w>
teratogen icity.</w>
temperat ure-
t ation.</w>
t apping</w>
system :</w>
syncyti otrophoblast</w>
synapt osomal</w>
symptom -free</w>
sulfon yl</w>
sulfasalaz ine.</w>
sulfasalaz ine,</w>
subcut aneously.</w>
stret ch
stres s/
strateg ies,</w>
stoichi ometry</w>
stiff ness,</w>
steroid ogenesis,</w>
spinal- epidural</w>
sphing os
sper mid
spac e,</w>
sotal ol-induced</w>
solu tion)</w>
sk ull</w>
situ .</w>
sin onasal</w>
signal ing
sigma 1</w>
sid ase,</w>
si ze
shun ting</w>
shor ten</w>
shoga ol</w>
she ep
sha k
sesqu iterpen
scre en.</w>
scintigraph y.</w>
scaffol ding</w>
sarcom eric</w>
sam e.</w>
salbutam ol,</w>
sPLA (2)-
s 1</w>
rs 49
rox ithromycin</w>
rol ling</w>
ro mi
risk- benefit</w>
ribo flav
ri de
response -
respir ation.</w>
ren in,</w>
relev ant.</w>
record ing.</w>
receptor- specific</w>
rec eptive</w>
reason s.</w>
realg ar</w>
re modell
re constructed</w>
rat e:</w>
radi ot
racem ate</w>
r ph
r arity</w>
ques tion.</w>
qu ick</w>
q .
public ly</w>
pu ff
pter yg
psych opath
prolifer ation/
profil ing,</w>
prof ylline</w>
prescri be</w>
pres pec
pre adipocytes.</w>
pra z</w>
pr t</w>
positiv e)</w>
posi tions.</w>
posi de</w>
po stres
pleur is
placebo ),</w>
pl ot
pindol ol,</w>
pigmentos a.</w>
pig .</w>
pict ure.</w>
phospho- Akt</w>
phleb itis.</w>
phil ia</w>
phenoxy acetic</w>
phenomen a,</w>
phenel z
pg/ mg</w>
peri aqueductal</w>
per oral</w>
per if
penetr ating</w>
pedigre es</w>
patient )</w>
pathophysi ology,</w>
pathogen s.</w>
pare sis,</w>
parameter .</w>
paradig ms.</w>
par tum
pamid ron
p21WAF1/CI P1</w>
p21(WAF1/CI P1)</w>
p- benzoquinone</w>
p 15</w>
oxaz a
oxaza phosphor
ox am
over sho
over came</w>
ous )</w>
osteoclas togenesis</w>
osteoblast s,</w>
oscill ation</w>
os yst
os -induced</w>
ortholog s</w>
orrh ag
organ ogenesis</w>
organ .</w>
ophthalm oplegia</w>
oph y
op ed
onych omycosis</w>
on ;</w>
omega- nitro-L-arginine</w>
ome dial</w>
ole ate</w>
ol onic</w>
ol den</w>
oc tr
oc ellul
obenz yl
o 's</w>
node- positive</w>
nitrofurant oin.</w>
nitro -L-
nit rate,</w>
nil otinib</w>
night ma
nigh tly</w>
neurolep tic,</w>
neuro toxic
neoplas m.</w>
ne ver-
nam bul
n m,</w>
n iflumic</w>
myelodys plasia</w>
multi modal</w>
multi disciplinary</w>
muc onic</w>
motone urons</w>
montelu kast,</w>
mon ogenic</w>
molyb den
mol/ L),</w>
mit ogenesis</w>
min (-1).</w>
migr ation/
micrograms/ mL</w>
microarra ys,</w>
micro g.
micro M/
miR- 30
mg/kg/ h</w>
methad one-induced</w>
mes h
men orrhag
mel oxic
me ter.</w>
me sial</w>
me 3</w>
maz indol</w>
materi als.</w>
materi al,</w>
marked ly,</w>
mang an
mal absorption</w>
macrom olecular</w>
ma de,</w>
mTOR .</w>
m antle</w>
lys ed</w>
lymphaden opathy</w>
lute ol
low- protein</w>
lipopolysacchari de,</w>
lipo proteins,</w>
lipo genesis.</w>
like )</w>
libr aries</w>
leukopen ia.</w>
leukemia /
leiomy osarcoma</w>
leg s,</w>
leg .</w>
lef tward</w>
le ach
lad dering</w>
lac un
labour .</w>
l n
kg(-1 )),</w>
kappa B
k ip
k et</w>
j et</w>
itro thi
itone al</w>
is omeric</w>
is m:</w>
ip ient</w>
ion oph
intim a</w>
inter species</w>
insulin- mediated</w>
inhibi tion).</w>
inflamm ation-associated</w>
ine- stimulated</w>
include :</w>
in side-out</w>
in expensive</w>
import ance,</w>
immunohist ological</w>
imin o
illness es.</w>
id )</w>
ibuprof en-induced</w>
i osis</w>
i es;</w>
hypox anthine</w>
hypox anth
hypoparathyroidis m</w>
hyperreflex ia</w>
hyperammon emia.</w>
hyper vitaminosis</w>
hyper thyroidism,</w>
hyper lipoprote
hydroxyp yr
hydroxyl ases</w>
hydroxy- 4-
hydr azone</w>
hormone- sensitive</w>
hor ses</w>
hierarch ical</w>
heterodi mer.</w>
heter omeric</w>
hes peretin</w>
her petic</w>
hepat oblast
he d,</w>
harmal ine</w>
hallucin atory</w>
hallucin ation</w>
haemat uria</w>
great er,</w>
granul ocytopen
gra vid
gr and
gp91 (phox)</w>
gover ned</w>
glucosaminid ase,</w>
genu ity</w>
gene- expression</w>
gen otoxicity,</w>
gen es)</w>
gel s</w>
gastro protection</w>
gas trec
gamma- GT</w>
gam mag
g omer
g odi
g (-1)</w>
fum es</w>
fulle rene</w>
full -term</w>
free- radical</w>
fre edom</w>
for c
fo x</w>
fo res
fluv oxamine,</w>
fluorourac il,</w>
fluoro phosphate</w>
fluo ren
fluc yt
flu xes</w>
fle st
fl ap
fix ation</w>
first- order</w>
filam ents.</w>
fibro sing</w>
fib res.</w>
fi refly</w>
ferul oyl
feat uring</w>
factor- alpha.</w>
fa ther</w>
f lies</w>
f idel
f ear
extravas ation.</w>
extracellul ar
expres sion)</w>
even ly</w>
etiolog ies.</w>
eth n
estrogen- receptor</w>
ester s,</w>
ero sion</w>
equ ations</w>
ept in,</w>
ept al</w>
epoxy eicosatrienoic</w>
enti a</w>
enter o
ent ing</w>
ent /
enol ase</w>
enhanc er.</w>
ene )</w>
encephal itis.</w>
en- 3-
en ge
en forced</w>
en de
employ ment</w>
empir ically</w>
emergenc ies</w>
el uted</w>
el abor
ejac ulatory</w>
effect )</w>
ec ze
ec SOD</w>
e mic,</w>
e at</w>
dysmorph ism</w>
du st
doub t
dopamine- mediated</w>
diure tic.</w>
diure sis,</w>
dissec tion.</w>
disproportion ately</w>
dis close</w>
din ucleoti
dimethyl thiazol-2-yl]
dichlorv os,</w>
dic t
diast ole</w>
diarrhoe a,</w>
diaph ore
destro yed</w>
desferri oxamine.</w>
des quam
dens ity-
denerv ation.</w>
demonstr ate,</w>
delta- opioid</w>
deliri ous</w>
dela yed.</w>
degener ated</w>
deep ly</w>
deep -
days/ week</w>
daunorubic in.</w>
daunorubic in,</w>
damage- inducible</w>
d, l-
d ot
d eng
d ab
cyto protection.</w>
cyt ology</w>
cyt ologic</w>
cyste amine</w>
cyclospor ine-treated</w>
cyclophosphamide -treated</w>
cyan uric</w>
curren ts,</w>
cu st
cross over,</w>
cre ates</w>
counter balanced</w>
corrobor ate</w>
coordin ation,</w>
conver sion,</w>
constric tion,</w>
consequenc es,</w>
con temporary</w>
complic ates</w>
complain ts,</w>
comparison s,</w>
colum ns</w>
collap se,</w>
co- immunoprecipitation</w>
co operatively</w>
clon azepam.</w>
clobet as
clinical trials
claud in-4</w>
classi cal
class es.</w>
clas togenic</w>
cisplat in
circumst ances,</w>
circumferen tial</w>
cilex etil</w>
cholecyst ectomy.</w>
chill s,</w>
chemotherapy- naive</w>
chemot axis,</w>
chall enge
caspase- 6</w>
cartil age.</w>
carboxy kinase</w>
canal icul
calc ified</w>
cal pa
cachex ia</w>
ca val</w>
buff ering</w>
bru x
bromi de.</w>
bro ken</w>
body weight</w>
bo w</w>
blast s.</w>
bio alle
bicalut amide.</w>
benzyloxy carbonyl-
benef ited</w>
bcr -
base- line</w>
bam buterol</w>
bacul o
b-caten in,</w>
b revi
azosulf apyridine</w>
az ide.</w>
aven ues</w>
auto regulatory</w>
auto receptor</w>
attention- deficit</w>
atraz ine,</w>
atracuri um.</w>
assign ment</w>
aspir in)</w>
as le
as es)</w>
are :</w>
ap illary</w>
antinocicep tion.</w>
antigen -positive</w>
antidepress ant-induced</w>
anti-oxid ant,</w>
anti- proliferation</w>
anti- carcinogenic</w>
anti fung
anth rop
angi osarcoma</w>
anesthe tics,</w>
analy sis)</w>
an sw
an iracetam</w>
an es.</w>
an emia:</w>
amyloid ogenic</w>
amoxicillin ,</w>
am sacrine</w>
am n
alpha ;</w>
alpha -1-
alkyl transferase</w>
alend ron
al ization.</w>
al ia</w>
ag matine</w>
ag gr
ag e),</w>
after wards.</w>
after discharge</w>
afil omycin</w>
adolesc ents,</w>
adipos ity,</w>
adipo kine</w>
adin azolam</w>
ad mixture</w>
activit y-dependent</w>
activ ator-
activ ation/
acro l</w>
acne ,</w>
acknowledg ed</w>
ac ec
ac ampros
abund ance.</w>
abstin ence,</w>
abol ishing</w>
abec arn
[CI ]:</w>
[ Case</w>
Zym bal</w>
XIAP .</w>
Wh at</w>
Wall is</w>
W is
W NT</w>
W F
Vi et
Vari ant</w>
VK OR</w>
V- FI
V O2</w>
V HD</w>
UR SE:</w>
UGT1A 9,</w>
U reth
Tript olide</w>
Trimethoprim -sulfamethox
Transcrip t</w>
To facitinib</w>
Tetra hydro
Td p</w>
TX B2</w>
TRAIL/ Apo2
TP 53,</w>
TNF- related</w>
TL C</w>
TI MP</w>
TH C.</w>
TGF-b 1-induced</w>
T h</w>
T Z
T 1-
Sub group</w>
Sixty- two</w>
Sixty- four</w>
Simpson- Angus</w>
Sil ver</w>
Sar CN
STAT 3.</w>
SR T17
SN P-
SLCO 1B
SK F-
SER M</w>
SELE N
SC 1</w>
S6 K</w>
S low</w>
S j</w>
S f9</w>
S can</w>
S X
S A-
S 2,</w>
Rem ifentan
Radi ation</w>
R us
R of
R NS</w>
R 1
R .
R (-)-
Pro pafen
Pl us</w>
Pi oglit
Pe op
PS- 341</w>
PP s</w>
PP ).</w>
PML- RAR</w>
PI3K/Akt/ mTOR</w>
PI3- K</w>
PH N</w>
PGHS -1</w>
PEPC K</w>
PDE 3</w>
PD I
PC a.</w>
PC NA
PC N</w>
PARP 1</w>
P< .001).</w>
P2X 3</w>
P-gp- mediated</w>
P s.</w>
P b-induced</w>
P S)</w>
P HT,</w>
P BP
P 300</w>
P (4)</w>
Ox idized</w>
Ox -
ON ),</w>
OH- PCBs</w>
OD ,</w>
O- acetylation</w>
O, O-
O EA</w>
Norm alization</w>
Niss l</w>
Nisol dipine</w>
Nim odipine</w>
Nic losamide</w>
Neuro psychological</w>
Neuro peptide</w>
Ne o
Na+/ K+</w>
NT69 L</w>
NT PD
NO P</w>
NMD AR
NM S.</w>
NK CC1</w>
NFkappa B,</w>
NAD(P)H :</w>
NA SH.</w>
N-acetyl- beta-
N- butyl-
N- Acet
N- 2</w>
N- (4-
N ucleotide</w>
N ov
N ative</w>
N GF-
N DU
MyD 88
My ocarditis</w>
Mont gomer
Methotrex ate-induced</w>
Med line</w>
MT T,</w>
MT 2</w>
MS P</w>
MR P-
MP O
MOLT -4</w>
MI ).</w>
MD CKII</w>
MCL R</w>
MB -2
MAPK s,</w>
MAP T</w>
MA N</w>
M igra
M ifepristone</w>
M 0
M -treated</w>
Levodop a</w>
Leth al</w>
Langendor ff</w>
Lam otrig
L yn
L t
L ocalization</w>
L CA
L A,</w>
K cn
K 1/
K (m
Jurk at
JNK s</w>
J ew
Intrav entricular</w>
Intra- arterial</w>
Indometh acin,</w>
Ifosfam ide-induced</w>
IMP DH
IL-1 b-induced</w>
IL 1R
III- IV</w>
IFN- gamma-
IFN /
IC C</w>
I rin
I X,</w>
I DA</w>
Hyper trophy</w>
Hyper trophic</w>
HgCl 2.</w>
HN 2</w>
HM G</w>
HER 2,</w>
HDAC 6</w>
HDAC 1</w>
HA AR
H2A X,</w>
H az
H S)</w>
H 1-receptor</w>
Glu 298
Gene Chip</w>
GL A</w>
G20 19
G i</w>
G L</w>
G 0
G (2)-
For khead</w>
Flut amide</w>
Fisch er-
Fe 3
FAD D</w>
F lun
F ent
F M</w>
Ex p
Es mol
Ep inephr
Eosin ophilic</w>
Elev ations</w>
ET -1.</w>
ERalpha- positive</w>
ER- beta</w>
ER +</w>
EP 4</w>
EGF .</w>
EC D</w>
E SR</w>
E SC</w>
E MB</w>
E D-
E 6
E (2).</w>
Double- blind,</w>
Dom in
DX M</w>
DO I</w>
DNA s</w>
DN CB
DMS A</w>
DM D</w>
DHE AS</w>
DH S</w>
DF P-induced</w>
DE A</w>
DA G</w>
D ab
D TT</w>
D CP
D C-
D 4,</w>
Cy ste
Consor tium</w>
Consider able</w>
Con trac
Cipro floxacin-induced</w>
Chol inergic</w>
Cdc25 C</w>
Caspase- 3,</w>
Carcin ogenicity</w>
Carcin ogenesis</w>
Canad a</w>
Ca2+ ,</w>
CYP2C 9.
CYP1A 1-
CXCR 4,</w>
CT C</w>
CP M</w>
COX -1,</w>
COUP- TF
CO URSE:</w>
CO N</w>
CM T-
CG RP-
CF .</w>
CD95 L</w>
CD 25</w>
CD ).</w>
CC D</w>
CB F)</w>
CB ),</w>
CA E</w>
C yn
C ha
C a,</w>
C SCs.</w>
C PAP</w>
C P-treated</w>
C :
Bud es
Bi oche
Bax -
BU D</w>
BCK DH</w>
BALB/ c
B- Raf</w>
B 1
Av ail
Arg/ Arg</w>
Ar ra
Ap paren
Anti epileptic</w>
Anti cholinergic</w>
Amis ul
Ami k
Am oxic
Alve olar</w>
Akt/ PKB</w>
Afric a.</w>
Adriamycin ,</w>
AS /
ARA- C</w>
AP -1-
ANOV A).</w>
AMP .</w>
AM T</w>
AM I.</w>
AL P,</w>
AL L)</w>
AL I.</w>
AIMS/ HYPOTHESIS:</w>
AI U</w>
AE s.</w>
ADP-rib osylation</w>
AD P-
AD C</w>
ACTH ,</w>
ABT-0 89</w>
ABCB 1,</w>
A dequate</w>
A ca
A 11</w>
> 10</w>
= 4.
= 3</w>
9. 0
9- OH-
9 1-
8- fold,</w>
7- fold,</w>
7 -10</w>
69 76</w>
6 8-
6 2)</w>
6 1)</w>
5alpha- dihydrotestosterone</w>
50 4</w>
50 -100</w>
5-bromo -2'-deoxyuridine</w>
5-HT -induced</w>
5-HT ,</w>
5-Fluoro urac
5 a
5 6-
5 21
49 8</w>
4- Hydroxy
37 9
30 3</w>
3. 5-fold</w>
3- mercapto
3- OH-
3- 7</w>
3, 17-
3, 0
3 R
3 L1</w>
3 65</w>
3 31</w>
3 1%,</w>
29 .</w>
28 4</w>
27 8</w>
26 7</w>
25 4</w>
20 -2
2. 6-fold</w>
2. 25</w>
2-amino-3-methyl imidazo[4,5-f]
2-amino -1-methyl-6-phenyl
2- deoxy-
2,4- dichloro
2 1.3</w>
1A .</w>
1999 -200
19 80
19 70
18 435
18 2,
17. 4</w>
16 A,</w>
15. 3</w>
15 5
15 3,</w>
14 643</w>
12. 9</w>
12. 5%</w>
10(- 5),</w>
10 7
10 1,</w>
1/ 2),</w>
1/ (*)
1.0 9</w>
1.0 7</w>
1. 18</w>
1- methyl
1- butanol</w>
1,25(OH)2D 3.</w>
1,2- dimethylhydrazine</w>
1,2- NQ</w>
1,1,1- trichloro
1, 2</w>
1 +/-1
1 %
00 .</w>
0.9 7</w>
0.8 8</w>
0.7 4</w>
0.7 %)</w>
0.000 1;</w>
0.0 2;</w>
0.0 2%</w>
0.0 17).</w>
/ METHODS:</w>
.0 4).</w>
.0 2),</w>
-2,5- diphenyl</w>
-1 30</w>
-1 23</w>
+/- 6</w>
+/- 3.
+ ),</w>
* OH</w>
)- deficient</w>
(r )</w>
(medi an:</w>
(h TER
(e NOS),</w>
(TL R)</w>
(T SH)</w>
(T SA),</w>
(T M)</w>
(SCL C)</w>
(S e
(S M)</w>
(Pr P
(PCR-RF LP)</w>
(PA F)</w>
(P MN
(P DE)</w>
(N Ox
(Mn SOD),</w>
(MMP)- 9</w>
(MMP -2)</w>
(MMP )-2</w>
(MAPK ).</w>
(M W
(LD L-
(I k
(HIF )-1
(HF D)</w>
(H SCs)</w>
(H S)</w>
(GT N)</w>
(GST P1)</w>
(GST -
(G PR
(Dox )</w>
(DF O)</w>
(D i
(D Z
(Co Cl
(CH D)</w>
(C ),</w>
(BEAS-2 B)</w>
(A z
(A SA</w>
(A OR</w>
(7 2%)</w>
(64) Cu</w>
(50 )
(5 9</w>
(5 +)</w>
(4- HN
(10(- 9)</w>
(1 8/
(1 5,</w>
(*) 1/(*)
( y-
( time</w>
( pre-
( i.p.,</w>
( decreased</w>
( decrease</w>
( cyt
( control,</w>
( CYP2A6*
' s.</w>
z aleplon</w>
ylchol inester
x ed</w>
x ).</w>
weigh ts.</w>
w t.</w>
voltage- clamp</w>
viz .</w>
vis ,</w>
veter ans</w>
ve ins.</w>
varic es</w>
van il</w>
vagotom ized</w>
uter i</w>
urso deoxycholate</w>
urin aly
ur o</w>
up take
unmas k</w>
under scoring</w>
un satisfactory</w>
un aware</w>
ultrasoun d.</w>
ultras truct
ulcer ated</w>
ulcer ,</w>
ul e</w>
tun nel</w>
tumor s:</w>
tubul e,</w>
tro vafloxacin</w>
trin it
trimet az
trim eric</w>
triglycer ide-
tric arboxylic</w>
treatment s:</w>
transfer rin,</w>
toxic ology,</w>
tor as
tococc al</w>
to o.</w>
to genesis.</w>
tiv e/
time- to-
tig abine</w>
thym ocyte</w>
thy mol</w>
throm bi
thix ene</w>
thi ur
therap y).</w>
ther petic</w>
tetrac yclic</w>
tender ness</w>
tem po
te d-
te ach
tachycardi a:</w>
tac hyp
t ude</w>
sw ine</w>
sw allowing</w>
suxamethoni um-induced</w>
supraph ysi
support ,</w>
subst ance,</w>
subject s;</w>
subjec t,</w>
sub convulsant</w>
sub anesthetic</w>
strength ens</w>
stere oselectivity</w>
stat ure,</w>
sta y.</w>
spond ylo
splen omegaly</w>
spermat ogenic</w>
spar se</w>
sp ring</w>
som an-induced</w>
socio economic</w>
sniff ing</w>
sivel y.</w>
single- drug</w>
simvastat in-treated</w>
si a:</w>
shel ves</w>
seroton in
ser a
sera dish</w>
sept um,</w>
selen ometh
selec tivity,</w>
se ated</w>
scop e</w>
scleroder ma
sc hi
sar izotan</w>
sal ine)</w>
s tic
rul ing</w>
rs2 1086
rol .</w>
righ tward</w>
rho dam
restless ness</w>
response :</w>
reserpin ized</w>
res titu
res ;</w>
replic on</w>
remedi es</w>
relapsed /
regul ator,</w>
registr ation</w>
referen ce.</w>
reduc tion)</w>
recogni tion.</w>
receptor- beta</w>
receptor -induced</w>
receptor -</w>
rec ep
reach es</w>
re t</w>
re construction</w>
ran king</w>
ramipr il.</w>
quinol in
quality- of-life</w>
q RT-PCR,</w>
pyrid ini
pyr one</w>
protein s:</w>
protein -3</w>
protein -1.</w>
protec tant</w>
prop eptide</w>
prol ine,</w>
progres s.</w>
pro ving</w>
pri t</w>
preval ence,</w>
prespec ified</w>
prepro enkephalin</w>
predis position.</w>
precl udes</w>
precipit ates</w>
pre- incubated</w>
pre treating</w>
pr as
potassium- sparing</w>
post exposure</w>
post dose</w>
pos therpetic</w>
popul ation:</w>
popul ation-
polyphen ols.</w>
poly glutamine</w>
poly glutam
poly (
po or-
ple thor
play ers</w>
plate au
pl i
piperid ino
piperazin -1-
physi ological,</w>
phyg mom
phygmom an
phthal ic</w>
phot odam
phosphoinositi de
phosphatidyl in
phosphat ase-
ph ilic</w>
pericardi tis.</w>
perc ent.</w>
per ine
parturi ents</w>
parthen olide</w>
parenchy ma.</w>
parameter s:</w>
pap ules</w>
pap ers</w>
palp able</w>
p53 R2</w>
p27 kip
p27 .</w>
p21(CIP 1/WAF
p n
p 15
oxylin- eosin</w>
oxpren olol,</w>
oxi b
oxcarb azep
ox- LDL</w>
ox ip
over looked</w>
over loaded</w>
out door</w>
ouabain -
ot otoxic
osteop ont
osteocal cin,</w>
osteoc lastic</w>
osteo arthritis,</w>
ospec ific
os es,</w>
orthopa edic</w>
origin ates</w>
orig ins</w>
organo phosphorous</w>
organ ism.</w>
orbi de-
oplast y.</w>
opiomelan ocortin</w>
oph os
oper ations.</w>
op sin</w>
onit ri
one ur
onco genes.</w>
onc ep
on dral</w>
on amide</w>
on af
om olyb
om ental</w>
olti praz</w>
oli pos
ol iv
ol der.</w>
